<SEC-DOCUMENT>0001213900-19-004295.txt : 20190318
<SEC-HEADER>0001213900-19-004295.hdr.sgml : 20190318
<ACCEPTANCE-DATETIME>20190315184426
ACCESSION NUMBER:		0001213900-19-004295
CONFORMED SUBMISSION TYPE:	10-KT/A
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20190318
DATE AS OF CHANGE:		20190315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-KT/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		19686361

	BUSINESS ADDRESS:	
		STREET 1:		10901 RED CIRCLE DR.
		STREET 2:		SUITE 150
		CITY:			MINNETONKA
		STATE:			MN
		ZIP:			55343
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		10901 RED CIRCLE DR.
		STREET 2:		SUITE 150
		CITY:			MINNETONKA
		STATE:			MN
		ZIP:			55343

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-KT/A
<SEQUENCE>1
<FILENAME>f10kt2018a1_neuroonemedical.htm
<DESCRIPTION>AMENDMENT NO. 1 TO 10-KT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-size: 12pt"><B>Form
10-KT/A</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-size: 12pt"><B>(Amendment
No. 1)&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Mark One)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the fiscal year ended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the transition period from January
1, 2018 to September 30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission file number 000-54716</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>NeuroOne
Medical Technologies Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><B>27-0863354</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(State or other jurisdiction of<BR>
incorporation or organization)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer<BR>
Identification No.)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>10901 Red Circle Drive, Suite 150<BR>
 Minnetonka, MN</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>54343</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>952-237-7412</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center">(Registrant&rsquo;s telephone number,
including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>Securities registered pursuant to
Section 12(b) of the Securities Exchange Act of 1934: </B>None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>Securities registered pursuant to
Section 12(g) of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center">Common stock, $0.001 par value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center">(Title of class)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT>No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if disclosure of
delinquent filers pursuant to Item 405 of Regulation S-K (&sect; 229.405 of this chapter) is not contained herein, and will not
be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-KT or any amendment to this Form 10-KT.&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 70%">Large accelerated filer&nbsp;&nbsp;&nbsp;&#9744;</TD>
    <TD STYLE="width: 30%">Accelerated filer&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">Non-accelerated filer&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top">Smaller reporting company&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Emerging growth company&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934). Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 29, 2018, the last business
day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate market value of shares of the registrant&rsquo;s
common stock held by non-affiliates of the registrant based upon the March 29, 2018 price at which the common equity was last sold
was $4,452,282.18. The number of outstanding shares of the registrant&rsquo;s common stock as of November 30, 2018 was 9,876,505.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"> <B>EXPLANATORY
NOTE</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> NeuroOne
Medical Technologies Corporation (the &ldquo;Company&rdquo;) is filing this Amendment No. 1 (this &ldquo;Amendment&rdquo;) to
its Transition Report on Form 10-KT for the period ended September 30, 2018, as filed on December 12, 2018 (the
&ldquo;Original Form 10-KT&rdquo;), solely to file certifications as Exhibits 31.1 and 32.1, which were inadvertently omitted
from the Original Form 10-KT and to update the exhibit index. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> Except
as described above, no other changes have been made to the Original Form 10-KT, and this Amendment does not amend, update
or change any other items or disclosures in the Original Form 10-KT. The original Form 10-KT continues to  speak as of
its original filing date. This Amendment does not reflect subsequent events occurring after the filing date of the Original Form
10-KT or modify or update in any way disclosures in the Original Form 10-KT.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>FORM 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>FOR THE TRANSITION PERIOD ENDED SEPTEMBER
30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_001">EXPLANATORY NOTE REGARDING THE TRANSITION REPORT</A></TD>
    <TD STYLE="width: 10%; text-align: center; font-weight: bold; vertical-align: bottom">iv</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_002">PART I</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_003">ITEM 1. BUSINESS</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_004">ITEM 1A. RISK FACTORS</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_005">ITEM 1B. UNRESOLVED STAFF COMMENTS</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_006">ITEM 2. PROPERTIES</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_007">ITEM 3. LEGAL PROCEEDINGS</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_008">ITEM 4. MINE SAFETY DISCLOSURES</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_009">PART II</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_010">ITEM 5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_011">ITEM 6. SELECTED FINANCIAL DATA</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_012">ITEM 7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_014">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">F-1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_015">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">80</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_016">ITEM 9A. CONTROLS AND PROCEDURES</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">80</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_017">ITEM 9B. OTHER INFORMATION</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">81</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_018">PART III</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">82</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_019">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">82</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_020">ITEM 11. EXECUTIVE COMPENSATION</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">86</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_021">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">97</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_022">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">98</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_023">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">102</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_024">PART IV</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">103</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_025">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</A></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">103</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless the context requires otherwise,
references in this Transition Report on Form 10-KT (this &ldquo;<B>Transition Report</B>&rdquo;) to &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;the Company&rdquo; and &ldquo;our&rdquo; refer to NeuroOne Medical Technologies Corporation (&ldquo;<B>the Company</B>&rdquo;),
together with its subsidiary, NeuroOne, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Transition Report contains forward-looking
statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections
entitled &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and &ldquo;Business,&rdquo; but are also contained elsewhere in this Transition Report. In some cases, you can identify forward-looking
statements by the words &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;objective,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;target,&rdquo; &ldquo;seek,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or the negative of these terms, or other comparable
terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from
the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this Transition Report, we caution you that these statements are based on a combination
of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking
statements include statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our plans to develop and commercialize our cortical
strip, grid and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our plans for and our expectations regarding the pre-clinical
testing and clinical trials of our cortical strip, grid and depth electrode technology that will be required by the U.S. Food
and Drug Administration (the &ldquo;<B><I>FDA</I></B>&rdquo;), or foreign regulatory bodies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the timing and availability of data from pre-clinical
tests or clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the timing of our planned regulatory filings;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the timing of and our ability to obtain and maintain
regulatory approval of our cortical strip, grid and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our expectations regarding international opportunities
for commercializing our cortical strip, grid and depth electrode technology under development;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the clinical utility of our cortical strip, grid and
depth electrode technology under development;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to develop our cortical strip, grid and
depth electrode technology with the benefits we hope to offer as compared to existing technology, or at all;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to develop future generations of our cortical
strip, grid and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our future development priorities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to obtain reimbursement coverage for our
cortical strip, grid and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our expectations about the willingness of healthcare
providers to recommend our cortical strip, grid and depth electrode technology to people with epilepsy, Parkinson&rsquo;s disease,
essential tremors, and other brain related disorders;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our future commercialization, marketing and manufacturing
capabilities and strategy;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">estimates of the impact of material weaknesses in the
internal control over financial reporting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to comply with applicable regulatory requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain our intellectual property position;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our estimates regarding the size of, and future growth
in, the market for our technology under development; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our estimates regarding our future expenses and needs
for additional financing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on
management&rsquo;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate,
and management&rsquo;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown
risks, uncertainties and other factors that are in some cases beyond our control. You should refer to the &ldquo;Risk Factors&rdquo;
section of this Transition Report for a discussion of important factors that may cause our actual results to differ materially
from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the
forward-looking statements in this Transition Report will prove to be accurate. Furthermore, if our forward-looking statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,
you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives
and plans in any specified time frame, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements speak
only as of the date of this Transition Report. Except as required by law, we assume no obligation to update or revise these forward-looking
statements for any reason, even if new information becomes available in the future. You should, however, review the factors and
risks and other information we describe in the reports we will file from time to time with the Securities and Exchange Commission
(the &ldquo;<B><I>SEC</I></B>&rdquo;) after the date of this Transition Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>EXPLANATORY NOTE REGARDING THE TRANSITION
REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2018, we changed our fiscal
year from December 31 to September 30. As a result, this Transition Report on Form 10-KT is a transition report and includes financial
information for the transition period from January 1, 2018 through September 30, 2018. Subsequent to this Transition Report, our
reports on Form 10-K will cover the period beginning October 1 and ending September 30, which will be our fiscal year. We refer
in this Transition Report to the period beginning on January 1, 2018 and ended on September 30, 2018 as the &ldquo;<B><I>Transition
Period</I></B>.&rdquo; Lastly, we included financial statements for the twelve months ended September 30, 2018 as supplemental
information in Exhibit 99.1 to this Transition Report.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_003"></A>ITEM 1. BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Overview of NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were originally incorporated as Original
Source Entertainment, Inc. under the laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as
defined below), we completed a series of steps contemplated by a Plan of Conversion pursuant to which we, among other things, changed
our name to NeuroOne Medical Technologies Corporation, increased our authorized number of shares of common stock from 45,000,000
to 100,000,000, increased our authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in
Delaware. On July 20, 2017, we acquired NeuroOne, Inc. (the &ldquo;<B><I>Acquisition</I></B>&rdquo;). Immediately following the
closing of the Acquisition, the business of NeuroOne, Inc. became our sole focus. Unless otherwise stated or unless the context
otherwise requires, the description of our business set forth below is provided on a combined basis, taking into account our wholly-owned
subsidiary, NeuroOne, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Overview and History of NeuroOne,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne, Inc. was incorporated under the
laws of the State of Delaware on October 7, 2016. Its predecessor entity, NeuroOne LLC (the &ldquo;<B><I>LLC</I></B>&rdquo;), was
formed on December 13, 2013 and operated as a limited liability company until it was merged with and into NeuroOne, Inc. on October
27, 2016 with NeuroOne, Inc. as the surviving entity (the &ldquo;<B><I>Merger</I></B>&rdquo;). As a result of the Merger, all of
the properties, rights, privileges and powers of the LLC vested in NeuroOne, Inc., and all debts, liabilities and duties of the
LLC became the debts, liabilities and duties of NeuroOne, Inc., except for the license agreement (the &ldquo;<B><I>WARF License</I></B>&rdquo;)
with the Wisconsin Alumni Research Foundation (&ldquo;<B><I>WARF</I></B>&rdquo;) which was not legally transferred until May 2017.
The purposes of the Merger were to: change the jurisdiction of incorporation from Minnesota to Delaware; change the ownership of
the LLC&rsquo;s underlying assets; and convert from a limited liability company to a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a medical technology company focused
on the development and commercialization of thin film electrode technology for cEEG and sEEG recording, brain stimulation and ablation
solutions for patients suffering from epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors and other related brain
related disorders. Members of our management team have held senior leadership positions at a number of medical technology and biopharmaceutical
companies, including Boston Scientific, St. Jude Medical, Stryker Instruments, C.R. Bard, A-Med Systems, Sunshine Heart, Empi,
Don-Joy and PMT Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing our cortical and sheet
and depth electrode technology to provide solutions for diagnosis through continuous electroencephalogram (cEEG) recording and
stereoelectroencephalography (sEEG) recording and treatment through brain stimulation and ablation, all in one product. A cEEG
is a continuous recording of the electrical activity of the brain that identifies the location of irregular brain activity, which
information is required for proper treatment. cEEG recording involves an invasive surgical procedure, referred to as a craniotomy.
sEEG involves a less invasive procedure whereby doctors place electrodes in targeted brain areas by drilling small holes through
the skull. Both methods of seizure diagnosis are used to identify areas of the brain where epileptic seizures originate in order
to precisely locate the seizure source for therapeutic treatment if possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deep brain stimulation, or DBS, therapies
involve activating or inhibiting the brain with electricity that can be given directly by electrodes on the surface or implanted
deeper in the brain via depth electrodes. Introduced in 1987, this procedure involves implanting a power source referred to as
a neurostimulator, which sends electrical impulses through implanted depth electrodes, to specific targets in the brain for the
treatment of disorders such as Parkinson&rsquo;s disease, essential tremor, dystonia, and chronic pain. Alzheimer&rsquo;s is another
indication evaluating the effects of DBS. Unlike ablative technologies, the effects of DBS are reversible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RF ablation is a procedure that uses radiofrequency
under the electrode contacts that is directed to the site of the brain tissue that is targeted for removal. The process involves
delivering energy to the contacts, thereby heating them and destroying the brain tissue. The ablation does not remove the tissue.
Rather, it is left in place and typically scar tissue forms in the place where the ablation occurs. This procedure is also known
as brain lesioning as it causes irreversible lesions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cortical sheet electrode and depth
electrode technology has been tested over the years by both WARF, the owners of our licensed patents, and Mayo Clinic located in
Rochester, Minnesota, in both pre-clinical models as well as through an IRB approval at Mayo Clinic for clinical research. Regarding
our ablation electrode, the Cleveland Clinic has performed testing in bench top models and pre-clinical (or animal testing) modes.
These pre-clinical tests have demonstrated that the technology is capable of recording, ablation and acute stimulation, although
our technology remains in product development for all of the recording (or diagnostic) and therapeutic modalities so additional
trials will need to be completed prior to it being approved for sale by the FDA) for all of the recording (or diagnostic) and therapeutic
modalities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to commercialization of our technology,
we will have to obtain regulatory approval as discussed in&rdquo;-Clinical Development and Regulatory Pathway&rdquo; and &ldquo;&mdash;Government
Regulation&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Epilepsy Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to initially target the diagnosis
and treatment of epilepsy. Epilepsy can be caused by a variety of conditions that affect a person&rsquo;s brain, some of which
are: stroke, brain tumor, traumatic brain injury and central nervous system infections. According to the Centers for Disease Control
and Prevention (the &ldquo;<B><I>CDC</I></B>&rdquo;) and Citizens United for Research in Epilepsy (&ldquo;<B><I>CURE</I></B>&rdquo;),
there are approximately 3,000,000 patients annually suffering with epilepsy in the United States, with an additional 200,000 diagnosed
every year. They also estimate that epilepsy costs the United States $15.5 billion per year. We believe the European market is
similar. Approximately 720,000 of these patients are not receptive to pharmaceutical treatment and therefore are appropriate for
surgical treatment of this disorder. In addition to poor quality of life, epilepsy also is associated with fairly high mortality
rates, especially in children. CURE reported that Sudden Unexpected Death in Epilepsy accounts for 34% of all deaths in children.
Such deaths have increased by close to 100% from 2005 to 2015 according to the CDC. Despite the large market opportunity, it is
estimated that there are only 16,000 craniotomies performed for epilepsy cases each year in the United States with 18,000 performed
in Europe.<SUP>1</SUP>&nbsp;These numbers represent an underpenetrated market due to the invasiveness of a full craniotomy required
just to perform the diagnostic procedure. After the diagnostic procedure, a second therapeutic procedure is required and at times
even a third surgery if the seizures persist. We believe patients are unwilling to proceed due to the long diagnostic times (one-four
weeks in the hospital with a craniotomy), infection rates and 50% rate of success in the diagnosis and treatment of the disorder.
As detailed above, after the diagnosis is completed, if successful, the patient must undergo an additional procedure to have the
affected area of brain tissue removed. The average cost for the diagnostic technology per procedure is $10,000, with ablation devices
costing $15,000 and brain stimulation devices costing $25,000 to $30,000. We believe our technology, once developed, will offer
an all in one solution with diagnostic and therapeutic capabilities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that many leading neurologists
believe that the limits of today&rsquo;s current technologies are the reason the exact affected area of the brain causing epileptic
seizures is not well-determined. We expect our technology, which has been developed to date by physicians at WARF and Mayo Clinic,
will provide a number of advantages over the current commercially available technologies, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Our proprietary thin film technology under development has a smaller footprint with many more electrodes.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">We expect that our technology will eventually be able to be implanted using a minimally invasive procedure utilizing a dime sized burr hole rather than a full craniotomy which is typically required to implant the currently available technology.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Our technology may provide more accurate detection of irregular brain activity over currently available technology. In limited clinical testing, doctors at Mayo Clinic have documented pre-seizure activity (micro-seizures) during their clinical research with their patients using our cEEG technology.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">American Association of Neurological Surgeons National
Neurosurgical Procedural Statistics 2012.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect our technology can ablate through
the electrodes as well as perform brain stimulation, allowing for diagnosis and treatment through the same product and in the same
procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Parkinson&rsquo;s Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parkinson&rsquo;s Disease Foundation
estimates that as many as 1,000,000 patients in the United States live with Parkinson&rsquo;s disease with an additional 60,000
patients diagnosed per year. Over 10,000,000 patients worldwide are living with Parkinson&rsquo;s disease. There have not been
any drugs introduced that have been effective at treating Parkinson&rsquo;s disease. The average onset is over 60 years old but
some people have been diagnosed as young as 40 years old. Parkinson&rsquo;s is a disorder of the central nervous system caused
by loss of brain cells throughout various regions of the brain. It is attributed to the loss of dopamine production in the brain,
a messenger in the brain that allows for movement and coordination. There are no objective tests to diagnose Parkinson&rsquo;s
disease, and misdiagnosis rates are still very high. Doctors look to find two or more signs to make a diagnosis, including balance
problems, rigidity and tremors that occur during rest. In 2011, the FDA approved the first imaging device called a DaTscan that
can capture images of the dopamine system in the brain. By itself, these scans cannot diagnose Parkinson&rsquo;s but can help confirm
a doctor&rsquo;s diagnosis. Parkinson&rsquo;s disease is typically not fatal; however, complications caused by the symptoms of
Parkinson&rsquo;s, such as difficulty swallowing causing food to travel to the lungs resulting in pulmonary issues or falls related
to loss of balance, can be fatal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today&rsquo;s primary treatment for Parkinson&rsquo;s
disease involves medications that have not proven to resolve symptoms but rather ease symptoms. Years ago, surgical procedures
such as thalamotomy and pallidotomy targeted certain parts of the brain and involved destroying the tissue. More recently, these
procedures have been replaced with DBS. A doctor evaluates the patient by reviewing the patient&rsquo;s symptoms and medications
taken and administering detailed memory, thinking and imaging tests to determine if they are appropriate for DBS. According to
the Michael J. Fox Parkinson&rsquo;s Disease Research Foundation website, patients that seem to do best with DBS are those that
have had the disease for at least four years and have benefited from taking medications prescribed to control the disease. In addition,
DBS seems to help with reducing the issues with motor functions such as tremors, stiffness and slowness but not for balance issues.
Doctors are evaluating treatment to other parts of the brain in an effort to address more symptoms to treat walking or balance
issues. In addition, research is being conducted to provide stimulation when the symptoms return as opposed to all of the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Essential Tremors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Essential tremors are thought to be due
to electrical irregularities in the brain that send abnormal signals to the muscles. It is a progressive condition that worsens
over time and is linked to genetic disorders that typically appear in people who are over 40. Essential tremors usually occur alone
and without any other neurological symptoms or signs. The tremors usually occur when the hands are raised and primarily affect
the hands. Muscles in the trunk, face and neck may also experience symptoms. Sometimes misdiagnosed as Parkinson&rsquo;s disease,
essential tremors are an involuntary rhythmic shaking of the hands that is not present at rest. It is apparent during activities
such as drinking, writing and eating. Symptoms can worsen due to stress, anxiety, smoking, caffeine, fatigue, etc. Genetics Home
Reference estimates that as many as 10,000,000 people in the United States are affected by the disease. Treatments for the disease
include medical therapy, weighting the limbs and DBS. Patients need to eliminate any medications they are taking that cause tremors
as this can exacerbate the symptoms. For some patients, using wrist weights may ease symptoms allowing the patient to function.
Other patients may also use relaxation techniques as stress can increase symptoms. Medical therapy is also used to treat patients&rsquo;
symptoms. Primidone is typically the first drug prescribed as it has had success in some situations for epilepsy. Botox is also
used at times to control head tremors. When these fail, surgery is the next alternative. A surgical procedure used years ago created
lesions in the ventral intermediate thalamus and was highly successful with treating essential tremors but is no longer commonly
used due to increased risk of developing speech problems. The latest therapy is DBS, which, unlike other therapies, is reversible
and programmable, helping to adjust the settings to maximize patient benefit. Similar to Parkinson&rsquo;s disease, the ability
to detect this irregular brain activity before it causes a tremor is highly desirable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dystonia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dystonia is a neurological condition recognized
as a motion disorder that involves over activity of a variety of different muscles simultaneously that work against each other.
It presents itself in a variety of symptoms but typically involves repetitive, patterned and often twisting involuntary muscle
contractions resembling tremors. According to the Dystonia Medical Research Foundation, over 300,000 people are affected in the
United States and Canada alone. Dystonia is the third most common problem seen in movement disorder clinics. Because it has many
different manifestations, it is often misdiagnosed. In addition, similar to Parkinson&rsquo;s disease, there are no specific tests
that can positively diagnose dystonia. A doctor typically will evaluate patient and family history, potentially do genetic testing,
EEG testing, blood and urine tests. There are also many treatment options for patients but depend on the type of dystonia. Botox
and certain medications may be helpful or DBS may be used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Artificial Intelligence</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brain consists of approximately 100
billion nerve cells, which are small wires that pass electrical signals to control all of its functions. There have been a number
of successful clinical trials in which small metal wires, known as electrodes, are implanted in the brain to correct nerve damage
using wireless communication between implanted wires to simulate functional nerve cells. In addition to correcting damaged nerve
cells, certain scientists have theorize that if millions of wires could be implanted in the brain, these electrodes could present
an opportunity to use artificial intelligence to create infrared sight, increase hearing or perfect memory recall. However, there
currently is no commercially available manufacturing platform capable of making thousands of wires that can be placed within or
on the brain and work reliably for the lifetime of a subject, and are soft enough to match the tissue of the brain, that avoid
damage to the brain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Currently Available Therapies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a limited number of currently
available products for diagnosis and treatment for people with neurological disorders such as epilepsy. Although the currently
available systems provide diagnosis and treatment for patients, they have certain inherent limitations and shortcomings that we
believe limit their use and validate the need for improved technology in the market. These limitations include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Lengthy diagnostic times:</B>&nbsp;&nbsp;Patients spend one to four weeks in the hospital waiting to have seizures that will allow doctors to determine where the seizures are occurring.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Lower Accuracy:</B>&nbsp;&nbsp;Historically, clinical electrode manufacturers primarily provided electrodes that sample brain tissue at approximately centimeter spacial scales. Advances in digital EEG acquisition have made recordings at sub-millimeter spatial scales possible, but high-spatial resolution EEG has been slow to impact clinical practice. Existing, higher spatial scales increase the potential for missing data that may be critical in the removal of brain tissue causing the irregular activity. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Need to perform a full craniotomy (invasiveness):</B>&nbsp;&nbsp;Currently available cortical electrode technology is placed through a craniotomy, which requires removing the top part of the cranium and is a very painful and invasive procedure. Procedural times for a craniotomy range from a minimum of four to eight hours. A variety of complications can occur when a full craniotomy is performed, including but not limited to: stroke, bleeding, infection, seizures, swelling of the brain (which may require a second craniotomy), nerve damage, which may cause muscle paralysis or weakness, cerebrospinal fluid (CSF) leak, which may require repair, loss of mental functions and permanent brain damage with associated disabilities. The invasiveness, procedural times and possible surgical complications have limited the growth of surgical treatment of epilepsy.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><B>Multiple technologies required for diagnosis and
treatment:</B> Currently, a patient undergoes a craniotomy for implantation of diagnostic film technologies. The patient then
waits in the hospital for one to four weeks waiting to have seizures that will allow doctors to pinpoint where the seizures are
occurring in the brain. After this is complete, a patient has to undergo another lengthy procedure to have the brain tissue removed
or undergo permanent implantation of depth electrodes for chronic stimulation. There is a need for an all in one technology that
can potentially allow for diagnosis and treatment concurrently and potentially offer real time treatment without the need for
surgery.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Solution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the inherent limitations
and inconvenience of existing systems, we believe that there is a significant unmet need among people with neurological disorders
for cortical strip, grid and depth electrodes that provide diagnostic capabilities through cEEG and sEEG recording in addition
to therapeutic modalities, such as brain stimulation and ablation, offered as an all in one product. In comparison to currently
available technologies, we are currently developing our strip, grid and depth electrodes with the goal of providing the following
expected advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Reduced time for diagnosis:</B>&nbsp;&nbsp;If we are successful in identifying brain activity more quickly, in offering a minimally invasive procedure and developing an all in one solution, we expect our technology will reduce overall procedural times. While our pre-clinical and clinical experience to date is very limited, our cortical grid technology under development has, in some cases, demonstrated the ability to provide hi fidelity recordings that have allowed physicians to identify the affected brain tissue causing seizures in hours versus weeks. This represents the potential for meaningful cost savings for hospitals and patients and improved quality of life for patients.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Improved accuracy of diagnostic technologies:</B>&nbsp;&nbsp;Because we believe our thin film technology will be capable of recording at higher fidelity than current technologies used in EEG recording, we believe our technology may be able to more precisely determine the brain tissue causing seizures. Additionally, in the limited clinical tests performed by Mayo Clinic with five patients to date, our technology under development has identified what clinicians refer to as pre-seizure activity (made possible by the ability to detect brain activity using sub-millimeter spatial scales). We believe our technology under development may be able to improve outcomes compared to using other therapeutic technologies regardless of whether we are able to offer an all in one diagnostic and therapeutic solution.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Implantation via minimally invasive procedure with fewer post-procedure complications:</B>&nbsp;&nbsp;We are currently developing an approach to deliver the cortical electrodes, including minimizing the invasiveness of the procedure. We expect that patients who have qualified for this therapy will be more accepting of a minimally-invasive procedure. Such a procedure would potentially reduce the patient&rsquo;s pain, bleeding and other adverse events associated with a full craniotomy. Our technology is expected to also have fewer wires, also referred to as tails, exiting the patient&rsquo;s head, which can also reduce the potential for infections. Furthermore, the material we currently use in our cortical electrodes has shown in pre-clinical evaluations to cause less inflammation than current electrode substrates as it appears more compatible with brain tissue. As discussed under &ldquo;Our Strategy&rdquo; below, our technology under development, if approved, will be implanted via a full craniotomy until such time, if ever, as we are able to develop our minimally invasive procedure.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>All-in-one diagnostic and therapeutic technology solution:</B>&nbsp;&nbsp;Due to the expected high fidelity recording capabilities of our technology under development, we have received feedback from physicians that they will attempt to perform the diagnosis and treatment in a single procedure, thereby eliminating the need for a second surgical procedure, reducing the likelihood of patient infection and minimizing the diagnostic, procedural and hospital costs. As discussed under &ldquo;Our Strategy&rdquo; below, our initial product offering will offer diagnostic-only capabilities while we advance the development of our all in one approach.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to be the global leader in
cEEG and sEEG recording, deep brain stimulation and ablation, owning the procedure from diagnosis through treatment. The key elements
of our strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Introduce cortical strip and grid electrodes for the diagnosis of epilepsy in United States:</B>&nbsp;&nbsp;In the fourth quarter of 2018, we intend to complete the required testing to make a 510(k) device submission to the FDA for our cortical and strip electrodes for temporary (less than 30 day) use with recording, monitoring, and acute stimulation equipment for the recording, monitoring and stimulation of electrical signals on the surface of the brain. As described in more detail in &ldquo;Government Regulation&rdquo; below, if the FDA determines to accept our submission for substantive review, the FDA will aim to complete its review within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. If the FDA agrees that the device is substantially equivalent to a legally marketed predicate device, it will grant clearance to commercially market the device. Our initial product offering will be placed through traditional surgical means involving a craniotomy until such time, if any, that we launch our minimally invasive procedure. We believe, due to physician feedback, that our technology under development would represent a major improvement over existing cortical electrodes for the recording of brain activity. We are initially targeting epilepsy as we believe this is a clinical area of great need and a market that is underserved with a quick path to commercialization. We believe the largest and quickest-to-market geography for our cortical strip and grid technology under development is in the United States for a number of reasons, including the following:&nbsp;&nbsp;(i)&nbsp;many industry sources believe there is a large underserved U.S. market, (ii)&nbsp;healthy procedural reimbursement for centers and physicians, (iii)&nbsp;robust average selling prices, (iv)&nbsp;physician enthusiasm for our technology under development. We expect to hire direct experienced sales representatives to market our technology, if approved, in the United States. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Launch depth electrodes for sEEG recording:</B>&nbsp;&nbsp;Given the reluctance of patients to undergo epilepsy surgery due to its invasiveness, a number of epilepsy centers have adopted the use of depth electrodes, which are placed by drilling small holes into the patient&rsquo;s cranium, thereby avoiding a craniotomy. We believe our technology will offer advantages to current depth electrode technology and will enable us to offer a therapeutic solution using this technology in the future. As we develop our technology, we plan to release further information about the expected advantages of our technology over currently available therapies.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Introduce minimally invasive delivery system for cortical electrodes:&nbsp;&nbsp;</B>Cortical electrodes generally require a craniotomy, which is a very invasive procedure that can cause patient complications. Because of this, many patients have opted to not have epilepsy surgery, instead accepting the consequences and risks associated with epilepsy. We intend to develop a procedure that may include a delivery system placed through a small circular incision in the skull for implantation of the cortical grid and strip electrodes. We believe this will increase patient willingness to accept the surgery and increase market penetration. Until we are able to develop this procedure, if at all, our initial product offering will be placed through traditional surgical means involving a craniotomy and may be less likely to be adopted by physicians and patients due to unwillingness of patients to undergo epilepsy surgery.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Utilize these core technologies to develop all in one diagnostic and therapeutic solutions:&nbsp;&nbsp;</B>Patients currently undergo one surgical procedure for diagnosis (either to have a cortical electrode placed via a craniotomy or depth electrodes placed via holes drilled into the skull) and, hopefully after the brain recordings successfully indicate where the affected brain tissue is located, a second procedure or surgery is then required to treat the patient. There is strong physician interest in being able to perform both the diagnostic and therapeutic procedure concurrently. We are developing our technology with the goal of being able to offer this benefit although there can be no assurance that we will be able to do so. We are pursuing cortical grid, strip and depth electrode technology that can record brain activity (diagnose), ablate brain tissue and also provide both acute and long term stimulation. The technology has demonstrated these functions in acute and short term animal models; however, additional development is required to offer a device that has long term therapeutic application. These therapeutic technologies are expected to require more robust regulatory approvals for the United States, ranging from a 510(k) with human clinical data to pre-market approvals (&ldquo;<B><I>PMAs</I></B>&rdquo;). We will engage the FDA at the proper time to determine the most efficient clinical path.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Gain approval for other brain or motor related disorders such as Parkinson&rsquo;s with the therapeutic technologies developed for epilepsy:&nbsp;</B>While we are developing our technology for the diagnosis and treatment of epilepsy, we believe that our technology has strong application and utilization for other brain or motor related disorders such as Parkinson&rsquo;s disease, dystonia, essential tremors and facial pain as these diseases are currently treated with DBS if medications are not effective. As previously mentioned, we are planning to offer electrodes that can be implanted for long term stimulation applications, but such use will require that we pursue additional approvals from the FDA and any international regulatory bodies where we seek to commercialize our technology.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Explore partnerships with other companies that leverage our core technology:&nbsp;&nbsp;</B>Given that our technology enables, complements and/or competes with a number of companies that are in the market or attempting to enter the market with diagnostic or therapeutic technologies to treat brain related disorders, we believe there may be opportunities to establish mutually beneficial relationships. In addition, our technology may have application in cardiovascular, orthopedic and pain related indications that could benefit from a hi-fidelity thin film electrode product that can provide stimulation and/or ablation therapies.&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><B>Investigate the potential applications associated with Artificial Intelligence:</B>&nbsp;&nbsp;We have been informed by some of our corporate advisors that the ability to offer scale-able&nbsp;&nbsp;electrode technology that can provide thousands of electrodes in&nbsp;&nbsp;the brain may be helpful in treating medical conditions that may benefit from using artificial intelligence.&nbsp;&nbsp;The Company has formed an advisory board that will provide guidance to the Company as we continue to explore the opportunities in this exciting field.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Epilepsy Mapping and Monitoring</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Epileptic seizures occur when the neurons
in the brain miscommunicate. This miscommunication typically results in involuntary muscle seizure activities and/or periods of
perceptual disconnect where the individual appears frozen. Modern medical science has advanced the treatment of epileptic seizures
by mapping the electrical communication activity of neurons and understanding their special orientation in the brain. This mapping
is accomplished by access to the cranium (through a craniotomy) and placing conductive contacts on the brain directly. The craniotomy
procedure is very invasive, traumatic to the surrounding tissue, results in high patient down time, and increases the risk of infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Technology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to leverage scale-able technology
and produce ultra-thin, or paper-thin electrodes that allow for high-resolution and high-definition recordings, which would improve
mapping resolution and signal acquisition. If&nbsp;the Company is able to leverage scale-able technology, it would mean that our
technology would be able to incorporate smaller electrodes and thereby increase the number of electrodes on a given surface area.
We expect that this would increase the imaging resolution so that brain activity is displayed in greater definition. We also believe
that the electrodes&rsquo; unique thinness and flexibility will provide a less invasive approach to electrode placement. The electrodes
would be able to be placed through a small quarter size hole instead of by an invasive full craniotomy procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The images under &ldquo;Cortical Electrode,&rdquo;
from bottom to top, are images of our cortical electrode strip, our&nbsp;grid electrode, and the grid electrode on the brain, respectively.
The images under &ldquo;High Density Interconnect&rdquo; are both images of our product that connects our electrodes to the head
box, which is a piece of hardware that connects to electrodes to acquire, amplify, display, store and archive electrophysiological
signals, and is integrated as part of our manufactured electrode product. The images under &ldquo;Head Box&rdquo; and &ldquo;Signal
Monitoring and Mapping&rdquo; are images of the device which processes information received through the high density interconnect,
and a sample output of data acquisition, respectively, neither of which is one of a Company product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technology consists of three primary
types of cortical electrodes: grid electrodes, strip electrodes and dual-sided electrodes. These electrodes have a patented design
that utilizes proprietary processing and materials technology, which we believe will allow the electrodes to have improved features
over the current industry standard recording electrodes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What sets our technology apart from others
is the integration of state of the art design leveraging the latest in flexible printed circuit technology. We believe our patented
designs will provide the surgeon a higher tactile perspective on electrode placement allowing for ultra-precise neuron recording.
We expect the benefits of our electrode designs to include the ability to detect better defined margins between healthy tissue
and resect-able tissue, less immune-response from the brain and surrounding tissue, better signal acquisition due to superior conformability
of the electrode over the brain, improved flexibility that physicians have requested, which we expect will enable a minimally invasive
approach and the electrodes unique thinness that is unmatched by current products being used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Future of Epilepsy Mapping </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to develop superior &ldquo;scale-able&rdquo;
technology for future product system iterations in higher density contact placement. This will open the doors to other brain related
disease recording procedures by providing hi-fidelity, more accurate diagnostic capabilities and also the ability to provide an
all in one therapy capable of diagnosis, ablation and/or stimulation. Beyond the brain, we believe our technology under development
has applications in other neurological signal recording disease states related to voluntary or involuntary motor neuron abnormalities,
understanding sensory neuro behavior (pain), limb prosthetics and degenerative muscle disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Development and Regulatory
Pathway</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical Experience, Future Development
and Clinical Trial Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technology under development has not
been approved for commercialization by any U.S. or foreign regulatory body. To date, the Company has performed a number of bench
top (which includes feasibility testing) and pre-clinical tests (which include animal testing of device placement, ergonomics,
performance, ease of use, and other tests required by FDA regulations). As&nbsp;described in&nbsp;&ldquo;&mdash;Government Regulation&rdquo;
below, the Company will be required to perform additional testing of its technology in connection with obtaining regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In parallel with the development and testing
needed to launch our cortical strip and grid electrodes, we intend to expand our product offerings to include less invasive means
and all in one solutions, thus providing both patients and physicians better options to treat epilepsy and other brain related
disorders. While we expect to make modifications to this initial system, we believe that most of our future product development
initiatives will involve unique and transformational next generation technology that should drive further appeal of our products
with both physicians and patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are utilizing a number of resources
to develop these technologies. We license three critical patents from WARF that are the foundation of the technology we are developing
and intend to commercialize and benefit from the thin film technology know-how of Mayo Clinic doctors through our license and development
agreement. WARF, Mayo Clinic and Cleveland Clinic have been responsible for all pre-clinical studies of our technology under development
to date. See &ldquo;&mdash;WARF License&rdquo; and &ldquo;&mdash;Mayo Foundation for Medical Education and Research License and
Development Agreement&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below we have summarized, for each component
of our technology under development, the current stage of development, the pre-clinical testing done to date by WARF or Mayo Clinic
on such component, if any, our plans for further testing or clinical trials and our expectations regarding the requirements for
regulatory approval and timing of regulatory submissions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 24%; border-bottom: Black 1.5pt solid"><B>Technology</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24%; border-bottom: Black 1.5pt solid"><B>Stage of Development and Pre-Clinical Testing to Date</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 50%; border-bottom: Black 1.5pt solid; text-align: justify"><B>Additional Expected Steps for Regulatory Approval</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Cortical strip and grid electrodes for the diagnosis of epilepsy</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company has finalized the design for the product and there are
        no further expected changes to the device (&ldquo;design freeze&rdquo;).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-clinical testing and clinical testing on the final design
        has been conducted by Mayo Clinic and WARF (as described in &ldquo;Mayo Clinic Studies&rdquo; below).</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional pre-clinical electrical,
        sterilization and packing         testing is required prior to FDA 510(k) submission and scheduled to be completed by the
        end         of the fourth calendar quarter of 2018. Such additional testing will need to demonstrate sterilization validation
        and adoption (validation of processes used to sterilize the device), which we estimate will require $25,000.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There may be continued clinical evaluation of the technology
        under a pre-existing IRB research protocol approved by Mayo&rsquo;s institutional review board, which will provide us with additional
        clinical evidence that may assist with product acceptance and launch.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If testing in fourth calendar quarter of 2018 is successful, we expect
        to file for FDA 510(k) marketing clearance in the fourth calendar quarter of 2018, with commercial launch planned to begin in the United
        States in the first half of 2019 pending FDA 510(k) clearance and sufficient capital to hire sales representatives.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in&nbsp;&ldquo;&mdash;Government Regulation&rdquo;
        below, FDA 510(k) clearance often takes longer than 90 days, and clearance is never assured. The FDA may require further information,
        including clinical data which could delay the planned launch.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Depth electrodes for recording (diagnostic) purposes</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No design freeze; currently there are two leading alternative
        designs.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bench top testing and pre-clinical tests (animal testing) were
        conducted in the third quarter of 2018.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No clinical testing has been conducted to date.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently evaluating
two different designs for this product, and design freeze expected to be complete in the fourth calendar quarter of 2018. Additional
pre-clinical tests (including safety and performance tests) expected to occur on the final design in the fourth calendar quarter
of 2018.&nbsp;The tests will need to demonstrate: biocompatibility (including extractables/leachables (whether the product results
in any leaching of metals), and ease of implantation)), which we estimate will require $100,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sterilization validation and adoption, which we estimate will
require $25,000 to complete; and</P>

<P STYLE="margin: 0pt 0">Electrical safety, which we estimate will require $60,000 to complete.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pending the outcome of these tests, we expect to file for FDA
        510(k) marketing clearance in the second calendar quarter of 2019.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Minimally invasive cortical electrode delivery system</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No design freeze.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No pre-clinical testing or clinical testing has been conducted
        to date.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical testing is expected to
        begin by the first calendar quarter of 2019, and regulatory requirements will continue to be evaluated as we develop the
        design of this product.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Mayo Clinic is conducting testing of its own device. In
the event the Mayo Clinic completes development of its own device prior to us, we may forego completing development of our device
and seek to enter into an arrangement with Mayo Clinic relating to its device (such as, for example, an acquisition/licensing,
or distribution agreement).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">Otherwise, to complete development of our own device, testing will need to demonstrate design verification,
which we estimate will require $50,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><B>Depth electrode diagnostic and ablation devices</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 25%; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">No design freeze.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pre-clinical testing, including benchtop and animal testing,
        has been conducted on early designs.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">No clinical testing has been conducted
        to date.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has partnered with the Cleveland Clinic to co-develop
        the product.</P></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional pre-clinical testing at the
        Cleveland Clinic is expected to begin in the fourth calendar quarter of 2018.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the design is finalized we will be required to conduct
        additional pre-clinical testing, which may include additional benchtop or animal testing for safety and performance. Additionally,
        the FDA may require that we conduct human clinical studies.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No FDA feedback has been sought or
        received by us to date on the clinical process that may be required for an ablation indication, but we expect regulatory
        clearance/approval will require a more robust clinical process, which could range from 510(k) clearance with human clinical
        data to a PMA, depending on proposed indications for use. We expect that we will need to demonstrate design verification,
        which we estimate will require $75,000 to complete, biocompatibility, which we estimate will require $100,000 to complete,
        and sterilization validation and adoption, which we estimate will require $25,000 to complete. We may also need to
        demonstrate electrical safety, which we estimate will require $60,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future pre-clinical and clinical
testing requirements for regulatory clearance will continue to be evaluated as we develop the design of this product.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Depth electrode chronic stimulation devices</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">No design freeze.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">No pre-clinical testing, or clinical testing has been conducted
        to date.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This device is in early development, and
        we do not expect to begin conducting bench top nor pre-clinical testing until the fourth calendar quarter of 2019.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following a design freeze, we will be required to conduct additional
        pre-clinical testing, which may include additional benchtop or animal testing for safety and performance. Additionally, FDA-approved
        human clinical studies will most likely be required.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No FDA feedback has been sought
or received by us to date on the clinical process that will be required for chronic stimulation, but we expect regulatory clearance/approval
for chronic stimulation may require a more robust clinical process, which could range from 510(k) clearance with human clinical
data to a PMA.&nbsp;Because we have not yet met with the FDA, we cannot yet determine what clinical data and testing
we will need to complete or what the testing will need to demonstrate. However, we believe, based on the experience of competitors
for similar technology, that we will need to conduct clinical trials, which we estimate will require approximately $1,000,000,
as well as demonstrate biocompatibility, which we estimate will require $100,000 to complete, and demonstrate sterilization validation
and adoption, which we estimate will require $25,000 to complete.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mayo Clinic Studies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cortical technology for the diagnosis
of epilepsy has been tested by doctors at Mayo Clinic in multiple pre-clinical tests conducted from 2012 to 2017. In pre-clinical
models, doctors examined the biological impact on mammalian brains. Polyimide substrate electrodes (NeuroOne technology) were implanted
on the pig&rsquo;s brain for one week alongside standard competitive electrodes. The tissue underneath the two types of electrodes
was removed, fixed, stained, and examined for immunological responses. The results of a histological (evaluation of brain tissue
under a microscope) analysis showed reduced immunological reaction to prolonged polyimide substrate implants (NeuroOne technology)
compared to standard silicone substrate clinical electrodes. Electrophysiological recordings showed data obtained from polyimide
electrodes which showed the feasibility of high fidelity multi-scale electrophysiology while also displaying easier deployment
of polyimide electrodes (NeuroOne technology) through minimally invasive burr holes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, doctors implanted our polyimide
thin film electrodes on five human patients who were undergoing surgery to remove brain tissue for drug resistant epilepsy. Electrophysiological
recordings from the polyimide thin film technology displayed in each of these patients demonstrated micro-seizure activity due
to the high fidelity multi-scale electrophysiology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conclusions reached by the physicians at
Mayo Clinic were that thin, flexible polyimide electrodes (NeuroOne technology) provided recordings similar to standard clinical
electrodes with reduced immunological response. In addition, the flexibility of polyimide electrodes may reduce pain and swelling
associated with implantation of the device, and the single wire exiting the skull may reduce infection risk. The ability to record
micro-seizure and single neuron brain activity may also provide additional useful clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our thin film cortical implant
technology has been tested by researchers at the University of Wisconsin-Madison in multiple pre-clinical animal studies conducted
from 2006 to 2016, which included mice, rats and primates. In these studies, our technology was able to record brain activity from
different areas of the brain, was implanted in a minimally invasive fashion, electrically provided brain stimulation and tissue
ablation, and had increased flexibility compared to existing commercially available technology, which allowed the grids to conform
more easily to the brain surface (and may have reduced pain and swelling, compared to less flexible devices).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the size and maturity of the U.S.
market, our initial commercial focus, if our technology is approved for commercialization for the diagnosis of epilepsy in the
United States, will be to invest in developing a direct sales force and infrastructure to support the launch of the product in
the United States and target what we estimate to be approximately 188 Level 4 epilepsy centers along with their respective epilepsy
teams comprised of neurologists, neurosurgeons and technicians in the United States who are clinically active.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In parallel, we have evaluated the opportunity
to commercialize our products in select European markets and have concluded that while there is a market for our technology in
Europe, the regulatory changes in the European Union will require a lengthy and costly approval pathway. At this time, we will
utilize our resources to remain focused on the opportunity in the United States but will reexamine international opportunities
at a later time. If our technology is approved for commercialization for the diagnosis of epilepsy in the United States, we will
look to educate neurologists, neurosurgeons and primary care physicians on the advantages to existing epilepsy approaches through
a variety of targeted marketing tools and social media.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reimbursement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Coverage in the United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursement from private third-party
healthcare payors and, to a lesser extent, Medicare will be an important element of our success. Although CMS and third-party payors
have adopted coverage policies for our targeted indications, there is no guarantee this will continue at the same levels or at
all in the future. Current Procedural Terminology, or CPT, is a medical code set that is used to report medical, surgical and diagnostic
procedures and services to entities such as physicians, health insurance companies and accreditation organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable diagnostic CPT codes for mapping
(diagnosing) the brain for diagnostic procedures are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">61531 Subdural implantation of strip electrodes through
one or more burr or trephine (saw) hole(s) for long-term seizure monitoring;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">61533 Craniotomy with elevation of bone flap: for subdural
implantation of an electrode array, for long term seizure monitoring;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">61535 Craniotomy with elevation of bone flap; for removal
of epidural or subdural electrode array, without excision of cerebral tissue (separate procedure); and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">61760 Stereotactic implantation of depth electrodes
into the cerebrum for long term seizure monitoring.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regarding ICD-10 codes, the International
Classification of Diseases, Tenth Edition (ICD-10) is a clinical cataloging system that went into effect for the U.S. healthcare
industry on October 1, 2015, after a series of lengthy delays. Accounting for modern advances in clinical treatment and medical devices,
ICD-10 codes offer many more classification options compared to those found in its predecessor, ICD-9. Within the healthcare industry,
providers, coders, IT professionals, insurance carriers, government agencies and others use ICD codes to properly note diseases
on health records, to track epidemiological trends and to assist in medical reimbursement decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICD-10 codes for epilepsy are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">G40.0 Localization-related (focal) (partial) idiopathic
epilepsy and epileptic syndromes with seizures of localized onset;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.1 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.2 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.3 Generalized idiopathic epilepsy and epileptic syndromes;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.A Absence epileptic syndrome;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.4 Other generalized epilepsy and epileptic syndromes;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.50 Epileptic seizures related to external causes, not intractable;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.80 Other epilepsy; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">G40.82 Epileptic spasms.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that many of the indications
we are pursuing with our technologies are currently reimbursed on a widespread basis by Medicare, Medicaid and private insurance
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medicare, Medicaid, health maintenance
organizations and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and
the level of reimbursement of new medical devices, and, as a result, their coverage policies may be restrictive, or they may not
cover or provide adequate payment for our products. In order to obtain reimbursement arrangements, we may have to agree to a net
sales price lower than the net sales price we might charge in other sales channels. Our revenue may be limited by the continuing
efforts of government and third-party payors to contain or reduce the costs of healthcare through various increasingly sophisticated
means, such as requiring prospective reimbursement and second opinions, purchasing in groups, or redesigning benefits. Our future
dependence on the commercial success of our technologies makes us particularly susceptible to any cost containment or reduction
efforts. Accordingly, unless government and other third-party payors provide adequate coverage and reimbursement for our products
and the related insertion and removal procedures, our financial performance may be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Coverage Outside the United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we seek to commercialize in countries
outside the United States, coverage for epilepsy surgical procedures are available from certain governmental authorities, private
health insurance plans, and labor unions. Coverage systems in international markets vary significantly by country and, within some
countries, by region. If we seek to commercialize our technology, if approved, outside the United States, coverage approvals must
be obtained on a country-by-country, region-by-region or, in some instances, a case-by case basis. Based on our ongoing evaluation,
certain countries reimburse more highly than others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluated international opportunities
to market our technology under development. While we believe there is a market for our technology in Europe and other foreign jurisdictions,
we have determined not to seek to commercialize in any foreign jurisdictions due to time intensive approval processes, the lack
of certainty regarding approval, significant cost and the stringency of the regulatory approval process in Europe in particular,
among other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing, Supply and Quality Assurance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently outsource the supply and manufacture
of all components of our prototypes of our technology under development. We plan to continue with an outsourced manufacturing arrangement
for the foreseeable future. Our third-party manufacturers are recognized in their field for their competency to manufacture the
respective portions of our system and have quality systems established that meet FDA requirements. We believe the manufacturers
we currently utilize have sufficient capacity to meet our launch requirements if our technology under development is approved in
the future and are able to scale up their capacity relatively quickly with minimal capital investment. We believe that, as we increase
our demand in the future, our per-unit costs will decrease materially. We have also identified capable second source manufacturers
and suppliers in the event of disruption from any of our primary vendors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our suppliers meet the latest ISO&nbsp;13485
certification, which includes design control requirements. As a medical device developer, the facilities of our sterilization and
other critical suppliers are subject to periodic inspection by the FDA and corresponding state and foreign agencies. We believe
that our quality systems and those of our suppliers are robust and achieve high product quality. We plan to audit our suppliers
periodically to ensure conformity with the specifications, policies and procedures for our devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development team, which
includes our Chief Development Officer who is a full-time employee, and two third party consultants who perform research and development
activities for us, is focused on the development of thin film cortical grid and strip electrodes and depth electrodes for recording,
ablation and chronic stimulation for brain related disorders. Our research and development expenses were $0.7 million for the year ended December&nbsp;31, 2017 and $0.7 for the nine months ended September&nbsp;30,&nbsp;2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the market for Epilepsy diagnosis, our
cortical strip, sheet and depth electrode technology will likely compete with Integra Life Science&rsquo;s Integra Epilepsy Strip,
Grid and depth electrodes, which provide a similar function to our diagnostic technologies under development. These products are
well established in the marketplace and Integra has greater resources than us, which could allow them to innovate faster. Ad-Tech
Medical Instrument Corporation&rsquo;s Epilepsy/LTM (subdural grid, strip and depth) electrodes, which have become the market leaders
for diagnostic mapping in epilepsy, and PMT Corporation&rsquo;s Cortac Strips and grid electrodes and Depthalon depth electrodes
are used for recording brain activity similar to other competitive technologies. Today&rsquo;s success rates for seizure free <B STYLE="font-style: normal; font-weight: normal">post</B>-operative
conditions remain at 50%, which has limited patients&rsquo; willingness to undergo the currently highly invasive surgical procedure.
We will also compete against other companies in early stages of development of thin film technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the neuro-ablation market, we expect
to compete with Medtronic&rsquo;s Visualase guided-laser ablation technology and Monteris Medical&rsquo;s NeuroBlate technology,
which use MRI guided laser surgical ablation for use to ablate, necrotize or coagulate soft tissue through interstitial irradiation
or thermal therapy in medicine and surgery in the discipline of neurosurgery with 1064 nm lasers. Their website claims it is used
for ablation in the brain for soft tissue and tumors. We believe there are other laser-based systems in development that will compete
with these technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the neurostimulation market, we expect
to compete with NeuroPace&rsquo;s RNS system approved for epilepsy, Medtronic&rsquo;s Activa system approved for Parkinson&rsquo;s
disease, Boston Scientific Vercise (indicated for Parkinson&rsquo;s, dystonia and essential tremors), Abbott/St. Jude Medical&rsquo;s
Infinity DBS system (approved for Parkinson&rsquo;s disease and essential tremors), Liva Nova/Cyberonic&rsquo;s VNS therapy intended
for patients suffering with epilepsy. We believe there are additional companies pursuing this high growth space although none are
expected to be commercially available in 2018 based on current reports. Although we will face potential competition from many different
sources, we believe that our technology, knowledge, experience and scientific resources will provide us with competitive advantages.
We expect the key competitive factors affecting the success of our cortical strip and sheet electrodes under development, if successfully
developed and approved, are likely to be: hi-fidelity recording that allows for detection of pre-seizure activity, ability to place
the devices minimally invasively, deliverability of cortical grid, strip and depth electrode technology, ability to offer grid,
strip and depth electrodes in various electrode shapes and sizes, potential reduction in infections and ability to record brain
activity both on the surface using cortical grid and strip technology and deeper into the brain using depth electrodes concurrently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of the companies against which we
may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers
and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and
retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WARF License</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an Exclusive Start-Up Company License
Agreement with WARF, pursuant to which WARF has granted us the WARF License, to make, use and sell, in the United States only,
products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. In exchange
for the WARF License, we have agreed to pay WARF $55,000 (representing a license fee) upon the earliest to occur of the date we
cumulatively raise at least $3.0 million in financing, which threshold was recently met, the date of a change of control, or our
revenue reaching a specified threshold amount, and to pay $65,000 (representing reimbursement for costs incurred by WARF in maintaining
the licensed patents) upon the earliest to occur of the date that we cumulatively raise at least $5 million in financing, the date
of a change of control, or our revenue reaching a specified threshold amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial $55,000 payment was due on
May 3, 2018 and was paid April 22, 2018. We have also agreed to pay WARF a royalty equal to a single-digit percentage of our product
sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2019, $100,000 for 2020 and $150,000 for
2021 and each calendar year thereafter that the WARF License is in effect. If we or any of our sublicenses contest the validity
of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found
to be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for the remaining term of
the WARF License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to diligently develop, manufacture,
market and sell products under the WARF License in the United States during the term of the agreement and, specifically, that we
would submit a business plan to WARF by February 1, 2018, which we submitted on January 18, 2018, and would file an application
for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate this license in the event that we fail to meet
these milestones on 30 days&rsquo; written notice, if we default on the payments of amounts due to WARF or fail to timely submit
development reports, actively pursue our development plan or breach any other covenant in the WARF License and fail to remedy such
default in 90 days or in the event of certain bankruptcy events involving us. WARF may also terminate the WARF License (i) on 90
days&rsquo; notice if we fail to have commercial sales of one or more FDA-approved products under the WARF License by March 31,
2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters.
The WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. We
expect the latest expiration of a licensed patent to occur in 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, WARF reserves the right to
grant non-profit research institutions and government agencies non-exclusive licenses to practice and use the inventions of the
licensed patents for non-commercial research purposes, and we grant WARF a non-exclusive, sub licensable, royalty-free right and
license for non-commercial research purposes to use improvements to the licensed patents. In the event that we discontinue use
or commercialization of the licensed patents or improvements thereon, we must grant WARF an option to obtain a non-exclusive, sub-licensable
royalty-bearing license to use the improvements for commercial purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;Risk Factors&rdquo;&mdash; We
depend on intellectual property licensed from Wisconsin Alumni Research Foundation for our technology under development, and the
termination of this license would harm our business&rdquo; for additional information regarding the WARF License and our past breach
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mayo Foundation for Medical Education
and Research License and Development Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into the Mayo Development
Agreement with Mayo Foundation for Medical Education and Research (&ldquo;<B><I>Mayo</I></B>&rdquo;) to license worldwide (i) certain
know how for the development and commercialization of products, methods and processes related to flexible circuit thin film technology
for the recording of tissue and (ii) the products developed therefrom, and to partner with Mayo to assist the Company in the investigation,
research application, development and improvement of such technology. Mayo has agreed to assist us by providing access to certain
individuals at Mayo, or the Mayo Principal Investigators, in developing our cortical thin film flexible circuit technology, including
prototype development, animal testing, protocol development for human and animal use, abstract development and presentation and
access to and license of any intellectual property that the Mayo Principal Investigators develop relating to the procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 25, 2017, prior to the closing of
the Acquisition, NeuroOne, Inc. issued Mayo 50,556 shares of common stock of NeuroOne, Inc. (the &ldquo;<B><I>NeuroOne Shares</I></B>&rdquo;),
pursuant to a subscription agreement, which shares were converted into 859,976 shares of the Company&rsquo;s common stock (&ldquo;<B><I>Common
Stock</I></B>&rdquo;) at the closing of the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not any such technology,
product, method, process, device or delivery system is developed, we agreed, in consideration for Mayo&rsquo;s efforts under
the Mayo Development Agreement, to pay Mayo a cash payment of approximately $92,000 on the earlier of September 30, 2017 or
the date we raise a minimum amount of financing. We did not make this payment by September 30, 2017 and breached this
provision of the Mayo Development Agreement. Mayo granted us an extension of this deadline to December 31, 2017, and we made
this payment within such extended deadline&nbsp;period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, we have agreed to pay Mayo a royalty
equal to a single-digit percentage of our product sales pursuant to the Mayo Development Agreement. Mayo may purchase any developed
products licensed under the Mayo Development Agreement at the best price offered by us to the end user in the prior year. The Mayo
Development Agreement generally will expire in October 2034, unless the Mayo know-how and improvements under the Mayo Development
Agreement remain in use, and the Mayo Development Agreement may be terminated by Mayo for cause or under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information regarding the
Mayo Development Agreement and our past breach thereof, see &ldquo;Risk Factors&mdash;We depend on our partnership with Mayo Foundation
for Medical Education and Research to license certain know how for the development and commercialization of our technology. Termination
of this partnership would harm our business, and even if this partnership continues, it may not be successful.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protection of our intellectual property
is a strategic priority for our business. We rely on a combination of patents, trademarks, copyrights, trade secrets as well as
nondisclosure and assignment of invention agreements, material transfer agreements, confidentiality agreements and other measures
to protect our intellectual property and other proprietary rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 30, 2018, our patent estate
consists of three issued United States patents licensed from WARF covering a neural probe array and thin-film micro electrode array
and method and two pending U.&nbsp;S. provisional patent applications filed by us on March 31, 2017 and October 26, 2017 covering
our applications and additional devices used during the diagnostic and therapeutic ablation and stimulation procedures. We also
filed a patent application on April 2, 2018, which was derived from the two provisional patents referenced above and are awaiting
a response from the U.&nbsp;S. and International Patent Offices. The licensed issued patents expire between 2025 and 2030, subject
to any patent extensions that may be available for such patents. If a patent or patents are issued on our pending patent application,
the resulting patent is projected to expire in 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our patent application may not result in
an issued patent, and any patents that have been issued or may be issued in the future may not protect the commercially important
aspects of our technology. Furthermore, the validity and enforceability of our issued patents may be challenged by third parties
and our patents could be invalidated or modified by the issuing governmental authority. Third parties may independently develop
technology that is not covered by our patents that is similar to, or competes with, our technology. In addition, our intellectual
property may be infringed or misappropriated by third parties, particularly in foreign countries where the laws and governmental
authorities may not protect our proprietary rights as effectively as those in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The medical device industry in general,
and the recording, ablation and neurostimulation sector of this industry in particular, are characterized by the existence of a
large number of patents and frequent litigation based on assertions of patent infringement. We are aware of numerous patents issued
to third parties that may relate to the technology used in our business, including the design and manufacture of electrodes and
pulse generators, as well as methods for device placement. Each of these patents contains multiple claims, any one of which may
be independently asserted against us. The owners of these patents may assert that the manufacture, use, sale or offer for sale
of our cortical strip and sheet electrodes infringe one or more claims of their patents. Furthermore, there may be additional patents
issued to third parties of which we are presently unaware that may relate to aspects of our technology that such third parties
could assert against us and materially and adversely affect our business. In addition, because patent applications can take many
years to issue, there may be patent applications that are currently pending and unknown to us, which may later result in issued
patents that third parties could assert against us and materially and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any adverse determination in litigations,
post grant trial proceedings, including interference proceedings, at the Patent Office relating to intellectual property to which
we are or may become a party could subject us to significant liabilities to third parties or require us to seek licenses from third
parties, and result in the cancellation and/or invalidation of our intellectual property. Furthermore, if a court finds that we
have willfully infringed a third party&rsquo;s intellectual property, we could be required to pay treble damages and/or attorney
fees for the prevailing party, in addition to other penalties. Although intellectual property disputes in the medical device area
are often settled through licensing or similar arrangements, costs associated with such arrangements can be substantial and often
require ongoing royalty payments. We may be unable to obtain necessary licenses on satisfactory terms, if at all. If we do not
obtain necessary licenses, we may not be able to redesign our products to avoid infringement; if we are able to redesign our products
to avoid infringement, we may not receive FDA approval in a timely manner. Adverse determinations in a judicial or administrative
proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our products, which could have
a significant adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have one pending U.S. trademark application
for the &ldquo;NeuroOne<SUP>TM</SUP>&rdquo; trademark. We were issued a notice of allowance from the U.S. Trademark and Patent
Office in December 2017 and will provide proof of use to the U.S. Trademark and Patent Office in the near future in order to establish
registration of the trademark. The trademark is subject to a 30 day period in which it can be contested by the public. If not contested,
the U.S. Trademark and Patent Office will issue the registered trademark for the &ldquo;NeuroOne&rdquo; name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trade Secrets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets, technical
know-how and continuing innovation to develop and maintain our competitive position. We seek to protect such intellectual property
and proprietary information by generally requiring our employees, consultants, contractors, scientific collaborators and other
advisors to execute non-disclosure and assignment of invention agreements upon the commencement of their employment or engagement
as the case may be. Our agreements with our employees prohibit them from providing us with any intellectual property or proprietary
information of third parties. We also generally require confidentiality agreements or material transfer agreements with third parties
that receive or have access to our confidential information, data or other materials. Notwithstanding the foregoing, there can
be no assurance that our employees and third parties that have access to our confidential proprietary information will abide by
the terms of their agreements. Despite the measures that we take to protect our intellectual property and confidential information,
unauthorized third parties may copy aspects of our products or obtain and use our proprietary information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cortical strip, grid and depth electrodes
are a medical device subject to extensive and ongoing regulation by the FDA, the U.S. CMS, the European Commission, and regulatory
bodies in other countries. Regulations cover virtually every critical aspect of a medical device company&rsquo;s business operations,
including research activities, product development, quality and risk management, contracting, reimbursement, medical communications,
and sales and marketing. In the United States, the Federal Food, Drug and Cosmetic Act, or FDCA, and the implementing regulations
of the FDA govern product design and development, pre-clinical and clinical testing, premarket clearance or approval, product manufacturing,
quality systems, import and export, product labeling, product storage, recalls and field safety corrective actions, advertising
and promotion, product sales and distribution, and post-market clinical surveillance. Our business is subject to federal, state,
local, and foreign regulations, such as ISO&nbsp;13485, ISO&nbsp;14971, FDA&rsquo;s Quality System Regulation, or QSR, contained
in 21 CFR Part&nbsp;820, and the European Commission&rsquo;s Directive 93/42/EEC concerning medical devices and its amendments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory Framework in the United
States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Device classification</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA characterizes medical devices into
one of three classes. Devices that are considered by the FDA to pose lower risk are classified as Class&nbsp;I or II. Class&nbsp;I
devices are subject to controls for labeling, pre-market notification and adherence to the FDA&rsquo;s QSR. This pertains to manufacturers&rsquo;
methods and documentation of the design, testing, production, control quality assurance, labeling, packaging, sterilization, storage
and shipping of products, but are usually exempt from premarket notification requirements. Class&nbsp;II devices are subject to
the same general controls but may be subject to special controls such as performance standards, post-market surveillance, FDA guidelines,
or particularized labeling, and may also require clinical testing prior to clearance or approval. Class&nbsp;III devices are those
for which insufficient information exists to assure safety and effectiveness solely through general or special controls, including
devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present
a potential, unreasonable risk of illness or injury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some Class&nbsp;I and Class&nbsp;II devices
are exempted by regulation from the pre-market notification requirement under Section&nbsp;510(k) of the FDCA, also referred to
as a 510(k) clearance, and the requirement of compliance with substantially all of the QSR. However, a pre-market approval, or
PMA application, is required for devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting
or certain implantable devices, or those that are &ldquo;not substantially equivalent&rdquo; either to a device previously cleared
through the 510(k) process or to a &ldquo;preamendment&rdquo; Class&nbsp;III device in commercial distribution before May&nbsp;28,
1976 when PMA applications were not required. The PMA approval process is more comprehensive than the 510(k) clearance process
and typically takes several years to complete. Based on FDA definitions, we believe our diagnostic strip, grid and depth electrode
technology will be categorized by the FDA as a Class II device that does not require clinical testing and can be filed as a 510(k),
similar to existing competitive technology. The Company expects that indications for treating epilepsy, Parkinson&rsquo;s and other
patients suffering from motor related neurological deficiencies via a permanent implant for chronic treatment will require a PMA
process to commercially distribute in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The 510(k) clearance process</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 510(k) clearance process, the
manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &ldquo;substantially equivalent&rdquo;
to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device
that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has
been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k)
process. To be &ldquo;substantially equivalent,&rdquo; the proposed device must have the same intended use as the predicate device,
and either have the same technological characteristics as the predicate device or have different technological characteristics
and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to
support substantial equivalence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a 510(k) premarket notification is
submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review,
the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute,
the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical
matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared
without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial
equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent,
it will grant clearance to commercially market the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA determines that the device is
not &ldquo;substantially equivalent&rdquo; to a predicate device, or if the device is automatically classified into Class III,
the device sponsor must then fulfill the more rigorous premarketing requirements of the PMA approval process, or seek reclassification
of the device through the de novo process. The de novo classification process is an alternate pathway to classify medical devices
that are automatically classified into Class III but which are low to moderate risk. A manufacturer can submit a petition for direct
de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device
presents a moderate or low risk. De novo classification may also be available after receipt of a &ldquo;not substantially equivalent&rdquo;
letter following submission of a 510(k) to FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a device receives 510(k) clearance,
any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in
its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA
requires each manufacturer to determine whether the proposed change requires a new submission in the first instance, but the FDA
can review any such decision and disagree with a manufacturer&rsquo;s determination. Many minor modifications are accomplished
by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu
of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection.
If the FDA disagrees with a manufacturer&rsquo;s determination regarding whether a new premarket submission is required for the
modification of an existing 510(k)-cleared device, the FDA can require the manufacturer to cease marketing and/or recall the modified
device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose
significant regulatory fines or penalties for failure to submit the requisite application(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The PMA approval process</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following receipt of a PMA application,
the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive
review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin
the review. The FDA has 180 days to review a filed PMA application, although the review of an application more often occurs over
a significantly longer period of time. During this review period, the FDA may request additional information or clarification of
information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&rsquo;s
response to deficiencies communicated by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving or denying a PMA, an FDA
advisory committee may review the PMA at a public meeting and provide the FDA with the committee&rsquo;s recommendation on whether
the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations
of an advisory committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to approval of a PMA, the FDA may
conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and
processes. Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly
longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the device may not be safe, effective, reliable or
accurate to the FDA&rsquo;s satisfaction;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the data from pre-clinical studies and clinical trials
may be insufficient to support approval;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the manufacturing process or facilities may not meet
applicable requirements; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in FDA approval policies or adoption of new
regulations may require additional data.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an FDA evaluation of a PMA application
is favorable, the FDA will either issue an approval letter, or approvable letter, which usually contains a number of conditions
that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction
of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of a device, subject to the conditions
of approval and the limitations established in the approval letter. If the FDA&rsquo;s evaluation of a PMA application or manufacturing
facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine
that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years
while the trials are conducted and data is submitted in an amendment to the PMA. The PMA process can be expensive, uncertain and
lengthy and a number of devices for which FDA approval has been sought by other companies have never been approved by the FDA for
marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New PMA applications or PMA supplements
may be required for modifications to the manufacturing process, labeling, device specifications, materials or design of a device
that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an
initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered
by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory
panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are typically required
to support a PMA application and are sometimes required for a 510(k) clearance. These trials generally require submission of an
application for an IDE, to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing
results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application
must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a non-significant risk
device and eligible for abbreviated IDE requirements. Generally, clinical trials for a significant risk device may begin once the
IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review
boards at the clinical trial sites. The FDA&rsquo;s approval of an IDE allows clinical testing to go forward, but it does not bind
the FDA to accept the results of the trial as sufficient to prove the product&rsquo;s safety and efficacy, even if the trial meets
its intended success criteria. All clinical trials must be conducted in accordance with the FDA&rsquo;s IDE regulations that govern
investigational device labeling, prohibit promotion, and specify an array of recordkeeping, reporting and monitoring responsibilities
of study sponsors and study investigators. Clinical trials must further comply with the FDA&rsquo;s regulations for institutional
review board approval and for informed consent and other human subject protections. Required records and reports are subject to
inspection by the FDA. The results of clinical testing may be unfavorable or, even if the intended safety and efficacy success
criteria are achieved, may not be considered sufficient for the FDA to grant approval or clearance of a product. Clinical trials
must be entered into the clinical trials registry at clinicaltrials.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commencement or completion of any clinical
trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but
not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the FDA or other regulatory authorities do not approve
a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">patients do not enroll in clinical trials at the rate
expected;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">patients, sponsor (NeuroOne) or study sites do not
comply with trial protocols;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">patient follow-up is not at the rate expected;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">patients experience adverse side effects;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">patients die during a clinical trial, even though their
death may not be related to the products that are part of our trial;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">institutional review boards and third-party clinical
investigators may delay or reject the trial protocol;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">third-party clinical investigators decline to participate
in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, good clinical
practices or other FDA requirements;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the sponsor (NeuroOne) or third-party organizations
do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol
or investigational or statistical plans;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">third-party clinical investigators have significant
financial interests related to the sponsor (NeuroOne) or the study that the FDA deems to make the study results unreliable, or
the company or investigators fail to disclose such interests;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulatory inspections of our clinical trials or manufacturing
facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in governmental regulations or administrative
actions;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the interim or final results of the clinical trial
are inconclusive or unfavorable as to safety or efficacy; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the FDA concludes that our trial design is inadequate
to demonstrate safety and efficacy.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>International Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International sales of medical devices
are subject to local government regulations, which may vary substantially from country to country. The time required to obtain
approval in another country may be longer or shorter than that required for FDA approval, and the requirements may differ. There
is a trend towards harmonization of quality system standards among the European Union, United States, Canada and various other
industrialized countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary regulatory body in Europe is
that of the European Union, the European Commission, which includes most of the major countries in Europe. Other countries, such
as Switzerland, have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices.
The European Union has adopted numerous directives and standards regulating the design, manufacture, clinical trials, labeling
and adverse event reporting for medical devices. Devices that comply with the requirements of these relevant directives will be
entitled to bear the CE conformity marking, indicating that the device conforms to the essential requirements of the applicable
directives and, accordingly, can be commercially distributed throughout Europe. The method of assessing conformity varies depending
on the class of the product, but normally involves a combination of self-assessment by the manufacturer and a third party assessment
by a &ldquo;Notified Body.&rdquo; This third-party assessment may consist of an audit of the manufacturer&rsquo;s quality system
and specific testing of the manufacturer&rsquo;s product. An assessment by a Notified Body of one country within the European Union
is required in order for a manufacturer to commercially distribute the product throughout the European Union. Additional local
requirements may apply on a country-by-country basis. Outside of the European Union, regulatory approval would need to be sought
on a country-by-country basis in order for us to market our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices in Europe are classified
into four primary categories.&nbsp; They are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Non-invasive devices;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Invasive medical devices;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Active medical devices; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Special Rules (including contraceptive, disinfectant, and radiological diagnostic medical devices).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Devices are further segmented into the
classes noted below. In Vitro Diagnostic devices have their own classification scheme and while active implantable devices do not
follow the same classification system as provided by the Medical Device Directive, they are subject to similar requirements as
Class III devices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Class I &ndash; Provided non-sterile or do not have a measuring function (low risk);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Class I &ndash; Provided sterile and/or have a measuring function (low/medium risk);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Class IIa (medium risk);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Class IIb (medium/high risk); and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Class III (high risk).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a review of our technology, an international
regulatory consultant advised us that our strip, grid and depth electrode diagnostic technology is likely a Class III device (since
it comes into contact with the central nervous system) which will require a lengthy approval process as a design dossier including
clinical data will be required for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Regulatory Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after a device receives clearance
or approval and is placed in commercial distribution, numerous regulatory requirements apply. These include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">establishment registration and device listing;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">QSR, which requires manufacturers, including third party manufacturers, to follow stringent design, testing, risk management, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">labeling regulations that prohibit the promotion of products for uncleared, unapproved or &ldquo;off-label&rdquo; uses, and impose other restrictions on labeling, advertising and promotion;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">MDR regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">voluntary and mandatory device recalls to address problems when a device is defective and could be a risk to health; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">corrections and removals reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, the FDA may require us to conduct
post-market surveillance studies or establish and maintain a system for tracking our products through the chain of distribution
to the patient level. The FDA enforces regulatory requirements by conducting periodic, unannounced inspections and market surveillance.
Inspections may include the manufacturing facilities of our subcontractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to comply with applicable regulatory
requirements can result in enforcement actions by the FDA and other regulatory agencies. These may include any of the following
sanctions or consequences:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">warning letters or untitled letters that require corrective action;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">fines and civil penalties;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">unanticipated expenditures;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">delays in approving or refusal to approve future products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">suspension or withdrawal of FDA clearance or approval;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">product recall or seizure; interruption of production;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">operating restrictions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">injunctions; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">criminal prosecution.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;Our contract manufacturers, specification developers and
some suppliers of components or device accessories, also are required to manufacture our products in compliance with current good
manufacturing practice requirements set forth in the QSR. The QSR requires a quality system for the design, manufacture, packaging,
labeling, storage, installation and servicing of marketed devices, and it includes extensive requirements with respect to quality
management and organization, device design, buildings, equipment, purchase and handling of components or services, production and
process controls, packaging and labeling controls, device evaluation, distribution, installation, complaint handling, servicing,
and record keeping. The FDA evaluates compliance with the QSR through periodic unannounced inspections that may include the manufacturing
facilities of our subcontractors. If the FDA believes that any of our contract manufacturers or regulated suppliers are not in
compliance with these requirements, it can shut down such manufacturing operations, require recall of our products, refuse to approve
new marketing applications, institute legal proceedings to detain or seize products, enjoin future violations or assess civil and
criminal penalties against us or our officers or other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Health Insurance Portability and
Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) and Similar Foreign and State Laws and Regulations Affecting the Transmission,
Security and Privacy of Health Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also be subject to data privacy
and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes
specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among
other things, HITECH makes HIPAA&rsquo;s security standards directly applicable to business associates, defined as service providers
of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service
for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&rsquo;
fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of
health information in certain circumstances, many of which differ from HIPAA and each other in significant ways and may not have
the same effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign data privacy regulations, such
as the EU Data Protection Directive (Directive 95/46/EC), the country-specific regulations that implement Directive 95/46/EC, and
the EU General Data Protection Regulation also govern the processing of personally identifiable data, and may be stricter than
U.S. laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fraud and Abuse Laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to FDA restrictions, there
are numerous U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral
laws. Our relationships with healthcare providers and other third parties are subject to scrutiny under these laws. Violations
of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation
in federal and state healthcare programs, including the Medicare, Medicaid and Veterans Administration health programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Federal Anti-Kickback and Self-Referral
Laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal Anti-Kickback Statute prohibits
persons from knowingly and willfully soliciting, receiving, offering or providing remuneration (including any kickback, bribe or
rebate), directly or indirectly, overtly or covertly, to induce either the referral of an individual, or the furnishing, recommending,
or arranging of a good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid
or other federal healthcare programs. The term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value,
including such items as gifts, discounts, the furnishing of supplies or equipment, credit arrangements, waiver of payments and
providing anything at less than its fair market value. Although there are a number of statutory exceptions and regulatory safe
harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that
involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny
if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory
exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality
of the arrangement will be evaluated on a case-by-case basis based on a review of all its relevant facts and circumstances. Several
courts have interpreted the statute&rsquo;s intent requirement to mean that if any one purpose of an arrangement involving remuneration
is to induce referrals of (or purchases, or recommendations related to) federal healthcare covered business, the Anti-Kickback
Statute has been implicated and potentially violated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalties for violating the federal
Anti-Kickback Statute include imprisonment for up to five years, fines of up to $25,000 per violation and possible exclusion from
federal healthcare programs such as Medicare and Medicaid. Many states have adopted prohibitions similar to the federal Anti-Kickback
Statute, some of which do not have the same exceptions and apply to the referral of patients for healthcare services reimbursed
by any source, not only by the Medicare and Medicaid programs. Further, the Anti-Kickback Statute was amended by the Patient Protection
and Affordable Care Act (&ldquo;<B><I>ACA</I></B>&rdquo;). Specifically, as noted above, under the Anti-Kickback Statute, the government
must prove the defendant acted &ldquo;knowingly&rdquo; to prove a violation occurred. The ACA added a provision to clarify that
with respect to violations of the Anti-Kickback Statute, &ldquo;a person need not have actual knowledge&rdquo; of the statute or
specific intent to commit a violation of the statute. This change effectively overturns case law interpretations that set a higher
standard under which prosecutors had to prove the specific intent to violate the law. In addition, the ACA codified case law that
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to provide the initial training
to providers and patients necessary for appropriate use of our technology either through our own educators or by contracting with
outside educators that have completed an appropriate training course. Outside educators are reimbursed for their services at fair
market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Noncompliance with the federal Anti-Kickback
Statute could result in our exclusion from Medicare, Medicaid or other governmental programs, restrictions on our ability to operate
in certain jurisdictions, and civil and criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal Physician Self-Referral Prohibition,
commonly known as the &ldquo;Stark Law,&rdquo; prohibits a physician from ordering &ldquo;designated health services,&rdquo; including
durable medical equipment, for Medicare and Medicaid patients from entities with which the physician (or an immediate family member)
has a &ldquo;financial relationship.&rdquo; Financial relationships include both compensation arrangements and investment and ownership
interests. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliant
arrangement, civil penalties, and exclusion from Medicare, Medicaid or other governmental programs. We believe that we have structured
our provider arrangements to comply with current Stark Law requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevertheless, a determination of liability
under such laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, as some of these laws are
still evolving, we lack definitive guidance as to the application of certain key aspects of these laws as they relate to our arrangements
with providers with respect to patient training. We cannot predict the final form that these regulations will take or the effect
that the final regulations will have on us. As a result, our provider and training arrangements may ultimately be found to be not
in compliance with applicable federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Federal False Claims Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Federal False Claims Act provides,
in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly presented, or caused
to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used
a false record to get a claim approved. In addition, amendments in 1986 to the Federal False Claims Act have made it easier for
private parties to bring &ldquo;qui tam&rdquo; whistleblower lawsuits against companies under the Federal False Claims Act. Penalties
include fines ranging from $5,500 to $11,000 for each false claim, plus three times the amount of damages that the federal government
sustained because of the act of that person. Qui tam actions have increased significantly in recent years, causing greater numbers
of healthcare companies to have to defend a false claim action, pay fines or be excluded from Medicare, Medicaid or other federal
or state healthcare programs as a result of an investigation arising out of such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are other federal anti-fraud laws
that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit
program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for healthcare benefits, items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, HIPAA established two federal
crimes related to making false statements in relation to healthcare matters. The healthcare fraud statute prohibits knowingly and
willfully executing a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is
a felony and may result in fines, imprisonment or exclusion from government sponsored programs. The false statements statute prohibits
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute
is a felony and may result in fines or imprisonment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Civil Monetary Penalties Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the Anti-Kickback Statute
and the False Claims Act, the federal government has the authority to seek civil monetary penalties, or CMPs, assessments, and
exclusion against an individual or entity based on a wide variety of prohibited conduct. For example, the Civil Monetary Penalties
Law authorizes the imposition of substantial CMPs against an entity that engages in activities including, but not limited to: (1)
knowingly presenting or causing to be presented, a claim for services not provided as claimed or which is otherwise false or fraudulent
in any way; (2) knowingly giving or causing to be given false or misleading information reasonably expected to influence the decision
to discharge a patient; (3) offering or giving remuneration to any beneficiary of a federal health care program likely to influence
the receipt of reimbursable items or services; (4) arranging for reimbursable services with an entity which is excluded from participation
from a federal health care program; (5) knowingly or willfully soliciting or receiving remuneration for a referral of a federal
health care program beneficiary; or (6) using a payment intended for a federal health care program beneficiary for another use.
The government is authorized to seek different amounts of CMPs and assessments based on underlying violation. For false or fraudulent
claims, the government may seek a penalty of up to $10,000 for each item or service improperly claimed, and an assessment of up
to three times the amount improperly claimed. For kickback violations, the government may seek a penalty of up to $50,000 for each
improper act and damages of up to three times the amount of remuneration at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>State Fraud and Abuse Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many states have also adopted some form
of anti-kickback and anti-referral laws and a false claims act. We believe that we are in conformance to such laws. Nevertheless,
a determination of liability under such laws could result in fines and penalties and restrictions on our ability to operate in
these jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Physician Payment Sunshine Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transparency laws regarding payments or
other items of value provided to healthcare providers and teaching hospitals may also impact our business practices. The federal
Physician Payment Sunshine Act requires most medical device manufacturers to report annually to the Secretary of Human Health Services
financial arrangements, payments, or other transfers of value made by that entity to physicians and teaching hospitals. The payment
information is made publicly available in a searchable format on a CMS website. Over the next several years, we will need to dedicate
significant resources to establish and maintain systems and processes in order to comply with these regulations. Failure to comply
with the reporting requirements can result in significant civil monetary penalties. Similar laws have been enacted or are under
consideration in foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Foreign Corrupt Practices Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FCPA prohibits U.S. corporations and
their representatives from offering, promising, authorizing or making corrupt payments, gifts or transfers to any foreign government
official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The
FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the
company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities
that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment,
disgorgement, oversight, and debarment from government contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 30, 2018, we had three employees,
all of whom are full-time, and all of whom are located in the United States, and we also retained the services of approximately seven
regular consultants. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We
consider our relationship with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2018, we entered into a
sublease agreement to sublease office space at 10901 Red Circle Drive, Suite 150, Minnetonka, Minnesota 54343, from December 1,
2018 through October 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at c/o David Rosa, 10901 Red Circle Drive, Suite 150, Minnetonka, Minnesota 54343, and our telephone number is 952-237-7412. Our
website address is <U>www.neurooneinc.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_004"></A>ITEM 1A. RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>Our business, prospects,
financial condition or results of operations could be materially adversely affected by any of the risks and uncertainties set forth
below, as well as in any amendments or updates reflected in subsequent filings with the SEC. In assessing these risks, you should
also refer to other information contained in this Transition Report, including our financial statements and related notes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We have incurred
significant operating losses since inception and cannot assure you that we will ever achieve or sustain profitability. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have incurred losses
since inception, and as of September 30, 2018 and December 31, 2017, we had an accumulated deficit of $10.5 million and $5.3 million,
respectively, primarily as a result of expenses incurred in connection with our general and administrative expenses associated
with our operations and from our research and development programs. We expect to continue to incur significant expenses and increasing
operating and net losses for the foreseeable future. To date, we have financed our operations primarily through debt and equity
financings, and our primary activities have been limited to, and our limited resources have been dedicated to, performing business
and financial planning, raising capital, recruiting personnel, negotiating with business partners and the licensors of our intellectual
property and conducting development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">To implement our business
strategy we need to, among other things, successfully complete the development, testing and 510(k) device submission to the FDA
for our cortical and strip electrodes for the diagnosis of epilepsy, successfully complete the development, testing and all required
steps for regulatory approval of our depth electrodes for sEEG recording in the U.S., develop and introduce a minimally invasive
delivery system for our cortical electrodes, develop an all-in-one diagnostic and therapeutic solution, successfully complete the
necessary testing and clinical trials required for regulatory approval of our technology for ablation and stimulation therapies,
gain approval for other brain or motor related disorders such as Parkinson&rsquo;s with the therapeutic technologies developed
for epilepsy, convince physicians and patients that our technology, if approved, represents an improvement over existing diagnostic
or treatment options, hire direct experienced sales representatives to market our technology, if approved, in the United States,
evaluate international opportunities and initiate and successfully complete the approval processes in targeted geographies and
engage in beneficial partnerships that can leverage our core technology. We have never been profitable and do not expect to be
profitable in the foreseeable future. We expect our expenses to increase significantly as we pursue our objectives. The extent
of our future operating losses and the timing of profitability are highly uncertain, and we expect to continue incurring significant
expenses and operating losses over the next several years. Our prior losses have had, and will continue to have, an adverse effect
on our stockholders&rsquo; equity and working capital. Any additional operating losses may have an adverse effect on our stockholders&rsquo;
equity, and we cannot assure you that we will ever be able to achieve profitability. Even if we achieve profitability, we may not
be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
depress the value of our Company and could impair our ability to raise capital, expand our business, maintain our development efforts,
obtain regulatory approvals or continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We are a development
stage company with a limited operating history, making it difficult for you to evaluate our business and your investment. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our operating subsidiary,
NeuroOne, Inc. was incorporated on October 7, 2016, and our predecessor, the LLC, had very limited operations. We are an early-stage
medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions
to diagnose and treat patients with epilepsy, Parkinson&rsquo;s disease, essential tremors, and other brain related disorders.
Our cortical strip technology under development has only been used by Mayo in five patients for research purposes and has not been
tested in any clinical trials. Our operations are subject to all of the risks inherent in the establishment of a new business enterprise,
including but not limited to the absence of an operating history, lack of fully-developed or commercialized products, insufficient
capital, expected substantial and continual losses for the foreseeable future, limited experience in dealing with regulatory issues,
lack of manufacturing and marketing experience, need to rely on third parties for the development and commercialization of our
proposed products, a competitive environment characterized by well-established and well-capitalized competitors and reliance on
key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Since inception, we have
not established any revenues or operations that will provide financial stability in the long term, and there can be no assurance
that we will realize our plans on our projected timetable (or at all) in order to reach sustainable or profitable operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Investors are subject
to all the risks incident to the creation and development of a new business and each investor should be prepared to withstand a
complete loss of his, her or its investment. Furthermore, the accompanying financial statements have been prepared assuming that
we will continue as a going concern. We have not emerged from the development stage, and may be unable to raise further equity.
These factors raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our Company has limited
experience in medical device development and may not be able to successfully develop any device or therapy. Our ability to become
profitable depends primarily on: our ability to develop our cortical strip, grid electrode and depth electrode technology, our
successful completion of all necessary pre-clinical testing and clinical trials on such technology, our ability to obtain approval
for such technology and, if approved, successfully commercialize such technology, our ongoing research and development efforts,
the timing and cost of clinical trials, our ability to identify personnel with the necessary skill sets or enter into favorable
alliances with third-parties who can provide substantial capabilities in clinical development, regulatory affairs, sales, marketing
and distribution and our ability to obtain and maintain necessary intellectual property rights to such technology. Our limited
experience in medical device development may make it more difficult for us to complete these tasks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Even if we successfully
develop and market such technology, we may not generate sufficient or sustainable revenue to achieve or sustain profitability,
which could cause us to cease operations and cause you to lose all of your investment. Because we are subject to these risks, you
may have a difficult time evaluating our business and your investment in our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our ability to
continue our operations requires that we raise additional capital and our operations could be curtailed if we are unable to obtain
the additional funding as or when needed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon the completion
of the audit of our financial statements for the nine months ended September 30, 2018 and the year ended December 31, 2017,
and management&rsquo;s assessment of our ability to continue as a going concern, we concluded there was substantial doubt
about our ability to continue as a going concern. Our independent registered public accounting firm included an explanatory
paragraph in its report on our financial statements as of and for the nine months ended September 30, 2018 and as of and for
the year ended December 31, 2017, noting the existence of substantial doubt about our ability to continue as a going concern.
At September 30, 2018 and December 31, 2017, we had only $13,260 and $26,467, respectively,&nbsp;in cash deposits. Our
existing cash and cash equivalents will not be sufficient to fund our operating expenses through December 31, 2018. To
continue to fund operations, we will need to secure additional funding. We may obtain additional financing in the future
through the issuance of our Common Stock, through other equity or debt financings or through collaborations or partnerships
with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all. Further, we may
not be able to modify terms of some of our existing debt that is coming due on December 31, 2018, and any failure to raise capital or to amend
existing debt that may be due as and when needed could compromise our ability to execute on our business plan, and we may be
forced to liquidate our assets. In such a scenario, the values we receive for our assets in liquidation or dissolution could
be significantly lower than the values reflected in our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our outstanding
notes require that we complete qualified financings by certain dates. If we are unable to, such notes become immediately due and
payable and we may not have sufficient cash to pay the principal and accrued and unpaid interest thereon. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The notes issued by us
provide that if we are unable to complete qualified financings by certain dates such notes will become immediately due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For a description of
our outstanding notes, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Liquidity
and Capital Resources&mdash;Historical Capital Resources.&rdquo; If we fail to complete a qualified financing pursuant to the terms
of the Series 3 Notes (as defined within Item 7 herein) by December 31, 2018, the Series 3 Notes will be immediately due and payable
on such date. As of September 30, 2018, the outstanding principal and accrued and unpaid interest on our outstanding Series 3 Notes
was $1,627,028. We may not have sufficient cash to pay the principal and accrued and unpaid interest thereon on such dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If our outstanding notes
become due and payable and we are unable to pay the principal and accrued and unpaid interest thereon, we may be unable to execute
our business plan and may be forced to liquidate our assets. In such a scenario, the values we receive for our assets in liquidation
or dissolution could be significantly lower than the values reflected in our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We will need to
raise substantial additional funds in the future, and these funds may not be available on acceptable terms or at all. A failure
to obtain this necessary capital when needed could force us to delay, limit, scale back or cease some or all operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The continued growth
of our business, including the development, regulatory approval and commercialization of our cortical strip, grid electrode and
depth electrode technology, will significantly increase our expenses going forward. As a result, we will be required to seek substantial
additional funds in the future. Our future capital requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the cost of developing our cortical strip, grid electrode
and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtaining and maintaining regulatory clearance or approval
for our cortical strip, grid electrode and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the costs associated with commercializing our cortical
strip, grid electrode and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any change in our development priorities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the revenue generated by sales of our cortical strip,
grid electrode and depth electrode technology, if approved;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the costs associated with expanding our sales and marketing
infrastructure for commercialization of our cortical strip grid electrode and depth electrode technology, if approved;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any change in our plans regarding the manner in which
we choose to commercialize any approved product in the United States or internationally;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the cost of ongoing compliance with regulatory requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">expenses we incur in connection with potential litigation
or governmental investigations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the costs to develop additional intellectual property;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">anticipated or unanticipated capital expenditures;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">unanticipated general and administrative expenses.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As a result of these
and other factors, we do not know whether and the extent to which we may be required to raise additional capital. We may in the
future seek additional capital from public or private offerings of our capital stock, borrowings under credit lines or other sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We may not be able to
raise additional capital on terms acceptable to us, or at all. Any failure to raise additional capital could compromise our ability
to execute on our business plan, and we may be forced to liquidate our assets. In such a scenario, the values we receive for our
assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If we issue equity or
debt securities to raise additional funds, our existing stockholders may experience dilution, and the new equity or debt securities
may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds
through collaborations, licensing, joint ventures, strategic alliances, partnership arrangements or other similar arrangements,
it may be necessary to relinquish valuable rights to our potential future products or proprietary technologies, or grant licenses
on terms that are not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Medical device
development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays
in completing, or ultimately be unable to complete, the development and commercialization of any product. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Before obtaining marketing
approval from regulatory authorities for the sale of our cortical strip, grid electrode and depth electrode technology under development
in the United States or elsewhere, we must complete all pre-clinical testing, clinical trials and other regulatory requirements
necessitated by the FDA and foreign regulatory bodies and demonstrate the performance and safety of our technology. Clinical testing
is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. A failure
of one or more clinical trials can occur at any stage of testing. Further, the outcomes of completed clinical trials may not be
predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
Clinical data is often susceptible to varying interpretations and analyses, and many companies that have believed their products
performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval. We have limited resources to
complete the expensive process of medical device development, pre-clinical testing and clinical trials, putting us at a disadvantage,
particularly compared to some of our larger and established competitors, and we may not have sufficient resources to commercialize
our products under development in a timely fashion, if ever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We may experience numerous
unforeseen events during or as a result of clinical trials that could delay or prevent our ability to receive marketing approval
or commercialize our products, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulators may not authorize us or our investigators
to commence a clinical trial or conduct a clinical trial at a prospective trial site;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the failure to successfully complete pre-clinical testing
requirements required by the FDA and international organizations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">we may experience delays in reaching, or fail to reach,
agreement on acceptable clinical trial contracts with third parties or clinical trial protocols with prospective trial sites,
the terms of which can be subject to extensive negotiation and may vary significantly among different trial sites;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">clinical trials of our cortical strip, grid electrode
and depth electrode technology may produce negative or inconclusive results, including failure to demonstrate statistical significance,
and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our development programs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the number of people with brain related disorders required
for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or
people may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our products may have undesirable side effects or other
unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate
the trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our third-party contractors conducting the clinical
trials may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulators may require that we or our investigators
suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding
that the participants are being exposed to unacceptable health risks;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the cost of clinical trials of our products may be
greater than we anticipate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the supply or quality of our products or other materials
necessary to conduct clinical trials of our products may be insufficient or inadequate; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">delays from our suppliers and manufacturers could impact
clinical trial completion and impact revenue.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If we are required to
conduct additional clinical trials or other testing of our cortical strip, grid electrode and depth electrode technology under
development beyond those that we contemplate, if we are unable to successfully complete clinical trials of our cortical strip,
grid electrode and depth electrode technology under development or other testing, if the results of these trials or tests are not
favorable or if there are safety concerns, we may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">not obtain marketing approval at all;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">be delayed in obtaining marketing approval for our
cortical strip, grid electrode and depth electrode technology under development in a jurisdiction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">be subject to additional post-marketing testing requirements;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">have our cortical strip, grid electrode and depth electrode
technology removed from the market after obtaining marketing approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our development costs
will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our clinical trials
will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays
also could allow our competitors to bring innovative products to market before we do and impair our ability to successfully commercialize
our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Changes in the
configuration of our cortical strip, grid electrode and depth electrode technology under development may result in additional costs
or delay. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As products are developed
through pre-clinical testing and clinical trials towards approval and commercialization, it is common that various aspects of the
development program, such as manufacturing methods and configuration, are altered along the way in an effort to optimize processes
and results. Any changes we make carry the risk that they will not achieve the intended objectives. Any of these changes could
cause our products to perform differently and affect the results of planned clinical trials or other future clinical trials conducted
with the altered device. Such changes may also require additional testing, regulatory notification or regulatory approval. This
could delay completion of pre-clinical testing or clinical trials, increase costs, delay approval of our future products and jeopardize
our ability to commence sales and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We have no products
that are approved for commercial sale. If we are unable to successfully develop, receive regulatory approval for and commercialize
our cortical strip, grid electrode and depth electrode technology under development, or if we experience significant delays in
doing so, our business will be harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have no products that
are approved for commercial sale. We initially plan to seek regulatory approval to commercialize our cortical strip, grid electrode
and depth electrode technology under development in the United States and we may seek approval to commercialize in select international
geographies. Our ability to generate revenue from our developed products, if any, will depend heavily on their successful development,
regulatory approval and eventual commercialization. The success of any products that we develop will depend on several factors,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">FDA approval of our planned regulatory pathway (or
approval of foreign regulatory body if we seek approval in any jurisdiction outside the United States);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">successful completion of all necessary pre-clinical
testing and clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">receipt of timely commercialization approvals from
applicable regulatory authorities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to procure and maintain suppliers and manufacturers
of the components of our current cortical strip, grid electrode and depth electrode technology and future versions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">launching commercial sales of our cortical strip, grid
electrode and depth electrode technology, if approved for marketing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">market acceptance of our cortical strip, grid electrode
and depth electrode technology, if approved, by people with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain
related disorders, the medical community and third-party payors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to obtain extensive coverage and reimbursement
for our cortical strip, grid electrode and depth electrode technology and implantation procedures;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our success in educating healthcare providers and people
with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders about the benefits, administration
and use of our cortical strip, grid electrode and depth electrode technology and future versions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the prevalence and severity of adverse events;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the perceived advantages, cost, safety, convenience
and accuracy of alternative therapies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtaining and maintaining patent, trademark and trade
secret protection and regulatory exclusivity for our cortical strip, grid electrode and depth electrode technology and otherwise
protecting our rights in our intellectual property portfolio;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">maintaining compliance with regulatory requirements,
including current good manufacturing practices; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">maintaining a continued acceptable performance and
safety profile of our cortical strip, grid electrode and depth electrode technology following approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Whether regulatory approval
will be granted is unpredictable and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
Our success in clinical trials will not guarantee regulatory approval. The FDA and, if we seek to commercialize in select international
geographies, other comparable foreign regulatory authorities may require that we conduct additional pre-clinical testing or clinical
trials, provide additional data, take additional manufacturing steps, or require other conditions before they will grant us approval.
If the FDA or other comparable foreign regulatory authorities require additional clinical trials or data, we would incur increased
costs and delays in the marketing approval process, which may require us to expend more resources than we have available. In addition,
the FDA or other comparable foreign regulatory authorities may not consider sufficient any additional required clinical trials,
data or information that we perform and complete or generate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In cases where we are
successful in obtaining regulatory approval to market one or more of our products, our revenue will be dependent, in part, upon
the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability
to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of people we target
is not as significant as we estimate or the treatment population is narrowed by competition, physician choice or treatment guidelines,
we may not generate significant revenue from sales of such products, even if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Approval or clearance
in the United States by the FDA or by a regulatory agency in another country does not guarantee approval by the regulatory authorities
in other countries or jurisdictions or ensure approval for the same conditions of use. In addition, clinical trials conducted in
one country may not be accepted by regulatory authorities in other countries. Approval processes vary among countries and can involve
additional product testing and validation and additional administrative review periods. It is possible that no product we develop
will ever obtain regulatory approval in the United States or any other jurisdiction, even if we expend substantial time and resources
seeking such approval. If we do not achieve one or more of these approvals in a timely manner or at all, we could experience significant
delays or an inability to fully commercialize any product and achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Both before and after
a product is commercially released, we will have ongoing responsibilities under U.S. and foreign regulations. We will also be subject
to periodic inspections by the FDA and comparable foreign authorities to determine compliance with regulatory requirements, such
as the Quality System Regulation, or QSR, of the FDA, medical device reporting regulations, vigilance in reporting of adverse events
and regulations regarding notification, corrections, and recalls. These inspections can result in observations or reports, warning
letters or other similar notices or forms of enforcement action. If the FDA or any comparable foreign authority concludes that
we are not in compliance with applicable laws or regulations, or that any of our products are ineffective or pose an unreasonable
health risk, such authority could ban these products, suspend or cancel our marketing authorizations, impose &ldquo;stop-sale&rdquo;
and &ldquo;stop-import&rdquo; orders, refuse to issue export certificates, detain or seize adulterated or misbranded products,
order a recall, repair, replacement, correction or refund of such products, or require us to notify health providers and others
that the products present unreasonable risks of substantial harm to the public health. Discovery of previously unknown problems
with our product&rsquo;s design or manufacture may result in restrictions on use, restrictions placed on us or our suppliers, or
withdrawal of an existing regulatory clearance. The FDA or comparable foreign authorities may also impose operating restrictions,
enjoin and restrain certain violations of applicable law pertaining to medical devices, assess civil or criminal penalties against
our officers, employees or us, or recommend criminal prosecution of our Company. Adverse regulatory action may restrict us from
effectively marketing and selling our products. In addition, negative publicity and product liability claims resulting from any
adverse regulatory action could have a material adverse effect on our business, financial condition, and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Foreign governmental
regulations have become increasingly stringent and more extensive, and we may become subject to even more rigorous regulation by
foreign governmental authorities in the future. Penalties for a company&rsquo;s noncompliance with foreign governmental regulation
could be severe, including revocation or suspension of a company&rsquo;s business license and civil or criminal sanctions. In some
jurisdictions, such as Germany, a violation of law related to medical devices may also be considered to be a violation of unfair
competition law. In such cases, governmental authorities, our competitors and business or consumer associations may file lawsuits
to prohibit us from commercializing a product in such jurisdictions. Our competitors may also sue us for damages. Any domestic
or foreign governmental law or regulation imposed in the future may have a material adverse effect on our business, financial condition
and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Depending on the cost
and market opportunity, we may never seek approval to commercialize our cortical strip, grid electrode and depth electrode technology
in the European Union. We anticipate the cost to seek approval to commercialize in the European Union will be significantly greater
than the cost to seek approval to commercialize in the United States. This is because we believe commercial approval by the corresponding
Notified Body in the European Union and the European Economic Area, or EEA, even for diagnostic purposes, will require human clinical
trials, which we do not believe will be required for regulatory approval by the FDA in the United States in order to seek approval
of the use of our technology for diagnostic purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our success depends
on our ability to continue to develop, commercialize and gain market acceptance for our product under development, our cortical
strip, grid electrode and depth electrode technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our current business
strategy is highly dependent on developing and commercially launching one product, our cortical strip, grid electrode and depth
electrode technology, and achieving and maintaining market acceptance. In order for us to sell cortical strip, grid electrode and
depth electrode technology to people with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders,
we must convince them, their caregivers and healthcare providers that cortical strip, grid electrode and depth electrode technology
is an attractive alternative to competitive products for neuromodulation cEEG and sEEG recording, ablation, and brain stimulation.
Market acceptance and adoption of our cortical strip, grid electrode and depth electrode technology depends on educating people
with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders, as well as their caregivers and
healthcare providers, and other perceived benefits of our cortical strip, grid electrode and depth electrode technology as compared
to competitive products. We may face challenges convincing physicians, many of whom have extensive experience with competitors&rsquo;
products and established relationships with other companies, to appreciate the benefits of our cortical strip, grid electrode and
depth electrode technology and, in particular, its ability to successfully diagnose and treat epilepsy, Parkinson&rsquo;s disease,
and other brain related disorders in a way that is superior to and differentiated from currently available technology, and adopt
it for treatment of their patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Achieving and maintaining
market acceptance of cortical strip, grid electrode and depth electrode technology could be negatively impacted by many factors,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the failure of our cortical strip, grid electrode and
depth electrode technology to achieve wide acceptance among people with epilepsy, Parkinson&rsquo;s disease, essential tremors
and other brain related disorders, their caregivers, healthcare providers, third-party payors and key opinion leaders in the community;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">lack of evidence supporting the performance criteria
or other perceived benefits of our cortical strip, grid electrode and depth electrode technology over competitive products or
other currently available technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">perceived risks associated with the use of our cortical
strip, grid electrode and depth electrode technology or similar products or technologies generally;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the introduction of competitive products and the rate
of acceptance of those products as compared to our cortical strip, grid electrode and depth electrode technology;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">adverse results of clinical trials relating to our
cortical strip, grid electrode and depth electrode technology or similar competitive products; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">loss of regulatory approval for our cortical strip,
grid electrode and depth electrode technology, adverse publicity or other adverse events including any product liability lawsuits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition, our cortical
strip, grid electrode and depth electrode technology may be perceived by people with epilepsy, Parkinson&rsquo;s disease, essential
tremors and other brain related disorders, their caregivers or healthcare providers to be more complicated or less effective than
current technology, and people may be unwilling to change their current regimens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Moreover, we believe
that healthcare providers tend to be slow to change their medical treatment practices because of perceived liability risks arising
from the use of new products and the uncertainty of third-party reimbursement. Accordingly, healthcare providers may not recommend
our cortical strip, grid electrode and depth electrode technology until, if ever, there is sufficient evidence to convince them
to alter the treatment methods they typically recommend, such as receiving recommendations from prominent healthcare providers
or other key opinion leaders in the community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If we are not successful
in convincing people with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders of the benefits
of our cortical strip, grid electrode and depth electrode technology, or if we are unable to achieve the support of caregivers
and healthcare providers or widespread market acceptance for our cortical strip, grid electrode and depth electrode technology,
then our sales potential, strategic objectives and profitability could be negatively impacted, which would adversely affect our
business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may fail to
obtain regulatory approvals to market our products in the United States or in other countries. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Before we can market
or sell a new regulated product in the United States, we must obtain either clearance under Section 510(k) of the FDCA or approval
of a PMA application from the FDA, unless an exemption from pre-market review applies. In the 510(k) clearance process, the FDA
must determine that a proposed device is &ldquo;substantially equivalent&rdquo; to a device legally on the market, known as a &ldquo;predicate&rdquo;
device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing.
Clinical data is sometimes required to support substantial equivalence. The PMA pathway requires an applicant to demonstrate the
safety and effectiveness of the device based, in part, on extensive data, including, but not limited to, technical, preclinical,
clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the
greatest risk, such as life-sustaining, life-supporting or implantable devices. Both the 510(k) and PMA processes can be expensive
and lengthy and require the payment of significant fees, unless exempt. The FDA&rsquo;s 510(k) clearance process usually takes
from three to 12 months, but may last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k)
clearance process and generally takes from one to three years, or even longer, from the time the application is submitted to the
FDA until an approval is obtained. The process of obtaining regulatory clearances or approvals to market a medical device can be
costly and time-consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Even if we obtain clearance
or approval by the FDA, said clearance or approval by the FDA does not ensure approval or certification by regulatory authorities
in other countries or jurisdictions, and approval or certification by one foreign regulatory authority does not ensure approval
or certification by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval or certification
process may include all of the risks associated with obtaining FDA clearance or approval. We may not obtain foreign regulatory
approvals on a timely basis, if at all. We may not be able to file for regulatory approvals or certifications and may not receive
necessary approvals to commercialize our products in any market. If we fail to receive necessary approvals or certifications to
commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, results of operations and financial
condition could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Failure to secure
or retain coverage or adequate reimbursement for our cortical strip, grid electrode and depth electrode technology or future versions
thereof, including the implantation procedures, by third-party payors could adversely affect our business, financial condition
and operating results. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We plan to derive nearly
all of our revenue from sales of our cortical strip, grid electrode and depth electrode technology under development, if approved,
in the United States and potentially select international geographies and expect to do so for the next several years. We anticipate
a substantial portion of the purchase price of our cortical strip, grid electrode and depth electrode technology will be paid for
by third-party payors, including private insurance companies, preferred provider organizations and other managed care providers.
Patients who receive treatment for their medical conditions and their healthcare providers generally rely on third-party payors
to reimburse all or part of the costs associated with their medical treatment, including healthcare providers&rsquo; services.
Coverage and adequate reimbursement from third-party payors, including governmental healthcare programs, such as Medicare and Medicaid,
and commercial payors, is critical to new product acceptance. Future sales of our cortical strip, grid electrode and depth electrode
technology will be limited unless people with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders
can rely on third-party payors to pay for all or part of the cost to purchase our cortical strip, grid electrode and depth electrode
technology. Access to adequate coverage and reimbursement for our cortical strip, grid electrode and depth electrode technology
by third-party payors is essential to the acceptance of our products by people with epilepsy, Parkinson&rsquo;s disease, essential
tremors and other brain related disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In the United States,
a third-party payor&rsquo;s decision to provide coverage for our products does not imply that an adequate reimbursement rate will
be obtained. Further, one third-party payor&rsquo;s decision to cover our products does not assure that other payors will also
provide coverage for the products or will provide coverage at an adequate reimbursement rate. Healthcare providers may choose not
to order a product unless third-party payors pay a substantial portion of the product. Within and outside the United States, reimbursement
is obtained from a variety of sources, including government-sponsored and private health insurance plans. These third-party payors
determine whether to provide coverage and reimbursement for specific products and procedures. Coverage determinations and reimbursement
levels of both our products and the healthcare provider&rsquo;s performance of the insertion and removal procedures are critical
to the commercial success of our product, and if we are not able to secure positive coverage determinations and reimbursement levels
for our products or the insertion and removal procedures, our business would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition, there may
be significant delays in obtaining reimbursement, and coverage may be more limited than the purposes for which the product is cleared
by the FDA or other foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any product will
be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.
Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments
allowed for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services.
Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or third-party
payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at
lower prices than in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Because there is generally
no separate reimbursement for medical devices and other supplies used in such procedures, including our cortical strip, grid electrode
and depth electrode technology, and because we believe that our cortical strip, grid electrode and depth electrode technology,
if approved, would be adequately described by existing DRG and ICD-9 codes for epilepsy surgery, some of our target customers may
be unwilling to adopt our cortical strip, grid electrode and depth electrode technology over more established or lower cost therapeutic
alternatives already available or subsequently become available. Further, any decline in the amount payors are willing to reimburse
our customers for procedures using our cortical strip, grid electrode and depth electrode technology could make it difficult for
new customers to adopt our cortical strip, grid electrode and depth electrode technology and could create additional pricing pressure
for us, which could adversely affect our ability to invest in and grow our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare
costs. In addition, in the United States, no uniform policy of coverage and reimbursement for medical device products and services
exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly
from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny
coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with
no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Reimbursement systems
in international markets vary significantly by country and by region within some countries, and reimbursement approvals must be
obtained on a country-by-country basis. In many international markets, a product must be approved for reimbursement before it can
be approved for sale in that country. Further, many international markets have government-managed healthcare systems that control
reimbursement for new devices and procedures. In most markets there are private insurance systems as well as government-managed
systems. If sufficient coverage and reimbursement is not available for our any product we develop, in either the United States
or internationally, the demand for our products and our revenues will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Reimbursement by
Medicare is highly regulated and subject to change.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Medicare program
is administered by the Centers for Medicare and Medicaid Services, or CMS, which imposes extensive and detailed requirements on
medical services providers, including, but not limited to, rules that govern how we structure our relationships with physicians,
and how and where we provide our solutions. Our failure to comply with applicable Medicare rules could result in discontinuing
the ability for physicians to receive reimbursement as they will likely utilize our cortical strip, grid electrode and depth electrode
technology under the Medicare payment program, civil monetary penalties, and/or criminal penalties, any of which could have a material
adverse effect on our business and revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>The impact of the
Patient Protection and Affordable Care Act remains uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In 2010, significant
reforms to the health care system were adopted as law in the United States. The law includes provisions that, among other things,
reduce or limit Medicare reimbursement, require all individuals to have health insurance (with limited exceptions) and impose increased
taxes. These factors, in turn, could result in reduced demand for our products, if approved, and increased downward pricing pressure.
Because other parts of the 2010 health care law remain subject to implementation, the long-term impact on us is uncertain. The
new law or any future legislation could reduce medical procedure volumes, lower reimbursement for our products, and impact the
demand for our products or the prices at which we sell our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition, some of
the provisions of the ACA have yet to be implemented, and there have been legal and political challenges to certain aspects of
the ACA. Since January 2017, President Trump has signed executive orders and other directives designed to delay, circumvent, or
loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal
and replace all or part of the ACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 (H.R.
1) (the &ldquo;<B><I>Tax Act</I></B>&rdquo;) includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility
payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that
is commonly referred to as the &ldquo;individual mandate.&rdquo; Congress may consider other legislation to repeal or replace
elements of the ACA. We continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business
but expect that the ACA, as currently enacted or as it may be amended in the future, and other healthcare reform measures that
may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully
commercialize our cortical strip, grid electrode and depth electrode technology, if approved. In addition to the ACA, there will
continue to be proposals by legislators at both the federal and state levels, regulators and third party payors to keep healthcare
costs down while expanding individual healthcare benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Accordingly, while it
is too early to understand and predict the ultimate impact of the ACA on our business, the legislation and resulting regulations
could have a material adverse effect on our business, cash flows, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>If our competitors
are better able to develop and market products for the diagnosis and treatment of epilepsy, Parkinson&rsquo;s disease, essential
tremors and other brain related disorders that are safer, more effective, less costly, easier to use or otherwise more attractive
than our cortical strip, grid electrode and depth electrode technology, our business will be adversely impacted. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The medical device industry
is highly competitive and subject to technological change. Our success depends, in part, upon our ability to establish a competitive
position in the market for the diagnosis and treatment of epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain
related disorders by securing broad market acceptance of our cortical strip, grid electrode and depth electrode technology under
development. Any product we develop that achieves regulatory clearance or approval will have to compete for market acceptance and
market share. If developed as anticipated, we believe that the primary competitive factors of our cortical strip, grid electrode
and depth electrode technology under development will be: reduced infections, ability to record additional brain activity, minimally
invasive surgical procedure, ease of use and cost effectiveness. We face significant competition in the United States and internationally,
which we believe will intensify. For example, our major competitors (i) in the market for diagnosis are PMT Corporation, Ad-Tec
Medical and Integra Lifesciences, (ii) in the market for neuro-ablation are Medtronic and Monteris Medical and (iii) in the market
for neurostimulation are Medtronic, Boston Scientific, NeuroPace Biotronik and Abbott. Each of the foregoing competitors has systems
approved in the United States and certain foreign jurisdictions and has been established for several years. We face a particular
challenge overcoming the long-standing practices by some physicians of using the existing technology of our larger, more established
competitors. Physicians may be reluctant to try new products from a source with which they are less familiar. If these physicians
do not try and subsequently adopt our product, then our revenue growth will slow or decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition to these
major competitors, we may also face competition from other emerging competitors or smaller companies with active development programs
that may emerge in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Many of the companies
developing or marketing competing products enjoy several advantages over us, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">more experienced sales forces;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">greater name recognition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">more established sales and marketing programs and distribution networks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">earlier regulatory approval in the United States or foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">long established relationships with physicians and hospitals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">significant patent portfolios, including issued U.S. and foreign patents and pending patent applications,
as well as the resources to enforce patents against us or any of our third-party suppliers and distributors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the ability to acquire and integrate our competitors and/or their technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">demonstrated ability to develop product enhancements and new product offerings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">established history of product reliability, safety and durability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the ability to offer rebates or bundle multiple product offerings to offer greater discounts or
incentives;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">greater financial and human resources for product development, sales, and marketing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">greater experience in and resources for conducting research and development, clinical studies,
manufacturing, preparing regulatory submissions, obtaining regulatory clearance or approval for products and marketing approved
products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our competitors may develop
and patent processes or products earlier than us, obtain patents that may apply to us at any time, obtain regulatory clearance
or approvals for competing products more rapidly than us or develop more effective or less expensive products or technologies that
render our technology or products obsolete or less competitive. Furthermore, the frequent introduction by competitors of products
that are, or claim to be, superior to our products may create market confusion that may make it difficult to differentiate the
benefits of our products over competitive products. In addition, the entry of multiple new products may lead some of our competitors
to employ pricing strategies that could adversely affect the pricing of any product we may develop and commercialize. We also face
fierce competition in recruiting and retaining qualified sales, scientific, and management personnel, establishing clinical trial
sites and enrolling patients in clinical studies. If our competitors are more successful than us in these matters, our business
may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>The size and future
growth in the market for our cortical strip, grid electrode and depth electrode technology under development has not been established
with precision and may be smaller than we estimate, possibly materially. If our estimates and projections overestimate the size
of this market, our sales growth may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our estimates of the
size and future growth in the market for our cortical strip, grid electrode and depth electrode technology under development, including
the number of people with epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders who may benefit
from and be amenable to using cortical strip, grid electrode and depth electrode technology for diagnosis and treatment, is based
on a number of internal and third-party studies, reports and estimates. In addition, our internal estimates are based in large
part on current treatment patterns by healthcare providers using current generation technology and our belief is that the incidence
of epilepsy, Parkinson&rsquo;s disease, essential tremors and other brain related disorders in the United States and worldwide
is increasing. While we believe these factors have historically provided and may continue to provide us with effective tools in
estimating the total market for cortical strip, grid electrode and depth electrode technology, these estimates may not be correct
and the conditions supporting our estimates may change at any time, thereby reducing the predictive accuracy of these underlying
factors. The actual incidence of brain related disorders, and the actual demand for our products or competitive products, could
differ materially from our projections if our assumptions are incorrect. As a result, our estimates of the size and future growth
in the market for cortical strip, grid electrode and depth electrode technology may prove to be incorrect. If the actual number
of people with brain related disorders who would benefit from cortical strip, grid electrode and depth electrode technology and
the size and future growth in the market for cortical strip, grid electrode and depth electrode technology is smaller than we have
estimated, it may impair our projected sales growth and have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We depend on intellectual
property licensed from Wisconsin Alumni Research Foundation for our technology under development, and the termination of this license
would harm our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">WARF has granted us the
WARF License, to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe
array or thin-film micro electrode array and method. See &ldquo;Business &mdash; WARF License&rdquo; for additional information
regarding our license agreement with WARF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have agreed to diligently
develop, manufacture, market and sell products under the WARF License in the United States during the term of the agreement and,
specifically, that we would submit a business plan to WARF by February 1, 2018, which we submitted on January 18, 2018 and file
an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate this license in the event that
we fail to meet these milestones on 30 days&rsquo; written notice, if we default on the payments of amounts due to WARF or fail
to timely submit development reports, actively pursue our development plan or breach any other covenant in the WARF License and
fail to remedy such default in 90 days or in the event of certain bankruptcy events involving us. WARF may also terminate this
license (i) on 90 days&rsquo; notice if we fail to have commercial sales of one or more FDA-approved products under the WARF License
by March 31, 2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four
calendar quarters. The WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder
remain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Disputes may arise between
us and WARF regarding intellectual property subject to this agreement, including with respect to: the scope of rights granted under
the WARF License and other interpretation-related issues; whether and the extent to which our technology and processes infringe
on intellectual property of WARF that is not subject to the WARF License; the amount and timing of milestones and royalty payments;
the rights of WARF under the license; our right to sublicense; and the ownership of inventions and know-how resulting from the
WARF License. For example, if we or any of our sublicenses for any reason contest the validity of any patent licensed under the
WARF License, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be
valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for the remaining term of the
WARF License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any disputes with WARF
may prevent or impair our ability to maintain our current licensing arrangement. We depend on the intellectual property licensed
from WARF to develop our cortical strip, grid electrode and depth electrode technology. We cannot assure you that we will be able
to meet the milestones or commercialize a product under the WARF License by the dates required. In fact, the original license agreement
entered into with WARF in 2014 required that we meet certain earlier milestones than set forth above and make certain payments
to WARF. We failed to do so and were in default under the original license agreement. Furthermore, the LLC was not able to transfer
the rights and obligations under the 2014 WARF Agreement to us at the time of the Merger without the consent of WARF. As a result,
in February 2017, we signed an amendment to the WARF License which, among other things, modified and removed certain previous milestones
and provided WARF&rsquo;s consent to such transfer. Because of this past breach, WARF may be less likely to waive future defaults
or breaches or further amend the WARF License in the future, to the extent we request any waiver or amendment. See &ldquo;Note
4&mdash;Commitments and Contingencies&rdquo; to the financial statements included in this Transition Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Termination of our license
could result in the loss of significant rights and would harm our ability to further develop our cortical strip, grid electrode
and depth electrode technology. In addition, WARF reserves the right to grant non-profit research institutions and government agencies
non-exclusive licenses to practice and use the inventions of the licensed patents for non-commercial research purposes, and we
grant WARF a non-exclusive, sub licensable, royalty-free right and license for non-commercial research purposes to use improvements
to the licensed patents. In the event that we discontinue use or commercialization of the licensed patents or improvements thereon,
we must grant WARF an option to obtain a non-exclusive, sub-licensable royalty-bearing license to use the improvements for commercial
purposes. Such rights, if exercised by WARF, could harm our ability to develop and commercialize our cortical strip, grid electrode
and depth electrode technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We depend on our
partnership with Mayo Foundation for Medical Education and Research to license certain know how for the development and commercialization
of our technology. Termination of this partnership would harm our business, and even if this partnership continues, it may not
be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have entered into
the Mayo Development Agreement to (i) exclusively license worldwide certain Mayo improvements for the development and commercialization
of products, methods and processes related to flexible circuit technology for the recording and stimulation of tissue and (ii)
license, on a non-exclusive basis, worldwide Mayo thin film electrode technology know-how for the development and commercialization
of products, methods and processes related to flexible circuit technology for the recording and stimulation of tissue. Mayo has
agreed to assist the Company by providing access to the Mayo Principal Investigators in developing a minimally invasive device/delivery
system and procedure for a minimally invasive approach for the implantation of any flexible circuit technology developed by the
Company, including prototype development, animal testing, protocol development for human and animal use, abstract development and
presentation and access to and license of any intellectual property that the Mayo Principal Investigators develop relating to the
procedure. See &ldquo;Business&mdash;Mayo Foundation for Medical Education and Research License and Development Agreement&rdquo;
for additional information regarding our agreement with Mayo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Mayo Development
Agreement generally will expire in October 2034, unless the Mayo know-how and improvements under the Mayo Development Agreement
remain in use, and the Mayo Development Agreement may be terminated by Mayo for cause or under certain circumstances. Mayo and
the Company may not be successful in their efforts to develop any product, method, process, device, delivery system or minimally
invasive approach by such expiration date or termination, if at all. If no such minimally invasive device or delivery system and
procedure for minimally invasive approach is developed, the Company may never receive regulatory approval of its cortical strip,
grid electrode and depth electrode technology under development or the market may never accept such technology, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Disputes may arise between
us and Mayo regarding intellectual property subject to the Mayo Development Agreement or other matters, including with respect
to: the scope of rights granted under the agreement and other interpretation-related issues; the amount and timing of payments;
the rights and obligations of Mayo under the license agreement; and the ownership of inventions and know-how resulting from the
joint creation or use of intellectual property by Mayo and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any disputes with Mayo
may prevent or impair our ability to maintain our current arrangement. We depend on the intellectual property licensed from and
development assistance from Mayo to develop our cortical strip, grid electrode and depth electrode technology. We cannot assure
you that we will be able to continue to comply with the Mayo Development Agreement. In fact, the original license and development
agreement entered into with Mayo in 2014 required that, upon the Merger with the LLC, we make certain payments and issue shares
of common stock to Mayo, which we failed to do at such time. We signed the Mayo Development Agreement in May 2017, which, among
other things, modified or removed certain provisions of the original agreement, including those we breached. In addition, pursuant
to the Mayo Development Agreement signed in May 2017, we agreed to pay Mayo a cash payment of approximately $92,000 on the earlier
of September 30, 2017 or the date we raise a minimum amount of financing. We did not make this payment by September 30, 2017 and
breached this provision of the Mayo Development Agreement. Mayo granted us an extension of this deadline to December 31, 2017,
and we made this payment within such extended deadline. Because of our past breach, Mayo may be less likely to waive future defaults
or breaches or further amend the Mayo Development Agreement in the future, to the extent we request any waiver or amendment. Termination
of the Mayo Development Agreement could result in the loss of significant rights and would harm our ability to further develop
our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We do not have
the sales and marketing personnel necessary to sell any products we may develop, if approved for commercialization. Even if we
have our cortical strip, grid electrode and depth electrode technology approved for commercial sale, if we are unable to establish
a sales and marketing infrastructure, we may not be successful in commercializing our cortical strip, grid electrode and depth
electrode technology in the United States. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are an early stage
development company with limited resources. Even if we had products available for sale, which we currently do not, we have not
secured sales and marketing staff at this early stage of operations to sell products. To achieve commercial success in the United
States for our cortical strip, grid electrode and depth electrode technology, we will need to establish and expand our sales and
marketing infrastructure to drive adoption of our products, which will include a team of educators that will train healthcare providers
and people with brain related disorders on the benefits and use of our cortical strip, grid electrode and depth electrode technology.
There is significant competition for sales personnel experienced in relevant medical device sales. We expect that we will face
significant challenges as we recruit and subsequently grow our sales and marketing infrastructure. If we are unable to attract
and retain sufficient, and skilled, sales and marketing representatives, our sales could be adversely affected. If one of our sales
or marketing representatives were to depart and be retained by one of our competitors, they could help competitors solicit business
from customers, which could further harm our sales. In addition, if our sales and marketing representatives or educators fail to
achieve their objectives or if we are not able to recruit and retain a network of educators, we may not be able to successfully
train healthcare providers on the use of our cortical strip, grid electrode and depth electrode technology, which could delay new
sales and harm our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As we increase our sales
and marketing expenditures with respect to our cortical strip, grid electrode and depth electrode technology under development,
if approved, or future versions thereof, we will need to hire, train, retain and motivate skilled sales and marketing representatives
with significant industry-specific knowledge in various areas. Our success will depend largely on the competitive landscape for
our products and the ability of our sales personnel to obtain access to healthcare providers and persuade those healthcare providers
to recommend our cortical strip, grid electrode and depth electrode technology. Recently hired sales representatives require training
and take time to achieve full productivity. If we fail to train new hires adequately, or if we experience high turnover in our
sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase
our sales. In addition, the expansion of our sales and marketing personnel will place significant burdens on our management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If approved for sale,
we anticipate that we will derive nearly all of our U.S. revenue from the sales of our cortical strip, grid electrode and depth
electrode technology or future versions thereof. As a result, our financial condition and operating results will be highly dependent
on the ability of our sales representatives to adequately promote, market and sell our cortical strip, grid electrode and depth
electrode technology and the ability of our educators to train healthcare providers on the use of our cortical strip, grid electrode
and depth electrode technology. If we are unable to establish and expand our sales and marketing capabilities, we may not be able
to effectively commercialize our existing or planned products, or enhance the strength of our brand, either of which could impair
our projected sales growth and have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We will depend
on a limited number of third-party suppliers for the components of our cortical strip, grid electrode and depth electrode technology
under development and the loss of any of these suppliers, or their inability to provide us with an adequate supply of materials,
could harm our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We will rely on third-party
suppliers to supply and manufacture the components of our cortical strip, grid electrode and depth electrode technology. For our
business strategy to be successful, our suppliers must be able to provide us with components in sufficient quantities, in compliance
with regulatory requirements and quality control standards, in accordance with agreed upon specifications, at acceptable costs
and on a timely basis. Future increases in sales of our cortical strip and sheet electrode technology, if approved, whether expected
or unanticipated, could strain the ability of our suppliers to deliver an increasingly large supply of components and our cortical
strip, grid electrode and depth electrode technology in a manner that meets these various requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We will likely use a
small number of suppliers of components for our products. Depending on a limited number of suppliers exposes us to risks, including
limited control over pricing, availability, quality and delivery schedules. We may not have long-term supply agreements with our
suppliers and, in many cases, we may make our purchases on a purchase order basis. Our ability to purchase adequate quantities
of components or our products may be limited and we may not be able to convince suppliers to make components and products available
to us. Additionally, our suppliers may encounter problems that limit their ability to supply components or manufacture products
for us, including financial difficulties, damage to their manufacturing equipment or facilities, or product discontinuations. As
a result, there is a risk that certain components could be discontinued and no longer available to us. We may be required to make
significant &ldquo;last time&rdquo; purchases of component inventory that is being discontinued by the supplier to ensure supply
continuity. If we fail to obtain sufficient quantities of high quality components to meet demand for our products in a timely manner
or on terms acceptable to us, we would have to seek alternative sources of supply. Because of factors such as the proprietary nature
of our products, our quality control standards and regulatory requirements, we may not be able to quickly engage additional or
replacement suppliers for some of our critical components. Failure of any supplier to deliver components at the level our business
requires could disrupt the manufacturing of our products and, if approved, limit our ability to meet our sales commitments, which
could harm our reputation and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Furthermore, vandalism,
terrorism or a natural or other disaster, such as an earthquake, fire or flood, could damage or destroy equipment or our inventory
of component supplies or finished products, cause substantial delays in development or our operations, result in the loss of key
information, and cause us to incur additional expenses. We do not currently have insurance to cover such losses or expenses and,
once we obtain such insurance, it may not cover our losses in any particular case. In addition, regardless of the level of insurance
coverage, damage to our or our suppliers&rsquo; facilities could harm our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We may also have difficulty
obtaining similar components from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure
of any supplier to comply with strictly enforced regulatory requirements could expose us to regulatory action including warning
letters, product recalls, and termination of distribution, product seizures or civil penalties. It could also require us to cease
using the components, seek alternative components or technologies and modify our products to incorporate alternative components
or technologies, which could result in a requirement to seek additional regulatory approvals. Any disruption of this nature or
increased expenses could harm our development, approval or commercialization efforts and adversely affect our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We plan to contract
with third parties for the manufacture of our cortical strip, grid electrode and depth electrode technology under development and
expect to continue to do so for clinical trials and commercialization. Risks associated with the manufacturing of our products
could reduce our gross margins and negatively affect our operating results. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We currently rely, and
expect to continue to rely, on third parties for the manufacture of our cortical strip, grid electrode and depth electrode technology
during development, for clinical testing, as well as for commercial manufacture if our cortical strip, grid electrode and depth
electrode technology receives regulatory approval. Therefore, our business strategy depends on our third-party manufacturers&rsquo;
ability to manufacture our cortical strip, grid electrode and depth electrode technology and future generations thereof in sufficient
quantities and on a timely basis so as to meet consumer demand, while adhering to product quality standards, complying with regulatory
requirements and managing manufacturing costs. To date, we have only had an initial supply of our product manufactured. As a result,
we currently have limited data and experience regarding the quality, reliability and timeliness of our third-party manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are subject to numerous
risks relating to the manufacturing capabilities of our third-party manufacturers, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">quality or reliability defects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inability to secure product components in a timely manner, in sufficient quantities or on commercially
reasonable terms;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to increase production to meet demand;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inability to modify production lines to enable us to efficiently produce future products or implement
changes in current products in response to regulatory requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">difficulty identifying and qualifying alternative manufacturers in a timely manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inability to manufacture product components cost-effectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inability to establish agreements with future third-party manufacturers or to do so on acceptable
terms; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">potential damage to or destruction of our manufacturers&rsquo; equipment or facilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">These risks are likely
to be exacerbated by our limited experience with our cortical strip, grid electrode and depth electrode technology and its manufacturing
process. As demand for our products increases, our third-party suppliers will need to invest additional resources to purchase components,
hire and train employees, and enhance their manufacturing processes. If our manufacturers fail to increase production capacity
efficiently, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline. In
addition, manufacturing any future versions of our cortical strip, grid electrode and depth electrode technology may require the
modification of production lines, the identification of new manufacturers for specific components, or the development of new manufacturing
technologies. It may not be possible for us to manufacture these products at a cost or in quantities sufficient to make any future
versions of our cortical strip, grid electrode and depth electrode technology commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>If we or our third-party
suppliers or manufacturers fail to comply with the FDA&rsquo;s good manufacturing practice regulations, this could impair our ability
to market our products in a cost-effective and timely manner. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We and our third-party
suppliers are required to comply with the FDA&rsquo;s QSR, which covers the methods and documentation of the design, testing, production,
control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. The FDA audits compliance
with the QSR through periodic announced and unannounced inspections of manufacturing and other facilities. The FDA may impose inspections
or audits at any time. If we or our suppliers or manufacturers have significant non-compliance issues or if any corrective action
plan that we or our suppliers propose in response to observed deficiencies is not sufficient, the FDA could take enforcement action
against us. Any of the foregoing actions could impair our reputation, business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Various factors
outside our direct control may adversely affect manufacturing, sterilization and distribution of our products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The manufacture, sterilization
and distribution of our products is challenging. Changes that our suppliers may make outside the purview of our direct control
can have an impact on our processes, quality of our products and the successful delivery of products to our customers. Necessary
materials for our product under development may not be available from our third-party suppliers in a timely fashion or at all.
Mistakes and mishandling are not uncommon and can affect supply and delivery. Some of these risks include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to complete sterilization on time or in compliance with the required regulatory standards;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">transportation and import and export risk;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">delays in analytical results or failure of analytical techniques that we will depend on for quality
control and release of products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">natural disasters, labor disputes, financial distress, raw material availability, issues with facilities
and equipment or other forms of disruption to business operations affecting our manufacturers or suppliers; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">latent defects that may become apparent after products have been released and that may result in
a recall of such products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If any of these risks
were to materialize, our ability to develop products, conduct clinical trials or provide our products to customers on a timely
basis, if approved, would be adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Potential complications
from our cortical strip, grid electrode and depth electrode technology may come to light or may not be revealed by our clinical
experience. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Based on our industry
experience and the experience of the physicians that use products similar to our cortical strip, grid electrode and depth electrode
technology, complications from use of our cortical strip, grid electrode and depth electrode technology may include post-operative
hemorrhage, infection, brain inflammation, brain tissue necrosis, inability to accurately localize the epileptogenic focus (the
area of the cerebral cortex responsible for causing epileptic seizures), neurologic deficit (abnormal function of a body area due
to weaker function of the brain, spinal cord, muscles or nerves, such as abnormal reflexes, inability to speak and decreased sensation)
and extra axial fluid collections (fluid that occurs in the brain after surgery). If these or unanticipated complications or side-effects
result from the use of our cortical strip, grid electrode and depth electrode technology, our product development may be delayed,
we may not be able to obtain regulatory approval for any product, we could be subject to liability and, even if approved, our technology
would not be widely adopted. Additionally, we have no clinical experience with use of our cortical strip, grid electrode and depth
electrode technology. We cannot assure you that use, even for a limited time, would not result in unanticipated complications,
even after the device is removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Undetected errors
or defects in our cortical strip, grid electrode and depth electrode technology under development or future versions thereof could
harm our reputation, decrease the market acceptance of our cortical strip, grid electrode and depth electrode technology or expose
us to product liability claims. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our cortical strip, grid
electrode and depth electrode technology may contain undetected errors or defects. Disruptions or other performance problems with
our cortical strip, grid electrode and depth electrode technology may delay development, prevent regulatory approval or harm our
reputation. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted or other significant
customer relations problems may arise. We may also be subject to warranty and liability claims for damages related to errors or
defects in our cortical strip and sheet electrode technology or future versions thereof. A material liability claim or other occurrence
that harms our reputation or decreases market acceptance of our cortical strip, grid electrode and depth electrode technology could
harm our business and operating results. This risk exists even if a device is cleared or approved for commercial sale and manufactured
in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products are designed to affect,
and any future products will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects,
misuse or abuse associated with our cortical strip, grid electrode and depth electrode technology or future versions thereof could
result in patient injury or death. The medical device industry has historically been subject to extensive litigation over product
liability claims, and we cannot offer any assurance that we will not face product liability lawsuits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The sale and use of our
cortical strip, grid electrode and depth electrode technology or future versions thereof could lead to the filing of product liability
claims if someone were to allege that our cortical strip, grid electrode and depth electrode technology or one of our products
contained a design or manufacturing defect. A product liability claim could result in substantial damages and be costly and time
consuming to defend, either of which could materially harm our business or financial condition. Product liability claims may be
brought against us by patients, healthcare providers or others selling or otherwise coming into contact with our products, among
others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and
reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">distraction of management&rsquo;s attention from our primary business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the inability to commercialize our cortical strip, grid electrode and depth electrode technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">decreased demand;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">damage to our business reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product recalls or withdrawals from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawal of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">substantial monetary awards to patients or other claimants; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">loss of revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Product liability lawsuits
and claims, safety alerts or product recalls, with or without merit, could cause us to incur substantial costs, delay our product
development efforts, place a significant strain on our financial resources, divert the attention of management from our core business,
harm our reputation, increase our product liability insurance rates, once we obtain such insurance, or prevent us from securing
such insurance coverage in the future and adversely affect our ability to attract and retain customers, if approved, any of which
could harm our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We do not currently maintain
any product liability insurance and do not anticipate obtaining product liability insurance until we commence clinical trials.
Once we obtain such insurance, we cannot assure you that such insurance would adequately protect our assets from the financial
impact of defending a product liability claim. Even if any product liability loss is covered by an insurance policy, these policies
typically have substantial deductibles for which we are responsible. Product liability claims in excess of applicable insurance
coverage would negatively impact our business, financial condition and operating results. Insurance coverage varies in cost and
can be difficult to obtain, and we cannot guarantee that we will be able to obtain insurance coverage in the future on terms acceptable
to us or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>If there are significant
disruptions in our information technology systems, our business, financial condition and operating results could be adversely affected.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The efficient operation
of our business depends on our information technology systems. We rely on our information technology systems to effectively manage
product development tasks, research and development data and accounting and financial functions. We expect in the future we will
rely on our information technology systems for inventory management and technical support functions, if and once implemented. Our
information technology systems are vulnerable to damage or interruption from earthquakes, fires, floods and other natural disasters,
terrorist attacks, attacks by computer viruses or hackers, power losses, and computer system or data network failures. In addition,
our data management application and a variety of our software systems are hosted by third-party service providers whose security
and information technology systems are subject to similar risks, which could be subject to computer viruses or hacker attacks or
other failures. If our or our third-party service provider&rsquo;s security systems are breached or fail, unauthorized persons
may be able to obtain access to sensitive data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">To the extent that any
disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure
of confidential or proprietary information, we could incur liability, and the failure of our or our service providers&rsquo; information
technology systems or our transmitter&rsquo;s software to perform as we anticipate or our failure to effectively implement new
information technology systems could disrupt our entire operation or adversely affect our products and could delay our product
development, clinical trial or commercialization efforts, result in increased overhead costs and damage our reputation, all of
which could negatively affect our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may enter into
collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third-parties that may not
result in the development of commercially viable products or the generation of significant future revenues. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In the ordinary course
of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships
or other arrangements to develop products and to pursue new markets. Proposing, negotiating and implementing collaborations, in-licensing
arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including
those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these
opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner,
on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to
these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement.
In particular, these collaborations may not result in the development of products that achieve commercial success or result in
significant revenues and could be terminated prior to developing any products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Additionally, we may
not be in a position to exercise sole decision making authority regarding the transaction or arrangement, which could create the
potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals
that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our
collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms
under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed
during the collaboration. If any conflicts arise with any future collaborators, they may act in their self-interest, which may
be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the
amount and timing of resources that any future collaborators devote to our or their future products. Disputes between us and our
collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management.
Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of
the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or
arrangement or may need to purchase such rights at a premium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If we enter into in-bound
intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain
those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us,
in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection
for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue
such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence,
commercialization, royalty or other obligations on us. Future licensors may allege that we have breached our license agreement
with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm
our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may seek to
grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the
failure to integrate them with our existing business, could harm our business, financial condition and operating results. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">From time to time, we
may consider opportunities to acquire other companies, products or technologies that may enhance our product platform or technology,
expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous
risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">problems assimilating the acquired products or technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">issues maintaining uniform standards, procedures, controls and policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unanticipated costs associated with acquisitions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">diversion of management&rsquo;s attention from our existing business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">risks associated with entering new markets in which we have limited or no experience;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">increased legal and accounting costs relating to the acquisitions or compliance with regulatory
matters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unanticipated or undisclosed liabilities of any target.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have no current commitments
with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be
able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate
any acquired products or technologies. Our potential inability to integrate any acquired products or technologies effectively may
adversely affect our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our future success
depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are highly dependent
on the management, research and development, clinical, financial and business development expertise of David Rosa, Mark Christianson
and Thomas Bachinski, as well as our Physician Advisory Board and Artificial Intelligence Advisory Board members. Although we have
an employment agreement with David Rosa, he (and each of our other key employees) may terminate his employment with us at any time
and will continue to be able to do so. We do not maintain &ldquo;key person&rdquo; insurance for any of our executives or employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recruiting and retaining
qualified scientific and clinical personnel will also be critical to our success. The loss of the services of our executive officers
or other key employees could impede the achievement of our research, development and commercialization objectives and seriously
harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may
be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth
of skills and experience required to successfully develop, gain regulatory approval of and commercialize our products. Competition
to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable
terms given the competition among numerous medical device companies for similar personnel, many of which have greater financial
and other resources dedicated to attracting and retaining personnel. We also experience competition for the hiring of scientific
and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including
scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts
with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel,
our ability to pursue our growth strategy will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Prolonged negative
economic conditions could adversely affect us, our customers and third-party partners, manufactures or suppliers, if any, which
could harm our financial condition. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are subject to the
risks arising from adverse changes in general economic and market conditions. Uncertainty about future economic conditions could
negatively impact our existing and potential customers, adversely affect the financial ability of health insurers to pay claims,
adversely impact our expenses and ability to obtain financing of our operations, and cause delays or other problems with key suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Healthcare spending in
Europe and the United States has been, and is expected to continue to be, under significant pressure and there are many initiatives
to reduce healthcare costs. As a result, we believe that some insurers are scrutinizing insurance claims more rigorously and delaying
or denying coverage and reimbursement more often. Because the sale, if approved, of our cortical strip, grid electrode and depth
electrode technology under development will generally depend on the availability of third-party coverage and reimbursement, any
delay or decline in coverage and reimbursement will adversely affect our sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Risks Related to our
Intellectual Property </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our ability to
protect our intellectual property and proprietary technology is uncertain. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We rely primarily on
patent, trademark and trade secret laws, as well as confidentiality and non-disclosure agreements, to protect our proprietary technologies.
Our patent estate consists of three issued United States patents licensed from WARF relating to a neural probe array and thin-film
micro electrode array and method, and two pending U.S. provisional patent applications filed by us relating to a wide variety of
concepts, ranging from accessories for brain surgery to ablation and stimulation concepts for both cortical and depth electrodes.
The licensed issued patents expire between 2025 and 2030, subject to any patent extensions that may be available for such patents.
If a patent is issued on our pending patent application, the resulting patent is projected to expire in 2038. We continue to review
new technological developments in order to make decisions about what additional filings would be the most appropriate for us. We
also plan to seek patent protection for our proprietary technology in select countries internationally. We also have one pending
U.S. trademark application and one pending foreign trademark application, as well as one foreign trademark registration. We have
applied for patent protection relating to certain existing and proposed products and processes. Currently, several of our issued
U.S. patents licensed from WARF as well as our pending U.S. patent application relate to our cortical and depth electrode technologies
and are therefore important to the functionality of our products. If we fail to timely file&nbsp;a patent application in any jurisdiction,
we may be precluded from doing so at a later date. Furthermore, we cannot assure you that any patent application will be approved
in a timely manner or at all. The rights granted to us under our patents, and the rights we are seeking to have granted in our
pending patent applications, may not be meaningful or provide us with any commercial advantage. In addition, those rights could
be opposed, contested or circumvented by our competitors, or be declared invalid or unenforceable in judicial or administrative
proceedings. The failure of our patents to adequately protect our technology might make it easier for our competitors to offer
the same or similar products or technologies. Even if we are successful in receiving patent protection for certain products and
processes, our competitors may be able to design around our patents or develop products that provide outcomes which are comparable
to ours without infringing on our intellectual property rights. Due to differences between foreign and U.S. patent laws, our patented
intellectual property rights may not receive the same degree of protection in foreign countries as they would in the United States.
Even if patents are granted outside the United States, effective enforcement in those countries may not be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We rely on our trademarks
and trade names to distinguish our products from the products of our competitors, and have registered or applied to register many
of these trademarks. For example, we have one pending application in the United States for the &ldquo;NeuroOne&rdquo; trademark.
We cannot assure you that our trademark applications will be approved in a timely manner or at all. Third parties also may oppose
our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully
challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to
devote additional resources to marketing new brands. Further, we cannot assure you that competitors will not infringe upon our
trademarks, or that we will have adequate resources to enforce our trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We also rely on trade
secrets, know-how and technology, which are not protectable by patents, to maintain our competitive position. We try to protect
this information by entering into confidentiality agreements and intellectual property assignment agreements with our officers,
employees, temporary employees and consultants regarding our intellectual property and proprietary technology. In the event of
unauthorized use or disclosure or other breaches of those agreements, we may not be provided with meaningful protection for our
trade secrets or other proprietary information. In addition, our trade secrets may otherwise become known or be independently discovered
by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property
owned by others in their work for us, disputes may arise as to the rights in the related or resulting know-how and inventions.
If any of our trade secrets, know-how or other technologies not protected by a patent were to be disclosed to or independently
developed by a competitor, our business, financial condition and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If a competitor infringes
upon one of our patents, trademarks or other intellectual property rights, enforcing those patents, trademarks and other rights
may be difficult and time-consuming. Patent law relating to the scope of claims in the industry in which we operate is subject
to rapid change and constant evolution and, consequently, patent positions in our industry can be uncertain. Even if successful,
litigation to defend our patents and trademarks against challenges or to enforce our intellectual property rights could be expensive
and time consuming and could divert management&rsquo;s attention from managing our business. Moreover, we may not have sufficient
resources or desire to defend our patents or trademarks against challenges or to enforce our intellectual property rights. Litigation
also puts our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing.
Additionally, we may provoke third-parties to assert claims against us. We may not prevail in any lawsuits that we initiate and
the damages or other remedies awarded, if any, may not be commercially valuable. The occurrence of any of these events may harm
our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may not be able
to establish or strengthen our brand.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We believe that establishing
and strengthening our brand is critical to achieving widespread acceptance of our cortical strip, grid electrode and depth electrode
technology. Promoting and positioning our brand will depend largely on the success of our marketing efforts and our ability to
provide physicians with a reliable product for successful treatment of brain-related disorders. Additionally, we believe the quality
and reliability of our product is critical to building physician support in the United States, and any negative publicity regarding
the quality or reliability of our cortical strip, grid electrode and depth electrode technology could significantly damage our
reputation in the market. Further, given the established nature of our competitors, it is likely that our future marketing efforts
will require us to incur significant additional expenses. These brand promotion activities may not yield increased sales and, even
if they do, any sales increases may not offset the expenses we incur to promote our brand. If we fail to successfully promote and
maintain our brand, or if we incur substantial expenses in an unsuccessful attempt to promote and maintain our brand, our cortical
strip, grid electrode and depth electrode technology may not be accepted by physicians, which would adversely affect our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>The medical device
industry is characterized by patent litigation, and we could become subject to litigation that could be costly, result in the diversion
of management&rsquo;s time and efforts, stop our development and commercialization measures or require us to pay damages. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our success will depend
in part on not infringing the patents or violating the other proprietary rights of third-parties. Significant litigation regarding
patent rights exists in our industry. Our competitors in both the United States and abroad, many of which have substantially greater
resources and have made substantial investments in competing technologies, may have applied for or obtained or may in the future
apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make and sell our products. The
large number of patents, the rapid rate of new patent issuances, and the complexities of the technology involved increase the risk
of patent litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In the future, we could
receive communications from various industry participants alleging our infringement of their intellectual property rights. Any
potential intellectual property litigation could force us to do one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">stop selling our products or using technology that contains the allegedly infringing intellectual
property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">incur significant legal expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">pay substantial damages to the party whose intellectual property rights we are allegedly infringing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">redesign those products that contain the allegedly infringing intellectual property; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">attempt to obtain a license to the relevant intellectual property from third-parties, which may
not be available on reasonable terms or at all, and if available, may be non-exclusive, thereby giving our competitors access to
the same technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Patent litigation can
involve complex factual and legal questions, and its outcome is uncertain. Any litigation or claim against us, even those without
merit, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention
of management from our core business and harm our reputation. Further, as the number of participants in the neurostimulation market
increases, the possibility of intellectual property infringement claims against us increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may be subject
to damages resulting from claims that we, or our employees, have wrongfully used or disclosed alleged trade secrets of our competitors
or are in breach of non-competition or non-solicitation agreements with our competitors. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Some of our current or
future employees may have previously been employed at other medical device companies, including those that are our direct competitors
or could potentially be our direct competitors. We may be subject to claims that we, or our employees, have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of these former employers or competitors. In addition, we may
in the future be subject to allegations that we caused an employee to breach the terms of his or her non-competition or non-solicitation
agreement. Litigation may be necessary to defend against these claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, NeuroOne, Inc. received a
letter from PMT, the former employer of Mark Christianson and Wade Fredrickson. PMT claimed that these officers had breached their
restrictive covenant obligations with PMT by virtue of their work for NeuroOne, Inc. and such officer&rsquo;s prior work during
employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT
and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for
tortious interference with the contracts. The letter demanded that Mr. Fredrickson (who resigned from the Company in June 2017),
Mr. Christianson and NeuroOne, Inc. cease and desist all competitive activities, that Mr. Fredrickson step down from his position
and that Mr. Christianson and NeuroOne, Inc. provide the former employer access to NeuroOne, Inc.&rsquo;s systems to demonstrate
that it is not using trade secrets or proprietary information nor competing with the former employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, we were served with
a complaint filed by PMT adding the Company, NeuroOne, Inc. and Mark Christianson to its existing lawsuit against Wade Fredrickson.
In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure
obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil
conspiracy, tortiously interfered with PMT&rsquo;s contracts and prospective economic advantage, and breached a covenant of good
faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made
negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort
of conversion and statutory civil theft. Against the Company and NeuroOne, Inc., PMT alleges that the Company and NeuroOne, Inc.
were unjustly enriched and engaged in unfair competition. PMT asks the Court to impose a constructive trust over the shares held
by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&rsquo;
fees, costs and interest. The Company, NeuroOne, Inc. and Mr. Christianson (who has not worked for PMT since 2012) intend to defend
themselves vigorously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2018, Mr. Christianson, the
Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. We expect a ruling on
the motion within 90 days of that date. The motion for dismissal states that: the contract claims against Mr. Christianson fail
because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&rsquo;s claims
for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the
duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently
pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Even if we successfully
defend against these claims, litigation could cause us to incur substantial costs, and could place a significant strain on our
financial resources, divert the attention of management from our core business and harm our reputation. If our defense to those
claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There can
be no assurance that this type of litigation will not occur, and any future litigation or the threat thereof may adversely affect
our ability to hire additional employees. A loss of key personnel or their work product could hamper or prevent our ability to
develop or commercialize our cortical strip, grid electrode and depth electrode technology or future versions thereof, which could
have an adverse effect on our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We are subject
to the patent laws of countries other than the United States, which may not offer the same level of patent protection and whose
rules could seriously affect how we draft, file, prosecute and maintain patents, trademarks and patent and trademark applications.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Many countries, including
certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties (for example, the patent owner has failed to &ldquo;work&rdquo; the invention in that country, or the third party has patented
improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors.
In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Moreover,
the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent
and other intellectual property protection which makes it difficult to stop infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We cannot be certain
that the patent or trademark offices of countries outside the United States will not implement new rules that increase costs for
drafting, filing, prosecuting and maintaining patents, trademarks and patent and trademark applications or that any such new rules
will not restrict our ability to file for patent protection. For example, we may elect not to seek patent protection in some jurisdictions
in order to save costs. We may be forced to abandon or return the rights to specific patents due to a lack of financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Intellectual property
rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and
may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may be able to make devices that are the same as or similar to our cortical strip, grid
electrode and depth electrode technology but that are not covered by the claims of the patents that we own;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we or any collaborators might not have been the first to make the inventions covered by the issued
patents or pending patent applications that we own;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we might not have been the first to file patent applications covering certain of our inventions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">it is possible that our pending patent applications will not lead to issued patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">issued patents that we own may not provide us with any competitive advantages, or may be held invalid
or unenforceable as a result of legal challenges;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we might enforce our patent rights or defend a challenge to our issued patents or pending application,
putting the patents and patent applications at risk of being invalidated or interpreted narrowly;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our competitors might conduct research and development activities in the United States and other
countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as
in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive
products for sale in our major commercial markets; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not develop additional proprietary technologies that are patentable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Risks Related to our
Legal and Regulatory Environment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our products and
operations are subject to extensive governmental regulation, and failure to comply with applicable requirements could cause our
business to suffer. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The medical device industry
is regulated extensively by governmental authorities, principally the FDA and corresponding state regulatory agencies in the United
States and the European Commission and corresponding Notified Body in the European Union and the EEA. The regulations are very
complex and are subject to rapid change and varying interpretations. Regulatory restrictions or changes could limit our ability
to carry on or expand our operations or result in higher than anticipated costs or lower than anticipated sales. These governmental
authorities enforce laws and regulations that are meant to assure product safety and effectiveness, including the regulation of,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product design and development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">pre-clinical studies and clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product safety;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">establishment registration and product listing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">labeling, content and language of instructions for use and storage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">marketing, manufacturing, sales and distribution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">pre-market clearance or approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">servicing and post-market surveillance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">record-keeping procedures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product import and export;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">advertising and promotion; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">recalls and field safety corrective actions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The regulations to which
we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions
on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Failure to comply with
applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as fines, civil
penalties, injunctions, warning letters, recalls of products, delays in the introduction of products into the market, refusal of
the regulatory agency or other regulators to grant future clearances or approvals, and the suspension or withdrawal of existing
approvals by such regulatory agencies. Any of these sanctions could result in higher than anticipated costs or lower than anticipated
sales and harm our reputation, business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>The FDA regulatory
clearance process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances
and approvals could prevent us from commercializing our cortical strip, grid electrode and depth electrode technology under development
and future versions thereof. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our products and operations
are subject to extensive and rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and its implementing
regulations, guidance, and standards. The FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping,
promotion, distribution, and production of medical devices in the United States to ensure that medical products distributed domestically
are safe and effective for their intended uses. The FDA also regulates the export of medical devices manufactured in the United
States to international markets. Any violations of these laws and regulations could result in a material adverse effect on our
business, financial condition and results of operations. In addition, if there is a change in law, regulation or judicial interpretation,
we may be required to change our business practices, which could have a material adverse effect on our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Under the FFDCA, medical
devices are classified into one of three classes&mdash;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&mdash;depending on the degree
of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Class&nbsp;I devices
are those for which safety and effectiveness can be assured by adherence to FDA&rsquo;s &ldquo;general controls&rdquo; for medical
devices, which include compliance with the applicable portions of the QSR facility registration and product listing, reporting
of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some
Class&nbsp;I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Class&nbsp;II devices
are subject to FDA&rsquo;s general controls, and any other &ldquo;special controls&rdquo; deemed necessary by FDA to ensure the
safety and effectiveness of the device. Premarket review and clearance by the FDA for Class&nbsp;II devices is accomplished through
the 510(k) premarket notification procedure, though certain Class&nbsp;II devices are exempt from this premarket review process.
When a 510(k) is required, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device
is &ldquo;substantially equivalent&rdquo; to a legally marketed device, which in some cases may require submission of clinical
data. A legally marketed device is defined by statute to mean a device that was legally marketed prior to May 28, 1976, the date
upon which the Medical Device Amendments of 1976 were enacted, or another commercially available, similar device that was cleared
through the 510(k) process.&nbsp;Unless a specific exemption applies, 510(k) premarket notification submissions are subject to
user fees. If the FDA determines that the device, or its intended use, is not substantially equivalent to a legally marketed device,
the FDA will place the device, or the particular use of the device, into Class&nbsp;III, and the device sponsor must then fulfill
much more rigorous premarketing requirements&nbsp;in the form of a premarket approval, or PMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A Class&nbsp;III device
includes devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable
devices, in addition to a device that has a new intended use or utilizes advanced technology that is not substantially equivalent
to that of a legally marketed device. The safety and effectiveness of Class&nbsp;III devices cannot be assured solely by general
and special controls. These devices almost always require formal clinical studies to demonstrate safety and effectiveness. Submission
and FDA approval of a PMA application is required before marketing of a Class&nbsp;III device can proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We believe our cortical
strip, grid electrode and depth electrode technology under development will be a Class II medical device. The FDA has not made
any determination about whether our specific technology is a Class II medical device. While such a determination is not necessary
in order for us to list a device with the FDA and bring that device to the U.S. market, we may decide to get clarification from
the FDA prior to introducing a product into the market. From time to time, the FDA may disagree with the classification and require
us to apply for approval as a Class III medical device. In the event that the FDA determines that our technology should be classified
as Class III, we could be precluded from marketing the devices for clinical use within the United States for months, years or longer,
depending on the specific change in the classification. Reclassification of our technology as Class III could significantly increase
our regulatory costs, including the timing and expense associated with required clinical trials and other costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If the FDA requires us
to go through more costly, lengthy and uncertain PMA process for our cortical strip, grid electrode and depth electrode technology,
future products or modifications to existing products than we had expected, we may be less likely to receive approval for our cortical
strip, grid electrode and depth electrode technology or such approval may take longer and be more costly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The FDA can delay, limit
or deny clearance or approval of a device for many reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not be able to demonstrate that our products are safe and effective for their intended users;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the data from our clinical trials may be insufficient to support clearance or approval; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the manufacturing process or facilities we use may not meet applicable requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">When FDA approval of
a device requires human clinical trials, and if the device presents a &ldquo;significant risk&rdquo; to human health, the device
sponsor is required to file an investigational device exemption, or IDE, application with the FDA and obtain IDE approval prior
to commencing the human clinical trial. If the device is considered a &ldquo;non-significant risk,&rdquo; IDE submission to FDA
is not required. Instead, only approval from the Institutional Review Board, or IRB, overseeing the investigation at each clinical
trial site is required. Human clinical studies are generally required in connection with approval of Class&nbsp;III devices and
may be required for Class&nbsp;I and II devices. The FDA or the IRB at each institution at which a clinical trial is being performed
may suspend a clinical trial at any time for various reasons, including a belief that the subjects are being exposed to an unacceptable
health risk. We believe that we will need to complete human clinical trials and submit an application for an IDE in order to seek
approval to use of our cortical strip, grid electrode and depth electrode technology for stimulation and ablation but not for diagnostic
purposes. Because any IDE, if required, must be cleared by the FDA prior to the start of a clinical investigation, this requirement
may delay our product development or clinical trial efforts. Any delay in, or failure to receive or maintain, clearance or approval
for our products under development could prevent us from generating revenue from these products or achieving profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition, the FDA
may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions
which may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently
cleared or approved products on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">After the FDA permits
a device to enter commercial distribution, numerous regulatory requirements apply. These include: compliance with the QSR, which
requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during
the manufacturing process; labeling regulations; the FDA&rsquo;s general prohibition against promoting products for unapproved
or &ldquo;off-label&rdquo; uses; the reports of Corrections and Removals regulation, which requires manufacturers to report recalls
and field actions to the FDA if initiated to reduce a risk of health posed by the device or to remedy a violation of the Federal
Food, Drug and Cosmetic Act; and the Medical Device Reporting regulation, which requires that manufacturers report to the FDA if
their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute
to a death or serious injury if it were to reoccur. Manufacturers are also required to register and list their devices with the
FDA, based on which the FDA will conduct inspections to ensure continued compliance with applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The FDA has broad post-market
and regulatory and enforcement powers. Failure to comply with the applicable U.S. medical device regulatory requirements could
result in, among other things, warning letters; fines; injunctions; consent decrees; civil penalties; repairs, replacements or
refunds; recalls, corrections or seizures of products; total or partial suspension of production; the FDA&rsquo;s refusal to grant
future premarket clearances or approvals; withdrawals or suspensions of current product applications; and criminal prosecution.
Regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some people with brain related disorders
from using our products and adversely affect our reputation and the perceived accuracy and safety of our products. If any of these
events were to occur, they could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">International sales are
subject to regulatory requirements in the countries in which our products are sold. The regulatory review process varies from country
to country and may in some cases require the submission of clinical data. In addition, the FDA must be notified of, or approve
the export to certain countries of devices that require a PMA, and are not yet approved in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>A recall of our
products, or the discovery of serious safety issues with our products, could have a significant negative impact on us. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The FDA has the authority
to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in
the event that a product poses an unacceptable risk to health. Our third-party suppliers may, under their own initiative, recall
a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our third-party
distributors, if any, could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design
or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources
and have an adverse effect on our reputation, financial condition and operating results, which could impair our ability to produce
our products in a cost-effective and timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Further, under the FDA&rsquo;s
medical device reporting regulations, we are required to report to the FDA any incident in which our product may have caused or
contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely
cause or contribute to death or serious injury. Repeated product malfunctions may result in a voluntary or involuntary product
recall, which could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective
and timely manner and have an adverse effect on our reputation, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any adverse event involving
our products could result in future voluntary corrective actions, such as recalls or customer notifications, or regulatory agency
action, which could include inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary
or involuntary, will require the dedication of our time and capital, distract management from operating our business and may harm
our reputation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We will be subject
to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anti-corruption and anti-money-laundering laws, as well
as export control laws, customs laws, sanctions laws and other laws governing our future global operations. If we fail to comply
with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely
affect our business, results of operations and financial condition. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our future global operations
will expose us to trade and economic sanctions and other restrictions imposed by the United States, the European Union and other
governments and organizations. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities
have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations
of economic sanctions laws, export control laws, the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes
and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the U.K. Bribery Act
of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public
sectors. An organization that &ldquo;fails to prevent bribery&rdquo; by anyone associated with the organization can be charged
under the Bribery Act unless the organization can establish the defense of having implemented &ldquo;adequate procedures&rdquo;
to prevent bribery. Under these laws and regulations, as well as other anti-corruption laws, anti-money-laundering laws, export
control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export
licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries
or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject
us to fines, penalties and other sanctions. A violation of these laws or regulations could adversely impact our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We will implement and
maintain policies and procedures designed to ensure compliance by us, and our directors, officers, employees, representatives,
third-party distributors, if any, consultants and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control,
anticorruption, anti-money-laundering and anti-terrorism laws and regulations. We cannot assure you, however, that our policies
and procedures will be sufficient or that directors, officers, employees, representatives, third-party distributors, if any, consultants
and agents have not engaged and will not engage in conduct for which we may be held responsible, nor can we assure you that our
business partners have not engaged and will not engage in conduct that could materially affect their ability to perform their contractual
obligations to us or even result in our being held liable for such conduct. Violations of the FCPA, OFAC restrictions, the Bribery
Act or other export control, anti-corruption, anti-money-laundering and anti-terrorism laws or regulations may result in severe
criminal or civil sanctions, and we may be subject to other liabilities, which could have a material adverse effect on our business,
financial condition, cash flows and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We are subject
to additional federal, state and foreign laws and regulations relating to our healthcare business; our failure to comply with those
laws could have an adverse impact on our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Although we will not
provide healthcare services, submit claims for third-party reimbursement, or receive payments directly from government health insurance
programs or other third-party payors for our cortical strip, grid electrode and depth electrode technology, we are subject to healthcare
fraud and abuse regulation and enforcement by federal, state and foreign governments, which could adversely impact our business.
Healthcare fraud and abuse and health information privacy and security laws potentially applicable to our operations include, but
are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the federal Anti-Kickback Statute, which will apply to our marketing practices, educational programs,
pricing policies and relationships with healthcare providers, by prohibiting, among other things, soliciting, receiving, offering
or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal
healthcare program, such as the Medicare or Medicaid programs. A person or entity does not need to have actual knowledge of this
statute or specific intent to violate it to have committed a violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">federal civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower
or qui tam actions that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval
to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or
transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing
an obligation to pay or transmit money or property to the federal government. The government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the false claims statutes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">HIPAA, and its implementing regulations, which created federal criminal laws that prohibit, among
other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters.
A person or entity does not need to have actual knowledge of these statutes or specific intent to violate them;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of
2009, and their implementing regulations, also imposes certain regulatory and contractual requirements regarding the privacy, security
and transmission of individually identifiable health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">federal &ldquo;sunshine&rdquo; requirements imposed by the ACA on device manufacturers regarding
any &ldquo;transfer of value&rdquo; made or distributed to physicians and teaching hospitals. Failure to submit required information
may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1&nbsp;million per
year for &ldquo;knowing failures&rdquo;), for all payments, transfers of value or ownership or investment interests that are not
timely, accurately, and completely reported in an annual submission. Manufacturers must submit reports by the 90th&nbsp;day of
each subsequent calendar year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities
and activities that potentially harm consumers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">state law equivalents of each of the above federal laws, such as anti-kickback and false claims
laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require
device companies to comply with the industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that require device
manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers
or marketing expenditures; and state laws governing the privacy and security of certain health information, many of which differ
from each other in significant ways and often are not preempted by HIPAA; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">foreign data privacy regulations, such as the EU Data Protection Directive (Directive&nbsp;95/46/EC),
and the country-specific regulations that implement Directive&nbsp;95/46/EC, which impose strict obligations and restrictions on
the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting,
and may be stricter than U.S. laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The risk of our being
found in violation of these laws and regulations is increased by the fact that the scope and enforcement of these laws is uncertain,
many of them have not been fully interpreted by the regulatory authorities or the courts, their provisions are open to a variety
of interpretations, or they vary country by country. We are unable to predict what additional federal, state or foreign legislation
or regulatory initiatives may be enacted in the future regarding our business or the healthcare industry in general, or what effect
such legislation or regulations may have on us. Federal, state or foreign governments may (i)&nbsp;impose additional restrictions
or adopt interpretations of existing laws that could have a material adverse effect on us or (ii)&nbsp;challenge our current or
future activities under these laws. Any of these challenges could impact our reputation, business, financial condition and operating
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If our operations are
found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the
future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement of profits, exclusion
from governmental health care programs, and the curtailment or restructuring of our operations, any of which could adversely affect
our ability to operate our business and our financial results. Any federal, state or foreign regulatory review to which we may
become subject, regardless of the outcome, would be costly and time-consuming.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For example, to enforce
compliance with the federal laws, the U.S. Department of Justice, or DOJ, has recently increased its scrutiny of interactions between
healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements
in the healthcare industry. Dealing with investigations can be time and resource consuming and can divert management&rsquo;s attention
from our core business. Additionally, if we settle an investigation with law enforcement or other regulatory agencies, we may be
forced to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity
agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may be liable
if the FDA or another regulatory agency concludes that we have engaged in the off-label promotion of our products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our promotional materials
and training methods must comply with FDA and other applicable laws and regulations, including the prohibition of the promotion
of the off-label use of our products. Healthcare providers may use our products, if approved, off-label, as the FDA does not restrict
or regulate a physician&rsquo;s choice of treatment within the practice of medicine. However, if the FDA determines that our promotional
materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials
or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction,
seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might
take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result
in significant fines or penalties. Although we intend to train our marketing and direct sales force to not promote our products
for uses outside of their cleared uses and our policy will be to refrain from statements that could be considered off-label promotion
of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion.
In addition, the off-label use of our products may increase the risk of product liability claims. Product liability claims are
expensive to defend and could result in substantial damage awards against us and harm our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Further, if we seek commercial
approval in Europe, the advertising and promotion of our products is subject to the laws of EEA Member States implementing Directive&nbsp;93/42/EEC
concerning medical devices, Directive 2006/114/EC concerning misleading and comparative advertising, and Directive 2005/29/EC on
unfair commercial practices, as well as other EEA Member State legislation governing the advertising and promotion of medical devices.
A new Medical Device Regulation (2017/745) that replaced Directive 93/42/EEC was published in 2017, with a three year implementation
period, which will impose significant additional premarket and post-market certification requirements on medical devices marketed
in the EU. EEA Member State legislation may also restrict or impose limitations on our ability to advertise our products directly
to the general public. In addition, voluntary EU and national codes of conduct provide guidelines on the advertising and promotion
of our products to the general public and may impose limitations on our promotional activities with healthcare providers harming
our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Legislative or
regulatory healthcare reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of our products.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recent political, economic
and regulatory influences are subjecting the healthcare industry to fundamental changes. The sales of our products depend in part
on the availability of coverage and reimbursement from third-party payors such as government health administration authorities,
private health insurers, health maintenance organizations and other healthcare-related organizations. Both the federal and state
governments in the United States continue to propose and pass new legislation and regulations designed to contain or reduce the
cost of healthcare. This legislation and regulation may result in decreased reimbursement for medical devices, which may further
exacerbate industry-wide pressure to reduce the prices charged for medical devices. This could harm our ability to market our products
and generate sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition, FDA regulations
and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products.
Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times
of our products. Delays in receipt of or failure to receive regulatory clearances or approvals for our products would harm our
business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">While one often stated
goal of healthcare reform is to expand coverage to more individuals, it also involves increased government price controls, additional
regulatory mandates and other measures designed to constrain medical costs. For example, the ACA was enacted in March 2010. The
ACA substantially changes the way healthcare is financed by both governmental and private insurers, encourages improvements in
the quality of healthcare items and services and significantly impacts the medical device industries. Among other things, the ACA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities
in and conduct comparative clinical effectiveness research;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">implements payment system reforms including value-based payment programs, increased funding for
comparative effectiveness research, reduced hospital payments for avoidable readmissions and hospital acquired conditions, and
pilot programs to evaluate alternative payment methodologies that promote care coordination (such as bundled physician and hospital
payments); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">creates an independent payment advisory board that will submit recommendations to reduce Medicare
spending if projected Medicare spending exceeds a specified growth rate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">At this time, we cannot
predict which, if any, additional healthcare reform proposals will be adopted, when they may be adopted or what impact they, or
the ACA, may have on our business and operations, and any of these impacts may be adverse on our operating results and financial
condition. Our financial performance may be adversely affected by medical device tax provisions in the healthcare reform laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The ACA imposes, among
other things, an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United
States beginning in 2013. Due to subsequent legislative amendments, the excise tax has been suspended from January 1, 2016 to December
31, 2019, and, absent further legislative action, will be reinstated starting January 1, 2020. We do not believe that our cortical
strip, grid electrode and depth electrode technology under development is currently subject to this tax based on the retail exemption
under applicable Treasury Regulations. However, the availability of this exemption is subject to interpretation by the Internal
Revenue Service, or IRS, and the IRS may disagree with our analysis. In addition, future products that we manufacture, produce
or import may be subject to this tax. The financial impact this tax may have on our business is unclear and there can be no assurance
that our business will not be materially adversely affected by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Tax matters, including
the changes in corporate tax rates, disagreements with taxing authorities and imposition of new taxes could impact our results
of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are subject to income
and other taxes in the U.S. and our operations, plans and results are affected by tax and other initiatives. On December 22, 2017,
the Tax Act was signed into law by President Trump. The Tax Act contains significant changes to corporate taxation, including reduction
of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense
to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current
year taxable income and elimination of net operating loss carrybacks, one-time taxation of offshore earnings at reduced rates regardless
of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate
deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many
business deductions and credits.&nbsp;Notwithstanding the reduction in the corporate income tax rate, the overall impact of the
new federal tax law is uncertain and our business and financial condition could be adversely affected.&nbsp;While the new federal
tax law did not extend the moratorium on the medical device excise tax, the reinstatement of which could negatively impact our
operating results as we begin full commercialization of our platforms in the United States, the moratorium was subsequently extended
until 2020. It is also unknown if and to what extent various states will conform to the newly enacted federal tax law. The impact
of this tax reform on holders of our Common Stock is likewise uncertain and could be adverse.&nbsp;We urge you to consult with
your legal and tax advisors with respect to this legislation and the potential tax consequences of investing in our Common Stock.
The decrease in the corporate tax rate will result in changes in the valuation of our deferred tax assets and liabilities. Any
such change in valuation could have a material impact on our income tax expense and deferred tax balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are also subject to
regular reviews, examinations, and audits by the Internal Revenue Service and other taxing authorities with respect to our taxes.
Although we believe our tax estimates are reasonable, if a taxing authority disagrees with the positions we have taken, we could
face additional tax liability, including interest and penalties. There can be no assurance that payment of such additional amounts
upon final adjudication of any disputes will not have a material impact on our results of operations and financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We also need to comply
with new, evolving or revised tax laws and regulations. The enactment of or increases in tariffs, or other changes in the application
or interpretation of the Tax Act, or on specific products that we sell or with which our products compete, may have an adverse
effect on our business or on our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Risks Related to our
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>An active and visible
public trading market for our Common Stock may not develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We do not currently have
an active or visible trading market. We cannot predict whether an active market for our Common Stock will ever develop in the future.
In the absence of an active trading market:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Investors may have difficulty buying and selling or obtaining market quotations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Trading of our Common Stock may be extremely sporadic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Market visibility for shares of our Common Stock may be limited; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">A lack of visibility for shares of our Common Stock may have a depressive effect on the market
price for shares of our Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our Common Stock is quoted
over-the-counter on a market operated by OTC Markets Group, Inc. These markets are relatively unorganized, inter-dealer, over-the-counter
markets that provide significantly less liquidity than NASDAQ or the NYSE MKT. No assurances can be given that our Common Stock,
even if quoted on such markets, will ever actively trade on such markets, much less a senior market like NASDAQ or NYSE MKT. In
this event, there would be a highly illiquid market for our Common Stock and you may be unable to dispose of your Common Stock
at desirable prices or at all. Moreover, there is a risk that our Common Stock could be delisted from its current tier of the OTC
Market, in which case our stock may be quoted on markets even more illiquid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>The price of our
Common Stock might fluctuate significantly, and you could lose all or part of your investment. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Volatility in the market
price of our Common Stock may prevent you from being able to sell your shares of our Common Stock at or above the price you paid
for your shares. The trading price of our Common Stock may be volatile and subject to wide price fluctuations in response to various
factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated fluctuations in our quarterly financial and operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our progress toward developing our cortical strip and sheet electrode technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the commencement, enrollment and results of our future clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">adverse results from, delays in or termination of our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">adverse regulatory decisions, including failure to receive regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">publication of research reports about us or our industry or positive or negative recommendations
or withdrawal of research coverage by securities analysts, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">perceptions about the market acceptance of our products and the recognition of our brand;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">adverse publicity about our products or industry in general;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">overall performance of the equity markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">introduction of products, or announcements of significant contracts, licenses or acquisitions,
by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">legislative, political or regulatory developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">additions or departures of key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">threatened or actual litigation and government investigations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">third-party promotional activities, which are subject to ongoing regulatory obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">sale of shares of our Common Stock by us or members of our management; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">general economic conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">These and other factors
might cause the market price of our Common Stock to fluctuate substantially, which may negatively affect the liquidity of our Common
Stock. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. This volatility
has had a significant impact on the market price of securities issued by many companies across many industries. The changes frequently
appear to occur without regard to the operating performance of the affected companies. Accordingly, the price of our Common Stock
could fluctuate based upon factors that have little or nothing to do with our Company, and these fluctuations could materially
reduce our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Securities class action
litigation has often been instituted against companies following periods of volatility in the overall market and in the market
price of a company&rsquo;s securities. This litigation, if instituted against us, could result in substantial costs, divert our
management&rsquo;s attention and resources, and harm our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Concentration of
ownership of our Common Stock among our existing executive officers, directors and principal stockholders may prevent new investors
from influencing significant corporate decisions. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As of November 30, 2018,
our executive officers, directors and current beneficial owners of 5% or more of our Common Stock and their respective affiliates,
in the aggregate, beneficially own approximately 79.9% of our outstanding Common Stock. As a result, these persons, acting together,
would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors,
any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Some of these persons
or entities may have interests different than yours. For example, they may be more interested in selling our Company to an acquirer
than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our management
has identified certain internal control deficiencies, which management believes constitute material weaknesses. Our failure to
establish and maintain an effective system of internal controls could result in material misstatements of our financial statements
or cause us to fail to meet our reporting obligations or fail to prevent fraud in which case, our stockholders could lose confidence
in our financial reporting, which would harm our business and could negatively impact the price of our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Prior to the Acquisition,
NeuroOne, Inc. was a private company with limited accounting personnel and other resources with which to address our internal controls
and procedures.&nbsp;We review and update our internal controls, disclosure controls and procedures, and corporate governance policies
as our Company continues to evolve. In addition, in connection with the Acquisition and becoming a company required to file reports
with the SEC, we are required to comply with the internal control evaluation and certification requirements of Section&nbsp;404
of the Sarbanes-Oxley Act of 2002 (&ldquo;<B><I>SOX</I></B>&rdquo;) and management is required to report annually on our internal
control over financial reporting. Our independent registered public accounting firm will not be required to formally attest to
the effectiveness of our internal control over financial reporting pursuant to Section&nbsp;404 of SOX until the date we are no
longer a &ldquo;smaller reporting company&rdquo; as defined by applicable SEC rules. We will remain a &ldquo;smaller reporting
company&rdquo; as long as (i) our public float remains less than $250 million or (ii) our annual revenues are less than $100 million
and we either have no public float, or our public float is less than $700 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">During the&nbsp;audits for the periods ended September 30, 2018 and December 31, 2017, it was determined that our internal
control over financial reporting is not effective. Such shortcoming could have an adverse effect on our business and
financial results. This reporting requirement could also make it more difficult or more costly for us to obtain certain types
of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and
coverage or incur substantially higher costs to obtain the same or similar coverage. Any system of internal controls, however
well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances
that the objectives of the system are met. Any failure or circumvention of the controls and procedures or failure to comply
with regulation concerning control and procedures could have a material effect on our business, results of operation and
financial condition. Any of these events could result in an adverse reaction in the financial marketplace due to a loss of
investor confidence in the reliability of our financial statements, which ultimately could negatively affect the market price
of our shares, increase the volatility of our stock price and adversely affect our ability to raise additional funding. The
effect of these events could also make it more difficult for us to attract and retain qualified persons to serve on our Board
and as executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our management&rsquo;s
evaluation of the effectiveness of our internal controls over financial reporting as of September 30, 2018 concluded that our controls
were not effective, due to material weaknesses resulting from an ineffective overall control environment. The material weaknesses
stem primarily from our small size and include the inability to (i) maintain effective controls over accounting for non-routine
and/or complex debt and equity transactions and (ii) maintain effective controls over the financial statement close and reporting
process, accounting for routine transactions and segregation of duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Management believes there
is a reasonable possibility that these control deficiencies, if uncorrected, could result in material misstatements in the annual
or interim financial statements that would not be prevented or detected in a timely manner. Accordingly, we have determined that
these control deficiencies constitute material weaknesses. Subject to limitations on liquidity, the Company is planning to take
steps to remediate these material weaknesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We will need to evaluate
our existing internal controls over financial reporting against the criteria set forth in Internal Control &ndash; Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. During the course of our ongoing evaluation
of the internal controls, we may identify other areas requiring improvement, and may have to design enhanced processes and controls
to address issues identified through this review. Remediating any deficiencies, significant deficiencies or material weaknesses
that we or our independent registered public accounting firm may identify may require us to incur significant costs and expend
significant time and management resources. We cannot assure you that any of the measures we implement to remedy any such deficiencies
will effectively mitigate or remedy such deficiencies. The existence of one or more material weaknesses could affect the accuracy
and timing of our financial reporting. Investors could lose confidence in our financial reports, and the value of our Common Stock
may be harmed, if our internal controls over financial reporting are found not to be effective by management or by an independent
registered public accounting firm or if we make disclosure of existing or potential material weaknesses in those controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Even if we conclude that
our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, because
of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure
to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating results
or cause us to fail to meet our future reporting obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our reporting obligations
as a public company will place a significant strain on our management, operational and financial resources and systems for the
foreseeable future. If we fail to timely achieve and maintain the adequacy of our internal control over financial reporting, we
may not be able to produce reliable financial reports or help prevent fraud. Our failure to achieve and maintain effective internal
control over financial reporting could prevent us from filing our periodic reports on a timely basis which could result in the
loss of investor confidence in the reliability of our financial statements, harm our business and negatively impact the trading
price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We intend to issue
more shares to raise capital, which will result in substantial dilution. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our certificate of incorporation
authorizes the issuance of a maximum of 100,000,000 shares of Common Stock and 10,000,000 shares of preferred stock. Any additional
financings effected by us may result in the issuance of additional securities without stockholder approval and the substantial
dilution in the percentage of Common Stock held by our then existing stockholders. Moreover, the Common Stock issued in any such
transaction may be valued on an arbitrary or non-arm&rsquo;s-length basis by our management, resulting in an additional reduction
in the percentage of Common Stock held by our current stockholders. Our Board has the power to issue any or all of such authorized
but unissued shares without stockholder approval. To the extent that additional shares of Common Stock are issued in connection
with a financing, dilution to the interests of our stockholders will occur and the rights of the holder of Common Stock might be
materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As of September 30,
2018, we had outstanding &nbsp;warrants to purchase an aggregate of 2,927,572 shares of Common Stock at a weighted average
exercise price of $1.98 per share, options to purchase an aggregate of 368,216 shares of Common Stock at a weighted average
exercise price of $0.07 per share, and notes and warrants convertible into or exercisable for shares of our Common Stock. As
of September 30, 2018, the principal and accrued and unpaid interest on our outstanding convertible promissory notes is
approximately $1,627,028. For a description of our outstanding convertible promissory notes and warrants and information
about the number of shares of Common Stock for which they are convertible or exercisable, see &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&mdash;Liquidity and Capital
Resources&mdash;Historical Capital Resources.&rdquo; To the extent these outstanding options or warrants are exercised or the
convertible promissory notes are converted, there will be further dilution to holders of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Anti-takeover provisions
in the Company&rsquo;s certificate of incorporation and bylaws may prevent or frustrate attempts by stockholders to change the
Board or current management and could make a third-party acquisition of the Company difficult.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company&rsquo;s certificate
of incorporation and bylaws contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control
that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their
shares. For example, our certificate of incorporation permits the Board without stockholder approval to issue up to 10,000,000
shares of preferred stock and to fix the designation, power, preferences, and rights of those shares. Furthermore, our Board has
the ability to increase the size of the Board and fill the newly created vacancies without stockholder approval. These provisions
could limit the price that investors might be willing to pay in the future for shares of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We are a smaller
reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our Common Stock less
attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are a &ldquo;smaller
reporting company&rdquo; as defined in Section 12 of the Exchange Act. For as long as we continue to be a smaller reporting company,
we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are
not smaller reporting companies, including not being required to comply with the auditor attestation requirements of SOX, reduced
disclosure obligations regarding executive compensation in our annual and periodic reports and proxy statements, and exemptions
from the requirements of holding nonbinding advisory votes on executive compensation, and stockholder approval of any golden parachute
payments not previously approved. We will remain a &ldquo;smaller reporting company&rdquo; as long as (i) our public float remains
less than $250 million or (ii) our annual revenues are less than $100 million and we either have no public float, or our public
float is less than $700 million. Public float is measured as of the last business day of our most recently-completed second fiscal
quarter, and annual revenues are as of the most recently completed fiscal year for which audited financial statements are available.
We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors
find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock
price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Our Common Stock
is subject to the &ldquo;penny stock&rdquo; rules of the SEC, which makes transactions in our stock cumbersome and may reduce the
value of an investment in our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The SEC has adopted regulations
which generally define a &ldquo;penny stock&rdquo; as an equity security that has a market price of less than $5.00 per share,
subject to specific exemptions. The SEC&rsquo;s penny stock rules require a broker-dealer, before a transaction in a penny stock
not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks
and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations
for the penny stock, the compensation of the broker-dealer and the salesperson in the transaction, and monthly account statements
showing the market value of each penny stock held in the customer&rsquo;s account. In addition, the penny stock rules generally
require that before a transaction in a penny stock occurs, the broker-dealer must make a special written determination that the
penny stock is a suitable investment for the purchaser and receive the purchaser&rsquo;s agreement to the transaction. These rules
may restrict the ability of brokers-dealers to sell our Common Stock and may affect the ability of investors to sell their shares,
until our Common Stock no longer is considered a penny stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>The market for
penny stocks has experienced numerous frauds and abuses, which could adversely impact investors in our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">OTC Market securities
are frequent targets of fraud or market manipulation, both because of their generally low prices and because reporting requirements
are less stringent than those of the stock exchanges such as NASDAQ and The New York Stock Exchange. Patterns of fraud and abuse
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Control of the market for the security by one or a few broker-dealers that are often related to
the promoter or issuer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Manipulation of prices through prearranged matching of purchases and sales and false and misleading
press releases;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;Boiler room&rdquo; practices involving high pressure sales tactics and unrealistic price
projections by inexperienced sales persons;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Wholesale dumping of the same securities by promoters and broker-dealers after prices have been
manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We have not paid
dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value
of our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have never declared
or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use
in the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Accordingly,
you may have to sell some or all of your shares of our Common Stock in order to generate cash flow from your investment. You may
not receive a gain on your investment when you sell shares and you may lose the entire amount of the investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We expect to incur
increased costs and demands upon management as a result of being a public company. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As a public company in
the United States, we expect to incur significant additional legal, accounting and other costs. These additional costs could negatively
affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public
disclosure, including regulations implemented by the SEC and the stock exchange on which we may list our Common Stock, may increase
legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject
to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this
investment may result in increased general and administrative expenses and a diversion of management&rsquo;s time and attention
from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations
and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Failure to comply with
these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability
insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the
same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons
to serve on our Board, on committees of our Board or as members of senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>A significant portion
of our total outstanding shares are restricted from immediate resale but may be sold into the market in the future. This could
cause the market price of our Common Stock to drop significantly, even if our business is doing well. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Sales of a substantial
number of shares of our Common Stock in the public market could occur at any time. If our stockholders sell, or the market perceives
that our stockholders intend to sell substantial amounts of our Common Stock in the public market, the market price of our Common
Stock could decline significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Certain shares of our
outstanding Common Stock are freely tradable without restriction by stockholders who are not our affiliates. However, we have shares
of Common Stock that are restricted under securities laws but will be able to be resold in the future. We also intend to register
all shares of Common Stock that we have issued in our 2018 Private Placement, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&nbsp;-&nbsp;Liquidity and Capital Resources.&rdquo; Once we register these shares, they can
be freely sold in the public market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Furthermore, shares issued
pursuant to awards under our equity incentive plans and registered under a registration statement on Form&nbsp;S-8 will be available
for sale in the public market subject to vesting arrangements and exercise of options and the restrictions of Rule&nbsp;144 in
the case of our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>If securities or
industry analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our
market, our stock price and trading volume could decline. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The trading market for
our Common Stock will be influenced by the research and reports that securities or industry analysts publish about us and our business.
Securities or industry analysts may elect not to provide coverage of our Common Stock, and such lack of coverage may adversely
affect the market price of our Common Stock. In the event we do not secure additional securities or industry analyst coverage,
we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could
decline if one or more securities or industry analysts downgrade our stock or issue other unfavorable commentary or research. If
one or more securities or industry analysts ceases coverage of our Company or fails to publish reports on us regularly, demand
for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Risks Related to the
Acquisition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>We may be subject
to unknown risks as a result of our completed acquisition by Original Source Entertainment, Inc. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Original Source Entertainment,
Inc., which was renamed NeuroOne Medical Technologies Corporation in connection with the Acquisition, was formed to license songs
to the television and movie industry and has generated very little revenues. Prior to the Acquisition, its operations have been
primarily limited to organizational, start-up, and capital formation activities, with no employees other than the former officers.
On February 5, 2014, the board of directors of Original Source Entertainment, Inc. authorized the spin-off of Original Source Music,
Inc., a wholly-owned subsidiary which then held all of our operations and assets, to our stockholders of record as of February
25, 2014. Under the terms of the spin-off, the common stock, par value $0.001 per share, of Original Source Music, Inc. was distributed
on a pro-rata basis to each holder of our Common Stock on the February 25, 2014 record date without any consideration or action
on the part of such holders, and the holders of our Common Stock as of the February 25, 2014 record date became owners of 100%
of the common stock of Original Source Music, Inc. The spin-off of Original Source Music, Inc. was effective as of May 13, 2016,
due to the satisfactory resolution of all comments from the SEC to the Registration Statement on Form 10 of Original Source Music,
Inc. and the Form 10&rsquo;s effectiveness. Therefore, upon the spinoff of Original Source Music, which held all of our operations
and assets at the time, on May 13, 2016, Original Source Entertainment, Inc. ceased having a specific business plan and purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In connection with the
Acquisition, the liabilities existing in Original Source Entertainment, Inc. at the time of the Acquisition were cancelled or paid
by a related party, as required by the Merger Agreement with NeuroOne, Inc. and OSOK Acquisition Company (the <B><I>&ldquo;Merger
Agreement&rdquo;</I></B>). Despite this requirement and the representations and warranties of Original Source Entertainment, Inc.
in the Merger Agreement, there may be unknown liabilities, or liabilities that were known but believed to be immaterial, related
to the business of Original Source Entertainment, Inc. that may become material liabilities we are subject to in the future. If
we are subject to material liability as a result of the conduct of Original Source Entertainment, Inc., we may have limited recourse
for such liabilities, which could have a material impact on our business and stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Because we were
engaged in a transaction that can be generally characterized as a &ldquo;reverse merger,&rdquo; we may not be able to attract the
attention of major brokerage firms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Additional
risks may exist since we were engaged in a transaction that can be generally characterized as a &ldquo;reverse merger.&rdquo; Securities
analysts of major brokerage firms may not provide coverage of the Company since there is little incentive to brokerage firms to
recommend the purchase of the Common Stock. No assurance can be given that brokerage firms will want to conduct any secondary offerings.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_005"></A>ITEM 1B. UNRESOLVED STAFF COMMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_006"></A>ITEM 2. PROPERTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We currently sublease
office space in Minnetonka, Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_007"></A>ITEM 3. LEGAL PROCEEDINGS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we are subject to litigation
and claims arising in the ordinary course of business. In May 2017, NeuroOne, Inc. received a letter from PMT, the former employer
of Mark Christianson and Wade Fredrickson. PMT claimed that these officers had breached their restrictive covenant obligations
with PMT by virtue of their work for NeuroOne, Inc. and such officer&rsquo;s prior work during employment with the prior employer,
that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating
confidential and trade secret information, and that the Company is responsible for tortious interference with the contracts. The
letter demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne, Inc. cease and
desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne, Inc.
provide the former employer access to NeuroOne, Inc.&rsquo;s systems to demonstrate that it is not using trade secrets or proprietary
information nor competing with the former employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, we were served with
a complaint filed by PMT adding the Company, NeuroOne, Inc. and Mark Christianson to its existing lawsuit against Wade Fredrickson.
In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure
obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil
conspiracy, tortiously interfered with PMT&rsquo;s contracts and prospective economic advantage, and breached a covenant of good
faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made
negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort
of conversion and statutory civil theft. Against the Company and NeuroOne, Inc., PMT alleges that the Company and NeuroOne, Inc.
were unjustly enriched and engaged in unfair competition. PMT asks the Court to impose a constructive trust over the shares held
by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&rsquo;
fees, costs and interest. The Company, NeuroOne, Inc. and Mr. Christianson (who has not worked for PMT since 2012) intend to defend
themselves vigorously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2018, Mr. Christianson, the
Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. We expect a ruling on
the motion within 90 days of that date. The motion for dismissal states that: the contract claims against Mr. Christianson fail
because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&rsquo;s claims
for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the
duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently
pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The outcome and potential
loss related to this matter is unknown as of the filing of this Transition Report.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_008"></A>ITEM 4. MINE SAFETY DISCLOSURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_010"></A>ITEM 5. MARKET FOR REGISTRANT&rsquo;S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Price Range of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our Common Stock is not
traded on any exchange. Our Common Stock has been quoted on the OTC Market (&ldquo;<B><I>OTCQB</I></B>&rdquo;) administered by
the Financial Industry Regulatory Authority under the symbol &ldquo;NMTC&rdquo; since December 19, 2017. Prior to that date, our
Common Stock had been quoted on the OTC Pink Sheets since November 2012, under the symbol &ldquo;NMTC&rdquo; since August 4, 2017
and under the symbol &ldquo;OSOK&rdquo; prior to that time. Trading in stocks quoted on the OTCQB is often thin and is characterized
by wide fluctuations in trading prices due to many factors that may be unrelated or have little to do with a company&rsquo;s operations
or business prospects. We cannot assure you that there will be a market for our Common Stock in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The following table presents
the range of high and low closing bid information for our common equity for each full quarterly period within the nine months ended
September 30, 2018 (the &ldquo;<B><I>Transition Period</I></B>&rdquo;) and the two most recent fiscal years, as quoted by the OTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">There is no established
public trading market for our Common Stock. The over-the-counter market quotations below reflect inter-dealer prices, without retail
mark-up, mark-down or commission and may not necessarily represent actual transactions. Prior to August 1, 2017, only one market
maker was quoting the bid price information for our Common Stock and only one bid price was available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>High</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Low</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Transition Period Ended September 30, 2018</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Fiscal Year Ended December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.02</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Fiscal Year Ended December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">On November 30, 2018,
there were 77 record holders of our Common Stock. The transfer agent and registrar for our Common Stock is Action Stock Transfer
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shares Available Under the Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The following table presents
information as of September 30, 2018 with respect to compensation plans under which shares of our Common Stock may be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>Plan Category</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number of Securities<BR> to be issued upon<BR>
    exercise of<BR> outstanding options<BR> (a)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted-average<BR> exercise price of<BR>
    outstanding options<BR> (b)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number of securities<BR> remaining available<BR>
    for future issuance<BR> under equity<BR> compensation plans<BR> (excluding securities<BR> reflected in column&nbsp;(a))(1)<BR>
    (c)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Equity compensation plans not approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Equity compensation plan approved by security holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,708,596</TD><TD STYLE="text-align: left">(2)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,708,596</TD><TD STYLE="text-align: left">(2)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The number of shares of Common Stock reserved for issuance
under our 2017 Equity Incentive Plan automatically increases on January 1st of each calendar year, starting on January 1, 2018
through January 1, 2027, to an amount equal to 13% of the total number of fully-diluted shares of our Common Stock as of December
31 of the preceding calendar year, or a lesser number of shares determined by our Board.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Consists of 1,297,500 shares remaining available for issuance
under the 2017 Equity Incentive Plan and 411,096 shares remaining available for issuance under the 2016 Equity Incentive Plan.
Upon the closing of the Acquisition, we no longer granted awards under the 2016 Equity Incentive Plan, and all awards are granted
under the 2017 Equity Incentive Plan.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Sales of Unregistered Equity
Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">All sales of unregistered
equity securities have previously been disclosed in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_011"></A>ITEM 6. SELECTED FINANCIAL DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_012"></A>ITEM 7. MANAGEMENT&rsquo;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should read the following discussion
and analysis of financial condition and results of operations of NeuroOne Medical Technologies Corporation together with our financial
statements and the related notes included elsewhere in this Transition Report. Some of the information contained in this discussion
and analysis or set forth elsewhere in this Transition Report, including information with respect to our plans and strategy for
our business, includes forward-looking statements that involve risks and uncertainties. You should review the &ldquo;Risk Factors&rdquo;
section of this Transition Report for a discussion of important factors that could cause actual results to differ materially from
the results described in or implied by the forward-looking statements contained in the following discussion and analysis. References
in this discussion to &ldquo;series&rdquo; or &ldquo;notes&rdquo; refer to all of our outstanding notes as of the relevant date
of the item being discussed. References in this discussion to &ldquo;convertible promissory notes&rdquo; refer to all of our outstanding
convertible promissory notes as of the relevant date of the item being discussed.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were originally
incorporated in the State of Nevada on August 20, 2009 as Original Source Entertainment, Inc. (&ldquo;<B>OSE</B>&rdquo;). OSE was
originally formed to license songs to the television and movie industry. From our inception and prior to the acquisition of NeuroOne,
Inc. on July 20, 2017 (the &ldquo;<B>Acquisition</B>&rdquo;), as described more fully below, our operations have been primarily
limited to organizational, start-up, and capital formation activities. Upon completion of the Acquisition, as more fully described
below, our operations consist of the development of comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain
stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors, and
other brain related disorders. Our cortical strip technology under development has only been used by Mayo in five patients for
research purposes and has not been tested in any clinical trials. We are based in Minnetonka, Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Acquisition was
accounted for as a capital transaction, or reverse recapitalization. As a result, the financial information contained in the Transition
Report reflect solely the operations of our wholly-owned subsidiary, NeuroOne, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our primary
activities have been limited to, and our limited resources have been dedicated to, performing business and financial planning,
raising capital, recruiting personnel, negotiating with business partners and the licensors of our intellectual property and conducting
research and development activities. Our cortical strip, grid electrode and depth electrode technology is still under development,
we do not yet have regulatory approval in any jurisdiction to sell any products and we have not generated any revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred losses since inception. As of September 30, 2018, we had an accumulated deficit of $10.5
million, primarily as a result of expenses incurred in connection with our research and development programs, from general and
administrative expenses associated with our operations and interest expense related to our debt. We expect to continue to incur
significant expenses and increasing operating and net losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to
generate revenue from product sales unless and until we obtain marketing authorization to sell our cortical strip, grid electrode
and depth electrode technology from applicable regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our source of cash to date has been proceeds from the issuances of notes with warrants and common stock
with warrants and unsecured loans. See &ldquo;&mdash;Liquidity and Capital Resources&mdash;Historical Capital Resources&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At September 30,
2018, we had $13,260 in cash deposits. Our existing cash and cash equivalents will not be sufficient to fund our operating
expenses in fiscal 2019. We need to obtain substantial additional funding in connection with our continuing operations
through public or private equity or debt financings or other sources, which may include collaborations with third parties.
However, we may be unable to raise additional funds when needed on favorable terms or at all. Our failure to raise such
capital as and when needed would have a negative impact on our financial condition and our ability to develop and
commercialize our cortical strip, grid electrode and depth electrode technology and future products and our ability to pursue
our business strategy. See &ldquo;&mdash;Liquidity and Capital Resources&mdash;Funding Requirements and Outlook&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 20, 2017, we
entered into a Merger Agreement with NeuroOne, Inc. and OSOK Acquisition Company to acquire NeuroOne, Inc. (the <B>&ldquo;Merger
Agreement&rdquo;</B>). The transactions contemplated by the Merger Agreement were consummated on July 20, 2017 and, pursuant to
the terms of the Merger Agreement, (i)&nbsp;all outstanding NeuroOne Shares were exchanged for shares of Common Stock, based on
the Exchange Ratio of 17.0103706 shares of Common Stock, for every one NeuroOne Share, which totaled 6,291,994 shares of Common
Stock, for all of the then-outstanding NeuroOne Shares, (ii)&nbsp;all NeuroOne Options were replaced with options <B>(&ldquo;Company
Options&rdquo;)</B> based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, (iii) all
NeuroOne Warrants were replaced with warrants to purchase Common Stock of the Company <B>(&ldquo;Company Warrants&rdquo;</B>) and
(iv) we assumed the outstanding convertible promissory notes of NeuroOne, Inc. Accordingly, we acquired 100% of NeuroOne, Inc.
in exchange for the issuance of shares of our Common Stock and NeuroOne, Inc. became our wholly-owned subsidiary. Our sole business
is the business of NeuroOne, Inc. Our management&rsquo;s discussion and analysis below is based on the financial results of NeuroOne,
Inc. Except as otherwise indicated herein, all share and per share information in this &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations&rdquo; section gives retroactive effect to the exchange of NeuroOne Shares,
NeuroOne Options and NeuroOne Warrants for shares of Common Stock, Company Options and Company Warrants, respectively, in the Acquisition,
as well as the corresponding exercise price adjustments for such Company Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Predecessor NeuroOne, Inc. and NeuroOne
LLC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NeuroOne LLC (the &ldquo;<B>LLC</B>&rdquo;)
was formed on December 12, 2013 and operated as a limited liability company until it was merged with and into NeuroOne, Inc. on
October 27, 2016 (the &ldquo;<B>Merger</B>&rdquo;) with NeuroOne, Inc. as the surviving entity of the Merger. NeuroOne, Inc. was
formed on October 7, 2016 under different ownership than the LLC. As a result of the Merger, all of the properties, rights, privileges
and powers of the LLC vested in NeuroOne, Inc., and all debts, liabilities and duties of the LLC became the debts, liabilities
and duties of NeuroOne, Inc. with the exception of the WARF License which required WARF&rsquo;s approval for transfer. The approval
for the WARF License transfer was finalized in February 2017. The purpose of the Merger was to change the jurisdiction of NeuroOne,
Inc.&rsquo;s incorporation from Minnesota to Delaware, change the ownership of the LLC&rsquo;s underlying assets, and to convert
from a limited liability company to a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;NeuroOne, Inc.
and the LLC were not entities under common control. As the LLC did not have an integrated set of activities that contained the
required complement of inputs, processes and outputs to be considered a business, the Merger was accounted for as an asset acquisition
as prescribed under ASC 805 &ndash; Business Combinations. As such, the activities of the LLC were not combined with NeuroOne,
Inc. in the accompanying financial statements included in this Transition Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B>Financial
Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not
generated any revenue. We do not expect to generate revenue unless or until we develop, obtain regulatory approval for and commercialize
our cortical strip, grid electrode and depth electrode technology. If we fail to complete the development of our cortical strip,
grid electrode and depth electrode technology, or any other product candidate we may pursue in the future, in a timely manner,
or fail to obtain regulatory approval, we may never be able to generate any revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly
associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial
matters and product costs. We anticipate that our general and administrative expenses will significantly increase in the future
to support our continued research and development activities, potential commercialization of our cortical strip, grid electrode
and depth electrode technology, if approved, and the increased costs of operating as a public company. These increases will include
increased costs related to the hiring of additional personnel and fees for legal and professional services, as well as other public-company
related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses consist of expenses incurred in performing research and development activities in developing our cortical strip, grid
electrode and depth electrode technology. Research and development expenses include compensation and benefits for research and
development employees including stock-based compensation, overhead expenses, cost of laboratory supplies, clinical trial and related
clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants and other outside expenses. Research
and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research
and development expenses to significantly increase over the next several years as we develop our cortical strip, grid electrode
and depth electrode technology and conduct preclinical testing and clinical trials and will depend on the duration, costs and timing
to complete our preclinical programs and clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense primarily
consists of amortized discount costs and interest costs related to our Series 1 Notes (as defined below), Series 2 Notes (as defined
below) and Series 3 Notes (as defined below) while outstanding. The Series 1 Notes, Series 2 Notes and Series 3 Notes bear interest
at a fixed rate of 8% per annum while outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net change in fair value for the
warrant liability and premium conversion derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The net change in fair
value for the warrant liability and premium conversion derivatives include the change in the fair value of warrant liability and
the premium conversion derivatives during the particular period while the warrant liability and the premium conversion derivatives
are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Loss on note extinguishments, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Loss on notes extinguishments,
net includes the gain or loss associated with debt instrument modifications accounted for as note extinguishments.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Comparison of the Nine Month Period
Ended September 30, 2018 and 2017 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth our results of operations for the nine month periods ended September 30,
2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period to<BR> Period<BR> Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>(unaudited)</B></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,676,872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,798,131</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">878,741</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">715,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">214,678</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,391,958</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,298,539</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,093,419</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,391,958</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,298,539</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,093,419</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(763,065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,057,024</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">293,959</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net change in fair value for the warrant liability and premium conversion derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">336,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(77,505</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Loss on note extinguishments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,314,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,314,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,132,914</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,433,068</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,699,846</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and administrative expenses
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and
administrative expenses were $2.7 million for the nine month period ended September 30, 2018, compared to $1.8 million for
the nine month period ended September 30, 2017. The $0.9 million increase was primarily due to an increase in public company costs and salary related expenses to support the
increased level of commercialization and development activities. The increase in spending was primarily attributable to
stock-based compensation of $0.5 million, corporate governance related to board of director and other policy and procedures
implementation costs of $0.2 million, legal, accounting and other corporate related service costs of $0.3 million, offset in
part by a $0.1 million reduction in salary related expenses. Legal and accounting expenses during the nine month period ended
September 30, 2018, were largely incurred in connection with financing matters and securities matters, and costs are expected
to be similar for future periods as we continue our financing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and development expenses </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses were $0.7 million for the nine month period ended September 30, 2018, compared to $0.5 million for the nine month period
ended September 30, 2017. The increase was primarily due to an increase in salary-related expenses and development materials and
supplies to support the increased level of development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Interest expense </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense for
the nine month period ended September 30, 2018 and 2017 was $0.8 million and $1.1 million, respectively. Interest expense primarily
consists of non-cash interest expense, inclusive of the amortization of debt discounts. The $0.3 million decrease in interest expense
was primarily due to the lower level of outstanding debt discounts and related amortization in 2018 given the debt modifications
that occurred in the fourth quarter of 2017 and first quarter of 2018 as well as the extinguishment and conversion of the Series
1 Notes and Series 2 Notes on July 2, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net change in fair value for the warrant
liability and premium conversion derivatives</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net change in fair value for the warrant liability and premium conversion derivatives for the nine
month periods ended September 30, 2018 and 2017 was a benefit of $0.3 million and an expense of $0.1 million, respectively. The
change was largely due to the impact of the July 2, 2018 extinguishment and conversion of the Series 1 Notes and Series 2 Notes
which resulted in the elimination of the associated premium conversion derivatives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Loss on note extinguishments, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-cash loss on note extinguishments, net for the nine month periods ended September 30, 2018 and 2017
was $1.3 million and zero, respectively. The Series 1 Notes and Series 2 Notes were extinguished and converted on July 2, 2018
which contributed to $1.2 million of the increase. The balance of the increase was due to the modification of the Series 2 Notes
in March 2018 which was accounted for as a note extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Historical Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30,
2018, our principal source of liquidity consisted of cash deposits of $13,260. We have not generated any revenue, and we anticipate
that we will continue to incur losses for the foreseeable future. We anticipate that our expenses will increase substantially as
we develop our cortical strip, grid electrode and depth electrode technology and pursue pre-clinical testing and clinical trials,
seek regulatory approvals, contract to manufacture any products, establish our own sales, marketing and distribution infrastructure
to commercialize our cortical strip, grid electrode and depth electrode technology under development, if approved, hire additional
staff, add operational, financial and management systems and continue to operate as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our source of cash to date has been proceeds from the issuances of notes with warrants, common stock with
warrants and unsecured loans, the terms of which are further described below. See &ldquo;&mdash;Funding Requirements and Outlook&rdquo;
below for the outstanding balances on our convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>2018 Private Placement </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From July 9, 2018 through
November 30, 2018, the Company entered into subscription agreements (each, a &ldquo;<B>Purchase Agreement</B>&rdquo;) with certain
accredited investors (the &ldquo;<B>Purchasers</B>&rdquo;), pursuant to which the Company, in a private placement (the &ldquo;<B>2018
Private Placement</B>&rdquo;), agreed to issue and sell to the Purchasers units (each, a &ldquo;<B>Unit</B>&rdquo;), each consisting
of (i) 1 share (each, a &ldquo;<B>Share</B>&rdquo;) of our Common Stock, and (ii) a warrant to purchase 1 share of Common Stock
at an initial exercise price of $3.00 per share (the &ldquo;<B>2018 Warrants</B>&rdquo;). The initial closing of the 2018 Private
Placement was consummated on July 9, 2018 (the &ldquo;<B>First Closing</B>&rdquo;), and through the issuance date of this Transition
Report, we issued and sold an aggregate of 615,200 Units to the Purchasers, for total gross proceeds to us of approximately $1,538,000
before deducting offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the 2018 Private Placement, the Company has agreed to issue and sell to accredited investors up to a maximum of 4,000,000 Units
(the &ldquo;<B>Maximum Offering</B>&rdquo;) at a price of $2.50 per Unit for total gross proceeds of up to $10,000,000. If the
2018 Private Placement is over-subscribed, the Company may, in its discretion sell up to an additional 600,000 Units (the &ldquo;<B>Over-Allotment</B>&rdquo;)
to cover such over subscriptions. If the Company issues the Maximum Offering amount, 4,000,000 shares of Common Stock (4,600,000
shares of Common Stock if the Over-Allotment is exercised) would be issuable upon exercise of the 2018 Warrants. The Purchase Agreement
provides that the Company may conduct any number of additional closings so long as the final closing occurs on or before October
4, 2018, which period may be extended by the Company for up to 90 days as long as the amount of Units sold does not exceed the
Maximum Offering and, if applicable, the Over-Allotment. In October 2018, the Board extended the offering period by 90 days to
January 2, 2019. Under the Purchase Agreement, the Company has agreed to use the net proceeds from the 2018 Private Placement to
pay the outstanding principal and accrued interest on our Series 3 Notes if such notes do not convert prior to maturity, to pay
the principal on its unsecured term loans, for research and development, clinical studies, legal fees and sales and marketing expenses,
as well as working capital and general corporate purposes. The Company has granted the Purchasers indemnification rights with respect
to its representations, warranties and agreements under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the 2018 Private Placement, the Company entered into registration rights agreements with each of the Purchasers pursuant to which
the Company agreed to file a registration statement with the SEC covering the resale of the shares of Common Stock sold in the
2018 Private Placement and the shares of Common Stock issuable upon exercise of the 2018 Warrants. The Company has agreed to file
such registration statement within 75 days of the final closing of the 2018 Private Placement. Each registration rights agreement
includes customary indemnification rights in connection with the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2018 Warrants are
exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the First Closing. Prior
to expiration, subject to the terms and conditions set forth in the 2018 Warrants, the holders of such 2018 Warrants may exercise
the 2018 Warrants for shares of Common Stock by providing notice to the Company and paying the exercise price per share for each
share so exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the 2018 Private Placement, the brokers will receive a cash commission equal to 10% of the eligible gross proceeds from the sale
of the Units. In addition to the brokers&rsquo; commission, we will issue 5-year warrants to the brokers to purchase an amount
of Common Stock equal to 10% of the total amount of qualifying Shares sold in the 2018 Private Placement at an exercise price
of $3.45 per share upon the close of the 2018 Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series 3 Notes and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From October 2017
to May 2018, the Company issued convertible notes (the &ldquo;<B>Series 3 Notes</B>&rdquo;) in an aggregate principal amount
of $1.5 million that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company&rsquo;s
capital stock (the &ldquo;<B>Series 3 Warrants</B>&rdquo;). The Company initially entered into a subscription agreement with
certain accredited investors and closed an initial private placement of the Series 3 Notes in October 2017. In December 2017,
the Company and holders of a majority in aggregate principal amount of the Series 3 Notes entered into an amended and
restated subscription agreement to amend the terms of the Series 3 Notes and Series 3 Warrants (the &ldquo;<B>Series 3
Amendment</B>&rdquo;). The Series 3 Notes require us to repay the principal and accrued and unpaid interest thereon at
December 31, 2018. If the Company consummates an equity round of financing resulting in more than $3 million in gross
proceeds before December 31, 2018 (the &ldquo;<B>Series 3 Qualified Financing</B>&rdquo;), the outstanding principal and
accrued and unpaid interest on the Series 3 Notes shall automatically convert into the securities issued by us in the Series
3 Qualified Financing equal to the outstanding principal and accrued interest on the Series 3 Notes divided by 80% of the
price per share of the securities issued by us in the Series 3 Qualified Financing. If a Change of Control (as defined below)
occurs prior to the earlier of a Series 3 Qualified Financing or December 31, 2018, the Series 3 Notes would, at the election
of the holders of a majority of the outstanding principal amount of the Series 3 Notes, either become payable on demand as of
the closing date of the Change of Control or become convertible into shares of Common Stock immediately prior to the Change
of Control at a price per share equal to the lesser of (i) the per share value of the Common Stock as determined by our Board
as if in connection with the granting of stock-based compensation or in a private sale to a third party in an
arms-length transaction or (ii) at the per share consideration to be paid in the Change of Control (the date of any such
conversion of the Series 3 Notes in connection with a Change of Control or Series 3 Qualified Financing, is referred to
herein as the &ldquo;Series 3 Conversion Date&rdquo;). Change of Control means a merger or consolidation with another entity
in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition
of all or substantially all of our assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Series
3 Amendment, if the Company raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal
and accrued and unpaid interest on the Series 3 Notes would have automatically converted into the securities issued by the Company
in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued
interest on the Series 3 Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Series 3 Notes multiplied
by 1.25, divided by the price paid per security in such financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series 3 Notes
are unsecured. If we fail to complete a Series 3 Qualified Financing by December 31, 2018, the Series 3 Notes will be immediately
due and payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Series 3 Warrant
grants the holder the option to purchase shares of our capital stock equal to the number of shares of capital stock of the Company
received by the holder upon conversion of the Series 3 Notes at a per share exercise price equal to (i) the actual per share price
of the securities issued in the Series 3 Qualified Financing if the Series 3 Notes convert in connection with such a qualified
financing or (ii) the price at which the Series 3 Notes converted if they converted in connection with a Change of Control. The
Series 3 Warrants are exercisable commencing on the Series 3 Conversion Date and expiring on the five year anniversary of that
date. The exercise price and number of the shares of our capital stock issuable upon exercising the Series 3 Warrants will be subject
to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization, business combination
or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series 2 Notes and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August
2017, the Company entered into a subscription agreement and issued interest free promissory notes in an aggregate principal
amount of $253,000 to certain accredited investors. In November 2017, the Company and each subscriber amended the notes to
extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage. In March 2018, the Company
and each subscriber entered into a written consent to again amend and restate the promissory notes (as amended, the
&ldquo;<B>Series 2 Notes</B>&rdquo;) and to amend the subscription agreement to replace the form of warrant agreement annexed
to the subscription agreement (the &ldquo;<B>Replacement Warrant</B>&rdquo;) and to provide for the issuance of an additional
warrant (the &ldquo;<B>Additional Warrant</B>&rdquo;). In March 2018, the Company issued and delivered the Series 2 Notes,
the Replacement Warrants and the Additional Warrants to the subscribers. Effective as of July 2, 2018, the Company amended
the Series 2 Notes by entering into debt conversion agreements (the &ldquo;<B>Series 2 Conversion Agreements</B>&rdquo;) with
each subscriber to (i) convert the outstanding principal and accrued and unpaid interest under the Series 2 Notes into shares
of Common Stock based on the outstanding balance divided by $1.80 per share (the &ldquo;<B>Series 2 Conversion
Shares</B>&rdquo;); (ii) cancel and extinguish the Series 2 Notes; and (iii) amend and restate the Replacement Warrants and
Additional Warrants to make them immediately exercisable upon conversion, at a per share exercise price equal to $1.80 per
share. As consideration for the early conversion of the Series 2 Notes, the Company issued each subscriber a new warrant (the
&ldquo;Series 2 Payment Warrants&rdquo;), exercisable for up to the number of shares of Common Stock equal to the number of
Series 2 Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The Series 2
Payment Warrants were exercisable commencing on July 2, 2018 and expire on November 21, 2021. The Replacement Warrants and
Additional Warrants became immediately exercisable upon the July 2, 2018 conversion date, at a per share exercise price equal
to $1.80 per share and will  expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price
and number of the shares issuable upon exercising the Series 2 Payment Warrants, Replacement Warrants and Additional Warrants are
subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or
similar transaction, as described therein. The Series 2 Notes were converted into 144,053 shares of Common Stock and warrants exercisable
for 477,856 shares of Common Stock were issued as a result of the Series 2 Notes conversion and extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Series 1 Notes and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From November
2016 to June 2017, the Company issued convertible promissory notes in an aggregate principal amount of $1.6 million that bear
interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company&rsquo;s capital stock equal to the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">number of conversion
shares received.</FONT> In June 2017
and November 2017, the terms of such notes (as amended, the &ldquo;<B>Series 1 Notes</B>&rdquo;) and warrants (as amended,
the &ldquo;<B>Series 1 Warrants</B>&rdquo;) were amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective as of
July 2, 2018, the Company amended the Series 1 Notes by entering into debt conversion agreements (the &ldquo;<B>Series 1
Conversion Agreements</B>&rdquo;) with each Series 1 Note subscriber to (i) convert the outstanding principal and accrued and
unpaid interest under the Series 1 Notes into shares of the Company&rsquo;s Common Stock based on the outstanding balance
divided by $1.80 per share (the &ldquo;<B>Series 1 Conversion Shares</B>&rdquo;); (ii) cancel and extinguish the Series 1
Notes; and (iii) amend and restate the Series 1 Warrants to make them immediately exercisable upon conversion, at a per share
exercise price equal to $1.80 per share. As consideration for the early conversion of the Series 1 Notes, the Company issued
each subscriber a new warrant (the &ldquo;Series 1 Payment Warrants&rdquo;), exercisable for up to the number of shares of
Common Stock equal to the number of Series 1 Conversion Shares received by such subscriber; at a per share exercise price of
$1.80 per share. The Series 1 Payment Warrants are exercisable commencing on July 2, 2018, and expire on November 21, 2021.
The Series 1 Warrants became immediately exercisable upon the July 2, 2018 conversion date, at a per share exercise price
equal to $1.80 per share, and will expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price
and number of the shares issuable upon exercising the Series 1 Payment Warrants and original Series 1 Warrants are subject to adjustment
in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as
described therein. The Series 1 Notes were converted into 1,002,258 shares of Common Stock and warrants exercisable for 2,004,516
shares of Common Stock were issued on July 2, 2018 as a result of the Series 1 Notes conversion and extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series 1 Notes,
prior to the July 2, 2018 conversion and extinguishment, required us to repay the principal and accrued and unpaid interest thereon
at the earlier of July 31, 2018, or the consummation of the next equity or equity-linked round of financing resulting in more than
$3 million in gross proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Unsecured Loans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, we
received cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from
stockholders owning over 5% of the Company&rsquo;s Common Stock. The loans are interest free and require that we repay the principal
in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross
proceeds or November 8, 2019. In May 2018, we received cash gross proceeds from unsecured loans represented by promissory notes
in the amount of $168,000, of which $84,000 was from a stockholder owning over 5% of the Company&rsquo;s Common Stock. The loans
are interest free and require that we repay the principal in full on the earlier of the closing of an equity round of financing
of the Company resulting in more than $5 million in gross proceeds or May 17, 2019. In March 2018, we also received cash gross
proceeds in the amount of $115,000 represented by a promissory note from a stockholder owning over 5% of the Company&rsquo;s Common
Stock. The loan is also interest free and requires that we repay the principal in full on the earlier of the closing of an equity
round of financing of the Company resulting in more than $3 million in gross proceeds or March 20, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Funding Requirements and Outlook</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no current
source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless, the FDA or other
regulatory authorities approve our cortical strip, grid electrode and depth electrode technology under development and we successfully
commercialize our cortical strip, grid electrode and depth electrode technology. Until such time, if ever, as we can generate substantial
product revenue, we expect to finance our cash needs through a combination of equity and debt financings as well as collaborations,
strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a
common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability
to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional
funds through collaborations, strategic alliances or licensing arrangements with third-party partners, we may have to relinquish
valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings or through collaborations, strategic alliances or licensing
arrangements when needed, we may be required to delay, limit, reduce or terminate our product development, future commercialization
efforts, or grant rights to develop and market our cortical strip, grid electrode and depth electrode technology that we would
otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent registered
public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the nine months
ended September 30, 2018 and for the year ended December 31, 2017, noting the existence of substantial doubt about our ability
to continue as a going concern. This uncertainty arose from management&rsquo;s review of our results of operations and financial
condition and its conclusion that, based on our operating plans, we did not have sufficient existing working capital to fund our
operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30,
2018, the outstanding principal and accrued and unpaid interest on the Series 3 Notes was $1,627,028. If we fail to complete the
Series 3 Qualified Financing by December 31, 2018, the Series 3 Notes will be immediately due and payable on such date, and we
may not have sufficient cash to pay the principal and accrued and unpaid interest thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreements
with WARF and Mayo that require us to make certain milestone and royalty payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the WARF
License, we have agreed to pay WARF $55,000 (representing a license fee) upon the earliest to occur of the date we
cumulatively raise at least $3 million in financing, which threshold was met, the date of a change of control, or our revenue
reaching a specified threshold amount, and to pay $65,000 (representing reimbursement for costs incurred by WARF in
maintaining the licensed patents) upon the earliest to occur of the date we cumulatively raise at least $5 million in
financing, the date of a change of control, or our revenue reaching a specified threshold amount. The initial $55,000 payment
was paid in April 2018. We have also agreed to pay WARF a royalty equal to a single-digit percentage of our product sales
pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2019, $100,000 for 2020 and $150,000 for
2021 and each calendar year thereafter that the WARF License is in effect. If we or any of our sublicenses contest the
validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested
patent is found to be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for
the remaining term of the WARF License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Mayo Development
Agreement, we agreed to pay Mayo a cash payment of approximately $92,000, which was paid in December 2017, and on May 25, 2017,
prior to the closing of the Acquisition, NeuroOne, Inc. issued Mayo NeuroOne Shares pursuant to a Subscription Agreement (which
were converted into 859,976 shares of Common Stock in the Acquisition). Finally, we have agreed to pay Mayo a royalty equal to
a single-digit percentage of our product sales pursuant to the Mayo Development Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &ldquo;Item 1&mdash;Business&mdash;WARF
License,&rdquo; &ldquo;Business&mdash;Mayo Foundation for Medical Education and Research License and Development Agreement,&rdquo;
&ldquo;Item 1A&mdash;Risk Factors&mdash;Risks Relating to Our Business&mdash;We depend on intellectual property licensed from Wisconsin
Alumni Research Foundation for our technology under development, and the termination of this license would harm our business&rdquo;
and &ldquo;Item 1A&mdash;Risk Factors&mdash;We depend on our partnership with Mayo Foundation for Medical Education and Research
to license certain know how for the development and commercialization of our technology.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing cash
and cash equivalents will not be sufficient to fund our operating expenses throughout our fiscal year ending September 30,
2019. To continue to fund operations, we will need to secure additional funding. We may obtain additional financing in the
future through the issuance of our Common Stock, through other equity or debt financings or through collaborations or
partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all.
Further, we may not be able to pay off or modify terms of our existing debt coming due &nbsp;in December 31, 2018, and any failure to
raise capital or to amend existing debt that may be due as and when needed could compromise our ability to execute on our
business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of
our cortical strip, grid electrode and depth electrode technology is subject to numerous uncertainties, and we have based these
estimates on assumptions that may prove to be substantially different than we currently anticipate and could use our cash resources
sooner than we expect. Additionally, the process of developing medical devices is costly, and the timing of progress in pre-clinical
tests and clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving
FDA approval and then a level of product sales adequate to support our cost structure. We cannot assure you that we will ever be
profitable or generate positive cash flow from operating activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a
summary of cash flows for each of the periods set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For&nbsp;the&nbsp;Nine Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="margin: 0pt 0"><B>(unaudited)</B></P>


</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,229,207</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,509,669</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,271,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,057,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net decrease in cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(13,207</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(452,188</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net cash used in operating activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $2.2 million for the nine months ended September 30, 2018, which consisted of a net loss of $5.1 million partially
offset primarily by non-cash interest, stock-based compensation for non-employee services, note discount amortization, revaluation
of premium debt conversion derivatives and warrant liabilities and note extinguishments, totaling $2.2 million in the aggregate,
and a net increase in accounts payable and accrued expenses of $0.7 million. Net cash used in operating activities over the next
year are expected to increase as payments are made related to accrued legal services incurred through September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating activities was $1.5 million for the nine months ended September 30, 2017, which
consisted of a net loss of $3.4 million partially offset primarily by non-cash interest, stock-based compensation, discount amortization,
warrant issuance costs and revaluation of premium debt conversion derivatives on the Series 1 Notes and Series 2 Notes totaling
$1.2 million in the aggregate, an increase in accrued expenses of $0.6 million, and a decrease in prepaid expenses of $46,677.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net cash used by investing activities
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used by investing
activities was $55,000 for the nine months ended September 30, 2018 and consisted of the payment owed under the terms of the 2017
WARF Agreement for the purchase of a patent license for research and development. There was no cash used for investing activities
during the nine months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net cash provided by financing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing activities was $2.3 million for the nine months ended September 30, 2018,
which consisted of net proceeds received from the 2018 Private Placement of common stock and warrants totaling $1.1 million, the
issuance of the Series 3 Notes and Warrants of $0.9 million and issuance of unsecured loans in the amount of $0.3 million during
the nine month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by
financing activities was $1.1 million for the nine months ended September 30, 2017, which consisted of $1.1 million in net proceeds
received upon the issuance of the Series 1 Notes and Warrants and Series 2 Notes and Warrants which was partially
offset by a $50,000 repayment of a short-term unsecured loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies and Significant
Judgments and Estimates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Critical Accounting Policies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&rsquo;s
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP.
The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect
the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance
sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates
on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such
estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions.
We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions
in estimates are reflected in our consolidated financial statements prospectively from the date of the change in estimate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our significant
accounting policies are more fully described in the notes to our consolidated financial statements appearing elsewhere in this
Transition Report, we believe the following are the critical accounting policies used in the preparation of our consolidated financial
statements that require significant estimates and judgments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fair Value of Financial Instruments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for fair
value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring
or nonrecurring basis adhering to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs
to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant
unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active
markets for identical assets or liabilities accessible to the Company at the measurement date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 2 Inputs: Other than quoted prices included in
Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term
of the asset or liability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or
liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in
which there is little, if any, market activity for the asset or liability at measurement date.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September
30, 2018 and December 31, 2017, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated
their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the notes was
based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion
derivatives associated with the convertible promissory notes was based on both the estimated fair value of our Common Stock of
$2.30 and $2.52 as of September 30, 2018 and December 31, 2017, respectively, and cash flow models discounted at current implied
market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments
which were based on Level&nbsp;3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intellectual Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into two
licensing agreements with major research institutions, which allow for access to certain patented technology and know-how. Milestone
payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life
of the acquired technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Impairment of Long-Lived Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We evaluate
long-lived assets, which consist entirely of licensed intellectual property for impairment whenever events or changes in
circumstances indicate that the carrying value of these assets may not be recoverable. We assess the recoverability of
long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted
expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the
difference between the carrying value and the fair value of the impaired asset. Through September 30, 2018, no milestones
triggering possible impairment of our long-lived assets have occurred.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Debt Issuance Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Debt issuance costs
are recorded as a reduction of the notes. Amortization of debt issuance costs is calculated using the straight-line method over
the term of the notes, which approximates the effective interest method, and is recorded in interest expense in the statements
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
costs are charged to expense as incurred. Research and development expenses may be comprised of costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as
well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services
that will be used in future research and development activities are expensed when the activity is performed or when the goods have
been received, rather than when payment is made, in accordance with ASC 730,&nbsp;<I>Research and Development</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrant Liability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We issued warrants
to purchase equity securities in connection with the issuance of convertible promissory notes. We account for these warrants as
a liability at fair value when the number of shares is not fixed and determinable and when warrant pricing protections in future
equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability
are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. We adjust
the liability for changes in fair value until the earlier of the exercise or expiration of the warrants, amendment of warrant terms
that no longer require liability treatment, or until such time, if any, as the number of shares to be exercised becomes fixed,
at which point the warrants will be classified in stockholders&rsquo; (deficit) equity provided that there are sufficient authorized
and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares
of common stock. Any change in fair value of the warrant liability while outstanding is recognized in the consolidated statements
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Premium Debt Conversion Derivative</I>s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We evaluate all conversion
and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation
from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and
a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over
the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated
embedded derivatives are accounted for separately on a fair value basis. We record the fair value changes of separated embedded
derivatives in the consolidated statements of operations at each reporting period while outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred
tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset
will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Earnings or Loss Per
Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic earnings or loss
per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding
during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diluted earnings or
loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding
are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. Our stock options,
warrants and convertible promissory notes are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the stock options and warrants. Diluted earnings with respect to the convertible promissory notes
utilizing the if-converted method was not applicable during the periods presented as no conditions required for conversion had
occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because
such inclusion would be anti-dilutive given the net loss reported for the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Stock Valuation Methodology</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prior to the Acquisition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Acquisition
on July 20, 2017, NeuroOne, Inc. was a private company with no active public market for its common stock. Therefore, at the time
of grant, NeuroOne, Inc. determined the fair value of its common stock using a contemporaneous valuation performed in accordance
with the guidance outlined in the <I>American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held
Company Equity Securities Issued as Compensation</I>, also known as the Practice Aid. We performed these contemporaneous valuations
on an as-needed basis. In conducting the contemporaneous valuations, NeuroOne, Inc. considered all objective and subjective factors
that it believed to be relevant for each valuation conducted, including its best estimate of our business condition, prospects
and operating performance at each valuation date. Within this contemporaneous valuation performed by us, a range of factors, assumptions
and methodologies were used. These significant factors included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
recent securities transactions;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
stage of development and business strategy;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
financial condition and operating results, including our projected results; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
financial condition and operating results of comparable publicly owned companies</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of NeuroOne,
Inc.&rsquo;s common stock prior to the Acquisition was determined during a period when there was limited data with regard to value
indication other than convertible notes issued between November 2016 and June 2017. At the time, such convertible notes contained
a $1.80 conversion cap, which was treated as an estimated price of preferred stock into which the notes would convert. A transaction
backsolve was performed that equated the $1.5 million investment in the convertible notes with the resulting equity allocation
to the hypothetical converted shares and warrants expected to be issued upon conversion. The resulting equity value was then used
to infer the value of common stock within the same option-pricing framework. This scenario implicitly assumed 100% likelihood of
a stock financing. In order to account for the possibility of dissolution, the transaction backsolve was used along with a dissolution
scenario within a hybrid Probability Weighted Expected Return Method (&ldquo;<B>PWERM</B>&rdquo;). The scenarios were weighted
50/50, and a Discount For Lack of Marketability (&ldquo;<B>DLOM</B>&rdquo;) applied, to determine the valuation conclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Following the Acquisition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For valuations following
the Acquisition, including the valuation of our common stock on December 31, 2017, management estimated our enterprise value on
a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the
Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack
of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, we relied on forward revenue multiples
from guideline public companies (&ldquo;<B>GPC</B>&rdquo;) for calendar year 2019 and 2020. The resulting equity value from the
GPC method was allocated to common stock using the option pricing method, and a DLOM was applied. Based on the above methodology
and weightings, we derived a valuation conclusion of $2.30 and $2.52 per share as of September 30, 2018 and December 31, 2017,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The significant factors
contributing to the increase in the fair value of our common stock following the Acquisition included the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The successful completion of the reverse merger;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Access to new capital as a public company;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Improved revenue projections;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Improved general economic conditions;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Additional issuance of convertible notes; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Important developments relating to achievement of our
business objectives</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are significant
judgments and estimates inherent in the determination of fair value of our common stock, including the contemporaneous valuations.
These judgments and estimates include assumptions regarding our future operating performance, and the determination of the appropriate
valuation methods. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per common
share could have been significantly different.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of our common stock is used as an input into the fair value determination
of the warrants, stock option or other equity awards that we have issued during the year or are outstanding liabilities at our
reporting date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">See Note 3 &mdash;&nbsp;&ldquo;Summary of
Significant Accounting Policies&rdquo;&nbsp;included in &ldquo;Item 8 &mdash; Financial Statements and Supplementary Data&rdquo;
in this Transition Report&nbsp;regarding the impact of certain recent accounting pronouncements on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the periods
presented, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_013"></A>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_014"></A>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 92%"><A HREF="#f_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="width: 8%; text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#f_002">Consolidated Balance Sheets</A></TD>
    <TD STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#f_003">Consolidated Statements of Operations</A></TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#f_004">Consolidated Statements of Changes in Stockholders&rsquo; Deficit</A></TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#f_005">Consolidated Statements of Cash Flows</A></TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#f_006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="text-align: center">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="f_001"></A>Report of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders and Board of Directors<BR>
NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Minnetonka, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Consolidated Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying
consolidated balance sheets of NeuroOne Medical Technologies Corporation (the &ldquo;Company&rdquo;) as of September 30, 2018
and December 31, 2017, the related consolidated statements of operations, changes in stockholders&rsquo; deficit, and cash
flows for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, and the related
notes (collectively referred to as the &ldquo;consolidated financial statements&rdquo;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2018
and December 31, 2017, and the results of their operations and their cash flows for the nine month transition period ended
September 30, 2018 and for the year ended December 31, 2017, in conformity with accounting principles generally accepted in
the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -45pt"><B>Going Concern
Uncertainty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated
financial statements, the Company has suffered recurring losses from operations and negative cash flows from operations that raise
substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also
described in Note 2 to the consolidated financial statements. The consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&rsquo;s auditor
since 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -45pt">Minneapolis,
Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">December 12, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_002"></A>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,260</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">26,467</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,378</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,613</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">200,081</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216,372</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">218,719</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">249,985</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">221,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,591,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,021,617</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Short-term promissory notes and unsecured loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">253,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Convertible promissory notes, net and accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,393,804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,168,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">308,395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,174</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,797,456</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,905,131</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">817,155</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,381,465</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,614,611</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,286,596</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of
    September 30, 2018 and December 31, 2017; no shares issued or outstanding as of September 30, 2018 and December 31, 2017.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 9,656,505 and 7,864,994 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,865</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid&ndash;in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,052,161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,457,710</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,324,796</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,395,892</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,036,611</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">218,719</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">249,985</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_003"></A>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended<BR>
 September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year ended<BR>
 December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,676,872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,798,131</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,336,988</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">715,086</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">735,333</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,391,958</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,298,539</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,072,321</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,391,958</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,298,539</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,072,321</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(763,065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,057,024</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,395,138</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in fair value for the warrant liability and premium conversion derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">336,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(77,505</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(240,053</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loss on note extinguishments, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,314,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(350,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,132,914</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,433,068</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,058,426</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.61</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.55</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.77</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Number of shares used in per share calculations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,420,529</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,217,076</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,610,072</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="f_004"></A>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consolidated Statements of Changes in
Stockholders&rsquo; Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&nbsp;Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid&ndash;In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,216,565</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">119</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(266,370</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(266,220</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of stock in connection with intellectual license agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">859,976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,415</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of restricted stock award</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215,453</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,220</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Transfer of shares in connection with merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,573,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,573</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Par value change in connection with merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,186</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,574</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Issuance of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of additional warrants in connection with short-term notes modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Forgiveness of subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,058,426</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,058,426</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Balance at December&nbsp;31,&nbsp;2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,864,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,324,796</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,036,611</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock upon short term notes and convertible notes extinguishments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,146,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,348,790</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,349,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of warrants and reclassification of warrant liability in connection with short-term notes and
convertible notes extinguishments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,008,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,008,796</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock under 2018 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of warrants under 2018 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,106</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance costs related to 2018 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173,067</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173,067</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.125in">Issuance of common stock for consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">469,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">469,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,467</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,467</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,132,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,132,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance at September 30,&nbsp;2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,656,505</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,657</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,052,161</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(10,457,710</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,395,892</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="f_005"></A>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year ended<BR>
 December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,132,914</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,433,068</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,058,426</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,633</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">486,120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,794</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Forgiveness of subscription</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash interest on convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash discount amortization on convertible and short-term promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">611,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,242,031</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Note issuance costs attributed to warrant liability and to convertible promissory note modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Revaluation of premium conversion derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(371,831</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,962</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Revaluation of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,707</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Loss on note extinguishments, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,314,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,914</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,677</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">437,337</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">642,099</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">813,215</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,229,207</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,509,669</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,108,073</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Purchase of intangible assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(91,709</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(55,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(91,709</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of convertible promissory notes and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">432,849</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,004,134</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of warrants associated with convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">442,151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">440,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">777,490</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of warrants associated with short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of common stock in connection with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of warrants in connection with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds (repayment)&nbsp;&nbsp;from unsecured loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance costs related to short-term note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,030</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,030</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance costs related to convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,689</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,468</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Issuance costs related to warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(31,920</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,590</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,271,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,057,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,704,032</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,207</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(452,188</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(495,750</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">522,217</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">522,217</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Cash at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,260</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">70,029</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26,467</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental non-cash financing and investing transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Bifurcation of premium conversion derivatives related to convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">168,384</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">213,961</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">342,486</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Conversion of short-term notes and convertible promissory notes into common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,063,361</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Issuance of additional warrants in connection with short-term notes and convertible promissory notes modifications</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><P STYLE="margin: 0pt 0">829,378</P> </TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">117,280</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Purchased intangible assets in accrued liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Common stock issued for the purchase of intangible assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,115</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,415</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs related to private placement</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">173,067</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs attributed to short-term promissory notes and convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,850</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">42,811</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">57,037</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs attributed to warrant liability</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,119</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,119</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="f_006"></A>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - Organization and Nature of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation
(the &ldquo;Company&rdquo;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the
laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed
a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne
Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased
its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017,
the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&ldquo;NeuroOne&rdquo;)
in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &ldquo;Acquisition&rdquo;).
The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in
this transaction. As such, the historical financial statements reflect the operations of NeuroOne for all periods presented prior
to the date of Acquisition. NeuroOne was formed on October 7, 2016. The accompanying consolidated financial statements subsequent
to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to the Acquisition, the Company&rsquo;s
operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive neuromodulation
cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&rsquo;s
disease, essential tremors, and other brain related disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company has recorded no product
sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology
and is seeking regulatory clearances required to initiate commercial activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is based in Minnetonka, Minnesota
effective December 1, 2018. The Company was previously based in Eden Prairie, Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisition of NeuroOne, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Acquisition was consummated on July
20, 2017 (the &ldquo;Closing&rdquo;) and, pursuant to the terms of the merger agreement, (i) all outstanding shares of common stock
of NeuroOne, par value $0.0001 per share (the &ldquo;NeuroOne Shares&rdquo;), were exchanged for shares of the Company&rsquo;s
common stock, par value $0.001 per share (the &ldquo;Company Shares&rdquo;), based on the exchange ratio of 17.0103706 Company
Shares for every one NeuroOne Share (the &ldquo;Exchange Ratio&rdquo;), resulting in the Company issuing, on July 20, 2017, an
aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne
were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective
exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii)
all warrants of NeuroOne were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible
promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to
the merger agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Acquisition, the Company
acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&rsquo;s wholly-owned
subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation
3,500,000 Company Shares held by him as part of the conditions to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issued and outstanding common stock
share amounts, options for common stock and per share amounts contained in the consolidated financial statements were retroactively
adjusted to reflect the Exchange Ratio for all periods presented.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 2 - Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>The accompanying consolidated
financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred
losses and negative cash flows from operations since inception and had an accumulated deficit of $10,457,710 as of September 30,
2018. In the event the Company is unable to complete an equity round of financing resulting in more than $3 million in gross proceeds
by December 31, 2018, the 2017 Convertible Notes and accrued interest thereon will become due. The Company does not have adequate
liquidity to fund the repayment of the 2017 Convertible Notes if they become due on December 31, 2018 or to fund its operations
throughout fiscal 2019 without raising additional funds. These factors raise substantial doubt about the Company&rsquo;s ability
to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the
outcome of this condition. If the Company is not able to raise additional working capital, it will have a material adverse effect
on the operations of the Company and the development of its technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through September 30, 2018, since inception,
the Company has completed unsecured loan financings for gross proceeds of $283,000, a $253,000 short-term promissory note financing
(which notes were amended and restated to become convertible promissory notes as described below), a $1,625,120 convertible promissory
note financing and a second $1,540,000 convertible note promissory financing. In addition, the Company entered into a private placement
transaction in July 2018 whereby $1,113,000 in gross proceeds were raised out of a planned $10.0 million maximum subscription amount
(assuming the over-allotment option is not exercised) through September 30, 2018. The Company does not have adequate liquidity
to fund its operations throughout fiscal 2019 without raising additional funds. Management intends to seek additional debt and/or
equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company&rsquo;s anticipated
operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time
period that existing resources can fund the Company&rsquo;s operations. If management is unable to obtain the necessary capital,
it may have to cease operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 3 - Summary of Significant
Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation and Change in Fiscal Year</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared in accordance with accounting standards generally accepted in the United States of America, In September
2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved
a change in the Company&rsquo;s fiscal year end from December 31 to September 30. The Company&rsquo;s fiscal year now begins on
October 1 and ends on September 30 of each year, starting on October 1, 2018. The required transition period of January 1, 2018
to September 30, 2018 is included in the consolidated financial statements. For comparative purposes, the unaudited consolidated
statements of operations and consolidated statements of cash flows for the nine months ended September 30, 2017 are also presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Management&rsquo;s Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could
differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
subject the Company to a concentration of credit risk consist of cash. The Company&rsquo;s cash is held by one financial institution
in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution
is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30,
2018, the Company did not have any deposits in excess of federally insured amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock Valuation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the limited market liquidity for
the Company&rsquo;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute
of Certified Public Accountants&rsquo; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as
Compensation&nbsp;(the &ldquo;Practice Aid&rdquo;), to estimate the fair value of its common stock. The valuation methodology
includes estimates and assumptions that require the Company&rsquo;s judgment. These estimates and assumptions include a number
of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the
likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the
valuations may result in different fair values of common stock at each valuation date. Following is a summary of underlying assumptions
used:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prior to the Acquisition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Acquisition on July 20, 2017,
NeuroOne was a private company with no active public market for its common stock. Therefore, at the time, NeuroOne determined the
fair value of its common stock using a contemporaneous valuation performed in accordance with the Practice Aid. Within this contemporaneous
valuation performed by NeuroOne included the following significant factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recent securities transactions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stage of development and business strategy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial condition and operating results, including our projected results; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial condition and operating results of comparable publicly owned companies</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of NeuroOne&rsquo;s common
stock prior to the Acquisition was determined during a period when there was limited data with regard to value indication other
than convertible notes issued between November 2016 and June 2017. At the time, such convertible notes contained a $1.80 conversion
cap, which was treated as an estimated price of preferred stock into which the notes would convert. A transaction backsolve was
performed that equated the $1.5 million investment in the convertible notes with the resulting equity allocation to the hypothetical
converted shares and warrants expected to be issued upon conversion. The resulting equity value was then used to infer the value
of common stock within the same option-pricing framework. This scenario implicitly assumed 100% likelihood of a stock financing.
In order to account for the possibility of dissolution, the transaction backsolve was used along with a dissolution scenario within
a hybrid Probability Weighted Expected Return Method (&ldquo;PWERM&rdquo;). The scenarios were weighted 50/50, and a Discount For
Lack of Marketability (&ldquo;DLOM&rdquo;) applied, to determine the valuation conclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Following the Acquisition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For valuations following the Acquisition,
including the valuation of common stock on December 31, 2017, the Company estimated our enterprise value on a continuing operations
basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price
of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore,
in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public
companies (&ldquo;GPC&rdquo;) for calendar year 2019 and 2020. The resulting equity value from the GPC method was allocated to
common stock using the option pricing method, and a DLOM was applied. Based on the above methodology and weightings, the Company
derived a valuation conclusion of $2.30 and $2.52 per share as of September 30, 2018 and December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The significant factors contributing to
the increase in the fair value the Company&rsquo;s common stock following the Acquisition included the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The successful completion of the reverse merger;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to new capital as a public company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved revenue projections;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved general economic conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of convertible notes; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important developments relating to achievement of our business objectives</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The fair value the Company&rsquo;s
common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the
Company has issued or are outstanding liabilities at the reporting date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s accounting for fair
value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring
or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs
to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant
unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active
markets for identical assets or liabilities accessible to the Company at the measurement date.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 2 Inputs: Other than quoted prices included in
Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term
of the asset or liability.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or
liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in
which there is little, if any, market activity for the asset or liability at measurement date.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018 and December 31,
2017, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated their carrying
values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible
promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant
liability and the premium conversion derivatives associated with the convertible promissory notes of the Company were based on both
the estimated fair value of our common stock of $2.30 and $2.52 as of September 30, 2018 and December 31, 2017, respectively, and
cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected
returns by market participants for similar instruments and are based on Level&nbsp;3 inputs. There were no transfers between fair
value hierarchy levels during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of financial instruments measured on a recurring
basis is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&nbsp;30,&nbsp;2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">817,155</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">817,155</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">308,395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">308,395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,125,550</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,125,550</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&nbsp;31,&nbsp;2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,174</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,174</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,843,639</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,843,639</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"></P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a roll-forward
of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level&nbsp;3 inputs for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Warrant liability</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">345,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Value assigned to warrants in connection with convertible promissory and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">777,490</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">Reclassification to equity</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,179,418</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">258,015</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">817,155</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,381,465</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Premium debt conversion derivatives</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">462,174</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">137,650</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">342,486</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of premium debt conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(371,831</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,962</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">308,395</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">462,174</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual Property </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into two licensing
agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under
those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired
technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impairment of Long-Lived Assets </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates its long-lived assets,
which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that
the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining
whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset
is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair
value of the impaired asset. Through September 30, 2018, no milestones triggering possible impairment of the Company&rsquo;s long-lived assets have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Debt Issuance Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt issuance costs are recorded as a reduction
of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using
the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and
is recorded in interest expense in the accompanying consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are charged
to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development
activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted
services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future
research and development activities are expensed when the activity is performed or when the goods have been received, rather than
when payment is made, in accordance with ASC 730, <I>Research and Development</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued warrants to purchase
equity securities in connection with the issuance of convertible promissory notes (See Note 7&ndash; Short-Term Promissory Notes
and Unsecured Loans and Note 8 &ndash; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants
as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections
in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant
liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations.
The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for
any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares
to be exercised becomes fixed, at which point the warrants will be classified in stockholders&rsquo; (deficit) equity provided
that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts
that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding,
is recognized in the consolidated statements of operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premium Debt Conversion Derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all conversion and
redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from
the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding
discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the
host debt instrument using the straight-line method which approximates the effective interest method.&nbsp; The separated embedded
derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded
derivatives at each reporting period in the consolidated statements of operations (See Note 7&ndash; Short-Term Promissory Notes
and Unsecured Loans and Note 8 &ndash; Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption
features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with
regard to the convertible promissory notes.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred
tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset
will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and
Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&rsquo;s consolidated
financial statements include, but are not limited to, a U.S federal corporate tax rate decrease from 35% to 21% effective for tax
years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the
valuation allowance recorded to reflect the new federal corporate tax rates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Loss Per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, basic loss per share of
common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings or loss per share of common
stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to
include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&rsquo;s convertible
promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the convertible promissory notes
utilizing the if-converted method was not applicable during the nine month transition period ended September 30, 2018 or for the
year ended December 31, 2017 as no conditions required for conversion had occurred during these periods. No incremental common
stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net
loss reported for the nine month transition period ended September 30, 2018 and for the year ended December&nbsp;31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares were
not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the nine month
transition period ended September 30, 2018 and for the year ended December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,927,572</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">189,750</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">(1)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,216</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,716</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">There are additional potential warrants to be included
which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017
Convertible Notes.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the FASB issued Accounting
Standards Update (ASU) 2017-09, <I>Compensation - Stock Compensation (Topic 718):&nbsp;Scope of Modification Accounting (ASU 2016-09)</I>,&nbsp;which
provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification
accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company
has adopted this standard for the nine month transition period ended September 30, 2018. The adoption of this standard did not
have any impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No. 2017-11,
<I>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</I>, which changes the accounting and
earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect
adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual
periods beginning after December&nbsp;15, 2018 for public business entities, including interim periods within those fiscal years.
Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined
its impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
<I>Compensation - Stock Compensation (Topic 718):&nbsp;Improvements to Nonemployee Share-Based Payment Accounting</I> (ASU 2018-07),&nbsp;which
expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees.
An entity should generally apply the requirements of Topic 718 to nonemployee awards except in circumstances where there is specific
guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all
share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s own
operations by issuing share-based payment awards. The guidance also clarifies that Topic 718 does not apply to share-based payments
used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to
customers as part of a contract accounted for under ASC 606<I>, Revenue from Contracts with Customers </I>(ASC 606)<I>.</I> This
guidance is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted, but no earlier
than an entity&rsquo;s adoption date of ASC 606. The Company is currently evaluating the impact of the new guidance on its consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13,&nbsp;<I>Fair
Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).</I>&nbsp;The
new guidance modifies the disclosure requirements in Topic 820 as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Removals: the amount of and reasons for transfers between
Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes
for Level 3 fair value measurements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Modifications: for investments in certain entities
that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&rsquo;s assets and
the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced
the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about
the uncertainty in measurement as of the reporting date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Additions: the changes in unrealized gains and losses
for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting
period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December
15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable
inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be
applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments
should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is
permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional
disclosures until their effective date. </FONT>The Company is currently evaluating the impact of the new guidance on its financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 4 - Commitments and
Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>WARF License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2014, NeuroOne LLC (the &ldquo;LLC&rdquo;),
NeuroOne&rsquo;s predecessor which was merged with and into NeuroOne on October 27, 2016 (the &ldquo;Merger&rdquo;), entered into
an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&ldquo;WARF&rdquo;) for WARF&rsquo;s
neural probe array and thin film micro electrode technology (the &ldquo;2014 WARF Agreement&rdquo;). The license agreement required
the LLC to make $110,000 in milestone payments depending on achievement of certain development and approval milestones or within
twelve months of signing the 2014 WARF Agreement. Additionally, if the LLC was successful in obtaining regulatory approval, the
LLC was to pay royalties to WARF on a percentage of net sales of products of the licensed technology. Under the terms of the 2014
WARF Agreement, amounts that remained unpaid more than 30 days after they were due, accrued interest at 1 percent per month. Milestone
payments due in 2015 were not made to WARF. From October 27, 2016 until the 2014 WARF Agreement was amended as described below,
the LLC was in default under the 2014 WARF Agreement. In addition, the LLC was not able to transfer the rights and obligations
under the 2014 WARF Agreement to NeuroOne at the time of the Merger without the consent of WARF, which was received when the 2014
WARF Agreement was amended in February 2017 as described below. In connection with the Merger and in accordance with ASC 805-50,
NeuroOne estimated the fair value of consideration payable to WARF and recorded an intangible asset of $120,000 with a corresponding
accrued expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This agreement was subsequently amended
in February 2017 (as so amended, the &ldquo;2017 WARF Agreement&rdquo;) whereby WARF consented to the transfer of the rights and
obligations under the license agreement from the LLC to NeuroOne (which are now the Company&rsquo;s rights and obligations, following
the Acquisition). In the 2017 WARF Agreement, the Company agreed to pay WARF $55,000 (representing a license fee) upon the earliest
to occur of the date the Company cumulatively raises at least $3 million in financing, the date of a change of control, or the
Company&rsquo;s revenue reaching a specified threshold amount. The Company met the milestone payment requirement with regard to
the $55,000 license fee which was paid in April 2018. In addition, the Company agreed to pay $65,000 (representing reimbursement
for costs incurred by WARF in maintaining the licensed patents) upon the earliest to occur of the date the Company cumulatively
raises at least $5 million in financing, the date of a change of control, or the Company&rsquo;s revenue reaching a specified threshold
amount. As of September 30, 2018, the Company has not met the requirements for the $65,000 milestone payment and this amount remains
in accrued expenses.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is also obligated to pay royalties
to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for
calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the 2017 WARF Agreement.
Subject to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents
licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. The 2017 WARF Agreement
is also subject to certain cancellation provisions with 90 days&rsquo; notice should the Company elect not to continue to use the
licensed technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has agreed to diligently develop,
manufacture, market and sell products under the WARF License in the United States during the term of the agreement and, specifically,
that the Company would submit a business plan to WARF by February 1, 2018, which the Company submitted on January 18, 2018, and
file an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the 2017 WARF Agreement
in the event that the Company fails to meet these milestones on 30 days&rsquo; written notice, if the Company defaults on the payments
of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other
covenant in the 2017 WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving
the Company. WARF may also terminate this license (i) on 90 days&rsquo; notice if the Company fails to have commercial sales of
one or more FDA-approved products under the 2017 WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales begin
to be paid, such earned royalties cease for more than four calendar quarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mayo Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2014, the LLC entered into
an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&ldquo;Mayo&rdquo;)
related to certain intellectual property and development services for thin film micro electrode technology (&ldquo;2014 Mayo Agreement&rdquo;).
The LLC was to make milestone payments depending on achievement of certain development and approval milestones and sales targets,
none of which were met as of December 31, 2015. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC
was to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the
2014 Mayo Agreement, set to expire May 25, 2037. Also, the LLC was obligated to issue common stock to Mayo if certain events occurred.
Upon the LLC&rsquo;s merger with NeuroOne on October 27, 2016, the rights under the 2014 Mayo Agreement transferred to NeuroOne,
and certain milestones were attained. Therefore, NeuroOne recorded liabilities of $300 related to shares of common stock expected
to be issued to Mayo and $91,709 for the intellectual property to be paid in cash. Under the terms of the 2014 Mayo Agreement,
amounts that remained unpaid accrued interest at 2 percent above the prime rate. Milestone payments due in 2016 were not made to
Mayo. As such, prior to the amendment of the 2014 Mayo Agreement in May 2017, NeuroOne was in default under the 2014 Mayo Agreement.
Mayo and NeuroOne amended and restated the 2014 Mayo Agreement in May 2017 (as so amended and restated, the &ldquo;2017 Mayo Agreement&rdquo;).
Pursuant to the 2017 Mayo Agreement, NeuroOne issued 859,976 shares of common stock (as converted based on the Exchange Ratio)
to Mayo to settle the amount of common stock NeuroOne was previously obligated to issue under the 2014 Mayo Agreement and as provided
by the terms of the 2017 Mayo Agreement. NeuroOne recorded an additional $23,115 to intangible assets related to the fair value
of the 2017 stock issuance to Mayo. As a part of the 2017 Mayo Agreement, as amended in November 2017, the $91,709 milestone payment
was paid in December 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject
to litigation and claims arising in the ordinary course of business.&nbsp; In May 2017, NeuroOne received a letter from PMT, the
former employer of Mark Christianson and Wade Fredrickson.&nbsp; PMT claimed that these officers had breached their restrictive
covenant obligations with PMT by virtue of their work for NeuroOne and such officer&rsquo;s prior work during employment with the
prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state
law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference
with the contracts.&nbsp; The letter demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson
and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson
and NeuroOne provide the former employer access to NeuroOne&rsquo;s systems to demonstrate that it is not using trade secrets or
proprietary information nor competing with the former employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, the Company was served
with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&nbsp;
In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure
obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil
conspiracy, tortiously interfered with PMT&rsquo;s contracts and prospective economic advantage, and breached a covenant of good
faith and fair dealing.&nbsp; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence,
made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the
tort of conversion and statutory civil theft.&nbsp; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne
were unjustly enriched and engaged in unfair competition.&nbsp; PMT asked the Court to impose a constructive trust over the shares
held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&rsquo;
fees, costs and interest.&nbsp; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend
themselves vigorously.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2018, Mr. Christianson, the
Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The Company expects
a ruling on the motion within 90 days of that date. The motion for dismissal states that: the contract claims against Mr. Christianson
fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&rsquo;s
claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach
of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently
pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outcome and potential loss related
to this matter is unknown as of September 30, 2018 and as of the issuance of these &nbsp;financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 5 - Intangibles</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets rollforward is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful Life</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Net Intangibles, December 31, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">12-13 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">180,890</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">License agreement amendment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,633</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net Intangibles, December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216,372</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,291</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net Intangibles, September 30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">200,081</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company anticipates amortization expense
of approximately $21,000 per year for fiscal year 2019 through 2023 based upon the two current license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 6 - Accrued Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses consisted of the following
at September 30, 2018 and December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Accrued&nbsp;license fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">65,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">120,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">833,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">553,037</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,083</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued payroll</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Advances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">211,913</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">47,302</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,591,022</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,021,617</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 7 - Short-Term Promissory
Notes and Unsecured Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> September&nbsp;30,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Short-term promissory notes</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">253,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Unsecured loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">283,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Short-Term Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued short-term unsecured
and interest-free promissory notes (the &ldquo;Short-Term Notes&rdquo;) for aggregate gross proceeds of $253,000 in August 2017
which included free standing equity warrants. The Short-Term Notes were subsequently amended in November 2017 and March 2018 to
become convertible, extend the maturity date and include additional warrant coverage, new interest payment provisions and new conversion
features described more fully below. Effective July 2, 2018, the Company entered into debt conversion agreements (the &ldquo;Short-Term
Note Conversion Agreements&rdquo;) with each Short-Term Note subscriber to (i) convert the outstanding principal and accrued and
unpaid interest (the &ldquo;Outstanding Balance&rdquo;) under the Short-Term Notes into shares of the Company&rsquo;s common stock
based on the Outstanding Balance divided by $1.80 per share (the &ldquo;Short-Term Note Conversion Shares&rdquo;); (ii) cancel
and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described
more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share.
As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the &ldquo;Short-Term
Note Payment Warrants&rdquo;), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note
Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The Short-Term Note Payment Warrants
became exercisable commencing on July 2, 2018, and expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Short-Term
Note Conversion Agreements, $259,297 of the outstanding principal and interest of the Short-Term Notes was converted into
144,053 shares of common stock with an additional 477,856 shares issuable upon
exercise of the Replacement Warrants, Additional Warrants and Short-Term Payment Warrants. The conversion of the Short Term
Notes was accounted for as an extinguishment. The difference in the carrying value of the Short-Term Notes coupled with the
fair value of the underlying Replacement Warrants and Additional Warrants on the date of extinguishment relative to the
higher fair value of the underlying common stock and collective Replacement Warrants, Additional Warrants and new Short-Term
Payment Warrants issued was $148,787. The $148,787 differential was recorded as a loss on note extinguishments in the
accompanying consolidated statements of operations during the nine month transition period ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Replacement Warrants, Additional Warrants and Short-Term
Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the July 2, 2018 Short-Term Note Conversion
Agreements. All of the warrant terms became fixed and have identical provisions. Due to the previously granted warrants now having
fixed terms, the warrant liability value of $148,053 was reclassified to equity. The warrants associated with the Short-Term Notes
became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the
July 2, 2018 fair value of the warrants associated with the Short-Term Warrants. Input assumptions used were as follows: a risk-free
interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of
0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach,
considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount
methodologies.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Activity Prior to the July 2, 2018 Cancellation,
Extinguishment and Conversion of the Short-Term Notes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2017, the Company&rsquo;s Board
of Directors (the &ldquo;Board&rdquo;) authorized, and the Company issued the Short-Term Notes for aggregate gross proceeds of
$253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest
expense over the original term of the Short-Term Notes up though November 2017. For the year ended December 31, 2017, discount
amortization charged to interest expense related to the issuance costs was $1,748 through the November 30, 2017 amendment date
as discussed further below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2017, the Short-Term Notes
were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common
stock purchase warrants (as amended, the &ldquo;Original Warrants&rdquo;). The Original Warrants had a term of 5 years and an exercise
price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017
amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The November 30, 2017 amendment resulted
in a substantial modification to the Short-Term Notes and was accounted for under the provisions of extinguishment accounting.
A loss on note extinguishments in the accompanying statements of operations for the year ended December&nbsp;31, 2017 was recorded
in the amount of $144,577, which represented the difference between the face value of the Short-Term Notes over the combined carrying
values of the Short-Term Notes and warrants on the date of the amendment. The fair value increase of the Short-Term Notes and the
warrants as amended over its adjusted carrying value at the time of the amendment was $117,280 which was recorded as additional
paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the November 30, 2017 amendment,
the holders were to receive 126,500 common stock purchase warrants upon maturity. A portion of the proceeds from the Short-Term
Notes upon issuance was allocated to the original warrants based on their relative fair value to the underlying Short-Term Notes
in the amount of $61,496 and was recorded in additional paid-in capital in the accompanying consolidated balance sheets and was
discounted from the Short-Term Notes and was being amortized to interest expense ratably over the term of the Short-Term Notes
which amounted to $35,479 during the year ended December 31, 2017. The fair value of the warrants was based on the Black-Scholes
method with the following assumptions: a risk-free interest rate of 2.1 percent; expected volatility of 47.8 percent; expected
life of 5.7 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable
basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies,
using allocation and marketability-discount methodologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Short-Term Notes were subsequently
amended and restated on March 12, 2018 (the &ldquo;Amended and Restated Short-Term Notes&rdquo;). The Amended and Restated Short-Term
Notes became convertible promissory notes that had interest assessed at a fixed rate of 8% per annum and would have required the
Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &ldquo;Short-Term
Note Maturity Date&rdquo;). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company
and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement
warrant (the &ldquo;Replacement Warrants&rdquo;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the
Original Warrant. In addition, each holder was issued an additional warrant (the &ldquo;Additional Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Replacement Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Replacement Warrant issued on March
12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New
Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share
exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted
in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted
in connection with a change of control transaction. The Replacement Warrants were exercisable commencing on the Conversion Date
and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement
Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization
or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Replacement Warrants were deemed to
be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with
a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an offset
to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Amended and
Restated Short-Term Notes were recorded at each reporting date in the consolidated statements of operations which amounted to an
expense of $10,330 for the nine month transition period ended September 30, 2018. A Monte Carlo simulation model was used to estimate
the aggregate fair value of the Replacement Warrants immediately prior to the July 2, 2018 Short-Term Note Conversion Agreement
amendment. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 50 percent;
expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a
non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline
public companies, using allocation and marketability-discount methodologies.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Additional Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Additional Warrant issued on March
12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product
obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and
(ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants were exercisable commencing on the Conversion Date and
would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants
were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization
or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Additional Warrants were deemed to
be free-standing instruments and were accounted for as equity as there were no variable terms. 189,750 shares of common stock were
issuable upon exercise of the Additional Warrants as of the March 12, 2018 amendment date with terms that largely paralleled the
provisions of the Original Warrants except that the Additional Warrants were exercisable on the Conversion Date as opposed to the
Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. The fair value differential
between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair value change was recorded as a reduction
to additional paid-in capital in the accompanying condensed balance sheets and was included as part of the extinguishment loss
discussed further below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premium Conversion Derivative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the March 2018 amendment, the Amended
and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred
at a price under $2.25 per share. The Company determined that the redemption feature under the Short-Term Notes qualified as an
embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with
a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative
was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion
derivative associated with the Short-Term Notes in the consolidated statements of operations for a benefit of $(49,668) for the
nine month transition period ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The March 2018 amendment resulted in a
substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company
recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on note extinguishments in the
accompanying consolidated statements of operations for the nine month transition period ended September 30, 2018 was recorded in
the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes and Original Warrants
over the combined fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants
on the date of the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated
embedded conversion feature and the Additional Warrants) relative to its adjusted carrying value at the time of the amendment was
$1,170 which was recorded as a reduction to additional paid-in capital on the accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unsecured Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 17, 2018, the Company received cash
proceeds of $168,000 from unsecured loans, represented by two promissory notes from existing stockholders of the Company. The loans
are interest free and require that the Company repay the principal in full on the earlier to occur of (i) May 17, 2019 or (ii)
the closing of an equity round of financing of the Company that raises more than $5 million in gross proceeds. The loans include
customary events of default provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2018, the Company received
cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan is
interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii) the
closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes customary
events of default provisions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 8 - Convertible Promissory
Notes and Warrant Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> September&nbsp;30,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">2016 convertible promissory notes, net of discounts</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,543,652</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2017 convertible promissory notes, net of discounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,306,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">504,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accrued interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">87,028</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120,223</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">1,393,804</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">2,168,340</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2016 Convertible Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From November 2016 to June 2017, the Company
issued convertible promissory notes (the &ldquo;Convertible Notes&rdquo;) and common stock purchase warrants (the &ldquo;Warrants&rdquo;)
in an aggregate principal amount of $1,625,120 and entered into subscription agreements with subscribers (the &ldquo;2016 Private
Placement&rdquo;). Effective July 2, 2018, however, the Company entered into debt conversion agreements (the &ldquo;2016 Note Conversion
Agreements&rdquo;) with each Convertible Note subscriber to (i) convert the Outstanding Balance under the Convertible Notes into
shares of the Company&rsquo;s common stock based on the Outstanding Balance divided by $1.80 per share (the &ldquo;2016 Note Conversion
Shares&rdquo;); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to
make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration
for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the &ldquo;2016
Note Payment Warrants&rdquo;), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion
Shares received by such subscriber; at a per share exercise price of $1.80 per share. The 2016 Note Payment Warrants became exercisable
commencing on July 2, 2018 and expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the 2016 Note Conversion Agreements,
$1,804,064 of the outstanding principal and interest of the 2016 Convertible Promissory Notes was converted into 1,002,258 shares
of common stock and an additional 2,004,516 shares of common stock became issuable upon exercise of the Warrants and 2016 Note
Payment Warrants. The conversion of the Convertible Notes was accounted for as an extinguishment. The difference in the carrying
value of the Convertible Notes coupled with the fair value of the underlying Warrants upon conversion relative to the higher fair
value of the underlying common stock and collective Warrants and new 2016 Note Payment Warrants issued was $979,480. The $979,480
differential total, inclusive of the unamortized discount remaining on the Convertible Notes of $11,143 as of July 2, 2018, was
recorded as a loss on note extinguishments in the accompanying consolidated statement of operations during the nine month transition
period ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; text-align: justify">The Warrants and 2016 Note Payment Warrants were deemed to be free-standing equity instruments upon execution
of the 2016 Note Conversion Agreements. All of the warrant terms became fixed and the terms were identical. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the previously granted warrants now having fixed terms, the adjusted warrant liability value of $1,031,366 was reclassified
to equity. The warrants associated with the Convertible Notes became immediately exercisable on July 2, 2018 and expire November
21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Convertible
Notes. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent;
expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a
non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline
public companies, using allocation and marketability-discount methodologies. &nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Activity Prior to the July 2, 2018 Cancellation,
Extinguishment and Conversion of the Convertible Notes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company amended the Convertible Notes
in December 2016 and November 2017 and the Warrants in June 2017 and November 2017 to, among other things, change the terms of
the underlying Warrants that include the removal of down-round pricing protection provisions as described more fully below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Convertible Notes were unsecured. The
Convertible Notes accrued interest at a fixed rate of 8 percent per annum and required the Company to repay the principal and accrued
and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked round of financing
resulting in more than $3.0 million in gross proceeds (a &ldquo;Qualified Financing&rdquo;). If a Qualified Financing had occurred
before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes would have automatically
converted into the securities issued by the Company in such financing based on the greater number of securities resulting from
either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and
accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing.
If the Company failed to complete a Qualified Financing by July 31, 2018, the Convertible Notes would have been immediately due
and payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a change of control transaction or initial
public offering occurred prior to a Qualified Financing, the Convertible Notes would have, at the election of the holders of a
majority of the outstanding principal of the Convertible Notes, either been payable on demand as of the closing date of such transaction,
or been convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser
of the per share value as determined by the Board as if in connection with the granting of stock-based compensation, or in a private
sale to a third party in an arms-length transaction, or at the per share consideration to be paid in such transaction. Change of
control means a merger or consolidation with another entity in which the Company&rsquo;s stockholders do not own more than 50 percent
of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the June 2017 amendment, the Warrants
granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares
equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised prior
to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest
on the Convertible Notes held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the date of
issuance and would have expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under
the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the
related Convertible Notes. The amount of warrant shares to be issued became contingent and were based on the number of shares of
common stock received by the holder of the Convertible Notes upon conversion of such holder&rsquo;s Convertible Notes, and at an
exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants would have expired
on November 21, 2021 in the event of a Qualified Financing or would have expired unissued if the notes were not converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the July 2018 Convertible Note
extinguishment, the Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable
number of shares issuable in connection with a possible change of control conversion event. For the December 31, 2017 liability
valuation of the Warrants, a Monte Carlo simulation model was used to estimate the aggregate fair value. Input assumptions used
were as follows: a risk-free interest rate of 2.08 percent; expected volatility of 50 percent; expected life of 3.89 years; and
expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according
to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation
and marketability-discount methodologies. &nbsp;The Convertible Note proceeds assigned to the Warrants were zero and $440,919 during
the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively, which represented
their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount
was amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximated
the effective interest method and was fully amortized by December 31, 2017; the amortization expense recorded was $759,004 during
the year ended December 31, 2017. The Company also recorded the fair value changes of the warrant liability associated with the
Convertible Notes in the consolidated statements of operations which amounted to a benefit of $(14,865) and an expense of $259,352
for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The November 2017 amendment resulted in
a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated with
the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of the
Convertible Notes on the date of the modification. The $97,223 difference was recorded as a gain on note extinguishments in the
accompanying statements of operations with an offsetting discount to the Convertible Notes. The discount was being amortized over
the amended term of the Convertible Notes. The amortization recorded during the nine month transition period ended September 30,
2018 and the year ended December 31, 2017 was $70,324 and $15,756, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of their issuance, the Convertible
Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share.
The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated
from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes
in the amount of zero and $213,961 during the nine month transition period ended September 30, 2018 and the year ended December
31, 2017, respectively. The discount was being amortized to interest expense over the original term of the Convertible Notes using
the straight-line method which approximates the effective interest method and was fully amortized by December 31, 2017; the amortization
expense recorded was $340,551 during the year ended December 31, 2017. The embedded derivative was accounted for separately on
a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with
the Convertible Notes in the consolidated statements of operations for a benefit of $(333,183) and $(18,428) for the nine month
transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Convertible Notes,
the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610
for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &ldquo;placement
agent warrant&rdquo;) which would have had an exercise price of $2.00 per share of common stock with a total fair value of $4,855
on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant was issuable at the time
the private placement transaction was fully subscribed. The placement agent warrant would have been immediately exercisable on
the date of issuance and would have expired five years following the date of issuance. The Company recorded an issuance cost discount
to the Convertible Notes in the amount of zero and $39,781 during the nine month transition period ended September 30, 2018 and
the year ended December 31, 2017, respectively, and was fully amortized by December 31, 2017; the amortization expense recorded
as interest was $74,264 during the year ended December 31, 2017. The balance of the issuance costs in the amount of $38,119 was
attributed to the Warrants and was immediately recorded as interest expense upon issuance during the year ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2017, the Company initially
entered into a subscription agreement with certain investors (the &ldquo;Subscribers&rdquo;), pursuant to which the Company, in
a private placement (the &ldquo;Private Placement&rdquo;), agreed to issue and sell to the Subscribers 8% convertible promissory
notes (the &ldquo;2017 Convertible Notes&rdquo;) and warrants (the &ldquo;New Warrants&rdquo;) to purchase shares of the Company&rsquo;s
capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the
underlying conversion event and are exercisable for five years commencing on the triggering conversion event. The subscription
agreement, the 2017 Convertible Notes and New Warrants were amended on December 14, 2017 to move up the maturity date of the 2017
Convertible Notes from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision
of the 2017 Convertible Notes in the event of a qualified financing as described more fully below, to modify the exercise price
of the New Warrants and to increase the authorized subscription amount to $1,500,000. In May 2018, the Board approved an increase
in the authorized subscription amount from $1,500,000 to $2,000,000 and extended the offering period from the five month anniversary
of the initial closing to the eight month anniversary of the initial closing. The initial closing of the Private Placement was
consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes
in an aggregate principal amount of $1,540,000 to the Subscribers through June 2018 when the Private Placement expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Convertible Notes bear interest
at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on December
31, 2018 (the &ldquo;2017 Convertible Notes Maturity Date&rdquo;). If the Company consummates an equity round of financing resulting
in more than $3 million in gross proceeds before December 31, 2018 (the &ldquo;2017 Convertible Notes Qualified Financing&rdquo;),
the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities
issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest
on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible
Notes Qualified Financing. The New Warrants also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount
of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price
per share of the securities issued in the 2017 Convertible Notes Qualified Financing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the December 2017 amendment, if
the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued
and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company
in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued
interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible
Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable
in conjunction with the 2017 Convertible Notes Qualified Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, if a change of control transaction
occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017
Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes,
either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately
prior to such transaction at a price per share equal to the lesser of (i) the per share value of the shares of common stock as
determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party
in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a
merger or consolidation with another entity in which the Company&rsquo;s stockholders do not own more than 50% of the outstanding
voting power of the surviving entity or the disposition of all or substantially all of the Company&rsquo;s assets. The New Warrants
also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by
the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted
in the change of control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The December 2017 amendment resulted in
a substantial modification to the original 2017 Convertible Notes. The Company recorded the 2017 Convertible Note amendment under
the provisions of extinguishment accounting. The fair value of the underlying Convertible Notes was $294,615 higher than the carrying
value of the Convertible Notes net of unamortized debt discount on the date of the modification. The $294,615 difference as well
as legal costs associated with the amendment in the amount of $8,945 were recorded as a loss on convertible notes extinguishments
totaling $303,560 in the accompanying statements of operations for the year ended December&nbsp;31, 2017. After the modification,
there remained a debt discount of $27,371 of which $19,510 and $1,286 was amortized during the nine month transition period ended
September 30, 2018 and for the year ended December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Convertible Notes contain a conversion
discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on
the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible
Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation
of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $168,384 and
$128,525 for the convertible debt issued during the nine month transition period ended September 30, 2018 and the year ended December
31, 2017, respectively. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the
straight-line method which approximates the effective interest method. The amortization expense was $143,166 and $3,815 for the
nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively. The embedded derivative
is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion
derivative associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an
expense of $11,020 and $466 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The New Warrants were deemed to be free-standing
instruments and were accounted for as a liability given the variable number of shares issuable in connection with a change of control
conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants. Input assumptions
used were as follows: a risk-free interest rate of 2.94 percent and 2.22 percent as of September 30, 2018 and December 31, 2017,
respectively; expected volatility of 50 percent as of September 30, 2018 and December 31, 2017; expected life of 5.21 years and
5.38 years as of September 30, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of September
30, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according
to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation
and marketability-discount methodologies. The 2017 Convertible Note proceeds assigned to the New Warrants were $442,151 and $336,571
during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively, which represented
their fair value at issuance and were discounted from the 2017 Convertible Notes and reflected as a warrant liability. The discount
is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates
the effective interest method. The amortization expense was $375,076 and $9,971 for the nine month transition period ended September
30, 2018 and for the year ended December 31, 2017, respectively. The Company also recorded the fair value changes of the warrant
liability associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense
of $39,770 and a benefit of $(1,337) for the nine month transition period ended September 30, 2018 and for the year ended December
31, 2017, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2017 Convertible
Notes, the Company incurred issuance costs in the amount of $8,133 which consisted of legal costs and was recorded as an issuance
cost discount to the 2017 Convertible Notes, of which $2,944 and $157 was amortized to interest expense during the nine month transition
period ended September 30, 2018 and the year ended December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Convertible Note Subscription Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the subscription agreements
entered into in connection with the Private Placement, the Company is entitled to receive notice in the event a holder elects to
sell or receives a bona fide offer for any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right
to purchase the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as
applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the
subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective
subscription agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 9 - Stock-Based
Compensation</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine month transition period
ended September 30, 2018 and for the year ended December 31, 2017, stock-based services expense related to the stock options, restricted
stock awards and stock-based award liabilities was included in general and administrative and research and development costs as
follows in the accompanying statements of operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 12pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">480,653</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,065</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 12pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">74,729</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total stock-based services expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">486,120</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">76,794</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne formally adopted an equity incentive
plan (the &ldquo;2016 Plan&rdquo;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition.
In addition, the Company adopted a 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) on April 17, 2017. The 2016 and 2017
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company.
The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for
issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards
in the second quarter of 2017. During the nine month transition period ended September 30, 2018 and for the year ended December
31, 2017, 2,500 and 365,716 stock options were granted to directors and consultants at a weighted average exercise price of $5.34
and $0.035 per share, respectively. The stock options granted during the nine month transition period ended September 30, 2018
and during the year ended December 31, 2017 had a weighted average grant date fair value of $2.48 and $0.014 per share, respectively,
with the vesting period ranging from several weeks upon grant to two months from grant. The options expire ten years from the date
of grant. In addition, the Company issued 215,453 shares of restricted common stock at a grant date fair value of $0.034 with performance
vesting conditions from the 2016 Plan during the year ended December 31, 2017. There were no restricted common stock awards issued
out of the 2016 Plan or 2017 Plan during the nine month transition period ended September 30, 2018. All performance vesting conditions
for the restricted common stock were met and there were no unvested shares as of September 30, 2018 and December 31, 2017. Compensation
expense associated with restricted common stock was zero and $7,220 for the nine month transition period ended September 30, 2018
and for the year ended December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the Company&rsquo;s stock option
plan activity for the nine month transition period ended September 30, 2018 and for the year ended December&nbsp;31, 2017 as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted-</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Term (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding at December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">365,716</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding at December 31, 2017</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">365,716</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">0.03</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9.3</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">908,920</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding at September 30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">368,216</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">0.07</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">8.6</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">820,862</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Vested and exercisable at September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">368,216</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">0.07</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">8.6</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">820,862</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify">The aggregate intrinsic value is calculated as the difference
between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018
and December 31, 2017 of $2.30 and $2.52 per share, respectively.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average assumptions
used in the Black-Scholes option-pricing model are as follows for the stock options granted during the nine month transition period
ended September 30, 2018 and the year ended December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Expected stock price volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">49.8</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">47.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.9</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine month transition period
ended September 30, 2018, 2,500 stock options vested, and the weighted average grant date fair value per option was $2.48. During
the year ended December 31, 2017, 365,716 stock options and 215,453 restricted stock awards vested. The weighted
average grant date fair value per share of common stock issuable upon exercise of options and of restricted stock awards vesting
during the year ended December 31, 2017 was $0.014 and $0.034, respectively. No stock options were forfeited during the nine month
transition period ended September 30, 2018 or during the year ended December 31, 2017. As of September 30, 2018, 1,708,596 shares
were available for future issuance on a combined basis under the 2016 and 2017 Plans.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Stock-Based Awards</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Up to 250,000 shares of common stock were
reserved in February 2018 as a result of a consulting agreement for investor relations services executed in February 2018. Under
the agreement, 200,000 shares of common stock were awarded during the nine month transactional period ended September 30, 2018.
The shares were awarded based on a performance vesting condition that was met in February 2018 and a time-based vesting condition
that was met in both May 2018 and August 2018. The compensation expense related to the vested common shares was included in the
total stock-based services expense referenced above which totaled $469,500. The expense was based on the fair value of the underlying
common stock at the point of vesting which was $2.52 per share for 100,000 shares that vested in February 2018, $2.30 per share
for the 50,000 shares that vested in May 2018, and $2.05 per share for the 50,000 shares that vested in August 2018. The underlying
stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded
price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&nbsp;The
remaining 50,000 shares of the share commitment under the agreement vested in November 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company recorded stock-based
services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares
and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering,
qualified financing, or December 31, 2018 (as amended from the originally stated June 30, 2018 date). The number of option shares
under the agreement is based on a $3,000 monthly compensation amount divided by the fair value of the underlying common stock on
the award date. The exercise price will also be set at the fair value of the underlying common stock on the award date. The liability
associated with the unissued options was based on an option share equivalent estimate that reflects the portion of the award where
performance vesting conditions have been met as of September 30, 2018 and was based on the fair value of the Company&rsquo;s common
stock on September 30, 2018 as the award date has not occurred. The common stock fair value on September 30, 2018 was $2.30 per
share and was determined based on a non-marketable basis and was according to the market approach, considering both the traded
price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock-based services expense associated with the unissued
stock options was $11,153 during the nine month transition period ended September 30, 2018 and is classified in accrued expenses
at September 30, 2018. The liability for the unissued stock options was based on the following weighted-average assumptions using
the Black-Scholes option-pricing model:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Expected stock price volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">49.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.9</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the issuance of all of the unissued
options associated with the stock-based award liabilities, the estimated number of shares available for future issuance as of September
30, 2018 would be reduced from 1,708,596 to 1,698,161 shares as a result of the remaining stock options to be issued upon vesting
under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018 consulting agreement
are not eligible for issuance under either the 2016 Plan or 2017 Plan because the 2016 Plan and 2017 Plan limit plan participants
to individuals.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 10 - Stockholders&rsquo;
Deficit</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Private Placement and Corresponding
Issuance of Common Stock and Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From July 9, 2018 through September
28, 2018, the Company entered into subscription agreements (each, a &ldquo;Purchase Agreement&rdquo;) with certain accredited investors
(the &ldquo;Purchasers&rdquo;), pursuant to which the Company, in a private placement (the &ldquo;2018 Private Placement&rdquo;),
agreed to issue and sell to the Purchasers units (each, a &ldquo;Unit&rdquo;), each consisting of (i) 1 share (each, a &ldquo;Share&rdquo;)
of the Company&rsquo;s common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00
per share (the &ldquo;2018 Warrants&rdquo;). The initial closing of the 2018 Private Placement was consummated on July 9, 2018.
As of September 30, 2018, the Company has issued and sold an aggregate of 445,200 Units to the Purchasers, for total gross proceeds
to the Company of approximately $1,113,000 before deducting offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2018 Private Placement,
the Company has agreed to issue and sell to accredited investors up to a maximum of 4,000,000 Units (the &ldquo;Maximum Offering&rdquo;)
at a price of $2.50 per Unit for total gross proceeds to the Company of up to $10,000,000. If the 2018 Private Placement is over-subscribed,
the Company may, in its discretion sell up to an additional 600,000 Units (the &ldquo;Over-Allotment&rdquo;) to cover such over
subscriptions. If the Company issues the Maximum Offering amount, 4,000,000 shares of Common Stock (4,600,000 shares of Common
Stock if the Over-Allotment is exercised) would be issuable upon exercise of the 2018 Warrants. The Company may conduct any number
of additional closings so long as the final closing occurs on or before January 2, 2019. Under the Purchase Agreement, the Company
has agreed to use the net proceeds from the 2018 Private Placement to pay the outstanding principal and accrued interest on its
2017 Convertible Notes if such notes do not convert prior to maturity, to pay the principal on its unsecured term loans, for research
and development, clinical studies, legal fees and sales and marketing expenses, as well as working capital and general corporate
purposes. The Company has granted the Purchasers indemnification rights with respect to its representations, warranties and agreements
under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2018 Warrants are exercisable beginning
on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were
accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying consolidated
balance sheets based on their relative fair value to the underlying common shares issued. The fair value of the 2018 Warrants issued
was $318,759 and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate
of 2.82 percent; expected volatility of 49.8 percent; expected life of 4.91 years; and expected dividend yield of 0 percent. The
underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering
both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2018 Private Placement,
the Company recorded issuance costs in the amount of $173,067 as of September 30, 2018. The issuance costs included commissions
to the brokers equal to 10% of the gross proceeds from the sale of the Units that qualify for the commission and amounted to $83,800.
In addition to the brokers&rsquo; commission, the issuance costs included the estimated value of the 5-year warrants to be issued
to the brokers to purchase an amount of Common Stock equal to 10% of the total amount of qualifying Shares sold in the 2018 Private
Placement at an exercise price of $3.45 per share upon the close of the 2018 Private Placement. A liability in the amount of $26,878
was recorded as of September 30, 2018 related to the broker warrants. Lastly, third party legal costs in the amount $62,389 comprised
the balance of the issuance costs incurred as of September 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2018 Private Placement,
the Company entered into registration rights agreements with each of the Purchasers pursuant to which the Company has agreed to
file a registration statement with the SEC covering the resale of the shares of common stock sold in the 2018 Private Placement
and the shares of Common Stock issuable upon exercise of the 2018 Warrants. The Company has agreed to file such registration statement
within 75 days of the final closing of the 2018 Private Placement. Each registration rights agreement includes customary indemnification
rights in connection with the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Activity and Summary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes warrant
activity during the year ended December&nbsp;31, 2017 and the nine month transition period ended September 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Exercise Price</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Weighted Average</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Warrants</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Per<BR>
Warrant</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Exercise<BR>
Price</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding at January&nbsp;1, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%">Issued</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">189,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Outstanding and exercisable at December&nbsp;31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,737,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">$1.80 - 3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Outstanding and exercisable at September 30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,927,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">$1.80 - 3.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.98</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information
about warrants outstanding at September 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Exercise Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number Outstanding</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted Average Remaining Contractual life (Years)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number Exercisable at September 30, 2018</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">2,482,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center; padding-left: 5.4pt">3.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">2,482,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">3.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">4.8</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-bottom: 4pt; text-align: left">Total</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,927,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,927,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The July 2017 Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Acquisition of NeuroOne
on July 20, 2017, the Company acquired 100% of NeuroOne shares in exchange for the issuance of Company shares and NeuroOne became
the Company&rsquo;s wholly-owned subsidiary. Also, at the closing, Mr. Samad (the majority owner of the Company prior to the Acquisition)
tendered for cancellation 3,500,000 Company shares held by him as part of the conditions to closing resulting in a net exchange
of 1,573,000 shares of common stock (see further details in Note 1 &ndash; Organization and Nature of Operations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of Acquisition, the Company
had authorized 100,000,000 shares of common stock with a par value of $0.001 and 10,000,000 shares of preferred stock with a par
value of $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Predecessor NeuroOne, Inc. Activity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2016, prior to the Merger
with the LLC, NeuroOne issued 5,131,514 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition)
as founders&rsquo; shares to seven individuals. Three of those investors were officers of NeuroOne. NeuroOne recorded $9,050 of
share subscription receivable for these stock issuances in 2016, which remained outstanding as of December 31, 2016. The shares
were subscribed at value of $0.03 per share based on a valuation prepared by NeuroOne utilizing a weighted average market value
of invested capital methodology. In June 2017, the purchase price owed by the seven individuals for the founders&rsquo; shares
of NeuroOne under their respective subscription agreements totaling $9,050 was forgiven by NeuroOne prior to the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 11 - Income Taxes</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and
Jobs Act (the TCJA), which significantly modified U.S. corporate income tax law, was signed into law by President Trump. The TCJA
contains significant changes to corporate income taxation, including, but not limited to, the reduction of the corporate income
tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of
earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable
income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration,
one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on
foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions
for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the deductibility
of research and experimental expenditures that will be effective in the future).&nbsp;Notwithstanding the reduction in the corporate
income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform
to the newly enacted federal tax law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has recorded the adjustments
in the consolidated financial statements in accordance with the TCJA and related guidance with a reduction of $420,000&nbsp;to
its net gross deferred tax assets in December 2017, the period in which the legislation was enacted. The reduction was fully offset
by an equal reduction in the Company&rsquo;s valuation allowance given the Company&rsquo;s historical net losses, resulting in
no net income tax expense being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rate for
the Company for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017 was zero percent.
A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included
in the accompanying consolidated statements of operations for the Company is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Income tax benefit at federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21.0</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(34.0</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income tax, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7.7</TD><TD STYLE="text-align: left; white-space: nowrap">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.5</TD><TD STYLE="text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.4</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.6</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Disqualified interest and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.9</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.5</TD><TD STYLE="text-align: left; white-space: nowrap">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.2</TD><TD STYLE="text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">U.S. tax reform</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.3</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Effective tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left; white-space: nowrap">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left; white-space: nowrap">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant components of the Company&rsquo;s
deferred tax assets and liabilities are summarized in the tables below as of September 30, 2018 and December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Federal and state operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,837,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">871,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Acquired intangibles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,763</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,151</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">28,863</P> </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">81,904</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development credit carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Stock-based compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,821</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,115,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,105,877</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,115,268</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,105,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The deferred tax asset for the convertible
notes and the valuation allowance at December 31, 2017 were misstated by $452,845 and have both been revised in the preceding
table.&nbsp; The effects of this revision also impacted the effective tax rate reconciliation by increasing the warrant expense
percent by 10.6%, decreasing the U.S. tax reform percent by 3.8% and decreasing the valuation allowance percent by 6.8% for the
year ended December 31, 2017. These immaterial adjustments to the 2017 disclosures had no impact on our net loss or reported net
loss per share for the year ended December 31, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018 and December 31,
2017, the Company had gross deferred tax assets of approximately $2,115,000 and $1,106,000, respectively. Realization of the deferred
assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has
had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges
to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of approximately
$2,115,000 and $1,106,000 as of September 30, 2018 and December 31, 2017, respectively. U.S. net deferred tax assets will continue
to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another
source of income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018 and December 31,
2017, the Company&rsquo;s federal net operating loss carryforwards were approximately $6,393,000 and $3,032,000, respectively.
The Company had federal research credit carryforwards as of September 30, 2018 and December&nbsp;31, 2017 of approximately $83,000
and $36,000, respectively. The federal net operating loss incurred prior to January 1, 2018 and tax credit carryforwards will begin
to expire in 2036 if not utilized. Federal net operating losses incurred after December 31, 2017 will not expire. As of September
30, 2018 and December&nbsp;31, 2017, the Company had state net operating loss carryforwards of approximately $6,393,000 and $3,032,000,
respectively. The Company had state research credit carryforwards of approximately $57,000 and $27,000 as of September 30, 2018
and December 31, 2017, respectively. The state net operating loss carryforwards will begin to expire in 2031, if not utilized,
and the state research credit carryforwards will begin to expire in 2032 if not utilized.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the net operating loss carryforwards
and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&nbsp;382
of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations,
the limitation applies when one or more &ldquo;5-percent shareholders&rdquo; increase their ownership, in the aggregate, by more
than 50&nbsp;percentage points over a 36-month time period testing period or beginning the day after the most recent ownership
change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <I>Income Taxes
</I>(&ldquo;ASC 740&rdquo;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold
and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken
in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination
by taxing authorities. The Company believes its income tax filing positions and deductions will be sustained upon examination,
and accordingly, no reserves or related accruals for interest and penalties have been recorded at September 30, 2018 and December
31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with this guidance, the Company
has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes
will be classified as a component of interest expense and any related penalties will be classified in operating expenses in the
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s corporate returns are
subject to examination for the 2016 and 2017 tax years for federal and subject to examination for the 2016 and 2017 tax years in
one state jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 12 - Defined Contribution
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted a 401(k) defined contribution
plan (the &ldquo;401K Plan&rdquo;) on January 1, 2017, which was amended and restated on March 1, 2018 (the &ldquo;Restatement&rdquo;),
for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K
Plan subject to federal law limits. The Company began matching in the fourth quarter of 2017 on deferrals at 100% of deferrals
up to 3% of one&rsquo;s contributions and 50% on deferrals over 3%, but not exceeding 5% of one&rsquo;s contributions up through
the Restatement. The Company&rsquo;s matching contributions to employee deferrals became discretionary after the Restatement. The
Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through
September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee contributions and any employer
matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon
contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary
of an employee&rsquo;s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first
anniversary of an employee&rsquo;s date of hire. The amount of matching contributions made during the nine month transition period
ended September 30, 2018 and the year ended December 31, 2017 was $7,779 and $27,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 13 -  Subsequent
Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2018 Private Placement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between October 1, 2018 through
November 30, 2018, the Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross
proceeds to the Company of approximately $425,000 before deducting offering expenses. The additional Units have identical
terms to the 2018 Private Placement disclosed in Note 10 &ndash; Stockholders&rsquo; Deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unsecured Loans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, the Company received
cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from stockholders
who each owned over 5% of the Company&rsquo;s common stock. The loans are interest free and require that we repay the principal
in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross
proceeds or November 14, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advisory Board Stock Option Grants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; text-align: justify">In November 2018 and December 2018 the Board of Directors approved for grant,
to seven scientific advisory board members, a total of 175,000 stock options for the purchase of common stock. The options
when issued will vest monthly over a three year period commencing January 1, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Office Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leased a 5,196 square foot facility for use as its
corporate headquarters location in Minnetonka, Minnesota effective December 1, 2018. The lease expires on October 31, 2019 and
the monthly rent is $4,763.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_015"></A>ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Original Source Entertainment, Inc.&rsquo;s financial statements
as of and for the fiscal years ended December 31, 2016 and 2015 were audited by, and Original Source Entertainment, Inc.&rsquo;s
financial statements as of and for the first quarter ended March 31, 2017 were reviewed by, Pritchett, Siler &amp; Hardy, P.C.
(&ldquo;<B><I>Pritchett</I></B>&rdquo;), which served as our independent registered public accountant prior to the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We provided Pritchett a copy of the disclosures in response
to Item 304 of Regulation S-K in conjunction with the filing of the Current Report on Form 8-K disclosing the 2017 Acquisition,
filed with the SEC on July 20, 2017 (the &ldquo;<B><I>Acquisition 8-K</I></B>&rdquo;), and requested that Pritchett provide us
with a letter addressed to the SEC stating whether it agrees with the statements we have made in response to Item 304(a) of Regulation
S-K. A copy of such letter was filed as an exhibit to the Acquisition 8-K and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_016"></A>ITEM 9A. CONTROLS AND PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Evaluation of Disclosure Controls and
Procedures</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disclosure controls and procedures (as
defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) are controls and other procedures that are designed to provide
reasonable assurance that that information required to be disclosed in the reports that we file or submit under the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and forms, and that
such information is accumulated and communicated to our management, including our Chief Executive Officer, as appropriate, to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the preparation of this
Transition Report on Form 10-KT, our management, with the participation of our Chief Executive Officer, carried out an evaluation
of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2018. Based on this
evaluation, our management, including our Chief Executive Officer, concluded that our disclosure controls and procedures over financial
reporting that existed as of September 30, 2018 were not effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s Annual Report on
Internal Control Over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of
our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted
accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance
with authorizations of our management and Board; and (iii) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, including our Chief Executive
Officer, recognizes that our internal control over financial reporting cannot prevent or detect all errors and all fraud. A control
system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&rsquo;s
objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits
of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control
issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals
under all potential future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management, with the participation of the
Chief Executive Officer, assessed our internal control over financial reporting as of September 30, 2018, the end of our fiscal
year. Management based its assessment on criteria established in Internal Control&mdash;Integrated Framework (2013) issued by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has concluded that our internal
control over financial reporting was not effective as of September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our assessment, our
management communicated to the Audit Committee of our Board of Directors that an ineffective overall control environment
existed as of September 30, 2018 given several material weaknesses. The material weaknesses stem primarily from our small
size and include the inability to (i) maintain effective controls over accounting for non-routine and/or complex debt and
equity transactions and (ii) maintain effective controls over the financial statement close and reporting process and
accounting for routine transactions, due to an overall lack of segregation of duties resulting from the limited number of
employees we have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to recruit additional professionals
to address these material weaknesses, as our business conditions warrant. However, we do not currently have adequate cash resources
to invest in these additional resources. Accordingly, our remediation plans may be delayed. Although we believe that these corrective
steps, when taken, will enable management to conclude that the internal controls over our financial reporting are effective when
the staff is in place and trained, we cannot provide assurance that these steps will be sufficient. We may be required to expend
additional resources to identify, assess and correct any additional weaknesses in internal control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Transition Report does not include
an attestation report of our independent registered public accounting firm regarding internal control over financial reporting.
Management&rsquo;s report was not subject to attestation by our independent registered public accounting firm pursuant to rules
of the SEC that permit us to provide only management&rsquo;s report in this Transition Report, as a smaller reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This Management&rsquo;s report is not deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, unless we specifically state in a future filing that such report is to be considered filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Changes in Internal Control Over
Financial Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-style: normal">During
the three months ended September 30, 2018, there were no changes in our internal
controls over financial reporting (as defined in Rule 13a- 15(f) and 15d-15(f) under the Exchange Act) that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><A NAME="a_017"></A>ITEM 9B. OTHER INFORMATION</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-style: normal">None.
</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_018"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_019"></A>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS
AND CORPORATE GOVERNANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is divided into three classes.
Members of each class serve staggered three-year terms. The following table provides information as to each person who is, as of
the filing hereof, a director and/or executive officer of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><B>Name</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 53%; border-bottom: black 1.5pt solid"><B>Position(s)</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><B>Age</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>David Rosa</TD>
    <TD>&nbsp;</TD>
    <TD>Class II Director, Chief Executive Officer, and President</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Mark Christianson</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President, Business Development and Marketing</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Thomas Bachinski</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Development Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Suraj Kalia</TD>
    <TD>&nbsp;</TD>
    <TD>Class III Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Jeffrey Mathiesen</TD>
    <TD>&nbsp;</TD>
    <TD>Class III Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Paul Buckman</TD>
    <TD>&nbsp;</TD>
    <TD>Class I Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">63</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no family relationship between
any director and executive officer or among any directors or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Experience and Background of Directors and Executive
Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>David Rosa</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rosa has served as the Chief Executive Officer, President
and a director of the Company since July 2017 and as Chief Executive Officer and a director of our wholly-owned subsidiary, NeuroOne,
Inc., since October 2016. From November 2009 to November 2015, Mr. Rosa served as the chief executive officer and president of
Sunshine Heart, Inc., a publicly-held early-stage medical device company. From 2008 to November 2009, Mr. Rosa served as chief
executive officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served
as the vice president of global marketing for cardiac surgery and cardiology at St. Jude Medical. Currently, he serves as a director
on the board of directors of Biotricity Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rosa&rsquo;s qualifications to serve
on the Board include his senior leadership experience in the medical device industry. In addition, his day-to-day leadership of
the Company gives him critical insights into the Company&rsquo;s operations, strategy and competition, and he facilitates the Board&rsquo;s
ability to perform its oversight function. Throughout his career at the Company and his former positions, he has demonstrated strong
technical, strategic, and operational expertise, and he possesses in-depth knowledge of the medical device industry on a global
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Mark Christianson</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Christianson has served as Vice President
of Business Development and Marketing of the Company since July 2017 and of our wholly-owned subsidiary, NeuroOne, Inc., since
December 2016. From May 2013 to December 2016 Mr. Christianson served as North American sales manager for Cortec Corporation. From
February 2012 to May 2013 Mr. Christianson held the position of business development executive for Robert Half International. From
May 2009 to February 2012 Mr. Christianson held the position of regional sales manager for PMT. Mr. Christianson studied accounting
at Augsburg College in Minneapolis. Mr. Christianson brings 15 years of high performing sales, sales management, and project management
experience to the team. In addition, he also has contributed to the development and corporate strategy of the Company given his
experience in the neurological field and his close relationships with key epilepsy opinion leaders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Thomas Bachinski</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Bachinski has served as Chief Development
Officer of the Company since July 2017 and of our wholly-owned subsidiary, NeuroOne, Inc., since January 2017. From July 2015 to
January 2017, Mr. Bachinski served as the vice president of research and development/engineering at Caerus Corporation, a privately
held medical device company developing products for both the human medical and animal veterinarian industries. In December 2014,
Mr. Bachinski founded FutureWorks Innovative Engineering where technology commercialization strategies are developed and executed
for a variety of clients across the medical device industry. Prior to FutureWorks, Mr. Bachinski was vice president of research
and development and director of the advanced concept development group at Empi, Inc., developing and commercializing a portfolio
of neuro-stimulation devices and technologies. He holds a Master&rsquo;s degree in Engineering and an MBA. We believe that Mr.
Bachinski&rsquo;s extensive engineering background and accomplishments in technology commercialization in the neurological market
space will bring key engineering solutions and insight into our future product portfolio under development and future commercialization
efforts, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Suraj Kalia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kalia has served as a member of our
Board since August 2017 and as a director of our wholly-owned subsidiary, NeuroOne, Inc., since March 2017. He currently serves
as a managing director and senior research analyst at Northland Capital Markets, where he covers the medical technology sector,
after rejoining the firm in August 2012. His previous positions include managing director and senior medical device analyst at
Rodman &amp; Renshaw Capital Group, senior vice president at Madison Williams and Company LLC, senior research analyst at Piper
Jaffray Companies, and project manager at Entegris, Inc. as part of the Business Development &amp; Engineering groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kalia has served as a member of the
Advisory Board of Levitronix, LLC from 2009 until its acquisition by Thoratec Corporation in 2011. He has more than 18 years of
experience working in the financial and health care industries. Mr. Kalia has also served as an Adjunct Professor of Finance and
taught MBA level courses on Investment Theory and Mergers &amp; Acquisitions at University of St. Thomas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kalia holds the Chartered Financial
Analyst (CFA) designation. He received a Master&rsquo;s of Business Administration degree in Finance from the University of St.
Thomas in Minneapolis, a Bachelor&rsquo;s degree in Chemical Engineering from the Indian Institute of Technology in Bombay, India
and a Master&rsquo;s degree in Chemical Engineering from Stevens Institute of Technology in Hoboken, N.J.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that Mr. Kalia&rsquo;s extensive
background in the financial and medtech industry bring important practical experience from a financial and strategic perspective.
In addition, his engineering background enables him to provide key insights with respect to the Company&rsquo;s product development
strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Jeffrey Mathiesen</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Mathiesen has served as a member of
the Board of the Company since August 2017 and as a director of our wholly-owned subsidiary, NeuroOne, Inc., since April 2017.
He served as the chief financial officer of Gemphire Therapeutics Inc., a publicly-held clinical-stage biopharmaceutical company
developing therapies for patients with cardiometabolic disorders, from September 2015 to September 2018. From August 2015 to September
2015 he was a consultant to Gemphire. Prior to joining Gemphire, Mr. Mathiesen served as chief financial officer of Sunshine Heart,
Inc., a publicly-held early-stage medical device company, from March 2011 to January 2015. From December 2005 to April 2010, Mr.
Mathiesen served as vice president and chief financial officer of Zareba Systems, Inc., a manufacturer and marketer of medical
products, perimeter fencing and security systems, which was purchased by Woodstream Corporation in April 2010. Mr. Mathiesen has
held executive positions with publicly traded companies dating back to 1993, including vice president and chief financial officer
positions. Mr. Mathiesen also serves as a director, audit committee chairman and nominating and governance committee member of
Sun BioPharma, Inc., a publicly traded clinical stage biopharmaceutical company that develops therapies for pancreatic diseases
and as a director and audit committee chairman of eNeura, Inc., a privately-held medical technology company providing therapy for
both acute treatment and prevention of migraine. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota
and is also a Certified Public Accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that Mr. Mathiesen brings financial
insight and leadership and a wealth of experience in capital markets to the Board, as well as knowledge of public company accounting
and financial reporting requirements and familiarity with the life sciences industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Paul Buckman</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Buckman has served as Chairman of the
Board of the Company since August 2017 and as Chairman of the Board of our wholly-owned subsidiary, NeuroOne, Inc., since October
2016. Mr. Buckman is currently the General Manager of Structural Heart for LivaNova PLC. Prior to joining LivaNova, Mr. Buckman
served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture
fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology
company focused on closure of various anatomic structures, from February 2012 to September 2013. Previously, Mr. Buckman served
as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company focused on treatment of
peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer
of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc.,
a publicly traded diversified medical products company, from August 2004 to December 2006; and as chairman of the board of directors
and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman
founded and developed into an $80 million business, from January 2001 to January 2004. Mr. Buckman has worked in the medical device
industry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation, a publicly traded
medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of
Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for NeuroOne, Inc. (Chairman), Ablative Solutions,
Inc., ActivOrtho, Aortica, Inc., DyaMX, Inc., Miromatrix, Inc. (Chairman), and NexGen Medical. He previously served as a director
of Conventus Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc.,
Sunshine Heart, Inc., a publicly-held early-stage medical device company, and Micro Therapeutics, Inc. In addition to having raised
in excess of $500M in private capital, the combined exit value of those companies in which Mr. Buckman has served as either CEO,
Director or Co-Founder is approximately $2.8B. Mr. Buckman received a Master&rsquo;s degree in Business Administration and Finance
and a B.A. degree in Business Administration from Western Michigan University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that Mr. Buckman&rsquo;s strong
executive experience in medical device companies provides the Company with valuable guidance on product development and operational
matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board and Committee Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Audit Committee Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee of our Board (the &ldquo;<B><I>Audit
Committee</I></B>&rdquo;) reviews with management and the Company&rsquo;s independent registered public accounting firm the Company&rsquo;s
financial statements, the accounting principles applied in their preparation, the scope of the audit, any comments made by the
independent accountants upon the financial condition of the Company and its accounting controls and procedures and such other matters
as the Audit Committee deems appropriate. The Audit Committee&rsquo;s charter is available on our website, <I>www.neurooneinc.com</I>,
under Investors &mdash; Corporate Governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee currently consists
of three directors: Mr. Mathiesen (chair), Mr. Buckman and Mr. Kalia. The Board has determined that each of Mr. Buckman, Mr. Kalia
and Mr. Mathiesen is &ldquo;independent&rdquo; under Nasdaq independence standards. Additionally, the Board has determined that
each of Mr. Mathiesen and Mr. Buckman qualifies as an &ldquo;audit committee financial expert&rdquo; as that term is defined in
rules promulgated by the SEC. The designation of an &ldquo;audit committee financial expert&rdquo; does not impose upon such persons
any duties, obligations or liabilities that are greater than those generally imposed on each of them as a member of the Audit Committee
and the Board, and such designation does not affect the duties, obligations or liabilities of any other member of the Audit Committee
or the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functions of the Audit Committee include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Selecting our independent auditors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Reviewing the results and scope of the audit and other services provided by our independent auditors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Reviewing and evaluating our audit and control functions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 121; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has adopted a code of business
conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer and other
executive officers. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or
waivers of these provisions in public filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Governance Guidelines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has adopted Corporate Governance
Guidelines that set forth expectations for directors, director independence standards, Board structure and functions and other
policies for the governance of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To our knowledge, our directors and executive
officers have not been involved in any of the following events during the past ten years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any bankruptcy petition filed by or against such person or any business of which such person was
a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding
traffic violations and other minor offenses);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in
any type of business, securities or banking activities or to be associated with any person practicing in banking or securities
activities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures
Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended,
or vacated;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being subject of, or a party to, any Federal or state judicial or administrative order, judgment
decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities
or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or
regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated,
of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that
has disciplinary authority over its members or persons associated with a member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 16(a) Beneficial Ownership Reporting Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 16&nbsp;of the Exchange Act requires
our directors, executive officers and any persons who own more than 10% of our Common Stock, to file initial reports of ownership
and reports of changes in ownership with the SEC. Such persons are required by SEC regulation to furnish us with copies of all&nbsp;Section
16(a) forms that they file. Based solely on our review of the copies of such forms furnished to us and written representations
from the directors and executive officers, no insider failed to file on a timely basis a&nbsp;Section 16(a) report during the Transition
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advisory Boards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has established two advisory
boards: a Physician Advisory Board, and an Artificial Intelligence Advisory Board. These advisory boards do not have decision-making
authority but solely provide advice to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Physician Advisory
Board has five members, including one Ph.D and four medical doctors. Company management generally meets with individuals on the
Physician Advisory Board on a weekly basis, and such members advise the Company on medical and scientific matters as they relate
to the Company&rsquo;s business. Three members are affiliated with the Mayo Clinic, and do not receive any additional compensation
for their services. The other two members, Dr. Justin Williams and Dr. Greg Esper, entered into consulting agreements NeuroOne,
Inc. (prior to the Acquisition) pursuant to which the NeuroOne agreed to grant each of them stock options, in addition to certain
benefits and reimbursement of certain business expenses. In April 2017 and June 2017, the Company granted Dr. Williams and Dr.
Esper, respectively, stock options exercisable for 2,500 shares of NeuroOne stock (42,525 shares of Company common stock after
conversion pursuant to the Exchange Ratio). These consulting agreements have expired, and Dr. Williams and Dr. Esper have not received
any additional compensation from the Company. The Company has not been party to any agreements with the other three members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Artificial Intelligence Advisory Board
was formed in September 2018, and is comprised of Kip Ludwig, PhD (chair), and six additional members. Members of the Artificial
Intelligence Advisory Board will provide guidance to management of the Company on the potential use of the Company&rsquo;s electrode
technology in bioelectronics, neuromodulation and artificial intelligence applications. The Company anticipates that this advisory
board will begin holding meetings in early 2019. Between September and November 2018, the Company entered into scientific advisory
board and consulting services agreements with these members, and may enter into SAB Agreements with additional members.
Under these agreements, each member agreed to serve on the Artificial Intelligence Advisory Board through January 1, 2022, and
the Company agreed to grant each member options to purchase 25,000 shares of common stock, which will vest monthly in 36 equal
increments beginning on January 1, 2019. If a member leaves the Artificial Intelligence Advisory Board prior to the three year
anniversary of the date of their agreement, any remaining unvested options will be forfeited. When the stock options are granted,
vested options will be exercisable at a per share exercise price equal to the fair value of the common stock on the date of
grant.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 122; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_020"></A>ITEM 11. EXECUTIVE COMPENSATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the compensation
earned or received during the Transition Period and the fiscal years ended December 31, 2017 and 2016 by each of our named executive
officers (as determined pursuant to the SEC&rsquo;s disclosure requirements for executive compensation in Item 402 of Regulation
S-K), as well as Mr. Samad, who served as the Chief Executive Officer of Original Source Entertainment from March 6, 2014 until
his resignation from such position upon the closing of the Acquisition. Compensation paid to Messrs. Rosa, Bachinski and Christianson
prior to the consummation of the Acquisition was paid by our accounting predecessor in the Acquisition, NeuroOne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal Position</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Non-Equity<BR>
 Incentive Plan<BR>
 Compensation<SUP>(1)</SUP><BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other Compensation ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Dave Rosa,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">2018 TP<SUP>(2)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">287,640</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">287,640</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; background-color: rgb(204,238,255); padding-left: 0.25in; text-indent: -0.125in">Chief Executive Officer and President</TD><TD STYLE="background-color: rgb(204,238,255)">&nbsp;</TD>
    <TD STYLE="text-align: center; background-color: rgb(204,238,255)">2017</TD><TD STYLE="background-color: rgb(204,238,255)">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="text-align: right; background-color: rgb(204,238,255)">356,667</TD><TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="background-color: rgb(204,238,255)">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="text-align: right; background-color: rgb(204,238,255)">131,600</TD><TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="background-color: rgb(204,238,255)">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="text-align: right; background-color: rgb(204,238,255)">1,400</TD><TD STYLE="text-align: left; white-space: nowrap; background-color: rgb(204,238,255)"><SUP>(3)</SUP></TD><TD STYLE="background-color: rgb(204,238,255)">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="text-align: right; background-color: rgb(204,238,255)">6,098</TD><TD STYLE="text-align: left; white-space: nowrap; background-color: rgb(204,238,255)"><SUP>(4)</SUP></TD><TD STYLE="background-color: rgb(204,238,255)">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD><TD STYLE="text-align: right; background-color: rgb(204,238,255)">495,765</TD><TD STYLE="text-align: left; background-color: rgb(204,238,255)">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,898</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,898</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amer Samad,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Former Chief Executive Officer<SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Thomas Bachinski,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018 TP<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Chief Development Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,595</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,220</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(7)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(8)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276,363</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mark Christianson,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2018 TP<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP></SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,500</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(9)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Vice President, Business Development and Marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,510</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,498</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(10)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,008</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">830</TD><TD STYLE="text-align: left; white-space: nowrap"><SUP>(11)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,497</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The amount of bonus
earned for the Transition Period is not calculable through November 30, 2018. The amount of bonus, if any, is expected to be
determined by February, 2019. Once such bonuses, if any, are determined, such amounts will be disclosed in a filing under Item
5.02(f) of Form 8-K.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">In September 2018, we changed our fiscal year end from
December 31 to September 30. The 2018 TP salary amounts reflect the compensation earned from January 1, 2018 to September 30,
2018.</TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">In October 2016, NeuroOne issued founders&rsquo; shares
to seven individuals, including Mr. Rosa and Mr. Christianson. Such individuals did not pay the purchase price for the shares.
The purchase price owed by the seven individuals for the founders&rsquo; shares under their respective subscription agreements
totaling $9,050 was recorded as share subscription receivable in 2016. The receivable was forgiven by NeuroOne prior to the Acquisition
in June 2017.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Represents an $800 per month car allowance that Mr. Rosa
received from January 2017 until August 4, 2017, the effective date of his amended employment agreement, and a $498 life insurance
premium paid in 2017.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Represents an $800 per month car allowance commencing in
October 2016 and a $498 life insurance premium paid in 2016.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Mr. Samad was Original Source Entertainment&rsquo;s sole
executive officer and director prior to the Acquisition and did not receive any compensation for his services rendered to Original
Source Entertainment in 2017 or 2016.</TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Pursuant to his offer letter with NeuroOne,&nbsp;Inc., Mr. Bachinski
was granted a restricted stock award under the 2016 Plan for 12,666 NeuroOne Shares (215,453 shares, as converted based on the
Exchange Ratio), which was subject to certain performance vesting conditions related to product development and was fully vested
in 2017. The amount reported reflects the grant date fair value of such restricted stock award.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Represents life insurance premium paid in 2017.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(9)</TD><TD STYLE="text-align: justify">Represents a $500 per month car allowance.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(10)</TD><TD STYLE="text-align: justify">Represents a $500 per month car allowance and a $498 life
insurance premium paid in 2017.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(11)</TD><TD STYLE="text-align: justify">Represents a $500 per month car allowance, which was received
for December 2016, and a $330 life insurance premium paid in 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Narrative to Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board sets the annual compensation
for our named executive officers. As we are a development-stage company with only three employees and commenced our operational
efforts in 2016, we have not hired a compensation consultant and do not currently target a specific competitive position or a specific
mix of compensation among base salary, bonus or long-term incentives. Except for car allowances provided to Mr. Rosa and Mr. Christianson
and payment of a portion of the premiums for life, medical and disability insurance for all employees, NeuroOne, Inc. did not,
and we do not, provide perquisites or personal benefits to our named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2016, NeuroOne entered into
an employment agreement with Mr. Rosa that governed the terms of his employment with us through August 3, 2017. Pursuant to the
agreement, Mr. Rosa was entitled to an annual base salary of $300,000 per year, and was eligible to earn an annual performance
bonus of up to 40% of his base salary, as determined by our Board. Mr. Rosa was also entitled to an equity award equal to 14% of
the fully diluted equity of NeuroOne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 123; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Acquisition, in August 2017,
the Company entered into a new employment agreement with Mr. Rosa (the &ldquo;<B><I>Amended Employment Agreement</I></B>&rdquo;)
that established his base salary of at least $376,000, which shall be reviewed by the Board at least annually, and an annual performance
bonus of up to 50% of his base salary, as determined by the Board. Mr. Bachinski&rsquo;s and Mr. Christianson&rsquo;s 2017 base
salaries of $231,000 and $200,000, respectively, and annual performance bonuses of up to 25% of base salary were established in
offer letters negotiated in connection with their hiring. Taking into account his contributions to the Company, Mr. Bachinski&rsquo;s
annual performance bonus target was increased from his offer letter to 35% of base salary for 2017.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Acquisition, the
named executive officers of NeuroOne were appointed as officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For fiscal 2017, the Board approved payment
of Mr. Rosa&rsquo;s bonus at 70% of target and authorized Mr. Rosa, in his discretion, to approve and pay bonuses to Mr. Bachinski
and Mr. Christianson of up to 70% of target. In approving discretionary bonus payments, the Board considered the achievement of
various corporate objectives related to company financing goals, regulatory submission preparation, research and development, adhering
to budget and establishing an advisory board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the calendar year ended 2018, our Board
approved a 2% cost of living increase in the base salaries of our officers and made no adjustment to the officers&rsquo; annual
performance bonus targets. In March 2018, the Board calendar year set various corporate objectives relating to company financing
goals, regulatory submissions, hiring additional staff and certain research and development milestones through December 31, 2018
that it would consider in approving bonus payments for the 2018 calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February, 2019, the Board will consider
the achievement of the corporate objectives and determine the amounts of the bonus payments, if any for the calendar year ended
December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an employment agreement with our
Chief Executive Officer, Mr. Rosa. We have entered into offer letters with each of our other executive officers, as described above.
Each of our named executive officers has also executed our standard form of proprietary information, inventions assignment and
non-competition agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rosa&rsquo;s Amended Employment Agreement
was effective on August 4, 2017, continues through the third anniversary and automatically renews for an additional one-year period
at the end of the initial term and each anniversary thereafter, provided that Mr. Rosa notifies the Board of such renewal at least
30 days prior to the expiration of the initial term or any renewal terms and the Board does not notify Mr. Rosa of its intention
not to renew the Amended Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amended Employment Agreement also entitles
Mr. Rosa to, among other benefits, the following compensation: (i) an opportunity to participate in any stock option, performance
share, performance unit or other equity based long-term incentive compensation plan commensurate with the terms and conditions
applicable to other senior executive officers; and (ii) participation in welfare benefit plans, practices, policies and programs
provided by the Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability,
employee life, group life, accidental death and travel accident insurance plans and programs) to the extent available generally
or to our other senior executive officers. Mr. Rosa is entitled to receive a target award value, determined in accordance with
the policies and practices generally available to other senior executive officers, for an annual cash bonus and if determined by
the Board or a committee of the Board, a long-term incentive bonus. Mr. Rosa is entitled to retain all shares of Common Stock he
held as of the commencement date. Mr. Rosa is also additionally entitled to certain severance benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Amended Employment Agreement,
regardless of the manner in which Mr. Rosa&rsquo;s service terminates, Mr. Rosa is entitled to receive amounts earned during his
term of service, including salary and other benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is permitted to terminate Mr.
Rosa&rsquo;s employment for the following reasons: (i) death or disability, (ii) Termination for Cause (as defined below) or (iii)
for any other reason or no reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rosa is permitted Termination for Good
Reason (as defined below) of his employment. In addition, he may terminate his employment upon written notice to the Company 30
days prior to the effective date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of Mr. Rosa&rsquo;s death
during the employment period or a termination due to his disability, his beneficiaries or legal representatives shall be provided
the sum of (i) any annual base salary earned, but unpaid, for services rendered to the Company on or prior to the date on which
the employment period ends and (ii) certain other benefits provided for in the employment agreement (the <B><I>&ldquo;Unconditional
Entitlements&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 124; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of Mr. Rosa&rsquo;s Termination
for Cause by the Company or the termination of Mr. Rosa&rsquo;s employment as a result of his resignation other than a Termination
for Good Reason, Mr. Rosa shall be provided the Unconditional Entitlements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a Termination for Good
Reason by Mr. Rosa or the exercise by the Company of its termination rights to terminate Mr. Rosa other than by Termination for
Cause, death or disability, Mr. Rosa shall be provided the Unconditional Entitlements and, subject to such officer signing and
delivering to the Company and not revoking a general release of claims in favor of the Company and certain related parties, the
Company shall provide Mr. Rosa a severance amount equal to the aggregate annual base salary he would have earned from the day after
his termination date through the end of the employment period and a prorated portion of his cash bonus for the year in which the
termination date occurs, provided, however, in no event would the severance amount be less than 12 months or more than 18 months
of his annual base salary, continued health insurance coverage for 12 months following his termination date, provided that such
coverage shall cease if Mr. Rosa becomes eligible to receive health insurance coverage from another employer group health plan,
vesting of all stock options in accordance with the stock option award documents, subject to the same conditions that would be
applicable to Mr. Rosa if he remained employed through the end of the employment period and continued vesting of equity awards
in accordance with the terms of the award agreements, provided, however, Mr. Rosa would have 90 days from the termination date
to exercise any vested options (the <B><I>&ldquo;Conditional Benefits&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change in control during
the employment period or within two years after a change in control, if the Company terminates Mr. Rosa other than due to Mr. Rosa&rsquo;s
death or disability or a Termination for Cause, or Mr. Rosa effects a Termination for Good Reason, the Company will pay to Mr.
Rosa, in a lump sum in cash within 30 days after the termination date, the aggregate of: (i) the Unconditional Entitlements; and
(ii) the amount equal to the product of 1.5 times the sum of (y) Mr. Rosa&rsquo;s annual base salary, and (z) the greater of the
target bonus for the then current fiscal year under the Plans or any successor annual bonus plan and the average annual bonus paid
to or for the benefit of Mr. Rosa for the prior three full years (or any shorter period during which Mr. Rosa had been employed
by the Company). In addition, the Company shall provide Mr. Rosa the Conditional Benefits minus Mr. Rosa&rsquo;s severance amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Amended Employment Agreement,
<B><I>&ldquo;Termination for Cause&rdquo;</I></B> means a termination of Mr. Rosa&rsquo;s employment by the Company due to (A)
an act or acts of dishonesty undertaken by Mr. Rosa and intended to result in substantial gain or personal enrichment to Mr. Rosa
at the expense of the Company, (B) unlawful conduct or gross misconduct that is willful and deliberate on Mr. Rosa&rsquo;s part
and that, in either event, is materially injurious to the Company, (C) the conviction of Mr. Rosa of, or Mr. Rosa&rsquo;s entry
of a no contest or nolo contendere plea to, a felony, (D) breach by Mr. Rosa of his fiduciary obligations as an officer or director
of the Company, (E) a persistent failure by Mr. Rosa to perform his duties and responsibilities of his employment under the Amended
Employment Agreement, which failure is not remedied by Mr. Rosa within 30 days after his receipt of written notice from the Company
of such failure, provided, however, the Company is not obligated to provide written notice and opportunity to cure if the action
or conduct is not reasonably susceptible to cure; or (F) material breach of any terms and conditions of the Amended Employment
Agreement, any contract or agreement between Mr. Rosa and the Company, or of any Company policy, or of any statutory duty he owes
to the Company, which breach has not been cured by Mr. Rosa within ten days after written notice thereof to Mr. Rosa from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Amended Employment Agreement,
<B><I>&ldquo;Termination for Good Reason&rdquo;</I></B> means a termination of Mr. Rosa&rsquo;s employment by Mr. Rosa within 30
days of the Company&rsquo;s failure to cure, in accordance with the procedures set forth below, any of the following events: (A)
a reduction in his annual base salary as in effect immediately prior to such reduction by more than 10% without his written consent,
unless such reduction is made pursuant to an across the board reduction applicable to all senior executives of the Company; (B)
a material reduction in his duties, position and responsibilities as in effect immediately prior to such reduction without his
written consent, provided, however, that a mere change in title or reporting relationship following a Change in Control by itself
will not constitute &ldquo;Good Reason&rdquo; for Executive&rsquo;s resignation, and further provided that the acquisition of the
Company and subsequent conversion of the Company to a division or unit of the acquiring entity will not by itself result in a &ldquo;reduction&rdquo;
of duties, position or responsibility; or (C) a material breach of any material provision of the Amended Employment Agreement by
the Company. A termination by Mr. Rosa shall not be treated as a Termination for Good Reason if Mr. Rosa consented in writing to
the occurrence of the event giving rise to the claim of Termination for Good Reason or unless Mr. Rosa shall have delivered a written
notice to the Board within 45 days of Mr. Rosa&rsquo;s having actual knowledge of the occurrence of one of such events stating
that Mr. Rosa intends to terminate his employment by Termination for Good Reason and specifying the factual basis for such termination,
and such event, if capable of being cured, shall not have been cured within 21 days of the receipt of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our named executive officers held any stock that has
not vested, unexercised stock options or other equity incentive plan awards as of September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2016 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2016 NeuroOne, Inc.&rsquo;s
board of directors adopted and its stockholders approved the 2016 Equity Incentive Plan (the &ldquo;<B><I>2016 Plan</I></B>&rdquo;).
In connection with the Acquisition, we assumed the 2016 Plan. As of September 30, 2018, there were outstanding options to purchase
a total of 365,716 shares of Common Stock issued and outstanding under the 2016 Plan and 215,453 restricted shares of Common Stock
granted under the 2016 Plan. We anticipate that no additional awards will be granted under the 2016 Plan, and all awards will be
granted under the 2017 Equity Incentive Plan (the &ldquo;<B><I>2017 Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Description of the 2016 Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 Plan authorizes the Board to provide
incentive compensation in the form of stock options, stock appreciation rights (&ldquo;<B><I>SARs</I></B>&rdquo;) and restricted
stock and restricted stock units (&ldquo;<B>RSUs</B>&rdquo;). Under the 2016 Plan, the Board is authorized to issue up to 992,266
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board, or a duly authorized committee
thereof, has the authority to administer the 2016 Plan. The Board may also delegate to one or more of its officers the authority
to (i) designate officers and employees to be recipients of certain stock awards, and (ii) determine the number of shares of Common
Stock to be subject to such stock awards. Subject to the terms of the 2016 Plan, the Board or the authorized committee, referred
to therein as the plan administrator, determines recipients, dates of grant, the numbers and types or combination of types of stock
awards to be granted and the terms and conditions of the stock awards, including the vesting schedule applicable to a stock award.
Subject to the limitations set forth below, the plan administrator also determines the exercise price, strike price or purchase
price of awards granted and the types of consideration to be paid for the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator has the authority
to modify outstanding awards under the 2016 Plan. Subject to the terms of the 2016 Plan, the plan administrator has the authority
to reduce the exercise, purchase or strike price of any outstanding stock award, cancel any outstanding stock award in exchange
for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted
accounting principles, with the consent of any adversely affected participant and subject to the requirements of Section 409A of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Options and SARs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator determines the term
of stock options and SARs granted under the 2016 Plan, up to a maximum of 10 years. Unless the terms of the participant&rsquo;s
award agreement provides otherwise, if a participant&rsquo;s service relationship with the Company, or any of its affiliates, ceases
for any reason other than disability, death or cause, the participant may generally exercise any vested options or SARs for a period
of three months following the cessation of service. The term may be extended in the event that exercise of the option following
such a termination of service is prohibited by applicable securities laws. If a participant&rsquo;s service relationship with the
Company or any of its affiliates ceases due to disability or death, or a participant dies within a certain period following cessation
of service, the participant or a beneficiary may generally exercise his or her options for a period of 12 months in the event of
disability and 18 months in the event of death. In the event of a termination for cause, options and SARs generally terminate upon
the termination date of the individual. In no event may an option or SAR be exercised beyond the expiration of its term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 126; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acceptable consideration for the purchase
of Common Stock issued upon the exercise of a stock option is determined by the plan administrator and may include (1) cash, check,
bank draft or money order, (2) the tender of shares of Common Stock previously owned by the optionholder, (3) a net exercise of
the option if it is a non-qualified stock option, or NSO, (4) a deferred payment or similar arrangement with the optionholder,
and (5) other legal consideration approved by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the plan administrator provides
otherwise, options and SARs generally are not transferable except by will, the laws of descent and distribution, or pursuant to
a domestic relations order. A Participant may designate a beneficiary, however, who may exercise the option or SAR following the
participant&rsquo;s death. The Board may also permit transfer of options to a trust provided certain conditions are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fair market value, determined
at the time of grant, of the Common Stock with respect to Incentive Stock Options, or ISOs, that are exercisable for the first
time by an optionholder during any calendar year under all of the Company&rsquo;s stock plans may not exceed $100,000. Options
or portions thereof that exceed such limit are generally treated as NSOs. No ISO may be granted to any person who, at the time
of the grant, owns or is deemed to own stock possessing more than 10% of the Company&rsquo;s total combined voting power or that
of any of the Company&rsquo;s affiliates unless (i) the option exercise price is at least 110% of the fair market value of the
stock subject to the option on the date of grant, and (ii) the term of the ISO does not exceed five years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Stock Awards and Restricted Stock Unit Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator determines the terms
of a restricted stock award or restricted stock unit award as set forth in the applicable award agreement. Shares of Common Stock
that are subject to a restricted stock award may be (i) held in a book entry from until restrictions lapse or (ii) evidenced by
a certificate which shall be held in such form and manner as determined by the Board. Shares of Common Stock awarded under a restricted
stock award may be subject to forfeiture in accordance with a vesting schedule. If a participant&rsquo;s employment is terminated,
the Company may receive through a forfeiture condition or repurchase right, any or all of the shares of Common Stock of the restricted
stock award. Upon the grant of restricted stock unit award, the Board may impose such restrictions and conditions to vesting as
it deems appropriate. A restricted stock unit award may be settled in shares of Common Stock, their cash equivalent, any combination
or such other form of consideration. Upon a participant&rsquo;s termination of employment, any unvested portion of the restricted
stock unit award is forfeited. Dividends and dividend equivalents may be provided under a restricted stock award or restricted
stock unit award, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in Capital Structure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that there is a specified
type of change in the Company&rsquo;s capital structure, such as a stock split or recapitalization, appropriate adjustments will
be made to (1) the class and maximum number of shares reserved for issuance under the 2016 Plan, (2) the class and maximum number
of shares that may be issued upon the exercise of ISOs, (3) the class and number of shares and exercise price, strike price, or
purchase price, if applicable, of all outstanding stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Corporate Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of certain specified significant
corporate transactions, the plan administrator has the discretion to take any of the following actions with respect to stock awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">arrange for the assumption, continuation or substitution
of stock awards outstanding under the 2016 Plan by a surviving or acquiring entity or parent company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">arrange for the reacquisition or repurchase rights held
by the Company to the surviving or acquiring entity or parent company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">accelerate the vesting of the stock award and provide for
its termination prior to the effective time of the corporate transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">terminate unexercised stock awards held by participants
no longer employed by the Company and that have not been assumed, continued or substituted; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">make a payment equal to the excess of (i) the value of
the property the participant would have received upon exercise of the stock award over (ii) the exercise price applicable to the
stock award.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 127; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s plan administrator
is not obligated to treat all stock awards, even those that are of the same type, in the same manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2016 Plan, a corporate transaction
is generally the consummation of (1) a sale or other disposition of all or substantially all of the Company&rsquo;s consolidated
assets, (2) a sale or other disposition of at least 90% of the Company&rsquo;s outstanding securities, (3) a merger, consolidation
or similar transaction following which the Company is not the surviving corporation, or (4) a merger, consolidation or similar
transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately prior
to such transaction are converted or exchanged into other property by virtue of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator may provide, in
an individual award agreement or in any other written agreement between a participant and the Company that the stock award will
be subject to additional acceleration of vesting and exercisability in the event of a change of control transaction. Under the
2016 Plan, a change of control is generally (1) the acquisition by a person or entity of more than 50% of the Company&rsquo;s combined
voting power other than by merger, consolidation or similar transaction; (2) a consummated merger, consolidation or similar transaction
immediately after which the Company&rsquo;s stockholders cease to own more than 50% of the combined voting power of the surviving
entity; or (3) a consummated sale, lease or license or other disposition of all or substantially of the Company&rsquo;s consolidated
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2017, the board of directors of
Original Source Entertainment adopted and the stockholders approved the 2017 Plan. The 2017 Plan is designed to provide a vehicle
under which a variety of stock-based and other awards can be granted to the Company&rsquo;s employees, consultants and directors,
which will align the interests of award recipients with those of our stockholders, reinforce key goals and objectives that help
drive stockholder value, and attract, motivate and retain experienced and highly qualified individuals who will contribute to the
Company&rsquo;s financial success. The Board believes that the 2017 Plan will serve a critical role in attracting and retaining
high caliber employees, consultants and directors essential to our success and in motivating these individuals to strive to meet
our goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Shares Available Under the Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Plan authorizes the compensation
committee or Board to provide incentive compensation in the form of stock options, SARs, restricted stock and stock units, performance
shares and units and other stock-based awards. Under the 2017 Plan, the Board is authorized to issue up to 1,300,000 shares, subject
to adjustment as provided below. As of September&nbsp;30, 2018, 1,297,500 shares remained available under the 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Section 162(m) Tax Considerations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 162(m) of the Internal Revenue
Code generally denies a corporate tax deduction for annual compensation exceeding $1 million paid to the principal executive officer,
the principal financial officer or to any of the three other most highly compensated officers of a publicly held corporation. Accordingly,
to the extent compensation income recognized by any such individual during a year as a result of an award made under the 2017 Plan
(either alone or when added to other compensation paid to any of such individual during such year) exceeds $1 million, then the
amount in excess of $1 million will not be deductible by us, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Description of the 2017 Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Authorized Shares. </I>The maximum
number of shares of Common Stock that may be issued under the 2017 Plan, is 1,300,000 shares. In addition, the number of shares
of Common Stock reserved for issuance under our 2017 Plan automatically increases on January 1<FONT STYLE="font-size: 10pt"><SUP>st</SUP></FONT>
of each calendar year, starting on January 1, 2018 through January 1, 2027, to an amount equal to 13% of the total number of fully-diluted
shares of our Common Stock as of December 31 of the preceding calendar year, or a lesser number of shares determined by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 128; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards granted under
the 2017 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do
not reduce the number of shares available for issuance under the 2017 Plan. Additionally, shares become available for future grant
under the 2017 Plan if they were issued under stock awards under the 2017 Plan and if we repurchase them or they are forfeited.
This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a
stock award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Plan Administration.</I> Our Board,
or a duly authorized committee of our Board, will administer the 2017 Plan. Our Board may also delegate to one or more of our officers
the authority to (1) designate employees (other than officers) to receive specified stock awards and (2) determine the number of
shares subject to such stock awards. Under the 2017 Plan, our Board has the authority to determine and amend the terms of awards
and underlying agreements, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">recipients;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">when and how the stock awards will be granted;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the provisions of each stock award (which need not be identical);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the number of shares subject to each stock award; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the vesting schedule applicable to the awards, together
with any vesting acceleration.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2017 Plan, the Board also generally
has the authority to effect, with the consent of any adversely affected participant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the reduction of the exercise, purchase, or strike price of any outstanding award;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the cancellation of any outstanding award and the grant in substitution therefore of other awards,
cash, or other consideration; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">any other action that is treated as a repricing under generally accepted accounting principles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, under the 2017 Plan, the Board
has the authority to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">construe and interpret the 2017 Plan and award agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">settle all controversies regarding the 2017 Plan and award agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">suspend or terminate the 2017 Plan at any time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">amend the 2017 Plan as deemed necessary or advisable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">approve form award agreements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.25pt; text-align: justify; text-indent: -23.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">adopt rules, procedures and subplans related to the operation and administration of the 2017 Plan
as are necessary and appropriate under local laws and regulations to permit participation in the 2017 Plan by employees, directors
or consultants who are foreign nationals or are employed outside of the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Stock Options.</I> Incentive
stock options and nonstatutory stock options are granted under stock option agreements adopted by the plan administrator. The
plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan,
provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of the Common
Stock on the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as
determined by the plan administrator. The exercise price of a stock option may be paid as follows: (i) by cash, check, bank
draft or money order, (ii) pursuant to a program developed under Regulation T that prior to the issuance of shares of Common
Stock, results in either the receipt of cash by the Company or receipt of irrevocable instructions to a broker selling such
Common Stock to pay the aggregate exercise price, (iii) by delivery of share of Common Stock, (iv) if  the stock option is a
nonstatutory stock option, by net exercise or (iv) any other form of legal consideration acceptable to the Board and
specified in the award agreement. Unless the terms of the participant&rsquo;s award agreement provides otherwise, if a
participant&rsquo;s service relationship with the Company, or any of its affiliates, ceases for any reason other than
disability, death or cause, the participant may generally exercise any vested stock options for a period of three months
following the cessation of service. The term may be extended in the event that exercise of the stock option following such a
termination of service is prohibited by applicable securities laws. If a participant&rsquo;s service relationship with
the Company or any of its affiliates ceases due to disability or death, or a participant dies within a certain period
following cessation of service, the participant or a beneficiary may generally exercise his or her options for a period of 12
months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock options
generally terminate upon the termination date of the individual. In no event may a stock option be exercised beyond the
expiration of its term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 129; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fair market value, determined
at the time of grant, of the Common Stock with respect to incentive stock options that are exercisable for the first time by a
participant during any calendar year under all of the Company&rsquo;s stock plans may not exceed $100,000. No incentive stock option
may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of the Company&rsquo;s
total combined voting power or that of any of the Company&rsquo;s affiliates unless (i) the option exercise price is at least 110%
of the fair market value of the Common Stock subject to the option on the date of grant, and (ii) the term of the incentive stock
does not exceed five years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Unit Awards. </I>RSUs
are granted under restricted stock unit award agreements adopted by the plan administrator. RSUs may be granted in consideration
for any form of legal consideration that may be acceptable to our Board and permissible under applicable law. An RSU may be settled
by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form
of consideration set forth in the RSU agreement. The Board may impose restrictions or conditions to the vesting of RSUs as it deems
appropriate. Additionally, dividend equivalents may be credited in respect of shares covered by an RSU. Except as otherwise provided
in the applicable award agreement, RSUs that have not vested will be forfeited once the participant&rsquo;s continuous service
ends for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Awards.</I> Restricted
stock awards are granted under restricted stock award agreements adopted by the plan administrator. Shares of Common Stock that
are subject to a restricted stock award may be (i) held in a book entry from until restrictions lapse or (ii) evidenced by a certificate
which shall be held in such form and manner as determined by the Board. A restricted stock award may be awarded in consideration
for cash, check, bank draft or money order, past services to us, or any other form of legal consideration that may be acceptable
to our Board and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock
awards, including vesting and forfeiture terms. If a participant&rsquo;s service relationship with us ends for any reason, we may
receive any or all of the shares of Common Stock held by the participant that have not vested as of the date the participant terminates
service with us through a forfeiture condition or a repurchase right. Additionally, dividend may be credited in respect of shares
covered by a restricted stock award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Stock Appreciation Rights.</I>
SARs are granted under stock appreciation grant agreements adopted by the plan administrator. The plan administrator
determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the
fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the 2017 Plan vests at
the rate specified in the stock appreciation right agreement as determined by the plan administrator. A participant may
exercise a stock appreciation right by notifying the Company. Upon exercise, a participant will receive the excess of (i) the
aggregate fair market value of the number of shares of Common Stock over (ii) the aggregate exercise price of such number of
shares of Common Stock. Such amounts will be paid in shares of Common Stock, cash, any combination of both or such other form
of consideration as determined by the Board. Unless the terms of the participant&rsquo;s award agreement provides otherwise,
if a participant&rsquo;s service relationship with the Company, or any of its affiliates, ceases for any reason other than
disability, death or cause, the participant may generally exercise any vested stock appreciate right for a period of three
months following the cessation of service. The term may be extended in the event that exercise of the stock appreciate right
following such a termination of service is prohibited by applicable securities laws. If a participant&rsquo;s service
relationship with the Company or any of its affiliates ceases due to disability or death, or a participant dies within a
certain period following cessation of service, the participant or a beneficiary may generally exercise his or her rights for
a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for
cause, stock appreciate rights generally terminate upon the termination date of the individual. In no event may a stock
appreciation right be exercised beyond the expiration of its term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Performance Awards.</I> The
2017 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation
that may not be subject to the $1,000,000 limitation on the income tax deductibility imposed by Section 162(m) of the Code.
Our compensation committee may structure awards so that the stock or cash will be issued or paid only following the
achievement of certain pre-established performance goals during a designated performance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 130; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The performance criteria that may be selected
include one or more of the following: (i) earnings (including earnings per share and net earnings); (ii) earnings before interest,
taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization; (iv) earnings before interest, taxes,
depreciation, amortization and legal settlements; (v) earnings before interest, taxes, depreciation, amortization, legal settlements
and other income (expense); (vi) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense)
and stock-based compensation; (vii) earnings before interest, taxes, depreciation, amortization, legal settlements, other income
(expense), stock-based compensation and changes in deferred revenue; (viii) earnings before interest, taxes, depreciation, amortization,
legal settlements, other income (expense), stock-based compensation, other non-cash expenses and changes in deferred revenue; (ix)
total stockholder return; (x) return on equity or average stockholder&rsquo;s equity; (xi) return on assets, investment, or capital
employed; (xii) stock price; (xiii) margin (including gross margin); (xiv) income (before or after taxes); (xv) operating income;
(xvi) operating income after taxes; (xvii) pre-tax profit; (xviii) operating cash flow; (xix) sales or revenue targets; (xx) increases
in revenue or product revenue; (xxi) expenses and cost reduction goals; (xxii) improvement in or attainment of working capital
levels; (xxiii) economic value added (or an equivalent metric); (xxiv) market share; (xxv) cash flow; (xxvi) cash flow per share;
(xxvii) cash balance; (xxviii) cash burn; (xxix) cash collections; (xxx) share price performance; (xxxi) debt reduction; (xxxii)
implementation or completion of projects or processes (including, without limitation, clinical trial initiation, new and supplemental
indications for existing products, and product supply); (xxxiii) stockholders&rsquo; equity; (xxxiv) capital expenditures; (xxxv)
debt levels; (xxxvi) operating profit or net operating profit; (xxxvii) workforce diversity; (xxxviii) growth of net income or
operating income; (xxxix) billings; (xl) bookings; (xli) employee retention; (xlii) initiation of phases of clinical trials and/or
studies by specific dates; (xliii) acquisition of new customers, including institutional accounts; (xliv) customer retention and/or
repeat order rate; (xlv) number of institutional customer accounts; (xlvi) budget management; (xlvii) improvements in sample and
test processing times; (xlviii) regulatory milestones; (xlix) progress of internal research or clinical programs; (l) progress
of partnered programs; (li) partner satisfaction; (lii) milestones related to samples received and/or tests run; (liii) expansion
of sales in additional geographies or markets; (liv) research progress, including the development of programs; (lv) patient samples
processed and billed; (lvi) sample processing operating metrics (including, without limitation, failure rate maximums and reduction
of repeat rates); (lvii) strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property);
and (lviii) and to the extent that an award is not intended to constitute &ldquo;qualified performance-based compensation&rdquo;
under Section 162(m) of the Code, other measures of performance selected by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The performance goals may be based on company-wide
performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute
or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified
otherwise by the Board or committee (as applicable) (i) in the award agreement at the time the award is granted or (ii) in such
other document setting forth the performance goals at the time the performance goals are established, the Board or committee (as
applicable) will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance
period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to
exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments
to corporate tax rates; (5) to exclude the effects of any &ldquo;extraordinary items&rdquo; as determined under generally accepted
accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested
by the Company achieved performance objectives at targeted levels during the balance of a performance period following such divestiture;
(8) to exclude the effect of any change in the outstanding shares of Common Stock of the Company by reason of any stock dividend
or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares
or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude
the effects of stock based compensation and the award of bonuses under the Company&rsquo;s bonus plans; (10) to exclude costs incurred
in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting
principles; (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally
accepted accounting principles; (12) to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary
item; and (13) to exclude the effects of the timing of acceptance for review and/or approval of submissions to any regulatory body.
In addition, subject to certain limitations, the Board or committee (as applicable) retains the discretion to reduce or eliminate
the compensation or economic benefit due on attainment of performance goals and to define the manner of calculating the performance
criteria it selects to use for such performance period. Partial achievement of the specified criteria may result in the payment
or vesting corresponding to the degree of achievement as specified in the award agreement or the written terms of a performance
cash award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 131; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Stock Awards.</I> The plan
administrator may grant other awards based in whole or in part by reference to our Common Stock. The plan administrator will set
the number of shares under the stock award and all other terms and conditions of such awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Changes to Capital Structure.</I> In
the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization,
appropriate adjustments will be made to (1) the class and maximum number of shares reserved for issuance under the 2017 Plan, (2)
the class and maximum number of shares that may be issued on the exercise of incentive stock options, (3) the class and maximum
number of shares subject to stock awards that can be granted to a person in a calendar year (as established under the 2017 Plan
under Section 162(m) of the Code), and (4) the class and number of shares and exercise price, strike price, or purchase price,
if applicable, of all outstanding stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Transactions.</I> The
2017 Plan provides that in the event of certain specified significant corporate transactions, including: (1) a sale of all or substantially
all of our assets, (2) the sale or disposition of more than 90% of our outstanding securities, (3) the consummation of a merger
or consolidation where we do not survive the transaction, and (4) the consummation of a merger or consolidation where we do survive
the transaction but the shares of our Common Stock outstanding before such transaction are converted or exchanged into other property
by virtue of the transaction, unless otherwise provided in an award agreement or other written agreement between us and the award
holder, the plan administrator may take one or more of the following actions with respect to such stock awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">arrange for the assumption, continuation, or substitution
of a stock award by a successor corporation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">arrange for the assignment of any reacquisition or repurchase
rights held by us to a successor corporation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">accelerate the vesting, in whole or in part, of the stock
award and provide for its termination before the transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">arrange for the lapse, in whole or in part, of any reacquisition
or repurchase rights held by us;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">cancel or arrange for the cancellation of the stock award
before the transaction in exchange for a cash payment, or no payment, as determined by the Board; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">make a payment, in the form determined by our Board, equal
to the excess, if any, of the value of the property the participant would have received on exercise of the awards before the transaction
over any exercise price payable by the participant in connection with the exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator is not obligated
to treat all stock awards or portions of stock awards, even those that are of the same type, in the same manner and is not obligated
to treat all participants in the same manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change in control, awards
granted under the 2017 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may
be provided for in an award agreement. Under the 2017 Plan, a change in control is defined to include (1) the acquisition by any
person or company of more than 50% of the combined voting power of our then outstanding stock, (2) a merger, consolidation, or
similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than
50% of the combined voting power of the surviving entity (or the parent of the surviving entity), (3) a sale, lease, exclusive
license, or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting
power of which is owned by our stockholders, and (4) an unapproved change in the majority of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Transferability.</I> A participant
may not transfer stock awards under the 2017 Plan other than by will, the laws of descent and distribution, or as otherwise provided
under the 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Plan Amendment or Termination</I>. Our
Board has the authority to amend, suspend, or terminate the 2017 Plan, provided that such action does not materially impair the
existing rights of any participant without such participant&rsquo;s written consent. Certain material amendments also require the
approval of our stockholders. No incentive stock options may be granted after the tenth anniversary of the date our Board adopted
the 2017 Plan. No stock awards may be granted under the 2017 Plan while it is suspended or after it is terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 132; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Employee Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, our Board approved a
Non-Employee Director Compensation Policy effective as of January 1, 2018 whereby our non-employee directors will receive a mix
of cash and share-based compensation intended to encourage non-employee directors to continue to serve on our Board, further align
the interests of the directors and stockholders, and attract new non-employee directors with outstanding qualifications. Directors
who are employees or officers of the Company do not receive any additional compensation for Board service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this policy, each of our non-employee
directors will receive an annual retainer of $50,000, except that our non-executive chairman will receive an annual retainer of
$100,000. Additionally, the chairman and members of our Audit Committee will receive an additional annual payment of $12,500 and
$5,000, respectively, and the chairmen and members of each of our Compensation and Nominating and Corporate Governance Committees,
if any are formed in the future, will receive an additional annual payment of $10,000 and $4,000, respectively. Such annual cash
retainers will be earned beginning on the effective date of the policy but shall not be payable until the last day of the fiscal
quarter in which the Company consummates an equity financing wherein it receives at least $3.0 million in gross cash proceeds.
On the date of each annual stockholder meeting of the Company commencing with the 2019 annual meeting of stockholders, each director
shall receive an annual equity award with an aggregate grant date fair value on the date of grant of $50,000, one third of which
will be in the form of an option and two thirds of which will be in the form of a restricted stock unit award, each of which will
vest in a series of 12 equal monthly installments subject to the director&rsquo;s continued service. Newly appointed directors,
on the date of their appointment, will receive a pro rata equity award, reflecting a reduction for each month prior to the date
of grant that has elapsed since the preceding annual stockholder meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides compensation
information for the Transition Period ended September 30, 2018 for each non-employee member of our Board.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees Earned or Paid in Cash<BR> ($)(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR>Awards ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Paul Buckman</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">78,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">78,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Suraj Kalia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Jeff Mathiesen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">These amounts reflect the pro-rated amount earned for the
nine months ended September 30, 2018 in which each director provided service. The amounts will not be paid until the last day
of the fiscal quarter in which the Company consummates an equity financing wherein it receives at least $3.0 million in gross
cash proceeds.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018, each of the non-employee
directors had 34,020 shares underlying outstanding stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a named executive officer of the Company,
compensation paid to Mr. Rosa for the Transition Period is fully reflected under &ldquo;Executive Compensation&mdash;Summary Compensation
Table.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 133; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_021"></A>ITEM 12. SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the beneficial
ownership of our Common Stock as of November 30, 2018 for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">each person, or group of affiliated persons, who is known
by us to beneficially own more than 5% of our Common Stock;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">each of our named executive officers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">each of our directors; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">all of our current executive officers and directors as
a group.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table lists applicable percentage ownership
based on 9,876,505 shares of Common Stock outstanding as of November 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have determined beneficial ownership
in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess
sole or shared voting power or investment power with respect to those securities. Unless otherwise indicated, the persons or entities
identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them,
subject to applicable community property laws. In addition, the rules include shares of our Common Stock issuable pursuant to the
exercise of stock options and warrants that are either immediately exercisable or exercisable within 60 days of November 30, 2018.
These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing
the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership
of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise noted below, the address
for persons listed in the table is c/o NeuroOne Medical Technologies Corporation, c/o David Rosa, 10901 Red Circle Drive, Suite
150, Minnetonka, Minnesota 54343.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name and address of beneficial owner</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number&nbsp;of&nbsp;shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of&nbsp;common&nbsp;stock beneficially owned</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage&nbsp;of common&nbsp;stock beneficially owned <SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Greater than 5% Stockholders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Wade Fredrickson<SUP>(2)</SUP></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4825 Suburban Drive</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Shorewood, Minnesota 55331</P></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,613,460</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">26.5</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mayo Foundation for Medical Education and Research<SUP>(3)</SUP></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">200 First Street SW</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Rochester, Minnesota 55905</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">859, 976</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lifestyle Healthcare LLC<SUP>(4)</SUP></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">404 East 79th Street, Apt 28G</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10075</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">855,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(4)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">FundRx NeuroOne Fund <BR> PO Box 171305 <BR> Salt Lake City, UT 84117</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">683,850</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Faisal Siddiqui <BR> 903 Georgetown Ridge Court <BR> Mclean, VA 22102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">611,247</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(6)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">Mohammad Jainal Bhuiyan<BR>
10605 SW 44<SUP>th</SUP> CT</P>

<P STYLE="margin: 0pt 0">Davie, FL 33328</P>


</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0">722,291</P>


</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Directors and Named Executive Officers:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">David Rosa</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">793,822</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Paul Buckman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Suraj Kalia</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jeffrey Mathiesen</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Thomas Bachinski</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">215,453</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Mark Christianson</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,423,206</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">All Directors and Officers as a Group (6 persons)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,534,541</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(8)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on based on 9,876,505 shares of common stock outstanding as of November 30, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on Schedule 13D/A filed by Mr. Fredrickson on March 5, 2018. Mr. Fredrickson is our former Vice President of Therapy and Product Development.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayo Clinic, a Minnesota corporation, is the controlling corporation of Mayo Foundation for Medical Education and Research. Mayo Clinic disclaims beneficial ownership of these shares. Dennis E. Dahlen, Harry N. Hoffman, Paul A. Gorman, Rick J. Haeflinger, Steven R. Stenhaug, and Jeffrey G. Torborg have voting and dispositive power over the shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 57,600 shares of common stock issuable upon exercise of outstanding warrants. Dmitri Saprykin, the owner of Lifestyle Healthcare LLC, has voting and dispositive power over the shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 455,900 shares of common stock issuable upon exercise of outstanding warrants. Zeshan Muhammedi has voting and dispositive power over the shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 352,222 shares of common stock issuable upon exercise of outstanding warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of shares of common stock issuable upon exercise of outstanding options.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 102,060 shares of common stock issuable upon exercise of outstanding options.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 134; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_022"></A>ITEM 13. CERTAIN RELATIONSHIPS AND
RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no transactions since January
1, 2017 to which NeuroOne, Inc. or the Company has been a participant in which the amount involved exceeded or will exceed the
lesser of $120,000 or 1% of the average of the Company&rsquo;s total assets at year end for the last two completed fiscal years,
and in which any of our directors, executive officers or holders of more than five percent of our capital stock, or any members
of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements which
are described under &ldquo;Executive Compensation&rdquo; and as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To identify related person transactions
in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. We maintain
a written policy for the review, approval or ratification of related person transactions, and our Board or Audit Committee reviews
all related person transactions identified by us. The Board or Audit Committee approves or ratifies only those related person transactions
that are determined by it to be, under all of the circumstances, in the best interests of the Company and its stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under our Code of Business
Conduct and Ethics, the Company&rsquo;s employees, officers and directors are discouraged from entering into any transaction that
may cause a conflict of interest for the Company. In addition, they must report any potential conflict of interest, including related
person transactions, to their supervisor or the Chief Executive Officer. The Company adopted a Related Persons Transactions Policy
in January 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NeuroOne, Inc. Founders&rsquo; Shares </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2016, NeuroOne, Inc. issued
905,000 shares of NeuroOne, Inc. common stock, par value $0.0001 (equivalent to 5,131,514 shares of Common Stock as converted based
on the Reverse Split and the Exchange Ratio) as founders&rsquo; shares (the &ldquo;<B><I>Founders&rsquo; Shares</I></B>&rdquo;)
in a private placement to seven accredited investors (the &ldquo;<B><I>Founders</I></B>&rdquo;), including 140,000 shares to David
Rosa, our Chief Executive Officer and director, 251,000 shares to Mark Christianson, our Vice President of Marketing and Sales
and 501,000 shares to Wade Fredrickson, our former Vice President of Therapy and Product Development. The Founders&rsquo; Shares
were issued pursuant to subscription agreements entered into between NeuroOne, Inc. and each Founder, in which each Founder agreed
to pay NeuroOne, Inc. a purchase price of $0.01 per Founders&rsquo; Share received by such Founder (equivalent to $0.001763631
per share of Common Stock as converted based on the Reverse Split and the Exchange Ratio). In June 2017, the purchase price owed
by the Founders totaling $9,050 was forgiven by NeuroOne, Inc. in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the
Founders&rsquo; Shares, NeuroOne, Inc. entered into a stockholders agreement (the &ldquo;<B><I>Stockholders Agreement</I></B>&rdquo;)
with the Founders. The Stockholders Agreement, among other things, granted certain stockholders of NeuroOne, Inc. drag-along rights
and preemptive rights with respect to subsequent offerings of certain equity securities of NeuroOne, Inc. The parties to the Stockholders
Agreement agreed to vote all of their shares of capital stock in NeuroOne, Inc. to ensure that the board size and composition is
as directed by the then current NeuroOne board of directors and designated David Rosa and Paul Buckman as the initial directors
of NeuroOne, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Original Source Entertainment, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the 2017 Acquisition, Original
Source Entertainment, Inc.&rsquo;s administrative functions were operated from the offices of Mr. Samad (the majority owner of
Original Source Entertainment, Inc.), and Original Source Entertainment, Inc. did not pay Mr. Samad for the use of such space.
Also, prior to the 2017 Acquisition, for the years ended December&nbsp;31, 2017 and 2016, Original Source Entertainment received
advances of $11,572 and $21,106 from a related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 135; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The 2017 Acquisition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement for the
2017 Acquisition whereby NeuroOne, Inc. became a wholly-owned subsidiary of the Company, each holder of NeuroOne Shares outstanding
immediately prior to the closing received shares of Common Stock in exchange therefore based on the Exchange Ratio, with all fractional
shares rounded down to the nearest whole share. Accordingly, we issued 793,822, 1,423,206 and 2,840,731 shares of Common Stock
to our officers, Messrs. Rosa, Christianson and Fredrickson, respectively, and options to purchase 34,020 shares of Common Stock
to each of Messrs. Buckman, Kalia and Mathiesen, members of our Board, and 859,976 shares of Common Stock to the Mayo Foundation
for Medical Education and Research (&ldquo;<B><I>Mayo</I></B>&rdquo;), a holder of over 5% of our outstanding Common Stock. The
Merger Agreement also provided that Mr. Rosa be appointed as a director of the Company upon the closing of the 2017 Acquisition.
Further, pursuant to the Merger Agreement, Mr. Samad (the majority owner of Original Source Entertainment, Inc.) tendered for cancellation
3,500,000 shares of Origin Source Entertainment, Inc. held by him as part of the conditions to closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Private Placements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series 1 Note Issuance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between November 2016 and June 2017, NeuroOne,
Inc. issued 8% convertible promissory notes (the &ldquo;<B><I>Series 1 Notes</I></B>&rdquo;) and warrants (the &ldquo;<B><I>Series
1 Warrants</I></B>&rdquo;) to investors in a private placement, including, in June 2017, a Series 1 Note for $50,000 and a Series
1 Warrant to <FONT STYLE="background-color: white">Sean Wambold</FONT>, the founder and former sole owner of the LLC. The Company
did not make any payments of principal or interest on the Series 1 Notes following issuance. In June 2017 and November 2017, the
terms of the Series 1 Notes and the Series 1 Warrants were amended. In July 2018, the Series 1 Notes were converted as described
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Series 2 Note Issuance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August, 2017, the Company issued interest-free
promissory notes (the &ldquo;<B><I>Series 2 Notes</I></B>&rdquo;) and warrants (the &ldquo;<B><I>Series&nbsp;2 Warrants</I></B>&rdquo;)
to two investors in a private placement, including a Series 2 Note for $103,000 and Series 2 Warrant to Mohammad Jainal Bhuiyan.
The Company did not make any payments of principal on the Series 2 Notes following issuance. In November 2017, the Company and
each holder of the Series 2 Notes amended the notes, and in March 2018, the Company and the holders of the Series 2 Notes converted
the Series 2 Notes from interest free promissory notes into convertible promissory notes with an interest rate of 8% per year.
In July 2018, the Series 2 Notes were converted as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series 3 Note Issuance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between September 2017 and June 2018, the
Company issued convertible promissory notes with an interest rate of 8% per year (the &ldquo;<B><I>Series 3 Notes</I></B>&rdquo;)
and warrants (the &ldquo;<B><I>Series 3 Warrants</I></B>&rdquo;) to several investors in several private placements, including
(i) in October 2017, a Series 3 Note for $50,000 and a Series 3 Warrant to Sean Wambold, the founder and former sole owner of the
LLC and (ii) in February 2018, a Series 3 Note for $125,000 and Series 3 Warrant to Lifestyle Healthcare LLC, a holder of over
5% of our outstanding Common Stock. The Company has not made any payments of principal or interest on the Series 3 Notes. As of
November 30, 2018, $50,000 and $125,000 aggregate principal amount are outstanding on Sean Wambold&rsquo;s and Lifestyle Healthcare
LLC&rsquo;s Series 3 Notes, respectively. For a more detailed description of our Series 3 Notes, see &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources &ndash; Historical Capital
Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Conversion of Series 1 Notes and
Series 2 Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2018, holders of the Series
1 Notes and Series 2 Notes agreed to convert the outstanding principal and interest of the Series 1 Notes and Series 2 Notes into
Common Stock, at a conversation rate of $1.80 per share; and to amend and restate the Series 1 Warrants and Series 2 Warrants to
make them immediately exercisable. As consideration for the early conversion of the Series 1 Notes and Series 2 Notes, the Company
issued each holder a new warrant. Mr. Wambold, the founder and sole owner of our predecessor, the LLC, agreed to convert $54,277.78
outstanding principal and interest of his Series 1 Notes into 30,154 shares of Common Stock and warrants immediately exercisable
for 125,482 shares of Common Stock with an exercise price of $1.80 per share. Mr. Bhuiyan agreed to convert $105,563.56 outstanding
principal and interest of his Series 2 Notes into 58,646 shares of Common Stock and warrants immediately exercisable for 194,542
shares of Common Stock with an exercise price of $1.80 per share, making him a holder of over 5% of our outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 136; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 30, 2018, no principal remains
outstanding on the Series 1 Notes and Series 2 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more detailed description of our
Series 1 Notes and Series 2 Notes and the conversion of such notes, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&mdash;Liquidity and Capital Resources&mdash;Historical Capital Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Ongoing Issuance of Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between July 2018 and November 2018, the
Company has issued and sold units (&ldquo;<B><I>Units</I></B>&rdquo;) to investors consisting of Common Stock and warrants for
$2.50 per Unit, including (i) in July 2018, the sale of 37,600 Units for $94,000 to each of Lifestyle Healthcare LLC and Mohammad
Jainal Bhuiyan and (ii) in September, the sale of 40,000 Units for $100,000 and 20,000 Units for $50,000 to Faisal Siddiqui and
Lifestyle Healthcare LLC, respectively, each  holders of over 5% of our Common Stock &nbsp;at the time of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more detailed description of our
issuance of Units, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Liquidity
and Capital Resources&mdash;Historical Capital Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, we received cash gross
proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from stockholders owning
over 5% of the Company&rsquo;s Common Stock. The loans are interest free and require that we repay the principal in full on the
earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or November
14, 2019. In May 2018, we received cash gross proceeds from unsecured loans represented by promissory notes in the amount of $168,000,
of which $84,000 was from a stockholder owning over 5% of the Company&rsquo;s Common Stock. The loans are interest free and require
that we repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more
than $5 million in gross proceeds or May 17, 2019. In March 2018, we also received cash gross proceeds in the amount of $115,000
represented by a promissory note from a stockholder owning over 5% of the Company&rsquo;s Common Stock. The loan is also interest
free and requires that we repay the principal in full on the earlier of the closing of an equity round of financing of the Company
resulting in more than $3.0 million in gross proceeds or March 20, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mayo Development Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Mayo Development Agreement,
we have agreed to license worldwide (i) certain know how for the development and commercialization of products, methods and processes
related to flexible circuit thin film technology for the recording of tissue and (ii) the products developed therefrom, and to
partner with Mayo to assist the Company in the investigation, research application, development and improvement of such technology.
Mayo has agreed to assist us by providing access to the Mayo Principal Investigators in developing a minimally invasive device/delivery
system and procedure for a minimally invasive approach for the implantation of our cortical thin film flexible circuit technology
developed by the Company, including prototype development, animal testing, protocol development for human and animal use, abstract
development and presentation and access to and license of any intellectual property that the Mayo Principal Investigators develop
relating to the procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not any such technology, product,
method, process, device or delivery system is developed, we agreed, in consideration for Mayo&rsquo;s efforts under the Mayo Development
Agreement, to pay Mayo a cash payment of approximately $92,000 on the earlier of September 30, 2017 or the date we raise a minimum
amount of financing. We did not make this payment by September 30, 2017 and breached this provision of the Mayo Development Agreement.
Mayo granted us an extension of this deadline to December 31, 2017, and we made this payment within such extended deadline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 25, 2017, NeuroOne issued Mayo 50,556
NeuroOne Shares (859,976 shares, as converted based on the Exchange Ratio) pursuant to a subscription agreement, pursuant to which
Mayo is a holder of over 5% of our outstanding Common Stock. Finally, we have agreed to pay Mayo a royalty equal to a single-digit
percentage of our product sales pursuant to the Mayo Development Agreement. Mayo may purchase any developed products licensed under
the Mayo Development Agreement at the best price offered by us to the end user in the prior year. The Mayo Development Agreement
will expire on May 25, 2037 and may be terminated by Mayo for cause or under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 137; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Placement Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HRA Capital&rsquo;s affiliate, Corinthian
Partners, has acted as a placement agent for private placements by us and NeuroOne. HRA Capital is affiliated with two parties
which are or were previously our greater than 5% stockholders, Chromium 24 LLC, which was previously a greater than 5% beneficial
owner, and Lifestyle Healthcare LLC, a greater than 5% beneficial owner. Pursuant to the engagement letter with such placement
agent, to date, NeuroOne paid the placement agent a cash fee of $113,610, agreed to issue to the placement agent a warrant to purchase
shares of Common Stock (or common stock equivalents) in an amount equal to 8% of the shares purchased by certain investors in the
transaction and agreed to issue to the placement agent warrants to purchase shares of common stock (or common stock equivalents)
in an amount equal to 10% of the shares purchased by certain investors in certain subsequent private placement transactions. Upon
issuance, the placement agent warrants will be immediately exercisable and expire five years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also received a short-term unsecured loan for $50,000 in
November 2016 from the placement agent. We incurred no fees or interest costs related to such temporary loan and repaid it in full
in February 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2018, Wade Fredrickson, a greater
than 5% stockholder of the Company, entered into a lock-up agreement with the Company in which he agreed, subject to certain exceptions,
not to offer, sell, transfer or otherwise dispose of the Company&rsquo;s securities for a period of 18 months following the effective
date of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation contains
provisions limiting the liability of directors, and our bylaws provides that we indemnify each of our directors to the fullest
extent permitted under Delaware law. Our certificate of incorporation and bylaws also provide our Board with discretion to indemnify
our officers and employees when determined appropriate by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have entered into an indemnification
agreement with our directors and our executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not currently listed on a national
securities exchange that has requirements that a majority of our Board be independent. However, our Board has undertaken a review
of the independence of the directors and considered whether any director has a material relationship with us that could compromise
his or her ability to exercise independent judgment in carrying out his or her responsibilities applying Nasdaq independence standards.
As a result of this review, our Board has determined that, Messrs. Buckman, Kalia and Mathiesen, representing three of our four
directors, are &ldquo;independent directors.&rdquo; Mr. Rosa is not considered independent due to his service as an executive officer
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 138; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_023"></A>ITEM 14. PRINCIPAL ACCOUNTING FEES
AND SERVICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the fees for professional services
rendered to us, NeuroOne, Inc. or Original Source Entertainment, Inc. by BDO USA, LLP (&ldquo;<B><I>BDO</I></B>&rdquo;) or Pritchett
for services in respect of the Transition Period and for the years ended December 31, 2017 and 2016, which were approved by the
Board in accordance with its established policies and procedures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">TRANSITION
    PERIOD</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">FISCAL<BR>
    YEAR 2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">FISCAL<BR>
    YEAR 2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">FEE
    CATEGORY</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">BDO</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">BDO</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">PRITCHETT</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">BDO</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">PRITCHETT</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit fees</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;179,953</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">197,801</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84,912</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,300</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related
    fees<SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    fees<SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All other fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">179,953</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">207,019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84,912</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><B>Audit fees</B> include fees for professional services
provided by BDO USA, LLP in connection with the audit of our consolidated financial statements, review of our quarterly consolidated
financial statements, and related services that are typically provided in connection with registration statements.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify"><B>Audit-related fees</B> include fees billed for assurance
and related services reasonably related to the performance of the audit or review of the Transition Period and our fiscal years
2017 and 2016 consolidated financial statements that are not included as audit fees.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify"><B>Tax fees</B> include fees for tax compliance, advice
and planning.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify"><B>All other fees</B> include fees for professional services
rendered by Pritchett in connection with the Acquisition.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Audit Committee is responsible for
pre-approving all audit and permitted non-audit and tax services provided by the independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 139; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_024"></A>PART IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_025"></A>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT
SCHEDULES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The following documents
are filed as part of this Transition Report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Financial Statements: The financial statements filed as
part of this Transition Report are listed in Part II, Item 8.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Financial Statement Schedules:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No financial statement schedules are provided
because the information called for is not required or is shown either in the financial statements or notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Exhibits: The exhibits incorporated by reference or filed
as part of this Transition Report are listed in the Index to Exhibits below.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><B>Exhibit&nbsp;No.</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><B>Document</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>2.1 *</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex2-1.htm">Agreement and Plan of Merger and Reorganization by and among NeuroOne Medical Technologies Corporation,&nbsp;OSOK Acquisition Company&nbsp;and NeuroOne, Inc. dated as of July 20, 2017 (incorporated by reference to Exhibit 2.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>2.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex2-1.htm">Plan of Conversion of NeuroOne Medical Technologies Corporation dated June 20, 2017 (incorporated by reference to Exhibit 2.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on June 29, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-4.htm">Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant&rsquo;s Current Report on Form 8-K filed on June, 29, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-5.htm">Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.5 on the Registrant&rsquo;s Current Report on Form 8-K filed on June 29, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex4-1.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.1 #</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-1.htm">Exclusive Start-Up Company License Agreement; WARF Agreement No. 14-00333 by and between Wisconsin Alumni Research Foundation and Neuro One LLC, dated October 1, 2014 (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.2 #</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-2.htm">Amendment to Exclusive Start-Up Company License Agreement by and between Wisconsin Alumni Research Foundation, Neuro One LLC, and NeuroOne, Inc. dated as of February 22, 2017 (incorporated by reference to Exhibit 10.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.3 #</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-3.htm">Mayo Foundation for Medical Education and Research Amended and Restated License and Development Agreement by and between Mayo Foundation for Medical Education and Research, and NeuroOne LLC dated as of May 25, 2017 (incorporated by reference to Exhibit 10.3 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-4.htm">Form of October 2016 Common Stock Subscription Agreement (incorporated by reference to Exhibit 10.4 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-5.htm">Form of November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 10.5 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-6.htm">Form of Promissory Note issued pursuant to November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 10.6 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-7.htm">First Amendment to Promissory Note issued pursuant to November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 10.7 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017012639/f8k112717ex4-3_neuroone.htm">Form of Second Amendment to Promissory Note issued pursuant to November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 4.3 on the Registrant&rsquo;s Current Report on Form 8-K filed on November 27, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-8.htm">Form of Capital Stock Purchase Warrant issued pursuant to November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 10.8 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-9.htm">Form of First Amendment to Capital Stock Purchase Warrant issued pursuant to November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 10.9 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.11</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017012639/f8k112717ex4-4_neuroone.htm">Form of Second Amendment to Capital Stock Purchase Warrant issued pursuant to November 2016 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 4.4 on the Registrant&rsquo;s Current Report on Form 8-K filed on November 27, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.12</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-10.htm">Stockholders Agreement by and among NeuroOne, Inc., and the stockholders party thereto dated as of October 20, 2016 (incorporated by reference to Exhibit 10.10 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 140; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><B>Exhibit&nbsp;No.</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><B>Document</B></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">10.13 +</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-11.htm">2016 Equity Incentive Plan of NeuroOne, Inc.&nbsp;(incorporated by reference to Exhibit 10.11 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.14</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-12.htm">Form of Stock Option Award Agreement pursuant to 2016 Equity Incentive Plan of NeuroOne, Inc.&nbsp;(incorporated by reference to Exhibit 10.12 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">10.15</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-13.htm">Restricted Stock Purchase Agreement by and between NeuroOne, Inc. and Thomas Bachinski, dated as of April 10, 2017&nbsp;(incorporated by reference to Exhibit 10.13 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.16 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417021319/v464727_def14c.htm">2017 Equity Incentive Plan of the Company (incorporated by reference to Appendix G to Schedule 14C filed on April&nbsp;20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.17&nbsp;+</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-15.htm">NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan Option Agreement (incorporated by reference to Exhibit 10.15 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.18&nbsp;+</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-16.htm">NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.16 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.19 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-17.htm">Employment Agreement by and between NeuroOne LLC and Dave Rosa, dated as of October 5, 2016 (incorporated by reference to Exhibit 10.17 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.20 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-18.htm">Offer Letter to Mark Christianson from NeuroOne, Inc. dated December 1, 2016 (incorporated by reference to Exhibit 10.18 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.21 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-19.htm">Offer Letter to Thomas Bachinski from NeuroOne, Inc. dated January 9, 2017 (incorporated by reference to Exhibit 10.19 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.22 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-20.htm">Offer Letter to Wade Fredrickson from NeuroOne, Inc. dated December 1, 2016 (incorporated by reference to Exhibit 10.20 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.23 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417021319/v464727_def14c.htm">Form of Indemnification Agreement with the Company&rsquo;s Officers and Directors (incorporated by reference to Appendix E to Schedule 14C filed on April 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.24</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-22.htm">Resignation Letter of&nbsp;Amer Samad&nbsp;(incorporated by reference to Exhibit 10.22 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.25 +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-23.htm">Release Agreement of Wade Fredrickson dated June 28, 2017 (incorporated by reference to Exhibit 10.23 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.26</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417040898/v472061_ex10-1.htm">Employment Agreement by and between NeuroOne Medical Technologies Corporation and David A. Rosa dated August 4, 2017 (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 7, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.27</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417044643/v473725_ex10-1.htm">Form of August 2017 Subscription Agreement (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 23, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.28</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417044643/v473725_ex4-1.htm">Form of Promissory Note issued pursuant to August 2017 Subscription Agreement (incorporated by reference to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 23, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.29</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017012956/f8k113017ex10-1_neuroone.htm">First Amendment to Promissory Note by and between NeuroOne Medical Technologies Corporation and the Subscribers dated as of November 30 (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on December 6, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417044643/v473725_ex4-2.htm">Form of Capital Stock Purchase Warrant pursuant to August 2017 Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 23, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.31</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017010361/f8k100417ex10-1_neuroone.htm">Form of October 2017 Subscription Agreement (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on October 6, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.32</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017010361/f8k100417ex4-1_neuroone.htm">Form of Promissory Note issued pursuant to October 2017 Subscription Agreement (incorporated by reference to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on October 6, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.33</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017010361/f8k100417ex4-2_neuroone.htm">Form of Capital Stock Purchase Warrant issued pursuant to October 2017 Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on October 6, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.34</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017013472/f8k121417ex10-1_neuroone.htm">Form of Amended and Restated Subscription Agreement (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on December 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.35</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017013472/f8k121417ex4-1_neuroone.htm">Form of Amended and Restated Promissory Note issued pursuant to Amended and Restated Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on December 20, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.36</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390017013472/f8k121417ex4-2_neuroone.htm">Form of Amended and Restated Capital Stock Purchase Warrant issued pursuant to Amended and Restated Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on December 20, 2017)</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 141; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><B>Exhibit&nbsp;No.</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><B>Document</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.37</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-1_neuroone.htm">Form
    of Amended and Restated Note issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference
    to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 16, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.38</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-2_neuroone.htm">Form
    of Replacement Warrant issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit
    4.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 16, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.39</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-3_neuroone.htm">Form
    of Additional Warrant issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit
    4.3 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 16, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.40</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-40_neuroone.htm">Non-Employee
    Director Compensation Policy (incorporated by reference to Exhibit 10.40 to 10-K filed April 16, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.41</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-41_neuroone.htm">Lock-up
    Agreement, effective as of March 1, 2018 by and between Wade Fredrickson and the Company (incorporated by reference to Exhibit
    10.41 to 10-K filed April 16, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.42</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018006757/f8k051718ex10-1_neuroone.htm">Promissory
    Note between the Company and Lifestyle Healthcare LLC, dated May 17, 2018 (incorporated by reference to Exhibit 10.1 to 8-K
    filed May 23, 2018)</A>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.43</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018006757/f8k051718ex10-2_neuroone.htm">Promissory
    Note between the Company and Jainal Bhuiyan, dated May 17, 2018 (incorporated by reference to Exhibit 10.2 to 8-K filed May
    23, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.44</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018008841/f8k070218ex10-1_neuroone.htm">Form
    of Series 1 Notes Debt Conversion Agreement (incorporated by reference to Exhibit 10.1 to 8-K filed July 6, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.45</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018008841/f8k070218ex10-2_neuroone.htm">Form
    of Series 2 Notes Debt Conversion Agreement (incorporated by reference to Exhibit 10.2 to 8-K filed July 6, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.46</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018009196/f8k070918ex4-1_neuroone.htm">Form
    of Warrant (incorporated by reference to Exhibit 4.1 to 8-K filed July 13, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.47</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018009196/f8k070918ex10-1_neuroone.htm">Form
    of Purchase Agreement (incorporated by reference to Exhibit 10.1 to 8-K filed July 13, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.48</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018009196/f8k070918ex10-2_neuroone.htm">Form
    of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to 8-K filed July 13, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.49</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018009527/f8k07172018ex10-1_neuroone.htm">Amendment
    to Lock-Up Agreement, dated July 17, 2018, between the Company and Wade Frederickson (incorporated by reference to 8-K filed
    July 23, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.50</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018014619/fs12018a1ex10-50_neuroone.htm">Description
    of compensatory arrangement with Thomas Bachinski (incorporated by reference to Exhibit 10.50 to Form S-1/A filed October
    30, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">10.51</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018017239/f10kt2018ex10-51_neuroone.htm"> Sublease
    Agreement between National American University and NeuroOne Medical Technologies Corporation, dated November 13, 2018. (incorporated
    by reference to Exhibit 10.51 on the Registrant&rsquo;s Transition Report on Form 10-KT filed on December 12, 2018) </A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">10.52</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018017239/f10kt2018ex10-52_neuroone.htm"> Employee
    Proprietary Information, Inventions, Assignment and Non-Competition Agreement. (incorporated by reference to Exhibit 10.52
    on the Registrant&rsquo;s Transition Report on Form 10-KT filed on December 12, 2018) </A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">16.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex16-2.htm">Letter
    from Pritchett, Siler &amp; Hardy, P.C., dated July 11, 2017 (incorporated by reference to Exhibit 16.2 on the Registrant&rsquo;s
    Current Report on Form 8-K filed on July 20, 2017)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">21.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex21-1_neuroone.htm">Subsidiaries
    of the Registrant (incorporated by reference to Exhibit 21.1 to 10-K filed April 16, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">23.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f10kt2018a1ex23-1_neuroone.htm">Consent of BDO USA, LLP</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 31.1 </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="f10kt2018a1ex31-1_neuroone.htm"> Certification of Principal Executive Officer
    and Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of
    the Sarbanes Oxley Act of 2002 </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 32.1 </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="f10kt2018a1ex32-1_neuroone.htm"> Certification of Principal Executive Officer
    and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley
    Act of 2002 </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"><A HREF="f10kt2018a1ex99-1_neuroone.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental Financial Information &ndash; Financial Statements for the Twelve Months Ended September 30, 2018</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">101.INS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">101.SCH</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">101.CAL</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation
    Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">101.DEF</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition
    Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">101.LAB</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Label Linkbase
    Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">101.PRE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation
    Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant to Item&nbsp;601(b)(2) of
    Regulation&nbsp;S-K, the Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Agreement
    and Plan of Merger to the Securities and Exchange Commission upon request.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">#</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions of this exhibit have been
    omitted pursuant to a request for confidential treatment and have been separately filed with the Securities and Exchange Commission.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicates management contract or
    compensatory plan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.6pt; text-indent: -0.05pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</FONT>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.6pt 6.75pt 0 1.25pt; text-indent: -0.05pt"></P>


<!-- Field: Page; Sequence: 142; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Transition Report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD> Date: March 15, 2019 </TD>
    <TD COLSPAN="2"> <B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"> &nbsp; </TD>
    <TD STYLE="width: 4%"> &nbsp; </TD>
    <TD STYLE="width: 36%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> /s/ DAVID ROSA </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> David Rosa </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <I>Chief Executive Officer</I> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this Transition Report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 30%; border-bottom: black 1.5pt solid"> <B>SIGNATURE</B> </TD>
    <TD STYLE="vertical-align: top; width: 1%"> <B>&nbsp;</B> </TD>
    <TD STYLE="vertical-align: bottom; width: 47%; border-bottom: black 1.5pt solid; text-align: center"> <B>TITLE</B> </TD>
    <TD STYLE="vertical-align: top; width: 1%"> <B>&nbsp;</B> </TD>
    <TD STYLE="vertical-align: bottom; width: 21%; border-bottom: black 1.5pt solid; text-align: center"> <B>DATE</B> </TD></TR>
<TR>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1.5pt solid"> /s/ <FONT STYLE="text-transform: uppercase">DAVID ROSA</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> Chief Executive Officer and Director </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 15, 2019 </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> David Rosa </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> (Principal&nbsp;Executive&nbsp;Officer and Principal Financial Officer) </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1.5pt solid"> /s/ <FONT STYLE="text-transform: uppercase">PAUL BUCKMAN</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> Chairman of the Board of Directors </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 15, 2019 </TD></TR>
<TR>
    <TD> Paul Buckman </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1.5pt solid"> /s/ SURAJ KALIA </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> Member of the Board of Directors </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 15, 2019 </TD></TR>
<TR>
    <TD> Suraj Kalia </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1.5pt solid"> /s/ JEFFREY MATHIESEN </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> Member of the Board of Directors </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 15, 2019 </TD></TR>
<TR>
    <TD> Jeffrey Mathiesen </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 143; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>f10kt2018a1ex23-1_neuroone.htm
<DESCRIPTION>CONSENT OF BDO USA, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Consent of Independent Registered Public
Accounting Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Minnetonka, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We hereby consent to the incorporation
by reference in the Registration Statement on Form S-8 (No. 333-224572) of NeuroOne Medical Technologies Corporation of our report dated December 12, 2018, relating to the consolidated
financial statements which appears in this Form 10-KT/A. Our report contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><U>/s/ BDO USA, LLP</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Minneapolis, MN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">March 15, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10kt2018a1ex31-1_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER AND PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO EXCHANGE ACT RULE 13a-14(a)
OR 15d-14(a), AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, David Rosa, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">1. I have reviewed the transition report
on Form 10-KT for the period ended September 30, 2018, filed on December 12, 2018 (the &ldquo;Original Report&rdquo;), and this
Amendment No. 1 to the Original Report (referred to jointly as &ldquo;this report&rdquo;) of NeuroOne Medical Technologies Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">4. I am responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d) Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">5. I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the
registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 15, 2019</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ DAVID ROSA</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">(Principal&nbsp;Executive&nbsp;Officer and Principal Financial Officer) &nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10kt2018a1ex32-1_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER AND PRINCIPAL FINANCIAL OFFICER,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO SECTION 906 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SARBANES-OXLEY ACT OF 2002*</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Pursuant to the requirement set forth in Rule 13a-14(b) or Rule
15d-14(b) of the Securities and Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and Section 1350 of Chapter
63 of Title 18 of the United States Code, David Rosa, Chief Executive Officer of NeuroOne Medical Technologies Corporation (the
&ldquo;Company&rdquo;) hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">1. The Company&rsquo;s Transition Report
on Form 10-KT for the period ended September 30, 2018 (the &ldquo;Original Report&rdquo;), as amended by Amendment No. 1 to the
Original Report to which this Certification is attached as Exhibit 32.1 (the &ldquo;Report&rdquo;) fully complies with the requirements
of Section 13(a) or Section 15(d) of the Exchange Act, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">2. The information contained in the Report
fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report
and results of operations of the Company for the period covered by the Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ DAVID ROSA</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David Rosa</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal&nbsp;Executive&nbsp;Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial Officer)</P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: March 15, 2019</P></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%"><FONT STYLE="font-family: Symbol">*</FONT></TD>
    <TD STYLE="text-align: justify; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif">This certification accompanies the report to which it relates, is not
deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NeuroOne
Medical Technologies Corporation under the Securities Act of 1933, as amended, or the Exchange Act made before or after the date
of the report, irrespective of any general incorporation language contained in such filing.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>f10kt2018a1ex99-1_neuroone.htm
<DESCRIPTION>SUPPLEMENTAL FINANCIAL INFORMATION ? FINANCIAL STATEMENTS FOR THE TWELVE MONTHS ENDED SEPTEMBER 30, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 &ndash; Consolidated Financial
Statements &ndash; Year Ended September 30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 91%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheet</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statement of Operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statement of Changes in Stockholders&rsquo; Deficit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statement of Cash Flows</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Report of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders and Board of Directors<BR>
NeuroOne Medical Technologies Corporation</P>

<P STYLE="margin: 0pt 0">Minnetonka, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Consolidated Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying
consolidated balance sheet of NeuroOne Medical Technologies Corporation (the &ldquo;Company&rdquo;) as of September&nbsp;30,
2018, the related consolidated statement of operations, changes in stockholders&rsquo; deficit, and cash flows for the year
ended September&nbsp;30, 2018, and the related notes (collectively referred to as the &ldquo;consolidated financial
statements&rdquo;). In our opinion, the consolidated financial statements present fairly, in all material respects, the
financial position of the Company at September&nbsp;30, 2018, and the results of their operations and their cash flows for
the year ended September&nbsp;30, 2018, in conformity with accounting principles generally accepted in the United States of
America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -45pt"><B>Going Concern
Uncertainty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated
financial statements, the Company has suffered recurring losses from operations and negative cash flows from operations that raise
substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also
described in Note 2 to the consolidated financial statements. The consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ BDO USA, LLP</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have served as the Company&rsquo;s auditor since 2016.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
Minnesota</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
12, 2018</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,260</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,378</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,638</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">200,081</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">218,719</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">221,235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,591,022</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Short-term promissory notes and unsecured loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Convertible promissory notes, net and accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,393,804</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">308,395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,797,456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">817,155</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,614,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September&nbsp;30, 2018; no shares issued or outstanding as of September&nbsp;30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Common stock, $0.001 par value; 100,000,000 shares authorized as of September&nbsp;30, 2018; 9,656,505 shares issued and outstanding as of September&nbsp;30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,657</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid&ndash;in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,052,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,457,710</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,395,892</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">218,719</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statement of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<BR> September&nbsp;30,<BR> 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,215,729</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">950,011</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,165,740</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,165,740</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,101,179</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in fair value for the warrant liability and premium conversion derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,048</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loss on note extinguishments, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,665,401</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,758,272</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.82</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Number of shares used in per share calculation:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,280,504</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statement of Changes in
Stockholders&rsquo; Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&nbsp;Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid&ndash;In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; white-space: nowrap">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-indent: -10pt; padding-left: 10pt">Balance at September&nbsp;30,&nbsp;2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,864,994</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,865</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">162,741</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,699,438</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,528,832</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Fair value adjustment for stock issued in connection with intellectual property</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock upon short term notes and convertible notes extinguishments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,146,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,348,790</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,349,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of warrants and warrant liability reclassification in connection with short-term notes and convertible notes extinguishments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,126,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,126,075</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock under 2018 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of warrants under 2018 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,106</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance costs related to 2018 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173,067</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173,067</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -10pt">Issuance of common stock for consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">469,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">469,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,467</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,467</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,758,272</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,758,272</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance at September&nbsp;30,&nbsp;2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,656,505</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,657</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,052,161</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(10,457,710</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,395,892</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statement of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year ended September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(6,758,272</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">486,120</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash interest on convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,554</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash discount amortization on convertible and short-term promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">909,625</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Revaluation of premium conversion derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(480,005</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Revaluation of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305,957</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Loss on note extinguishments, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,656,456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,768</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">604,529</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,840,477</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Purchase of intangible assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(147,009</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(147,009</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of convertible promissory notes and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">761,278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of warrants associated with convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">778,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of common stock in connection with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of warrants in connection with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,106</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds (repayment)&nbsp;&nbsp;from unsecured loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Issuance costs related to convertible promissory notes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,283</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,930,717</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56,769</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70,029</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Cash at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,260</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental non-cash financing and investing transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Bifurcation of premium conversion derivative related to convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">296,909</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0"><P STYLE="margin: 0pt 0">Conversion of short-term notes and convertible promissory notes into common stock</P>


</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,063,361</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Issuance of additional warrants in connection with short-term notes and convertible promissory notes modifications</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">946,658</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Purchased intangible assets in accrued liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,300</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs related to private placement</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">173,067</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs attributed to &nbsp;convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,850</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 &ndash; Organization and Nature of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation
(the &ldquo;Company&rdquo;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the
laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed
a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne
Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased
its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017,
the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&ldquo;NeuroOne&rdquo;)
in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &ldquo;Acquisition&rdquo;).
The Acquisition was accounted for as a capital transaction, or reverse recapitalization. The accompanying consolidated financial
statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to the Acquisition, the Company&rsquo;s
operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive neuromodulation
cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&rsquo;s
disease, essential tremors, and other brain related disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company has recorded no product
sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology
and is seeking regulatory clearances required to initiate commercial activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is based in Minnetonka, Minnesota
effective December 1, 2018. The Company was previously based in Eden Prairie, Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 2 &ndash; Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses and
negative cash flows from operations since inception and had an accumulated deficit of $10,457,710 as of September 30, 2018. In
the event the Company is unable to complete an equity round of financing resulting in more than $3 million in gross proceeds by
December 31, 2018, the 2017 Convertible Notes and accrued interest thereon will become due. The Company does not have adequate
liquidity to fund the repayment of the 2017 Convertible Notes if they become due on December 31, 2018 or to fund its operations
throughout fiscal 2019 without raising additional funds. These factors raise substantial doubt about the Company&rsquo;s ability
to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the
outcome of this condition. If the Company is not able to raise additional working capital, it will have a material adverse effect
on the operations of the Company and the development of its technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through September&nbsp;30, 2018, since
inception, the Company has completed unsecured loan financings for gross proceeds of $283,000, a $253,000 short-term promissory
note financing (which notes were amended and restated to become convertible promissory notes as described below), a $1,625,120
convertible promissory note financing and a second $1,540,000 convertible note promissory financing. In addition, the Company
entered into a private placement transaction in July 2018 whereby $1,113,000 in gross proceeds were raised out of a planned $10.0
million maximum subscription amount (assuming the over-allotment option is not exercised) through September&nbsp;30, 2018. The
Company does not have adequate liquidity to fund its operations throughout fiscal 2019 without raising additional funds. Management
intends to seek additional debt and/or equity financing to fund operations. However, if the Company is unable to raise additional
funds, or the Company&rsquo;s anticipated operating results are not achieved, management believes planned expenditures may need
to be reduced in order to extend the time period that existing resources can fund the Company&rsquo;s operations. If management
is unable to obtain the necessary capital, it may have to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 3 &ndash; Summary of Significant
Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation and Change in Fiscal Year</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared in accordance with accounting standards generally accepted in the United States of America. In September
2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved
a change in the Company&rsquo;s fiscal year end from December 31 to September 30. The Company&rsquo;s fiscal year now begins on
October 1 and ends on September 30 of each year. Accordingly, these consolidated financial statements reflect the financial position
of the Company as of September&nbsp;30, 2018, and the results of their operations and cash flows for the twelve month period ended
September 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Management&rsquo;s Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could
differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
subject the Company to a concentration of credit risk consist of cash. The Company&rsquo;s cash is held by one financial institution
in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution
is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September&nbsp;30,
2018, the Company did not have any deposits in excess of federally insured amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock Valuation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the limited market liquidity for
the Company&rsquo;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute
of Certified Public Accountants&rsquo; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as
Compensation (the &ldquo;Practice Aid&rdquo;), to estimate the fair value of its common stock. The valuation methodology includes
estimates and assumptions that require the Company&rsquo;s judgment. These estimates and assumptions include a number of objective
and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of
achieving a liquidity event, such as an offering or sale. The Company estimated enterprise value on a continuing operations basis,
using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the
Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore,
in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public
companies (&ldquo;GPC&rdquo;) for calendar year 2019 and 2020. The resulting equity value from the GPC method was allocated to
common stock using the option pricing method, and a Discount For Lack of Marketability (&ldquo;DLOM &ldquo;) was applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The significant factors contributing to
the increase in the fair value the Company&rsquo;s common stock included the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The successful completion of the reverse merger;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to new capital as a public company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved revenue projections;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved general economic conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of convertible notes; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important developments relating to achievement of our business objectives</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant changes to the key assumptions
used in the valuations may result in different fair values of common stock at each valuation date. The fair value of common stock
is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has
issued or are outstanding liabilities at the reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s accounting for fair
value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring
or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs
to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant
unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the asset or liability.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not
available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement
date.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of September&nbsp;30,
2018, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated their carrying values because
of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory
notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability
and the premium conversion derivatives associated with the convertible promissory notes of the Company were based on both the
estimated fair value of our common stock of $2.30 as of September&nbsp;30, 2018, and cash flow models discounted at current implied
market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments
and are based on Level&nbsp;3 inputs. There were no transfers between fair value hierarchy levels during the year ended September&nbsp;30,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of financial instruments measured on a recurring
basis is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&nbsp;30,&nbsp;2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">817,155</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">817,155</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">308,395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">308,395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,125,550</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,125,550</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a roll-forward
of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level&nbsp;3 inputs for the year ended September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Warrant liability</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">774,172</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Value assigned to warrants in connection with convertible promissory and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">916,444</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">Reclassification to equity</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,179,418</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">305,957</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">817,155</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Premium debt conversion derivatives</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">441,823</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,577</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of premium debt conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(480,005</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">308,395</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual Property </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into two licensing
agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under
those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired
technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impairment of Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates its long-lived assets,
which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate
that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by
determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows.
If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value
and the fair value of the impaired asset. Through September&nbsp;30, 2018, no milestones triggering possible impairment of the
Company&rsquo;s long-lived assets have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Debt Issuance Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt issuance costs are recorded as a reduction
of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using
the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and
is recorded in interest expense in the accompanying consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are charged
to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development
activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted
services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future
research and development activities are expensed when the activity is performed or when the goods have been received, rather than
when payment is made, in accordance with ASC 730, <I>Research and Development</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued warrants to purchase
equity securities in connection with the issuance of convertible promissory notes (See Note 7&ndash; Short-Term Promissory Notes
and Unsecured Loan and Note 8 &ndash; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants
as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections
in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant
liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statement of operations.
The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for
any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares
to be exercised becomes fixed, at which point the warrants will be classified in stockholders&rsquo; (deficit) equity provided
that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts
that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding,
is recognized in the consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premium Debt Conversion Derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all conversion
and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require
separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt
instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to
interest expense over the term of the host debt instrument using the straight-line method which approximates the effective
interest method.&nbsp; The separated embedded derivatives are accounted for separately on a fair value basis. The Company
records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statement of
operations (See Note 7&ndash; Short-Term Promissory Notes and Unsecured Loans and Note 8 &ndash; Convertible Promissory Notes
and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified
as embedded derivative and therefore separated from the debt host with regard to the convertible promissory notes.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred
tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset
will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and
Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&rsquo;s consolidated
financial statements include, but are not limited to, a U.S federal corporate tax rate decrease from 35% to 21% effective for tax
years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the
valuation allowance recorded to reflect the new federal corporate tax rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Loss Per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, basic loss per share of
common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings or loss per share of common
stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to
include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&rsquo;s convertible
promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the convertible promissory notes
utilizing the if-converted method was not applicable during the year ended September&nbsp;30, 2018 as no conditions required for conversion
had occurred during this period. No incremental common stock equivalents were included in calculating diluted loss per share because
such inclusion would be anti-dilutive given the net loss reported for the year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares were
not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the year ended
September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,927,572</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">(1)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,216</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are
                                                                                                                                                               additional potential warrants to be included, which will not be known until such time, if ever, a qualified financing event
                                                                                                                                                               greater than $3 million occurs in the future related to the 2017 Convertible Notes.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the FASB issued Accounting
Standards Update (ASU) 2017-09, <I>Compensation - Stock Compensation (Topic 718):&nbsp;Scope of Modification Accounting (ASU 2016-09)</I>,&nbsp;which
provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification
accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company
has adopted this standard for the year ended September&nbsp;30, 2018. The adoption of this standard did not have any impact on the Company&rsquo;s
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No. 2017-11,
<I>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</I>, which changes the accounting and
earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect
adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual
periods beginning after December&nbsp;15, 2018 for public business entities, including interim periods within those fiscal years.
Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined
its impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
<I>Compensation - Stock Compensation (Topic 718):&nbsp;Improvements to Nonemployee Share-Based Payment Accounting</I> (ASU 2018-07),&nbsp;which
expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees.
An entity should generally apply the requirements of Topic 718 to nonemployee awards except in circumstances where there is specific
guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all
share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s own
operations by issuing share-based payment awards. The guidance also clarifies that Topic 718 does not apply to share-based payments
used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to
customers as part of a contract accounted for under ASC 606<I>, Revenue from Contracts with Customers </I>(ASC 606)<I>.</I> This
guidance is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted, but no earlier
than an entity&rsquo;s adoption date of ASC 606. The Company is currently evaluating the impact of the new guidance on its consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13,&nbsp;<I>Fair
Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).</I>&nbsp;The
new guidance modifies the disclosure requirements in Topic 820 as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Removals:
the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers
between levels; and the valuation processes for Level 3 fair value measurements.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Modifications:
for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation
of an investee&rsquo;s assets and the date when restrictions from redemption might lapse only if the investee has communicated
the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure
is to communicate information about the uncertainty in measurement as of the reporting date.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additions:
the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value
measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used
to develop Level 3 fair value measurements.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This guidance is effective for all entities for fiscal years,
and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains
and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements,
and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or
annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods
presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified
disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company
is currently evaluating the impact of the new guidance on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 4 &ndash; Commitments and
Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>WARF License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into an exclusive
start-up company license agreement with the Wisconsin Alumni Research Foundation (&ldquo;WARF&rdquo;) for WARF&rsquo;s neural probe
array and thin film micro electrode technology (the &ldquo;WARF Agreement&rdquo;). Under the WARF Agreement, the Company agreed
to pay WARF $55,000 (representing a license fee) upon the earliest to occur of the date the Company cumulatively raises at least
$3 million in financing, the date of a change of control, or the Company&rsquo;s revenue reaching a specified threshold amount.
The Company met the milestone payment requirement with regard to the $55,000 license fee which was paid in April 2018. In addition,
the Company agreed to pay $65,000 (representing reimbursement for costs incurred by WARF in maintaining the licensed patents) upon
the earliest to occur of the date the Company cumulatively raises at least $5 million in financing, the date of a change of control,
or the Company&rsquo;s revenue reaching a specified threshold amount. As of September&nbsp;30, 2018, the Company has not met the requirements
for the $65,000 milestone payment and this amount remains in accrued expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is also obligated to pay royalties
to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for
calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the WARF Agreement.
Subject to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents
licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. The WARF Agreement
is also subject to certain cancellation provisions with 90 days&rsquo; notice should the Company elect not to continue to use the
licensed technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has agreed to diligently develop,
manufacture, market and sell products under the WARF License in the United States during the term of the agreement and, specifically,
that the Company would submit a business plan to WARF by February 1, 2018, which the Company submitted on January 18, 2018, and
file an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the WARF Agreement in the
event that the Company fails to meet these milestones on 30 days&rsquo; written notice, if the Company defaults on the payments
of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other
covenant in the WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving
the Company. WARF may also terminate this license (i) on 90 days&rsquo; notice if the Company fails to have commercial sales of
one or more FDA-approved products under the WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales begin
to be paid, such earned royalties cease for more than four calendar quarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mayo Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an exclusive
license and development agreement with the Mayo Foundation for Medical Education and Research (&ldquo;Mayo&rdquo;) related to
certain intellectual property and development services for thin film micro electrode technology (&ldquo;Mayo Agreement&rdquo;).
If the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of
net sales of products of the licensed technology through the term of the Mayo Agreement, set to expire May 25, 2037. As a part
of the Mayo Agreement, as amended in November 2017, a $91,709 milestone payment was paid in December 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements, continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject
to litigation and claims arising in the ordinary course of business.&nbsp; In May 2017, NeuroOne received a letter from PMT, the
former employer of Mark Christianson and Wade Fredrickson.&nbsp; PMT claimed that these officers had breached their restrictive
covenant obligations with PMT by virtue of their work for NeuroOne and such officer&rsquo;s prior work during employment with the
prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state
law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference
with the contracts.&nbsp; The letter demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson
and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson
and NeuroOne provide the former employer access to NeuroOne&rsquo;s systems to demonstrate that it is not using trade secrets or
proprietary information nor competing with the former employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, the Company was served
with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&nbsp;
In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure
obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil
conspiracy, tortiously interfered with PMT&rsquo;s contracts and prospective economic advantage, and breached a covenant of good
faith and fair dealing.&nbsp; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence,
made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the
tort of conversion and statutory civil theft.&nbsp; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne
were unjustly enriched and engaged in unfair competition.&nbsp; PMT asked the Court to impose a constructive trust over the shares
held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&rsquo;
fees, costs and interest.&nbsp; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend
themselves vigorously.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2018, Mr. Christianson, the
Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The Company expects
a ruling on the motion within 90 days of that date. The motion for dismissal states that: the contract claims against Mr. Christianson
fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&rsquo;s
claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach
of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently
pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outcome and potential loss related
to this matter is unknown as of September&nbsp;30, 2018 and as of the issuance date of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 5 &ndash; Intangibles</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets rollforward is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful Life</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Net Intangibles, September&nbsp;30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">12-13 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">190,637</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">License agreement amendment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,556</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net Intangibles, September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">200,081</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company anticipates amortization expense
of approximately $21,000 per year for fiscal year 2019 through 2023 based upon the two current license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 6 &ndash; Accrued Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses consisted of the following
at September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Accrued&nbsp;license fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">65,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">833,470</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued payroll</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">211,913</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,591,022</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 7 &ndash; Short-Term Promissory
Notes and Unsecured Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> September&nbsp;30,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unsecured loans</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">283,000</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Short-Term Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued short-term unsecured
and interest-free promissory notes (the &ldquo;Short-Term Notes&rdquo;) for aggregate gross proceeds of $253,000 in August 2017
which included free standing equity warrants. The Short-Term Notes were subsequently amended in November 2017 and March 2018 to
become convertible, extend the maturity date and include additional warrant coverage, new interest payment provisions and new conversion
features described more fully below. Effective July 2, 2018, the Company entered into debt conversion agreements (the &ldquo;Short-Term
Note Conversion Agreements&rdquo;) with each Short-Term Note subscriber to (i) convert the outstanding principal and accrued and
unpaid interest (the &ldquo;Outstanding Balance&rdquo;) under the Short-Term Notes into shares of the Company&rsquo;s common stock
based on the Outstanding Balance divided by $1.80 per share (the &ldquo;Short-Term Note Conversion Shares&rdquo;); (ii) cancel
and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described
more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share.
As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the &ldquo;Short-Term
Note Payment Warrants&rdquo;), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note
Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The Short-Term Note Payment Warrants
became exercisable commencing on July 2, 2018, and expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Short-Term
Note Conversion Agreements, $259,297 of the outstanding principal and interest of the Short-Term Notes was converted into
144,053 shares of common stock with an additional 477,856 shares issuable
upon exercise of the Replacement Warrants, Additional Warrants and Short-Term Payment Warrants. The conversion of the Short
Term Notes was accounted for as an extinguishment. The difference in the carrying value of the Short-Term Notes coupled with
the fair value of the underlying Replacement Warrants and Additional Warrants on the date of extinguishment relative to the
higher fair value of the underlying common stock and collective Replacement Warrants, Additional Warrants and new Short-Term
Payment Warrants issued was $148,787. The $148,787 differential was recorded as a loss on note extinguishments in the
accompanying consolidated statement of operations during the year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Replacement Warrants, Additional Warrants
and Short-Term Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the July 2, 2018 Short-Term
Note Conversion Agreements. All of the warrant terms became fixed and have identical provisions. Due to the previously granted
warrants now having fixed terms, the warrant liability value of $148,053 was reclassified to equity. The warrants associated with
the Short-Term Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used
to determine the July 2, 2018 fair value of the warrants associated with the Short-Term Warrants. Input assumptions used were as
follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected
dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to
the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation
and marketability-discount methodologies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Activity Prior to the July 2, 2018 Cancellation,
Extinguishment and Conversion of the Short-Term Notes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2017, the Company&rsquo;s Board
of Directors (the &ldquo;Board&rdquo;) authorized, and the Company issued, the Short-Term Notes for aggregate gross proceeds of
$253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest
expense over the original term of the Short-Term Notes up though November 2017. For the year ended September&nbsp;30, 2018, discount
amortization charged to interest expense related to the issuance costs was $1,017 through the November 30, 2017 amendment date
as discussed further below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2017, the Short-Term Notes
were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common
stock purchase warrants (as amended, the &ldquo;Original Warrants&rdquo;). The Original Warrants had a term of 5 years and an exercise
price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017
amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The November 30, 2017 amendment resulted
in a substantial modification to the Short-Term Notes and was accounted for under the provisions of extinguishment accounting.
A loss on note extinguishments in the accompanying statement of operations for the year ended September&nbsp;30, 2018 was recorded in
the amount of $144,577, which represented the difference between the face value of the Short-Term Notes over the combined carrying
values of the Short-Term Notes and warrants on the date of the amendment. The fair value increase of the Short-Term Notes and the
warrants as amended over its adjusted carrying value at the time of the amendment was $117,280 which was recorded as additional
paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the November 30, 2017 amendment,
the holders were to receive 126,500 common stock purchase warrants upon maturity. A portion of the proceeds from the Short-Term
Notes upon issuance was allocated to the original warrants based on their relative fair value to the underlying Short-Term Notes
in the amount of $61,496 and was recorded in additional paid-in capital and was discounted from the Short-Term Notes and was being
amortized to interest expense ratably over the term of the Short-Term Notes which amounted to $20,611 during the year ended September
30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Short-Term Notes were subsequently
amended and restated on March 12, 2018 (the &ldquo;Amended and Restated Short-Term Notes&rdquo;). The Amended and Restated Short-Term
Notes became convertible promissory notes that had interest assessed at a fixed rate of 8% per annum and would have required the
Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &ldquo;Short-Term
Note Maturity Date&rdquo;). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company
and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement
warrant (the &ldquo;Replacement Warrants&rdquo;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the
Original Warrant. In addition, each holder was issued an additional warrant (the &ldquo;Additional Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Replacement Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Replacement Warrant issued on March
12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New
Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share
exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted
in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted
in connection with a change of control transaction. The Replacement Warrants were exercisable commencing on the Conversion Date
and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement
Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization
or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Replacement Warrants were deemed to
be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with
a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an offset
to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Amended and
Restated Short-Term Notes were recorded at each reporting date in the consolidated statement of operations which amounted to an
expense of $10,330 for the year ended September&nbsp;30, 2018. A Monte Carlo simulation model was used to estimate the aggregate fair
value of the Replacement Warrants immediately prior to the July 2, 2018 Short-Term Note Conversion Agreement amendment. Input assumptions
used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 50 percent; expected life of 3.39 years;
and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was
according to the market approach, considering both the traded price and forward multiples from guideline public companies, using
allocation and marketability-discount methodologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Additional Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Additional Warrant issued on March
12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product
obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and
(ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants were exercisable commencing on the Conversion Date and
would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants
were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization
or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Additional Warrants were deemed to
be free-standing instruments and were accounted for as equity as there were no variable terms. 189,750 shares of common stock were
issuable upon exercise of the Additional Warrants as of the March 12, 2018 amendment date with terms that largely paralleled the
provisions of the Original Warrants except that the Additional Warrants were exercisable on the Conversion Date as opposed to the
Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. The fair value differential
between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair value change was recorded as a reduction
to additional paid-in capital in the accompanying consolidated balance sheet and was included as part of the extinguishment loss discussed
further below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premium Conversion Derivative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the March 2018 amendment, the Amended
and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred
at a price under $2.25 per share. The Company determined that the redemption feature under the Short-Term Notes qualified as an
embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with
a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative
was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion
derivative associated with the Short-Term Notes in the consolidated statement of operations for a benefit of $(49,668) for the
year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The March 2018 amendment resulted in a
substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company
recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on note extinguishments in the
accompanying consolidated statement of operations for the year ended September&nbsp;30, 2018 was recorded in the amount of $186,220,
which represented the difference between the carrying value of the Short-Term Notes and Original Warrants over the combined fair
values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of the amendment.
The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion feature
and the Additional Warrants) relative to its adjusted carrying value at the time of the amendment was $1,170 which was recorded
as a reduction to additional paid-in capital on the accompanying consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit 99.1
- Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unsecured Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 17, 2018, the Company received cash
proceeds of $168,000 from unsecured loans, represented by two promissory notes from existing stockholders of the Company. The loans
are interest free and require that the Company repay the principal in full on the earlier to occur of (i) May 17, 2019 or (ii)
the closing of an equity round of financing of the Company that raises more than $5 million in gross proceeds. The loans include
customary events of default provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2018, the Company received
cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan is
interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii) the
closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes customary
events of default provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 8 &ndash; Convertible Promissory
Notes and Warrant Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> September&nbsp;30,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">2017 convertible promissory notes, net of discounts</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,306,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accrued interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">87,028</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,393,804</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2016 Convertible Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From November 2016 to June 2017, the Company
issued convertible promissory notes (the &ldquo;Convertible Notes&rdquo;) and common stock purchase warrants (the &ldquo;Warrants&rdquo;)
in an aggregate principal amount of $1,625,120 and entered into subscription agreements with subscribers (the &ldquo;2016 Private
Placement&rdquo;). Effective July 2, 2018, however, the Company entered into debt conversion agreements (the &ldquo;2016 Note Conversion
Agreements&rdquo;) with each Convertible Note subscriber to (i) convert the Outstanding Balance under the Convertible Notes into
shares of the Company&rsquo;s common stock based on the Outstanding Balance divided by $1.80 per share (the &ldquo;2016 Note Conversion
Shares&rdquo;); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to
make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration
for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the &ldquo;2016
Note Payment Warrants&rdquo;), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion
Shares received by such subscriber; at a per share exercise price of $1.80 per share. The 2016 Note Payment Warrants became exercisable
commencing on July 2, 2018 and expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the 2016 Note Conversion Agreements,
$1,804,064 of the outstanding principal and interest of the 2016 Convertible Promissory Notes was converted into 1,002,258 shares
of common stock and an additional 2,004,516 shares of common stock became issuable upon exercise of the Warrants and 2016 Note
Payment Warrants. The conversion of the Convertible Notes was accounted for as an extinguishment. The difference in the carrying
value of the Convertible Notes coupled with the fair value of the underlying Warrants upon conversion relative to the higher fair
value of the underlying common stock and collective Warrants and new 2016 Note Payment Warrants issued was $979,480. The $979,480
differential total, inclusive of the unamortized discount remaining on the Convertible Notes of $11,143 as of July 2, 2018, was
recorded as a loss on note extinguishments in the accompanying consolidated statement of operations during the year ended September
30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and 2016 Note Payment Warrants
were deemed to be free-standing equity instruments upon execution of the 2016 Note Conversion Agreements. All of the warrant terms
became fixed and the terms were identical. Due to the previously granted warrants now having fixed terms, the warrant liability
value of $1,031,366 was reclassified to equity. The warrants associated with the Convertible Notes became immediately exercisable
on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the
warrants associated with the Convertible Notes. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent;
expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock
price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded
price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Activity Prior to the July 2, 2018 Cancellation,
Extinguishment and Conversion of the Convertible Notes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company amended the Convertible Notes
in December 2016 and November 2017 and the Warrants in June 2017 and November 2017 to, among other things, change the terms of
the underlying Warrants that include the removal of down-round pricing protection provisions as described more fully below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Convertible Notes were unsecured. The
Convertible Notes accrued interest at a fixed rate of 8 percent per annum and required the Company to repay the principal and accrued
and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked round of financing
resulting in more than $3.0 million in gross proceeds (a &ldquo;Qualified Financing&rdquo;). If a Qualified Financing had occurred
before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes would have automatically
converted into the securities issued by the Company in such financing based on the greater number of securities resulting from
either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and
accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing.
If the Company failed to complete a Qualified Financing by July 31, 2018, the Convertible Notes would have been immediately due
and payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a change of control transaction or initial
public offering occurred prior to a Qualified Financing, the Convertible Notes would have, at the election of the holders of a
majority of the outstanding principal of the Convertible Notes, either been payable on demand as of the closing date of such transaction,
or been convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser
of the per share value as determined by the Board as if in connection with the granting of stock-based compensation, or in a private
sale to a third party in an arms-length transaction, or at the per share consideration to be paid in such transaction. Change of
control means a merger or consolidation with another entity in which the Company&rsquo;s stockholders do not own more than 50 percent
of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the June 2017 amendment, the Warrants
granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares
equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised prior
to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest
on the Convertible Notes held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the date of
issuance and would have expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under
the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the
related Convertible Notes. The amount of warrant shares to be issued became contingent and were based on the number of shares of
common stock received by the holder of the Convertible Notes upon conversion of such holder&rsquo;s Convertible Notes, and at an
exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants would have expired
on November 21, 2021 in the event of a Qualified Financing or would have expired unissued if the notes were not converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the July 2018 Convertible Note
extinguishment, the Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable
number of shares issuable in connection with a possible change of control conversion event. The discount was amortized to interest
expense over the original term of the Convertible Notes using the straight-line method which approximated the effective interest
method and was fully amortized by November 21, 2017; the amortization expense recorded was $157,210 during the year ended September
30, 2018. The Company also recorded the fair value changes of the warrant liability associated with the Convertible Notes in the
consolidated statement of operations which amounted to an expense of $257,194 for the year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The November 2017 amendment resulted in
a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated with
the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of the
Convertible Notes on the date of the modification. The $97,223 difference was recorded as a gain on note extinguishments in the
accompanying statement of operations with an offsetting discount to the Convertible Notes. The discount was being amortized over
the amended term of the Convertible Notes. The amortization recorded during the year ended September&nbsp;30, 2018 was $86,080.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of their issuance, the Convertible
Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share.
The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated
from its debt host. There was no bifurcation of the embedded derivative during the year ended September&nbsp;30, 2018. The discount
was being amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates
the effective interest method and was fully amortized by November 21, 2017; the amortization expense recorded was $73,702 during
the year ended September&nbsp;30, 2018. The embedded derivative was accounted for separately on a fair market value basis. The Company
recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes in the consolidated
statement of operations for a benefit of $(441,824) for the year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Convertible Notes,
the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610
for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &ldquo;placement
agent warrant&rdquo;) which would have had an exercise price of $2.00 per share of common stock with a total fair value of $4,855
on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant was issuable at the time
the private placement transaction was fully subscribed. The placement agent warrant would have been immediately exercisable on
the date of issuance and would have expired five years following the date of issuance. The Company recorded an issuance cost discount
to the Convertible Notes upon issuance; there were no issuance discounts during the year ended September&nbsp;30, 2018. The issuance
cost discounts were fully amortized by November 21, 2017; the amortization expense recorded as interest was $15,080 during the
year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2017, the Company initially
entered into a subscription agreement with certain investors (the &ldquo;Subscribers&rdquo;), pursuant to which the Company, in
a private placement (the &ldquo;Private Placement&rdquo;), agreed to issue and sell to the Subscribers 8% convertible promissory
notes (the &ldquo;2017 Convertible Notes&rdquo;) and warrants (the &ldquo;New Warrants&rdquo;) to purchase shares of the Company&rsquo;s
capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the
underlying conversion event and are exercisable for five years commencing on the triggering conversion event. The subscription
agreement, the 2017 Convertible Notes and New Warrants were amended on December 14, 2017 to move up the maturity date of the 2017
Convertible Notes from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision
of the 2017 Convertible Notes in the event of a qualified financing as described more fully below, to modify the exercise price
of the New Warrants and to increase the authorized subscription amount to $1,500,000. In May 2018, the Board approved an increase
in the authorized subscription amount from $1,500,000 to $2,000,000 and extended the offering period from the five month anniversary
of the initial closing to the eight month anniversary of the initial closing. The initial closing of the Private Placement was
consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes
in an aggregate principal amount of $1,540,000 to the Subscribers through June 2018 when the Private Placement expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Convertible Notes bear interest
at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on December
31, 2018 (the &ldquo;2017 Convertible Notes Maturity Date&rdquo;). If the Company consummates an equity round of financing resulting
in more than $3 million in gross proceeds before December 31, 2018 (the &ldquo;2017 Convertible Notes Qualified Financing&rdquo;),
the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities
issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest
on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible
Notes Qualified Financing. The New Warrants also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount
of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price
per share of the securities issued in the 2017 Convertible Notes Qualified Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the December 2017 amendment, if
the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued
and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company
in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued
interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible
Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable
in conjunction with the 2017 Convertible Notes Qualified Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, if a change of control transaction
occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017
Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes,
either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately
prior to such transaction at a price per share equal to the lesser of (i) the per share value of the shares of common stock as
determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party
in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a
merger or consolidation with another entity in which the Company&rsquo;s stockholders do not own more than 50% of the outstanding
voting power of the surviving entity or the disposition of all or substantially all of the Company&rsquo;s assets. The New Warrants
also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by
the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted
in the change of control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The December 2017 amendment resulted in
a substantial modification to the original 2017 Convertible Notes. The Company recorded the 2017 Convertible Note amendment under
the provisions of extinguishment accounting. The fair value of the underlying Convertible Notes was $294,615 higher than the carrying
value of the Convertible Notes net of unamortized debt discount on the date of the modification. The $294,615 difference as well
as legal costs associated with the amendment in the amount of $8,945 were recorded as a loss on convertible notes extinguishments
totaling $303,560 in the accompanying statement of operations for the year ended September&nbsp;30, 2018. After the modification, there
remained a debt discount of $27,371 of which $20,796 was amortized during the year ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Convertible Notes contain a conversion
discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on
the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible
Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation
of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $296,909 for
the convertible debt issued during the year ended September&nbsp;30, 2018. The discount is being amortized to interest expense over
the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization
expense was $146,981 for the year ended September&nbsp;30, 2018. The embedded derivative is accounted for separately on a fair market
value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with all of the 2017
Convertible Notes in the consolidated statement of operations which amounted to an expense of $11,487 for the year ended September
30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The New Warrants were deemed to be free-standing
instruments and were accounted for as a liability given the variable number of shares issuable in connection with a change of control
conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants. Input assumptions
used were as follows as of September&nbsp;30, 2018: a risk-free interest rate of 2.94 percent; expected volatility of 50 percent; expected
life of 5.21 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable
basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies,
using allocation and marketability-discount methodologies. The 2017 Convertible Note proceeds assigned to the New Warrants were
$778,722 during the year ended September&nbsp;30, 2018, which represented their fair value at issuance and were discounted from the
2017 Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term
of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization
expense was $385,047 for the year ended September&nbsp;30, 2018. The Company also recorded the fair value changes of the warrant liability
associated with &nbsp;all of the 2017 Convertible Notes in the consolidated statement of operations which amounted to an expense
of $38,433 for the year ended September&nbsp;30, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2017 Convertible
Notes, the Company incurred issuance costs in the amount of $8,133 which consisted of legal costs and was recorded as an issuance
cost discount to the 2017 Convertible Notes, of which $3,101 was amortized to interest expense during the year ended September
30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Convertible Note Subscription Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the subscription agreements
entered into in connection with the Private Placement, the Company is entitled to receive notice in the event a holder elects to
sell or receives a bona fide offer for any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right
to purchase the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as
applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the
subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective
subscription agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 9 &ndash; Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended September&nbsp;30, 2018,
stock-based services expense related to the stock options and stock-based award liabilities was included in general and administrative
and research and development costs as follows in the accompanying statement of operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 12pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">480,653</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 12pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total stock-based services expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">486,120</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne formally adopted an equity incentive
plan (the &ldquo;2016 Plan&rdquo;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition.
In addition, the Company adopted a 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) on April 17, 2017. The 2016 and 2017
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company.
The Company reserved 2,292,265 shares of common stock for issuance under the 2016 Plan and 2017 Plan on a combined basis. The Company
began granting stock options and restricted stock awards in the second quarter of 2017. During the year ended September&nbsp;30, 2018,
2,500 stock options were granted to a consultant at a weighted average exercise price of $5.34 per share. The stock options granted
during the year ended September&nbsp;30, 2018 had a weighted average grant date fair value of $2.48 per share and vested within several
weeks from grant. The options expire ten years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the Company&rsquo;s stock option
plan activity for the year ended September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Weighted-</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Weighted</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Average</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Average</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Remaining</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Aggregate</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Number of</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Exercise</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Contractual</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 0">Intrinsic</TD><TD STYLE="padding-bottom: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Term (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; padding-bottom: 4pt">Outstanding at September&nbsp;30, 2017</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">365,716</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">0.03</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">9.6</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">612,690</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding at September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">368,216</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.07</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8.6</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">820,862</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Vested and exercisable at September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">368,216</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.07</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8.6</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">820,862</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated
fair value of our common stock as of September&nbsp;30, 2018 and 2017 of $2.30 and $1.71 per share, respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average assumptions
used in the Black-Scholes option-pricing model are as follows for the stock options granted during the year ended September&nbsp;30,
2018:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Expected stock price volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">49.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended September&nbsp;30, 2018,
2,500 stock options vested, and the weighted average grant date fair value per option was $2.48. No stock options were forfeited
during the year ended September&nbsp;30, 2018. As of September&nbsp;30, 2018, 1,708,596 shares were available for future issuance on a combined
basis under the 2016 and 2017 Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Stock-Based Awards </I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Up to 250,000 shares of common stock were
reserved in February 2018 as a result of a consulting agreement for investor relations services executed in February 2018. Under
the agreement, 200,000 shares of common stock were awarded during the year ended September&nbsp;30, 2018. The shares were awarded based
on a performance vesting condition that was met in February 2018 and a time-based vesting condition that was met in both May 2018
and August 2018. The compensation expense related to the vested common shares was included in the total stock-based services expense
referenced above which totaled $469,500. The expense was based on the fair value of the underlying common stock at the point of
vesting which was $2.52 per share for 100,000 shares that vested in February 2018, $2.30 per share for the 50,000 shares that vested
in May 2018, and $2.05 per share for the 50,000 shares that vested in August 2018. The underlying stock price used in the analysis
was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples
from guideline public companies, using allocation and marketability-discount methodologies.&nbsp;The remaining 50,000 shares of
the share commitment under the agreement vested in November 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company recorded stock-based
services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares
and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering,
qualified financing, or December 31, 2018 (as amended from the originally stated June 30, 2018 date). The number of option shares
under the agreement is based on a $3,000 monthly compensation amount divided by the fair value of the underlying common stock on
the award date. The exercise price will also be set at the fair value of the underlying common stock on the award date. The liability
associated with the unissued options was based on an option share equivalent estimate that reflects the portion of the award where
performance vesting conditions have been met as of September&nbsp;30, 2018 and was based on the fair value of the Company&rsquo;s common
stock on September&nbsp;30, 2018 as the award date has not occurred. The common stock fair value on September&nbsp;30, 2018 was $2.30 per
share and was determined based on a non-marketable basis and was according to the market approach, considering both the traded
price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The stock-based services expense associated with the unissued
stock options was $11,153 during the year ended September&nbsp;30, 2018 and is classified in accrued expenses at September&nbsp;30, 2018.
The liability for the unissued stock options was based on the following weighted-average assumptions using the Black-Scholes option-pricing
model:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Expected stock price volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">49.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.9</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the issuance of all of the unissued
options associated with the stock-based award liabilities, the estimated number of shares available for future issuance as of September
30, 2018 would be reduced from 1,708,596 to 1,698,161 shares as a result of the remaining stock options to be issued upon vesting
under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018 consulting agreement
are not eligible for issuance under either the 2016 Plan or 2017 Plan because the 2016 Plan and 2017 Plan limit plan participants
to individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 10 &ndash; Stockholders&rsquo;
Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Private Placement and Corresponding
Issuance of Common Stock and Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From July 9, 2018 through September 28,
2018, the Company entered into subscription agreements (each, a &ldquo;Purchase Agreement&rdquo;) with certain accredited investors
(the &ldquo;Purchasers&rdquo;), pursuant to which the Company, in a private placement (the &ldquo;2018 Private Placement&rdquo;),
agreed to issue and sell to the Purchasers units (each, a &ldquo;Unit&rdquo;), each consisting of (i) 1 share (each, a &ldquo;Share&rdquo;)
of the Company&rsquo;s common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00
per share (the &ldquo;2018 Warrants&rdquo;). The initial closing of the 2018 Private Placement was consummated on July 9, 2018.
As of September&nbsp;30, 2018, the Company has issued and sold an aggregate of 445,200 Units to the Purchasers, for total gross proceeds
to the Company of approximately $1,113,000 before deducting offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2018 Private Placement,
the Company has agreed to issue and sell to accredited investors up to a maximum of 4,000,000 Units (the &ldquo;Maximum Offering&rdquo;)
at a price of $2.50 per Unit for total gross proceeds to the Company of up to $10,000,000. If the 2018 Private Placement is over-subscribed,
the Company may, in its discretion sell up to an additional 600,000 Units (the &ldquo;Over-Allotment&rdquo;) to cover such over
subscriptions. If the Company issues the Maximum Offering amount, 4,000,000 shares of Common Stock (4,600,000 shares of Common
Stock if the Over-Allotment is exercised) would be issuable upon exercise of the 2018 Warrants. The Company may conduct any number
of additional closings so long as the final closing occurs on or before January 2, 2019. Under the Purchase Agreement, the Company
has agreed to use the net proceeds from the 2018 Private Placement to pay the outstanding principal and accrued interest on its
2017 Convertible Notes if such notes do not convert prior to maturity, to pay the principal on its unsecured term loans, for research
and development, clinical studies, legal fees and sales and marketing expenses, as well as working capital and general corporate
purposes. The Company has granted the Purchasers indemnification rights with respect to its representations, warranties and agreements
under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2018 Warrants are exercisable beginning
on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were
accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying consolidated
balance sheet based on their relative fair value to the underlying common shares issued. The fair value of the 2018 Warrants issued
was $318,759 and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate
of 2.82 percent; expected volatility of 49.8 percent; expected life of 4.91 years; and expected dividend yield of 0 percent. The
underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering
both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2018 Private Placement,
the Company recorded issuance costs in the amount of $173,067 as of September&nbsp;30, 2018. The issuance costs included commissions
to the brokers equal to 10% of the gross proceeds from the sale of the Units that qualify for the commission and amounted to $83,800.
In addition to the brokers&rsquo; commission, the issuance costs included the estimated value of the 5-year warrants to be issued
to the brokers to purchase an amount of Common Stock equal to 10% of the total amount of qualifying Shares sold in the 2018 Private
Placement at an exercise price of $3.45 per share upon the close of the 2018 Private Placement. A liability in the amount of $26,878
was recorded as of September&nbsp;30, 2018 related to the broker warrants. Lastly, third party legal costs in the amount $62,389 comprised
the balance of the issuance costs incurred as of September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2018 Private Placement,
the Company entered into registration rights agreements with each of the Purchasers pursuant to which the Company has agreed to
file a registration statement with the SEC covering the resale of the shares of common stock sold in the 2018 Private Placement
and the shares of Common Stock issuable upon exercise of the 2018 Warrants. The Company has agreed to file such registration statement
within 75 days of the final closing of the 2018 Private Placement. Each registration rights agreement includes customary indemnification
rights in connection with the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Activity and Summary</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes warrant
activity during the year ended September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Exercise Price</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Weighted Average</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Warrants</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Per Warrant</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Exercise Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Outstanding at September&nbsp;30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">126,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,801,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80&nbsp;-&nbsp;3.00</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Outstanding and exercisable at September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,927,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80&nbsp;-&nbsp;3.00</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.98</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information
about warrants outstanding at September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Exercise Price</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number Outstanding</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted
    Average Remaining Contractual life (Years)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number Exercisable at September&nbsp;30, <BR>
2018</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">2,482,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center">3.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">2,482,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">3.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">4.8</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-bottom: 4pt; text-align: left">Total</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,927,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,927,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 11 &ndash; Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and
Jobs Act (the TCJA), which significantly modified U.S. corporate income tax law, was signed into law by President Trump. The TCJA
contains significant changes to corporate income taxation, including, but not limited to, the reduction of the corporate income
tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of
earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable
income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration,
one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on
foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions
for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the deductibility
of research and experimental expenditures that will be effective in the future).&nbsp;Notwithstanding the reduction in the corporate
income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform
to the newly enacted federal tax law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has recorded the
adjustments in the consolidated financial statements in accordance with the TCJA and related guidance with a reduction of $420,000&nbsp;to
its net gross deferred tax assets in December 2017, the period in which the legislation was enacted. The reduction was fully offset
by an equal reduction in the Company&rsquo;s valuation allowance given the Company&rsquo;s historical net losses, resulting in
no net income tax expense being recorded.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rate for the Company
was zero percent for the year ended September&nbsp;30, 2018. A reconciliation of income tax computed at the statutory federal income
tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statement of operations for the
Company is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Income tax benefit at federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(24.3</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income tax, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7.4</TD><TD STYLE="text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin: 0pt 0">Warrant expense</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">12.9</P>


</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Disqualified interest and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.4</TD><TD STYLE="text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">U.S. tax reform</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.2</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Effective tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left; white-space: nowrap">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant components of the Company&rsquo;s
deferred tax assets and liabilities are summarized in the tables below as of September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left">Federal and state operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,837,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Acquired intangibles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,116</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,763</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development credit carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Stock-based compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,115,268</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,115,268</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September&nbsp;30, 2018, the Company had
gross deferred tax assets of approximately $2,115,000. Realization of the deferred assets is primarily dependent upon future taxable
income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception.
The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred
tax assets have been fully offset by a valuation allowance of approximately $2,115,000 as of September&nbsp;30, 2018. U.S. net deferred
tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained
profitability or another source of income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September&nbsp;30, 2018, the Company&rsquo;s
federal net operating loss carryforwards were approximately $6,393,000. The Company had federal research credit carryforwards as
of September&nbsp;30, 2018 of approximately $83,000. The federal net operating loss incurred prior to January 1, 2018 and tax credit
carryforwards will begin to expire in 2036 if not utilized. Federal net operating losses incurred after December 31, 2017 will
not expire. As of September&nbsp;30, 2018, the Company had state net operating loss carryforwards of approximately $6,393,000. The Company
had state research credit carryforwards of approximately $57,000 as of September&nbsp;30, 2018. The state net operating loss carryforwards
will begin to expire in 2031, if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not
utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the net operating loss carryforwards
and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&nbsp;382
of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations,
the limitation applies when one or more &ldquo;5-percent shareholders&rdquo; increase their ownership, in the aggregate, by more
than 50&nbsp;percentage points over a 36-month time period testing period or beginning the day after the most recent ownership
change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <I>Income Taxes
</I>(&ldquo;ASC 740&rdquo;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold
and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken
in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination
by taxing authorities. The Company believes its income tax filing positions and deductions will be sustained upon examination,
and accordingly, no reserves or related accruals for interest and penalties have been recorded at September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with this guidance, the Company
has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes
will be classified as a component of interest expense and any related penalties will be classified in operating expenses in the
consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s corporate returns are
subject to examination for the 2016 and 2017 tax years for federal and subject to examination for the 2016 and 2017 tax years in
one state jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 99.1 - Form 10-KT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements,
continued</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 12 &ndash; Defined Contribution
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company adopted a
401(k) defined contribution plan (the &ldquo;401K Plan&rdquo;) on January 1, 2017, which was amended and restated on March 1, 2018
(the &ldquo;Restatement&rdquo;), for all employees over age&nbsp;21. Employees can defer up to 100% of their compensation through
payroll withholdings into the 401K Plan subject to federal law limits. The Company began matching in the fourth quarter of 2017
on deferrals at 100% of deferrals up to 3% of one&rsquo;s contributions and 50% on deferrals over 3%, but not exceeding 5% of one&rsquo;s
contributions up through the Restatement. The Company&rsquo;s matching contributions to employee deferrals became discretionary
after the Restatement. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future,
but it has not done so through September&nbsp;30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Employee contributions
and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code
are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on
the second anniversary of an employee&rsquo;s date of hire. Discretionary profit sharing contributions vest over a five year period
beginning on the first anniversary of an employee&rsquo;s date of hire. The amount of matching contributions made during the year
ended September&nbsp;30, 2018 was $34,779. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 13 - Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2018 Private Placement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between October 1, 2018 through November
30, 2018, the Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the
Company of approximately $425,000 before deducting offering expenses. The additional Units have identical terms to the 2018 Private
Placement disclosed in Note 10 &ndash; Stockholders&rsquo; Deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Unsecured Loans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, the Company received
cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from stockholders
owning over 5% of the Company&rsquo;s common stock. The loans are interest free and require that we repay the principal in full
on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds
or November 14, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advisory Board Stock Option Grants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018 and December 2018
the Board of Directors approved for grant, to seven scientific advisory board members, a total of 175,000 stock options for
the purchase of common stock. The options when issued will vest monthly over a three year period commencing January 1,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Office Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leased a 5,196 square foot facility for use as its
corporate headquarters location in Minnetonka, Minnesota effective December 1, 2018. The lease expires on October 31, 2019 and
the monthly rent is $4,763.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "- G # 2(  A$! Q$!_\0
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MH *IWU_!I]N9IV(7.  ,LQ] *M.X12S'"@9)KB[NYAU2\=Y9BN>(\Y*QKV(
MZD]SV% $^J3&\FB+2,\;/L2VC((&><MSR<=N@K/O;IM-LI+F&98Y%.U FUW
MSU /RBD1XE7[08RJ1G9E$R';!!R>W7M535U"Z'*\$(\IV55*Q>:">X(/7UI-
M70TE?4@2YB:XE>*XNO.%W&!DQH ",E?7:?S]*BU634[:TM;E9[E)DNF.1+&P
M/S@'*]_E)'\Z=:03F:Y<PNH^V1*Q%J'(&/U_WNU5%*7CVJ^7 +5KB1XIC"0)
M6ZX7'W1P"6_BQBN>$9*>A,W'H7FU"]5X6N05B$<1D++@A2V&&Y<C.3G K9LK
MR72;]F3S)H9,KL4<\'J1V.*Y]8K<6GRR6$F^T&UH9FBP-_H?NCKSUS6R4B,;
M,'82A-Z%3D[0/7^=='-=BBFEJ=W!/'<0K-$P9&&01WJ6N5\,:BQN)+&1OE*[
MX@1CCO754R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHJA<ZI9VA;[1*$"L$.5/4C/\C0!?HK+/B#2P 3=* 1D':?\ "D_X2'2@
M&)O8UV]=V10!JT5EC7]+*Y-[& >QR#4-UXIT2RM9;FYU&&.&(;G=LX _*@#:
MHKC?^%K^!?\ H9;/_P >_P */^%K>!?^AELOS;_"@#LJ*XW_ (6OX%_Z&6S_
M /'O\*/^%K^!?^AEL_\ Q[_"@#LJ*XW_ (6MX%_Z&6S_ /'O\*/^%K>!?^AD
ML_\ Q[_"@#LJ*XW_ (6MX%_Z&6S_ /'O\*!\5? Q.!XDLR3V&[_"@#LJ*X]O
MBAX*4X;Q!; ^A#?X5NZ-KFFZ_8_;=*O$NK;>4\Q,XW#J.:!V9IT444""BBB@
M HHHH **** "BBB@# \32M]BBMHY!&T\FTY.,X&?RZ5S49F:9MTB;Y%'F.6"
MKSR,>GTKIO%%N)-.$V/]6<$XR<'T_'%<G:% IV)YSE1A>H SD\4 7;6!))(V
M#N"1M=W;*AL<TW5IWFT\PRI',J@8D-P(H^OKCZ_6K$4ETH6&TEAC@G9BS/%_
M=&<>X]Q2+#_HSV]PJ2,1YC"4#/KQ_>!Z^U I*ZL8M[:RRV>H6 D EFO8F9XK
MK_6)CYA[<?P]\TJ*UE%$76_@2W=W;=(K(F!P&]L?= [U:M(;,P*\]O$SB3<0
M1@C'\1]\=_2BZT'2[@?N8;2S1XF:,98EE)Y?OSUQ36UC.-/OT.>EG^WH[3-<
MI%LC$)FM\>;DCYWV_D%Z<9KK92<.&Z)&V HX52!D ^M53H,HD;-W+#;.4<%V
M.Y]@X..P/?UJ>XFCV *=XE^52?E.?7'84VHI:&SL09FMM1AGA5@;;:'3^+;[
MGZ5Z"CB2-77HP!%>>[3=78AMHW#/(D7+<D  D9_#.:]"C01QJBC"J  *D1)1
M110 4444 %%%% !1110 4444 %%%% !16%XJE:+2 RL5/FJ,@XKCEO9%R?/E
M^I<T >G45YI]OD'2:3..?G-1'4Y N/.DXX^^: /3Z*\;O=;\H$O?%<]1YIR/
MPK(37A.V$O9\EL#,C#)]N:GGC>UQM-(]\HKP5[ZXV<W,^/\ KJW^-59+JZ Y
MNK@#VE;_ !JA'T)17@^@W-P?$VEJUS.0;J,;?-8@\_6O>* "BBB@ HHHH **
M** "BBB@#GO&'BVS\&Z$=6O8)YH1*L16$ MENG4BL[0O$\^M:/;:G"Q$5ROF
M()%&X*>@.*U_$WAG3?%FCMIFJ)*UL9%DQ&Y0[EZ<US.@6<.FZ1#86V?(MLQ1
MY;<< X&3WI,"?6/'MEH,R0ZG?VUL\@)3S!C=C&?YBL[_ (6UH)_YCFF_BQ_P
MKC?B7X+U?Q9J%F^FFV MED63SI=G+$$8X]JX7_A3GBKUT[_P)_\ K5K&,6M6
M3J>X#XMZ!WUG3/PD-:^E>-;?7(WDTRXM+E4.UFC8D ^E?//_  IWQ5ZZ;_X$
M_P#UJ]+^&7AC4?"FG75IJ7D&6:?S4\F3>,;<<\4I1BM@5SUG3;V6[,BRJ@*8
MQMK2K$T,YEN/HM;=04%%%% !1110 5S/C!2;.VPH)\T\8]JZ:N9\8C-E;<J/
MWAY)]J .1"DYVJ,YY! J-AP.%YXSM''YC/Y4\QDC[T>,_P">*C=55U&2?;I_
M,4 ."?*HV\GC(Z'\,5C^-8V7P1K&=A'V4_=4CN/6M?*@[3N7/0-Q6-XR0#P3
MK1$BG%L> ,'J* -#X5^'/#EY\--/O=0T33[F=C)NDFMU9FPQZDBM;68? >C#
M:_AK2YY1_!%9IC]1BL[X5%IOAE8Q(?FC21L=R"YJMKNE2,A+ Y<9Q@UC7G*"
M]T]++L+2K3M5>A7LO$G@&2<17G@VPA0L1YJVD;KC/&>,UW-EX:\$7P1H/#VC
M21R89&6T3OZ\=:\AC\/3S2$HK8!ST->D^';:73-!N9W.T1*&^8$="*QP]:<Y
M<LD>CFN7X.C#GHRU['S9XMLXX_'&MVUO''#%%=3!(U&U5 )X K%CM'DS@,<=
M0HSBN@\51_:OB!K&>-]Z_/IENM:4=O%;QK"B@=%7) )SQDG^M=MG>Q\X<<]J
MZ@<,"1D!AC-.N81:W 6.>.7"JV].F2,XY[CI77W-C%,IMW_AX89R1[Y[_6N/
MO8C%.RL<L"5)]<'%&SL"U5SOO BO?6-P\V)&5U4$J.!@FO</@XNSPE?)C&-3
MN!^HKQ[X50>=I-^<=)T_D:]G^$B[?#6I#TU6Y'ZBN"C.^(G'L>MB9+ZG31Z!
M1117<>2%%%% !1110 4444 %%%% $<L23Q-'(H9&&"#WKDI?"=RD\SP312(P
MQ&),J4'ID?E78T4 <D^GW=O&A\F:,0L2GEX?:3Z8YQ^%9%ZH:YVJI9R<%Y#T
M],_Y%>B5@:KI$LDYN[14:?<I.YL#C]#^- ',7-T(GMQ;3^9(BD/,0/F/ICT%
M6+:\F$S3^:3*X"EB!T]O2JGB!+FSDMOM-O%#(X;YH\?-SWQ5*&[*D '![>]
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M\K#$[(7C/8 >M)I>A075E-). ,';&Z]"W]16Q',PMG ^Z81CW&.@J?3+3[3
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MNM*QB=C\)SFSU3VF0?\ CM>BUP?PWTG4-*M=16_M);9I)5*"0@Y&WM@UWE,
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M?-GA*?R7NN>H6OHWX)MO\#7+>NI7']*Z:G^[Q.2G3:Q$I'I5%%%<AV!1110
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MY?YCS_HX_P#BJJPCS7<,?>.5'7%)N^5AM.0>_4FO2Q\)8AA?[9?"G@?9Q_\
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H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>nmtc-20180930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 8.0.2.0 [03/16/2019 02:14:10 AM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:nmtc="http://www.originalsourcemusic.com/20180930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
 xmlns:us-types="http://fasb.org/us-types/2018-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
 xmlns:srt-types="http://fasb.org/srt-types/2018-01-31"
 xmlns:srt="http://fasb.org/srt/2018-01-31"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="nmtc-20180930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_20_Oct_2016T00_00_00_TO_20_Oct_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Oct_2016T00_00_00_TO_20_Oct_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-13
</xbrli:startDate>
<xbrli:endDate>
2016-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nmtc:StockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-04
</xbrli:startDate>
<xbrli:endDate>
2017-07-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-04
</xbrli:startDate>
<xbrli:endDate>
2017-07-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:CancellationExtinguishmentAndConversionOfShortTermNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:SubscriptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-10-04
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:SubscriptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-01
</xbrli:startDate>
<xbrli:endDate>
2017-10-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Nov_2017T00_00_00_TO_20_Nov_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_11_Nov_2017T00_00_00_TO_20_Nov_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-11
</xbrli:startDate>
<xbrli:endDate>
2017-11-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:CancellationExtinguishmentAndConversionOfShortTermNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:CancellationExtinguishmentAndConversionOfShortTermNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-16
</xbrli:startDate>
<xbrli:endDate>
2017-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2017T00_00_00_TO_22_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-12-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nmtc:StockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:CancellationExtinguishmentAndConversionOfShortTermNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:NewWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_NewWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:NewWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nmtc:StockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_22_Feb_2018T00_00_00_TO_01_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-22
</xbrli:startDate>
<xbrli:endDate>
2018-03-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-03-03
</xbrli:startDate>
<xbrli:endDate>
2018-03-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-03-15
</xbrli:startDate>
<xbrli:endDate>
2018-03-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-03-15
</xbrli:startDate>
<xbrli:endDate>
2018-03-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Mar_2018T00_00_00_TO_29_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-04-01
</xbrli:startDate>
<xbrli:endDate>
2018-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2018T00_00_00_TO_17_May_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-05-01
</xbrli:startDate>
<xbrli:endDate>
2018-05-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2018T00_00_00_TO_17_May_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-05-01
</xbrli:startDate>
<xbrli:endDate>
2018-05-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2018T00_00_00_TO_31_May_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-05-01
</xbrli:startDate>
<xbrli:endDate>
2018-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-06-15
</xbrli:startDate>
<xbrli:endDate>
2018-07-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-06-15
</xbrli:startDate>
<xbrli:endDate>
2018-07-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-07-01
</xbrli:startDate>
<xbrli:endDate>
2018-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-08-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-08-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-08-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-08-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-08-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09_Jul_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-07-09
</xbrli:startDate>
<xbrli:endDate>
2018-08-03
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2018T00_00_00_TO_30_Sep_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-07-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nmtc:StockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:CancellationExtinguishmentAndConversionOfShortTermNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:NewWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_NewWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:NewWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:PremiumConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OneExercisePriceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:OneExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ThreeExercisePriceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ThreeExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_OtherDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:OtherDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nmtc:StockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OneExercisePriceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:OneExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ThreeExercisePriceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ThreeExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_OtherDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:OtherDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_RangeAxis_MaximumMember_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14_Nov_2018T00_00_00_TO_14_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-11-14
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2018T00_00_00_TO_14_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-09-01
</xbrli:startDate>
<xbrli:endDate>
2018-11-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2018T00_00_00_TO_30_Nov_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-10-01
</xbrli:startDate>
<xbrli:endDate>
2018-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-10-01
</xbrli:startDate>
<xbrli:endDate>
2018-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-11-02
</xbrli:startDate>
<xbrli:endDate>
2018-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-12-01
</xbrli:startDate>
<xbrli:endDate>
2018-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevE645<1Y:c444c555cT{h>F467F;I71GFH81898;1E98H1GEFF=:F9JF47 -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Agreements"><xbrli:measure>nmtc:Agreements</xbrli:measure></xbrli:unit>
<xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">NEUROONE MEDICAL TECHNOLOGIES Corp</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">0001500198</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">true</dei:AmendmentFlag>
<dei:TradingSymbol contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">NMTC</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">--09-30</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">10-KT</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">2018-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">2018</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
<dei:EntityWellKnownSeasonedIssuer contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">false</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">false</dei:EntityShellCompany>
<dei:EntityExTransitionPeriod contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">false</dei:EntityExTransitionPeriod>
<dei:EntityPublicFloat contextRef="Context_As_Of_29_Mar_2018T00_00_00_TO_29_Mar_2018T00_00_00" unitRef="USD" decimals="2">4452282.18</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_30_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00" unitRef="shares" decimals="0">9876505</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">522217</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">486418</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">486418</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">70029</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">26467</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">13260</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">7146</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">5378</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">33613</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">18638</us-gaap:AssetsCurrent>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">216372</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">200081</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">249985</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">218719</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">221235</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1021617</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1591022</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:ShortTermBorrowings contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">253000</us-gaap:ShortTermBorrowings>
<us-gaap:ShortTermBorrowings contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">283000</us-gaap:ShortTermBorrowings>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">2168340</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1393804</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">462174</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">308395</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">3905131</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">3797456</us-gaap:LiabilitiesCurrent>
<nmtc:WarrantsLiabilityNonCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1381465</nmtc:WarrantsLiabilityNonCurrent>
<nmtc:WarrantsLiabilityNonCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">817155</nmtc:WarrantsLiabilityNonCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">5286596</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">4614611</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">26878</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">7865</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">9657</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">280320</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">6052161</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-5324796</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-10457710</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-266220</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">31</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">119</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-266370</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-5036611</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">7865</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">280320</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-5324796</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-4395892</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">9657</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6052161</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-10457710</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">249985</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">218719</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_20_Oct_2016T00_00_00_TO_20_Oct_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">5131514</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="INF">9656505</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="INF">9656505</us-gaap:CommonStockSharesOutstanding>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1798131</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">2336988</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2676872</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">500408</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">735333</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">715086</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2298539</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">3072321</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">3391958</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-2298539</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-3072321</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-3391958</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-1057024</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-1395138</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-763065</us-gaap:InterestIncomeExpenseNet>
<nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-77505</nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative>
<nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-240053</nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative>
<nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">336596</nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-350914</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">303560</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">11143</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-1314487</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">8945</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-3433068</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-5058426</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-5058426</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-5132914</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-5132914</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.77</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="2">-0.61</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">6217076</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="0">6610072</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="0">8420529</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">5216565</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">7864994</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">9656505</us-gaap:SharesOutstanding>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2349937</nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1147</nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2348790</nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<nmtc:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1146311</nmtc:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2008796</nmtc:StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2008796</nmtc:StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability>
<nmtc:StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">824894</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">445</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">824449</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="shares" decimals="0">859976</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">445200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<nmtc:IssuanceOfWarrantsPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">288106</nmtc:IssuanceOfWarrantsPrivatePlacement>
<nmtc:IssuanceOfWarrantsPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<nmtc:IssuanceOfWarrantsPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">288106</nmtc:IssuanceOfWarrantsPrivatePlacement>
<nmtc:IssuanceOfWarrantsPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<nmtc:IssuanceCostsRelatedToPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-173067</nmtc:IssuanceCostsRelatedToPrivatePlacement>
<nmtc:IssuanceCostsRelatedToPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<nmtc:IssuanceCostsRelatedToPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-173067</nmtc:IssuanceCostsRelatedToPrivatePlacement>
<nmtc:IssuanceCostsRelatedToPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">469500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">200</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">469300</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">200000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">300</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">23415</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">860</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22555</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">1573000</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">859976</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">7220</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">215</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7005</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">215453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<nmtc:StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1573</nmtc:StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger>
<nmtc:StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1573</nmtc:StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger>
<nmtc:StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<nmtc:StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1573000</nmtc:StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger>
<nmtc:ParValueChangeInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:ParValueChangeInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">5186</nmtc:ParValueChangeInConnectionWithMerger>
<nmtc:ParValueChangeInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-5186</nmtc:ParValueChangeInConnectionWithMerger>
<nmtc:ParValueChangeInConnectionWithMerger contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">69574</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">69574</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">5467</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5467</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">61496</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">61496</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_3ME_01_Jul_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">12701</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">117280</nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">117280</nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<nmtc:AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">9050</nmtc:AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription>
<nmtc:AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<nmtc:AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9050</nmtc:AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription>
<nmtc:AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">13368</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">17633</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">16291</us-gaap:AdjustmentForAmortization>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">76794</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">76794</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">486120</us-gaap:ShareBasedCompensation>
<nmtc:ForgivenessOfSubscription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">9051</nmtc:ForgivenessOfSubscription>
<nmtc:ForgivenessOfSubscription contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">9050</nmtc:ForgivenessOfSubscription>
<nmtc:ForgivenessOfSubscription contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:NonCashInterestOnShortTermAndConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">76359</nmtc:NonCashInterestOnShortTermAndConvertiblePromissoryNotes>
<nmtc:NonCashInterestOnShortTermAndConvertiblePromissoryNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">115867</nmtc:NonCashInterestOnShortTermAndConvertiblePromissoryNotes>
<nmtc:NonCashInterestOnShortTermAndConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">152045</nmtc:NonCashInterestOnShortTermAndConvertiblePromissoryNotes>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">943427</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1242031</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">35479</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">611020</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">1748</us-gaap:AmortizationOfDebtDiscountPremium>
<nmtc:WarrantIssuanceCostsRelatedToDebtFinancing contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">38119</nmtc:WarrantIssuanceCostsRelatedToDebtFinancing>
<nmtc:WarrantIssuanceCostsRelatedToDebtFinancing contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">38119</nmtc:WarrantIssuanceCostsRelatedToDebtFinancing>
<nmtc:WarrantIssuanceCostsRelatedToDebtFinancing contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">90212</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-17962</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-371831</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-12707</nmtc:RevaluationOfWarrantLiability>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">258015</nmtc:RevaluationOfWarrantLiability>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">35235</nmtc:RevaluationOfWarrantLiability>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-46677</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-46677</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-1768</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">221235</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">642099</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">813215</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">437337</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-1509669</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-2108073</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-2229207</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">91709</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">55000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-91709</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-55000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">675705</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1004134</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">432849</us-gaap:ProceedsFromConvertibleDebt>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">440919</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">777490</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">442151</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">61496</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">61496</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00" unitRef="USD" decimals="0">1113000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">824894</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<nmtc:ProceedsFromIssuanceOfWarrantsWithPrivatePlacement contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:ProceedsFromIssuanceOfWarrantsWithPrivatePlacement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:ProceedsFromIssuanceOfWarrantsWithPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">288106</nmtc:ProceedsFromIssuanceOfWarrantsWithPrivatePlacement>
<us-gaap:ProceedsFromRepaymentsOfDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-50000</us-gaap:ProceedsFromRepaymentsOfDebt>
<us-gaap:ProceedsFromRepaymentsOfDebt contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-50000</us-gaap:ProceedsFromRepaymentsOfDebt>
<us-gaap:ProceedsFromRepaymentsOfDebt contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">283000</us-gaap:ProceedsFromRepaymentsOfDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">253000</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">253000</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-3030</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-3030</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsOfLoanCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">35689</us-gaap:PaymentsOfLoanCosts>
<us-gaap:PaymentsOfLoanCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">45468</us-gaap:PaymentsOfLoanCosts>
<us-gaap:PaymentsOfLoanCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:PaymentsRelatedToWarrantIssuanceCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">31920</nmtc:PaymentsRelatedToWarrantIssuanceCosts>
<nmtc:PaymentsRelatedToWarrantIssuanceCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">40590</nmtc:PaymentsRelatedToWarrantIssuanceCosts>
<nmtc:PaymentsRelatedToWarrantIssuanceCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1057481</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1704032</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2271000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-452188</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-495750</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">-13207</us-gaap:CashPeriodIncreaseDecrease>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">213961</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">342486</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">128525</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">168384</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">168384</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2063361</nmtc:ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">117280</nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">829378</nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications>
<nmtc:PurchasedIntangibleAssetsInAccruedLiabilities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:PurchasedIntangibleAssetsInAccruedLiabilities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">30000</nmtc:PurchasedIntangibleAssetsInAccruedLiabilities>
<nmtc:PurchasedIntangibleAssetsInAccruedLiabilities contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssued1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">23115</us-gaap:StockIssued1>
<us-gaap:StockIssued1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">23415</us-gaap:StockIssued1>
<us-gaap:StockIssued1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:AccruedIssuanceCostsRelatedToPrivatePlacement contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:AccruedIssuanceCostsRelatedToPrivatePlacement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:AccruedIssuanceCostsRelatedToPrivatePlacement contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">173067</nmtc:AccruedIssuanceCostsRelatedToPrivatePlacement>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">42811</nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">57037</nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2850</nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">38119</nmtc:AccruedIssuanceCostsAttributedToWarrantLiability>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">38119</nmtc:AccruedIssuanceCostsAttributedToWarrantLiability>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 1 - Organization and Nature of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;NeuroOne Medical Technologies Corporation (the &amp;#8220;Company&amp;#8221;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017, the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&amp;#8220;NeuroOne&amp;#8221;) in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &amp;#8220;Acquisition&amp;#8221;). The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical financial statements reflect the operations of NeuroOne for all periods presented prior to the date of Acquisition. NeuroOne was formed on October 7, 2016. The accompanying consolidated financial statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Subsequent to the Acquisition, the Company&amp;#8217;s operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&amp;#8217;s disease, essential tremors, and other brain related disorders.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology and is seeking regulatory clearances required to initiate commercial activities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company is based in Minnetonka, Minnesota effective December 1, 2018. The Company was previously based in Eden Prairie, Minnesota.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Acquisition of NeuroOne, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Acquisition was consummated on July 20, 2017 (the &amp;#8220;Closing&amp;#8221;) and, pursuant to the terms of the merger agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &amp;#8220;NeuroOne Shares&amp;#8221;), were exchanged for shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Company Shares&amp;#8221;), based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &amp;#8220;Exchange Ratio&amp;#8221;), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the merger agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&amp;#8217;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;All issued and outstanding common stock share amounts, options for common stock and per share amounts contained in the consolidated financial statements were retroactively adjusted to reflect the Exchange Ratio for all periods presented.&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 2 - Going Concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;/b&gt;The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $10,457,710 as of September 30, 2018. In the event the Company is unable to complete an equity round of financing resulting in more than $3 million in gross proceeds by December 31, 2018, the 2017 Convertible Notes and accrued interest thereon will become due. The Company does not have adequate liquidity to fund the repayment of the 2017 Convertible Notes if they become due on December 31, 2018 or to fund its operations throughout fiscal 2019 without raising additional funds. These factors raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this condition. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Through September 30, 2018, since inception, the Company has completed unsecured loan financings for gross proceeds of $283,000, a $253,000 short-term promissory note financing (which notes were amended and restated to become convertible promissory notes as described below), a $1,625,120 convertible promissory note financing and a second $1,540,000 convertible note promissory financing. In addition, the Company entered into a private placement transaction in July 2018 whereby $1,113,000 in gross proceeds were raised out of a planned $10.0 million maximum subscription amount (assuming the over-allotment option is not exercised) through September 30, 2018. The Company does not have adequate liquidity to fund its operations throughout fiscal 2019 without raising additional funds. Management intends to seek additional debt and/or equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company&amp;#8217;s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company&amp;#8217;s operations. If management is unable to obtain the necessary capital, it may have to cease operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 3 - Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Change in Fiscal Year&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America, In September 2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved a change in the Company&amp;#8217;s fiscal year end from December 31 to September 30. The Company&amp;#8217;s fiscal year now begins on October 1 and ends on September 30 of each year, starting on October 1, 2018. The required transition period of January 1, 2018 to September 30, 2018 is included in the consolidated financial statements. For comparative purposes, the unaudited consolidated statements of operations and consolidated statements of cash flows for the nine months ended September 30, 2017 are also presented.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Management&amp;#8217;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&amp;#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of
 September 30, 2018, the Company did not have any deposits in excess of federally insured amounts.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Common Stock Valuation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Due to the limited market liquidity for the Company&amp;#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&amp;#8217; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation&amp;#160;(the &amp;#8220;Practice Aid&amp;#8221;), to estimate the fair value of its common stock. The valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations may result in different fair values of common stock at each valuation date. Following is a summary of underlying assumptions used:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;Prior to the Acquisition&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the Acquisition on July 20, 2017, NeuroOne was a private company with no active public market for its common stock. Therefore, at the time, NeuroOne determined the fair value of its common stock using a contemporaneous valuation performed in accordance with the Practice Aid. Within this contemporaneous valuation performed by NeuroOne included the following significant factors:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;recent securities transactions;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify;
 font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;stage of development and business strategy;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;the likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;financial condition and operating results, including our projected results; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;financial condition and operating results of comparable publicly owned companies&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of NeuroOne&amp;#8217;s common stock prior to the Acquisition was determined during a period when there was limited data with regard to value indication other than convertible notes issued between November 2016 and June 2017. At the time, such convertible notes contained a $1.80 conversion cap, which was treated as an estimated price of preferred stock into which the notes would convert. A transaction backsolve was performed that equated the $1.5 million investment in the convertible notes with the resulting equity allocation to the hypothetical converted shares and warrants expected to be issued upon conversion. The resulting equity value was then used to infer the value of common stock within the same option-pricing framework. This scenario implicitly assumed 100% likelihood of a stock financing. In order to account for the possibility of dissolution, the transaction backsolve was used along with a dissolution scenario within a hybrid Probability Weighted Expected Return Method (&amp;#8220;PWERM&amp;#8221;). The scenarios were weighted 50/50, and a Discount For Lack of Marketability (&amp;#8220;DLOM&amp;#8221;) applied, to determine the valuation conclusion.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;Following the Acquisition&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new
 roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For valuations following the Acquisition, including the valuation of common stock on December 31, 2017, the Company estimated our enterprise value on a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public companies (&amp;#8220;GPC&amp;#8221;) for calendar year 2019 and 2020. The resulting equity value from the GPC method was allocated to common stock using the option pricing method, and a DLOM was applied. Based on the above methodology and weightings, the Company derived a valuation conclusion of $2.30 and $2.52 per share as of September 30, 2018 and December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The significant factors contributing to the increase in the fair value the Company&amp;#8217;s common stock following the Acquisition included the following:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The successful completion of the reverse merger;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Access to new capital as a public company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Improved revenue projections;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px;
 orphans:
 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Improved general economic conditions;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Additional issuance of convertible notes; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Important developments relating to achievement of our business objectives&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value the Company&amp;#8217;s common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has issued or are outstanding liabilities at the reporting date.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font:
 10pt/normal 'times
 new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of September 30, 2018 and December 31, 2017, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes of the Company were based on both the estimated fair value of our common stock of $2.30 and $2.52 as of September 30, 2018 and December 31, 2017, respectively, and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level&amp;#160;3 inputs. There were no transfers between fair value hierarchy levels during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial;
 text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of September&amp;#160;30,&amp;#160;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;817,155&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;817,155&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,125,550&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,125,550&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial;
 text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width:
 0px;
 text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&amp;#160;3 inputs for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to warrants in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;579,873&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;777,490&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;p style="margin: 0pt 0px;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,179,418&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;35,235&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;258,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;817,155&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,381,465&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Premium debt conversion derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning
 of
 period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,174&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in;"&gt;Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;218,052&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;342,486&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium debt conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(371,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(17,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2018, no milestones triggering possible impairment of the Company&amp;#8217;s long-lived assets have occurred.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times
 new
 roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Debt Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company issued warrants to purchase equity securities in connection with the issuance of convertible promissory notes (See Note 7&amp;#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&amp;#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle
 the
 warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Premium Debt Conversion Derivatives&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&amp;#160; The separated embedded derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statements of operations (See Note 7&amp;#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with regard to the convertible promissory notes.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&amp;#8217;s consolidated financial statements include, but are not limited to, a U.S federal corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the valuation allowance recorded to reflect the new federal corporate tax rates.&lt;/p&gt;&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#8217;s convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the nine month transition period ended September 30, 2018 and for the year ended December&amp;#160;31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,927,572&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;(1)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;(1)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; white-space:
 nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;&lt;div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, the FASB issued Accounting Standards Update (ASU) 2017-09,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Scope of Modification Accounting (ASU 2016-09)&lt;/i&gt;,&amp;#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the nine month transition period ended September 30, 2018. The adoption of this standard did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2017, the FASB issued ASU No. 2017-11,&amp;#160;&lt;i&gt;Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging&lt;/i&gt;, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&amp;#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In June 2018, the FASB issued ASU 2018-07,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt;&amp;#160;(ASU 2018-07),&amp;#160;which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should generally apply the requirements of Topic 718 to nonemployee awards except in circumstances where there is specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The guidance also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606&lt;i&gt;, Revenue from Contracts with Customers&amp;#160;&lt;/i&gt;(ASC 606)&lt;i&gt;.&lt;/i&gt;&amp;#160;This guidance is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted, but no earlier than an entity&amp;#8217;s adoption date of ASC 606. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In August 2018, the FASB issued ASU 2018-13,&amp;#160;&lt;i&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).&lt;/i&gt;&amp;#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&amp;#8217;s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date.&amp;#160;&lt;/font&gt;The Company is currently evaluating the impact of the new guidance on its financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 4 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;WARF License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 1, 2014, NeuroOne LLC (the &amp;#8220;LLC&amp;#8221;), NeuroOne&amp;#8217;s predecessor which was merged with and into NeuroOne on October 27, 2016 (the &amp;#8220;Merger&amp;#8221;), entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&amp;#8220;WARF&amp;#8221;) for WARF&amp;#8217;s neural probe array and thin film micro electrode technology (the &amp;#8220;2014 WARF Agreement&amp;#8221;). The license agreement required the LLC to make $110,000 in milestone payments depending on achievement of certain development and approval milestones or within twelve months of signing the 2014 WARF Agreement. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to WARF on a percentage of net sales of products of the licensed technology. Under the terms of the 2014 WARF Agreement, amounts that remained unpaid more than 30 days after they were due, accrued interest at 1 percent per month. Milestone payments due in 2015 were not made to WARF. From October 27, 2016 until the 2014 WARF Agreement was amended as described below, the LLC was in default under the 2014 WARF Agreement. In addition, the LLC was not able to transfer the rights and obligations under the 2014 WARF Agreement to NeuroOne at the time of the Merger without the consent of WARF, which was received when the 2014 WARF Agreement was amended in February 2017 as described below. In connection with the Merger and in accordance with ASC 805-50, NeuroOne estimated the fair value of consideration payable to WARF and recorded an intangible asset of $120,000 with a corresponding accrued expense.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;This agreement was subsequently amended in February 2017 (as so amended, the &amp;#8220;2017 WARF Agreement&amp;#8221;) whereby WARF consented to the transfer of the rights and obligations under the license agreement from the LLC to NeuroOne (which are now the Company&amp;#8217;s rights and obligations, following the Acquisition). In the 2017 WARF Agreement, the Company agreed to pay WARF $55,000 (representing a license fee) upon the earliest to occur of the date the Company cumulatively raises at least $3 million in financing, the date of a change of control, or the Company&amp;#8217;s revenue reaching a specified threshold amount. The Company met the milestone payment requirement with regard to the $55,000 license fee which was paid in April 2018. In addition, the Company agreed to pay $65,000 (representing reimbursement for costs incurred by WARF in maintaining the licensed patents) upon the earliest to occur of the date the Company cumulatively raises at least $5 million in financing, the date of a change of control, or the Company&amp;#8217;s revenue reaching a specified threshold amount. As of September 30, 2018, the Company has not met the requirements for the $65,000 milestone payment and this amount remains in accrued expenses.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company is also obligated to pay royalties to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the 2017 WARF Agreement. Subject to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a
 licensed patent to occur in 2030. The 2017 WARF Agreement is also subject to certain cancellation provisions with 90 days&amp;#8217; notice should the Company elect not to continue to use the licensed technology.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has agreed to diligently develop, manufacture, market and sell products under the WARF License in the United States during the term of the agreement and, specifically, that the Company would submit a business plan to WARF by February 1, 2018, which the Company submitted on January 18, 2018, and file an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the 2017 WARF Agreement in the event that the Company fails to meet these milestones on 30 days&amp;#8217; written notice, if the Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other covenant in the 2017 WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving the Company. WARF may also terminate this license (i) on 90 days&amp;#8217; notice if the Company fails to have commercial sales of one or more FDA-approved products under the 2017 WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Mayo Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 3, 2014, the LLC entered into an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&amp;#8220;Mayo&amp;#8221;) related to certain intellectual property and development services for thin film micro electrode technology (&amp;#8220;2014 Mayo Agreement&amp;#8221;). The LLC was to make milestone payments depending on achievement of certain development and approval milestones and sales targets, none of which were met as of December 31, 2015. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the 2014 Mayo Agreement, set to expire May 25, 2037. Also, the LLC was obligated to issue common stock to Mayo if certain events occurred. Upon the LLC&amp;#8217;s merger with NeuroOne on October 27, 2016, the rights under the 2014 Mayo Agreement transferred to NeuroOne, and certain milestones were attained. Therefore, NeuroOne recorded liabilities of $300 related to shares of common stock expected to be issued to Mayo and $91,709 for the intellectual property to be paid in cash. Under the terms of the 2014 Mayo Agreement, amounts that remained unpaid accrued interest at 2 percent above the prime rate. Milestone payments due in 2016 were not made to Mayo. As such, prior to the amendment of the 2014 Mayo Agreement in May 2017, NeuroOne was in default under the 2014 Mayo Agreement. Mayo and NeuroOne amended and restated the 2014 Mayo Agreement in May 2017 (as so amended and restated, the &amp;#8220;2017 Mayo Agreement&amp;#8221;). Pursuant to the 2017 Mayo Agreement, NeuroOne issued 859,976 shares of common stock (as converted based on the Exchange Ratio) to Mayo to settle the amount of common stock NeuroOne was previously obligated to issue under the 2014 Mayo Agreement and as provided by the terms of the 2017 Mayo Agreement. NeuroOne recorded an additional $23,115 to intangible assets related to the fair value of the 2017 stock issuance to Mayo. As a part of the 2017 Mayo Agreement, as amended in November 2017, the $91,709 milestone payment was paid in December 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Legal&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust:
 none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;From time to time, the Company is subject to litigation and claims arising in the ordinary course of business.&amp;#160; In May 2017, NeuroOne received a letter from PMT, the former employer of Mark Christianson and Wade Fredrickson.&amp;#160; PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer&amp;#8217;s prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with the contracts.&amp;#160; The letter demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne&amp;#8217;s systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March 29, 2018, the Company was served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&amp;#160; In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT&amp;#8217;s contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing.&amp;#160; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft.&amp;#160; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition.&amp;#160; PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&amp;#8217; fees, costs and interest.&amp;#160; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend themselves vigorously.&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The Company expects a ruling on the motion within 90 days of that date. The motion for dismissal states that: the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&amp;#8217;s claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The outcome and potential loss related to this matter is unknown as of September 30, 2018 and as of the issuance of these &amp;#160;financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 5 - Intangibles&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Intangible assets rollforward is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: justify;"&gt;Net Intangibles, December 31, 2016&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 173px; text-align: center;"&gt;12-13 years&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;180,890&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;License agreement amendment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;53,115&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(17,633&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify;"&gt;Net Intangibles, December 31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;216,372&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(16,291&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Net Intangibles, September 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;200,081&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company anticipates amortization expense of approximately $21,000 per year for fiscal year 2019 through 2023 based upon the two current license agreements.&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 6 - Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Accrued expenses consisted of the following at September 30, 2018 and December 31, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Accrued&amp;#160;license fees&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;65,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Legal costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;833,470&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;553,037&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Accrued issuance costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;204,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;28,083&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Accrued payroll&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;276,639&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;223,195&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Advances&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;211,913&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;47,302&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,591,022&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,021,617&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ShortTermDebtTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 7 - Short-Term Promissory Notes and Unsecured Loans&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Short-term promissory notes&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;253,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Unsecured loans&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;283,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Short-Term Promissory Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company issued short-term unsecured and interest-free promissory notes (the &amp;#8220;Short-Term Notes&amp;#8221;) for aggregate gross proceeds of $253,000 in August 2017 which included free standing equity warrants. The Short-Term Notes were subsequently amended in November 2017 and March 2018 to become convertible, extend the maturity date and include additional warrant coverage, new interest payment provisions and new conversion features described more fully below. Effective July 2, 2018, the Company entered into debt conversion agreements (the &amp;#8220;Short-Term Note Conversion Agreements&amp;#8221;) with each Short-Term Note subscriber to (i) convert the outstanding principal and accrued and unpaid interest (the &amp;#8220;Outstanding Balance&amp;#8221;) under the Short-Term Notes into shares of the Company&amp;#8217;s common stock based on the Outstanding Balance divided by $1.80 per share (the &amp;#8220;Short-Term Note Conversion Shares&amp;#8221;); (ii) cancel and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the &amp;#8220;Short-Term Note Payment Warrants&amp;#8221;), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The Short-Term Note Payment Warrants became exercisable commencing on July 2, 2018, and expire on November 21, 2021.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the Short-Term Note Conversion Agreements, $259,297 of the outstanding principal and interest of the Short-Term Notes was converted into 144,053 shares of common stock with an additional 477,856 shares issuable upon exercise of the Replacement Warrants, Additional Warrants and Short-Term Payment Warrants. The conversion of the Short Term Notes was accounted for as an extinguishment. The difference in the carrying value of the Short-Term Notes coupled with the fair value of the underlying Replacement Warrants and Additional Warrants on the date of extinguishment relative to the higher fair value of the underlying common stock and collective Replacement Warrants, Additional Warrants and new Short-Term Payment Warrants issued was $148,787. The $148,787 differential was recorded as a loss on note
 extinguishments in the accompanying consolidated
 statements of operations during the nine month transition period ended September 30, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Replacement Warrants, Additional Warrants and Short-Term Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the July 2, 2018 Short-Term Note Conversion Agreements. All of the warrant terms became fixed and have identical provisions. Due to the previously granted warrants now having fixed terms, the warrant liability value of $148,053 was reclassified to equity. The warrants associated with the Short-Term Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Short-Term Warrants. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Short-Term Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2017, the Company&amp;#8217;s Board of Directors (the &amp;#8220;Board&amp;#8221;) authorized, and the Company issued the Short-Term Notes for aggregate gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest expense over the original term of the Short-Term Notes up though November 2017. For the year ended December 31, 2017, discount amortization charged to interest expense related to the issuance costs was $1,748 through the November 30, 2017 amendment date as discussed further below.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On November 30, 2017, the Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (as amended, the &amp;#8220;Original Warrants&amp;#8221;). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017 amendment.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The November 30, 2017 amendment resulted in a substantial modification to the Short-Term Notes and was accounted for under the provisions of extinguishment accounting. A loss on note extinguishments in the accompanying statements of operations for the year ended December&amp;#160;31, 2017 was recorded in the amount of $144,577, which represented the difference between the face value of the Short-Term Notes over the combined carrying values of the Short-Term Notes and warrants on the date of the amendment. The fair value increase of the Short-Term Notes and the warrants as amended over its adjusted carrying value at the time of the amendment was $117,280 which was recorded as additional paid-in capital.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Prior to the November 30, 2017 amendment, the holders were to receive 126,500 common stock purchase warrants upon maturity. A portion of the proceeds from the Short-Term Notes upon issuance was allocated to the original warrants based on their relative fair value to the underlying Short-Term Notes in the amount of $61,496 and was recorded in additional paid-in
 capital in the accompanying consolidated balance sheets and was
 discounted from the Short-Term Notes and was being amortized to interest expense ratably over the term of the Short-Term Notes which amounted to $35,479 during the year ended December 31, 2017. The fair value of the warrants was based on the Black-Scholes method with the following assumptions: a risk-free interest rate of 2.1 percent; expected volatility of 47.8 percent; expected life of 5.7 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Short-Term Notes were subsequently amended and restated on March 12, 2018 (the &amp;#8220;Amended and Restated Short-Term Notes&amp;#8221;). The Amended and Restated Short-Term Notes became convertible promissory notes that had interest assessed at a fixed rate of 8% per annum and would have required the Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &amp;#8220;Short-Term Note Maturity Date&amp;#8221;). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement warrant (the &amp;#8220;Replacement Warrants&amp;#8221;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the Original Warrant. In addition, each holder was issued an additional warrant (the &amp;#8220;Additional Warrants&amp;#8221;).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Replacement Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Each Replacement Warrant issued on March 12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted in connection with a change of control transaction. The Replacement Warrants were exercisable commencing on the Conversion Date and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Replacement Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an offset to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Amended and Restated Short-Term Notes were recorded at each reporting date in the consolidated statements of operations which amounted to an expense of $10,330 for the nine month transition period ended September 30, 2018. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Replacement Warrants immediately prior to the July 2, 2018 Short-Term Note Conversion Agreement amendment. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 50 percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;"&gt;&lt;b&gt;&lt;i&gt;Additional Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman',
 times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Each Additional Warrant issued on March 12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants were exercisable commencing on the Conversion Date and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Additional Warrants were deemed to be free-standing instruments and were accounted for as equity as there were no variable terms. 189,750 shares of common stock were issuable upon exercise of the Additional Warrants as of the March 12, 2018 amendment date with terms that largely paralleled the provisions of the Original Warrants except that the Additional Warrants were exercisable on the Conversion Date as opposed to the Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. The fair value differential between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair value change was recorded as a reduction to additional paid-in capital in the accompanying condensed balance sheets and was included as part of the extinguishment loss discussed further below.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Premium Conversion Derivative&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Upon the March 2018 amendment, the Amended and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred at a price under $2.25 per share. The Company determined that the redemption feature under the Short-Term Notes qualified as an embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Short-Term Notes in the consolidated statements of operations for a benefit of $(49,668) for the nine month transition period ended September 30, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Other&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The March 2018 amendment resulted in a substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on note extinguishments in the accompanying consolidated statements of operations for the nine month transition period ended September 30, 2018 was recorded in the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes and Original Warrants over the combined fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion feature and the Additional Warrants) relative to its adjusted carrying
 value at the time of the amendment was $1,170 which was recorded as a reduction to additional paid-in
 capital on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Unsecured Loans&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 17, 2018, the Company received cash proceeds of $168,000 from unsecured loans, represented by two promissory notes from existing stockholders of the Company. The loans are interest free and require that the Company repay the principal in full on the earlier to occur of (i) May 17, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $5 million in gross proceeds. The loans include customary events of default provisions.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On March 20, 2018, the Company received cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan is interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes customary events of default provisions.&lt;/p&gt;&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 8 - Convertible Promissory Notes and Warrant Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2016 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,543,652&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2017 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,306,776&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;504,465&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;87,028&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;120,223&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 9pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,393,804&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,168,340&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2016 Convertible Promissory Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;From November 2016 to June 2017, the Company issued convertible promissory notes (the &amp;#8220;Convertible Notes&amp;#8221;) and common stock purchase warrants (the &amp;#8220;Warrants&amp;#8221;) in an aggregate principal amount of $1,625,120 and entered into subscription agreements with subscribers (the &amp;#8220;2016 Private Placement&amp;#8221;). Effective July 2, 2018, however, the Company entered into debt conversion agreements (the &amp;#8220;2016 Note Conversion Agreements&amp;#8221;) with each Convertible Note subscriber to (i) convert the Outstanding Balance under the Convertible Notes into shares of the Company&amp;#8217;s
 common stock based on the Outstanding Balance divided by $1.80 per share (the &amp;#8220;2016 Note Conversion Shares&amp;#8221;); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the &amp;#8220;2016 Note Payment Warrants&amp;#8221;), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The 2016 Note Payment Warrants became exercisable commencing on July 2, 2018 and expire on November 21, 2021.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the 2016 Note Conversion Agreements, $1,804,064 of the outstanding principal and interest of the 2016 Convertible Promissory Notes was converted into 1,002,258 shares of common stock and an additional 2,004,516 shares of common stock became issuable upon exercise of the Warrants and 2016 Note Payment Warrants. The conversion of the Convertible Notes was accounted for as an extinguishment. The difference in the carrying value of the Convertible Notes coupled with the fair value of the underlying Warrants upon conversion relative to the higher fair value of the underlying common stock and collective Warrants and new 2016 Note Payment Warrants issued was $979,480. The $979,480 differential total, inclusive of the unamortized discount remaining on the Convertible Notes of $11,143 as of July 2, 2018, was recorded as a loss on note extinguishments in the accompanying consolidated statement of operations during the nine month transition period ended September 30, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;The Warrants and 2016 Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the 2016 Note Conversion Agreements. All of the warrant terms became fixed and the terms were identical.&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Due to the previously granted warrants now having fixed terms, the adjusted warrant liability value of $1,031,366 was reclassified to equity. The warrants associated with the Convertible Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Convertible Notes. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. &amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Convertible Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company amended the Convertible Notes in December 2016 and November 2017 and the Warrants in June 2017 and November 2017 to, among other things, change the terms of the underlying Warrants that include the removal of down-round pricing protection provisions as described more fully below.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Convertible Notes were unsecured. The Convertible Notes accrued interest at a fixed rate of 8 percent per annum and required the Company to repay the principal and accrued and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &amp;#8220;Qualified Financing&amp;#8221;). If a Qualified Financing had occurred before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company failed to complete a Qualified Financing by July 31, 2018, the Convertible Notes would have been immediately due and payable on such date.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;If a change of control transaction or initial public offering occurred prior to a Qualified Financing, the Convertible Notes would have, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either been payable on demand as of the closing date of such transaction, or been convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of the per share value as determined by the Board as if in connection with the granting of stock-based compensation, or in a private sale to a third party in an arms-length transaction, or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&amp;#8217;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the June 2017 amendment, the Warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Notes held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the date of issuance and would have expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes. The amount of warrant shares to be issued became contingent and were based on the number of shares of common stock received by the holder of the Convertible Notes upon conversion of such holder&amp;#8217;s Convertible Notes, and at an exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants would have expired on November 21, 2021 in the event of a Qualified Financing or would have expired unissued if the notes were not converted.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the July 2018 Convertible Note extinguishment, the Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. For the December 31, 2017 liability valuation of the Warrants, a Monte Carlo simulation model was used to estimate the aggregate fair value. Input assumptions used were as follows: a risk-free interest rate of 2.08 percent; expected volatility of 50 percent; expected life of 3.89 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount
 methodologies. &amp;#160;The Convertible Note proceeds assigned to the Warrants were zero and $440,919 during the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively, which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount was amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximated the effective interest method and was fully amortized by December 31, 2017; the amortization expense recorded was $759,004 during the year ended December 31, 2017. The Company also recorded the fair value changes of the warrant liability associated with the Convertible Notes in the consolidated statements of operations which amounted to a benefit of $(14,865) and an expense of $259,352 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The November 2017 amendment resulted in a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated with the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of the Convertible Notes on the date of the modification. The $97,223 difference was recorded as a gain on note extinguishments in the accompanying statements of operations with an offsetting discount to the Convertible Notes. The discount was being amortized over the amended term of the Convertible Notes. The amortization recorded during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017 was $70,324 and $15,756, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes in the amount of zero and $213,961 during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively. The discount was being amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates the effective interest method and was fully amortized by December 31, 2017; the amortization expense recorded was $340,551 during the year ended December 31, 2017. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes in the consolidated statements of operations for a benefit of $(333,183) and $(18,428) for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &amp;#8220;placement agent warrant&amp;#8221;) which would have had an exercise price of $2.00 per share of common stock with a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant was issuable at the time the private placement transaction was fully subscribed. The placement agent warrant would have been immediately exercisable on the date of issuance and would have expired five years following the date of issuance. The Company recorded an issuance cost discount to the Convertible Notes in the amount of zero and $39,781 during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively, and was fully amortized by December 31, 2017; the amortization expense recorded as interest was $74,264 during the year ended December 31, 2017. The balance of the issuance costs in the amount of $38,119 was attributed to the Warrants and was immediately recorded as interest expense upon issuance during the year ended December 31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2017 Convertible Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 4, 2017, the Company initially entered into a subscription agreement with certain investors (the &amp;#8220;Subscribers&amp;#8221;), pursuant to which the Company, in a private placement (the &amp;#8220;Private Placement&amp;#8221;), agreed to issue and sell to the Subscribers 8% convertible promissory notes (the &amp;#8220;2017 Convertible Notes&amp;#8221;) and warrants (the &amp;#8220;New Warrants&amp;#8221;) to purchase shares of the Company&amp;#8217;s capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. The subscription agreement, the 2017 Convertible Notes and New Warrants were amended on December 14, 2017 to move up the maturity date of the 2017 Convertible Notes from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision of the 2017 Convertible Notes in the event of a qualified financing as described more fully below, to modify the exercise price of the New Warrants and to increase the authorized subscription amount to $1,500,000. In May 2018, the Board approved an increase in the authorized subscription amount from $1,500,000 to $2,000,000 and extended the offering period from the five month anniversary of the initial closing to the eight month anniversary of the initial closing. The initial closing of the Private Placement was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes in an aggregate principal amount of $1,540,000 to the Subscribers through June 2018 when the Private Placement expired.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The 2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the &amp;#8220;2017 Convertible Notes Maturity Date&amp;#8221;). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the &amp;#8220;2017 Convertible Notes Qualified Financing&amp;#8221;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The New Warrants also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price per share of the securities issued in the 2017 Convertible Notes Qualified Financing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial;
 text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Lastly, if a change of control transaction occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the shares of common stock as determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&amp;#8217;s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&amp;#8217;s assets. The New Warrants also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted in the change of control transaction.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The December 2017 amendment resulted in a substantial modification to the original 2017 Convertible Notes. The Company recorded the 2017 Convertible Note amendment under the provisions of extinguishment accounting. The fair value of the underlying Convertible Notes was $294,615 higher than the carrying value of the Convertible Notes net of unamortized debt discount on the date of the modification. The $294,615 difference as well as legal costs associated with the amendment in the amount of $8,945 were recorded as a loss on convertible notes extinguishments totaling $303,560 in the accompanying statements of operations for the year ended December&amp;#160;31, 2017. After the modification, there remained a debt discount of $27,371 of which $19,510 and $1,286 was amortized during the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The 2017 Convertible Notes contain a conversion discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $168,384 and $128,525 for the convertible debt issued during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $143,166 and $3,815 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense of $11,020 and $466 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The New Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants. Input assumptions used were as follows: a risk-free interest rate of 2.94 percent and 2.22 percent as of September 30, 2018
 and December 31, 2017, respectively; expected volatility of 50 percent as of September 30, 2018 and December 31, 2017; expected life of 5.21 years and 5.38 years as of September 30, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of September 30, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. The 2017 Convertible Note proceeds assigned to the New Warrants were $442,151 and $336,571 during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively, which represented their fair value at issuance and were discounted from the 2017 Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $375,076 and $9,971 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively. The Company also recorded the fair value changes of the warrant liability associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense of $39,770 and a benefit of $(1,337) for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In connection with the 2017 Convertible Notes, the Company incurred issuance costs in the amount of $8,133 which consisted of legal costs and was recorded as an issuance cost discount to the 2017 Convertible Notes, of which $2,944 and $157 was amortized to interest expense during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2017 Convertible Note Subscription Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the subscription agreements entered into in connection with the Private Placement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective subscription agreements.&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 9 - Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, stock-based services expense related to the stock options, restricted stock awards and stock-based award liabilities was included in general and administrative and research and development costs as follows in the accompanying statements of operations:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1175px; text-align: left; padding-left: 12pt;"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;480,653&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,065&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 12pt;"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;5,467&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,729&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total stock-based services expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;486,120&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;76,794&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;NeuroOne formally adopted an equity incentive plan (the &amp;#8220;2016 Plan&amp;#8221;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition. In addition, the Company adopted a 2017 Equity Incentive Plan (the &amp;#8220;2017
 Plan&amp;#8221;) on April 17, 2017. The 2016 and 2017 Plans provide
 for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards in the second quarter of 2017. During the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, 2,500 and 365,716 stock options were granted to directors and consultants at a weighted average exercise price of $5.34 and $0.035 per share, respectively. The stock options granted during the nine month transition period ended September 30, 2018 and during the year ended December 31, 2017 had a weighted average grant date fair value of $2.48 and $0.014 per share, respectively, with the vesting period ranging from several weeks upon grant to two months from grant. The options expire ten years from the date of grant. In addition, the Company issued 215,453 shares of restricted common stock at a grant date fair value of $0.034 with performance vesting conditions from the 2016 Plan during the year ended December 31, 2017. There were no restricted common stock awards issued out of the 2016 Plan or 2017 Plan during the nine month transition period ended September 30, 2018. All performance vesting conditions for the restricted common stock were met and there were no unvested shares as of September 30, 2018 and December 31, 2017. Compensation expense associated with restricted common stock was zero and $7,220 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table summarizes the Company&amp;#8217;s stock option plan activity for the nine month transition period ended September 30, 2018 and for the year ended December&amp;#160;31, 2017 as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Weighted-&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Aggregate&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Value(1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight:
 bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Outstanding at December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 815px;"&gt;Granted&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;0.03&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding at December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;9.3&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;908,920&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.34&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding at September 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;8.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;820,862&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Vested and exercisable at September&amp;#160;30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;8.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;820,862&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;&lt;div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018 and December 31, 2017 of $2.30 and $2.52 per share, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial; text-decoration-color: initial;"&gt;The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;49.8&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the nine month transition period ended September 30, 2018, 2,500 stock options vested, and the weighted average grant date fair value per option was $2.48. During the year ended December 31, 2017, 365,716 stock options and 215,453 restricted stock awards vested. The weighted average grant date fair value per share of common stock issuable upon exercise of options and of restricted stock awards vesting during the year ended December 31, 2017 was $0.014 and $0.034, respectively. No stock options were forfeited during the nine month transition period ended September 30, 2018 or during the year ended December 31, 2017. As of September 30, 2018, 1,708,596 shares were available for future issuance on a combined basis under the 2016 and 2017 Plans.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Other Stock-Based Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust:
 none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Up to 250,000 shares of common stock were reserved in February 2018 as a result of a consulting agreement for investor relations services executed in February 2018. Under the agreement, 200,000 shares of common stock were awarded during the nine month transactional period ended September 30, 2018. The shares were awarded based on a performance vesting condition that was met in February 2018 and a time-based vesting condition that was met in both May 2018 and August 2018. The compensation expense related to the vested common shares was included in the total stock-based services expense referenced above which totaled $469,500. The expense was based on the fair value of the underlying common stock at the point of vesting which was $2.52 per share for 100,000 shares that vested in February 2018, $2.30 per share for the 50,000 shares that vested in May 2018, and $2.05 per share for the 50,000 shares that vested in August 2018. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&amp;#160;The remaining 50,000 shares of the share commitment under the agreement vested in November 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Additionally, the Company recorded stock-based services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering, qualified financing, or December 31, 2018 (as amended from the originally stated June 30, 2018 date). The number of option shares under the agreement is based on a $3,000 monthly compensation amount divided by the fair value of the underlying common stock on the award date. The exercise price will also be set at the fair value of the underlying common stock on the award date. The liability associated with the unissued options was based on an option share equivalent estimate that reflects the portion of the award where performance vesting conditions have been met as of September 30, 2018 and was based on the fair value of the Company&amp;#8217;s common stock on September 30, 2018 as the award date has not occurred. The common stock fair value on September 30, 2018 was $2.30 per share and was determined based on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The stock-based services expense associated with the unissued stock options was $11,153 during the nine month transition period ended September 30, 2018 and is classified in accrued expenses at September 30, 2018. The liability for the unissued stock options was based on the following weighted-average assumptions using the Black-Scholes option-pricing model:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;49.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: right;"&gt;2.9&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Upon the issuance of all of the unissued options associated with the stock-based award liabilities, the estimated number of shares available for future issuance as of September 30, 2018 would be reduced from 1,708,596 to 1,698,161 shares as a result of the remaining stock options to be issued upon vesting under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018 consulting agreement are not eligible for issuance under either the 2016 Plan or 2017 Plan because the 2016 Plan and 2017 Plan limit plan participants to individuals.&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 10 - Stockholders&amp;#8217; Deficit&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Private Placement and Corresponding Issuance of Common Stock and Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;From July 9, 2018 through September 28, 2018, the Company entered into subscription agreements (each, a &amp;#8220;Purchase Agreement&amp;#8221;) with certain accredited investors (the &amp;#8220;Purchasers&amp;#8221;), pursuant to which the Company, in a private placement (the &amp;#8220;2018 Private Placement&amp;#8221;), agreed to issue and sell to the Purchasers units (each, a &amp;#8220;Unit&amp;#8221;), each consisting of (i) 1 share (each, a &amp;#8220;Share&amp;#8221;) of the Company&amp;#8217;s common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the &amp;#8220;2018 Warrants&amp;#8221;). The initial closing of the 2018 Private Placement was consummated on July 9, 2018. As of September 30, 2018, the Company has issued and sold an aggregate of 445,200 Units to the Purchasers, for total gross proceeds to the Company of approximately $1,113,000 before deducting offering expenses.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the 2018 Private Placement, the Company has agreed to issue and sell to accredited investors up to a maximum of 4,000,000 Units (the &amp;#8220;Maximum Offering&amp;#8221;) at a price of $2.50 per Unit for total gross proceeds to the Company of up to $10,000,000. If the 2018 Private Placement is over-subscribed, the Company may, in its discretion sell up to an additional 600,000 Units (the &amp;#8220;Over-Allotment&amp;#8221;) to cover such over subscriptions. If the Company issues the Maximum Offering amount, 4,000,000 shares of Common Stock (4,600,000 shares of Common Stock if the Over-Allotment is exercised) would be issuable upon exercise of the 2018 Warrants. The Company may conduct any number of additional closings so long as the final closing occurs on or before January 2, 2019. Under the Purchase Agreement, the Company has agreed to use the net proceeds from the 2018 Private Placement to pay the outstanding principal and accrued interest on its 2017 Convertible Notes if such notes do not convert prior to maturity, to pay the principal on its unsecured term loans, for research and development, clinical studies, legal fees and sales and marketing expenses, as well as working capital and general corporate purposes. The Company has granted the Purchasers indemnification rights with respect to its representations, warranties and agreements under the Purchase Agreement.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying consolidated balance sheets based on their relative fair value to the underlying common shares issued. The fair value of the 2018 Warrants issued was $318,759 and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of 2.82 percent; expected volatility of 49.8 percent; expected life of 4.91 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. &amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the 2018 Private Placement, the Company recorded issuance costs in the amount of $173,067 as of September 30, 2018. The issuance costs included commissions to the brokers equal to 10% of the gross proceeds from the sale of the Units that qualify for the commission and amounted to $83,800. In addition to the brokers&amp;#8217; commission, the issuance costs included the estimated value of the 5-year
 warrants
 to be issued to the brokers to purchase an amount of Common Stock equal to 10% of the total amount of qualifying Shares sold in the 2018 Private Placement at an exercise price of $3.45 per share upon the close of the 2018 Private Placement. A liability in the amount of $26,878 was recorded as of September 30, 2018 related to the broker warrants. Lastly, third party legal costs in the amount $62,389 comprised the balance of the issuance costs incurred as of September 30, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the 2018 Private Placement, the Company entered into registration rights agreements with each of the Purchasers pursuant to which the Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the 2018 Private Placement and the shares of Common Stock issuable upon exercise of the 2018 Warrants. The Company has agreed to file such registration statement within 75 days of the final closing of the 2018 Private Placement. Each registration rights agreement includes customary indemnification rights in connection with the registration statement.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Warrant Activity and Summary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following table summarizes warrant activity during the year ended December&amp;#160;31, 2017 and the nine month transition period ended September 30, 2018:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Per&lt;br /&gt;Warrant&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Exercise&lt;br /&gt;Price&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Outstanding at January&amp;#160;1, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 972px;"&gt;Issued&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 172px; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr
 style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Outstanding and exercisable at December&amp;#160;31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,737,822&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$1.80 - 3.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Outstanding and exercisable at September 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,927,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$1.80 - 3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.98&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following table summarizes information about warrants outstanding at September 30, 2018:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Number Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom:
 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom:
 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;Weighted Average Remaining Contractual life (Years)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Number Exercisable at September 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 361px; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 345px; text-align: right;"&gt;2,482,372&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 368.81px; text-align: center; padding-left: 5.4pt;"&gt;3.1&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 344px; text-align: right;"&gt;2,482,372&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;445,200&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt;"&gt;4.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;445,200&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,927,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 5.4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,927,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;The July 2017 Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the Acquisition of NeuroOne on July 20, 2017, the Company acquired 100% of NeuroOne shares in exchange for the issuance of Company shares and NeuroOne became the Company&amp;#8217;s wholly-owned subsidiary. Also, at the closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation 3,500,000 Company shares held by him as part of the conditions to closing resulting in a net exchange of 1,573,000 shares of common stock (see further details in Note 1 &amp;#8211; Organization and Nature of Operations).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;At the time of Acquisition, the Company had authorized 100,000,000 shares of common stock with a par value of $0.001 and 10,000,000 shares of preferred stock with a par value of $0.001.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Predecessor NeuroOne, Inc. Activity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color:
 #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On October 20, 2016, prior to the Merger with the LLC, NeuroOne issued 5,131,514 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) as founders&amp;#8217; shares to seven individuals. Three of those investors were officers of NeuroOne. NeuroOne recorded $9,050 of share subscription receivable for these stock issuances in 2016, which remained outstanding as of December 31, 2016. The shares were subscribed at value of $0.03 per share based on a valuation prepared by NeuroOne utilizing a weighted average market value of invested capital methodology. In June 2017, the purchase price owed by the seven individuals for the founders&amp;#8217; shares of NeuroOne under their respective subscription agreements totaling $9,050 was forgiven by NeuroOne prior to the Acquisition.&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;NOTE 11 - Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act (the TCJA), which significantly modified U.S. corporate income tax law, was signed into law by President Trump. The TCJA contains significant changes to corporate income taxation, including, but not limited to, the reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the deductibility of research and experimental expenditures that will be effective in the future).&amp;#160;Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform to the newly enacted federal tax law.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;The Company has recorded the adjustments in the consolidated financial statements in accordance with the TCJA and related guidance with a reduction of $420,000&amp;#160;to its net gross deferred tax assets in December 2017, the period in which the legislation was enacted. The reduction was fully offset by an equal reduction in the Company&amp;#8217;s valuation allowance given the Company&amp;#8217;s historical net losses, resulting in no net income tax expense being recorded.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;The effective tax rate for the Company for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017 was zero percent. A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statements of operations for the Company is as follows:&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Income tax benefit at federal statutory rate&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;(21.0&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;)%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align:
 right;"&gt;(34.0&lt;/td&gt;&lt;td
 style="width: 15px; text-align: left; white-space: nowrap;"&gt;)%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;State income tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6.5&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Warrant expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.4&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.6&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Disqualified interest and other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.9&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Research credits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1.5&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1.2&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;U.S. tax reform&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;19.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;21.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and liabilities are summarized in the tables below as of September 30, 2018 and December 31, 2017:&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Federal and state operating loss carryforwards&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width:
 142px; text-align: right;"&gt;1,837,375&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:
 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;871,371&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Acquired intangibles&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10,116&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,433&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73,763&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;64,151&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;p style="margin: 0pt 0px;"&gt;28,863&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;p style="margin: 0pt 0px;"&gt;81,904&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Research and development credit carryforwards&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;140,553&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;63,197&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;24,598&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;19,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,115,268&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,105,877&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(2,115,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(1,105,877&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;The deferred tax asset for the convertible notes and the valuation allowance at December 31, 2017 were misstated by $452,845 and have both been revised in the preceding table.&amp;#160; The effects of this revision also impacted the effective tax rate reconciliation by increasing the warrant expense percent by 10.6%, decreasing the U.S. tax reform percent by 3.8% and decreasing the valuation allowance percent by 6.8% for the year ended December 31, 2017. These immaterial adjustments to the 2017 disclosures had no impact on our net loss or reported net loss per share for the year ended December 31, 2017.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal;
 font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;
 font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;As of September 30, 2018 and December 31, 2017, the Company had gross deferred tax assets of approximately $2,115,000 and $1,106,000, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of approximately $2,115,000 and $1,106,000 as of September 30, 2018 and December 31, 2017, respectively. U.S. net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;As of September 30, 2018 and December 31, 2017, the Company&amp;#8217;s federal net operating loss carryforwards were approximately $6,393,000 and $3,032,000, respectively. The Company had federal research credit carryforwards as of September 30, 2018 and December&amp;#160;31, 2017 of approximately $83,000 and $36,000, respectively. The federal net operating loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating losses incurred after December 31, 2017 will not expire. As of September 30, 2018 and December&amp;#160;31, 2017, the Company had state net operating loss carryforwards of approximately $6,393,000 and $3,032,000, respectively. The Company had state research credit carryforwards of approximately $57,000 and $27,000 as of September 30, 2018 and December 31, 2017, respectively. The state net operating loss carryforwards will begin to expire in 2031, if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&amp;#160;382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &amp;#8220;5-percent shareholders&amp;#8221; increase their ownership, in the aggregate, by more than 50&amp;#160;percentage points over a 36-month time period testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In accordance with ASC 740,&amp;#160;&lt;i&gt;Income Taxes&amp;#160;&lt;/i&gt;(&amp;#8220;ASC 740&amp;#8221;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company believes its income tax filing positions and deductions will be sustained upon examination, and accordingly, no reserves or related accruals for interest and penalties have been recorded at September 30, 2018 and December 31, 2017.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In accordance with this guidance, the Company has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income
 taxes will be classified as a component of interest expense and any related penalties will be classified in operating expenses in the statements of operations.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif;
 font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;The Company&amp;#8217;s corporate returns are subject to examination for the 2016 and 2017 tax years for federal and subject to examination for the 2016 and 2017 tax years in one state jurisdiction.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 12 - Defined Contribution Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company adopted a 401(k) defined contribution plan (the &amp;#8220;401K Plan&amp;#8221;) on January 1, 2017, which was amended and restated on March 1, 2018 (the &amp;#8220;Restatement&amp;#8221;), for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company began matching in the fourth quarter of 2017 on deferrals at 100% of deferrals up to 3% of one&amp;#8217;s contributions and 50% on deferrals over 3%, but not exceeding 5% of one&amp;#8217;s contributions up through the Restatement. The Company&amp;#8217;s matching contributions to employee deferrals became discretionary after the Restatement. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through September 30, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee&amp;#8217;s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee&amp;#8217;s date of hire. The amount of matching contributions made during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017 was $7,779 and $27,000, respectively.&lt;/p&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;NOTE 13 - Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&lt;b&gt;&lt;i&gt;2018 Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;Between October 1, 2018 through November 30, 2018, the Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses. The additional Units have identical terms to the 2018 Private Placement disclosed in Note 10 &amp;#8211; Stockholders&amp;#8217; Deficit.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Unsecured Loans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In November 2018, the Company received cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from stockholders who each owned over 5% of the Company&amp;#8217;s common stock. The loans are interest free and require that we repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or November 14, 2019.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Advisory Board Stock Option Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0pt 0px; text-align: justify;"&gt;In November 2018 and December 2018 the Board of Directors approved for grant, to seven scientific advisory board members, a total of 175,000 stock options for the purchase of common stock. The options when issued will vest monthly over a three year period commencing January 1, 2019.&lt;/p&gt;&lt;p style="color: #000000; font-family:
 'times new
 roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Office Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;The Company leased a 5,196 square foot facility for use as its corporate headquarters location in Minnetonka, Minnesota effective December 1, 2018. The lease expires on October 31, 2019 and the monthly rent is $4,763.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<nmtc:BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Change in Fiscal Year&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America, In September 2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved a change in the Company&amp;#8217;s fiscal year end from December 31 to September 30. The Company&amp;#8217;s fiscal year now begins on October 1 and ends on September 30 of each year, starting on October 1, 2018. The required transition period of January 1, 2018 to September 30, 2018 is included in the consolidated financial statements. For comparative purposes, the unaudited consolidated statements of operations and consolidated statements of cash flows for the nine months ended September 30, 2017 are also presented.&lt;/p&gt;&lt;/div&gt;</nmtc:BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Management&amp;#8217;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:ConcentrationRiskCreditRisk contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&amp;#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30, 2018, the Company did not have any deposits in excess of federally insured amounts.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
<nmtc:CommonStockValuationPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Common Stock Valuation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Due to the limited market liquidity for the Company&amp;#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&amp;#8217; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation&amp;#160;(the &amp;#8220;Practice Aid&amp;#8221;), to estimate the fair value of its common stock. The valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations may result in different fair values of common stock at each valuation date. Following is a summary of underlying assumptions used:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;Prior to the Acquisition&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the Acquisition on July 20, 2017, NeuroOne was a private company with no active public market for its common stock. Therefore, at the time, NeuroOne determined the fair value of its common stock using a contemporaneous valuation performed in accordance with the Practice Aid. Within this contemporaneous valuation performed by NeuroOne included the following significant factors:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;recent securities transactions;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;stage of development and business strategy;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;the likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;financial condition and operating results, including our projected results; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;financial condition and operating results of comparable publicly owned companies&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of NeuroOne&amp;#8217;s common stock prior to the Acquisition was determined during a period when there was limited data with regard to value indication other than convertible notes issued between November 2016 and June 2017. At the time, such convertible notes contained a $1.80 conversion cap, which was treated as an estimated price of preferred stock into which the notes would convert. A transaction backsolve was performed that equated the $1.5 million investment in the convertible notes with the resulting equity allocation to the hypothetical converted shares and warrants expected to be issued upon conversion. The resulting equity value was then used to infer the value of common stock within the same option-pricing framework. This scenario implicitly assumed 100% likelihood of a stock financing. In order to account for the possibility of dissolution, the transaction backsolve was used along with a dissolution scenario within a hybrid Probability Weighted Expected Return Method (&amp;#8220;PWERM&amp;#8221;). The scenarios were weighted 50/50, and a Discount For Lack of Marketability (&amp;#8220;DLOM&amp;#8221;) applied, to determine the valuation conclusion.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;Following the Acquisition&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For valuations following the Acquisition, including the valuation of common stock on December 31, 2017, the Company estimated our enterprise value on a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public companies (&amp;#8220;GPC&amp;#8221;) for calendar year 2019 and 2020. The resulting equity value from the GPC method was allocated to common stock using the option pricing method, and a DLOM was applied. Based on the above methodology and weightings, the Company derived a valuation conclusion of $2.30 and $2.52 per share as of September 30, 2018 and December 31, 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The significant factors contributing to the increase in the fair value the Company&amp;#8217;s common stock following the Acquisition included the following:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The successful completion of the reverse merger;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Access to new capital as a public company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Improved revenue projections;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri,
 helvetica,
 sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Improved general economic conditions;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Additional issuance of convertible notes; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Important developments relating to achievement of our business objectives&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value the Company&amp;#8217;s common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has issued or are outstanding liabilities at the reporting date.&lt;/p&gt;&lt;/div&gt;</nmtc:CommonStockValuationPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of September 30, 2018 and December 31, 2017, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes of the Company were based on both the estimated fair value of our common stock of $2.30 and $2.52 as of September 30, 2018 and December 31, 2017, respectively, and cash
 flow
 models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level&amp;#160;3 inputs. There were no transfers between fair value hierarchy levels during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of September&amp;#160;30,&amp;#160;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;817,155&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;817,155&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color:
 black;
 border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,125,550&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,125,550&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color:
 black;
 border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&amp;#160;3 inputs for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to warrants in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;579,873&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;777,490&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;p style="margin: 0pt 0px;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,179,418&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;35,235&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;258,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;817,155&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt;
 border-bottom-style: double;"&gt;1,381,465&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Premium debt conversion derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,174&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in;"&gt;Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;218,052&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;342,486&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium debt conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(371,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(17,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<nmtc:IntellectualPropertyPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.&lt;/p&gt;&lt;/div&gt;</nmtc:IntellectualPropertyPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2018, no milestones triggering possible impairment of the Company&amp;#8217;s long-lived assets have occurred.&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DebtPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Debt Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<nmtc:WarrantLiabilityPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company issued warrants to purchase equity securities in connection with the issuance of convertible promissory notes (See Note 7&amp;#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&amp;#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;</nmtc:WarrantLiabilityPolicyTextBlock>
<nmtc:PremiumDebtConversionDerivativePolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Premium Debt Conversion Derivatives&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&amp;#160; The separated embedded derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statements of operations (See Note 7&amp;#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with regard to the convertible promissory notes.&lt;/p&gt;&lt;/div&gt;</nmtc:PremiumDebtConversionDerivativePolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&amp;#8217;s consolidated financial statements include, but are not limited to, a U.S federal corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the valuation allowance recorded to reflect the new federal corporate tax rates.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#8217;s convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the nine month transition period ended September 30, 2018 and for the year ended December&amp;#160;31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,927,572&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;(1)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;(1)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;&lt;div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, the FASB issued Accounting Standards Update (ASU) 2017-09,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Scope of Modification Accounting (ASU 2016-09)&lt;/i&gt;,&amp;#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the nine month transition period ended September 30, 2018. The adoption of this standard did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2017, the FASB issued ASU No. 2017-11,&amp;#160;&lt;i&gt;Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging&lt;/i&gt;, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&amp;#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In June 2018, the FASB issued ASU 2018-07,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt;&amp;#160;(ASU 2018-07),&amp;#160;which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should generally apply the requirements of Topic 718 to nonemployee awards except in circumstances where there is specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The guidance also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606&lt;i&gt;, Revenue from Contracts with Customers&amp;#160;&lt;/i&gt;(ASC 606)&lt;i&gt;.&lt;/i&gt;&amp;#160;This guidance is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted, but no earlier than an entity&amp;#8217;s adoption date of ASC 606. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In August 2018, the FASB issued ASU 2018-13,&amp;#160;&lt;i&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).&lt;/i&gt;&amp;#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&amp;#8217;s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date.&amp;#160;&lt;/font&gt;The Company is currently evaluating the impact of the new guidance on its financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<nmtc:SummaryOfWarrantActivityTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Per&lt;br /&gt;Warrant&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Exercise&lt;br /&gt;Price&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Outstanding at January&amp;#160;1, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 972px;"&gt;Issued&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 172px; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Outstanding and exercisable at December&amp;#160;31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,737,822&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$1.80 - 3.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Outstanding and exercisable at September 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,927,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$1.80 - 3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.98&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nmtc:SummaryOfWarrantActivityTableTextBlock>
<nmtc:SummaryInformationAboutWarrantsOutstandingTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Number Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;Weighted Average Remaining Contractual life (Years)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;Number Exercisable at September 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 361px; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 345px; text-align: right;"&gt;2,482,372&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 368.81px; text-align: center; padding-left: 5.4pt;"&gt;3.1&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 344px; text-align: right;"&gt;2,482,372&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;445,200&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt;"&gt;4.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;445,200&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,927,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 5.4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,927,572&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nmtc:SummaryInformationAboutWarrantsOutstandingTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of September&amp;#160;30,&amp;#160;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;817,155&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;817,155&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,125,550&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,125,550&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to warrants in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;579,873&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;777,490&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&lt;p style="margin: 0pt 0px;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,179,418&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;35,235&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;258,015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;817,155&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,381,465&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Premium debt conversion derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,174&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td
 style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in;"&gt;Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;218,052&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;342,486&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium debt conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(371,831&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(17,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;308,395&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,927,572&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;(1)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;(1)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;&lt;div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: justify;"&gt;Net Intangibles, December 31, 2016&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 173px; text-align: center;"&gt;12-13 years&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;180,890&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;License agreement amendment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;53,115&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(17,633&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify;"&gt;Net Intangibles, December 31, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;216,372&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(16,291&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Net Intangibles, September 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;200,081&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Accrued&amp;#160;license fees&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;65,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Legal costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;833,470&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;553,037&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Accrued issuance costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;204,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;28,083&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Accrued payroll&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;276,639&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;223,195&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Advances&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;211,913&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;47,302&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,591,022&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,021,617&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfDebtTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Short-term promissory notes&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;253,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;Unsecured loans&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;283,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
<us-gaap:ConvertibleDebtTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2016 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,543,652&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2017 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,306,776&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;504,465&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;87,028&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;120,223&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 9pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,393,804&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,168,340&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1175px; text-align: left; padding-left: 12pt;"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;480,653&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,065&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 12pt;"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;5,467&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,729&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total stock-based services expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;486,120&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;76,794&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;49.8&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;49.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.9&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Weighted-&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Aggregate&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Value(1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Outstanding at December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 815px;"&gt;Granted&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;0.03&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding at December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;9.3&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;908,920&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.34&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Outstanding at September 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;8.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;820,862&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Vested and exercisable at September&amp;#160;30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;368,216&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 4pt;"&gt;8.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;820,862&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;&lt;div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018 and December 31, 2017 of $2.30 and $2.52 per share, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Income tax benefit at federal statutory rate&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(21.0&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;)%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(34.0&lt;/td&gt;&lt;td style="width: 16px; text-align: left; white-space: nowrap;"&gt;)%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;State income tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6.5&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Warrant expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.4&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.6&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Disqualified interest and other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.9&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Research credits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1.5&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1.2&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;U.S. tax reform&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;19.8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;21.9&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Federal and state operating loss carryforwards&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,837,375&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;871,371&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Acquired intangibles&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10,116&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,433&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73,763&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;64,151&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;p style="margin: 0pt 0px;"&gt;28,863&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;p style="margin: 0pt 0px;"&gt;81,904&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Research and development credit carryforwards&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;140,553&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;63,197&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;24,598&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;19,821&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,115,268&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,105,877&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(2,115,268&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,105,877&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00" unitRef="pure" decimals="2">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="2">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
<us-gaap:ConversionOfStockDescription contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware.</us-gaap:ConversionOfStockDescription>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:SharesIssuedPricePerShare>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="7">17.0103706</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00" unitRef="shares" decimals="INF">3500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">6291994</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">365716</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">215453</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">992265</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">365716</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00" unitRef="shares" decimals="INF">250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">2292265</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">2500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_RangeAxis_MaximumMember_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember" unitRef="shares" decimals="INF">1708596</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_RangeAxis_MinimumMember" unitRef="shares" decimals="INF">1698161</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_Custom_04_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">3500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">283000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_14_Nov_2018T00_00_00_TO_14_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">100000</us-gaap:UnsecuredDebt>
<nmtc:BankLoansAndNotesPayable contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">253000</nmtc:BankLoansAndNotesPayable>
<us-gaap:LongtermCommercialPaperCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1625120</us-gaap:LongtermCommercialPaperCurrentAndNoncurrent>
<nmtc:ConvertibleNotesPayableOne contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1540000</nmtc:ConvertibleNotesPayableOne>
<nmtc:MaximumSubscriptionAmount contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00" unitRef="USD" decimals="-5">10000000</nmtc:MaximumSubscriptionAmount>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="-5">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1381465</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1381465</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<nmtc:WarrantLiability contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">817155</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">148053</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">817155</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:WarrantLiability contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">462174</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">462174</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">308395</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">308395</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1843639</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1843639</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1125550</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1125550</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">345960</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1381465</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">817155</us-gaap:WarrantsAndRightsOutstanding>
<nmtc:ProceedsAndValueAssignedToWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">777490</nmtc:ProceedsAndValueAssignedToWarrants>
<nmtc:ProceedsAndValueAssignedToWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">579873</nmtc:ProceedsAndValueAssignedToWarrants>
<nmtc:ReclassificationToEquity contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true"/>
<nmtc:ReclassificationToEquity contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">-1179418</nmtc:ReclassificationToEquity>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">258015</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">259352</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">-1337</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">10330</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">35235</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">-14865</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">39770</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember" unitRef="USD" decimals="0">-49668</us-gaap:FairValueAdjustmentOfWarrants>
<nmtc:PremiumDebtConversionDerivative contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">137650</nmtc:PremiumDebtConversionDerivative>
<nmtc:PremiumDebtConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">462174</nmtc:PremiumDebtConversionDerivative>
<nmtc:PremiumDebtConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">462174</nmtc:PremiumDebtConversionDerivative>
<nmtc:PremiumDebtConversionDerivative contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">328609</nmtc:PremiumDebtConversionDerivative>
<nmtc:PremiumDebtConversionDerivative contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">308395</nmtc:PremiumDebtConversionDerivative>
<nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">342486</nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes>
<nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">218052</nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes>
<nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">-17962</nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition>
<nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">-371831</nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">365716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF" id="Item_1">189750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">368216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF" id="Item_3">2927572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="2">2.52</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.30</us-gaap:SharePrice>
<nmtc:AdditionalPotentialWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="-6">3000000</nmtc:AdditionalPotentialWarrants>
<nmtc:NumberOfLicencingAgreements contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="Agreements" decimals="INF">2</nmtc:NumberOfLicencingAgreements>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:DebtInstrumentConvertibleStockPriceTrigger contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="2">1.80</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
<us-gaap:ConvertibleDebt contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="-5">1500000</us-gaap:ConvertibleDebt>
<us-gaap:LongTermPurchaseCommitmentAmount contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">110000</us-gaap:LongTermPurchaseCommitmentAmount>
<us-gaap:LongTermPurchaseCommitmentAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">55000</us-gaap:LongTermPurchaseCommitmentAmount>
<us-gaap:LongTermPurchaseCommitmentAmount contextRef="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">55000</us-gaap:LongTermPurchaseCommitmentAmount>
<us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="Context_As_Of_27_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">120000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
<nmtc:CummulativeFinancingTriggersPayment contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="-5">3000000</nmtc:CummulativeFinancingTriggersPayment>
<us-gaap:OtherCommitmentDueInThirdYear contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">50000</us-gaap:OtherCommitmentDueInThirdYear>
<us-gaap:OtherCommitmentDueInFourthYear contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">100000</us-gaap:OtherCommitmentDueInFourthYear>
<nmtc:OtherCommitmentDueAfterFourthYear contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">150000</nmtc:OtherCommitmentDueAfterFourthYear>
<us-gaap:DebtInstrumentIssuanceDate1 contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">2037-05-25</us-gaap:DebtInstrumentIssuanceDate1>
<us-gaap:DebtInstrumentIssuanceDate1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">2030-12-31</us-gaap:DebtInstrumentIssuanceDate1>
<nmtc:CostIncurredMaintainingLicensedPatents contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">65000</nmtc:CostIncurredMaintainingLicensedPatents>
<nmtc:CummulativeFinancingTriggersPayment1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="-5">5000000</nmtc:CummulativeFinancingTriggersPayment1>
<nmtc:AmountRecordedForIntellectualProperty contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">91709</nmtc:AmountRecordedForIntellectualProperty>
<us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">91709</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">65000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
<nmtc:PercentageOfAccruedInterest contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="pure" decimals="2">0.01</nmtc:PercentageOfAccruedInterest>
<nmtc:PercentageOfAccruedInterest contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="pure" decimals="2">0.02</nmtc:PercentageOfAccruedInterest>
<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">23115</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_RangeAxis_MinimumMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_RangeAxis_MaximumMember">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">180890</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">216372</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">200081</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedLicenseAgreementsGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">53115</us-gaap:FiniteLivedLicenseAgreementsGross>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">17633</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">16291</us-gaap:AmortizationOfIntangibleAssets>
<nmtc:AmortizationExpenseDescription contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">Approximately $21,000 per year for fiscal year 2019 through 2023 based upon the two current license agreements.</nmtc:AmortizationExpenseDescription>
<nmtc:AccruedLicenseFees contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">120000</nmtc:AccruedLicenseFees>
<nmtc:AccruedLicenseFees contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">65000</nmtc:AccruedLicenseFees>
<nmtc:AccruedLegalCosts contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">553037</nmtc:AccruedLegalCosts>
<nmtc:AccruedLegalCosts contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">833470</nmtc:AccruedLegalCosts>
<nmtc:AccruedLegalCosts contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">62389</nmtc:AccruedLegalCosts>
<nmtc:AccruedIssuanceCosts contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">28083</nmtc:AccruedIssuanceCosts>
<nmtc:AccruedIssuanceCosts contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">204000</nmtc:AccruedIssuanceCosts>
<nmtc:AccruedPayroll contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">223195</nmtc:AccruedPayroll>
<nmtc:AccruedPayroll contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">276639</nmtc:AccruedPayroll>
<nmtc:AccruedExpensesAdvances contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">50000</nmtc:AccruedExpensesAdvances>
<nmtc:AccruedExpensesAdvances contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">47302</us-gaap:OtherAccruedLiabilitiesNoncurrent>
<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">211913</us-gaap:OtherAccruedLiabilitiesNoncurrent>
<nmtc:BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">253000</nmtc:BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable>
<nmtc:BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:UnsecuredDebtCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:UnsecuredDebtCurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">283000</us-gaap:UnsecuredDebtCurrent>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">3030</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:ShortTermDebtDescription contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">(i) convert the outstanding principal and accrued and unpaid interest (the "Outstanding Balance") under the Short-Term Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "Short-Term Note Conversion Shares"); (ii) cancel and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the "Short-Term Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share.</us-gaap:ShortTermDebtDescription>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">2019-03-20</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_May_2018T00_00_00_TO_17_May_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">2019-05-17</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">2018-07-31</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="shares" decimals="INF">144053</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="shares" decimals="INF">1002258</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="shares" decimals="INF">477856</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<nmtc:ShortTermPaymentWarrants contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">61496</nmtc:ShortTermPaymentWarrants>
<nmtc:ShortTermPaymentWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">148787</nmtc:ShortTermPaymentWarrants>
<nmtc:CommonStockPurchaseOfWarrants contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="shares" decimals="INF">126500</nmtc:CommonStockPurchaseOfWarrants>
<nmtc:WarrantsMaturityTerm contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">P5Y</nmtc:WarrantsMaturityTerm>
<nmtc:ValueOfPremiumConversionDerivative contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember" unitRef="USD" decimals="0">49668</nmtc:ValueOfPremiumConversionDerivative>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="pure" decimals="3">0.021</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="4">0.0208</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="4">0.0222</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="4">0.0265</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="4">0.0265</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="4">0.0265</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="4">0.0294</nmtc:FairValueAssumptionRiskFreeInterestRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="pure" decimals="3">0.478</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.50</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.50</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="3">0.498</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="2">0.50</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="3">0.498</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.50</nmtc:FairValueAssumptionExpectedVolatilityRate>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">P5Y8M12D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">P3Y10M21D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">P5Y4M17D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">P3Y4M20D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">P3Y4M20D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">P3Y4M20D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedTerm contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">P5Y2M16D</nmtc:FairValueAssumptionExpectedTerm>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:FairValueAssumptionExpectedDividendRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.00</nmtc:FairValueAssumptionExpectedDividendRate>
<nmtc:AdditionalWarrantsAllocated contextRef="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="INF">189750</nmtc:AdditionalWarrantsAllocated>
<nmtc:WarrantsExpirationDate contextRef="Context_Custom_03_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00">2021-11-21</nmtc:WarrantsExpirationDate>
<nmtc:WarrantsExpirationDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">2021-11-21</nmtc:WarrantsExpirationDate>
<nmtc:LossOnShortTermNotesExtinguishment contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">144577</nmtc:LossOnShortTermNotesExtinguishment>
<nmtc:LossOnShortTermNotesExtinguishment contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">137722</nmtc:LossOnShortTermNotesExtinguishment>
<nmtc:LossOnShortTermNotesExtinguishment contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">148787</nmtc:LossOnShortTermNotesExtinguishment>
<nmtc:LossOnShortTermNotesExtinguishment contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_OtherDebtMember" unitRef="USD" decimals="0">186220</nmtc:LossOnShortTermNotesExtinguishment>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">1625120</us-gaap:DebtInstrumentAnnualPrincipalPayment>
<us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">1804064</us-gaap:DebtInstrumentAnnualPrincipalPayment>
<us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">259297</us-gaap:DebtInstrumentAnnualPrincipalPayment>
<us-gaap:DebtConversionDescription contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember">The Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (as amended, the "Original Warrants"). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017 amendment.</us-gaap:DebtConversionDescription>
<us-gaap:DebtConversionDescription contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember">The Amended and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred at a price under $2.25 per share.</us-gaap:DebtConversionDescription>
<us-gaap:OtherLiabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00" unitRef="USD" decimals="-6">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="0">115000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_Custom_01_May_2018T00_00_00_TO_17_May_2018T00_00_00" unitRef="USD" decimals="-6">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_Custom_01_May_2018T00_00_00_TO_17_May_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="0">168000</us-gaap:ProceedsFromIssuanceOfDebt>
<nmtc:WarrantsExercisableDescription contextRef="Context_Custom_03_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00">The holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80.</nmtc:WarrantsExercisableDescription>
<nmtc:AdjustmentToAccountForChangeInValuation contextRef="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00" unitRef="USD" decimals="0">22624</nmtc:AdjustmentToAccountForChangeInValuation>
<nmtc:AdjustmentToAccountForChangeInValuation contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ExtinguishmentOfDebtAxis_OtherDebtMember" unitRef="USD" decimals="0">1170</nmtc:AdjustmentToAccountForChangeInValuation>
<nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes contextRef="Context_Custom_16_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ExtinguishmentOfDebtAxis_CancellationExtinguishmentAndConversionOfShortTermNotesMember" unitRef="USD" decimals="0">117280</nmtc:IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes>
<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">120223</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">87028</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">2168340</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="0">1543652</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember" unitRef="USD" decimals="0">504465</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1393804</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember" unitRef="USD" decimals="0">1306776</us-gaap:ConvertibleNotesPayable>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="pure" decimals="2">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">Pursuant to which the Company, in a private placement (the "Private Placement"), agreed to issue and sell to the Subscribers 8% convertible promissory notes (the "2017 Convertible Notes") and warrants (the "New Warrants") to purchase shares of the Company's capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. The subscription agreement, the 2017 Convertible Notes and New Warrants were amended on December 14, 2017 to move up the maturity date of the 2017 Convertible Notes from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision of the 2017 Convertible Notes in the event of a qualified financing as described more fully below, to modify the exercise price of the New Warrants and to increase the authorized subscription amount to $1,500,000. In May 2018, the Board approved an increase in the authorized subscription amount from $1,500,000 to $2,000,000 and extended the offering period from the five month anniversary of the initial closing to the eight month anniversary of the initial closing. The initial closing of the Private Placement was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes in an aggregate principal amount of $1,540,000 to the Subscribers through June 2018 when the Private Placement expired.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">The Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the "2017 Convertible Notes Maturity Date"). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the "2017 Convertible Notes Qualified Financing"), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:DebtInstrumentInterestRateTerms contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">If a Qualified Financing had occurred before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company failed to complete a Qualified Financing by July 31, 2018, the Convertible Notes would have been immediately due and payable on such date.</us-gaap:DebtInstrumentInterestRateTerms>
<nmtc:DescriptionOfMaximumVotingPowerOfSurvivingEntity contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</nmtc:DescriptionOfMaximumVotingPowerOfSurvivingEntity>
<nmtc:AmountOfConvertibleNoteHeldByWarrantHolder contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="2">1.80</nmtc:AmountOfConvertibleNoteHeldByWarrantHolder>
<us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">2021-11-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">440919</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">336571</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">0</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">442151</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">340551</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">759004</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">15756</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">74264</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">1286</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">9971</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">3815</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">70324</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">19510</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">375076</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">143166</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:DebtConversionConvertedInstrumentRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">1.25</us-gaap:DebtConversionConvertedInstrumentRate>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_Custom_11_Nov_2017T00_00_00_TO_20_Nov_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">97223</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">213961</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">39781</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">27371</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">157</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">0</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">0</nmtc:AmortizationOfDiscountToConvertibleNotes>
<nmtc:AmortizationOfDiscountToConvertibleNotes contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">2944</nmtc:AmortizationOfDiscountToConvertibleNotes>
<us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">8133</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
<us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">173067</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
<us-gaap:DebtInstrumentFee contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.</us-gaap:DebtInstrumentFee>
<us-gaap:DebtInstrumentFee contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the "placement agent warrant") which would have had an exercise price of $2.00 per share of common stock with a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450.</us-gaap:DebtInstrumentFee>
<nmtc:PercentageOfCommonStockPurchaseWarrants contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="pure" decimals="2">0.80</nmtc:PercentageOfCommonStockPurchaseWarrants>
<nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">38119</nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_20_Nov_2017T00_00_00_TO_20_Nov_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">97223</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">294615</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">979480</us-gaap:DebtInstrumentUnamortizedDiscount>
<nmtc:ConvertibleNotesMaximumExtensionLimit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">1500000</nmtc:ConvertibleNotesMaximumExtensionLimit>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">-18428</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">466</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">-333183</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">11020</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<us-gaap:DebtInstrumentDescription contextRef="Context_Custom_15_Jun_2018T00_00_00_TO_02_Jul_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">(i) convert the Outstanding Balance under the Convertible Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "2016 Note Conversion Shares"); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the "2016 Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share.</us-gaap:DebtInstrumentDescription>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="shares" decimals="INF">2004516</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<nmtc:DebtConversionConvertedNotePaymentWarrantsIssued contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">979480</nmtc:DebtConversionConvertedNotePaymentWarrantsIssued>
<nmtc:WarrantLiabilityValueOfReclassifiedToEquity contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">1031366</nmtc:WarrantLiabilityValueOfReclassifiedToEquity>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">76794</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">2065</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">74729</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">486120</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">480653</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">5467</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" decimals="INF">365716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" decimals="INF">368216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OneExercisePriceMember" unitRef="shares" decimals="INF">2482372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ThreeExercisePriceMember" unitRef="shares" decimals="INF">445200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" decimals="0">365716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" decimals="INF">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_02_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2927572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="shares" decimals="INF">368216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OneExercisePriceMember" unitRef="shares" decimals="INF">2482372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ThreeExercisePriceMember" unitRef="shares" decimals="INF">445200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" decimals="2">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" decimals="2">0.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="3">0.035</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" decimals="2">5.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="2">5.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OneExercisePriceMember" unitRef="USD_per_Share" decimals="2">1.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ThreeExercisePriceMember" unitRef="USD_per_Share" decimals="2">3.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" decimals="2">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">P9Y3M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OneExercisePriceMember">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ThreeExercisePriceMember">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD" xsi:nil="true" id="Item_4"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD" decimals="0" id="Item_6">908920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD" decimals="0" id="Item_7">820862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true" id="Item_8"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true" id="Item_9"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD" xsi:nil="true" id="Item_10"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD" xsi:nil="true" id="Item_11"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true" id="Item_12"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD_per_Share" xsi:nil="true" id="Item_13"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_OptionIndexedToIssuersEquityTypeAxis_StockOptionPlanMember" unitRef="USD" decimals="0" id="Item_14">820862</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="3">0.478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">0.498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="3">0.498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="3">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="pure" decimals="3">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<nmtc:FairValueOfCommonStockPricePerShare contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="2">2.52</nmtc:FairValueOfCommonStockPricePerShare>
<nmtc:FairValueOfCommonStockPricePerShare contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.30</nmtc:FairValueOfCommonStockPricePerShare>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">The remaining 50,000 shares of the share commitment under the agreement vested in November 2018.</us-gaap:SaleOfStockDescriptionOfTransaction>
<nmtc:MonthlyCompensationAmount contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">3000</nmtc:MonthlyCompensationAmount>
<nmtc:ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.034</nmtc:ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<nmtc:ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="3">0.014</nmtc:ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<nmtc:ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="3">0.035</nmtc:ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">215453</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">323191</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00" unitRef="shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_01_May_2018T00_00_00_TO_31_May_2018T00_00_00" unitRef="shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="INF">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">215453</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue contextRef="Context_Custom_01_May_2018T00_00_00_TO_31_May_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="3">0.034</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="3">0.034</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="3">0.014</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue>
<us-gaap:RestrictedStockExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD" decimals="0">7220</us-gaap:RestrictedStockExpense>
<us-gaap:RestrictedStockExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">189750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2927572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">189750</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2737822</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.80</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.80</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.80</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">3.00</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.80</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">1.80</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">3.00</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.80</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.00</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" xsi:nil="true"/>
<nmtc:PurchaseAgreementDescription contextRef="Context_Custom_09_Jul_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">(i) 1 share (each, a "Share") of the Company's common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2018 Warrants").</nmtc:PurchaseAgreementDescription>
<nmtc:PurchaseAgreementDescription contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_30_Nov_2018T00_00_00">The Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses.</nmtc:PurchaseAgreementDescription>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="shares" decimals="INF">445200</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<nmtc:DeductingOfferingExpenses contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">1113000</nmtc:DeductingOfferingExpenses>
<us-gaap:SharesIssued contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00" unitRef="shares" decimals="INF">4600000</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4000000</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="INF">4000000</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="shares" decimals="INF">600000</us-gaap:SharesIssued>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:SaleOfStockPricePerShare>
<us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage contextRef="Context_Custom_09_Jul_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="pure" decimals="2">0.10</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_13_Oct_2016T00_00_00_TO_20_Oct_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="2">0.03</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_09_Jul_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD_per_Share" decimals="2">3.45</invest:InvestmentWarrantsExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="Context_Custom_09_Jul_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="pure" decimals="2">0.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_03_Aug_2018T00_00_00_TO_03_Aug_2018T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="Context_As_Of_20_Oct_2016T00_00_00_TO_20_Oct_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="INF">9050</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">-0.065</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
<nmtc:EffectiveIncomeTaxRateReconciliationWarrantExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">0.106</nmtc:EffectiveIncomeTaxRateReconciliationWarrantExpense>
<nmtc:EffectiveIncomeTaxRateReconciliationWarrantExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">0.094</nmtc:EffectiveIncomeTaxRateReconciliationWarrantExpense>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
<nmtc:EffectiveIncomeTaxRateReconciliationResearchCredits contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">-0.012</nmtc:EffectiveIncomeTaxRateReconciliationResearchCredits>
<nmtc:EffectiveIncomeTaxRateReconciliationResearchCredits contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">-0.015</nmtc:EffectiveIncomeTaxRateReconciliationResearchCredits>
<nmtc:EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">0.083</nmtc:EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent>
<nmtc:EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="3">0.219</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" decimals="3">0.198</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1837375</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">871371</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">5433</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">10116</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">64151</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">73763</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
<nmtc:DeferredTaxAssetsConvertibleNotes contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">81904</nmtc:DeferredTaxAssetsConvertibleNotes>
<nmtc:DeferredTaxAssetsConvertibleNotes contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">28863</nmtc:DeferredTaxAssetsConvertibleNotes>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">63197</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">140553</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">19821</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">24598</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1105877</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2115268</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1105877</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">2115268</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:EffectiveCorporateIncomeTaxRateDescription contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_22_Dec_2017T00_00_00">Corporate income taxation, including, but not limited to, the reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the deductibility of research and experimental expenditures that will be effective in the future). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform to the newly enacted federal tax law.</nmtc:EffectiveCorporateIncomeTaxRateDescription>
<nmtc:DeductionOfNetGrossDeferredTaxAssets contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_22_Dec_2017T00_00_00" unitRef="USD" decimals="0">420000</nmtc:DeductionOfNetGrossDeferredTaxAssets>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">3032000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">6393000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<nmtc:ResearchCreditCarryforwardsFederal contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">36000</nmtc:ResearchCreditCarryforwardsFederal>
<nmtc:ResearchCreditCarryforwardsFederal contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">83000</nmtc:ResearchCreditCarryforwardsFederal>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">3032000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">6393000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">2031-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<nmtc:ResearchCreditCarryforwardsExpirationDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">2036-12-31</nmtc:ResearchCreditCarryforwardsExpirationDate>
<nmtc:ResearchCreditCarryforwardsExpirationDate contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">2032-12-31</nmtc:ResearchCreditCarryforwardsExpirationDate>
<nmtc:ResearchCreditCarryforwardsState contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">27000</nmtc:ResearchCreditCarryforwardsState>
<nmtc:ResearchCreditCarryforwardsState contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">57000</nmtc:ResearchCreditCarryforwardsState>
<us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">The deferred tax asset for the convertible notes and the valuation allowance at December 31, 2017 were misstated by $452,845 and have both been revised in the preceding table. The effects of this revision also impacted the effective tax rate reconciliation by increasing the warrant expense percent by 10.6%, decreasing the U.S. tax reform percent by 3.8% and decreasing the valuation allowance percent by 6.8% for the year ended December 31, 2017.</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="Context_Custom_22_Feb_2018T00_00_00_TO_01_Mar_2018T00_00_00" unitRef="pure" decimals="2">1.00</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
<us-gaap:DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability contextRef="Context_Custom_22_Feb_2018T00_00_00_TO_01_Mar_2018T00_00_00">The Company began matching in the fourth quarter of 2017 on deferrals at 100% of deferrals up to 3% of one's contributions and 50% on deferrals over 3%, but not exceeding 5% of one's contributions up through the Restatement.</us-gaap:DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability>
<us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage contextRef="Context_Custom_22_Feb_2018T00_00_00_TO_01_Mar_2018T00_00_00" unitRef="pure" decimals="2">1.00</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
<nmtc:DefinedContributionPlanVestingTerm contextRef="Context_Custom_22_Feb_2018T00_00_00_TO_01_Mar_2018T00_00_00">P6Y</nmtc:DefinedContributionPlanVestingTerm>
<us-gaap:DefinedContributionPlanCostRecognized contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">27000</us-gaap:DefinedContributionPlanCostRecognized>
<us-gaap:DefinedContributionPlanCostRecognized contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">7779</us-gaap:DefinedContributionPlanCostRecognized>
<nmtc:CashGrossProceeds contextRef="Context_Custom_01_Sep_2018T00_00_00_TO_14_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">45000</nmtc:CashGrossProceeds>
<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="Context_Custom_01_Sep_2018T00_00_00_TO_14_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.05</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="Context_Custom_02_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.05</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_02_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="-6">5000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
<us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="Context_Custom_01_Sep_2018T00_00_00_TO_14_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="-6">5000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
<us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="Context_Custom_02_Nov_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="-6">5000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
<us-gaap:LeaseAndRentalExpense contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="USD" decimals="0">4763</us-gaap:LeaseAndRentalExpense>
<us-gaap:AreaOfLand contextRef="Context_As_Of_30_Sep_2018T00_00_00_TO_30_Sep_2018T00_00_00" unitRef="sqft" decimals="0">5196</us-gaap:AreaOfLand>
<nmtc:LeaseExpires contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">2019-10-31</nmtc:LeaseExpires>
<us-gaap:SubsequentEventDescription contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_30_Nov_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">The Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses.</us-gaap:SubsequentEventDescription>
<dei:AmendmentDescription contextRef="Context_9ME_01_Jan_2018T00_00_00_TO_30_Sep_2018T00_00_00">NeuroOne Medical Technologies Corporation (the ''Company'') is filing this Amendment No. 1 (this ''Amendment'') to its Transition Report on Form 10-KT for the period ended September 30, 2018, as filed on December 12, 2018 (the ''Original Form 10-KT''), solely to file certifications as Exhibits 31.1 and 32.1, which were inadvertently omitted from the Original Form 10-KT and to update the exhibit index.
Except as described above, no other changes have been made to the Original Form 10-KT, and this Amendment does not amend, update or change any other items or disclosures in the Original Form 10-KT. The original Form 10-KT continues to speak as of its original filing date. This Amendment does not reflect subsequent events occurring after the filing date of the Original Form 10-KT or modify or update in any way disclosures in the Original Form 10-KT.</dei:AmendmentDescription>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Item_1" xlink:label="lab_Item_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_1" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_3" xlink:label="lab_Item_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_3" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_4" xlink:label="lab_Item_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_4" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_6" xlink:label="lab_Item_6"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_6" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_7" xlink:label="lab_Item_7"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_7" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_8" xlink:label="lab_Item_8"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_8" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_9" xlink:label="lab_Item_9"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_9" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_10" xlink:label="lab_Item_10"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_10" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_11" xlink:label="lab_Item_11"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_11" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_12" xlink:label="lab_Item_12"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_12" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_13" xlink:label="lab_Item_13"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_13" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_14" xlink:label="lab_Item_14"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_14" xlink:to="Footnote_5" order="1.0"/>
<link:footnote xlink:type="resource" xlink:label="Footnote_2" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_5" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018 and December 31, 2017 of $2.30 and $2.52 per share, respectively.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nmtc-20180930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.originalsourcemusic.com/20180930" elementFormDefault="qualified"
xmlns:nmtc="http://www.originalsourcemusic.com/20180930"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2018-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:srt-types="http://fasb.org/srt-types/2018-01-31"
 xmlns:srt="http://fasb.org/srt/2018-01-31"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" id="ConsolidatedStatementsOfChangesInStockholdersDeficit">
<link:definition>005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows" id="Consolidatedstatementsofcashflows">
<link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperations" id="OrganizationAndNatureOfOperations">
<link:definition>007 - Disclosure - Organization and Nature of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/GoingConcern" id="GoingConcern">
<link:definition>008 - Disclosure - Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>010 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Intangibles" id="Intangibles">
<link:definition>011 - Disclosure - Intangibles</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>012 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoans" id="ShortTermPromissoryNotesAndUnsecuredLoans">
<link:definition>013 - Disclosure - Short-Term Promissory Notes and Unsecured Loans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements" id="ConvertiblePromissoryNotesAndWarrantAgreements">
<link:definition>014 - Disclosure - Convertible Promissory Notes and Warrant Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>015 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficit" id="StockholdersDeficit">
<link:definition>016 - Disclosure - Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>017 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/DefinedContributionPlan" id="DefinedContributionPlan">
<link:definition>018 - Disclosure - Defined Contribution Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>019 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies" id="Summaryofsignificantaccountingpoliciespolicies">
<link:definition>020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitTables" id="StockholdersDeficitTables">
<link:definition>021 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
<link:definition>022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesTables" id="IntangiblesTables">
<link:definition>023 - Disclosure - Intangibles (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>024 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansTables" id="ShortTermPromissoryNotesAndUnsecuredLoansTables">
<link:definition>025 - Disclosure - Short-Term Promissory Notes and Unsecured Loans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables" id="ConvertiblePromissoryNotesandWarrantAgreementsTables">
<link:definition>026 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>027 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>028 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperationsdetails" id="OrganizationAndNatureOfOperationsdetails">
<link:definition>029 - Disclosure - Organization and Nature of Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails" id="GoingConcernDetails">
<link:definition>030 - Disclosure - Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
<link:definition>031 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1" id="SummaryofSignificantAccountingPoliciesDetails1">
<link:definition>032 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2" id="SummaryofSignificantAccountingPoliciesDetails2">
<link:definition>033 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3" id="SummaryofSignificantAccountingPoliciesDetails3">
<link:definition>034 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>035 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>036 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails" id="IntangiblesDetails">
<link:definition>037 - Disclosure - Intangibles (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual" id="IntangiblesDetailsTextual">
<link:definition>038 - Disclosure - Intangibles (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
<link:definition>039 - Disclosure - Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetails" id="ShortTermPromissoryNotesAndUnsecuredLoansDetails">
<link:definition>040 - Disclosure - Short-Term Promissory Notes and Unsecured Loans (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual" id="ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual">
<link:definition>041 - Disclosure - Short-Term Promissory Notes and Unsecured Loans (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails" id="ConvertiblePromissoryNotesAndWarrantAgreementsDetails">
<link:definition>042 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual" id="ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual">
<link:definition>043 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails" id="Stockbasedcompensationdetails">
<link:definition>044 - Disclosure - Stock-Based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1" id="StockBasedCompensationDetails1">
<link:definition>045 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2" id="StockBasedCompensationDetails2">
<link:definition>046 - Disclosure - Stock-Based Compensation (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetailstextual" id="Stockbasedcompensationdetailstextual">
<link:definition>047 - Disclosure - Stock-Based Compensation (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails" id="StockholdersDeficitDetails">
<link:definition>048 - Disclosure - Stockholders' Deficit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails1" id="StockholdersDeficitDetails1">
<link:definition>049 - Disclosure - Stockholders' Deficit (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetailsTextual" id="StockholdersDeficitDetailsTextual">
<link:definition>050 - Disclosure - Stockholders' Deficit (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>051 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
<link:definition>052 - Disclosure - Income Taxes (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
<link:definition>053 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/DefinedContributionPlanDetails" id="DefinedContributionPlanDetails">
<link:definition>054 - Disclosure - Defined Contribution Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>055 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd"/>
<import  namespace="http://fasb.org/us-roles/2018-01-31"  schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd"/>
<import  namespace="http://fasb.org/srt-types/2018-01-31"  schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd"/>
<import  namespace="http://fasb.org/srt/2018-01-31"  schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="nmtc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsLiabilityNonCurrent" id="nmtc_WarrantsLiabilityNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" id="nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" id="nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" id="nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" id="nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfWarrantsPrivatePlacement" id="nmtc_IssuanceOfWarrantsPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceCostsRelatedToPrivatePlacement" id="nmtc_IssuanceCostsRelatedToPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" id="nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" id="nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ParValueChangeInConnectionWithMerger" id="nmtc_ParValueChangeInConnectionWithMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" id="nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" id="nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForgivenessOfSubscription" id="nmtc_ForgivenessOfSubscription" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NonCashInterestOnShortTermAndConvertiblePromissoryNotes" id="nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantIssuanceCostsRelatedToDebtFinancing" id="nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevaluationOfPremiumDebtConversionDerivative" id="nmtc_RevaluationOfPremiumDebtConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevaluationOfWarrantLiability" id="nmtc_RevaluationOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" id="nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" id="nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" id="nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentsRelatedToWarrantIssuanceCosts" id="nmtc_PaymentsRelatedToWarrantIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionDerivativeRelatedToConvertiblePromissoryNotes" id="nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" id="nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" id="nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PurchasedIntangibleAssetsInAccruedLiabilities" id="nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCostsRelatedToPrivatePlacement" id="nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" id="nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCostsAttributedToWarrantLiability" id="nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" id="nmtc_GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" id="nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockValuationPolicyTextBlock" id="nmtc_CommonStockValuationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IntellectualPropertyPolicyTextBlock" id="nmtc_IntellectualPropertyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilityPolicyTextBlock" id="nmtc_WarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumDebtConversionDerivativePolicyTextBlock" id="nmtc_PremiumDebtConversionDerivativePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfWarrantActivityTableTextBlock" id="nmtc_SummaryOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryInformationAboutWarrantsOutstandingTableTextBlock" id="nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OrganizationAndNatureOfOperationsTextualAbstract" id="nmtc_OrganizationAndNatureOfOperationsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernTable" id="nmtc_GoingConcernTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="GoingConcernLineItems" id="nmtc_GoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernTextualAbstract" id="nmtc_GoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BankLoansAndNotesPayable" id="nmtc_BankLoansAndNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertibleNotesPayableOne" id="nmtc_ConvertibleNotesPayableOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubscriptionAmountToConvertiblePromissoryNote" id="nmtc_SubscriptionAmountToConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubscriptionAmountToConvertiblePromissoryNoteOne" id="nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaximumSubscriptionAmount" id="nmtc_MaximumSubscriptionAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantLiability" id="nmtc_WarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumConversionDerivative" id="nmtc_PremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfWarrantLiabilityAbstract" id="nmtc_ScheduleOfWarrantLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsAndValueAssignedToWarrants" id="nmtc_ProceedsAndValueAssignedToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReclassificationToEquity" id="nmtc_ReclassificationToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtConversionDerivativeMember" id="nmtc_DebtConversionDerivativeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPremiumConversionDerivativeAbstract" id="nmtc_ScheduleOfPremiumConversionDerivativeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumDebtConversionDerivative" id="nmtc_PremiumDebtConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" id="nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" id="nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdditionalPotentialWarrants" id="nmtc_AdditionalPotentialWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfLicencingAgreements" id="nmtc_NumberOfLicencingAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="nmtc_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CummulativeFinancingTriggersPayment" id="nmtc_CummulativeFinancingTriggersPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentDueAfterFourthYear" id="nmtc_OtherCommitmentDueAfterFourthYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CostIncurredMaintainingLicensedPatents" id="nmtc_CostIncurredMaintainingLicensedPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CummulativeFinancingTriggersPayment1" id="nmtc_CummulativeFinancingTriggersPayment1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountRecordedForIntellectualProperty" id="nmtc_AmountRecordedForIntellectualProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfAccruedInterest" id="nmtc_PercentageOfAccruedInterest" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoodwilAndIntangibleAssetsTextualAbstract" id="nmtc_GoodwilAndIntangibleAssetsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmortizationExpenseDescription" id="nmtc_AmortizationExpenseDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedLicenseFees" id="nmtc_AccruedLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedLegalCosts" id="nmtc_AccruedLegalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCosts" id="nmtc_AccruedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedPayroll" id="nmtc_AccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedExpensesAdvances" id="nmtc_AccruedExpensesAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" id="nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OtherDebtMember" id="nmtc_OtherDebtMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumConversionDerivativeMember" id="nmtc_PremiumConversionDerivativeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CancellationExtinguishmentAndConversionOfShortTermNotesMember" id="nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" id="nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShortTermPaymentWarrants" id="nmtc_ShortTermPaymentWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockPurchaseOfWarrants" id="nmtc_CommonStockPurchaseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsMaturityTerm" id="nmtc_WarrantsMaturityTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValueOfPremiumConversionDerivative" id="nmtc_ValueOfPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionRiskFreeInterestRate" id="nmtc_FairValueAssumptionRiskFreeInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionExpectedVolatilityRate" id="nmtc_FairValueAssumptionExpectedVolatilityRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionExpectedTerm" id="nmtc_FairValueAssumptionExpectedTerm" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionExpectedDividendRate" id="nmtc_FairValueAssumptionExpectedDividendRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdditionalWarrantsAllocated" id="nmtc_AdditionalWarrantsAllocated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsExpirationDate" id="nmtc_WarrantsExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LossOnShortTermNotesExtinguishment" id="nmtc_LossOnShortTermNotesExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAdjustmentOfShortTermNotesAndWarrants" id="nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShortTermNoteQualifiedFinancingDescription" id="nmtc_ShortTermNoteQualifiedFinancingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisableDescription" id="nmtc_WarrantsExercisableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentToAccountForChangeInValuation" id="nmtc_AdjustmentToAccountForChangeInValuation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" id="nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNoteMember" id="nmtc_ConvertiblePromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubscriptionAgreementMember" id="nmtc_SubscriptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NovemberTwoThousandSeventeenMember" id="nmtc_NovemberTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoZeroOneSevenConvertibleNoteAmendmentMember" id="nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertibleDebtOneMember" id="nmtc_ConvertibleDebtOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NewWarrantsMember" id="nmtc_NewWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" id="nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfMaximumVotingPowerOfSurvivingEntity" id="nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountOfConvertibleNoteHeldByWarrantHolder" id="nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNoteProceedsAssignedToWarrants" id="nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmortizationOfDiscountToConvertibleNotes" id="nmtc_AmortizationOfDiscountToConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertibleNotesOfConversionPremiumAmortizationExpense" id="nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumDebtConversionDerivativeInterestExpense" id="nmtc_PremiumDebtConversionDerivativeInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseSharesOfCommonStock" id="nmtc_WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfCommonStockPurchaseWarrants" id="nmtc_PercentageOfCommonStockPurchaseWarrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceCostsAttributedToCommonStockPurchaseWarrants" id="nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertibleNotesMaximumExtensionLimit" id="nmtc_ConvertibleNotesMaximumExtensionLimit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAdjustmentOfPremiumConversionDerivative" id="nmtc_FairValueAdjustmentOfPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueChangesOfWarrantLiability" id="nmtc_FairValueChangesOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtConversionConvertedNotePaymentWarrantsIssued" id="nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilityValueOfReclassifiedToEquity" id="nmtc_WarrantLiabilityValueOfReclassifiedToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOptionPlanMember" id="nmtc_StockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandSixteenPlanMember" id="nmtc_TwoThousandSixteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandSixteenAndSeventeenPlanMember" id="nmtc_TwoThousandSixteenAndSeventeenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeesDirectorsAndConsultantsMember" id="nmtc_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockBasedCompensationTextualAbstract" id="nmtc_StockBasedCompensationTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" id="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfCommonStockPricePerShare" id="nmtc_FairValueOfCommonStockPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MonthlyCompensationAmount" id="nmtc_MonthlyCompensationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" id="nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OneExercisePriceMember" id="nmtc_OneExercisePriceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ThreeExercisePriceMember" id="nmtc_ThreeExercisePriceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccreditedInvestorsMember" id="nmtc_AccreditedInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockholdersMemberDeficitTextualAbstract" id="nmtc_StockholdersMemberDeficitTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PurchaseAgreementDescription" id="nmtc_PurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DeductingOfferingExpenses" id="nmtc_DeductingOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationWarrantExpense" id="nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationResearchCredits" id="nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" id="nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsConvertibleNotes" id="nmtc_DeferredTaxAssetsConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesTextualAbstract" id="nmtc_IncomeTaxesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EffectiveCorporateIncomeTaxRateDescription" id="nmtc_EffectiveCorporateIncomeTaxRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DeductionOfNetGrossDeferredTaxAssets" id="nmtc_DeductionOfNetGrossDeferredTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchCreditCarryforwardsFederal" id="nmtc_ResearchCreditCarryforwardsFederal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchCreditCarryforwardsExpirationDate" id="nmtc_ResearchCreditCarryforwardsExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchCreditCarryforwardsState" id="nmtc_ResearchCreditCarryforwardsState" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DefinedContributionPlanTextualAbstract" id="nmtc_DefinedContributionPlanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DefinedContributionPlanVestingTerm" id="nmtc_DefinedContributionPlanVestingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionAgreementsMember" id="nmtc_ConversionAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsTextualAbstract" id="nmtc_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CashGrossProceeds" id="nmtc_CashGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="LeaseExpires" id="nmtc_LeaseExpires" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nmtc-20180930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ShortTermBorrowings" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsLiabilityNonCurrent" xlink:label="loc_nmtc_WarrantsLiabilityNonCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_nmtc_WarrantsLiabilityNonCurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestIncomeExpenseNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:label="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="40" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Consolidatedstatementsofcashflows" roleURI="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ForgivenessOfSubscription" xlink:label="loc_nmtc_ForgivenessOfSubscription" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_ForgivenessOfSubscription" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xlink:label="loc_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xlink:label="loc_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_RevaluationOfWarrantLiability" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="110" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="120" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="130" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" order="10" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaap_PaymentsOfLoanCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfLoanCosts" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PaymentsRelatedToWarrantIssuanceCosts" xlink:label="loc_nmtc_PaymentsRelatedToWarrantIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_nmtc_PaymentsRelatedToWarrantIssuanceCosts" order="90" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedLicenseFees" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLegalCosts" xlink:label="loc_nmtc_AccruedLegalCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedLegalCosts" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedIssuanceCosts" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedPayroll" xlink:label="loc_nmtc_AccruedPayroll" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedPayroll" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedExpensesAdvances" xlink:label="loc_nmtc_AccruedExpensesAdvances" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedExpensesAdvances" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" order="60" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nmtc-20180930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensationTables" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#OrganizationAndNatureOfOperationsdetails" roleURI="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperationsdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#GoingConcernDetails" roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails1" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails2" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails3" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IntangiblesDetails" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IntangiblesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetails" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Stockbasedcompensationdetails" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensationDetails1" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensationDetails2" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Stockbasedcompensationdetailstextual" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitDetails" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitDetails1" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SubsequentEventsDetails" roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:label="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:label="loc_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xlink:label="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfWarrantsPrivatePlacement" xlink:label="loc_nmtc_IssuanceOfWarrantsPrivatePlacement_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_IssuanceOfWarrantsPrivatePlacement_14" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceCostsRelatedToPrivatePlacement" xlink:label="loc_nmtc_IssuanceCostsRelatedToPrivatePlacement_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_IssuanceCostsRelatedToPrivatePlacement_15" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_16" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_17" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_18" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_19" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_20" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_21" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xlink:label="loc_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger_22" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xlink:label="loc_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger_23" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ParValueChangeInConnectionWithMerger" xlink:label="loc_nmtc_ParValueChangeInConnectionWithMerger_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_ParValueChangeInConnectionWithMerger_24" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_25" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_26" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xlink:label="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification_27" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xlink:label="loc_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription_28" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_29" order="230" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaap_OffsettingAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_OffsettingAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_StockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_8" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperationsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3" xlink:to="loc_srt_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OrganizationAndNatureOfOperationsTextualAbstract" xlink:label="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaap_ConversionOfStockDescription_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_ConversionOfStockDescription_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_13" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_14" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcernDetails">
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernLineItems" xlink:label="loc_nmtc_GoingConcernLineItems_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernTable" xlink:label="loc_nmtc_GoingConcernTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmtc_GoingConcernLineItems_0" xlink:to="loc_nmtc_GoingConcernTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmtc_GoingConcernTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_nmtc_GoingConcernTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernLineItems_0" xlink:to="loc_nmtc_GoingConcernTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_UnsecuredDebt_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BankLoansAndNotesPayable" xlink:label="loc_nmtc_BankLoansAndNotesPayable_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_nmtc_BankLoansAndNotesPayable_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" xlink:label="loc_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesPayableOne" xlink:label="loc_nmtc_ConvertibleNotesPayableOne_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_nmtc_ConvertibleNotesPayableOne_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:label="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNote_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNote_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:label="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_13" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_MaximumSubscriptionAmount" xlink:label="loc_nmtc_MaximumSubscriptionAmount_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_nmtc_MaximumSubscriptionAmount_14" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_15" order="90" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiability" xlink:label="loc_nmtc_WarrantLiability_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" xlink:to="loc_nmtc_WarrantLiability_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumConversionDerivative" xlink:label="loc_nmtc_PremiumConversionDerivative_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" xlink:to="loc_nmtc_PremiumConversionDerivative_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_10" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsAndValueAssignedToWarrants" xlink:label="loc_nmtc_ProceedsAndValueAssignedToWarrants_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_nmtc_ProceedsAndValueAssignedToWarrants_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ReclassificationToEquity" xlink:label="loc_nmtc_ReclassificationToEquity_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_nmtc_ReclassificationToEquity_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_nmtc_DebtConversionDerivativeMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_nmtc_DebtConversionDerivativeMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivative" xlink:label="loc_nmtc_PremiumDebtConversionDerivative_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_PremiumDebtConversionDerivative_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:label="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_8" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_IntellectualPropertyMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7" xlink:to="loc_srt_SubsidiariesMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CummulativeFinancingTriggersPayment" xlink:label="loc_nmtc_CummulativeFinancingTriggersPayment_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_CummulativeFinancingTriggersPayment_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OtherCommitmentDueAfterFourthYear" xlink:label="loc_nmtc_OtherCommitmentDueAfterFourthYear_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_OtherCommitmentDueAfterFourthYear_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CostIncurredMaintainingLicensedPatents" xlink:label="loc_nmtc_CostIncurredMaintainingLicensedPatents_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_CostIncurredMaintainingLicensedPatents_17" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CummulativeFinancingTriggersPayment1" xlink:label="loc_nmtc_CummulativeFinancingTriggersPayment1_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_CummulativeFinancingTriggersPayment1_18" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_19" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmountRecordedForIntellectualProperty" xlink:label="loc_nmtc_AmountRecordedForIntellectualProperty_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_AmountRecordedForIntellectualProperty_20" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_21" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PercentageOfAccruedInterest" xlink:label="loc_nmtc_PercentageOfAccruedInterest_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_PercentageOfAccruedInterest_22" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_24" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_25" order="150" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_srt_RangeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2" xlink:to="loc_srt_RangeMember_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2" xlink:to="loc_srt_RangeMember_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3" xlink:to="loc_srt_MinimumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3" xlink:to="loc_srt_MaximumMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="loc_us-gaap_FiniteLivedLicenseAgreementsGross_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6" xlink:to="loc_us-gaap_FiniteLivedLicenseAgreementsGross_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_10" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmortizationExpenseDescription" xlink:label="loc_nmtc_AmortizationExpenseDescription_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_5" xlink:to="loc_nmtc_AmortizationExpenseDescription_6" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_us-gaap_ShortTermDebtMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OtherDebtMember" xlink:label="loc_nmtc_OtherDebtMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_OtherDebtMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumConversionDerivativeMember" xlink:label="loc_nmtc_PremiumConversionDerivativeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_PremiumConversionDerivativeMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" xlink:label="loc_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_us-gaap_UnsecuredDebtMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_11" xlink:to="loc_srt_ConsolidatedEntitiesDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_11" xlink:to="loc_srt_ConsolidatedEntitiesDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_12" xlink:to="loc_srt_SubsidiariesMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaap_ShortTermDebtDescription_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_ShortTermDebtDescription_17" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_18" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_19" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_20" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermPaymentWarrants" xlink:label="loc_nmtc_ShortTermPaymentWarrants_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_ShortTermPaymentWarrants_21" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_22" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_WarrantsMaturityTerm_23" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_25" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ValueOfPremiumConversionDerivative" xlink:label="loc_nmtc_ValueOfPremiumConversionDerivative_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_ValueOfPremiumConversionDerivative_26" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_27" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_28" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedTerm" xlink:label="loc_nmtc_FairValueAssumptionExpectedTerm_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_FairValueAssumptionExpectedTerm_29" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedDividendRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedDividendRate_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_FairValueAssumptionExpectedDividendRate_30" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_31" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdditionalWarrantsAllocated" xlink:label="loc_nmtc_AdditionalWarrantsAllocated_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_AdditionalWarrantsAllocated_32" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_33" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsExpirationDate" xlink:label="loc_nmtc_WarrantsExpirationDate_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_WarrantsExpirationDate_34" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_LossOnShortTermNotesExtinguishment" xlink:label="loc_nmtc_LossOnShortTermNotesExtinguishment_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_LossOnShortTermNotesExtinguishment_35" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:label="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_36" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_38" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:label="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_39" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_DebtConversionDescription_40" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_OtherLiabilities_41" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_42" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsExercisableDescription" xlink:label="loc_nmtc_WarrantsExercisableDescription_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_WarrantsExercisableDescription_43" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdjustmentToAccountForChangeInValuation" xlink:label="loc_nmtc_AdjustmentToAccountForChangeInValuation_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_AdjustmentToAccountForChangeInValuation_44" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_45" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xlink:label="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes_46" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiability" xlink:label="loc_nmtc_WarrantLiability_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_14" xlink:to="loc_nmtc_WarrantLiability_47" order="320" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleDebtMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNoteMember" xlink:label="loc_nmtc_ConvertiblePromissoryNoteMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_nmtc_ConvertiblePromissoryNoteMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleNotesPayable_10" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAgreementMember" xlink:label="loc_nmtc_SubscriptionAgreementMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_SubscriptionAgreementMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NovemberTwoThousandSeventeenMember" xlink:label="loc_nmtc_NovemberTwoThousandSeventeenMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_NovemberTwoThousandSeventeenMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:label="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleDebtOneMember" xlink:label="loc_nmtc_ConvertibleDebtOneMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_nmtc_ConvertibleDebtOneMember_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_us-gaap_PrivatePlacementMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NewWarrantsMember" xlink:label="loc_nmtc_NewWarrantsMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_nmtc_NewWarrantsMember_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_18" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_19" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_20" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_21" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_22" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_23" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_24" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_25" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_26" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_27" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedTerm" xlink:label="loc_nmtc_FairValueAssumptionExpectedTerm_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionExpectedTerm_28" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedDividendRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedDividendRate_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionExpectedDividendRate_29" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_30" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_InterestExpense_32" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_33" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_34" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmortizationOfDiscountToConvertibleNotes" xlink:label="loc_nmtc_AmortizationOfDiscountToConvertibleNotes_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_AmortizationOfDiscountToConvertibleNotes_35" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_36" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_37" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_38" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_39" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_us-gaap_DebtInstrumentFee_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentFee_40" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_WarrantsMaturityTerm_41" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:label="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_42" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_43" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_44" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_45" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_46" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:label="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_47" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_LegalFees_48" order="320" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49" order="330" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_50" order="340" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_51" order="350" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_52" order="360" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:label="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_53" order="370" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueChangesOfWarrantLiability" xlink:label="loc_nmtc_FairValueChangesOfWarrantLiability_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueChangesOfWarrantLiability_54" order="380" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentDescription_55" order="390" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_56" order="400" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_57" order="410" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_58" order="420" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xlink:label="loc_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued_59" order="430" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xlink:label="loc_nmtc_WarrantLiabilityValueOfReclassifiedToEquity_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_WarrantLiabilityValueOfReclassifiedToEquity_60" order="440" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockOptionPlanMember" xlink:label="loc_nmtc_StockOptionPlanMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" xlink:to="loc_nmtc_StockOptionPlanMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_12" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_13" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_16" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_18" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_19" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_20" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21" order="170" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaap_OffsettingAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_OffsettingAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_StockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenPlanMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenPlanMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_RestrictedStockMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_14_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_nmtc_StockBasedCompensationTextualAbstract_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmtc_StockBasedCompensationTextualAbstract_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueOfCommonStockPricePerShare" xlink:label="loc_nmtc_FairValueOfCommonStockPricePerShare_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_nmtc_FairValueOfCommonStockPricePerShare_21" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_22" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_MonthlyCompensationAmount" xlink:label="loc_nmtc_MonthlyCompensationAmount_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_nmtc_MonthlyCompensationAmount_23" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_24" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_25" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_27" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_28" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_29" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues_30" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue_31" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_32" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_RestrictedStockExpense_33" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34" order="160" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_12" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance_13" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum_14" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum_15" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised_16" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited_17" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable_18" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue_20" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_21" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_22" order="140" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OneExercisePriceMember" xlink:label="loc_nmtc_OneExercisePriceMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_nmtc_OneExercisePriceMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ThreeExercisePriceMember" xlink:label="loc_nmtc_ThreeExercisePriceMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_nmtc_ThreeExercisePriceMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3" xlink:to="loc_srt_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" xlink:to="loc_us-gaap_PrivatePlacementMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccreditedInvestorsMember" xlink:label="loc_nmtc_AccreditedInvestorsMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_13" xlink:to="loc_nmtc_AccreditedInvestorsMember_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_16_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_CommonStockMember_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_WarrantMember_18" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockSharesIssued_22" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_23" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_25" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PurchaseAgreementDescription" xlink:label="loc_nmtc_PurchaseAgreementDescription_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_nmtc_PurchaseAgreementDescription_26" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_27" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeductingOfferingExpenses" xlink:label="loc_nmtc_DeductingOfferingExpenses_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_nmtc_DeductingOfferingExpenses_28" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_SharesIssued_29" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_30" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_31" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_33" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_34" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_36" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_37" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_38" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_39" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_40" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_Liabilities_41" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLegalCosts" xlink:label="loc_nmtc_AccruedLegalCosts_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_nmtc_AccruedLegalCosts_42" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_43" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_44" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_45" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_46" order="260" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_DomesticCountryMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_nmtc_IncomeTaxesTextualAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_nmtc_IncomeTaxesTextualAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveCorporateIncomeTaxRateDescription" xlink:label="loc_nmtc_EffectiveCorporateIncomeTaxRateDescription_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_nmtc_EffectiveCorporateIncomeTaxRateDescription_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeductionOfNetGrossDeferredTaxAssets" xlink:label="loc_nmtc_DeductionOfNetGrossDeferredTaxAssets_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_nmtc_DeductionOfNetGrossDeferredTaxAssets_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsFederal" xlink:label="loc_nmtc_ResearchCreditCarryforwardsFederal_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_nmtc_ResearchCreditCarryforwardsFederal_14" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_15" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_16" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsExpirationDate" xlink:label="loc_nmtc_ResearchCreditCarryforwardsExpirationDate_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_nmtc_ResearchCreditCarryforwardsExpirationDate_17" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsState" xlink:label="loc_nmtc_ResearchCreditCarryforwardsState_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_nmtc_ResearchCreditCarryforwardsState_18" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_19" order="120" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_5" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_5" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_us-gaap_ConvertibleDebtMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionAgreementsMember" xlink:label="loc_nmtc_ConversionAgreementsMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_nmtc_ConversionAgreementsMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" xlink:label="loc_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10" xlink:to="loc_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccreditedInvestorsMember" xlink:label="loc_nmtc_AccreditedInvestorsMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_13" xlink:to="loc_nmtc_AccreditedInvestorsMember_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_PrivatePlacementMember_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_OverAllotmentOptionMember_18" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_CommonStockMember_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_WarrantMember_22" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_23" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_23" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_23" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24" xlink:to="loc_us-gaap_ShortTermDebtMember_25" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_nmtc_SubsequentEventsTextualAbstract_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmtc_SubsequentEventsTextualAbstract_26" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CashGrossProceeds" xlink:label="loc_nmtc_CashGrossProceeds_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_nmtc_CashGrossProceeds_27" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_UnsecuredDebt_28" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_29" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_31" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_32" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_LeaseAndRentalExpense_33" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_AreaOfLand_34" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_LeaseExpires" xlink:label="loc_nmtc_LeaseExpires_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_nmtc_LeaseExpires_35" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_26" xlink:to="loc_us-gaap_SubsequentEventDescription_36" order="90" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nmtc-20180930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DocumentAndEntityInformationAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DocumentAndEntityInformationAbstract" xlink:to="lab_JHII63I2MI70_nmtc_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_G578G2J8HGI99092F09I_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_EntityRegistrantName" xlink:to="lab_I790I4L0JIK11214H21K_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_HFGG41G0KG58_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_EntityCentralIndexKey" xlink:to="lab_JHII63I2MI70_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_G578G2J8HGI99092F09I_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_AmendmentFlag" xlink:to="lab_I790I4L0JIK11214H21K_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_HFGG41G0KG58_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_TradingSymbol" xlink:to="lab_JHII63I2MI70_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_G578G2J8HGI99092F09I_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_AmendmentDescription" xlink:to="lab_I790I4L0JIK11214H21K_dei_AmendmentDescription"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_HFGG41G0KG58_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_CurrentFiscalYearEndDate" xlink:to="lab_JHII63I2MI70_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_G578G2J8HGI99092F09I_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_DocumentType" xlink:to="lab_I790I4L0JIK11214H21K_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_HFGG41G0KG58_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_DocumentPeriodEndDate" xlink:to="lab_JHII63I2MI70_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_G578G2J8HGI99092F09I_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_DocumentFiscalYearFocus" xlink:to="lab_I790I4L0JIK11214H21K_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_HFGG41G0KG58_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_DocumentFiscalPeriodFocus" xlink:to="lab_JHII63I2MI70_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_G578G2J8HGI99092F09I_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_I790I4L0JIK11214H21K_dei_EntityWellKnownSeasonedIssuer"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_HFGG41G0KG58_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_EntityVoluntaryFilers" xlink:to="lab_JHII63I2MI70_dei_EntityVoluntaryFilers"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_G578G2J8HGI99092F09I_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_EntityCurrentReportingStatus" xlink:to="lab_I790I4L0JIK11214H21K_dei_EntityCurrentReportingStatus"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_HFGG41G0KG58_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_EntityFilerCategory" xlink:to="lab_JHII63I2MI70_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_G578G2J8HGI99092F09I_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_EntitySmallBusiness" xlink:to="lab_I790I4L0JIK11214H21K_dei_EntitySmallBusiness"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_HFGG41G0KG58_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_EntityEmergingGrowthCompany" xlink:to="lab_JHII63I2MI70_dei_EntityEmergingGrowthCompany"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_G578G2J8HGI99092F09I_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_EntityShellCompany" xlink:to="lab_I790I4L0JIK11214H21K_dei_EntityShellCompany"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_HFGG41G0KG58_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_EntityExTransitionPeriod" xlink:to="lab_JHII63I2MI70_dei_EntityExTransitionPeriod"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_G578G2J8HGI99092F09I_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_dei_EntityPublicFloat" xlink:to="lab_I790I4L0JIK11214H21K_dei_EntityPublicFloat"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_HFGG41G0KG58_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_JHII63I2MI70_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AssetsAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AssetsCurrentAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_HFGG41G0KG58_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_JHII63I2MI70_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AssetsCurrent" xlink:to="lab_JHII63I2MI70_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_HFGG41G0KG58_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_Assets" xlink:to="lab_JHII63I2MI70_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AccountsPayableCurrent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term promissory notes and unsecured loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term promissory notes, including accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermBorrowings" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermBorrowings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_ConvertibleNotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes, net and accrued interest - current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes and warrant agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes, net and accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Debt Instrument, Unamortized Premium, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Balance as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium conversion derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentUnamortizedPremiumCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_LiabilitiesCurrent" xlink:to="lab_JHII63I2MI70_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsLiabilityNonCurrent" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_WarrantsLiabilityNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantsLiabilityNonCurrent" xml:lang="en-US">Warrants Liability Non Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantsLiabilityNonCurrent" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantsLiabilityNonCurrent" xml:lang="en-US">This concept represents about warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_WarrantsLiabilityNonCurrent" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_WarrantsLiabilityNonCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_HFGG41G0KG58_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_Liabilities" xml:lang="en-US">Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_Liabilities" xlink:to="lab_JHII63I2MI70_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CommitmentsAndContingencies" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockholdersEquityAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2018 and December 31, 2017; no shares issued or outstanding as of September 30, 2018 and December 31, 2017.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PreferredStockValue" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_HFGG41G0KG58_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 9,656,505 and 7,864,994 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CommonStockValue" xlink:to="lab_JHII63I2MI70_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AdditionalPaidInCapital" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_HFGG41G0KG58_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JHII63I2MI70_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_JHII63I2MI70_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockholdersEquity" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_HFGG41G0KG58_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_JHII63I2MI70_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_HFGG41G0KG58_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_JHII63I2MI70_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PreferredStockSharesIssued" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_HFGG41G0KG58_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_JHII63I2MI70_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_HFGG41G0KG58_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_JHII63I2MI70_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CommonStockSharesIssued" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_HFGG41G0KG58_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_JHII63I2MI70_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements of Operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncomeStatementAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OperatingExpensesAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_HFGG41G0KG58_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_JHII63I2MI70_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OperatingExpenses" xml:lang="en-US">Operations expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OperatingExpenses" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_HFGG41G0KG58_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OperatingIncomeLoss" xlink:to="lab_JHII63I2MI70_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_InterestIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_InterestIncomeExpenseNet"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:label="loc_HFGG41G0KG58_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xml:lang="en-US">Net Change In Fair Value Of Warrant Liability And Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xml:lang="en-US">Net change in fair value for the warrant liability and premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xml:lang="en-US">Net change in fair value for the warrant liability and premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:to="lab_JHII63I2MI70_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on note extinguishments, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Recognition of gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on convertible notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on convertibles notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on note extinguishments, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on convertible notes extinguishment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_HFGG41G0KG58_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_NetIncomeLoss" xlink:to="lab_JHII63I2MI70_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_HFGG41G0KG58_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_JHII63I2MI70_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Number of shares used in per share calculations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_HFGG41G0KG58_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_JHII63I2MI70_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_HFGG41G0KG58_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StatementTable" xlink:to="lab_JHII63I2MI70_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_EquityComponentDomain" xlink:to="lab_JHII63I2MI70_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CommonStockMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_HFGG41G0KG58_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_JHII63I2MI70_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_RetainedEarningsMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_HFGG41G0KG58_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StatementLineItems" xlink:to="lab_JHII63I2MI70_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SharesOutstanding" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:label="loc_HFGG41G0KG58_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Stock And Convertible Notes Extinguishments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xml:lang="en-US">Issuance of common stock upon short term notes and convertible notes extinguishments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xml:lang="en-US">Stock issued during period value issuance of common stock and convertible notes extinguishments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:to="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xml:lang="en-US">Stock Issued During Period Share Issuance Of Common Stock And Convertible Notes Extinguishments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xml:lang="en-US">Issuance of common stock upon short term notes and convertible notes extinguishments, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xml:lang="en-US">Stock issued during period share issuance of common stock and convertible notes extinguishments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xlink:label="loc_HFGG41G0KG58_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xml:lang="en-US">Stock Issued During Period Value Issuance Of Warrants And Reclassification Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xml:lang="en-US">Issuance of warrants and reclassification of warrant liability in connection with short-term notes and convertible notes extinguishments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xml:lang="en-US">Stock issued during period value issuance of warrants and reclassification of warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xlink:to="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock under 2018 private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock-based services expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock under 2018 private placement, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/commentaryGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfWarrantsPrivatePlacement" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_IssuanceOfWarrantsPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfWarrantsPrivatePlacement" xml:lang="en-US">Issuance Of Warrants Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfWarrantsPrivatePlacement" xml:lang="en-US">Issuance of warrants under 2018 private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfWarrantsPrivatePlacement" xml:lang="en-US">Issuance of warrants private placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_IssuanceOfWarrantsPrivatePlacement" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfWarrantsPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceCostsRelatedToPrivatePlacement" xlink:label="loc_HFGG41G0KG58_nmtc_IssuanceCostsRelatedToPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceCostsRelatedToPrivatePlacement" xml:lang="en-US">Issuance Costs Related To Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceCostsRelatedToPrivatePlacement" xml:lang="en-US">Issuance costs related to 2018 private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceCostsRelatedToPrivatePlacement" xml:lang="en-US">Issuance costs related to private placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_IssuanceCostsRelatedToPrivatePlacement" xlink:to="lab_JHII63I2MI70_nmtc_IssuanceCostsRelatedToPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock for consulting services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock-based services expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for consulting services, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Value of share issued as royalty upon the achievement of milestone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of stock in connection with intellectual license agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issuance of stock in connection with intellectual license agreement, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Net exchanges of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Issuance of restricted stock award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Shares of restricted common stock vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Issuance of restricted stock award, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xml:lang="en-US">Stock Issued During Period Value Transfer Of Share In Connection With Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xml:lang="en-US">Transfer of shares in connection with merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xml:lang="en-US">Transfer of values in connection with Merger.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xlink:label="loc_HFGG41G0KG58_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xml:lang="en-US">Stock Issued During Period Shares Transfer Of Shares In Connection With Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xml:lang="en-US">Transfer of shares in connection with merger, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xml:lang="en-US">Transfer of shares in connection with merger.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xlink:to="lab_JHII63I2MI70_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ParValueChangeInConnectionWithMerger" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ParValueChangeInConnectionWithMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ParValueChangeInConnectionWithMerger" xml:lang="en-US">Par Value Change In Connection With Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ParValueChangeInConnectionWithMerger" xml:lang="en-US">Par value change in connection with merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ParValueChangeInConnectionWithMerger" xml:lang="en-US">Par value change in connection with merger.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ParValueChangeInConnectionWithMerger" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ParValueChangeInConnectionWithMerger"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_HFGG41G0KG58_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_JHII63I2MI70_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Initial warrant liability changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Issuance of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Aggregate fair value to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xlink:label="loc_HFGG41G0KG58_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xml:lang="en-US">Issuance Of Additional Warrants In Connection With Short Term Notes Modification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xml:lang="en-US">Issuance of additional warrants in connection with short-term notes modification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xml:lang="en-US">Issuance of additional warrants in connection with short term notes modification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xlink:to="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xml:lang="en-US">Adjustments To Additional Paid In Capital Forgiveness Of Subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xml:lang="en-US">Forgiveness of subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xml:lang="en-US">Forgiveness of subscription receivable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Cash Flows:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AdjustmentForAmortization" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensation" xml:lang="en-US">Obligation to issue stock awards and stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensation" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ForgivenessOfSubscription" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ForgivenessOfSubscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ForgivenessOfSubscription" xml:lang="en-US">Forgiveness Of Subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ForgivenessOfSubscription" xml:lang="en-US">Forgiveness of subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ForgivenessOfSubscription" xml:lang="en-US">Forgiveness of subscription.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ForgivenessOfSubscription" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ForgivenessOfSubscription"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xlink:label="loc_HFGG41G0KG58_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xml:lang="en-US">Non Cash Interest On Short Term And Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xml:lang="en-US">Non-cash interest on convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xml:lang="en-US">Amount of non-cash interest on short-term and convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xlink:to="lab_JHII63I2MI70_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Discount to convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Non-cash discount amortization on convertible and short-term promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Non-cash discount amortization on short-term promissory notes and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization charged to interest expense related to issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xlink:label="loc_HFGG41G0KG58_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xml:lang="en-US">Warrant Issuance Costs Related To Debt Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xml:lang="en-US">Note issuance costs attributed to warrant liability and to convertible promissory note modification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xml:lang="en-US">Warrant issuance costs related to debt financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xlink:to="lab_JHII63I2MI70_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_RevaluationOfPremiumDebtConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation Of Premium Debt Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_RevaluationOfPremiumDebtConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_HFGG41G0KG58_nmtc_RevaluationOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_JHII63I2MI70_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_RevaluationOfWarrantLiability" xlink:to="lab_JHII63I2MI70_nmtc_RevaluationOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_HFGG41G0KG58_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JHII63I2MI70_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_JHII63I2MI70_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_HFGG41G0KG58_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_JHII63I2MI70_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PaymentsToAcquireIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Purchase of intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Purchase of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_HFGG41G0KG58_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_JHII63I2MI70_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_HFGG41G0KG58_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of convertible promissory notes and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Gross proceeds by convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of warrants associated with convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_JHII63I2MI70_us-gaap_ProceedsFromConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xml:lang="en-US">Proceeds From Issuance Of Warrants Associated With Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xml:lang="en-US">Proceeds from issuance of warrants associated with convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xml:lang="en-US">The cash inflow from issuance of warrants associated with convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xlink:label="loc_HFGG41G0KG58_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xml:lang="en-US">Proceeds From Issuance Of Warrants Associated With Short Term Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xml:lang="en-US">Proceeds from issuance of warrants associated with short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xml:lang="en-US">Proceeds from issuance of warrants associated with short term notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xlink:to="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from issuance of common stock in connection with private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Gross proceeds from offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Gross proceeds were raised out</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xlink:label="loc_HFGG41G0KG58_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xml:lang="en-US">Proceeds From Issuance Of Warrants With Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xml:lang="en-US">Proceeds from issuance of warrants in connection with private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xml:lang="en-US">Proceeds from issuance of warrants with private placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xlink:to="lab_JHII63I2MI70_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ProceedsFromRepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromRepaymentsOfDebt" xml:lang="en-US">Proceeds from (Repayments of) Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromRepaymentsOfDebt" xml:lang="en-US">Proceeds (repayment) from unsecured loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromRepaymentsOfDebt" xml:lang="en-US">Proceeds (repayment) from unsecured loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromRepaymentsOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_HFGG41G0KG58_us-gaap_ProceedsFromShortTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Aggregate gross proceeds of short-term unsecured promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from issuance of short-term promissory notes and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Issuance costs related to short-term note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_JHII63I2MI70_us-gaap_ProceedsFromShortTermDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PaymentsOfLoanCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsOfLoanCosts" xml:lang="en-US">Payments of Loan Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsOfLoanCosts" xml:lang="en-US">Issuance costs related to convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PaymentsOfLoanCosts" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PaymentsOfLoanCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PaymentsRelatedToWarrantIssuanceCosts" xlink:label="loc_HFGG41G0KG58_nmtc_PaymentsRelatedToWarrantIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_PaymentsRelatedToWarrantIssuanceCosts" xml:lang="en-US">Payments Related To Warrant Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_PaymentsRelatedToWarrantIssuanceCosts" xml:lang="en-US">Payments related to warrant issuance costs.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JHII63I2MI70_nmtc_PaymentsRelatedToWarrantIssuanceCosts" xml:lang="en-US">Issuance costs related to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_PaymentsRelatedToWarrantIssuanceCosts" xlink:to="lab_JHII63I2MI70_nmtc_PaymentsRelatedToWarrantIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_HFGG41G0KG58_us-gaap_CashPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_JHII63I2MI70_us-gaap_CashPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental non-cash financing and investing transactions:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_HFGG41G0KG58_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Conversion Derivative Related To Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Bifurcation of premium conversion derivatives related to convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Bifurcation of premium conversion derivative related to convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:to="lab_JHII63I2MI70_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" xml:lang="en-US">Conversion Of Short Term Notes And Convertible Promissory Notes Into Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" xml:lang="en-US">Conversion of short-term notes and convertible promissory notes into common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" xml:lang="en-US">Conversion of short term notes and convertible promissory notes into common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" xlink:label="loc_HFGG41G0KG58_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" xml:lang="en-US">Issuance Of Additional Warrants In Connection With Short Term Notes And Convertible Promissory Notes Modifications</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" xml:lang="en-US">Issuance of additional warrants in connection with short-term notes and convertible promissory notes modifications</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" xml:lang="en-US">Issuance of additional warrants in connection with short term notes and convertible promissory notes modifications.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" xlink:to="lab_JHII63I2MI70_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" xml:lang="en-US">Purchased Intangible Assets In Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" xml:lang="en-US">Purchased intangible assets in accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" xml:lang="en-US">Purchased intangible assets in accrued liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_HFGG41G0KG58_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssued1" xml:lang="en-US">Common stock issued for the purchase of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockIssued1" xlink:to="lab_JHII63I2MI70_us-gaap_StockIssued1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" xml:lang="en-US">Accrued Issuance Costs Related To Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" xml:lang="en-US">Accrued issuance costs related to private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" xml:lang="en-US">Accrued issuance costs related to private placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_HFGG41G0KG58_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued Issuance Costs Attributed To Short Term Promissory Notes And Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued issuance costs attributed to short-term promissory notes and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:to="lab_JHII63I2MI70_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued Issuance Costs Attributed To Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued issuance costs attributed to warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued issuance costs attributed to warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization and Nature of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Operations and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Nature of Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_GoingConcernAbstract" xlink:to="lab_JHII63I2MI70_nmtc_GoingConcernAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Intangibles [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IntangibleAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Accrued Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_PayablesAndAccrualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loans\Convertible Promissory Notes and Warrant Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Description of convertible notes issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtDisclosureAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Deficit [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Defined Contribution Plan [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_CompensationAndRetirementDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Defined Contribution Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventsAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" xml:lang="en-US">Basis Of Presentation And Change In Fiscal Year [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Change in Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" xml:lang="en-US">Basis of presentation and change in fiscal year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_HFGG41G0KG58_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_UseOfEstimates" xml:lang="en-US">Management's Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_UseOfEstimates" xlink:to="lab_JHII63I2MI70_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ConcentrationRiskCreditRisk"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommonStockValuationPolicyTextBlock" xlink:label="loc_HFGG41G0KG58_nmtc_CommonStockValuationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_CommonStockValuationPolicyTextBlock" xml:lang="en-US">Common Stock Valuation [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_CommonStockValuationPolicyTextBlock" xml:lang="en-US">Common Stock Valuation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_CommonStockValuationPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for common stock valuation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_CommonStockValuationPolicyTextBlock" xlink:to="lab_JHII63I2MI70_nmtc_CommonStockValuationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IntellectualPropertyPolicyTextBlock" xlink:label="loc_HFGG41G0KG58_nmtc_IntellectualPropertyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Intellectual Property [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Intellectual Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy fori ntellectual property.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_IntellectualPropertyPolicyTextBlock" xlink:to="lab_JHII63I2MI70_nmtc_IntellectualPropertyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtPolicyTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_DebtPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiabilityPolicyTextBlock" xlink:label="loc_HFGG41G0KG58_nmtc_WarrantLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_WarrantLiabilityPolicyTextBlock" xlink:to="lab_JHII63I2MI70_nmtc_WarrantLiabilityPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Premium Debt Conversion Derivative [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Premium Debt Conversion Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_SummaryOfWarrantActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfWarrantActivityTableTextBlock" xml:lang="en-US">Summary Of Warrant Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfWarrantActivityTableTextBlock" xml:lang="en-US">Summary of warrant activity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfWarrantActivityTableTextBlock" xml:lang="en-US">The entire disclosure of warrant activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfWarrantActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" xlink:label="loc_HFGG41G0KG58_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" xml:lang="en-US">Summary Information About Warrants Outstanding [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" xml:lang="en-US">Summary of information about warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" xml:lang="en-US">The entire disclosure of summarizes information about warrants outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" xlink:to="lab_JHII63I2MI70_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value of financial instruments measured on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of short-term promissory notes, unsecured loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfDebtTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Schedule of convertible promissory notes and warrant agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebtTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_HFGG41G0KG58_us-gaap_OffsettingAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OffsettingAssetsTable" xml:lang="en-US">Offsetting Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OffsettingAssetsTable" xlink:to="lab_JHII63I2MI70_us-gaap_OffsettingAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DerivativeInstrumentRiskAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_JHII63I2MI70_us-gaap_DerivativeContractTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockOptionMember" xml:lang="en-US">Stock option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockOptionMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_HFGG41G0KG58_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_EmployeeStockOptionMember" xlink:to="lab_JHII63I2MI70_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OffsettingAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OffsettingAssetsLineItems" xml:lang="en-US">Offsetting Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OffsettingAssetsLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OffsettingAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of stock-based services expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xml:lang="en-US">Schedule of stock option plan activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of reconciliation of income tax computed at the statutory federal income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_HFGG41G0KG58_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_srt_ConsolidatedEntitiesAxis" xlink:to="lab_JHII63I2MI70_srt_ConsolidatedEntitiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_G578G2J8HGI99092F09I_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_srt_ConsolidatedEntitiesDomain" xlink:to="lab_I790I4L0JIK11214H21K_srt_ConsolidatedEntitiesDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_HFGG41G0KG58_srt_SubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_srt_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_srt_SubsidiariesMember" xml:lang="en-US">NeuroOne, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_srt_SubsidiariesMember" xml:lang="en-US">NeuroOne, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_srt_SubsidiariesMember" xlink:to="lab_JHII63I2MI70_srt_SubsidiariesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OrganizationAndNatureOfOperationsTextualAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_OrganizationAndNatureOfOperationsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_OrganizationAndNatureOfOperationsTextualAbstract" xml:lang="en-US">Organization And Nature Of Operations Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_OrganizationAndNatureOfOperationsTextualAbstract" xml:lang="en-US">Organization and Nature of Operations (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_OrganizationAndNatureOfOperationsTextualAbstract" xlink:to="lab_JHII63I2MI70_nmtc_OrganizationAndNatureOfOperationsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Acquired percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Common stock, ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Common stock, ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_HFGG41G0KG58_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Description of acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="lab_JHII63I2MI70_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ConversionOfStockDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConversionOfStockDescription" xml:lang="en-US">Conversion of Stock, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConversionOfStockDescription" xml:lang="en-US">Conversation of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ConversionOfStockDescription" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ConversionOfStockDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_HFGG41G0KG58_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Par value of outstanding shares of common stock of NeuroOne</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_JHII63I2MI70_us-gaap_BusinessAcquisitionSharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Par value of company's common stock issued in lieu of exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_HFGG41G0KG58_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Common shares exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_JHII63I2MI70_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate shares issued of the then-outstanding NeuroOne shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate shares issued of the then-outstanding NeuroOne shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_HFGG41G0KG58_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Reserved shares of common stock for issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Reserve related future issuance of shares associated with the stock award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Restricted common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_JHII63I2MI70_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Tendered for cancellation of shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Tendered for cancellation of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernTable" xlink:label="loc_HFGG41G0KG58_nmtc_GoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_GoingConcernTable" xml:lang="en-US">Going Concern [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_GoingConcernTable" xlink:to="lab_JHII63I2MI70_nmtc_GoingConcernTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_JHII63I2MI70_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">2016 Convertible Promissory Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">2017 Convertible Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernLineItems" xlink:label="loc_HFGG41G0KG58_nmtc_GoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_GoingConcernLineItems" xml:lang="en-US">Going Concern [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_GoingConcernLineItems" xlink:to="lab_JHII63I2MI70_nmtc_GoingConcernLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_GoingConcernTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_GoingConcernTextualAbstract" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_GoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_HFGG41G0KG58_us-gaap_UnsecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebt" xml:lang="en-US">Unsecured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebt" xml:lang="en-US">Unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_UnsecuredDebt" xlink:to="lab_JHII63I2MI70_us-gaap_UnsecuredDebt"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BankLoansAndNotesPayable" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_BankLoansAndNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BankLoansAndNotesPayable" xml:lang="en-US">Bank Loans And Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BankLoansAndNotesPayable" xml:lang="en-US">Short-term promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BankLoansAndNotesPayable" xml:lang="en-US">Bank loans and notes payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_BankLoansAndNotesPayable" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_BankLoansAndNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" xml:lang="en-US">Long-term Commercial Paper</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" xml:lang="en-US">Convertible promissory note financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" xlink:to="lab_JHII63I2MI70_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesPayableOne" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConvertibleNotesPayableOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesPayableOne" xml:lang="en-US">Convertible Notes Payable One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesPayableOne" xml:lang="en-US">Second convertible promissory note financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesPayableOne" xml:lang="en-US">Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConvertibleNotesPayableOne" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesPayableOne"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:label="loc_HFGG41G0KG58_nmtc_SubscriptionAmountToConvertiblePromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xml:lang="en-US">Subscription Amount To Convertible Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xml:lang="en-US">Convertible promissory note, subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xml:lang="en-US">Amount of subscription to convertible promissory note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:to="lab_JHII63I2MI70_nmtc_SubscriptionAmountToConvertiblePromissoryNote"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xml:lang="en-US">Subscription Amount To Convertible Promissory Note One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xml:lang="en-US">Convertible promissory note, subscription one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xml:lang="en-US">Amount of subscription to convertible promissory note one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_MaximumSubscriptionAmount" xlink:label="loc_HFGG41G0KG58_nmtc_MaximumSubscriptionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_MaximumSubscriptionAmount" xml:lang="en-US">Maximum Subscription Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_MaximumSubscriptionAmount" xml:lang="en-US">Maximum subscription amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_MaximumSubscriptionAmount" xml:lang="en-US">Maximum subscription amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_MaximumSubscriptionAmount" xlink:to="lab_JHII63I2MI70_nmtc_MaximumSubscriptionAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Gross proceeds of equity qualified financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiability" xlink:label="loc_HFGG41G0KG58_nmtc_WarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_WarrantLiability" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantLiability" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_WarrantLiability" xml:lang="en-US">Warant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_WarrantLiability" xlink:to="lab_JHII63I2MI70_nmtc_WarrantLiability"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumConversionDerivative" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_PremiumConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumConversionDerivative" xml:lang="en-US">Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumConversionDerivative" xml:lang="en-US">Premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumConversionDerivative" xml:lang="en-US">Premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_PremiumConversionDerivative" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_PremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_HFGG41G0KG58_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_JHII63I2MI70_us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantMember" xml:lang="en-US">2018 Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantMember" xml:lang="en-US">Warrant liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_WarrantMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_ScheduleOfWarrantLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ScheduleOfWarrantLiabilityAbstract" xml:lang="en-US">Schedule Of Warrant Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ScheduleOfWarrantLiabilityAbstract" xml:lang="en-US">Schedule of warrant liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:to="lab_JHII63I2MI70_nmtc_ScheduleOfWarrantLiabilityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance as of end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsAndValueAssignedToWarrants" xlink:label="loc_HFGG41G0KG58_nmtc_ProceedsAndValueAssignedToWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Proceeds And Value Assigned To Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Value assigned to warrants in connection with convertible promissory and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Proceeds and value assigned to warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Value assigned to warrants in connection with convertible promissory and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_JHII63I2MI70_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ProceedsAndValueAssignedToWarrants" xlink:to="lab_JHII63I2MI70_nmtc_ProceedsAndValueAssignedToWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ReclassificationToEquity" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ReclassificationToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ReclassificationToEquity" xml:lang="en-US">Reclassification To Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ReclassificationToEquity" xml:lang="en-US">Reclassification to equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ReclassificationToEquity" xml:lang="en-US">Reclassification to equity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ReclassificationToEquity" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ReclassificationToEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value changes of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability and derecognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Aggregate fair value attributed to the warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value changes of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_DebtConversionDerivativeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Debt Conversion Derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Premium debt conversion derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Debt Conversion Derivative [Member].</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Premium debt conversion derivatives [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_DebtConversionDerivativeMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_DebtConversionDerivativeMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xml:lang="en-US">Schedule Of Premium Conversion Derivative [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xml:lang="en-US">Schedule of Premium debt conversion derivative [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:to="lab_JHII63I2MI70_nmtc_ScheduleOfPremiumConversionDerivativeAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivative" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_PremiumDebtConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivative" xml:lang="en-US">Premium Debt Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivative" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivative" xml:lang="en-US">Balance as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivative" xml:lang="en-US">Premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_PremiumDebtConversionDerivative" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_HFGG41G0KG58_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value Assigned To Underlying Derivative In Connection With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value assigned to the underlying derivative in connection with convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:to="lab_JHII63I2MI70_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xml:lang="en-US">Change In Fair Value Of Premium Debt Conversion Derivative And Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xml:lang="en-US">Change in fair value of premium debt conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xml:lang="en-US">Change in fair value of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_JHII63I2MI70_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_HFGG41G0KG58_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_JHII63I2MI70_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_HFGG41G0KG58_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharePrice" xml:lang="en-US">Estimated fair value of our common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SharePrice" xlink:to="lab_JHII63I2MI70_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdditionalPotentialWarrants" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AdditionalPotentialWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdditionalPotentialWarrants" xml:lang="en-US">Additional Potential Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdditionalPotentialWarrants" xml:lang="en-US">Additional potential warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdditionalPotentialWarrants" xml:lang="en-US">Fair Value Adjustment Of Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AdditionalPotentialWarrants" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AdditionalPotentialWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NumberOfLicencingAgreements" xlink:label="loc_HFGG41G0KG58_nmtc_NumberOfLicencingAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_NumberOfLicencingAgreements" xml:lang="en-US">Number Of Licencing Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_NumberOfLicencingAgreements" xml:lang="en-US">Number of licencing agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_NumberOfLicencingAgreements" xml:lang="en-US">Number of agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_NumberOfLicencingAgreements" xlink:to="lab_JHII63I2MI70_nmtc_NumberOfLicencingAgreements"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. federal corporate tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at federal statutory rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xml:lang="en-US">Convertible estimated price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebt" xml:lang="en-US">Investment on convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleDebt" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_HFGG41G0KG58_us-gaap_OtherCommitmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OtherCommitmentsTable" xml:lang="en-US">Other Commitments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OtherCommitmentsTable" xlink:to="lab_JHII63I2MI70_us-gaap_OtherCommitmentsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">WARF License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_TechnologyBasedIntangibleAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_HFGG41G0KG58_us-gaap_IntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Mayo Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IntellectualPropertyMember" xlink:to="lab_JHII63I2MI70_us-gaap_IntellectualPropertyMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OtherCommitmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherCommitmentsLineItems" xml:lang="en-US">Other Commitments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OtherCommitmentsLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_JHII63I2MI70_nmtc_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_LongTermPurchaseCommitmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Long-term Purchase Commitment, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Milestone payments in connection with WARF License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_LongTermPurchaseCommitmentAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Estimated fair value of intangible asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CummulativeFinancingTriggersPayment" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_CummulativeFinancingTriggersPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment" xml:lang="en-US">Cummulative Financing Triggers Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment" xml:lang="en-US">Cummulative financing triggers payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment" xml:lang="en-US">Cummulative financing triggers payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_CummulativeFinancingTriggersPayment" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_HFGG41G0KG58_us-gaap_OtherCommitmentDueInThirdYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">Other Commitment, Due in Third Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">Minimum royalties for the year 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_JHII63I2MI70_us-gaap_OtherCommitmentDueInThirdYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OtherCommitmentDueInFourthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Other Commitment, Due in Fourth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Minimum royalties for the year 2020</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Royalties per year beginning from 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OtherCommitmentDueInFourthYear"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OtherCommitmentDueAfterFourthYear" xlink:label="loc_HFGG41G0KG58_nmtc_OtherCommitmentDueAfterFourthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_OtherCommitmentDueAfterFourthYear" xml:lang="en-US">Other Commitment Due After Fourth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_OtherCommitmentDueAfterFourthYear" xml:lang="en-US">Royalties per year beginning from 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_OtherCommitmentDueAfterFourthYear" xml:lang="en-US">Other Commitment Due After Fourth Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_OtherCommitmentDueAfterFourthYear" xlink:to="lab_JHII63I2MI70_nmtc_OtherCommitmentDueAfterFourthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentIssuanceDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentIssuanceDate1" xml:lang="en-US">Debt Instrument, Issuance Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentIssuanceDate1" xml:lang="en-US">Expiry date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentIssuanceDate1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentIssuanceDate1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CostIncurredMaintainingLicensedPatents" xlink:label="loc_HFGG41G0KG58_nmtc_CostIncurredMaintainingLicensedPatents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_CostIncurredMaintainingLicensedPatents" xml:lang="en-US">Cost Incurred Maintaining Licensed Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_CostIncurredMaintainingLicensedPatents" xml:lang="en-US">Cost incurred maintaining licensed patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_CostIncurredMaintainingLicensedPatents" xml:lang="en-US">The amount cost incurred in maintaning licensed patents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_CostIncurredMaintainingLicensedPatents" xlink:to="lab_JHII63I2MI70_nmtc_CostIncurredMaintainingLicensedPatents"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CummulativeFinancingTriggersPayment1" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_CummulativeFinancingTriggersPayment1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment1" xml:lang="en-US">Cummulative Financing Triggers Payment1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment1" xml:lang="en-US">Additional cummulative financing triggers payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment1" xml:lang="en-US">Cummulative financing triggers payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_CummulativeFinancingTriggersPayment1" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_CummulativeFinancingTriggersPayment1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmountRecordedForIntellectualProperty" xlink:label="loc_HFGG41G0KG58_nmtc_AmountRecordedForIntellectualProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AmountRecordedForIntellectualProperty" xml:lang="en-US">Amount Recorded For Intellectual Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AmountRecordedForIntellectualProperty" xml:lang="en-US">Milestone amount recorded for intellectual property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AmountRecordedForIntellectualProperty" xml:lang="en-US">Amount recorded for intellectual property.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AmountRecordedForIntellectualProperty" xlink:to="lab_JHII63I2MI70_nmtc_AmountRecordedForIntellectualProperty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Milestone payments paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PercentageOfAccruedInterest" xlink:label="loc_HFGG41G0KG58_nmtc_PercentageOfAccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_PercentageOfAccruedInterest" xml:lang="en-US">Percentage Of Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_PercentageOfAccruedInterest" xml:lang="en-US">Percentage of unpaid accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_PercentageOfAccruedInterest" xml:lang="en-US">Percentage of accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_PercentageOfAccruedInterest" xlink:to="lab_JHII63I2MI70_nmtc_PercentageOfAccruedInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">Additional amount of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesFairValueDisclosure" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesFairValueDisclosure" xml:lang="en-US">Accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_HFGG41G0KG58_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_srt_RangeAxis" xlink:to="lab_JHII63I2MI70_srt_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_G578G2J8HGI99092F09I_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_srt_RangeMember" xlink:to="lab_I790I4L0JIK11214H21K_srt_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_HFGG41G0KG58_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_srt_MinimumMember" xlink:to="lab_JHII63I2MI70_srt_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_G578G2J8HGI99092F09I_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_srt_MaximumMember" xlink:to="lab_I790I4L0JIK11214H21K_srt_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsRollForward" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsRollForward" xml:lang="en-US">Schedule of Intangible Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Net Intangibles, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Intangibles, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Intangibles, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="loc_HFGG41G0KG58_us-gaap_FiniteLivedLicenseAgreementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedLicenseAgreementsGross" xml:lang="en-US">Finite-Lived License Agreements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedLicenseAgreementsGross" xml:lang="en-US">License agreement amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="lab_JHII63I2MI70_us-gaap_FiniteLivedLicenseAgreementsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Less: amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Less: amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_JHII63I2MI70_us-gaap_FairValueByAssetClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Intangible Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="lab_JHII63I2MI70_us-gaap_FiniteLivedIntangibleAssetsMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Goodwil And Intangible Assets Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Intangibles (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Goodwil And Intangible Assets Textual [Abstract].</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_GoodwilAndIntangibleAssetsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmortizationExpenseDescription" xlink:label="loc_HFGG41G0KG58_nmtc_AmortizationExpenseDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AmortizationExpenseDescription" xml:lang="en-US">Amortization Expense Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AmortizationExpenseDescription" xml:lang="en-US">Amortization expense, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AmortizationExpenseDescription" xml:lang="en-US">Amortization expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AmortizationExpenseDescription" xlink:to="lab_JHII63I2MI70_nmtc_AmortizationExpenseDescription"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AccruedLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued license fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued License Fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AccruedLicenseFees" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AccruedLicenseFees"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLegalCosts" xlink:label="loc_HFGG41G0KG58_nmtc_AccruedLegalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AccruedLegalCosts" xml:lang="en-US">Accrued Legal Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AccruedLegalCosts" xml:lang="en-US">Legal costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AccruedLegalCosts" xml:lang="en-US">Accrued legal costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AccruedLegalCosts" xlink:to="lab_JHII63I2MI70_nmtc_AccruedLegalCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AccruedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued Issuance Costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AccruedIssuanceCosts" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AccruedIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedPayroll" xlink:label="loc_HFGG41G0KG58_nmtc_AccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AccruedPayroll" xml:lang="en-US">Accrued Payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AccruedPayroll" xml:lang="en-US">Accrued compensation and payroll related costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AccruedPayroll" xml:lang="en-US">Accrued payroll.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AccruedPayroll" xlink:to="lab_JHII63I2MI70_nmtc_AccruedPayroll"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedExpensesAdvances" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AccruedExpensesAdvances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedExpensesAdvances" xml:lang="en-US">Accrued Expenses Advances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedExpensesAdvances" xml:lang="en-US">Advances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccruedExpensesAdvances" xml:lang="en-US">Accrued Expenses Advances.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AccruedExpensesAdvances" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AccruedExpensesAdvances"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_OtherAccruedLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Accrued expenses include an obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="lab_JHII63I2MI70_us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" xml:lang="en-US">Borrowings Including Accrued Interest Bank Loans And Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" xml:lang="en-US">Short-term promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" xml:lang="en-US">Borrowings including accrued interest bank loans and notes payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_HFGG41G0KG58_us-gaap_UnsecuredDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Unsecured Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Short-term unsecured loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Unsecured loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Unsecured loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_UnsecuredDebtCurrent" xlink:to="lab_JHII63I2MI70_us-gaap_UnsecuredDebtCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShortTermDebtTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_ExtinguishmentOfDebtAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ExtinguishmentOfDebtAxis" xml:lang="en-US">Extinguishment of Debt [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_JHII63I2MI70_us-gaap_ExtinguishmentOfDebtAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ExtinguishmentOfDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ExtinguishmentOfDebtTypeDomain" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ExtinguishmentOfDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_HFGG41G0KG58_us-gaap_ShortTermDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-term Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-Term Promissory Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-Term Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShortTermDebtMember" xlink:to="lab_JHII63I2MI70_us-gaap_ShortTermDebtMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OtherDebtMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_OtherDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_OtherDebtMember" xml:lang="en-US">Other Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_OtherDebtMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_OtherDebtMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_OtherDebtMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumConversionDerivativeMember" xlink:label="loc_HFGG41G0KG58_nmtc_PremiumConversionDerivativeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_PremiumConversionDerivativeMember" xml:lang="en-US">Premium Conversion Derivative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_PremiumConversionDerivativeMember" xlink:to="lab_JHII63I2MI70_nmtc_PremiumConversionDerivativeMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" xml:lang="en-US">Cancellation Extinguishment And Conversion Of Short Term Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" xml:lang="en-US">Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Short-Term Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_JHII63I2MI70_us-gaap_LongtermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_LongtermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_HFGG41G0KG58_us-gaap_UnsecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_UnsecuredDebtMember" xlink:to="lab_JHII63I2MI70_us-gaap_UnsecuredDebtMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShortTermDebtLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShortTermDebtLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xml:lang="en-US">Short Term Promissory Notes And Unsecured Loan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:to="lab_JHII63I2MI70_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Issuance costs discounted of short-term unsecured promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_HFGG41G0KG58_us-gaap_ShortTermDebtDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShortTermDebtDescription" xml:lang="en-US">Short-term Debt, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShortTermDebtDescription" xml:lang="en-US">Short-term debt, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShortTermDebtDescription" xlink:to="lab_JHII63I2MI70_us-gaap_ShortTermDebtDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Short-term unsecured promissory notes maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Repay principal and accrued and unpaid interest earlier</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_HFGG41G0KG58_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Converted into shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_JHII63I2MI70_us-gaap_ConversionOfStockSharesConverted1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Convertible promissory notes converted into common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Shares of common stock issuable upon exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermPaymentWarrants" xlink:label="loc_HFGG41G0KG58_nmtc_ShortTermPaymentWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShortTermPaymentWarrants" xml:lang="en-US">Short Term Payment Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShortTermPaymentWarrants" xml:lang="en-US">Short-term payment warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShortTermPaymentWarrants" xml:lang="en-US">Short term payment warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShortTermPaymentWarrants" xlink:to="lab_JHII63I2MI70_nmtc_ShortTermPaymentWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_CommonStockPurchaseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common Stock Purchase Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common stock purchase of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_CommonStockPurchaseOfWarrants" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_CommonStockPurchaseOfWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_HFGG41G0KG58_nmtc_WarrantsMaturityTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants Maturity Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants maturity term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrant term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants maturity term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_WarrantsMaturityTerm" xlink:to="lab_JHII63I2MI70_nmtc_WarrantsMaturityTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ValueOfPremiumConversionDerivative" xlink:label="loc_HFGG41G0KG58_nmtc_ValueOfPremiumConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ValueOfPremiumConversionDerivative" xml:lang="en-US">Value Of Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ValueOfPremiumConversionDerivative" xml:lang="en-US">Value of premium conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ValueOfPremiumConversionDerivative" xml:lang="en-US">Value of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ValueOfPremiumConversionDerivative" xlink:to="lab_JHII63I2MI70_nmtc_ValueOfPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_FairValueAssumptionRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumption Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionRiskFreeInterestRate" xml:lang="en-US">Fair value of warrants risk-free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_FairValueAssumptionRiskFreeInterestRate" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_HFGG41G0KG58_nmtc_FairValueAssumptionExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumption Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedVolatilityRate" xml:lang="en-US">Fair value of warrants expected volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedVolatilityRate" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_FairValueAssumptionExpectedVolatilityRate" xlink:to="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedTerm" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_FairValueAssumptionExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionExpectedTerm" xml:lang="en-US">Fair Value Assumption Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionExpectedTerm" xml:lang="en-US">Fair value of warrants expected life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionExpectedTerm" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_FairValueAssumptionExpectedTerm" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_FairValueAssumptionExpectedTerm"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedDividendRate" xlink:label="loc_HFGG41G0KG58_nmtc_FairValueAssumptionExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedDividendRate" xml:lang="en-US">Fair Value Assumption Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedDividendRate" xml:lang="en-US">Fair value of warrants expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedDividendRate" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_FairValueAssumptionExpectedDividendRate" xlink:to="lab_JHII63I2MI70_nmtc_FairValueAssumptionExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdditionalWarrantsAllocated" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AdditionalWarrantsAllocated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdditionalWarrantsAllocated" xml:lang="en-US">Additional Warrants Allocated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdditionalWarrantsAllocated" xml:lang="en-US">Additional warrants allocated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AdditionalWarrantsAllocated" xml:lang="en-US">Additional warrants allocated additional coverage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AdditionalWarrantsAllocated" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AdditionalWarrantsAllocated"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsExpirationDate" xlink:label="loc_HFGG41G0KG58_nmtc_WarrantsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsExpirationDate" xml:lang="en-US">Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsExpirationDate" xml:lang="en-US">Warrants expiration date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_WarrantsExpirationDate" xlink:to="lab_JHII63I2MI70_nmtc_WarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_LossOnShortTermNotesExtinguishment" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_LossOnShortTermNotesExtinguishment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_LossOnShortTermNotesExtinguishment" xml:lang="en-US">Loss On Short Term Notes Extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_LossOnShortTermNotesExtinguishment" xml:lang="en-US">Loss on short-term notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_LossOnShortTermNotesExtinguishment" xml:lang="en-US">Difference between the face value of the short-term notes over the combined carrying values of the short-term notes and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_LossOnShortTermNotesExtinguishment" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_LossOnShortTermNotesExtinguishment"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:label="loc_HFGG41G0KG58_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xml:lang="en-US">Fair Value Adjustment Of Short Term Notes And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xml:lang="en-US">Fair value decrease of short-term notes and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of short term notes and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:to="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Convertible notes bear interest at fixed rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Percentage of convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Outstanding principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShortTermNoteQualifiedFinancingDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShortTermNoteQualifiedFinancingDescription" xml:lang="en-US">Short Term Note Qualified Financing, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShortTermNoteQualifiedFinancingDescription" xml:lang="en-US">Shor-term note qualified financing, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShortTermNoteQualifiedFinancingDescription" xml:lang="en-US">Description of short-term note qualified financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShortTermNoteQualifiedFinancingDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtConversionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtConversionDescription" xml:lang="en-US">Debt Conversion, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtConversionDescription" xml:lang="en-US">Short-term notes conversion, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtConversionDescription" xml:lang="en-US">Debt conversion, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtConversionDescription" xlink:to="lab_JHII63I2MI70_us-gaap_DebtConversionDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherLiabilities" xml:lang="en-US">Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherLiabilities" xml:lang="en-US">Advances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OtherLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OtherLiabilities" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OtherLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_HFGG41G0KG58_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Gross proceeds upon equity qualified financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfDebt"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsExercisableDescription" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_WarrantsExercisableDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantsExercisableDescription" xml:lang="en-US">Warrants Exercisable Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantsExercisableDescription" xml:lang="en-US">Warrants exercisable, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantsExercisableDescription" xml:lang="en-US">Warrants exercisable description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_WarrantsExercisableDescription" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_WarrantsExercisableDescription"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdjustmentToAccountForChangeInValuation" xlink:label="loc_HFGG41G0KG58_nmtc_AdjustmentToAccountForChangeInValuation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AdjustmentToAccountForChangeInValuation" xml:lang="en-US">Adjustment To Account For Change In Valuation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AdjustmentToAccountForChangeInValuation" xml:lang="en-US">Adjustment to account for change in valuation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AdjustmentToAccountForChangeInValuation" xml:lang="en-US">Adjustment to account for change in valuation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AdjustmentToAccountForChangeInValuation" xlink:to="lab_JHII63I2MI70_nmtc_AdjustmentToAccountForChangeInValuation"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xml:lang="en-US">Issuance Of Additional Warrants In Connection With Short Term Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xml:lang="en-US">Issuance of additional warrants in connection with short term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xml:lang="en-US">Issuance of additional warrants in connection with short term notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_HFGG41G0KG58_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleDebtMember" xml:lang="en-US">2016 convertible promissory notes, net of discounts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ConvertibleDebtMember" xlink:to="lab_JHII63I2MI70_us-gaap_ConvertibleDebtMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNoteMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConvertiblePromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteMember" xml:lang="en-US">2017 convertible promissory notes, net of discounts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConvertiblePromissoryNoteMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FinancialInstrumentAxis" xlink:to="lab_JHII63I2MI70_us-gaap_FinancialInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_JHII63I2MI70_us-gaap_AccruedLiabilitiesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_InterestPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Interest Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_InterestPayableCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_HFGG41G0KG58_us-gaap_ConvertibleNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible promissory notes, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible notes and common stock purchase warrants to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Balance as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Long-term portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ConvertibleNotesPayable" xlink:to="lab_JHII63I2MI70_us-gaap_ConvertibleNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentTable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentTable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAgreementMember" xlink:label="loc_HFGG41G0KG58_nmtc_SubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_SubscriptionAgreementMember" xml:lang="en-US">Subscription Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_SubscriptionAgreementMember" xlink:to="lab_JHII63I2MI70_nmtc_SubscriptionAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NovemberTwoThousandSeventeenMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_NovemberTwoThousandSeventeenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_NovemberTwoThousandSeventeenMember" xml:lang="en-US">November Two Thousand Seventeen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_NovemberTwoThousandSeventeenMember" xml:lang="en-US">November 2017 amendment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_NovemberTwoThousandSeventeenMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_NovemberTwoThousandSeventeenMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:label="loc_HFGG41G0KG58_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xml:lang="en-US">Two Zero One Seven Convertible Note Amendment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xml:lang="en-US">2017 Convertible Note amendment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:to="lab_JHII63I2MI70_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleDebtOneMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConvertibleDebtOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">Convertible Debt One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">2017 Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">2017 Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConvertibleDebtOneMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleDebtOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_JHII63I2MI70_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_HFGG41G0KG58_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private placement agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_PrivatePlacementMember" xml:lang="en-US">2018 Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_PrivatePlacementMember" xlink:to="lab_JHII63I2MI70_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NewWarrantsMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_NewWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_NewWarrantsMember" xml:lang="en-US">New Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_NewWarrantsMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_NewWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentLineItems" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xml:lang="en-US">Convertible Promissory Notes And Warrant Agreements Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_HFGG41G0KG58_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Exchange for the issuance of company shares acquisition percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JHII63I2MI70_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of outstanding voting power</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_JHII63I2MI70_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Issuance of Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Outstanding principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Qualified financing that tirggers note conversion amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible notes, principal balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Description of subscription agreement with certain investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentInterestRateTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Description of outstanding principal and accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentInterestRateTerms" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentInterestRateTerms"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_HFGG41G0KG58_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description Of Maximum Voting Power Of Surviving Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description of maximum voting power of surviving entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description of maximum voting power of surviving entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:to="lab_JHII63I2MI70_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount Of Convertible Note Held By Warrant Holder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount of convertible note held by warrant holder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount of convertible note held by warrant holder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_HFGG41G0KG58_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Warrants exercisable date of issuance and expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_JHII63I2MI70_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible Promissory Note Proceeds Assigned To Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible promissory note proceeds assigned to warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible promissory note proceeds assigned to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_HFGG41G0KG58_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Non-cash interest or non-cash interest on principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_JHII63I2MI70_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_InterestExpense" xml:lang="en-US">Convertible notes to interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_InterestExpense" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtConversionConvertedInstrumentRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtConversionConvertedInstrumentRate" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtConversionConvertedInstrumentRate" xml:lang="en-US">Convertible notes conversion premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="lab_JHII63I2MI70_us-gaap_DebtConversionConvertedInstrumentRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Convertible notes conversion price per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion shares, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmortizationOfDiscountToConvertibleNotes" xlink:label="loc_HFGG41G0KG58_nmtc_AmortizationOfDiscountToConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_AmortizationOfDiscountToConvertibleNotes" xml:lang="en-US">Amortization Of Discount To Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_AmortizationOfDiscountToConvertibleNotes" xml:lang="en-US">Amortization of discount to convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_AmortizationOfDiscountToConvertibleNotes" xml:lang="en-US">Amount of noncash expense included in interest expense to amortize debt discount and premium associated with debt financing costs. Alternate captions include noncash interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_AmortizationOfDiscountToConvertibleNotes" xlink:to="lab_JHII63I2MI70_nmtc_AmortizationOfDiscountToConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Cost of issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_HFGG41G0KG58_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible Notes Of Conversion Premium Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible notes of conversion premium amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible notes of conversion premium amortization expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:to="lab_JHII63I2MI70_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_PremiumDebtConversionDerivativeInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium Debt Conversion Derivative Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium debt conversion derivative interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium debt conversion derivative interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_PremiumDebtConversionDerivativeInterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_HFGG41G0KG58_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Convertible notes incurred issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_JHII63I2MI70_us-gaap_DeferredFinanceCostsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFee" xml:lang="en-US">Debt Instrument, Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFee" xml:lang="en-US">Description of convertible notes issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentFee" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentFee"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:label="loc_HFGG41G0KG58_nmtc_WarrantsToPurchaseSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsToPurchaseSharesOfCommonStock" xml:lang="en-US">Warrants To Purchase Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsToPurchaseSharesOfCommonStock" xml:lang="en-US">Common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_WarrantsToPurchaseSharesOfCommonStock" xml:lang="en-US">Warrants to purchase shares of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:to="lab_JHII63I2MI70_nmtc_WarrantsToPurchaseSharesOfCommonStock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_PercentageOfCommonStockPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage Of Common Stock Purchase Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage of common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage of common stock purchase warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_PercentageOfCommonStockPurchaseWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_HFGG41G0KG58_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance Costs Attributed To Common Stock Purchase Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance costs attributed to common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance costs attributed to common stock purchase warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:to="lab_JHII63I2MI70_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleDebtFairValueDisclosures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Fair value change of the amended convertible notes carrying value at time of the amendment resulting in note discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ConvertibleDebtFairValueDisclosures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt issuance cost discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConvertibleNotesMaximumExtensionLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Convertible Notes Maximum Extension Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Convertible notes maximum extension limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Convertible notes maximum extension limit.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Subscription agreement limit 2017 convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConvertibleNotesMaximumExtensionLimit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_HFGG41G0KG58_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_LegalFees" xlink:to="lab_JHII63I2MI70_us-gaap_LegalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Fair value of underlying convertible notes, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:label="loc_HFGG41G0KG58_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xml:lang="en-US">Fair Value Adjustment Of Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xml:lang="en-US">Fair value changes on premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xml:lang="en-US">Fair value adjustment of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:to="lab_JHII63I2MI70_nmtc_FairValueAdjustmentOfPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueChangesOfWarrantLiability" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_FairValueChangesOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueChangesOfWarrantLiability" xml:lang="en-US">Fair Value Changes Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueChangesOfWarrantLiability" xml:lang="en-US">Fair value changes of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueChangesOfWarrantLiability" xml:lang="en-US">Fair value changes of warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_FairValueChangesOfWarrantLiability" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_FairValueChangesOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_HFGG41G0KG58_us-gaap_DebtInstrumentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt Instrument, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Conversion agreements, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DebtInstrumentDescription" xlink:to="lab_JHII63I2MI70_us-gaap_DebtInstrumentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Shares of common stock issuable upon exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xlink:label="loc_HFGG41G0KG58_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xml:lang="en-US">Debt Conversion Converted Note Payment Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xml:lang="en-US">Note payment warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xml:lang="en-US">The amount of note payment warrants issued in debt conversion.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xlink:to="lab_JHII63I2MI70_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_WarrantLiabilityValueOfReclassifiedToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xml:lang="en-US">Warrant Liability Value Of Reclassified To Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xml:lang="en-US">Warrant liability value of reclassified to equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xml:lang="en-US">Warrant liability value of reclassified to equity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_WarrantLiabilityValueOfReclassifiedToEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_JHII63I2MI70_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_HFGG41G0KG58_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_JHII63I2MI70_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_HFGG41G0KG58_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based services expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_JHII63I2MI70_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OptionIndexedToIssuersEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OptionIndexedToIssuersEquityTable" xml:lang="en-US">Option Indexed to Issuer's Equity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OptionIndexedToIssuersEquityTable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OptionIndexedToIssuersEquityTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_JHII63I2MI70_us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockOptionPlanMember" xlink:label="loc_HFGG41G0KG58_nmtc_StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_StockOptionPlanMember" xml:lang="en-US">Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_StockOptionPlanMember" xml:lang="en-US">Stock option plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_StockOptionPlanMember" xlink:to="lab_JHII63I2MI70_nmtc_StockOptionPlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_OptionIndexedToIssuersEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_OptionIndexedToIssuersEquityLineItems" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_OptionIndexedToIssuersEquityLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Number of Warrant Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock options, granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Warrants, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_JHII63I2MI70_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Number of Options, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options, Vested and exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Outstanding, Number Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock options weighted average exercise price for shares of common stock granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Vested and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years), Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual life (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years), Vested and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Vested and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of options (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_PlanNameAxis" xlink:to="lab_JHII63I2MI70_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_PlanNameDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_HFGG41G0KG58_nmtc_TwoThousandSixteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_TwoThousandSixteenPlanMember" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_TwoThousandSixteenPlanMember" xml:lang="en-US">2016 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_TwoThousandSixteenPlanMember" xlink:to="lab_JHII63I2MI70_nmtc_TwoThousandSixteenPlanMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_TwoThousandSixteenAndSeventeenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xml:lang="en-US">Two Thousand Sixteen And Seventeen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xml:lang="en-US">2016 and 2017 Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_TitleOfIndividualAxis" xlink:to="lab_JHII63I2MI70_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_HFGG41G0KG58_nmtc_EmployeesDirectorsAndConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees, directors, and consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_JHII63I2MI70_nmtc_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_AwardTypeAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_RestrictedStockMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_StockBasedCompensationTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockBasedCompensationTextualAbstract" xml:lang="en-US">Stock Based Compensation Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockBasedCompensationTextualAbstract" xml:lang="en-US">Stock-Based Compensation (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_StockBasedCompensationTextualAbstract" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_StockBasedCompensationTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_HFGG41G0KG58_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Vested Restricted Common Stock Capital Shares Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Restricted common stock not yet issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of vested restricted shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_JHII63I2MI70_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueOfCommonStockPricePerShare" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_FairValueOfCommonStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueOfCommonStockPricePerShare" xml:lang="en-US">Fair Value Of Common Stock Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueOfCommonStockPricePerShare" xml:lang="en-US">Fair value of common stock price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_FairValueOfCommonStockPricePerShare" xml:lang="en-US">Fair value of common stock price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_FairValueOfCommonStockPricePerShare" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_FairValueOfCommonStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_HFGG41G0KG58_us-gaap_SaleOfStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Description of founders' shares subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Stock award vesting and issued, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_JHII63I2MI70_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_MonthlyCompensationAmount" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_MonthlyCompensationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_MonthlyCompensationAmount" xml:lang="en-US">Monthly Compensation Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_MonthlyCompensationAmount" xml:lang="en-US">Monthly compensation amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_MonthlyCompensationAmount" xml:lang="en-US">Monthly compensation amount divided by the fair value of the underlying common stock on the award date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_MonthlyCompensationAmount" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_MonthlyCompensationAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xml:lang="en-US">Compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Grant date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value of restricted stock award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Option expiry term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Vested shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xml:lang="en-US">Vested per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Vested In Period Intrinsic Values</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xml:lang="en-US">Vested per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xml:lang="en-US">Per share weighted average grant date fair value of equity-based compensation awards vested. Excludes stock options and unit options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xlink:label="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Option Vested In Period Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xml:lang="en-US">Vested per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xml:lang="en-US">Per share weighted average grant date fairvalue of equity-based compensation awards vested. Excludes stock awards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xlink:to="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_RestrictedStockExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RestrictedStockExpense" xml:lang="en-US">Compensation expense associated with restricted common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_RestrictedStockExpense" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_RestrictedStockExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Outstanding, Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Outstanding, Exercisable Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xml:lang="en-US">Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options issued in period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xml:lang="en-US">Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xlink:label="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Exercise Price Warrant Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xml:lang="en-US">Exercise Price Per Warrant, Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xml:lang="en-US">Share based compensation arrangement by share based payment award warrant outstanding exercise price warrant beginning balance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xlink:to="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Exercise Price Warrant Issued Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xml:lang="en-US">Exercise Price Per Warrant, Issued Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xml:lang="en-US">share based compensation arrangement by share based payment award warrant outstanding exercise price warrant issued maximum.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xlink:label="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Exercise Price Warrant Issued Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xml:lang="en-US">Exercise Price Per Warrant, Issued Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xml:lang="en-US">Share based compensation arrangement by share based payment award warrant outstanding exercise price warrant issued minimum.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xlink:to="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Exercise Price Warrant Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xml:lang="en-US">Exercise Price Per Warrant, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xml:lang="en-US">share based compensation arrangement by share based payment award warrant outstanding exercise price warrant exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xlink:label="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Exercise Price Warrant Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xml:lang="en-US">Exercise Price Per Warrant, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xml:lang="en-US">share based compensation arrangement by share based payment award warrant outstanding exercise price warrant forfeited.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xlink:to="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Exercise Price Warrant Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xml:lang="en-US">Exercise Price Per Warrant, Exercisable Ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xml:lang="en-US">Share based compensation arrangement by share based payment award warrant outstanding exercise price warrant exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Begining</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Exercisable Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xml:lang="en-US">share based compensation arrangement by share based payment award equity instruments other than options issued weighted average grant date fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xml:lang="en-US">share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="lab_JHII63I2MI70_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_JHII63I2MI70_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OneExercisePriceMember" xlink:label="loc_HFGG41G0KG58_nmtc_OneExercisePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_OneExercisePriceMember" xml:lang="en-US">One Exercise Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_OneExercisePriceMember" xml:lang="en-US">1.80 Exercise Prices [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_OneExercisePriceMember" xlink:to="lab_JHII63I2MI70_nmtc_OneExercisePriceMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ThreeExercisePriceMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ThreeExercisePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ThreeExercisePriceMember" xml:lang="en-US">Three Exercise Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ThreeExercisePriceMember" xml:lang="en-US">3.00 Exercise Price [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ThreeExercisePriceMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ThreeExercisePriceMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_HFGG41G0KG58_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_JHII63I2MI70_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_JHII63I2MI70_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_HFGG41G0KG58_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OverAllotmentOptionMember" xlink:to="lab_JHII63I2MI70_us-gaap_OverAllotmentOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_RelatedPartyDomain" xlink:to="lab_JHII63I2MI70_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccreditedInvestorsMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_AccreditedInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_AccreditedInvestorsMember" xml:lang="en-US">Accredited Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_AccreditedInvestorsMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_AccreditedInvestorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_HFGG41G0KG58_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ClassOfStockLineItems" xlink:to="lab_JHII63I2MI70_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_StockholdersMemberDeficitTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockholdersMemberDeficitTextualAbstract" xml:lang="en-US">Stockholders Member Deficit Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_StockholdersMemberDeficitTextualAbstract" xml:lang="en-US">Stockholders' Deficit (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_StockholdersMemberDeficitTextualAbstract" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_StockholdersMemberDeficitTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PurchaseAgreementDescription" xlink:label="loc_HFGG41G0KG58_nmtc_PurchaseAgreementDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_PurchaseAgreementDescription" xml:lang="en-US">Purchase Agreement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_PurchaseAgreementDescription" xml:lang="en-US">Purchase agreement, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_PurchaseAgreementDescription" xml:lang="en-US">Purchase agreement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_PurchaseAgreementDescription" xlink:to="lab_JHII63I2MI70_nmtc_PurchaseAgreementDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Aggregrate sale of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeductingOfferingExpenses" xlink:label="loc_HFGG41G0KG58_nmtc_DeductingOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DeductingOfferingExpenses" xml:lang="en-US">Deducting Offering Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DeductingOfferingExpenses" xml:lang="en-US">Deducting offering expenses.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_DeductingOfferingExpenses" xml:lang="en-US">Deducting offering expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DeductingOfferingExpenses" xlink:to="lab_JHII63I2MI70_nmtc_DeductingOfferingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharesIssued" xml:lang="en-US">Maximum offering, units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SharesIssued" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_HFGG41G0KG58_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Offering price, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_JHII63I2MI70_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrant issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="loc_HFGG41G0KG58_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xml:lang="en-US">Cash commission, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="lab_JHII63I2MI70_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_G578G2J8HGI99092F09I_invest_InvestmentWarrantsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Investment Warrants, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Exercise price, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_invest_InvestmentWarrantsExercisePrice" xlink:to="lab_I790I4L0JIK11214H21K_invest_InvestmentWarrantsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Common stock purchase price, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_JHII63I2MI70_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants exercisable, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_WarrantsAndRightsOutstandingTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_HFGG41G0KG58_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="lab_JHII63I2MI70_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">State income tax, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" xlink:label="loc_HFGG41G0KG58_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation Warrant Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" xml:lang="en-US">Warrant expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) attributable to warrant expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" xlink:to="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Disqualified interest and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" xlink:label="loc_HFGG41G0KG58_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation Research Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" xml:lang="en-US">Research credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) attributable to Research credits.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" xlink:to="lab_JHII63I2MI70_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation Research Credits Federal Tax Reform Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" xml:lang="en-US">U.S. tax reform</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" xml:lang="en-US">Percentage of federal tax reform.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_HFGG41G0KG58_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_JHII63I2MI70_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsNetAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Federal and state operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Acquired intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeferredTaxAssetsConvertibleNotes" xlink:label="loc_HFGG41G0KG58_nmtc_DeferredTaxAssetsConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DeferredTaxAssetsConvertibleNotes" xml:lang="en-US">Deferred Tax Assets Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DeferredTaxAssetsConvertibleNotes" xml:lang="en-US">Convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_DeferredTaxAssetsConvertibleNotes" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DeferredTaxAssetsConvertibleNotes" xlink:to="lab_JHII63I2MI70_nmtc_DeferredTaxAssetsConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_JHII63I2MI70_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_HFGG41G0KG58_us-gaap_IncomeTaxContingencyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US">Income Tax Contingency [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_JHII63I2MI70_us-gaap_IncomeTaxContingencyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncomeTaxAuthorityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_HFGG41G0KG58_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_JHII63I2MI70_us-gaap_IncomeTaxAuthorityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DomesticCountryMember" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DomesticCountryMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_HFGG41G0KG58_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_JHII63I2MI70_us-gaap_StateAndLocalJurisdictionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_IncomeTaxContingencyLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_IncomeTaxContingencyLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_IncomeTaxesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_IncomeTaxesTextualAbstract" xlink:to="lab_JHII63I2MI70_nmtc_IncomeTaxesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveCorporateIncomeTaxRateDescription" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_EffectiveCorporateIncomeTaxRateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_EffectiveCorporateIncomeTaxRateDescription" xml:lang="en-US">Effective Corporate Income Tax Rate Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_EffectiveCorporateIncomeTaxRateDescription" xml:lang="en-US">Corporate income tax rate, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_EffectiveCorporateIncomeTaxRateDescription" xml:lang="en-US">Effective corporate income tax rate descriptions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_EffectiveCorporateIncomeTaxRateDescription" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_EffectiveCorporateIncomeTaxRateDescription"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeductionOfNetGrossDeferredTaxAssets" xlink:label="loc_HFGG41G0KG58_nmtc_DeductionOfNetGrossDeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DeductionOfNetGrossDeferredTaxAssets" xml:lang="en-US">Deduction Of Net Gross Deferred Tax Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DeductionOfNetGrossDeferredTaxAssets" xml:lang="en-US">Reduction in net gross deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_DeductionOfNetGrossDeferredTaxAssets" xml:lang="en-US">Amount of reduction in net gross deferred tax assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DeductionOfNetGrossDeferredTaxAssets" xlink:to="lab_JHII63I2MI70_nmtc_DeductionOfNetGrossDeferredTaxAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Federal net operating loss carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Federal net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsFederal" xlink:label="loc_HFGG41G0KG58_nmtc_ResearchCreditCarryforwardsFederal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsFederal" xml:lang="en-US">Research Credit Carryforwards Federal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsFederal" xml:lang="en-US">Federal research credit carryforwads</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsFederal" xml:lang="en-US">Amount of federal research credit carryforwards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ResearchCreditCarryforwardsFederal" xlink:to="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsFederal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">State net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_HFGG41G0KG58_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating loss carryforwards, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_JHII63I2MI70_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsExpirationDate" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ResearchCreditCarryforwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ResearchCreditCarryforwardsExpirationDate" xml:lang="en-US">Research Credit Carryforwards Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ResearchCreditCarryforwardsExpirationDate" xml:lang="en-US">Research credit carryforwards, expiration dat</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ResearchCreditCarryforwardsExpirationDate" xml:lang="en-US">Research credit carryforwards expiration date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ResearchCreditCarryforwardsExpirationDate" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ResearchCreditCarryforwardsExpirationDate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsState" xlink:label="loc_HFGG41G0KG58_nmtc_ResearchCreditCarryforwardsState" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsState" xml:lang="en-US">Research Credit Carryforwards State</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsState" xml:lang="en-US">State research credit carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsState" xml:lang="en-US">State research credit carryforwards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_ResearchCreditCarryforwardsState" xlink:to="lab_JHII63I2MI70_nmtc_ResearchCreditCarryforwardsState"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Explanation of Change</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xml:lang="en-US">Valuation allowance, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DefinedContributionPlanTextualAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_DefinedContributionPlanTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DefinedContributionPlanTextualAbstract" xml:lang="en-US">Defined Contribution Plan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DefinedContributionPlanTextualAbstract" xml:lang="en-US">Defined Contribution Plan (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DefinedContributionPlanTextualAbstract" xlink:to="lab_JHII63I2MI70_nmtc_DefinedContributionPlanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Employees defer compensation, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability" xlink:label="loc_HFGG41G0KG58_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability" xml:lang="en-US">Defined Contribution Plan, Nature and Effect of Change, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability" xml:lang="en-US">Employee deferrals contributions, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability" xlink:to="lab_JHII63I2MI70_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xml:lang="en-US">Employee contributions, vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DefinedContributionPlanVestingTerm" xlink:label="loc_HFGG41G0KG58_nmtc_DefinedContributionPlanVestingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_DefinedContributionPlanVestingTerm" xml:lang="en-US">Defined Contribution Plan Vesting Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_DefinedContributionPlanVestingTerm" xml:lang="en-US">Employee deferrals, vesting term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JHII63I2MI70_nmtc_DefinedContributionPlanVestingTerm" xml:lang="en-US">Deferred contributions vesting term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_DefinedContributionPlanVestingTerm" xlink:to="lab_JHII63I2MI70_nmtc_DefinedContributionPlanVestingTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Contributions cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_DefinedContributionPlanCostRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_HFGG41G0KG58_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SubsequentEventTable" xlink:to="lab_JHII63I2MI70_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionAgreementsMember" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_ConversionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConversionAgreementsMember" xml:lang="en-US">Conversion Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_ConversionAgreementsMember" xml:lang="en-US">Convertible Notes and Short-Term Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_ConversionAgreementsMember" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_ConversionAgreementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="loc_HFGG41G0KG58_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_JHII63I2MI70_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" xlink:label="loc_HFGG41G0KG58_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" xml:lang="en-US">Financial Support, Purchase Agreement of Financial Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" xml:lang="en-US">Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" xlink:to="lab_JHII63I2MI70_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SubsequentEventLineItems" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_HFGG41G0KG58_nmtc_SubsequentEventsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_nmtc_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_nmtc_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_nmtc_SubsequentEventsTextualAbstract" xlink:to="lab_JHII63I2MI70_nmtc_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CashGrossProceeds" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_CashGrossProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CashGrossProceeds" xml:lang="en-US">Cash Gross Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CashGrossProceeds" xml:lang="en-US">Cash gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_CashGrossProceeds" xml:lang="en-US">Cash gross proceeds.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_CashGrossProceeds" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_CashGrossProceeds"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_HFGG41G0KG58_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xml:lang="en-US">Percentage vote of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_JHII63I2MI70_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years), Vested and expected to vest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_HFGG41G0KG58_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xml:lang="en-US">Gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xml:lang="en-US">Proceeds (repayment) from unsecured loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="lab_JHII63I2MI70_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_G578G2J8HGI99092F09I_us-gaap_LeaseAndRentalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Monthly rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_us-gaap_LeaseAndRentalExpense" xlink:to="lab_I790I4L0JIK11214H21K_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_HFGG41G0KG58_us-gaap_AreaOfLand" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_AreaOfLand" xlink:to="lab_JHII63I2MI70_us-gaap_AreaOfLand"/>
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_LeaseExpires" xlink:label="loc_G578G2J8HGI99092F09I_nmtc_LeaseExpires" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_LeaseExpires" xml:lang="en-US">Lease Expires</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_LeaseExpires" xml:lang="en-US">Lease expires</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_I790I4L0JIK11214H21K_nmtc_LeaseExpires" xml:lang="en-US">Lease expires.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_G578G2J8HGI99092F09I_nmtc_LeaseExpires" xlink:to="lab_I790I4L0JIK11214H21K_nmtc_LeaseExpires"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_HFGG41G0KG58_us-gaap_SubsequentEventDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JHII63I2MI70_us-gaap_SubsequentEventDescription" xml:lang="en-US">Subsequent Event, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JHII63I2MI70_us-gaap_SubsequentEventDescription" xml:lang="en-US">Purchase agreement, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HFGG41G0KG58_us-gaap_SubsequentEventDescription" xlink:to="lab_JHII63I2MI70_us-gaap_SubsequentEventDescription"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nmtc-20180930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#DocumentAndEntityInformation" roleURI="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Consolidatedstatementsofcashflows" roleURI="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#OrganizationAndNatureOfOperations" roleURI="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperations"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#GoingConcern" roleURI="http://www.originalsourcemusic.com/role/GoingConcern"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#CommitmentsAndContingencies" roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Intangibles" roleURI="http://www.originalsourcemusic.com/role/Intangibles"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#AccruedExpenses" roleURI="http://www.originalsourcemusic.com/role/AccruedExpenses"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ShortTermPromissoryNotesAndUnsecuredLoans" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoans"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConvertiblePromissoryNotesAndWarrantAgreements" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensation" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficit" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IncomeTaxes" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#DefinedContributionPlan" roleURI="http://www.originalsourcemusic.com/role/DefinedContributionPlan"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SubsequentEvents" roleURI="http://www.originalsourcemusic.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Summaryofsignificantaccountingpoliciespolicies" roleURI="http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitTables" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IntangiblesTables" roleURI="http://www.originalsourcemusic.com/role/IntangiblesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#AccruedExpensesTables" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ShortTermPromissoryNotesAndUnsecuredLoansTables" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConvertiblePromissoryNotesandWarrantAgreementsTables" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensationTables" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IncomeTaxesTables" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#OrganizationAndNatureOfOperationsdetails" roleURI="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperationsdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#GoingConcernDetails" roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails1" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails2" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryofSignificantAccountingPoliciesDetails3" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IntangiblesDetails" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IntangiblesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ShortTermPromissoryNotesAndUnsecuredLoansDetails" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetails" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Stockbasedcompensationdetails" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensationDetails1" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockBasedCompensationDetails2" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#Stockbasedcompensationdetailstextual" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitDetails" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitDetails1" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#StockholdersDeficitDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficitDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IncomeTaxesDetails" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IncomeTaxesDetails1" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#DefinedContributionPlanDetails" roleURI="http://www.originalsourcemusic.com/role/DefinedContributionPlanDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180930.xsd#SubsequentEventsDetails" roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DocumentAndEntityInformationAbstract" xlink:label="loc_nmtc_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentDescription_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_10" order="90" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_11" order="100" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_12" order="110" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_13" order="120" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_14" order="130" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_15" order="140" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_16" order="150" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityShellCompany_17" order="160" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityExTransitionPeriod_18" order="170" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityPublicFloat_19" order="180" use="optional" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_20" order="190" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccountsPayableCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_ShortTermBorrowings_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsLiabilityNonCurrent" xlink:label="loc_nmtc_WarrantsLiabilityNonCurrent_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_nmtc_WarrantsLiabilityNonCurrent_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_Liabilities_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_PreferredStockValue_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_CommonStockValue_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_AdditionalPaidInCapital_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_StockholdersEquity_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:label="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_10" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_12" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:label="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments" xlink:label="loc_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability" xlink:label="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfWarrantsPrivatePlacement" xlink:label="loc_nmtc_IssuanceOfWarrantsPrivatePlacement_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_IssuanceOfWarrantsPrivatePlacement_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceCostsRelatedToPrivatePlacement" xlink:label="loc_nmtc_IssuanceCostsRelatedToPrivatePlacement_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_IssuanceCostsRelatedToPrivatePlacement_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger" xlink:label="loc_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger" xlink:label="loc_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger_24" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ParValueChangeInConnectionWithMerger" xlink:label="loc_nmtc_ParValueChangeInConnectionWithMerger_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_ParValueChangeInConnectionWithMerger_25" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification" xlink:label="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification_28" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription" xlink:label="loc_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription_29" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_30" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_31" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_32" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentForAmortization_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ForgivenessOfSubscription" xlink:label="loc_nmtc_ForgivenessOfSubscription_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_ForgivenessOfSubscription_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes" xlink:label="loc_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantIssuanceCostsRelatedToDebtFinancing" xlink:label="loc_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_RevaluationOfWarrantLiability_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaap_PaymentsOfLoanCosts_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_PaymentsOfLoanCosts_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PaymentsRelatedToWarrantIssuanceCosts" xlink:label="loc_nmtc_PaymentsRelatedToWarrantIssuanceCosts_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_nmtc_PaymentsRelatedToWarrantIssuanceCosts_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock" xlink:label="loc_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock_37" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications" xlink:label="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications_38" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PurchasedIntangibleAssetsInAccruedLiabilities" xlink:label="loc_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities_39" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_us-gaap_StockIssued1_40" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement" xlink:label="loc_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement_41" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_42" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_43" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_nmtc_GoingConcernAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernAbstract_0" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Intangibles">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/DefinedContributionPlan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock" xlink:label="loc_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommonStockValuationPolicyTextBlock" xlink:label="loc_nmtc_CommonStockValuationPolicyTextBlock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_CommonStockValuationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IntellectualPropertyPolicyTextBlock" xlink:label="loc_nmtc_IntellectualPropertyPolicyTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_IntellectualPropertyPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiabilityPolicyTextBlock" xlink:label="loc_nmtc_WarrantLiabilityPolicyTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_WarrantLiabilityPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:label="loc_nmtc_PremiumDebtConversionDerivativePolicyTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_PremiumDebtConversionDerivativePolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_nmtc_SummaryOfWarrantActivityTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_nmtc_SummaryOfWarrantActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock" xlink:label="loc_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaap_OffsettingAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_OffsettingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_StockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_OffsettingAssetsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_6" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperationsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3" xlink:to="loc_srt_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OrganizationAndNatureOfOperationsTextualAbstract" xlink:label="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5" xlink:to="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaap_ConversionOfStockDescription_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_ConversionOfStockDescription_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndNatureOfOperationsTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcernDetails">
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_nmtc_GoingConcernAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernTable" xlink:label="loc_nmtc_GoingConcernTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernAbstract_0" xlink:to="loc_nmtc_GoingConcernTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernLineItems" xlink:label="loc_nmtc_GoingConcernLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTable_1" xlink:to="loc_nmtc_GoingConcernLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_nmtc_GoingConcernTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernLineItems_5" xlink:to="loc_nmtc_GoingConcernTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_UnsecuredDebt_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BankLoansAndNotesPayable" xlink:label="loc_nmtc_BankLoansAndNotesPayable_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_nmtc_BankLoansAndNotesPayable_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermCommercialPaperCurrentAndNoncurrent" xlink:label="loc_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesPayableOne" xlink:label="loc_nmtc_ConvertibleNotesPayableOne_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_nmtc_ConvertibleNotesPayableOne_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:label="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNote_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNote_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:label="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_MaximumSubscriptionAmount" xlink:label="loc_nmtc_MaximumSubscriptionAmount_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_nmtc_MaximumSubscriptionAmount_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiability" xlink:label="loc_nmtc_WarrantLiability_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" xlink:to="loc_nmtc_WarrantLiability_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumConversionDerivative" xlink:label="loc_nmtc_PremiumConversionDerivative_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" xlink:to="loc_nmtc_PremiumConversionDerivative_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ProceedsAndValueAssignedToWarrants" xlink:label="loc_nmtc_ProceedsAndValueAssignedToWarrants_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_nmtc_ProceedsAndValueAssignedToWarrants_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ReclassificationToEquity" xlink:label="loc_nmtc_ReclassificationToEquity_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_nmtc_ReclassificationToEquity_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_nmtc_DebtConversionDerivativeMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_nmtc_DebtConversionDerivativeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivative" xlink:label="loc_nmtc_PremiumDebtConversionDerivative_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_PremiumDebtConversionDerivative_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:label="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivative" xlink:label="loc_nmtc_PremiumDebtConversionDerivative_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_PremiumDebtConversionDerivative_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_SharePrice_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdditionalPotentialWarrants" xlink:label="loc_nmtc_AdditionalPotentialWarrants_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_nmtc_AdditionalPotentialWarrants_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NumberOfLicencingAgreements" xlink:label="loc_nmtc_NumberOfLicencingAgreements_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_nmtc_NumberOfLicencingAgreements_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_ConvertibleDebt_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_IntellectualPropertyMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7" xlink:to="loc_srt_SubsidiariesMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CummulativeFinancingTriggersPayment" xlink:label="loc_nmtc_CummulativeFinancingTriggersPayment_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_CummulativeFinancingTriggersPayment_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OtherCommitmentDueAfterFourthYear" xlink:label="loc_nmtc_OtherCommitmentDueAfterFourthYear_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_OtherCommitmentDueAfterFourthYear_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CostIncurredMaintainingLicensedPatents" xlink:label="loc_nmtc_CostIncurredMaintainingLicensedPatents_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_CostIncurredMaintainingLicensedPatents_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CummulativeFinancingTriggersPayment1" xlink:label="loc_nmtc_CummulativeFinancingTriggersPayment1_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_CummulativeFinancingTriggersPayment1_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmountRecordedForIntellectualProperty" xlink:label="loc_nmtc_AmountRecordedForIntellectualProperty_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_AmountRecordedForIntellectualProperty_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PercentageOfAccruedInterest" xlink:label="loc_nmtc_PercentageOfAccruedInterest_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_PercentageOfAccruedInterest_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/commentaryGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_srt_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2" xlink:to="loc_srt_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3" xlink:to="loc_srt_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3" xlink:to="loc_srt_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="loc_us-gaap_FiniteLivedLicenseAgreementsGross_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" xlink:to="loc_us-gaap_FiniteLivedLicenseAgreementsGross_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" xlink:to="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmortizationExpenseDescription" xlink:label="loc_nmtc_AmortizationExpenseDescription_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_6" xlink:to="loc_nmtc_AmortizationExpenseDescription_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedLicenseFees_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLegalCosts" xlink:label="loc_nmtc_AccruedLegalCosts_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedLegalCosts_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedIssuanceCosts_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedPayroll" xlink:label="loc_nmtc_AccruedPayroll_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedPayroll_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedExpensesAdvances" xlink:label="loc_nmtc_AccruedExpensesAdvances_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedExpensesAdvances_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable" xlink:label="loc_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_us-gaap_ShortTermDebtMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OtherDebtMember" xlink:label="loc_nmtc_OtherDebtMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_OtherDebtMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumConversionDerivativeMember" xlink:label="loc_nmtc_PremiumConversionDerivativeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_PremiumConversionDerivativeMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember" xlink:label="loc_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_us-gaap_UnsecuredDebtMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_11" xlink:to="loc_srt_ConsolidatedEntitiesDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_12" xlink:to="loc_srt_SubsidiariesMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_14" xlink:to="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaap_ShortTermDebtDescription_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_ShortTermDebtDescription_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermPaymentWarrants" xlink:label="loc_nmtc_ShortTermPaymentWarrants_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_ShortTermPaymentWarrants_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_WarrantsMaturityTerm_24" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_25" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_26" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ValueOfPremiumConversionDerivative" xlink:label="loc_nmtc_ValueOfPremiumConversionDerivative_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_ValueOfPremiumConversionDerivative_27" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_28" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_29" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedTerm" xlink:label="loc_nmtc_FairValueAssumptionExpectedTerm_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionExpectedTerm_30" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedDividendRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedDividendRate_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_FairValueAssumptionExpectedDividendRate_31" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_32" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdditionalWarrantsAllocated" xlink:label="loc_nmtc_AdditionalWarrantsAllocated_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_AdditionalWarrantsAllocated_33" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_34" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsExpirationDate" xlink:label="loc_nmtc_WarrantsExpirationDate_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_WarrantsExpirationDate_35" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_LossOnShortTermNotesExtinguishment" xlink:label="loc_nmtc_LossOnShortTermNotesExtinguishment_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_LossOnShortTermNotesExtinguishment_36" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:label="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_37" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_39" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:label="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_40" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_DebtConversionDescription_41" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_OtherLiabilities_42" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_43" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsExercisableDescription" xlink:label="loc_nmtc_WarrantsExercisableDescription_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_WarrantsExercisableDescription_44" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AdjustmentToAccountForChangeInValuation" xlink:label="loc_nmtc_AdjustmentToAccountForChangeInValuation_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_AdjustmentToAccountForChangeInValuation_45" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_46" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes" xlink:label="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes_47" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiability" xlink:label="loc_nmtc_WarrantLiability_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_15" xlink:to="loc_nmtc_WarrantLiability_48" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleDebtMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNoteMember" xlink:label="loc_nmtc_ConvertiblePromissoryNoteMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_nmtc_ConvertiblePromissoryNoteMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_9" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_9" xlink:to="loc_us-gaap_ConvertibleNotesPayable_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubscriptionAgreementMember" xlink:label="loc_nmtc_SubscriptionAgreementMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_SubscriptionAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NovemberTwoThousandSeventeenMember" xlink:label="loc_nmtc_NovemberTwoThousandSeventeenMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_NovemberTwoThousandSeventeenMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:label="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleDebtOneMember" xlink:label="loc_nmtc_ConvertibleDebtOneMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_nmtc_ConvertibleDebtOneMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_us-gaap_PrivatePlacementMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_NewWarrantsMember" xlink:label="loc_nmtc_NewWarrantsMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_nmtc_NewWarrantsMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueAssumptionRiskFreeInterestRate_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueAssumptionExpectedVolatilityRate_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedTerm" xlink:label="loc_nmtc_FairValueAssumptionExpectedTerm_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueAssumptionExpectedTerm_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAssumptionExpectedDividendRate" xlink:label="loc_nmtc_FairValueAssumptionExpectedDividendRate_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueAssumptionExpectedDividendRate_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_InterestExpense_33" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AmortizationOfDiscountToConvertibleNotes" xlink:label="loc_nmtc_AmortizationOfDiscountToConvertibleNotes_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_AmortizationOfDiscountToConvertibleNotes_36" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_us-gaap_DebtInstrumentFee_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentFee_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_WarrantsMaturityTerm_42" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:label="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_43" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_44" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_45" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_46" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:label="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_48" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_LegalFees_49" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_50" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_51" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_52" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_53" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:label="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_54" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueChangesOfWarrantLiability" xlink:label="loc_nmtc_FairValueChangesOfWarrantLiability_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueChangesOfWarrantLiability_55" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentDescription_56" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_57" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_58" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_59" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DebtConversionConvertedNotePaymentWarrantsIssued" xlink:label="loc_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued_60" order="430" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_WarrantLiabilityValueOfReclassifiedToEquity" xlink:label="loc_nmtc_WarrantLiabilityValueOfReclassifiedToEquity_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_WarrantLiabilityValueOfReclassifiedToEquity_61" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockOptionPlanMember" xlink:label="loc_nmtc_StockOptionPlanMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" xlink:to="loc_nmtc_StockOptionPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_21" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_22" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_23" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_24" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaap_OffsettingAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_OffsettingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_StockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_OffsettingAssetsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenPlanMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_RestrictedStockMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_nmtc_StockBasedCompensationTextualAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_nmtc_StockBasedCompensationTextualAbstract_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_FairValueOfCommonStockPricePerShare" xlink:label="loc_nmtc_FairValueOfCommonStockPricePerShare_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_nmtc_FairValueOfCommonStockPricePerShare_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_MonthlyCompensationAmount" xlink:label="loc_nmtc_MonthlyCompensationAmount_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_nmtc_MonthlyCompensationAmount_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_RestrictedStockExpense_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_24" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_25" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_OneExercisePriceMember" xlink:label="loc_nmtc_OneExercisePriceMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_nmtc_OneExercisePriceMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ThreeExercisePriceMember" xlink:label="loc_nmtc_ThreeExercisePriceMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_nmtc_ThreeExercisePriceMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficitDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3" xlink:to="loc_srt_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" xlink:to="loc_us-gaap_PrivatePlacementMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccreditedInvestorsMember" xlink:label="loc_nmtc_AccreditedInvestorsMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_13" xlink:to="loc_nmtc_AccreditedInvestorsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_CommonStockMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_WarrantMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_19" xlink:to="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockSharesIssued_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_PurchaseAgreementDescription" xlink:label="loc_nmtc_PurchaseAgreementDescription_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_nmtc_PurchaseAgreementDescription_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeductingOfferingExpenses" xlink:label="loc_nmtc_DeductingOfferingExpenses_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_nmtc_DeductingOfferingExpenses_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_SharesIssued_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_31" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_32" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_34" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_35" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_36" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_37" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_38" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_39" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_40" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_41" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_Liabilities_42" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccruedLegalCosts" xlink:label="loc_nmtc_AccruedLegalCosts_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_nmtc_AccruedLegalCosts_43" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_44" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_45" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_46" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_47" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense" xlink:label="loc_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits" xlink:label="loc_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent" xlink:label="loc_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeferredTaxAssetsConvertibleNotes" xlink:label="loc_nmtc_DeferredTaxAssetsConvertibleNotes_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_nmtc_DeferredTaxAssetsConvertibleNotes_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_DomesticCountryMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_nmtc_IncomeTaxesTextualAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_6" xlink:to="loc_nmtc_IncomeTaxesTextualAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_EffectiveCorporateIncomeTaxRateDescription" xlink:label="loc_nmtc_EffectiveCorporateIncomeTaxRateDescription_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_nmtc_EffectiveCorporateIncomeTaxRateDescription_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DeductionOfNetGrossDeferredTaxAssets" xlink:label="loc_nmtc_DeductionOfNetGrossDeferredTaxAssets_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_nmtc_DeductionOfNetGrossDeferredTaxAssets_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsFederal" xlink:label="loc_nmtc_ResearchCreditCarryforwardsFederal_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_nmtc_ResearchCreditCarryforwardsFederal_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsExpirationDate" xlink:label="loc_nmtc_ResearchCreditCarryforwardsExpirationDate_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_nmtc_ResearchCreditCarryforwardsExpirationDate_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ResearchCreditCarryforwardsState" xlink:label="loc_nmtc_ResearchCreditCarryforwardsState_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_nmtc_ResearchCreditCarryforwardsState_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_7" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/DefinedContributionPlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DefinedContributionPlanTextualAbstract" xlink:label="loc_nmtc_DefinedContributionPlanTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_nmtc_DefinedContributionPlanTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability" xlink:label="loc_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_DefinedContributionPlanVestingTerm" xlink:label="loc_nmtc_DefinedContributionPlanVestingTerm_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DefinedContributionPlanTextualAbstract_1" xlink:to="loc_nmtc_DefinedContributionPlanVestingTerm_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_5" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_us-gaap_ConvertibleDebtMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_ConversionAgreementsMember" xlink:label="loc_nmtc_ConversionAgreementsMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_nmtc_ConversionAgreementsMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember" xlink:label="loc_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_10" xlink:to="loc_us-gaap_FinancialSupportPurchaseAgreementOfFinancialAssetsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_AccreditedInvestorsMember" xlink:label="loc_nmtc_AccreditedInvestorsMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_13" xlink:to="loc_nmtc_AccreditedInvestorsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_PrivatePlacementMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_OverAllotmentOptionMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_CommonStockMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_WarrantMember_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_23" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_24" xlink:to="loc_us-gaap_ShortTermDebtMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_nmtc_SubsequentEventsTextualAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_26" xlink:to="loc_nmtc_SubsequentEventsTextualAbstract_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_CashGrossProceeds" xlink:label="loc_nmtc_CashGrossProceeds_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_nmtc_CashGrossProceeds_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_UnsecuredDebt_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_LeaseAndRentalExpense_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_AreaOfLand_35" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20180930.xsd#nmtc_LeaseExpires" xlink:label="loc_nmtc_LeaseExpires_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_nmtc_LeaseExpires_36" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_27" xlink:to="loc_us-gaap_SubsequentEventDescription_37" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778344368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Mar. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROONE MEDICAL TECHNOLOGIES Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001500198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">NeuroOne Medical Technologies Corporation (the ''Company'') is filing this Amendment No. 1 (this ''Amendment'') to its Transition Report on Form 10-KT for the period ended September 30, 2018, as filed on December 12, 2018 (the ''Original Form 10-KT''), solely to file certifications as Exhibits 31.1 and 32.1, which were inadvertently omitted from the Original Form 10-KT and to update the exhibit index.
Except as described above, no other changes have been made to the Original Form 10-KT, and this Amendment does not amend, update or change any other items or disclosures in the Original Form 10-KT. The original Form 10-KT continues to speak as of its original filing date. This Amendment does not reflect subsequent events occurring after the filing date of the Original Form 10-KT or modify or update in any way disclosures in the Original Form 10-KT.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-KT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,452,282.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,876,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778015776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 13,260<span></span>
</td>
<td class="nump">$ 26,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">5,378<span></span>
</td>
<td class="nump">7,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,638<span></span>
</td>
<td class="nump">33,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">200,081<span></span>
</td>
<td class="nump">216,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">218,719<span></span>
</td>
<td class="nump">249,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">221,235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,591,022<span></span>
</td>
<td class="nump">1,021,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term promissory notes and unsecured loans</a></td>
<td class="nump">283,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes, net and accrued interest</a></td>
<td class="nump">1,393,804<span></span>
</td>
<td class="nump">2,168,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivatives</a></td>
<td class="nump">308,395<span></span>
</td>
<td class="nump">462,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,797,456<span></span>
</td>
<td class="nump">3,905,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsLiabilityNonCurrent', window );">Warrant liability</a></td>
<td class="nump">817,155<span></span>
</td>
<td class="nump">1,381,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,614,611<span></span>
</td>
<td class="nump">5,286,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2018 and December 31, 2017; no shares issued or outstanding as of September 30, 2018 and December 31, 2017.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 9,656,505 and 7,864,994 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively.</a></td>
<td class="nump">9,657<span></span>
</td>
<td class="nump">7,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">6,052,161<span></span>
</td>
<td class="nump">280,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(10,457,710)<span></span>
</td>
<td class="num">(5,324,796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(4,395,892)<span></span>
</td>
<td class="num">(5,036,611)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 218,719<span></span>
</td>
<td class="nump">$ 249,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This concept represents about warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt premium to be amortized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778330368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">9,656,505<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">9,656,505<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779229888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,676,872<span></span>
</td>
<td class="nump">$ 1,798,131<span></span>
</td>
<td class="nump">$ 2,336,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">715,086<span></span>
</td>
<td class="nump">500,408<span></span>
</td>
<td class="nump">735,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,391,958<span></span>
</td>
<td class="nump">2,298,539<span></span>
</td>
<td class="nump">3,072,321<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,391,958)<span></span>
</td>
<td class="num">(2,298,539)<span></span>
</td>
<td class="num">(3,072,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(763,065)<span></span>
</td>
<td class="num">(1,057,024)<span></span>
</td>
<td class="num">(1,395,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative', window );">Net change in fair value for the warrant liability and premium conversion derivatives</a></td>
<td class="nump">336,596<span></span>
</td>
<td class="num">(77,505)<span></span>
</td>
<td class="num">(240,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on note extinguishments, net</a></td>
<td class="num">(1,314,487)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(350,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,132,914)<span></span>
</td>
<td class="num">$ (3,433,068)<span></span>
</td>
<td class="num">$ (5,058,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">8,420,529<span></span>
</td>
<td class="nump">6,217,076<span></span>
</td>
<td class="nump">6,610,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net change in fair value for the warrant liability and premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778128960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="num">$ (266,220)<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="num">$ (266,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,216,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of stock in connection with intellectual license agreement</a></td>
<td class="nump">23,415<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">22,555<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of stock in connection with intellectual license agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock award</a></td>
<td class="nump">7,220<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock award, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger', window );">Transfer of shares in connection with merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,573<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger', window );">Transfer of shares in connection with merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ParValueChangeInConnectionWithMerger', window );">Par value change in connection with merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,186<span></span>
</td>
<td class="num">(5,186)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">69,574<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,574<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">61,496<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61,496<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification', window );">Issuance of additional warrants in connection with short-term notes modification</a></td>
<td class="nump">117,280<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117,280<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription', window );">Forgiveness of subscription receivable</a></td>
<td class="nump">9,050<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,050<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,058,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,058,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="num">(5,036,611)<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
<td class="nump">280,320<span></span>
</td>
<td class="num">(5,324,796)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments', window );">Issuance of common stock upon short term notes and convertible notes extinguishments</a></td>
<td class="nump">2,349,937<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
<td class="nump">2,348,790<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments', window );">Issuance of common stock upon short term notes and convertible notes extinguishments, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability', window );">Issuance of warrants and reclassification of warrant liability in connection with short-term notes and convertible notes extinguishments</a></td>
<td class="nump">2,008,796<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,008,796<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under 2018 private placement</a></td>
<td class="nump">824,894<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
<td class="nump">824,449<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under 2018 private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfWarrantsPrivatePlacement', window );">Issuance of warrants under 2018 private placement</a></td>
<td class="nump">288,106<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288,106<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsRelatedToPrivatePlacement', window );">Issuance costs related to 2018 private placement</a></td>
<td class="num">(173,067)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(173,067)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting services</a></td>
<td class="nump">469,500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">469,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">5,467<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,467<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,132,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,132,914)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2018</a></td>
<td class="num">$ (4,395,892)<span></span>
</td>
<td class="nump">$ 9,657<span></span>
</td>
<td class="nump">$ 6,052,161<span></span>
</td>
<td class="num">$ (10,457,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,656,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AdjustmentsToAdditionalPaidInCapitalForgivenessOfSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsRelatedToPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs related to private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsRelatedToPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional warrants in connection with short term notes modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfWarrantsPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfWarrantsPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ParValueChangeInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value change in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ParValueChangeInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share issuance of common stock and convertible notes extinguishments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndConvertibleNotesExtinguishments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer of shares in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodSharesTransferOfSharesInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock and convertible notes extinguishments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndConvertibleNotesExtinguishments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of warrants and reclassification of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodValueIssuanceOfWarrantsAndReclassificationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer of values in connection with Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodValueTransferOfShareInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779272336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,132,914)<span></span>
</td>
<td class="num">$ (3,433,068)<span></span>
</td>
<td class="num">$ (5,058,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">16,291<span></span>
</td>
<td class="nump">13,368<span></span>
</td>
<td class="nump">17,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">486,120<span></span>
</td>
<td class="nump">76,794<span></span>
</td>
<td class="nump">76,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ForgivenessOfSubscription', window );">Forgiveness of subscription</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,051<span></span>
</td>
<td class="nump">9,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes', window );">Non-cash interest on convertible promissory notes</a></td>
<td class="nump">152,045<span></span>
</td>
<td class="nump">76,359<span></span>
</td>
<td class="nump">115,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash discount amortization on convertible and short-term promissory notes</a></td>
<td class="nump">611,020<span></span>
</td>
<td class="nump">943,427<span></span>
</td>
<td class="nump">1,242,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing', window );">Note issuance costs attributed to warrant liability and to convertible promissory note modification</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38,119<span></span>
</td>
<td class="nump">38,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfPremiumDebtConversionDerivative', window );">Revaluation of premium conversion derivatives</a></td>
<td class="num">(371,831)<span></span>
</td>
<td class="nump">90,212<span></span>
</td>
<td class="num">(17,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfWarrantLiability', window );">Revaluation of warrant liability</a></td>
<td class="nump">35,235<span></span>
</td>
<td class="num">(12,707)<span></span>
</td>
<td class="nump">258,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on note extinguishments, net</a></td>
<td class="nump">1,314,487<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">350,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,768<span></span>
</td>
<td class="nump">46,677<span></span>
</td>
<td class="nump">46,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">221,235<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">437,337<span></span>
</td>
<td class="nump">642,099<span></span>
</td>
<td class="nump">813,215<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,229,207)<span></span>
</td>
<td class="num">(1,509,669)<span></span>
</td>
<td class="num">(2,108,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(55,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(91,709)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(55,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(91,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes and short-term notes</a></td>
<td class="nump">432,849<span></span>
</td>
<td class="nump">675,705<span></span>
</td>
<td class="nump">1,004,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes', window );">Proceeds from issuance of warrants associated with convertible promissory notes</a></td>
<td class="nump">442,151<span></span>
</td>
<td class="nump">440,919<span></span>
</td>
<td class="nump">777,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes', window );">Proceeds from issuance of warrants associated with short-term notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,496<span></span>
</td>
<td class="nump">61,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock in connection with private placement</a></td>
<td class="nump">824,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement', window );">Proceeds from issuance of warrants in connection with private placement</a></td>
<td class="nump">288,106<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Proceeds (repayment) from unsecured loans</a></td>
<td class="nump">283,000<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Issuance costs related to short-term note</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,030)<span></span>
</td>
<td class="num">(3,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">Issuance costs related to convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(35,689)<span></span>
</td>
<td class="num">(45,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PaymentsRelatedToWarrantIssuanceCosts', window );">Issuance costs related to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(31,920)<span></span>
</td>
<td class="num">(40,590)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,271,000<span></span>
</td>
<td class="nump">1,057,481<span></span>
</td>
<td class="nump">1,704,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="num">(13,207)<span></span>
</td>
<td class="num">(452,188)<span></span>
</td>
<td class="num">(495,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="nump">26,467<span></span>
</td>
<td class="nump">522,217<span></span>
</td>
<td class="nump">522,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">70,029<span></span>
</td>
<td class="nump">26,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing and investing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivatives related to convertible promissory notes</a></td>
<td class="nump">168,384<span></span>
</td>
<td class="nump">213,961<span></span>
</td>
<td class="nump">342,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock', window );">Conversion of short-term notes and convertible promissory notes into common stock</a></td>
<td class="nump">2,063,361<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications', window );">Issuance of additional warrants in connection with short-term notes and convertible promissory notes modifications</a></td>
<td class="nump">829,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities', window );">Purchased intangible assets in accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for the purchase of intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">23,115<span></span>
</td>
<td class="nump">23,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement', window );">Accrued issuance costs related to private placement</a></td>
<td class="nump">173,067<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes', window );">Accrued issuance costs attributed to short-term promissory notes and convertible promissory notes</a></td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">42,811<span></span>
</td>
<td class="nump">57,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability', window );">Accrued issuance costs attributed to warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 38,119<span></span>
</td>
<td class="nump">$ 38,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs attributed to short term promissory notes and convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs attributed to warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsAttributedToWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs related to private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsRelatedToPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bifurcation of premium conversion derivative related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of short term notes and convertible promissory notes into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionOfShortTermNotesAndConvertiblePromissoryNotesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ForgivenessOfSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of subscription.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ForgivenessOfSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional warrants in connection with short term notes and convertible promissory notes modifications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotesAndConvertiblePromissoryNotesModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest on short-term and convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PaymentsRelatedToWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to warrant issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PaymentsRelatedToWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of warrants associated with convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of warrants associated with short term notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithShortTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of warrants with private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PurchasedIntangibleAssetsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased intangible assets in accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PurchasedIntangibleAssetsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevaluationOfPremiumDebtConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevaluationOfPremiumDebtConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevaluationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevaluationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantIssuanceCostsRelatedToDebtFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant issuance costs related to debt financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantIssuanceCostsRelatedToDebtFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769317920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Nature of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 1 - Organization and Nature of Operations</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NeuroOne Medical Technologies Corporation (the &#8220;Company&#8221;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017, the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&#8220;NeuroOne&#8221;) in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &#8220;Acquisition&#8221;). The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical financial statements reflect the operations of NeuroOne for all periods presented prior to the date of Acquisition. NeuroOne was formed on October 7, 2016. The accompanying consolidated financial statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Subsequent to the Acquisition, the Company&#8217;s operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&#8217;s disease, essential tremors, and other brain related disorders.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology and is seeking regulatory clearances required to initiate commercial activities.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is based in Minnetonka, Minnesota effective December 1, 2018. The Company was previously based in Eden Prairie, Minnesota.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Acquisition of NeuroOne, Inc.</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Acquisition was consummated on July 20, 2017 (the &#8220;Closing&#8221;) and, pursuant to the terms of the merger agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &#8220;NeuroOne Shares&#8221;), were exchanged for shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Company Shares&#8221;), based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &#8220;Exchange Ratio&#8221;), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the merger agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&#8217;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">All issued and outstanding common stock share amounts, options for common stock and per share amounts contained in the consolidated financial statements were retroactively adjusted to reflect the Exchange Ratio for all periods presented.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6660658848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 2 - Going Concern</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b></b>The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $10,457,710 as of September 30, 2018. In the event the Company is unable to complete an equity round of financing resulting in more than $3 million in gross proceeds by December 31, 2018, the 2017 Convertible Notes and accrued interest thereon will become due. The Company does not have adequate liquidity to fund the repayment of the 2017 Convertible Notes if they become due on December 31, 2018 or to fund its operations throughout fiscal 2019 without raising additional funds. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this condition. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Through September 30, 2018, since inception, the Company has completed unsecured loan financings for gross proceeds of $283,000, a $253,000 short-term promissory note financing (which notes were amended and restated to become convertible promissory notes as described below), a $1,625,120 convertible promissory note financing and a second $1,540,000 convertible note promissory financing. In addition, the Company entered into a private placement transaction in July 2018 whereby $1,113,000 in gross proceeds were raised out of a planned $10.0 million maximum subscription amount (assuming the over-allotment option is not exercised) through September 30, 2018. The Company does not have adequate liquidity to fund its operations throughout fiscal 2019 without raising additional funds. Management intends to seek additional debt and/or equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company&#8217;s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company&#8217;s operations. If management is unable to obtain the necessary capital, it may have to cease operations.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769280864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 3 - Summary of Significant Accounting Policies</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Basis of Presentation and Change in Fiscal Year</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America, In September 2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved a change in the Company&#8217;s fiscal year end from December 31 to September 30. The Company&#8217;s fiscal year now begins on October 1 and ends on September 30 of each year, starting on October 1, 2018. The required transition period of January 1, 2018 to September 30, 2018 is included in the consolidated financial statements. For comparative purposes, the unaudited consolidated statements of operations and consolidated statements of cash flows for the nine months ended September 30, 2017 are also presented.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Management&#8217;s Use of Estimates</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of
 September 30, 2018, the Company did not have any deposits in excess of federally insured amounts.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Common Stock Valuation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Due to the limited market liquidity for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation&#160;(the &#8220;Practice Aid&#8221;), to estimate the fair value of its common stock. The valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations may result in different fair values of common stock at each valuation date. Following is a summary of underlying assumptions used:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Prior to the Acquisition</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the Acquisition on July 20, 2017, NeuroOne was a private company with no active public market for its common stock. Therefore, at the time, NeuroOne determined the fair value of its common stock using a contemporaneous valuation performed in accordance with the Practice Aid. Within this contemporaneous valuation performed by NeuroOne included the following significant factors:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">recent securities transactions;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify;
 font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">stage of development and business strategy;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">the likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">financial condition and operating results, including our projected results; and</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">financial condition and operating results of comparable publicly owned companies</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of NeuroOne&#8217;s common stock prior to the Acquisition was determined during a period when there was limited data with regard to value indication other than convertible notes issued between November 2016 and June 2017. At the time, such convertible notes contained a $1.80 conversion cap, which was treated as an estimated price of preferred stock into which the notes would convert. A transaction backsolve was performed that equated the $1.5 million investment in the convertible notes with the resulting equity allocation to the hypothetical converted shares and warrants expected to be issued upon conversion. The resulting equity value was then used to infer the value of common stock within the same option-pricing framework. This scenario implicitly assumed 100% likelihood of a stock financing. In order to account for the possibility of dissolution, the transaction backsolve was used along with a dissolution scenario within a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;). The scenarios were weighted 50/50, and a Discount For Lack of Marketability (&#8220;DLOM&#8221;) applied, to determine the valuation conclusion.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Following the Acquisition</i></p><p style="font: 10pt/normal 'times new
 roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For valuations following the Acquisition, including the valuation of common stock on December 31, 2017, the Company estimated our enterprise value on a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public companies (&#8220;GPC&#8221;) for calendar year 2019 and 2020. The resulting equity value from the GPC method was allocated to common stock using the option pricing method, and a DLOM was applied. Based on the above methodology and weightings, the Company derived a valuation conclusion of $2.30 and $2.52 per share as of September 30, 2018 and December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The significant factors contributing to the increase in the fair value the Company&#8217;s common stock following the Acquisition included the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The successful completion of the reverse merger;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Access to new capital as a public company;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Improved revenue projections;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px;
 orphans:
 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Improved general economic conditions;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Additional issuance of convertible notes; and</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Important developments relating to achievement of our business objectives</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value the Company&#8217;s common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has issued or are outstanding liabilities at the reporting date.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</p><p style="font:
 10pt/normal 'times
 new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of September 30, 2018 and December 31, 2017, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes of the Company were based on both the estimated fair value of our common stock of $2.30 and $2.52 as of September 30, 2018 and December 31, 2017, respectively, and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level&#160;3 inputs. There were no transfers between fair value hierarchy levels during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of financial instruments measured on a recurring basis is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial;
 text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of September&#160;30,&#160;2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">817,155</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">817,155</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">308,395</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">308,395</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,125,550</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,125,550</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial;
 text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,381,465</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width:
 0px;
 text-decoration-style: initial; text-decoration-color: initial;">The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&#160;3 inputs for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Warrant liability</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to warrants in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">579,873</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">777,490</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><p style="margin: 0pt 0px;">Reclassification to equity</p></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,179,418</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,235</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">258,015</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">817,155</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,381,465</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Premium debt conversion derivatives</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning
 of
 period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">462,174</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in;">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">218,052</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">342,486</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium debt conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(371,831</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(17,962</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">308,395</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">462,174</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Intellectual Property</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2018, no milestones triggering possible impairment of the Company&#8217;s long-lived assets have occurred.</p><p style="font: 10pt/normal 'times
 new
 roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Debt Issuance Costs</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Research and Development Costs</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrant Liability</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company issued warrants to purchase equity securities in connection with the issuance of convertible promissory notes (See Note 7&#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle
 the
 warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Premium Debt Conversion Derivatives</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&#160; The separated embedded derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statements of operations (See Note 7&#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with regard to the convertible promissory notes.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Income Taxes</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&#8217;s consolidated financial statements include, but are not limited to, a U.S federal corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the valuation allowance recorded to reflect the new federal corporate tax rates.</p><p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;<b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the nine month transition period ended September 30, 2018 and for the year ended December&#160;31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">2,927,572</td><td style="width: 16px; text-align: left; white-space: nowrap;">(1)</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">189,750</td><td style="width: 16px; text-align: left; white-space: nowrap;">(1)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Stock options</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">368,216</td><td style="text-align: left; white-space:
 nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">365,716</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"><div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">&#160;</div></div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.25in; text-align: left;">(1)</td><td style="text-align: justify;">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, the FASB issued Accounting Standards Update (ASU) 2017-09,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Scope of Modification Accounting (ASU 2016-09)</i>,&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the nine month transition period ended September 30, 2018. The adoption of this standard did not have any impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2017, the FASB issued ASU No. 2017-11,&#160;<i>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</i>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In June 2018, the FASB issued ASU 2018-07,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Improvements to Nonemployee Share-Based Payment Accounting</i>&#160;(ASU 2018-07),&#160;which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should generally apply the requirements of Topic 718 to nonemployee awards except in circumstances where there is specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The guidance also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606<i>, Revenue from Contracts with Customers&#160;</i>(ASC 606)<i>.</i>&#160;This guidance is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted, but no earlier than an entity&#8217;s adoption date of ASC 606. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In August 2018, the FASB issued ASU 2018-13,&#160;<i>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).</i>&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#8217;s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date.&#160;</font>The Company is currently evaluating the impact of the new guidance on its financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760282752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 4 - Commitments and Contingencies</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>WARF License Agreement</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 1, 2014, NeuroOne LLC (the &#8220;LLC&#8221;), NeuroOne&#8217;s predecessor which was merged with and into NeuroOne on October 27, 2016 (the &#8220;Merger&#8221;), entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) for WARF&#8217;s neural probe array and thin film micro electrode technology (the &#8220;2014 WARF Agreement&#8221;). The license agreement required the LLC to make $110,000 in milestone payments depending on achievement of certain development and approval milestones or within twelve months of signing the 2014 WARF Agreement. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to WARF on a percentage of net sales of products of the licensed technology. Under the terms of the 2014 WARF Agreement, amounts that remained unpaid more than 30 days after they were due, accrued interest at 1 percent per month. Milestone payments due in 2015 were not made to WARF. From October 27, 2016 until the 2014 WARF Agreement was amended as described below, the LLC was in default under the 2014 WARF Agreement. In addition, the LLC was not able to transfer the rights and obligations under the 2014 WARF Agreement to NeuroOne at the time of the Merger without the consent of WARF, which was received when the 2014 WARF Agreement was amended in February 2017 as described below. In connection with the Merger and in accordance with ASC 805-50, NeuroOne estimated the fair value of consideration payable to WARF and recorded an intangible asset of $120,000 with a corresponding accrued expense.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">This agreement was subsequently amended in February 2017 (as so amended, the &#8220;2017 WARF Agreement&#8221;) whereby WARF consented to the transfer of the rights and obligations under the license agreement from the LLC to NeuroOne (which are now the Company&#8217;s rights and obligations, following the Acquisition). In the 2017 WARF Agreement, the Company agreed to pay WARF $55,000 (representing a license fee) upon the earliest to occur of the date the Company cumulatively raises at least $3 million in financing, the date of a change of control, or the Company&#8217;s revenue reaching a specified threshold amount. The Company met the milestone payment requirement with regard to the $55,000 license fee which was paid in April 2018. In addition, the Company agreed to pay $65,000 (representing reimbursement for costs incurred by WARF in maintaining the licensed patents) upon the earliest to occur of the date the Company cumulatively raises at least $5 million in financing, the date of a change of control, or the Company&#8217;s revenue reaching a specified threshold amount. As of September 30, 2018, the Company has not met the requirements for the $65,000 milestone payment and this amount remains in accrued expenses.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is also obligated to pay royalties to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the 2017 WARF Agreement. Subject to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a
 licensed patent to occur in 2030. The 2017 WARF Agreement is also subject to certain cancellation provisions with 90 days&#8217; notice should the Company elect not to continue to use the licensed technology.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has agreed to diligently develop, manufacture, market and sell products under the WARF License in the United States during the term of the agreement and, specifically, that the Company would submit a business plan to WARF by February 1, 2018, which the Company submitted on January 18, 2018, and file an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the 2017 WARF Agreement in the event that the Company fails to meet these milestones on 30 days&#8217; written notice, if the Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other covenant in the 2017 WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving the Company. WARF may also terminate this license (i) on 90 days&#8217; notice if the Company fails to have commercial sales of one or more FDA-approved products under the 2017 WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Mayo Agreement</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 3, 2014, the LLC entered into an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;) related to certain intellectual property and development services for thin film micro electrode technology (&#8220;2014 Mayo Agreement&#8221;). The LLC was to make milestone payments depending on achievement of certain development and approval milestones and sales targets, none of which were met as of December 31, 2015. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the 2014 Mayo Agreement, set to expire May 25, 2037. Also, the LLC was obligated to issue common stock to Mayo if certain events occurred. Upon the LLC&#8217;s merger with NeuroOne on October 27, 2016, the rights under the 2014 Mayo Agreement transferred to NeuroOne, and certain milestones were attained. Therefore, NeuroOne recorded liabilities of $300 related to shares of common stock expected to be issued to Mayo and $91,709 for the intellectual property to be paid in cash. Under the terms of the 2014 Mayo Agreement, amounts that remained unpaid accrued interest at 2 percent above the prime rate. Milestone payments due in 2016 were not made to Mayo. As such, prior to the amendment of the 2014 Mayo Agreement in May 2017, NeuroOne was in default under the 2014 Mayo Agreement. Mayo and NeuroOne amended and restated the 2014 Mayo Agreement in May 2017 (as so amended and restated, the &#8220;2017 Mayo Agreement&#8221;). Pursuant to the 2017 Mayo Agreement, NeuroOne issued 859,976 shares of common stock (as converted based on the Exchange Ratio) to Mayo to settle the amount of common stock NeuroOne was previously obligated to issue under the 2014 Mayo Agreement and as provided by the terms of the 2017 Mayo Agreement. NeuroOne recorded an additional $23,115 to intangible assets related to the fair value of the 2017 stock issuance to Mayo. As a part of the 2017 Mayo Agreement, as amended in November 2017, the $91,709 milestone payment was paid in December 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Legal</b>&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust:
 none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">From time to time, the Company is subject to litigation and claims arising in the ordinary course of business.&#160; In May 2017, NeuroOne received a letter from PMT, the former employer of Mark Christianson and Wade Fredrickson.&#160; PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer&#8217;s prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with the contracts.&#160; The letter demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne&#8217;s systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March 29, 2018, the Company was served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&#160; In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT&#8217;s contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing.&#160; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft.&#160; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition.&#160; PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&#8217; fees, costs and interest.&#160; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend themselves vigorously.&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The Company expects a ruling on the motion within 90 days of that date. The motion for dismissal states that: the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&#8217;s claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The outcome and potential loss related to this matter is unknown as of September 30, 2018 and as of the issuance of these &#160;financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769250400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangibles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 5 - Intangibles</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Intangible assets rollforward is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Useful Life</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: justify;">Net Intangibles, December 31, 2016</td><td style="width: 16px;">&#160;</td><td style="width: 173px; text-align: center;">12-13 years</td><td style="width: 16px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">180,890</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">License agreement amendment</td><td>&#160;</td><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">53,115</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt;">Less: amortization</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: justify; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(17,633</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify;">Net Intangibles, December 31, 2017</td><td>&#160;</td><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">216,372</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt;">Less: amortization</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: justify; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,291</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 4pt;">Net Intangibles, September 30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: justify; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">200,081</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company anticipates amortization expense of approximately $21,000 per year for fiscal year 2019 through 2023 based upon the two current license agreements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769323360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 6 - Accrued Expenses</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accrued expenses consisted of the following at September 30, 2018 and December 31, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Accrued&#160;license fees</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">65,000</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">120,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Legal costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">833,470</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">553,037</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Accrued issuance costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">204,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">28,083</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Accrued payroll</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">276,639</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">223,195</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Advances</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">50,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Other</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">211,913</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">47,302</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,591,022</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,021,617</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761733872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loans\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Promissory Notes and Unsecured Loans</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 7 - Short-Term Promissory Notes and Unsecured Loans</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />September&#160;30,<br />2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;">Short-term promissory notes</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">253,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt;">Unsecured loans</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">283,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Short-Term Promissory Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company issued short-term unsecured and interest-free promissory notes (the &#8220;Short-Term Notes&#8221;) for aggregate gross proceeds of $253,000 in August 2017 which included free standing equity warrants. The Short-Term Notes were subsequently amended in November 2017 and March 2018 to become convertible, extend the maturity date and include additional warrant coverage, new interest payment provisions and new conversion features described more fully below. Effective July 2, 2018, the Company entered into debt conversion agreements (the &#8220;Short-Term Note Conversion Agreements&#8221;) with each Short-Term Note subscriber to (i) convert the outstanding principal and accrued and unpaid interest (the &#8220;Outstanding Balance&#8221;) under the Short-Term Notes into shares of the Company&#8217;s common stock based on the Outstanding Balance divided by $1.80 per share (the &#8220;Short-Term Note Conversion Shares&#8221;); (ii) cancel and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the &#8220;Short-Term Note Payment Warrants&#8221;), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The Short-Term Note Payment Warrants became exercisable commencing on July 2, 2018, and expire on November 21, 2021.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the Short-Term Note Conversion Agreements, $259,297 of the outstanding principal and interest of the Short-Term Notes was converted into 144,053 shares of common stock with an additional 477,856 shares issuable upon exercise of the Replacement Warrants, Additional Warrants and Short-Term Payment Warrants. The conversion of the Short Term Notes was accounted for as an extinguishment. The difference in the carrying value of the Short-Term Notes coupled with the fair value of the underlying Replacement Warrants and Additional Warrants on the date of extinguishment relative to the higher fair value of the underlying common stock and collective Replacement Warrants, Additional Warrants and new Short-Term Payment Warrants issued was $148,787. The $148,787 differential was recorded as a loss on note
 extinguishments in the accompanying consolidated
 statements of operations during the nine month transition period ended September 30, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Replacement Warrants, Additional Warrants and Short-Term Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the July 2, 2018 Short-Term Note Conversion Agreements. All of the warrant terms became fixed and have identical provisions. Due to the previously granted warrants now having fixed terms, the warrant liability value of $148,053 was reclassified to equity. The warrants associated with the Short-Term Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Short-Term Warrants. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Short-Term Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2017, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) authorized, and the Company issued the Short-Term Notes for aggregate gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest expense over the original term of the Short-Term Notes up though November 2017. For the year ended December 31, 2017, discount amortization charged to interest expense related to the issuance costs was $1,748 through the November 30, 2017 amendment date as discussed further below.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On November 30, 2017, the Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (as amended, the &#8220;Original Warrants&#8221;). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017 amendment.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The November 30, 2017 amendment resulted in a substantial modification to the Short-Term Notes and was accounted for under the provisions of extinguishment accounting. A loss on note extinguishments in the accompanying statements of operations for the year ended December&#160;31, 2017 was recorded in the amount of $144,577, which represented the difference between the face value of the Short-Term Notes over the combined carrying values of the Short-Term Notes and warrants on the date of the amendment. The fair value increase of the Short-Term Notes and the warrants as amended over its adjusted carrying value at the time of the amendment was $117,280 which was recorded as additional paid-in capital.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Prior to the November 30, 2017 amendment, the holders were to receive 126,500 common stock purchase warrants upon maturity. A portion of the proceeds from the Short-Term Notes upon issuance was allocated to the original warrants based on their relative fair value to the underlying Short-Term Notes in the amount of $61,496 and was recorded in additional paid-in
 capital in the accompanying consolidated balance sheets and was
 discounted from the Short-Term Notes and was being amortized to interest expense ratably over the term of the Short-Term Notes which amounted to $35,479 during the year ended December 31, 2017. The fair value of the warrants was based on the Black-Scholes method with the following assumptions: a risk-free interest rate of 2.1 percent; expected volatility of 47.8 percent; expected life of 5.7 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Short-Term Notes were subsequently amended and restated on March 12, 2018 (the &#8220;Amended and Restated Short-Term Notes&#8221;). The Amended and Restated Short-Term Notes became convertible promissory notes that had interest assessed at a fixed rate of 8% per annum and would have required the Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &#8220;Short-Term Note Maturity Date&#8221;). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement warrant (the &#8220;Replacement Warrants&#8221;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the Original Warrant. In addition, each holder was issued an additional warrant (the &#8220;Additional Warrants&#8221;).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Replacement Warrants</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Each Replacement Warrant issued on March 12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted in connection with a change of control transaction. The Replacement Warrants were exercisable commencing on the Conversion Date and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Replacement Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an offset to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Amended and Restated Short-Term Notes were recorded at each reporting date in the consolidated statements of operations which amounted to an expense of $10,330 for the nine month transition period ended September 30, 2018. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Replacement Warrants immediately prior to the July 2, 2018 Short-Term Note Conversion Agreement amendment. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 50 percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;"><b><i>Additional Warrants</i></b></p><p style="font: 10pt/normal 'times new roman',
 times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Each Additional Warrant issued on March 12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants were exercisable commencing on the Conversion Date and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Additional Warrants were deemed to be free-standing instruments and were accounted for as equity as there were no variable terms. 189,750 shares of common stock were issuable upon exercise of the Additional Warrants as of the March 12, 2018 amendment date with terms that largely paralleled the provisions of the Original Warrants except that the Additional Warrants were exercisable on the Conversion Date as opposed to the Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. The fair value differential between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair value change was recorded as a reduction to additional paid-in capital in the accompanying condensed balance sheets and was included as part of the extinguishment loss discussed further below.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Premium Conversion Derivative</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Upon the March 2018 amendment, the Amended and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred at a price under $2.25 per share. The Company determined that the redemption feature under the Short-Term Notes qualified as an embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Short-Term Notes in the consolidated statements of operations for a benefit of $(49,668) for the nine month transition period ended September 30, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Other</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The March 2018 amendment resulted in a substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on note extinguishments in the accompanying consolidated statements of operations for the nine month transition period ended September 30, 2018 was recorded in the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes and Original Warrants over the combined fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion feature and the Additional Warrants) relative to its adjusted carrying
 value at the time of the amendment was $1,170 which was recorded as a reduction to additional paid-in
 capital on the accompanying consolidated balance sheets.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Unsecured Loans</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 17, 2018, the Company received cash proceeds of $168,000 from unsecured loans, represented by two promissory notes from existing stockholders of the Company. The loans are interest free and require that the Company repay the principal in full on the earlier to occur of (i) May 17, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $5 million in gross proceeds. The loans include customary events of default provisions.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On March 20, 2018, the Company received cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan is interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes customary events of default provisions.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769281664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loans\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes and Warrant Agreements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 8 - Convertible Promissory Notes and Warrant Agreements</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />September&#160;30,<br />2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;">2016 convertible promissory notes, net of discounts</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,543,652</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt;">2017 convertible promissory notes, net of discounts</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,306,776</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">504,465</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;">Accrued interest</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">87,028</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">120,223</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 9pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,393,804</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,168,340</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;<b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2016 Convertible Promissory Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">From November 2016 to June 2017, the Company issued convertible promissory notes (the &#8220;Convertible Notes&#8221;) and common stock purchase warrants (the &#8220;Warrants&#8221;) in an aggregate principal amount of $1,625,120 and entered into subscription agreements with subscribers (the &#8220;2016 Private Placement&#8221;). Effective July 2, 2018, however, the Company entered into debt conversion agreements (the &#8220;2016 Note Conversion Agreements&#8221;) with each Convertible Note subscriber to (i) convert the Outstanding Balance under the Convertible Notes into shares of the Company&#8217;s
 common stock based on the Outstanding Balance divided by $1.80 per share (the &#8220;2016 Note Conversion Shares&#8221;); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the &#8220;2016 Note Payment Warrants&#8221;), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The 2016 Note Payment Warrants became exercisable commencing on July 2, 2018 and expire on November 21, 2021.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the 2016 Note Conversion Agreements, $1,804,064 of the outstanding principal and interest of the 2016 Convertible Promissory Notes was converted into 1,002,258 shares of common stock and an additional 2,004,516 shares of common stock became issuable upon exercise of the Warrants and 2016 Note Payment Warrants. The conversion of the Convertible Notes was accounted for as an extinguishment. The difference in the carrying value of the Convertible Notes coupled with the fair value of the underlying Warrants upon conversion relative to the higher fair value of the underlying common stock and collective Warrants and new 2016 Note Payment Warrants issued was $979,480. The $979,480 differential total, inclusive of the unamortized discount remaining on the Convertible Notes of $11,143 as of July 2, 2018, was recorded as a loss on note extinguishments in the accompanying consolidated statement of operations during the nine month transition period ended September 30, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;">The Warrants and 2016 Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the 2016 Note Conversion Agreements. All of the warrant terms became fixed and the terms were identical.&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Due to the previously granted warrants now having fixed terms, the adjusted warrant liability value of $1,031,366 was reclassified to equity. The warrants associated with the Convertible Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Convertible Notes. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. &#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Convertible Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company amended the Convertible Notes in December 2016 and November 2017 and the Warrants in June 2017 and November 2017 to, among other things, change the terms of the underlying Warrants that include the removal of down-round pricing protection provisions as described more fully below.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Convertible Notes were unsecured. The Convertible Notes accrued interest at a fixed rate of 8 percent per annum and required the Company to repay the principal and accrued and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &#8220;Qualified Financing&#8221;). If a Qualified Financing had occurred before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company failed to complete a Qualified Financing by July 31, 2018, the Convertible Notes would have been immediately due and payable on such date.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">If a change of control transaction or initial public offering occurred prior to a Qualified Financing, the Convertible Notes would have, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either been payable on demand as of the closing date of such transaction, or been convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of the per share value as determined by the Board as if in connection with the granting of stock-based compensation, or in a private sale to a third party in an arms-length transaction, or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&#8217;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the June 2017 amendment, the Warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Notes held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the date of issuance and would have expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes. The amount of warrant shares to be issued became contingent and were based on the number of shares of common stock received by the holder of the Convertible Notes upon conversion of such holder&#8217;s Convertible Notes, and at an exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants would have expired on November 21, 2021 in the event of a Qualified Financing or would have expired unissued if the notes were not converted.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the July 2018 Convertible Note extinguishment, the Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. For the December 31, 2017 liability valuation of the Warrants, a Monte Carlo simulation model was used to estimate the aggregate fair value. Input assumptions used were as follows: a risk-free interest rate of 2.08 percent; expected volatility of 50 percent; expected life of 3.89 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount
 methodologies. &#160;The Convertible Note proceeds assigned to the Warrants were zero and $440,919 during the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively, which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount was amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximated the effective interest method and was fully amortized by December 31, 2017; the amortization expense recorded was $759,004 during the year ended December 31, 2017. The Company also recorded the fair value changes of the warrant liability associated with the Convertible Notes in the consolidated statements of operations which amounted to a benefit of $(14,865) and an expense of $259,352 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The November 2017 amendment resulted in a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated with the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of the Convertible Notes on the date of the modification. The $97,223 difference was recorded as a gain on note extinguishments in the accompanying statements of operations with an offsetting discount to the Convertible Notes. The discount was being amortized over the amended term of the Convertible Notes. The amortization recorded during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017 was $70,324 and $15,756, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes in the amount of zero and $213,961 during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively. The discount was being amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates the effective interest method and was fully amortized by December 31, 2017; the amortization expense recorded was $340,551 during the year ended December 31, 2017. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes in the consolidated statements of operations for a benefit of $(333,183) and $(18,428) for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &#8220;placement agent warrant&#8221;) which would have had an exercise price of $2.00 per share of common stock with a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant was issuable at the time the private placement transaction was fully subscribed. The placement agent warrant would have been immediately exercisable on the date of issuance and would have expired five years following the date of issuance. The Company recorded an issuance cost discount to the Convertible Notes in the amount of zero and $39,781 during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively, and was fully amortized by December 31, 2017; the amortization expense recorded as interest was $74,264 during the year ended December 31, 2017. The balance of the issuance costs in the amount of $38,119 was attributed to the Warrants and was immediately recorded as interest expense upon issuance during the year ended December 31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2017 Convertible Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 4, 2017, the Company initially entered into a subscription agreement with certain investors (the &#8220;Subscribers&#8221;), pursuant to which the Company, in a private placement (the &#8220;Private Placement&#8221;), agreed to issue and sell to the Subscribers 8% convertible promissory notes (the &#8220;2017 Convertible Notes&#8221;) and warrants (the &#8220;New Warrants&#8221;) to purchase shares of the Company&#8217;s capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. The subscription agreement, the 2017 Convertible Notes and New Warrants were amended on December 14, 2017 to move up the maturity date of the 2017 Convertible Notes from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision of the 2017 Convertible Notes in the event of a qualified financing as described more fully below, to modify the exercise price of the New Warrants and to increase the authorized subscription amount to $1,500,000. In May 2018, the Board approved an increase in the authorized subscription amount from $1,500,000 to $2,000,000 and extended the offering period from the five month anniversary of the initial closing to the eight month anniversary of the initial closing. The initial closing of the Private Placement was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes in an aggregate principal amount of $1,540,000 to the Subscribers through June 2018 when the Private Placement expired.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The 2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the &#8220;2017 Convertible Notes Maturity Date&#8221;). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the &#8220;2017 Convertible Notes Qualified Financing&#8221;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The New Warrants also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price per share of the securities issued in the 2017 Convertible Notes Qualified Financing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial;
 text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Lastly, if a change of control transaction occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the shares of common stock as determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&#8217;s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&#8217;s assets. The New Warrants also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted in the change of control transaction.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The December 2017 amendment resulted in a substantial modification to the original 2017 Convertible Notes. The Company recorded the 2017 Convertible Note amendment under the provisions of extinguishment accounting. The fair value of the underlying Convertible Notes was $294,615 higher than the carrying value of the Convertible Notes net of unamortized debt discount on the date of the modification. The $294,615 difference as well as legal costs associated with the amendment in the amount of $8,945 were recorded as a loss on convertible notes extinguishments totaling $303,560 in the accompanying statements of operations for the year ended December&#160;31, 2017. After the modification, there remained a debt discount of $27,371 of which $19,510 and $1,286 was amortized during the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The 2017 Convertible Notes contain a conversion discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $168,384 and $128,525 for the convertible debt issued during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $143,166 and $3,815 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense of $11,020 and $466 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The New Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants. Input assumptions used were as follows: a risk-free interest rate of 2.94 percent and 2.22 percent as of September 30, 2018
 and December 31, 2017, respectively; expected volatility of 50 percent as of September 30, 2018 and December 31, 2017; expected life of 5.21 years and 5.38 years as of September 30, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of September 30, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. The 2017 Convertible Note proceeds assigned to the New Warrants were $442,151 and $336,571 during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively, which represented their fair value at issuance and were discounted from the 2017 Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $375,076 and $9,971 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively. The Company also recorded the fair value changes of the warrant liability associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense of $39,770 and a benefit of $(1,337) for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the 2017 Convertible Notes, the Company incurred issuance costs in the amount of $8,133 which consisted of legal costs and was recorded as an issuance cost discount to the 2017 Convertible Notes, of which $2,944 and $157 was amortized to interest expense during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2017 Convertible Note Subscription Agreement</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the subscription agreements entered into in connection with the Private Placement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective subscription agreements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933455488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 9 - Stock-Based Compensation</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, stock-based services expense related to the stock options, restricted stock awards and stock-based award liabilities was included in general and administrative and research and development costs as follows in the accompanying statements of operations:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1175px; text-align: left; padding-left: 12pt;">General and administrative</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">480,653</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">2,065</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 12pt;">Research and development</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">5,467</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">74,729</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total stock-based services expense</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">486,120</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">76,794</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NeuroOne formally adopted an equity incentive plan (the &#8220;2016 Plan&#8221;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition. In addition, the Company adopted a 2017 Equity Incentive Plan (the &#8220;2017
 Plan&#8221;) on April 17, 2017. The 2016 and 2017 Plans provide
 for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards in the second quarter of 2017. During the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, 2,500 and 365,716 stock options were granted to directors and consultants at a weighted average exercise price of $5.34 and $0.035 per share, respectively. The stock options granted during the nine month transition period ended September 30, 2018 and during the year ended December 31, 2017 had a weighted average grant date fair value of $2.48 and $0.014 per share, respectively, with the vesting period ranging from several weeks upon grant to two months from grant. The options expire ten years from the date of grant. In addition, the Company issued 215,453 shares of restricted common stock at a grant date fair value of $0.034 with performance vesting conditions from the 2016 Plan during the year ended December 31, 2017. There were no restricted common stock awards issued out of the 2016 Plan or 2017 Plan during the nine month transition period ended September 30, 2018. All performance vesting conditions for the restricted common stock were met and there were no unvested shares as of September 30, 2018 and December 31, 2017. Compensation expense associated with restricted common stock was zero and $7,220 for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table summarizes the Company&#8217;s stock option plan activity for the nine month transition period ended September 30, 2018 and for the year ended December&#160;31, 2017 as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Weighted-</td><td style="font-weight: bold;">&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Weighted</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Average</td><td style="font-weight: bold;">&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Average</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Remaining</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Aggregate</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Number of</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Exercise</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Contractual</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Intrinsic</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Value(1)</td><td style="padding-bottom: 1.5pt; font-weight:
 bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Outstanding at December 31, 2016</td><td>&#160;</td><td
 style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 815px;">Granted</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">365,716</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">0.03</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Outstanding at December 31, 2017</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">365,716</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">$</td><td style="text-align: right; padding-bottom: 4pt;">0.03</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">9.3</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">908,920</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">5.34</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom:
 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom:
 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Outstanding at September 30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">368,216</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">$</td><td style="text-align: right; padding-bottom: 4pt;">0.07</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">8.6</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">820,862</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Vested and exercisable at September&#160;30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">368,216</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">$</td><td style="text-align: right; padding-bottom: 4pt;">0.07</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">8.6</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">820,862</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"><div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">&#160;</div></div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.25in; text-align: left;"><sup>(1)</sup></td><td style="text-align: justify;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018 and December 31, 2017 of $2.30 and $2.52 per share, respectively.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial; text-decoration-color: initial;">The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">49.8</td><td style="width: 16px; text-align: left;">%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">47.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.8</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.9</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the nine month transition period ended September 30, 2018, 2,500 stock options vested, and the weighted average grant date fair value per option was $2.48. During the year ended December 31, 2017, 365,716 stock options and 215,453 restricted stock awards vested. The weighted average grant date fair value per share of common stock issuable upon exercise of options and of restricted stock awards vesting during the year ended December 31, 2017 was $0.014 and $0.034, respectively. No stock options were forfeited during the nine month transition period ended September 30, 2018 or during the year ended December 31, 2017. As of September 30, 2018, 1,708,596 shares were available for future issuance on a combined basis under the 2016 and 2017 Plans.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Other Stock-Based Awards</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust:
 none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Up to 250,000 shares of common stock were reserved in February 2018 as a result of a consulting agreement for investor relations services executed in February 2018. Under the agreement, 200,000 shares of common stock were awarded during the nine month transactional period ended September 30, 2018. The shares were awarded based on a performance vesting condition that was met in February 2018 and a time-based vesting condition that was met in both May 2018 and August 2018. The compensation expense related to the vested common shares was included in the total stock-based services expense referenced above which totaled $469,500. The expense was based on the fair value of the underlying common stock at the point of vesting which was $2.52 per share for 100,000 shares that vested in February 2018, $2.30 per share for the 50,000 shares that vested in May 2018, and $2.05 per share for the 50,000 shares that vested in August 2018. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&#160;The remaining 50,000 shares of the share commitment under the agreement vested in November 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Additionally, the Company recorded stock-based services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering, qualified financing, or December 31, 2018 (as amended from the originally stated June 30, 2018 date). The number of option shares under the agreement is based on a $3,000 monthly compensation amount divided by the fair value of the underlying common stock on the award date. The exercise price will also be set at the fair value of the underlying common stock on the award date. The liability associated with the unissued options was based on an option share equivalent estimate that reflects the portion of the award where performance vesting conditions have been met as of September 30, 2018 and was based on the fair value of the Company&#8217;s common stock on September 30, 2018 as the award date has not occurred. The common stock fair value on September 30, 2018 was $2.30 per share and was determined based on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The stock-based services expense associated with the unissued stock options was $11,153 during the nine month transition period ended September 30, 2018 and is classified in accrued expenses at September 30, 2018. The liability for the unissued stock options was based on the following weighted-average assumptions using the Black-Scholes option-pricing model:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">49.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align:
 left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td
 style="text-align: right;">2.9</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Upon the issuance of all of the unissued options associated with the stock-based award liabilities, the estimated number of shares available for future issuance as of September 30, 2018 would be reduced from 1,708,596 to 1,698,161 shares as a result of the remaining stock options to be issued upon vesting under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018 consulting agreement are not eligible for issuance under either the 2016 Plan or 2017 Plan because the 2016 Plan and 2017 Plan limit plan participants to individuals.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769280064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 10 - Stockholders&#8217; Deficit</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Private Placement and Corresponding Issuance of Common Stock and Warrants</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">From July 9, 2018 through September 28, 2018, the Company entered into subscription agreements (each, a &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Purchasers&#8221;), pursuant to which the Company, in a private placement (the &#8220;2018 Private Placement&#8221;), agreed to issue and sell to the Purchasers units (each, a &#8220;Unit&#8221;), each consisting of (i) 1 share (each, a &#8220;Share&#8221;) of the Company&#8217;s common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the &#8220;2018 Warrants&#8221;). The initial closing of the 2018 Private Placement was consummated on July 9, 2018. As of September 30, 2018, the Company has issued and sold an aggregate of 445,200 Units to the Purchasers, for total gross proceeds to the Company of approximately $1,113,000 before deducting offering expenses.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In connection with the 2018 Private Placement, the Company has agreed to issue and sell to accredited investors up to a maximum of 4,000,000 Units (the &#8220;Maximum Offering&#8221;) at a price of $2.50 per Unit for total gross proceeds to the Company of up to $10,000,000. If the 2018 Private Placement is over-subscribed, the Company may, in its discretion sell up to an additional 600,000 Units (the &#8220;Over-Allotment&#8221;) to cover such over subscriptions. If the Company issues the Maximum Offering amount, 4,000,000 shares of Common Stock (4,600,000 shares of Common Stock if the Over-Allotment is exercised) would be issuable upon exercise of the 2018 Warrants. The Company may conduct any number of additional closings so long as the final closing occurs on or before January 2, 2019. Under the Purchase Agreement, the Company has agreed to use the net proceeds from the 2018 Private Placement to pay the outstanding principal and accrued interest on its 2017 Convertible Notes if such notes do not convert prior to maturity, to pay the principal on its unsecured term loans, for research and development, clinical studies, legal fees and sales and marketing expenses, as well as working capital and general corporate purposes. The Company has granted the Purchasers indemnification rights with respect to its representations, warranties and agreements under the Purchase Agreement.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying consolidated balance sheets based on their relative fair value to the underlying common shares issued. The fair value of the 2018 Warrants issued was $318,759 and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of 2.82 percent; expected volatility of 49.8 percent; expected life of 4.91 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. &#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In connection with the 2018 Private Placement, the Company recorded issuance costs in the amount of $173,067 as of September 30, 2018. The issuance costs included commissions to the brokers equal to 10% of the gross proceeds from the sale of the Units that qualify for the commission and amounted to $83,800. In addition to the brokers&#8217; commission, the issuance costs included the estimated value of the 5-year
 warrants
 to be issued to the brokers to purchase an amount of Common Stock equal to 10% of the total amount of qualifying Shares sold in the 2018 Private Placement at an exercise price of $3.45 per share upon the close of the 2018 Private Placement. A liability in the amount of $26,878 was recorded as of September 30, 2018 related to the broker warrants. Lastly, third party legal costs in the amount $62,389 comprised the balance of the issuance costs incurred as of September 30, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In connection with the 2018 Private Placement, the Company entered into registration rights agreements with each of the Purchasers pursuant to which the Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the 2018 Private Placement and the shares of Common Stock issuable upon exercise of the 2018 Warrants. The Company has agreed to file such registration statement within 75 days of the final closing of the 2018 Private Placement. Each registration rights agreement includes customary indemnification rights in connection with the registration statement.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Warrant Activity and Summary</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The following table summarizes warrant activity during the year ended December&#160;31, 2017 and the nine month transition period ended September 30, 2018:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;" colspan="2"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;" colspan="2"><b>Exercise Price</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;" colspan="2"><b>Weighted Average</b></td><td style="text-align: center;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Warrants</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Per<br />Warrant</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Exercise<br />Price</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Outstanding at January&#160;1, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 972px;">Issued</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">189,750</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 172px; text-align: right;">1.80</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1.80</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align:
 left;">&#160;</td></tr><tr
 style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Outstanding and exercisable at December&#160;31, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">189,750</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.80</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,737,822</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">$1.80 - 3.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.00</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Outstanding and exercisable at September 30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,927,572</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$1.80 - 3.00</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1.98</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The following table summarizes information about warrants outstanding at September 30, 2018:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Exercise Price</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Number Outstanding</b></td><td style="padding-bottom:
 1.5pt;"><b>&#160;</b></td><td style="padding-bottom:
 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><b>Weighted Average Remaining Contractual life (Years)</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Number Exercisable at September 30, 2018</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 16px; text-align: left;">$</td><td style="width: 361px; text-align: right;">1.80</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 345px; text-align: right;">2,482,372</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 368.81px; text-align: center; padding-left: 5.4pt;">3.1</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 344px; text-align: right;">2,482,372</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">$</td><td style="text-align: right; padding-bottom: 1.5pt;">3.00</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">445,200</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt;">4.8</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">445,200</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;" colspan="2">Total</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,927,572</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 5.4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,927,572</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>The July 2017 Acquisition</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the Acquisition of NeuroOne on July 20, 2017, the Company acquired 100% of NeuroOne shares in exchange for the issuance of Company shares and NeuroOne became the Company&#8217;s wholly-owned subsidiary. Also, at the closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation 3,500,000 Company shares held by him as part of the conditions to closing resulting in a net exchange of 1,573,000 shares of common stock (see further details in Note 1 &#8211; Organization and Nature of Operations).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">At the time of Acquisition, the Company had authorized 100,000,000 shares of common stock with a par value of $0.001 and 10,000,000 shares of preferred stock with a par value of $0.001.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Predecessor NeuroOne, Inc. Activity</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color:
 #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On October 20, 2016, prior to the Merger with the LLC, NeuroOne issued 5,131,514 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) as founders&#8217; shares to seven individuals. Three of those investors were officers of NeuroOne. NeuroOne recorded $9,050 of share subscription receivable for these stock issuances in 2016, which remained outstanding as of December 31, 2016. The shares were subscribed at value of $0.03 per share based on a valuation prepared by NeuroOne utilizing a weighted average market value of invested capital methodology. In June 2017, the purchase price owed by the seven individuals for the founders&#8217; shares of NeuroOne under their respective subscription agreements totaling $9,050 was forgiven by NeuroOne prior to the Acquisition.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769300784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b>NOTE 11 - Income Taxes</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">On December 22, 2017, the Tax Cuts and Jobs Act (the TCJA), which significantly modified U.S. corporate income tax law, was signed into law by President Trump. The TCJA contains significant changes to corporate income taxation, including, but not limited to, the reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the deductibility of research and experimental expenditures that will be effective in the future).&#160;Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform to the newly enacted federal tax law.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The Company has recorded the adjustments in the consolidated financial statements in accordance with the TCJA and related guidance with a reduction of $420,000&#160;to its net gross deferred tax assets in December 2017, the period in which the legislation was enacted. The reduction was fully offset by an equal reduction in the Company&#8217;s valuation allowance given the Company&#8217;s historical net losses, resulting in no net income tax expense being recorded.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The effective tax rate for the Company for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017 was zero percent. A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statements of operations for the Company is as follows:</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Income tax benefit at federal statutory rate</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">(21.0</td><td style="width: 16px; text-align: left; white-space: nowrap;">)%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align:
 right;">(34.0</td><td
 style="width: 15px; text-align: left; white-space: nowrap;">)%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">State income tax, net of federal benefit</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(7.7</td><td style="text-align: left; white-space: nowrap;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(6.5</td><td style="text-align: left; white-space: nowrap;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Warrant expense</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9.4</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.6</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Disqualified interest and other</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.0</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.9</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Research credits</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1.5</td><td style="text-align: left; white-space: nowrap;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1.2</td><td style="text-align: left; white-space: nowrap;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">U.S. tax reform</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.3</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">19.8</td><td style="padding-bottom: 1.5pt; text-align: left; white-space: nowrap;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">21.9</td><td style="padding-bottom: 1.5pt; text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Effective tax rate</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">&#8212;</td><td style="padding-bottom: 4pt; text-align: left; white-space: nowrap;">%</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">&#8212;</td><td style="padding-bottom: 4pt; text-align: left; white-space: nowrap;">%</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Significant components of the Company&#8217;s deferred tax assets and liabilities are summarized in the tables below as of September 30, 2018 and December 31, 2017:</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Deferred tax assets:</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Federal and state operating loss carryforwards</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width:
 142px; text-align: right;">1,837,375</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width:
 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">871,371</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Acquired intangibles</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10,116</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,433</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Accruals</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73,763</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">64,151</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Convertible notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><p style="margin: 0pt 0px;">28,863</p></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><p style="margin: 0pt 0px;">81,904</p></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Research and development credit carryforwards</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">140,553</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">63,197</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Stock-based compensation</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">24,598</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">19,821</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt;">Total deferred tax assets</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,115,268</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,105,877</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(2,115,268</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(1,105,877</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Net deferred tax assets</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">&#8212;</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">&#8212;</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The deferred tax asset for the convertible notes and the valuation allowance at December 31, 2017 were misstated by $452,845 and have both been revised in the preceding table.&#160; The effects of this revision also impacted the effective tax rate reconciliation by increasing the warrant expense percent by 10.6%, decreasing the U.S. tax reform percent by 3.8% and decreasing the valuation allowance percent by 6.8% for the year ended December 31, 2017. These immaterial adjustments to the 2017 disclosures had no impact on our net loss or reported net loss per share for the year ended December 31, 2017.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal;
 font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;
 font-stretch: normal; margin: 0pt 0px; text-align: justify;">As of September 30, 2018 and December 31, 2017, the Company had gross deferred tax assets of approximately $2,115,000 and $1,106,000, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of approximately $2,115,000 and $1,106,000 as of September 30, 2018 and December 31, 2017, respectively. U.S. net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">As of September 30, 2018 and December 31, 2017, the Company&#8217;s federal net operating loss carryforwards were approximately $6,393,000 and $3,032,000, respectively. The Company had federal research credit carryforwards as of September 30, 2018 and December&#160;31, 2017 of approximately $83,000 and $36,000, respectively. The federal net operating loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating losses incurred after December 31, 2017 will not expire. As of September 30, 2018 and December&#160;31, 2017, the Company had state net operating loss carryforwards of approximately $6,393,000 and $3,032,000, respectively. The Company had state research credit carryforwards of approximately $57,000 and $27,000 as of September 30, 2018 and December 31, 2017, respectively. The state net operating loss carryforwards will begin to expire in 2031, if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&#160;382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#8220;5-percent shareholders&#8221; increase their ownership, in the aggregate, by more than 50&#160;percentage points over a 36-month time period testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In accordance with ASC 740,&#160;<i>Income Taxes&#160;</i>(&#8220;ASC 740&#8221;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company believes its income tax filing positions and deductions will be sustained upon examination, and accordingly, no reserves or related accruals for interest and penalties have been recorded at September 30, 2018 and December 31, 2017.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In accordance with this guidance, the Company has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income
 taxes will be classified as a component of interest expense and any related penalties will be classified in operating expenses in the statements of operations.</p><p style="color: #000000; font-family: 'times new roman', times, serif;
 font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The Company&#8217;s corporate returns are subject to examination for the 2016 and 2017 tax years for federal and subject to examination for the 2016 and 2017 tax years in one state jurisdiction.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769280064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Defined Contribution Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 12 - Defined Contribution Plan</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company adopted a 401(k) defined contribution plan (the &#8220;401K Plan&#8221;) on January 1, 2017, which was amended and restated on March 1, 2018 (the &#8220;Restatement&#8221;), for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company began matching in the fourth quarter of 2017 on deferrals at 100% of deferrals up to 3% of one&#8217;s contributions and 50% on deferrals over 3%, but not exceeding 5% of one&#8217;s contributions up through the Restatement. The Company&#8217;s matching contributions to employee deferrals became discretionary after the Restatement. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through September 30, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee&#8217;s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee&#8217;s date of hire. The amount of matching contributions made during the nine month transition period ended September 30, 2018 and the year ended December 31, 2017 was $7,779 and $27,000, respectively.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639171088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b>NOTE 13 - Subsequent Events</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><b><i>2018 Private Placement</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><b><i>&#160;</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Between October 1, 2018 through November 30, 2018, the Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses. The additional Units have identical terms to the 2018 Private Placement disclosed in Note 10 &#8211; Stockholders&#8217; Deficit.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>&#160;</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>Unsecured Loans</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>&#160;</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In November 2018, the Company received cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from stockholders who each owned over 5% of the Company&#8217;s common stock. The loans are interest free and require that we repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or November 14, 2019.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>Advisory Board Stock Option Grants</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>&#160;</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0pt 0px; text-align: justify;">In November 2018 and December 2018 the Board of Directors approved for grant, to seven scientific advisory board members, a total of 175,000 stock options for the purchase of common stock. The options when issued will vest monthly over a three year period commencing January 1, 2019.</p><p style="color: #000000; font-family:
 'times new
 roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>Office Lease</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><b><i>&#160;</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The Company leased a 5,196 square foot facility for use as its corporate headquarters location in Minnetonka, Minnesota effective December 1, 2018. The lease expires on October 31, 2019 and the monthly rent is $4,763.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778484224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock', window );">Basis of Presentation and Change in Fiscal Year</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Basis of Presentation and Change in Fiscal Year</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America, In September 2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved a change in the Company&#8217;s fiscal year end from December 31 to September 30. The Company&#8217;s fiscal year now begins on October 1 and ends on September 30 of each year, starting on October 1, 2018. The required transition period of January 1, 2018 to September 30, 2018 is included in the consolidated financial statements. For comparative purposes, the unaudited consolidated statements of operations and consolidated statements of cash flows for the nine months ended September 30, 2017 are also presented.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Management's Use of Estimates</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Management&#8217;s Use of Estimates</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30, 2018, the Company did not have any deposits in excess of federally insured amounts.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommonStockValuationPolicyTextBlock', window );">Common Stock Valuation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Common Stock Valuation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Due to the limited market liquidity for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation&#160;(the &#8220;Practice Aid&#8221;), to estimate the fair value of its common stock. The valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations may result in different fair values of common stock at each valuation date. Following is a summary of underlying assumptions used:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Prior to the Acquisition</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the Acquisition on July 20, 2017, NeuroOne was a private company with no active public market for its common stock. Therefore, at the time, NeuroOne determined the fair value of its common stock using a contemporaneous valuation performed in accordance with the Practice Aid. Within this contemporaneous valuation performed by NeuroOne included the following significant factors:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">recent securities transactions;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">stage of development and business strategy;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">the likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">financial condition and operating results, including our projected results; and</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">financial condition and operating results of comparable publicly owned companies</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of NeuroOne&#8217;s common stock prior to the Acquisition was determined during a period when there was limited data with regard to value indication other than convertible notes issued between November 2016 and June 2017. At the time, such convertible notes contained a $1.80 conversion cap, which was treated as an estimated price of preferred stock into which the notes would convert. A transaction backsolve was performed that equated the $1.5 million investment in the convertible notes with the resulting equity allocation to the hypothetical converted shares and warrants expected to be issued upon conversion. The resulting equity value was then used to infer the value of common stock within the same option-pricing framework. This scenario implicitly assumed 100% likelihood of a stock financing. In order to account for the possibility of dissolution, the transaction backsolve was used along with a dissolution scenario within a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;). The scenarios were weighted 50/50, and a Discount For Lack of Marketability (&#8220;DLOM&#8221;) applied, to determine the valuation conclusion.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Following the Acquisition</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For valuations following the Acquisition, including the valuation of common stock on December 31, 2017, the Company estimated our enterprise value on a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public companies (&#8220;GPC&#8221;) for calendar year 2019 and 2020. The resulting equity value from the GPC method was allocated to common stock using the option pricing method, and a DLOM was applied. Based on the above methodology and weightings, the Company derived a valuation conclusion of $2.30 and $2.52 per share as of September 30, 2018 and December 31, 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The significant factors contributing to the increase in the fair value the Company&#8217;s common stock following the Acquisition included the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The successful completion of the reverse merger;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Access to new capital as a public company;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Improved revenue projections;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri,
 helvetica,
 sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Improved general economic conditions;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Additional issuance of convertible notes; and</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;">&#160;</td><td style="font: 10pt/normal calibri, helvetica, sans-serif; width: 24px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#9679;</font></td><td style="font: 10pt/normal calibri, helvetica, sans-serif; text-align: justify; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Important developments relating to achievement of our business objectives</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value the Company&#8217;s common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has issued or are outstanding liabilities at the reporting date.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of September 30, 2018 and December 31, 2017, the fair values of cash, accounts payable, accrued expenses and the unsecured loans approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes of the Company were based on both the estimated fair value of our common stock of $2.30 and $2.52 as of September 30, 2018 and December 31, 2017, respectively, and cash
 flow
 models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level&#160;3 inputs. There were no transfers between fair value hierarchy levels during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of financial instruments measured on a recurring basis is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of September&#160;30,&#160;2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">817,155</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">817,155</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">308,395</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">308,395</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color:
 black;
 border-bottom-width: 4pt; border-bottom-style: double;">1,125,550</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,125,550</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,381,465</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color:
 black;
 border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&#160;3 inputs for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Warrant liability</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to warrants in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">579,873</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">777,490</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><p style="margin: 0pt 0px;">Reclassification to equity</p></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,179,418</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,235</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">258,015</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">817,155</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt;
 border-bottom-style: double;">1,381,465</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Premium debt conversion derivatives</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">462,174</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in;">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">218,052</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">342,486</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium debt conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(371,831</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(17,962</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">308,395</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">462,174</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IntellectualPropertyPolicyTextBlock', window );">Intellectual Property</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Intellectual Property</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2018, no milestones triggering possible impairment of the Company&#8217;s long-lived assets have occurred.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Debt Issuance Costs</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Research and Development Costs</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrant Liability</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company issued warrants to purchase equity securities in connection with the issuance of convertible promissory notes (See Note 7&#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivativePolicyTextBlock', window );">Premium Debt Conversion Derivatives</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Premium Debt Conversion Derivatives</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&#160; The separated embedded derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statements of operations (See Note 7&#8211; Short-Term Promissory Notes and Unsecured Loans and Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with regard to the convertible promissory notes.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Income Taxes</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&#8217;s consolidated financial statements include, but are not limited to, a U.S federal corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the valuation allowance recorded to reflect the new federal corporate tax rates.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;<b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the nine month transition period ended September 30, 2018 or for the year ended December 31, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the nine month transition period ended September 30, 2018 and for the year ended December&#160;31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the nine month transition period ended September 30, 2018 and for the year ended December 31, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">2,927,572</td><td style="width: 16px; text-align: left; white-space: nowrap;">(1)</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">189,750</td><td style="width: 16px; text-align: left; white-space: nowrap;">(1)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Stock options</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">368,216</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">365,716</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"><div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">&#160;</div></div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.25in; text-align: left;">(1)</td><td style="text-align: justify;">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, the FASB issued Accounting Standards Update (ASU) 2017-09,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Scope of Modification Accounting (ASU 2016-09)</i>,&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the nine month transition period ended September 30, 2018. The adoption of this standard did not have any impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2017, the FASB issued ASU No. 2017-11,&#160;<i>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</i>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In June 2018, the FASB issued ASU 2018-07,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Improvements to Nonemployee Share-Based Payment Accounting</i>&#160;(ASU 2018-07),&#160;which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should generally apply the requirements of Topic 718 to nonemployee awards except in circumstances where there is specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The guidance also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606<i>, Revenue from Contracts with Customers&#160;</i>(ASC 606)<i>.</i>&#160;This guidance is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted, but no earlier than an entity&#8217;s adoption date of ASC 606. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In August 2018, the FASB issued ASU 2018-13,&#160;<i>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).</i>&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#8217;s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in; text-align: left;">&#9679;</td><td style="text-align: justify;">Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date.&#160;</font>The Company is currently evaluating the impact of the new guidance on its financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and change in fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_BasisOfPresentationAndChangeInFiscalYearPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommonStockValuationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for common stock valuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommonStockValuationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IntellectualPropertyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy fori ntellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IntellectualPropertyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumDebtConversionDerivativePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumDebtConversionDerivativePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760271520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryOfWarrantActivityTableTextBlock', window );">Summary of warrant activity</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;" colspan="2"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;" colspan="2"><b>Exercise Price</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;"><b>&#160;</b></td><td style="text-align: center;" colspan="2"><b>Weighted Average</b></td><td style="text-align: center;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Warrants</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Per<br />Warrant</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Exercise<br />Price</b></td><td style="text-align: center; padding-bottom: 1.5pt;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Outstanding at January&#160;1, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 972px;">Issued</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">189,750</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 172px; text-align: right;">1.80</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1.80</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Outstanding and exercisable at December&#160;31, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">189,750</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.80</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,737,822</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">$1.80 - 3.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.00</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Outstanding and exercisable at September 30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,927,572</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$1.80 - 3.00</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1.98</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock', window );">Summary of information about warrants outstanding</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Exercise Price</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Number Outstanding</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><b>Weighted Average Remaining Contractual life (Years)</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><b>Number Exercisable at September 30, 2018</b></td><td style="padding-bottom: 1.5pt;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 16px; text-align: left;">$</td><td style="width: 361px; text-align: right;">1.80</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 345px; text-align: right;">2,482,372</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 368.81px; text-align: center; padding-left: 5.4pt;">3.1</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 344px; text-align: right;">2,482,372</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">$</td><td style="text-align: right; padding-bottom: 1.5pt;">3.00</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">445,200</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt;">4.8</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">445,200</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;" colspan="2">Total</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,927,572</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 5.4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,927,572</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of summarizes information about warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SummaryInformationAboutWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SummaryOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of warrant activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SummaryOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761676256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial instruments measured on a recurring basis</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of September&#160;30,&#160;2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">817,155</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">817,155</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">308,395</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">308,395</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,125,550</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,125,550</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,381,465</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Warrant liability</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to warrants in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">579,873</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">777,490</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;"><p style="margin: 0pt 0px;">Reclassification to equity</p></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,179,418</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,235</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">258,015</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">817,155</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,381,465</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Premium debt conversion derivatives</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">462,174</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td
 style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in;">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">218,052</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">342,486</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium debt conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(371,831</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(17,962</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">308,395</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">462,174</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of computation of diluted net loss per share</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">2,927,572</td><td style="width: 16px; text-align: left; white-space: nowrap;">(1)</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">189,750</td><td style="width: 16px; text-align: left; white-space: nowrap;">(1)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Stock options</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">368,216</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">365,716</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"><div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">&#160;</div></div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.25in; text-align: left;">(1)</td><td style="text-align: justify;">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769247680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangibles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Useful Life</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: justify;">Net Intangibles, December 31, 2016</td><td style="width: 16px;">&#160;</td><td style="width: 173px; text-align: center;">12-13 years</td><td style="width: 16px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">180,890</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">License agreement amendment</td><td>&#160;</td><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">53,115</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt;">Less: amortization</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: justify; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(17,633</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify;">Net Intangibles, December 31, 2017</td><td>&#160;</td><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">216,372</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 1.5pt;">Less: amortization</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: justify; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,291</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 4pt;">Net Intangibles, September 30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: justify; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">200,081</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769336672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Accrued&#160;license fees</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">65,000</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">120,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Legal costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">833,470</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">553,037</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Accrued issuance costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">204,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">28,083</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Accrued payroll</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">276,639</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">223,195</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Advances</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">50,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Other</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">211,913</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">47,302</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,591,022</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,021,617</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769247680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loans\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of short-term promissory notes, unsecured loans</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />September&#160;30,<br />2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;">Short-term promissory notes</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">253,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt;">Unsecured loans</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">283,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639624720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loans\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible promissory notes and warrant agreements</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />September&#160;30,<br />2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;">2016 convertible promissory notes, net of discounts</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,543,652</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt;">2017 convertible promissory notes, net of discounts</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,306,776</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">504,465</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;">Accrued interest</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">87,028</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">120,223</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 9pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,393,804</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,168,340</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762404736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based services expense</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1175px; text-align: left; padding-left: 12pt;">General and administrative</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">480,653</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">2,065</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 12pt;">Research and development</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">5,467</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">74,729</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total stock-based services expense</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">486,120</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">76,794</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">49.8</td><td style="width: 16px; text-align: left;">%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">47.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.8</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.9</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of stock option plan activity</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Weighted-</td><td style="font-weight: bold;">&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Weighted</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Average</td><td style="font-weight: bold;">&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Average</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Remaining</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Aggregate</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Number of</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Exercise</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Contractual</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2">Intrinsic</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Value(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Outstanding at December 31, 2016</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 815px;">Granted</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">365,716</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">0.03</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom:
 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Outstanding at December 31, 2017</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">365,716</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">$</td><td style="text-align: right; padding-bottom: 4pt;">0.03</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">9.3</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">908,920</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">5.34</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Outstanding at September 30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">368,216</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">$</td><td style="text-align: right; padding-bottom: 4pt;">0.07</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">8.6</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">820,862</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Vested and exercisable at September&#160;30, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">368,216</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">$</td><td style="text-align: right; padding-bottom: 4pt;">0.07</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt;">8.6</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">820,862</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="left" style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"><div style="width: 391.75px; font-size: 1pt; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">&#160;</div></div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.25in; text-align: left;"><sup>(1)</sup></td><td style="text-align: justify;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018 and December 31, 2017 of $2.30 and $2.52 per share, respectively.</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">49.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.9</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6929079664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax computed at the statutory federal income tax rate</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Income tax benefit at federal statutory rate</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">(21.0</td><td style="width: 16px; text-align: left; white-space: nowrap;">)%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">(34.0</td><td style="width: 16px; text-align: left; white-space: nowrap;">)%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">State income tax, net of federal benefit</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(7.7</td><td style="text-align: left; white-space: nowrap;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(6.5</td><td style="text-align: left; white-space: nowrap;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Warrant expense</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9.4</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.6</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Disqualified interest and other</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.0</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.9</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Research credits</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1.5</td><td style="text-align: left; white-space: nowrap;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1.2</td><td style="text-align: left; white-space: nowrap;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">U.S. tax reform</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left; white-space: nowrap;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.3</td><td style="text-align: left; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">19.8</td><td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">21.9</td><td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Effective tax rate</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt; white-space: nowrap;">%</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt; white-space: nowrap;">%</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Deferred tax assets:</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left;">Federal and state operating loss carryforwards</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,837,375</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">871,371</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Acquired intangibles</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10,116</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,433</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Accruals</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73,763</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">64,151</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Convertible notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><p style="margin: 0pt 0px;">28,863</p></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><p style="margin: 0pt 0px;">81,904</p></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Research and development credit carryforwards</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">140,553</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">63,197</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Stock-based compensation</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">24,598</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">19,821</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt;">Total deferred tax assets</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,115,268</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,105,877</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(2,115,268</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,105,877</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Net deferred tax assets</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778687280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OrganizationAndNatureOfOperationsTextualAbstract', window );"><strong>Organization and Nature of Operations (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Common stock, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Par value of company's common stock issued in lieu of exchange | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued of the then-outstanding NeuroOne shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserve related future issuance of shares associated with the stock award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OrganizationAndNatureOfOperationsTextualAbstract', window );"><strong>Organization and Nature of Operations (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Common stock, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversation of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Par value of company's common stock issued in lieu of exchange | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common shares exchange ratio</a></td>
<td class="nump">17.0103706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued of the then-outstanding NeuroOne shares</a></td>
<td class="nump">6,291,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserve related future issuance of shares associated with the stock award</a></td>
<td class="nump">992,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Tendered for cancellation of shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OrganizationAndNatureOfOperationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OrganizationAndNatureOfOperationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778706576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,457,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,324,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_BankLoansAndNotesPayable', window );">Short-term promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent', window );">Convertible promissory note financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesPayableOne', window );">Second convertible promissory note financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds were raised out</a></td>
<td class="nump">$ 1,113,000<span></span>
</td>
<td class="nump">824,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_MaximumSubscriptionAmount', window );">Maximum subscription amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2017 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds of equity qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_BankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bank loans and notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_BankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesPayableOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesPayableOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_MaximumSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum subscription amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_MaximumSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermCommercialPaperCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermCommercialPaperCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779620864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 817,155<span></span>
</td>
<td class="nump">$ 1,381,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivatives</a></td>
<td class="nump">308,395<span></span>
</td>
<td class="nump">462,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">1,125,550<span></span>
</td>
<td class="nump">1,843,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">817,155<span></span>
</td>
<td class="nump">1,381,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivatives</a></td>
<td class="nump">308,395<span></span>
</td>
<td class="nump">462,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">$ 1,125,550<span></span>
</td>
<td class="nump">$ 1,843,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6929221808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWarrantLiabilityAbstract', window );"><strong>Schedule of warrant liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">$ 10,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWarrantLiabilityAbstract', window );"><strong>Schedule of warrant liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of beginning of period</a></td>
<td class="nump">1,381,465<span></span>
</td>
<td class="nump">$ 345,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsAndValueAssignedToWarrants', window );">Value assigned to warrants in connection with convertible promissory and short-term notes</a></td>
<td class="nump">579,873<span></span>
</td>
<td class="nump">777,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ReclassificationToEquity', window );">Reclassification to equity</a></td>
<td class="num">(1,179,418)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">35,235<span></span>
</td>
<td class="nump">258,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of end of period</a></td>
<td class="nump">$ 817,155<span></span>
</td>
<td class="nump">$ 1,381,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsAndValueAssignedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds and value assigned to warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsAndValueAssignedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6767229248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract', window );"><strong>Schedule of Premium debt conversion derivative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivative', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 462,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivative', window );">Balance as of end of period</a></td>
<td class="nump">328,609<span></span>
</td>
<td class="nump">$ 462,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember', window );">Premium debt conversion derivatives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract', window );"><strong>Schedule of Premium debt conversion derivative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivative', window );">Balance as of beginning of period</a></td>
<td class="nump">462,174<span></span>
</td>
<td class="nump">137,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes', window );">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</a></td>
<td class="nump">218,052<span></span>
</td>
<td class="nump">342,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition', window );">Change in fair value of premium debt conversion derivatives</a></td>
<td class="num">(371,831)<span></span>
</td>
<td class="num">(17,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivative', window );">Balance as of end of period</a></td>
<td class="nump">$ 308,395<span></span>
</td>
<td class="nump">$ 462,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumDebtConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumDebtConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfPremiumConversionDerivativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value assigned to the underlying derivative in connection with convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6776392752">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive computation of diluted net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,927,572<span></span>
</td>
<td class="nump">189,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive computation of diluted net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">368,216<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million occurs in the future related to the 2017 Convertible Notes.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6657599696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>Agreements </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Estimated fair value of our common stock | $ / shares</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AdditionalPotentialWarrants', window );">Additional potential warrants | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOfLicencingAgreements', window );">Number of licencing agreements | Agreements</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Convertible estimated price per share | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Investment on convertible notes | $</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AdditionalPotentialWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AdditionalPotentialWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NumberOfLicencingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NumberOfLicencingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6766461952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Oct. 27, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Value of share issued as royalty upon the achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">WARF License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Milestone payments in connection with WARF License Agreement</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Estimated fair value of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CummulativeFinancingTriggersPayment', window );">Cummulative financing triggers payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">Minimum royalties for the year 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">Minimum royalties for the year 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OtherCommitmentDueAfterFourthYear', window );">Royalties per year beginning from 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CostIncurredMaintainingLicensedPatents', window );">Cost incurred maintaining licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CummulativeFinancingTriggersPayment1', window );">Additional cummulative financing triggers payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfAccruedInterest', window );">Percentage of unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Mayo Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 25,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Value of share issued as royalty upon the achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmountRecordedForIntellectualProperty', window );">Milestone amount recorded for intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfAccruedInterest', window );">Percentage of unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Additional amount of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmountRecordedForIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recorded for intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmountRecordedForIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CostIncurredMaintainingLicensedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount cost incurred in maintaning licensed patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CostIncurredMaintainingLicensedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CummulativeFinancingTriggersPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cummulative financing triggers payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CummulativeFinancingTriggersPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CummulativeFinancingTriggersPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cummulative financing triggers payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CummulativeFinancingTriggersPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OtherCommitmentDueAfterFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Commitment Due After Fourth Year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OtherCommitmentDueAfterFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the fourth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the third fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6766654448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangibles, Beginning Balance</a></td>
<td class="nump">$ 216,372<span></span>
</td>
<td class="nump">$ 180,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">License agreement amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Less: amortization</a></td>
<td class="num">(16,291)<span></span>
</td>
<td class="num">(17,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangibles, Ending Balance</a></td>
<td class="nump">$ 200,081<span></span>
</td>
<td class="nump">$ 216,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Net Intangibles, Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Net Intangibles, Useful Life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769258560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract', window );"><strong>Intangibles (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmortizationExpenseDescription', window );">Amortization expense, description</a></td>
<td class="text">Approximately $21,000 per year for fiscal year 2019 through 2023 based upon the two current license agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmortizationExpenseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmortizationExpenseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwil And Intangible Assets Textual [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoodwilAndIntangibleAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761715376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLegalCosts', window );">Legal costs</a></td>
<td class="nump">833,470<span></span>
</td>
<td class="nump">553,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCosts', window );">Accrued issuance costs</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="nump">28,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">276,639<span></span>
</td>
<td class="nump">223,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedExpensesAdvances', window );">Advances</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">211,913<span></span>
</td>
<td class="nump">47,302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,591,022<span></span>
</td>
<td class="nump">$ 1,021,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedExpensesAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses Advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedExpensesAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Issuance Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedLegalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued legal costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedLegalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761796800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loans\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable', window );">Short-term promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Unsecured loans</a></td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowings including accrued interest bank loans and notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_BorrowingsIncludingAccruedInterestBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6782153904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loans (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 20, 2018</div></th>
<th class="th"><div>Mar. 12, 2018</div></th>
<th class="th"><div>Jul. 02, 2018</div></th>
<th class="th"><div>May 17, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Aggregate gross proceeds of short-term unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,030)<span></span>
</td>
<td class="num">$ (3,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Initial warrant liability changes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Short-term unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,000<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LossOnShortTermNotesExtinguishment', window );">Loss on short-term notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds upon equity qualified financing</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsExercisableDescription', window );">Warrants exercisable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AdjustmentToAccountForChangeInValuation', window );">Adjustment to account for change in valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization charged to interest expense related to issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,020<span></span>
</td>
<td class="nump">$ 943,427<span></span>
</td>
<td class="nump">1,242,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,155<span></span>
</td>
<td class="nump">$ 817,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Short-term unsecured promissory notes maturity date</a></td>
<td class="text">Mar. 20,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds upon equity qualified financing</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember', window );">Short-Term Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Aggregate gross proceeds of short-term unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtDescription', window );">Short-term debt, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) convert the outstanding principal and accrued and unpaid interest (the "Outstanding Balance") under the Short-Term Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "Short-Term Note Conversion Shares"); (ii) cancel and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the "Short-Term Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares of common stock issuable upon exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPaymentWarrants', window );">Short-term payment warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AdditionalWarrantsAllocated', window );">Additional warrants allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LossOnShortTermNotesExtinguishment', window );">Loss on short-term notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,297<span></span>
</td>
<td class="nump">259,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,053<span></span>
</td>
<td class="nump">148,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_OtherDebtMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LossOnShortTermNotesExtinguishment', window );">Loss on short-term notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AdjustmentToAccountForChangeInValuation', window );">Adjustment to account for change in valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_PremiumConversionDerivativeMember', window );">Premium Conversion Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValueOfPremiumConversionDerivative', window );">Value of premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Short-term notes conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Amended and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred at a price under $2.25 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember', window );">Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Short-Term Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Aggregate gross proceeds of short-term unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Issuance costs discounted of short-term unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPaymentWarrants', window );">Short-term payment warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommonStockPurchaseOfWarrants', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LossOnShortTermNotesExtinguishment', window );">Loss on short-term notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Short-term notes conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (as amended, the "Original Warrants"). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017 amendment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization charged to interest expense related to issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes', window );">Issuance of additional warrants in connection with short term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AdditionalWarrantsAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional warrants allocated additional coverage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AdditionalWarrantsAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AdjustmentToAccountForChangeInValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to account for change in valuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AdjustmentToAccountForChangeInValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommonStockPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommonStockPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional warrants in connection with short term notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfAdditionalWarrantsInConnectionWithShortTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LossOnShortTermNotesExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the face value of the short-term notes over the combined carrying values of the short-term notes and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LossOnShortTermNotesExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShortTermPaymentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term payment warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShortTermPaymentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValueOfPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValueOfPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsExercisableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsExercisableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about borrowings which initially required repayment in less than twelve months (or normal operating cycle, if longer) after its issuance and that does not otherwise qualify as long-term debt. It typically is comprised of borrowings under letters of credit, lines of credit, commercial paper, and notes payable of short duration. Disclosures include amounts of borrowings under each arrangement, description of underlying arrangements, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements such as the effects of refinancings and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_OtherDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=nmtc_OtherDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_PremiumConversionDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=nmtc_PremiumConversionDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=nmtc_CancellationExtinguishmentAndConversionOfShortTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6766675824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">$ 87,028<span></span>
</td>
<td class="nump">$ 120,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory notes, net</a></td>
<td class="nump">1,393,804<span></span>
</td>
<td class="nump">2,168,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2016 convertible promissory notes, net of discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory notes, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,543,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember', window );">2017 convertible promissory notes, net of discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory notes, net</a></td>
<td class="nump">$ 1,306,776<span></span>
</td>
<td class="nump">$ 504,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778541632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2017</div></th>
<th class="th"><div>Oct. 04, 2017</div></th>
<th class="th"><div>Jul. 02, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,314,487)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(350,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivatives related to convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,384<span></span>
</td>
<td class="nump">$ 213,961<span></span>
</td>
<td class="nump">$ 342,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Cost of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants', window );">Convertible promissory note proceeds assigned to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2016 Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Repay principal and accrued and unpaid interest earlier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds of equity qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If a Qualified Financing had occurred before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company failed to complete a Qualified Financing by July 31, 2018, the Convertible Notes would have been immediately due and payable on such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity', window );">Description of maximum voting power of surviving entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder', window );">Amount of convertible note held by warrant holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date of issuance and expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAssumptionExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants', window );">Convertible promissory note proceeds assigned to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Convertible notes conversion premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible notes conversion price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmortizationOfDiscountToConvertibleNotes', window );">Amortization of discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt issuance cost discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Conversion agreements, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) convert the Outstanding Balance under the Convertible Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "2016 Note Conversion Shares"); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the "2016 Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,804,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible promissory notes converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued', window );">Note payment warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiabilityValueOfReclassifiedToEquity', window );">Warrant liability value of reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2016 Convertible Promissory Notes [Member] | Private placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmortizationOfDiscountToConvertibleNotes', window );">Amortization of discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Description of convertible notes issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the "placement agent warrant") which would have had an exercise price of $2.00 per share of common stock with a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsMaturityTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants', window );">Issuance costs attributed to common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember', window );">2017 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesMaximumExtensionLimit', window );">Subscription agreement limit 2017 convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivatives related to convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAdjustmentOfPremiumConversionDerivative', window );">Fair value changes on premium debt conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(333,183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember', window );">2017 Convertible Notes [Member] | Private placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAdjustmentOfPremiumConversionDerivative', window );">Fair value changes on premium debt conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember', window );">2017 Convertible Notes [Member] | New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmortizationOfDiscountToConvertibleNotes', window );">Amortization of discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Cost of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | 2017 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of outstanding voting power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Description of subscription agreement with certain investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to which the Company, in a private placement (the "Private Placement"), agreed to issue and sell to the Subscribers 8% convertible promissory notes (the "2017 Convertible Notes") and warrants (the "New Warrants") to purchase shares of the Company's capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. The subscription agreement, the 2017 Convertible Notes and New Warrants were amended on December 14, 2017 to move up the maturity date of the 2017 Convertible Notes from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision of the 2017 Convertible Notes in the event of a qualified financing as described more fully below, to modify the exercise price of the New Warrants and to increase the authorized subscription amount to $1,500,000. In May 2018, the Board approved an increase in the authorized subscription amount from $1,500,000 to $2,000,000 and extended the offering period from the five month anniversary of the initial closing to the eight month anniversary of the initial closing. The initial closing of the Private Placement was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes in an aggregate principal amount of $1,540,000 to the Subscribers through June 2018 when the Private Placement expired.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Description of convertible notes issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfCommonStockPurchaseWarrants', window );">Percentage of common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_NovemberTwoThousandSeventeenMember', window );">November 2017 amendment [Member] | 2016 Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmortizationOfDiscountToConvertibleNotes', window );">Amortization of discount to convertible notes</a></td>
<td class="nump">$ 97,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value change of the amended convertible notes carrying value at time of the amendment resulting in note discount</a></td>
<td class="nump">$ 97,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember', window );">2017 Convertible Note amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Description of subscription agreement with certain investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the "2017 Convertible Notes Maturity Date"). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the "2017 Convertible Notes Qualified Financing"), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmortizationOfDiscountToConvertibleNotes', window );">Amortization of discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value change of the amended convertible notes carrying value at time of the amendment resulting in note discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmortizationOfDiscountToConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with debt financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmortizationOfDiscountToConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible note held by warrant holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmountOfConvertibleNoteHeldByWarrantHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bifurcation of premium conversion derivative related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesMaximumExtensionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes maximum extension limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesMaximumExtensionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note proceeds assigned to warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DebtConversionConvertedNotePaymentWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of note payment warrants issued in debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DebtConversionConvertedNotePaymentWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of maximum voting power of surviving entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAdjustmentOfPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAdjustmentOfPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs attributed to common stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfCommonStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock purchase warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfCommonStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiabilityValueOfReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability value of reclassified to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiabilityValueOfReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmtc_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nmtc_NovemberTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nmtc_NovemberTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6929204400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based services expense</a></td>
<td class="nump">$ 486,120<span></span>
</td>
<td class="nump">$ 76,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based services expense</a></td>
<td class="nump">480,653<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based services expense</a></td>
<td class="nump">$ 5,467<span></span>
</td>
<td class="nump">$ 74,729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778307504">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) - Stock option plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">365,716<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">368,216<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Vested and exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">368,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.34<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.07<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">9 years 3 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (years), Vested and exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 908,920<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 820,862<span></span>
</td>
<td class="nump">$ 908,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 820,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2018 and December 31, 2017 of $2.30 and $2.52 per share, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=nmtc_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=nmtc_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778133488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 2)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">49.80%<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">49.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779182240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueOfCommonStockPricePerShare', window );">Fair value of common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_MonthlyCompensationAmount', window );">Monthly compensation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested per share</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based services expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Stock award vesting and issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The remaining 50,000 shares of the share commitment under the agreement vested in November 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,708,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,698,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,292,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,453<span></span>
</td>
<td class="nump">215,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues', window );">Vested per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.034<span></span>
</td>
<td class="nump">$ 0.034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue', window );">Vested per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Employees, directors, and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price for shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Compensation expense associated with restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueOfCommonStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueOfCommonStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_MonthlyCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly compensation amount divided by the fair value of the underlying common stock on the award date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_MonthlyCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average grant date fairvalue of equity-based compensation awards vested. Excludes stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average grant date fair value of equity-based compensation awards vested. Excludes stock options and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodIntrinsicValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of restricted stock award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockBasedCompensationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockBasedCompensationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nmtc_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nmtc_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778303824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning</a></td>
<td class="nump">189,750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Issued</a></td>
<td class="nump">2,737,822<span></span>
</td>
<td class="nump">189,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Exercisable Ending</a></td>
<td class="nump">2,927,572<span></span>
</td>
<td class="nump">189,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance', window );">Exercise Price Per Warrant, Beginning</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum', window );">Exercise Price Per Warrant, Issued Maximum</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="nump">1.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum', window );">Exercise Price Per Warrant, Issued Minimum</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised', window );">Exercise Price Per Warrant, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited', window );">Exercise Price Per Warrant, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable', window );">Exercise Price Per Warrant, Exercisable Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="nump">1.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Exercisable Ending</a></td>
<td class="nump">1.98<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable', window );">Exercise Price Per Warrant, Exercisable Ending</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable', window );">Exercise Price Per Warrant, Exercisable Ending</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options issued in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>share based compensation arrangement by share based payment award equity instruments other than options issued weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award warrant outstanding exercise price warrant beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award warrant outstanding exercise price warrant exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>share based compensation arrangement by share based payment award warrant outstanding exercise price warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>share based compensation arrangement by share based payment award warrant outstanding exercise price warrant forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>share based compensation arrangement by share based payment award warrant outstanding exercise price warrant issued maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award warrant outstanding exercise price warrant issued minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingExercisePriceWarrantIssuedMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768417968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details 1) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding, Number Exercisable</a></td>
<td class="nump">2,927,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">1.80 Exercise Prices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Number of Warrant Shares</a></td>
<td class="nump">2,482,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual life (Years)</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding, Number Exercisable</a></td>
<td class="nump">2,482,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">3.00 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Number of Warrant Shares</a></td>
<td class="nump">445,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual life (Years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding, Number Exercisable</a></td>
<td class="nump">445,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_OneExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_OneExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ThreeExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ThreeExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6776366112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2016</div></th>
<th class="th"><div>Aug. 03, 2018</div></th>
<th class="th"><div>Jul. 20, 2017</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,656,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,656,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregrate sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeductingOfferingExpenses', window );">Deducting offering expenses.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Maximum offering, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.80%<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,614,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,286,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLegalCosts', window );">Legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Acquired percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued of the then-outstanding NeuroOne shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Maximum offering, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Net exchanges of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">2018 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">2018 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 1 share (each, a "Share") of the Company's common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2018 Warrants").<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Maximum offering, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Cost of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Cash commission, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Common stock purchase price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLegalCosts', window );">Legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Maximum offering, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,131,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price, per share</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Acquired percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued of the then-outstanding NeuroOne shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,291,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Net exchanges of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">$ 9,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedLegalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued legal costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedLegalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeductingOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deducting offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeductingOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockholdersMemberDeficitTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockholdersMemberDeficitTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761745488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">State income tax, net of federal benefit</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense', window );">Warrant expense</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Disqualified interest and other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits', window );">Research credits</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent', window );">U.S. tax reform</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">19.80%<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) attributable to Research credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EffectiveIncomeTaxRateReconciliationResearchCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of federal tax reform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EffectiveIncomeTaxRateReconciliationResearchCreditsFederalTaxReformPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) attributable to warrant expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EffectiveIncomeTaxRateReconciliationWarrantExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768413744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state operating loss carryforwards</a></td>
<td class="nump">$ 871,371<span></span>
</td>
<td class="nump">$ 1,837,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">10,116<span></span>
</td>
<td class="nump">5,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals</a></td>
<td class="nump">73,763<span></span>
</td>
<td class="nump">64,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferredTaxAssetsConvertibleNotes', window );">Convertible notes</a></td>
<td class="nump">28,863<span></span>
</td>
<td class="nump">81,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">140,553<span></span>
</td>
<td class="nump">63,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">24,598<span></span>
</td>
<td class="nump">19,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">2,115,268<span></span>
</td>
<td class="nump">1,105,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(2,115,268)<span></span>
</td>
<td class="num">(1,105,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferredTaxAssetsConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferredTaxAssetsConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761758464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EffectiveCorporateIncomeTaxRateDescription', window );">Corporate income tax rate, description</a></td>
<td class="text">Corporate income taxation, including, but not limited to, the reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the deductibility of research and experimental expenditures that will be effective in the future). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform to the newly enacted federal tax law.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeductionOfNetGrossDeferredTaxAssets', window );">Reduction in net gross deferred tax assets</a></td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,115,268<span></span>
</td>
<td class="nump">$ 1,105,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115,268<span></span>
</td>
<td class="nump">1,105,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,393,000<span></span>
</td>
<td class="nump">3,032,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ResearchCreditCarryforwardsFederal', window );">Federal research credit carryforwads</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,393,000<span></span>
</td>
<td class="nump">3,032,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ResearchCreditCarryforwardsState', window );">State research credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Valuation allowance, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The deferred tax asset for the convertible notes and the valuation allowance at December 31, 2017 were misstated by $452,845 and have both been revised in the preceding table. The effects of this revision also impacted the effective tax rate reconciliation by increasing the warrant expense percent by 10.6%, decreasing the U.S. tax reform percent by 3.8% and decreasing the valuation allowance percent by 6.8% for the year ended December 31, 2017.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ResearchCreditCarryforwardsExpirationDate', window );">Research credit carryforwards, expiration dat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ResearchCreditCarryforwardsExpirationDate', window );">Research credit carryforwards, expiration dat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeductionOfNetGrossDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction in net gross deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeductionOfNetGrossDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EffectiveCorporateIncomeTaxRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective corporate income tax rate descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EffectiveCorporateIncomeTaxRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ResearchCreditCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research credit carryforwards expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ResearchCreditCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ResearchCreditCarryforwardsFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of federal research credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ResearchCreditCarryforwardsFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ResearchCreditCarryforwardsState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State research credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ResearchCreditCarryforwardsState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761787088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DefinedContributionPlanTextualAbstract', window );"><strong>Defined Contribution Plan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees defer compensation, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability', window );">Employee deferrals contributions, description</a></td>
<td class="text">The Company began matching in the fourth quarter of 2017 on deferrals at 100% of deferrals up to 3% of one's contributions and 50% on deferrals over 3%, but not exceeding 5% of one's contributions up through the Restatement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employee contributions, vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DefinedContributionPlanVestingTerm', window );">Employee deferrals, vesting term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,779<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DefinedContributionPlanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DefinedContributionPlanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DefinedContributionPlanVestingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred contributions vesting term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DefinedContributionPlanVestingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of nature and effect of change affecting comparability of defined contribution plan. Includes, but is not limited to, change in rate of employer contributions, business combination, or divestiture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6766767152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th">
<div>Nov. 14, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseExpires', window );">Lease expires</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CashGrossProceeds', window );">Cash gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage vote of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted | shares</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member] | 2018 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CashGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CashGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseExpires">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseExpires</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??1=@Z;7;F'QN?!;L6?MU%]P502P,$%     @ BY5O3IE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M=SNQ&GM9:?<;[2_:R'J(8K=2\]?^63;N>>O?9&R@X00Z$.A(*-)/"6P@L)%
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M][J?4?N%-:=A_DYN_P0L_P-02P,$%     @ BY5O3K)%HD;&!   [A<  !@
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M^,$60T$3XO$MGMTT9I,1;#__(+9\X_(74$L#!!0    ( (N5;TX7\H%XM $
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MVL?C?3C;<<Q&PV,W_2 V?^/B%U!+ P04    " "+E6].8@6_;[8!  #2 P
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MQ[.=QFPRO.GG'\26;US^ E!+ P04    " "+E6].UR"!G[0!  #2 P  &0
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M\6H(:*S?OG=[/;_EV;!J6,:4K/^*\@]02P,$%     @ BY5O3KVH887. 0
MG 0  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL;51M;]L@$/XKB!]0
M$IRX761;:EI5F[1*4:>UGXE]?E'!>(#C]M\/L.-Z'E\"=WY>[@A',DCUKFL
M@SX$;W6*:V.Z R$ZKT$P?2,[:.V74BK!C U5172G@!6>)#BAFTU,!&M:G"4^
M=U)9(GO#FQ9."NE>"*8^C\#ED.(MOB9>FJHV+D&RI&,5_ +SNSLI&Y%9I6@$
MM+J1+5)0IOA^>SC&#N\!KPT,>K%'KI.SE.\N^%&D>.,* @ZY<0K,+A=X ,Z=
MD"WCSZ2)9TM'7.ZOZD^^=]O+F6EXD/RM*4R=XCN,"BA9S\V+'+[#U,\>HZGY
MGW !;N&N$NN12Z[]+\I[;:285&PI@GV,:]/Z=9CTK[0P@4X$NB*0T<A7_L@,
MRQ(E!Z3&L^^8^XNW!VK/)G=)?Q3^FRU>V^PEHU&4D(L3FC#'$4,7F.V,(%9]
MMJ ABR/]CT[#]"A88>3IT=(]_A86V 4%=EY@]T^+NU6+(<P^;+(/FNP# O'*
M)(2Y#9O$09,X('"W,@EAUL=%%K=#@*K\7&B4R[[U,[G(SJ-W3_WM^H*/<_O,
M5-6T&IVEL7?4WZ122@.VE,V-;;BV3\4<<"B-V][:O1H'9@R,[*:W@,P/4O87
M4$L#!!0    ( (N5;TZA-@EJM0$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;&U3VVZ<,!#]%<L?$(.77+0"I&RJ*)5::96H[;,7!K#B"['-
MDOY];,,2FO)B>\9SSIP9C_-1FU?; 3CT+H6R!>Z<Z_>$V*H#R>R5[D'YFT8;
MR9PW34ML;X#5$20%H4ER0R3C"I=Y]!U-F>O!":[@:) =I&3F[P&$'@N<XHOC
MF;>="PY2YCUKX07<K_YHO$46EII+4)9KA0PT!;Y/]X<LQ,> WQQ&NSJC4,E)
MZ]=@?*\+G 1!(*!R@8'Y[0P/($0@\C+>9DZ\I S ]?G"_AAK][6<F(4'+?[P
MVG4%OL.HAH8-PCWK\0GF>JXQFHO_ 6<0/CPH\3DJ+6Q<4358I^7,XJ5(]C[M
M7,5]G&YV%]@V@,X N@#N(H!,B:+R;\RQ,C=Z1&;J?<_"$Z=[ZGM3!6=L1;SS
MXJWWGDN:)3DY!Z(YYC#%T%5,ND00S[ZDH%LI#O0_.-V&[S85[B)\M\Y^>[U-
MD&T29)$@^Z?$]$N)6S%?59)53R68-DZ3194>5)SDE7<9V'L:W^0S?)KVG\RT
M7%ETTLZ_;.Q_H[4#+R6Y\B/4^0^V& (:%XZW_FRF,9L,I_OY!Y'E&Y<?4$L#
M!!0    ( (N5;T[ .X'XMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;&U3VV[<(!#]%<0'A%W62;8KVU(V4=1*K;1*U>:9M<<V"GA<P.OT
M[PO8<9W$+\ ,YYRY,*0#FA?; #CRJE5K,]HXUQT8LT4#6M@K[*#U-Q4:+9PW
M3<UL9T"4D:05XYO-#=-"MC1/H^]D\A1[IV0+)T-LK[4P?X^@<,CHEKXYGF3=
MN.!@>=J)&GZ"^]6=C+?8K%)*#:V5V!(#54;OMH=C$O 1\%O"8!=G$BHY([X$
MXUN9T4U("!04+B@(OUW@'I0*0CZ-/Y,FG4,&XO+\IOX8:_>UG(6%>U3/LG1-
M1O>4E%")7KDG'+["5,\U)5/QW^$"RL-#)CY&@<K&E12]=:@G%9^*%J_C+MNX
M#^,-_S+1U@E\(O"9L(]QV!@H9OX@G,A3@P,Q8^\[$9YX>^"^-T5PQE;$.Y^\
M]=Y+SI-=RBY!:,(<1PQ?8+8S@GGU.01?"W'DG^A\G;Y;S7 7Z;ME]-O]ND"R
M*I!$@>1=B<F'$M<PUQ^"L$5/-9@Z3I,E!?9MG.2%=Q[8.Q[?Y#]\G/8?PM2R
MM>2,SK]L['^%Z,"GLKGR(]3X#S8;"BH7CK?^;,8Q&PV'W?2#V/R-\W]02P,$
M%     @ BY5O3ELW#&RT 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL=5-M;YLP$/XKEG] G3BTC2) :CI5F[1)4:=MGQTXP*J-F6U"]^]W
M-H2QC'W!=\?S//?B<SH8^^8: $_>M6I=1AOONP-CKFA "W=G.FCQ3V6L%AY=
M6S/761!E)&G%^&;SP+20+<W3&#O9/#6]5[*%DR6NUUK87T=09LCHEEX#K[)N
M? BP/.U$#5_!?^M.%CTVJY120^ND:8F%*J-/V\,Q"?@(^"YA< N;A$[.QKP%
MYU.9T4TH"!04/B@(/"[P#$H%(2SCYZ1)YY2!N+2OZB^Q=^SE+!P\&_5#EK[)
MZ)Z2$BK1*_]JAH\P]7-/R=3\9[B 0GBH!',41KGX)47OO-&3"I:BQ?MXRC:>
MPZ1_I:T3^$3@-P0V)HJ5?Q!>Y*DU ['C[#L1KGA[X#B;(@3C*.(_+-YA])+S
MY"%EER T88XCAB\PVQG!4'U.P==2'/D_=+Y.WZU6N(OTW3+[_C_YDU6!) HD
M?[7X>-/B&F9_DX0M9JK!UG&;'"E,W\9-7D3GA7WB\4[^P,=M_R)L+5M'SL;C
MS<;Y5\9XP%(V=[A"#3ZPV5%0^6 ^HFW'-1L=;[KI!;'Y&>>_ 5!+ P04
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M:6PK^H:II#1@4XD>[+LV=B+.!H?*N.W6[M4X%T;#R'X:>62>N_D_4$L#!!0
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MV\)5<==1_##<4++QFK3\#U!+ P04    " "+E6].\V7C[JL"  !T"P  &0
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MJMM&>B_ZL=$?%&^&D>B-<SG["U!+ P04    " "+E6].(:\*Y#X"  #3!@
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MX9H;#;LH4R6Z+L;K>VPHWD\O4S0_C^4?4$L#!!0    ( (N5;TYH2.KOR@$
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M95+$/3KN;$8=SG#ZD2+N#,@ 0!(=#>!V4!*GJB2U7/<D&5!(J@4)\H$2<?G
M4$)2?4J0#V&?<C')&5!( A2 +T)($;,%2882DJ $H"Y@+D-*@$XAM7CR[^KZ
M8V)H(HFC#VYT9'C8:I[S.23]D-[5]>\(&.@HXB@%#"05PQ,EAN^*BD&%&G+\
M4<3Q)S$ W+T(0PM%'7_0!C)7X16,$!:CWZL,I^J/A[NHH:#"I)9B8*'T!]:
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MCX31!>NT.X_A10!>O*$X[47#OH9Q3CL $483 30E#DJ2:'(MF()5"A/";"*
MG<P/$R2;3$>#!^.) )ZRV-*P-62]5F\%3*@ ")65[1XP5H(]_000,"X"P@6'
M8"\:Y!AR6AT;,"X"P(4@<I"]'.&,)$5;F&0%R &#(@ &9)Z'H$A;M-)0!J 0
M3PJ@2-M,./8#B'W>7KT+,O9]MEI1$G#D!W3$TBX^#NB0S]BV.% #"E3^\"2
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MJ<--YA;(G +9X_W 3@'\0#]Z3';3CR!+9Q_/]AX6:93;S,)I9N$P@]T"2Z?
M\O%VZ(GD/"7! PT90--7GR89GO7#@<()CI8S/VAR@!F(DYUUTBOYN5'FJ$RB
MXSQ]CLP F,4W9L[:P? ATP_I[T2<ZD9Z>Z[T>+%#X,BY NTR>-+?8*7_"^.&
MPE&9)=9KT0_'?J-X.PQ^-/Y]BK]02P,$%     @ BY5O3L_T$RIY P  -1
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M3?1]W1>R_8.2IZ%(]\9_"I9_ 5!+ P04    " "+E6]./F 8H%8"   @"
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M&%;/>7OSU+Z4ZJAOU;S+U=[\?U!+ P04    " "+E6].+_$QFR\#  !7#@
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M!$1)W/@TL5 2!P63B&38GE=79R%/>%*0)P5X4HL'T-C3,BN98! 0@P 8Q,(
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M[^[ U<J;6$YU ZVH6>MP.&_=QV"S#XR!03S7T(O9W-&N'!E[T8OOIZWK:T5
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M9IKL5K'Q%0A,DD0#3!19D"*S]O"&@H0=P* #:!V@&P>%D\:@(5;364U! "3
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M",T-E_C!;/J3^988!B4_Z/8V,_>R:ZB[@19-_[$0#5\LR[]02P,$%     @
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M!%].% )!62U@"8$RW]9S'S04 U]T-+[I.$-VDXY&-8N2P1$;T9_BAI+@GH"
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MDPSN04!*Q]_H^A;9+RN/#"/K0',JM,@>\V[7]]\JUW<N_VE?)VJ\O,GPTBS
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M:+?P/M-CCDP'WO#6?5"4%MGFA<&V<Y(593OLBDLE3B>-P7 %4X?@MXF6]UJ
M E-BP&P+WT8!YNQ<ZC>*.5*Q]>[+QI1!WS_Q3H!"Q#)$=L4Z-/W-^=W@ DTR
M3.?#:3J>#I/SP44RF,W3Z;A//[_WV,%H,DN'@PG\=YQ.X;_XQ =K'3MM6LVV
MNN[2&X>\!"8GSA;J52YN'?$;98[2;VM!<0+I+64"B@/X;&02\>@BF$;SQD5M
MI"K^EE;N&CBO6<E_Q_ PMR90797P\T)TC!=E\BI[</0C!%ZK5S@*T/YI2^4X
MSJ_?_W1![UWVYZF?IW\I.^PG[W^HMB"&IH/9Q7?)^P6HS93XY31D<+^'PU/^
M)8Q^@;/4NF6Q:<*CKZL>3V8 )/%<^:<1_RFFG6GS,AS?P16QD)(B!.P]]RVP
M/^=+:JY.L^!$T%E\%OB7R_[TT=LA:1JFBNCKJL3Z^-5#+@4A+SEC1^+T[D:E
MIKHY+>.I\9>1['@*JAFHTT ^E'%HJOT?7,!@E+K9":\<L*W,>C;LPZR?667O
M1U-)XM*HOT*:SE/OF-W;N$S75YRI7%C<\[M\4P%;;[X+8L/HM,D:K>,8X@X5
M789/*L+L -*=$[ZW6#U+D,C%1O!%X=@,7_P^HLA2$3V*T.,8BFCK2-BPRW2O
M!*R58 <F%Y=C, +L0&YD4SI,Z)7[II-U1-])-3V/XU)N16I-^F"5Q:R2\^^,
M-,@T&SBW&=TM]9UX K$X[<?)N95(DXZ+9(/:)5A56]0 ,1=1*MWI\%HT<K,O
MBX7)2Y:)*3J=5T)>>69EWE.:IFY/A,H_\N8M0"DN5@_6?>,BR7$HVMC=@VO(
M%(TFWLFD,)FXJC=BK=Q@J4"&-]G7B](;.3.HY'864#OU2HC;B63L2S5KD]NL
M$-<6RN3<@O&,D\VJ.28*Y!2.%[_ BM!$"OP[0I=<0$AV2\!/_D+XXW:[:_*R
MVQQ"QYA <^A(IHIF)TC8]?BUH7QL3--D_T+3LFW1>V#N"25,V?II$E8F3VNQ
M,75632XX7@S_\4[[># F360N?0\LQ6%ZY$F'F?[VFV?KO92HT-">+1UH+GRQ
MZWXT=Z3V9:SI2&(I<CR+=*?=IDM.%PV=E()6UPWG*TP@*R9@VX="M!VMI$'*
M'W*B)6MM7.]7FO;9S999.3.BPKO.G-!=%FU\H57_C&)+FT%W]#D9TOII">U3
M];\E1SL,:S6_)SR'?2UAY_J&4C%AU=R&*G<+HC4\ S>4[DA!B2"O,V<>"IES
M"HZZHVG4,[*@6-NJ8F<Q_D^U,%NLLN7!AX^5%[Y"_>#@ '^[?O<C:&<,_3">
M>'3H^14*KYQ*-R]?/O5J0\&_;4FHH!;)%N41"F:"96A>"Z7D2N1;F(+3/,@I
MD#B4#B?>%U]10J_]J%^5ERJ%H1'Y*>>:BY?[K2G]$[3)MM'WOV&,"C&A0.W[
M35E8D,>/6!I-%$F9 FZ<EX>NOZ!%8\\0!C/BY8#+KODW& TMUAN0S(L::!9]
M;#6VR7&PHNY"<>?YC,S9^#4@PN58?>..CTK+#)X-N)$124N%TUG@SC*G:K-<
MGK*50:P:4+N&#]?B1+"1A>?A,0M'O\^Q4(:4=51^*JZ/R,H"P,3*K($<Q3;5
M&P4N59XM_$8@.I_4>Q%!-AC(KAZR->MO%7^90G3 1)!+"LM'78X;GA"&F3J@
M&&W"(%9=N.Q/)C;C-=*(K"\U3EH)SFXX@+POJ4$JN>C)&AWU@7,\-"+T8#1)
MJUKNG?PX$["$H0:Z"G(<T(;WDE>1,^8$XR%"V8UW L%.NB4],"U A0PNGP5U
M1-;%Q0ZTZ'=0P-L_#**B588%QFQ4*TH,00UN'8+\:9J?JDWB29JC")<&LZ"5
MWDI\\^!WO*9E3F4O/4=F-:9(M495Y6+@6&YY(8676:32L?W"4L#Y34V57=5K
MU]I VHH8$.R5[=;5@56;]<>76 O&K-#FX;6L,<:2D9M*S"E.R#27Q8O5DXGB
M-U6DS+W!D%F,5,-I]>[P,SM%E\R\;;$]J5"8=^T1=L/#!@K\=Z8.RS&G'1S3
ME&"G/\LI6J>.(255N8]14\A[C?]=^*[9=BF2SU&E^VB *OZYM+L^Q@71A7%'
MM7F-\PV>X5(9(3UY-J8>=]2FUJ8L9BX,],+I>$)0KH9N"SG(3(A02S_JIQ9[
M;G=%ZA\53R>8PAH4VYWK9BN<I@2I'8JJ-PERB$D2Y..ZL]RZ5N.H$0;!"T#M
MD[4]S+1O$&\E?-</IFUR,4G;;%(EJ%4._#B_[IRS4PX'(%:.*L2V+M92V[FS
MFX!_+F>3V)'4>;&YV=>-4!AY[CW(L1(TBG6T%D0L>@*+<U*:7^%$Q[_OB7;E
M@8:],4C4Y8HB:7G&Z%QE^T."$-6M42<82VZO2ZWBPX.N8E2P6BZT/>I0%[&I
MX*=J)!%M1!*8L&#O?N-\!%GSV':P/)-NF6']I,8OH!3+I3X;R$BH:I"A:*UT
MTBV&@T0358@(]C[0,\*LJ"G@SQ)T4]2H4T.&#],S5<@6O<?()D%)<PH-(XY-
ME+#2I66@UI(JE<#57*RSPCX@]\+92Q01S.+YE/T#9;2&@&$Q^+UK05FS)ZT[
M9^\7;8Z6F8_L@J&6QFZ&*MY>&Q^"B#8DC.B\YZPN*J04"!WKB(EQ[EX#,C>T
MC)B4/R,!OQ>79%3!#1 (AFDM"R!K%M5B&;C9"KDM,T&9 .NU)5\K1+U3C591
M=^*E7LD.LV\9EJT6)K%@TR&H'\1A,]A9L(7ABIER2-AKP][!!ZMG#)2/A$W#
M>!1MOJ=5^6?Z D71BC55:9.P+^/5X+*-!_WSCQ>R+YSR(:T+K5;WX[/KR$SF
M/9XC0G+U:N1=%THWDB-=P6: VK=NN"8),\0F]RPX8X$H2=W7N-Y22"MHF"(*
MO7.K'FQ5)#%YEGNK2G(=)9X"ZMIKW5//P&27)WK-U)M$O21XT>Z#=(:8$$,R
M@Z)(%L\,.Y#9#8GM%9V73@>%PO*!0]%JI\"[<L6XNHRSM8YM?).5'^O]=K=X
MT!1%6R_(V2SG&.FRNV=9&$9$71>KLN-JM[;?3)ZBP@O;[-*(#11FY >KB;PN
M30^-R(6,;1&0XRMRA$@$>(ZC46? 8I6*F6JE#>(I^'+P!$@^2.P6U2,IY"J/
MV?>X/\Q*)TJF\(H*A*B(^CM<B!VE5KS*'JJXOVJD_BK5P[N=0T:!;^<=A;XA
M^I[C!L)9:HOKY["%ML6+<1JIIPA?-2:($TA6PHFGO[;G9#*I!"9S@A_)]2'Y
M^^7[D!P_"3F*?D7G$$D"(HH=)N+A[2Z).%>J0N<$Q]083AMZ,/XM?42T9X_7
MRSH$J:<4N8(L<CXI0C\E21&S 0@S0"&/T92;!_JS]_1+BB\'*2#T@<*>EJ91
MF_S7G]0R$'<N:>,;Z_TXZ)U-78NYY6]I754ULR4DZK9J7IK9.23#+>5VG&SA
M%2@U$S)N"1?7BSKO"-14Y\9U8 /C]8]USTCGG0_2:7]N6T-&KZSE<))P=G?8
M.]@^\X/>P9C;;VC<?EQ4E&1OC<ZKF@(/!SV D] #B!-RNI][A<--V.? $G!D
M"V_Q:O!WN_W\(7IVTZU73EV+I=M/\/@46FXB[_W09]3%(=M-1B,/.VL5XIF-
MY^E\.NFBN//,X"GSY:$>N!>&#$T6EYR&HC&\<;TM=YI01_C#X4O*#3-L,IK@
M;MLTW-Z(7N1.9J4;,SL;CM+!8"S)/IX#T<,NA]Y)\TF%WTKDSJ7;S&M=&CTI
MW_7JUIX7J)/>]= -X+IW+-R= ($O\UM8'/G.R7DLBJWOA2@:U[1#-G5KU0:Q
M2[.:FR"*EDE=>*BG7H4N("H*(Z9+SP>3N1N?2\G@-1",-E1Z^^J#E.'#).DZ
M$< 3N7VP''CR]*Y&S%:&?>8E/V>)2*-\61=8\QS[^[[ZP//,;48.30KL+L3H
M4!-A5L*=- Z&IY!F*LJXZTXET8(# XE]*NJ=.6QXF1!.R',M*Z#6+* GR#>=
M*"/R*GI![$5>H*_%\5.Z]/3416!7,"Z;F9E24*"V7+K]M9PEP>'B@LBN$-@\
MHX^I2V9V3W7@BH84$9@18V/=;[##":MI8S9XC;4[+ 1&400MFXZ01NAJYX(8
M)*DHJ6,OJ<%:K<.MZL?8-8DD,K$L0>Z4)O\46Q([)(!^;+21)&?#N+O-)"QD
M;WK!#8T#LC)GR>H^Z[G48(LS+S?;'.$CGW*O2$)T-LTNWR;+ZEYR) D[7C6V
MQ89YJ7L2PN&B-\.6]@F"VLT#?'O3,/@#^"_W,.$/<L(-RE7)270.DBQ(/O9\
MA_?:Q3:5TH2//0.V;90_+<JV86ML.(\Y.TD/YJ[F)@P#[Z)KF/P2Q,V)0)?+
MEG&:^C<MV#KDVM0P0K*XL)7C'ATJA*X)#L@$*.2YU'*0)GZBT:^V;B/>/$,F
M>!_P%PWUWG0Z;7;?S[0](-R[_:*@Y*S][L%_E'2D?8DY-VOL_@L3O4/M(2]O
MLUN6(?N2!)4W)>?/L/U Q913W*"G<('N*;F9U,!,[N;2L$(WY4+0I5S=H[)M
M[K6N.-7?0).$V8)96>9PVQ55P4!Q*F +FN\2D5'4RCM^>'Q8Y*. BYG?*NY1
MU-]2;3 J:)3?&D]@@T!.3EF5RIDI*YCF(?+_U-E^N<>< 62%)N"AV^ZQQWS9
MND.PJZ#9K(W3]551@D2L=AD2FA@2TC!4L(I5O;/5,DQ>-[5D(*.0CP@>7>WL
MAGB1&H=IZ,XXF]+U: ?]T#,'28B%;=9\S-6%NZ]);2@V6ZH61O2TJ_>2(EDC
MT-AD2S=^6_>3;ADQS(H+L/-,$#N-F[/,-C!1.!4J44!!86KHL,+NKF4A2"=Y
M!BRUJBYSZ[/B>C)2\Z*T!HSG6#[&>$CN:!0'I;PD>^ F<5=TX(/#"Z9,D_S&
M:+M-@S"4!DCFMJKITA$+Y0"===NVOYD>./\7Y:(GO#1+-I7Q" '#P00A="[8
MB.!=CCLJ&C2?HV-!#[P.L.TX0Y;4^[6X72A861D$@.N57#$5,MSL@WW.FQ,K
M($RPWWD:@%$^'4[@;3]Z&$V:3ABTQT-I]EM)PKEY\)$$#.^V=_2GLD"1EGR@
M._U>[C2FA6YQT.V.O/)PDL5J95DASY"3H4-^VV:Q4A@#KYU<.ISL]W9@ZS1E
MM2SC+TBHE^*.=+^5I9KHZ%Z="VMR%?&7+'_]UN6M[O<6B)[&J.DM,TUNG!V[
MQNY;U/:@M+4_T F.5$>1KJAZQQO%\."WWCAT2FP\ZVKCV\DD5.UW!%\FT6-2
M<23?RK'3J%P2J8[4&9RR< Z7;+;P;!=^R6IXM#UQ&]OXPEB. 5S2^=,Q<.0X
MN4S<QU^$]FBU7FM=V%;]X9^XF.)++*:(Z:_.0&G@M9PD@R&B2CG">@9,IY_.
MX/*^#  DULLR9COY)6B@WVG%#$$@@KDW&8V2B^,?GB;#P20=38?Q<2;I<#Z(
MC1,YN#/X3S_MSP9^<2#3[K[Q!S<%/%9NT0T@W[/AP(\>MT#B'%Y07^FP/QRU
M^X1C]4ZMV!U <$)BN1;'V7.)T!_[^V<UB)\ +04#7;<KV4L9S-R@^BVV![CW
MJ07.W>P[_81;O V.2I ,0&F"QV+_! OAV6B47DW[R1A(K#^R8[3J4PW[5_3J
M< :G/C)/;;,'O!;)<#JAVLI#=.C,Q\DU%X)K3(U=00EP#X@AB+DYW("K:3KJ
M#ZE [G@.A##DG_M %!-83OML'EF&Y M?_W\_HV3),28SQ72T1Q9384R+(%ML
MI<@@^]@M=CW$PX3MMF-QDP3XRVPDQ*!/'YJ/CUZ1LE)F"K8%@ZO)7:ZPHTE8
M?<[QL#J?I.]XR.GL]A;%+DCAVYJ27S&1*U^R"U\75KCI=%-1KTP&#LW 9,Q+
M*2U-&V5YUIX"J^9=>$//,<@Z*9O<>/7(T4_"T<D.3[F/!ZOK&RQ-@W,@! IO
M5I"TKT6PN)0LFG!8:<$X^-7MZ, ]R+#%EE76CC%5<"QHE**GV.+D0?&CSTU&
M N=UQMP&7IBT7;79*4Y\X%C=0EOVBECX)=J?I$RUW\-3H,E3N %CW[*Q[ 1U
MBB& TEZBP)':Q\*46-L3WZQLGSO/-\X(4E_:S,HZP@,*H:VP+OP87,USOWN.
M_,@WN: %J\C<J-3F>9^XK92>:K;T>P[",SJ(C<I?-.TVNB36"^$E>(NHW0V*
MT!OO<BJ9Y]:R9+ISNI7I[U,?K-RFN]1$E-$* \MUDR\+U@*D+@79DD:P6WJC
MZGJ95S)#ZEAPCT3LHKK&T5N[2$$ '\:L(3M.#W)(6@ZTO4-MESVQ0"):AT@S
MNH5Z?P\=G:80ZY8Y.2O.%I >OM6XQ]%B)F;Y_M-'R<;&!FX$XF+7]/V1+2=T
M=VNS(VPU6#"9C9O<6RY!5#@7ORI;+(F)F*+>E<N&2?D9#L)XW$D\*$5!,@=U
M=ZKGWLU4# ?IH! R>6WTCIC$X J4I?&HZ\ DS<EE_E?3:3H;3VS]4EB4N0UN
MV9:N2YG&;B0MP)7OK=/@,^NX!4EKC7X-,NF8;/@+Q_MP.*<4N):WB)5;#S<2
MAB=KUKJZ@XB?T\3@,9S) X!2W3%WVM(L\9/IP$6]Y^K#G_<.E%V,! ' 81YW
M/L@[#IR1+1(,ZMO@:I9.9U)R1/]E=ERJ8S@5M[E\+FI1%%#8Y4_\I9O"%IUE
M89]TU@G\TL(UO(C/IN4X>^'$*-,EZR8G7?"RK0NZC8;TBBWV+B[994.G,17)
MBO4KFG*(7)B>+4=,T#S;>L_J=+WDF>T$YX3L;W&TW"D5C7DC, JU>Z-AZ4NI
M]W%;$]!0,=$,LB8A$UN1UO1(X7-Q*C"'A8F#JRL+[)+I+;;N<O4(2\?/_X!-
MB2_?+^XJ],50FR[;8GO7[D'M#=Y97O;H6BQ;I.9^7#9+ZM30AQE\Y/A]LJ0N
MFH]L\1A!40N7&?8F8X7D?&]A19\H5*&-(J[FO=DWD:>T+\>H!U8U>8J^UVWC
M!UAYA-\\%.C7AT?[.@QOH<.LF$NQY-9JZW3KX8(]8.<A0HVA_Q'C9!MI![[.
MM8=HN302@+VA0J!!,VQ5MJBGD39[\_I92U$A<J*=W.U9&W [?>UQG(W;M_S2
MU)2US92I:=^U5H5_ZP*8/))YZN#IT^2Y+QTD2_J(HN@7>/'[CQOS@-NK(I"1
M.E)B_V176Z0_VY;KIJZSK1304D2C$SG9AC: KI:KAZ!R:7_4=T&83HL1$^</
M/LV5$[C\H-3TA<L E/1PN)PO+/.V0&;O B&#T5$EOB,_H&>.]TQUP4-%JE);
M<]CS3#HM((+YM0!(K6UB@9Q.KV8>EM/,3>3<U/'BLOG/_0;W#5[$U;XFCYA8
MYF_*\/VT0^WD?>;E$C:TP]U QV73!R3"A:_0'9 -FFG$SS3O;OLC\(]:Q\O3
M?DS+ L-GSRVLRD/6O=%S;ML_S+&"/Q/Z)C-4,1:7.=GZ9:=)0E38JHMVT-HT
M^]5%>1[T\< !\S(.40!WGU<H@-.*5JI2V(9EW1<LT,6MS\)Q#H5JKNU=#4S1
MTPJ34[3"3D7PI.J#GEJJPQO8XAE:3&.P@83E& 1 KI5-H^V%5J Y'C$J#(^!
ME=P0@K;=%;;K3=[KN '!L_=.W6O:+5?HT- MQ<1<99HP!O1,:==V$Z4P*]W2
M%S,E8!K#6=]/1+<&@5-3+RN6EP1.INYB/5]$'J!COM72O(!9$67+D#\A&0PG
MZ;A_E$MX=P])TBD[+,3,0JM;X/A56^AFL(I@N;:1+>:[KE^.,(EB_86MF!T5
M*N(-;-/P9)!>S2?FCKK4'N[Y$]GSXWTY;L1;V-SE6O,+AG]RND#&SL*Y5-ZV
M3>-":2>2.EID/Q0_G,&^D2F@\VTT3J^F<]<N?&PG6.].>!V1=Z%-(!55+2[.
M!,^LVGY40Q\<5]"GO=D!_7S<F_Y+/?\2]?R1P1@/]5\I]'&@FKRK3E\[K[S3
M5[I"3SR1DUY1:_=@+6 &QV5NA@9W#%RR9Y6-=B5$-@&I'M>FK;]X%7S4 "!N
MBRE*S"A/C8*@KIDCARTCBB+,P]<(#WFR7^FKS^#5[O0(DR) /O-3MI?78*JJ
M"+;8X*4L_HI&9!'$XBA4'P\$<SBS3"N!:2F0MF??0<_7CJ,JYNJ/.;)L5$F#
M&BV(RTD[0JW'UD6^UY?:"VV5E' VAI-MV%CT'<ZQ)42\;O9DH_[6Y_BIR%_T
MF^$%54>6U1]82F]5[S5ZPI$(B(A/TR;>)0\O(O(ZOT_>8:JF%(+5J=4M+[L?
M<WK, 1ED)0519%4GAJSR@NP_#'*R&K"3BGSRGK%M@F6</C\_/A'4#LJ"]?P_
MIDSRCZ9,LJ;X"L-9Y+;EU5>;1U 7A-W)V<+BT*)D2)>Y.Z3$I&&;/FD0WF&R
M[(U<=@29\,.M R3/O:%+_,*AT(TJ1-VS=U*!6/$/$_<K+MK/%*_ZA231;D'&
M-BF52\'$('Z&?HN_--V#Q<,%,J"^!=&M#45K;5G@[G<KG$NBHSAZ"@=\[Z[3
MW7J*@JB2X[:VQ=T_975!NQII]2?[':4HTQ(V)"WGKM/^QIHQY5+;BNM@VHF1
MR3J:IM/AL&V#2&RO6JU,TJYGA9/=;;>UY0!JZ<1.[Z>X8S_FT3[M*M+NVU4&
MK:.67&M7V>()C:-"DR#SD']G@WXZ&O6_K"H]VHFOX!TXJ:Q>5TBX>X'^AU$"
M+6_&K-7X1$.C(TK/KL]HV^D[/B4VY/H*?KO0PKC_K[C"KQE7B,0H21\*__#?
M21V2V@0".6?56C:,SE0UD0Y$A'%W?)ERQ+"CBZ3?FXY/Q9J(B1;9]G\:^=\Y
M^7\N\=^YC"^6_A*?YS8G=:Y%":S\)X.R9P(170@;ZCMS$$03A1@82=NZIJT0
M#HM:,FW)SE]C# FE1%9CGLA:+K3OC8^;J*;[D[AU3R+O+IJ&[VPQ'VS9$4#P
MK7;CAG9JEO'RL"(S%01BIA/<".:KCK-@. I4%P^4XCKMPSW0>4373BHA=;93
MW_#9<)A.AE<=RE($ &/?INO5Y?[N<L4NN79+W ]K0<=4#L"6&XBJ?5UQ/^U/
M&VU-:VNQ.*#CEBO^9/-+F'X&M#W^QM6!MS*%L%98UL:#Q>U#[1C%S)QU O*_
MG U[PW$;*/BXKIZ'/#E>(\\LWO[6^N2=%MFNI1%Z\Z_FZ60RB]8 [N(-T3*W
MAPT! :X?L C>&R]H4'N%CSZVWC!&&&U%*WK6D8ZT>5 =N&66*.FT8>+N 9R"
M(GJ4M4$" S:IS%<%G]@Y']G%EQH8G*/RH>.^?6D(5UV-#A^*X?>=Z*.-P+/,
M7)HVRM%S"ORI9N:_39SX]./[[#,Z&DV>3=(AUBM]5#3Y1)@JGDPHP\(XL[TO
MG3'FU%R=Z*U)HZ[5$S&N'J<(I7-^)$1]+IWW/M$C<4@TUUIPVH<;5A12]"$A
M?^$A<*.Q[R<GQ[[3P;0S\GU,$S!!V>IQ0=E>D+0EQ7@&TUANC8DJ8%$P'YLU
MF,RX%"\J6'L_>ROU"!DC(O=5&'BB-TU)#E*'-4[OFX52YX4;=M>.DX%<#AQG
MX^[S04V#6.@)2Q#NUV;K3-U>IYXTFI;.KLP]GS*6YI &6"C$V0ZHR>$-O[+M
M^EJV+5='XS+4MDZD7X?:Q\"YZ]8TK 5U:D-\E!;"6YD"92XXU]9:B1:6[CA8
M.I*L;)UG<)Q9^S!3XI)G@\'8T@2YU,+#M8M"9:+S*"/U*;[H+)VM^#5/<W3*
M:>IA-J>>9MA;Y]'YGM$DSQFUV7E\[JB;Z$EIXH=[[);<9$'=4WX"Z" =7XW2
MR7C(P)U'CC1(1_U).IU.DG'_*KV:C&U6L%+6;)KVAS/**!X.1\F'"MDFO#<?
MI;/^53),D9.-KOJ\DH/;07727$CGA,&)4CDJFH)U,/;NQC2#MIP67UNVN@]'
M<(S.0$%,%]6_TO$JQYQD((XFPW$*NR0U7IRD2@DSLYWC9%22?FQCT$V[ ] $
M45J?\(MO53>P4=JNU,Z[ZAY]0U^>XTD3>%1V9_L$CJ1WQA(EK>(:'.<)69E/
M?I6LS.A&/#(?,UC-\81,UU<%/(T]N&@I_C-D5P;K/2V]T@,N=*5:VO/X+9,L
M#U#!KY%>V;W(QR56/CZO\LB]3Y'5S;!&Q.3J\3F5QV5$+,D2E*)A.AS/NHY,
M8.(.[0SAE:MT/.BLQ*IY3 <]QY[?LOM$NI(K0Q;V:V17AE]Y7'JEQ5#A%CBK
M^-K)DD$NY $:=U,AY]-Y>J5!(?V7[W7>H5*2)IXERS.S2%@3W>,*RT'$R-U!
MNI5@8%Z-)%+@R]C#F9=?X#OY51(O3Z3BKY=1>82#/"9]DGP ]"<.]&@BY5?)
MGC2^AX-IE&E_!-KN9/)EB90AC?T39U(&B_E7'N7_*+S#KY)'&=X U[%M\MLZ
M5'^O\#:G7H2E>CR9[=8DCCR_JZCP/DH!B@)@8<5;+%C)L47+> Y(3"[[*YXE
MCF=MJ/,%VMC5?7G)?A \1U:-8#&+=BNG@Z54U/L?*!)<7E2\3%U/Q7H'!(!T
MKX6HQ:7_&F!T;6\N7J8 AEZI8[T$-K+QNH>5(%15 F$I;_KI$F@?*X)&W$T<
MNY&*ZJZ#J=?O=C$EYYD:&9' I[6]7V!KNUAH%-, 3'CTAMI5^$M,C^C+AW:Q
M4UMQT"W9'OUA.VZ'U=:C\6VB&&Z4(3I6"W /FT(FC-U*SXX&*9YAS4?'C+(C
MVDUGWW0A-^N4%1]?9MM<-ZT$O\;@PED+'G_0PZXKS@>%WA?2YH.,-5ZWB2A'
MZ($HQ=U<+#[*PIA*<^=4@#1&2/#)"-T<//H@^Q5;?N F:$/72DZ6J\6^B+9G
M='%!W/2* ;$B7RK4N3T,@(%+1M=Q?-JI80KK?.%>>">4D8'<^KER\W;C)][M
M>Q!*I"URMH-KWCM@('5F:VB-]LN#2E4RBNN6;#FF/!LH"BUM#^LB*1Q/@>N(
M6&-&D4&@V8<D6M:X\ JA5ZY!@,"550PRS;<YXV:CN%:<[R5?=E,&6M=,$?"M
M>".Q^Q$?.0C->DE@F ?UDH+(O%SGY>TNW#@Y:3MYWZ?DM]%I[Q%6)FX3ZR:G
MD)9V*Z(R^FI666AXR0(>+0>>9M#9SY;W=X-HRXI*YV)96RM +-0V1HN?*MK-
M;77OH 7W]:>"#!"9@7 MT+Y,TP(D<K2):A=E@+EPUE"2TK3MR%Y+13/ZCH\<
M,1J+VD>Z1EI "$%U<E6*E7&++*7CV\GNOL#7UN%;:T(WFLL"#B3M1#YL.]0Y
M$S=7[_/G?M!/^#5$D >?59-48+1MV=>R[-DX[K8DB=Z$IYD$AD<!8U^4;IPF
M&F1P57A/=8YDZ86KY]OOSWMMA*OMNAB<W^.W7JM]1,Q8W%4;U-%#$ KPVH39
MU%"\\FKVT$%X"M-1.HI3?;?5U';3J9CB]PPKBY U[<DN4E##(^4&E]661<K+
M NWQD/+CD^AIE!8BH;MRU"(#[DN=E1@-UE9"3F[4X8!MKA_$K&U'L'Q77HN9
M_M.G06DYG;"(A^\)\RPQIPCH5\S/^6H>I'XLA_]1Z3*S?[F/'N4^>A+)\P\N
MDC&QT7M*B=ZR)/\V_2.OI?/BU54_G0_F7^P#UPV@$0[7C?)[GD<1A847_\AV
M1IJF]H;'ZG5$?#/D8_% RH$;6@-!XJ8CDCA8V>-PG:V(+#'Y*EC+'+MX7A(]
M:,D-SO.S=?PEB\! #\P$Y 4E7/9@V;F": OVF]N#1)L'F-@*Q7^FXSE&\QY7
M;L0H)=C'Z$1T\VE)EU'OI+JM/BMWTL<V#Z[2V61\86M?V;1*+&4[&@^_$%+[
M>1>B5?'JBZI=&>J,> 8$-,W<SBU:@;3 I<_<.GFL:,;.R6<L&")JU%-Z)(1I
MYU2:J.W9?$KPIS69=F0*TIF?&)*-0';=C3&Q3?J&$_D-(XW8JN?K5//R$Y@Y
M%5A9C1Q4AX;L<:1VQ2'#@XP]<(@%&97;<@&SWJ_"^H]1N?"8?CH:7K'D&8S3
MZ7C2IO[K )!<U [WCQ_[YZ;A=*;=-(>2;M2L^ JY-^%2'I-\HRDH(@ +:B1^
M@\:LMO]2*+FC5\8&#%]O<9JC!!OF#%@58S@8I?/)X+>ALQ@W/7B/?@_YWOP>
M\GT$FMYX/'B<?/^GS87Z0O4AD@PU&HW2P6S$&@/H#[/T:OBEN5&?K22\B#N:
MC^$!2PDGM"JO1A)^QMA0:)RV&\&@JS)+; Y-1BX90N>O\MQMRW<V@&L_&=CJ
M%)$3T:*[7.R5'%^#N<@+@WRW_4)M=VVKQ"LVI34C%\C8_IN\:I&U/&?KYZ B
MJ=%RJ&#W]GUW3:0/ <.D6MK/&:B;XW&B&<'PF\!V\VT<QJQ2/SO;X0H'PO92
M8_%,=BS-5*DB8]?-\>$;Q?$%^[(;([%\QZ KET<^=F)IV$<Z2%=XM;D^K2U%
M&!O@0)T9E\R_3(B-YNET]KO(L/2KBX/,26AAM>PJ'4X>:?EIPE;5:C78Q5%&
MLW0PF+/PV.V K/9.35$/.T?$Z]!0=-ZZ*+]8T,DK(!83$L ;VSCTRBT6;1EH
M(2$C#^J?=>0>,$-8P#?0FBC@:TU0H_R]34RPN.JM Q8.PFBI'R:TU](=MC.E
M(>7I+1UFB@4O\K7Q3#LSPCJ*)V>&Q/?42P^))H)@(;8@&<0-DQUI$>55:@G]
MVO&R5(&_-W,11&V'O#M%RNWS8@^!56L_QNZ%5K4);LEHN%M86P6NQ^TM>QOC
MLX^3&]-J!VD3-,M=AE?OO'*07P,A?4J  %68Z\1'BEL>^!I9%-Y5&@YQO/95
MG*4,YJ(ED1,V"X!;2)[%9@MFT4,[/&D>.S*=D"JLG641."=TVT)G L\BU Y"
M0BG] O#$$4T3@M8A;E0TG0VPUC,F*/8TZ]5"4P1L@*;$)Y%Q.KJRW,,?H(.Q
MGZ /(HJ?_R4I-3; :) H(M>,IY7HEZ5?5I8%'@CF!ZHT$#R+ CV$L^1H&IW\
M%I-Z>RAY-N!OFM' D#8FZ8"7J_2-)FPY>0U=J624:\%::S>EG9+$-KXRV]]F
MN9XZS,GY=Q*M"A<MRI))9HE-Z08EX4%L8KM8KLU3_IH%<H.[?X+TZ"J+VP)\
MV7-O#J?'=N(5#Z 5!6#X6=,_@&_\"AC%CH^"Z )I'L4H/@ZA>. ;,=?9%T(U
M.K[D8#)F_6^L6^#$R/F7KDH<\AY?QV"'="@-<@&SQ^P8N1E*AS5\ 8#G,PY,
M+,//@B(\9@<]&("+,/<05(5_I]$*I\SUI7=1C:QB3BM7W8'1\FUMZ1Z_WF7[
MG5'!E 9Y#!I\I 3A%]U)]HN[I0J^VE>^#"SL;V3D&KLGUW&C&?OQ\[YL^=D>
M0_POLV:'5GQQ A*88P]>;50'Q?\HUB)>MU/$ZD&[@7;I5X /QS_G8(CI,+X"
MBKC=2/HWQA'KW6MCB96_=J3:?BVD<1(BC;\&T-A<^/\98.-O8B3[*Z*,VW-D
MU/'C58W#[.2K:A=M/&2$ &/WI%._, '2#K[CBD^^[L=KV7>H%I\+FXC/[$ 4
M*_K"E]6+PV\=Q%'$L]_/AO.K=#(8:S;YHY$44L+&R^S&")QQHI\&M=!I.%B+
M#%U/:)\T$MU@CW$LB&=W+O0GS]+YU;A==-W-$0\!)FT8!\5I<"_.1OU1.I[T
M'P?L."5NUTNN"<O?WIZ4#6-)DB?@0FM[,=HT34?3 2&DB;N=#>;I>- 7^$0Z
MG$U:6+7?"<1WT/L@V S?$6N6&3KF'J'B<&(XLK+_<?:FB;LK9N2? Q=RV/WJ
M>L"PF-5,D4##63H&(T(IS[VY]&79VM\?0%(\$C_BPD8Z]N8K8T<B0"^=E30\
M'Z6#R42"FNEL,/X=88XQFBO^FX-+'"WN,+5_-DZUU>-CD/:EVMG9%1S<[PA*
M#:)'_\V2,D[)Q?@UFIVX&_/5$BSF5R8#D@K*](9#^PNBHO!XG^"31\[RA'2-
MSO&3Z/C1)H[#@=-;>-P;S?2?CQJZ/?53,T4>^9G_?R>6Q!I(QBV9SNR2D#6<
M75T-T\%X(()F-$G'T]\)/O.X#)/#"28'@NN/S#+YYU<E1M-QVI^**C%/YW"^
MOY]P^G4247YK88\HLRD+^W:Z2CH:3?^;H4V[7+B^_7,JY'26#D8CV2)BBU0S
M#/[B>0G*99BL<0SHUS5/:U@/T_F524N8GI !]KN8(G&F_-[%*M@.:>UZDUV0
M!@\"T>%5#G '[3*C[ V5FBO:M;RL=H6MJBAP*'4G4B"!<KT)>E:9UK#(.V^J
M$C$*2\&?B"/SH=W/O.-*PL.N/**^2\#U0$"BB+8@D)K0*"[0[ B'=[B#)_#$
MGT!N3DV44B\?=P\B#SM&(_R%A5-KDG7%2"1W@Q5K)*6P>.)X.K"WZ%S+'HC3
M\ XB7=[7Q6Z7EW($/H>$E7I=TMS*R 40XJ:T'E'ZDJ0P"2UJ1P$C3YFWI<I-
M2?O !ANEP4 YU&8]H):TNT@SJ"=.?5HO?Z" QE,GH''J<\G_OKY!R;C8_9]H
MG?%Y<IETOOOLM_.MN25BFKS^!$?8."A>KJJ@UYK[TVWE$)!)@=K(4H@"2:@X
M"HC.&99^;01?(5YC _-'$ Q(GUH]:,M-41:X=<;/A&=/U>KQ'TNXW.MJ2WQ'
MO;EJZ#S*I_H=;Q7=P3]U3^ LN9KUT\EX!#\-T_YDC"V:XM,9IU>3:3*]2J?#
MN115/[B]./2$ZHN?)=-).@4S['6^KZLW)>$V-QS)6<*&,_S.5.M$LP/GMEW#
M;\,*X_!;@VUUD&E#[MPP<1(G_"[M\J665U&",53;RF&(UPN8#9-CJX6U^[*9
M/>_S<U[!"[."MY$53)^T5W -YLE:.T],G6K*62G@.'RCX4C',G^BI.\V[':I
MU:)P/9(F0QS663WDR%B6!3 YQ% S&R?<UWJ7E9&2/;X[" \:47OI< [_ XKI
M"+R>9TZS%%-^^Q=Q+1"9=DE)9_=943-+M5POMD,<R=,N-Q%GU@TH0*4-[?K[
M(Y<Q>NOEZC6@+,%3?]]G]2[7*MO3WF_)TH8(.*7G1Y-Q.L6"T=XJR. R4JFR
MYQP<,\7>[PE)BC3\B1LY17)UQKV1J'3]7G_D]$N+F0_^;'0B7T7+.S$G@;..
MPI717#C,ULHH&O:N9F:!@ZNN!::60C'_P 'SPLBW!BK48*4A[&.?YQ^E^LVM
MR;"ZKWCMZGC /_#&Z99)S5Q4.B1G1TUFC1#*2YUL27&U V#9P-GM_72HV\=(
M("5T;P^>^A6O'=9+O!OOHNX!7HE" GF.=<^L^E&I,$Y7S<ZIRGV4KK5[OU [
M?;&J+4_X"A6IL?;SL6571A.+3IH6M<EWJC [Z]Q3*HO#MA_I;O,T*Q6];>.[
M<U[P-9N8A;G\7]@"^XL<#TYN&GD "8>,^'M/A??1*%H+CG2%3,L _S9K\'S0
M?Q-N<VE^2JZ%[^A_WYDR[M?&!?[:^.6?*]]]BAYW6 J&8U_ CP7,>Y&\$>[P
MEK@R=4,[)_9PD?P5+^KYX,)K&0)7NCWAB6G"T_7?/PFW5LEREN#5#QY[;JK4
M'1OPQZI>Y04,^:W47S[AG2.KF+9G-^^A\CKOS](YD*\N@<7D64*RZW==0(3"
M1I-9.M053)-9#W^<#?OI;#),_LK\@!WT%J?T&2,A37SP(BZ%H2?F[@4F?:T7
M>S:$Q%;NZ$$83]-Q7/VN'D4O2-1GV9(GU;YN\?1'\3R1V".)Y U[X^%AC405
M@4M5!(*(DFAW?CUZ7LZE9K)Q5"OS0D^&3?R*2L\Q+N0:>L\UH.-&79S8%%:B
M3[Y)KJ;TG^?M6)/.7QG+N->G_SWOB!/U81#\W[NB^9A$HF]#^LR@-X?__Z4:
MLBJ^_DZS[+2.J!-U/B07$1P,\0+]SU/B#XNNN.)-MHBH7%UF!,_7)\L3YAK/
MD>]N!>-.J64<MF=#L-\3]6K:*]:0C35PU;YQKZN80;)2/OKEEP*NW,DZY74'
M9TF303H%B3&>FWX['%7^E!5KFUFZ)\"0M;-#\_*P0:H->UU7V#7O_4_4WVDX
MY@R,0[WBC<4-7.K'_*;>8YX?LP?N&XH&G4G0U:0%FSE-]K,D3$N+'#P6QU^#
MW5 BXV/K4%V<DQD[[!^?,Q'8X<-FM&FV/JTEC'=(,KA)Z,@.Z^?LZJ7.\?DN
MLHL4(L*:#N+).CX Q9<UG90&N-[?[H'MV0DO8GIYR^,HFK];!2GT'E+$\KBW
MK<Y%9L-B;C +6&#<^&9.@)<Y\D]!"SG!1R\MYA&MD@2M7A4<=-)-<\J6^)*9
MZ'#@TP[MJ^Q"^UQ2$?+^ /C-\:$Q;)*O: ?]\6.'",[R7W &"V>PO:@"UK73
M>TJ44NQ:0&W+D>Q6N]7YT-0V></H;'%=&B9*>:I'WU36;0GI=EA:77I1UNG6
M]K,(*M$<(M4.[HOUFK(B;M!5B(L'Q8O>EO8#3ID/CAMPH4"N#&2[)HHB'FMN
MF[4[&Z2Q!'Q*V(FDV5(TECFM<=4H2!_KU.QH9RA?VLA;G.)%N]2#OP>Q0RX:
MET%SMB'S?\KH<[BC1*Y;^6BGLR+A779#E<EY]@J=C22!T.$(!_OB[QPNOFGH
MT*A#+L]%;Y6SDQ0#@;E0/KK%S&&@DB$Q$@SU@[<\(:+58XXJ6UJ(O%&'[*X3
M9$-0/Z2U6[&1FS;Q8Q"5$HFD08<1GW8H]\O1447<>-)"U^ F?UEZ_!_*G0]R
MQX/DV=+9N>Q8.@!;YJM8L>AHL'WH$/$NJ02F(%?4O]&^82J_#TS;IUGC4CSB
M!- 5'G<!B+U]HJE]DHU]R+[NMJW1JOY)&TVXL4 ':A5PGQ@-'(QFIRU73ECM
MYZ#)U,EB.&7XAJIZ[A<JCZQ51EU4)_-9.I@,'-^X:^_L/'4DB'7:S@=D'RLW
MM++J@.27(.QAZ\S:WV9(W[*(ZA29U/8'#G!;Z+:UXIM.'ZJ.L 8V<]A;G(T\
MXEF?<(J@A+%G'/-0"\SCX60M1*<@J8'BT($-D2S//X(2L8(7=R<]= P5,N@K
M+$3>%,EAW@^KLN"*GE8UNA@J]JB^<"C]*1_'>].\U0")J'$[M4F8"\%I,1A+
MB\.9WZHJ4LBF"^IUGI,8,,W7WBKNR:#&_&[C6K@,N5Z^+%C[C=4PTX&^;@DS
MVH OJ&-F9X4<);+^G^"W3B_KS (/)8,:<[<'VJJ\]3+UI+: B!-T"ZGJ>.%7
MKS3@LT&'PXQ;B6@9I$B@>^07I0RVL%U;[6!=I?BFQXHKN71ZR&?EDNE=9H*@
M=%IPH?QR23#&U=4X'<**?J(S"\XR97%*OH56H1Y3UY$_AD+%@IW7V-(GQ:*D
MR!RE2L@2V;B<MA2Z4M%^"/4:V:%PG8?(,WJCN'DZEE& &>\)['UEJIWP;KAG
M^TH>>R,SMX7V;'4"#CIP9@<-\9C-X_F<#?HZ"5-VJ8-(0%U"N/JE+1SJ[\HF
MXXM/&86@#]8,7J)-D<5[W<4GG6M_@Y^Y!BUIYW$M:CR%@'G*1)>?+"]L@KI1
M=#*LW+>W4PR\U#D#*U$]%GY^E4X./R&5;?Q9$VQ60WH75K4XW"O=N]$^3 BV
MEZPFH&A"RUJEQ]E3N>X-W#T/:KHJ2I<9<"$2KO.@#3:SDI4$NMASU\\:"I)#
MUT$U $PQ-^3G8C!BM(6<4HJ//2[3%TFG"[LO-4,X.UQ*0VBA+%/]0\L>INX<
MG'(F_ G3))83-=955@JKZD)*@CT&YA06"P)&OU^2ULI0]U6N2+AL+3^Q,>7R
MI]1-I+^OZH]D-$LM3'Q% 9Q@%8+I36)V7R,<N3F,!W;$YM>! W=C@$.Z,3C"
MF5]OTXTIW^2W1>DVEH]7%$;/B:"2/&DU'*5>;>$V3HEO0PW4X]4A].<43V<D
MB^=0(W<"LUF+DK"&YFIBE91+Q!;*(1[M9Z\E>)N[''L6NC9DH4&33YX+1)A\
MQ%=D\RN[NW?X6R!RG%.!0-!/Q_.X"\:W3CVS]*ME2\Y,<N3!AN8'&E)=]>:#
M?S6D^A)7SA?H2\91?KPP_104N,FTTT07Y;8]C$2FR,7?-&ILX]@W=?41>9TI
MBC.P11]:*I)A%9S.P<^(FHKN3G9I6W^/_1JS0"?OZVPV2F=2X5590&M&:F;:
M45+?:=):F^_Q\"[N^!()^XE67W[B^1E:^^":)%[Q($^CB>T6JY7V!=D.I*?W
MS%Y(W[<5,6)R/MHXD:V<*S<F9IN5 I/.#ULOF/5MO7$A30TGZ6PZ"_+*XBZ@
M5C24M\T4MK;EWMQ26FX&F__YL\DP'<WF= -KPG;1H$=JJTM*7?<=^(*KZ'D2
MP"J3K LK_1U)3@.3W2PS=72'@_9_2R-<%0@5\[]F4D3L]-\_?\KZO?H]@::<
MF]CA\#J%Z 2(TZ6^?ZY&'EDE*9P'%@H3G=J,KHAF?IC0GV?MX=NGI@P#[/E]
M@_4JZX<N/:\CSR$^^Y[N07*M@%;<UO<$AWTX!I55AX@!PYZ*[M&C^RPG_W<6
MO\H(U0 %:[2=M_":>;B%E53+2.>DD,JSR$\OF.D.9G-0F!#JB6V&]3\APC,V
MA$%W'GS*FV.(R@QW,CXEF>\PG8ZF*9C9W!<YN4S(ZW264$>4WW#>$8X\3.?#
M:3J>!G,;].:S8X17E!1Y9%7G!I'YID=!=0P1&Y"/X*+=)0049?'4+F2:M-#S
M_^+HB@SS_.C*Y8R&Z=4,Q ALP*@W</YUQANA#K4KT'_U9\Z$LSMG?\+]TDZ]
M4S>G*<@H=O\&;,FDR:FU->S'6FAD"ZHMOD14S3?>>VJ#E#;?*I8TI@,Y2 8S
MA'2+CKEB[\'\6#]<5O<84T6O4+$LX-)BID13F?JFPF;3Y%7=2]YGFVS)?B=;
MVA3>=[I&\U2\@JU>&AB5TJ_%0EPP&)N);61*\+<6I/W)[XH-2GC4(/1[3DP<
M75TB$KR:YAFY5<P&PHL#.-;1H8C0>9-CIX.:HC=+T/.+=<,PEQUZI6D'!W Q
MZUNP$?YAK8+77)D,AGMC$C@O@@Y^SG:TG4)+MUF!@*P.@O2D]W+62O/I<Y61
M06R +4',:A/R[!X#RU3G2V"+V-_$D%2*B9$]*]/>.+F;3-^3U#__5URXU(C+
MER^?II9"1>D>IP-@O./!U:^=AT@V-%FHQJ"P;=8QYZOTPFIP_='")GJKJ*F$
M>J?)(J]6H"-(O5]=4L\NSFC/9_.T#Z)$XZU^1(K3U$WP%:;<Y&YPLEPP%^"]
MU>HM4B?18\HTCR!A),1>6H<TWG,_1<RQ*1RDA6W'O<6N!S4C?,Q"]^A6^ ?-
M(41$>[7)T"VER5+JV+%V,]?6T$X/PBF-^27&S[V%%P4'9DBCXY!=_FK\;N0<
M.I9][U3'Y,.D#E15S66ZW,WHXGY!C!9N$M:Q_9#]DC>'_G8T(CL &>^]\,;I
M+C$<NF('_IX\W8OK[2_538-7F7GZAZ=_N;Y0 L-Z1J0 4]HUE^J$??^I][[G
M>% +_N@.!EUG]RGG:W,E)+*7X)>X-<!(T#L#HO)#O=]LF2#Q<UH-LW&_9\K2
M4/@B_)04#&6]G833#:@IZ*NF6#D9%ZEHYA3.LB"KZ,SIW^3+P%9U6Z17KG>K
M[K31^!N.1*W6F>-D&WR3\A>]NI$XXM)\EV';K6(I,-:(93WH-R5%'\Z!E8$^
MPV)1PLP-)M?#VD"H8?7LYB+V.?]35*66A0\0*E9^Y6V4PIV,7MRQ!8$[R:7C
M:"<<%SFV\\(OE3Q,."A7S;W)%A_1[:ZZ9-?'Z6%UO2%71JV2/-%RDE697W(W
M/CE<@MBL5LT=QEG,'A& CF$F-55KPAAIO<32XERZ)E>\Q0/YR)%1[6J"R:1V
M03PZT3$>%6\<L*S2.0Q@ 3^++]\T*]L@7B^C%C-X4B3<4UL?W1Y$XQUBF=\+
MP]-6R<#Z,G*;MMY88L0 43TNUIS+7<'>,!*:^RT57,X>UI<S1]I05KP0BCLN
M^=<IL@JK,A?&O6 .#=T8U[ 7HL&IU 7.7CLOPG![@[BFN,*-7S:+.3"!B"XP
MEV2'IV[$E'\S3<&HCILIG2HH&7N-QP!L4(D?-W>5+RFL(SPHH6P.V7V'2;#;
M)=MQ.Z<=U52L]@W;ZPVO I@1&C^F$GA^3XWM,G)[M[X3.C:\(ENLJGC=L;U0
MA6!\*=9E2G\PM 0&(=7>Z"_$*+FL ;O:T%]M'\E\-G=V-32ME/#8\5:RWW:I
MFA\N@2NLXR>](N$B<=E-X)617Z.70W1UZHG.^Z)X<IV![<O(_;V1_7-9$&2H
M[5-O&R56S2"N0HNT=3#;3]\5J(I1Q!!7R1PG]?7_LJ*_.42E5XNKS>FI"=K8
M$+$5#*9=*Q_U;Y25;)*Z36CEFN8*1+,N#!MSEH4>4TH TB+S0%?['78F5,IM
MBSQM%6MZQIU+A36IUF$>S\-<ENX@W-'RX$Z5+#>@9?,?7]AY:LDW6).NPJZ+
M%G$^'/3ZR<4WR?GHBG]XO_.Y2*JUVW4$'?1\VILF%\GYI#>&_ZBW3LECWKL"
M"ZHW29X5C<7FV[9AF)1'\@:_W^_-;<D=PW '-##\9PC_,1*GSHG)J']GUAM1
M[G>;[ <8GAMBVN7SD"CUY6^<G]Z[&A3L,4C5L R,N3LQ9H!K<DL@L:4BKB&;
MQH1:0\-- !^9].N>\K-P M\E/\H1<=D;4K0BBH?H$@WZ>]+9"*O"CS%A>CJ@
M^O#7ZE&!P\**'C1=,(8'@PF6/QJ-X(E%3=;"=)1.)Z-D<D6E.9\&%?*'LW0&
M?Y\-TGG_JKNH$I]X:W(#ZB\.@X_2P7PJV8.1[B/#JW0\GV&C9S@:<43%3F<(
M"QBGPPD\F@[ZXW0VG48)Y]P^B,1GGKT "V47'3GF=OQ >D'[V6A)\M(4A,._
MQ%AXU+_*Y33 PN5T%6R==#4>IK.K,8W%20X8RJ5,ASK_5#@!9%25\J7Q8+K<
M6TB^:/@=GDE3B>J@@<'P3K6XZPT5L<)6DJJSW+<XA-;6Q5Y,P"C &ECFW@OM
M*^^\,.K-OA$R\EZ)[9[SV@1?.ZW/P@=R(Q2$3ZQ1T7!5$K<0)(:OX6Z11H<^
MJ+(R6E9)6?XJ6T7GK*@)B?EEF);W><F\706/VRZR;ETFQ#?R3=!&G@AW[$_(
M)];*=GZ'>O0_6G:5?$ 5)4)J("N$@4%5Q_5A8AQ&P 0N[QM4W."JE PX"6_2
M)4%#Y)8M%BI_BM%;U5A#M1+7[!K'0/F7I(.R?=5@I352]/"'+9<Z:X^!MO$#
MZH%DW^'QU>@XV<NU766+/+# U]CD*!<,/BR(T645"$Z^<->*R= DO[*#N]AL
MI4 OC)+[Z<?X1<6S>WP]NV:M!@&('L8):0_0^*1MCJ#N^R*C%EU52:'!W/B9
MB-+$U%(T>P,7D]UYNL-BBF&93]8R&KB)B]SJ?%]TD8P6H"I1EXEOA!GCC_QC
MF:2C^<@>"_PX&L9NUX?6#=:/UK["U/KBX\N)M*8W<^<6O?84"NO> 8,K, X]
M/[ IE3U0]XXM0 SCVX* +(*\(S?N:(*\ 2\E^TW1^OBQ<QZYBW"@YCD16:HI
MJ_R9+^>RK'P=)8MPUS^7*/B#ATDB_-IX:C\UG'X%GO!!+*<3UG[@? =I^X!M
M<9-3%GI@Z&%(.C_13Y[T.CIYUS&$..D;\GNKT\OO"89]D"DD:WR/2PN=I/A?
M<U=LM=N$?<S4NB3E[KV$94:SH<[R!1I3Z&A]Q](("&+)(;KY;,*U@#G-F7>O
M@9'7H%KP#MJ.83TMC;J6/!H'/Z9N..E.5^>5$[63M#AG851[&-U!V&&Z*JE&
M,?7%$YS]^%*5,5)YG 2HX>![U1>5UYNM28W5K'D=*>Z(VW!/E3R,EU U!DX=
M@),832[%RX >4O$O[/S"A01*5Q P:2]PI)G3:(L:%=&\V^=%E(J.5GA8"MP'
MQXT$(@E[6KS:>&_QN*(\RZ4P0<SO+:$RT*_E[+I^_S29@M7DQS(B#Y)VKUZP
M"+3>%'3=5NMB\2"1'E*W:+TBR[53"VK^H/LX-BYK=*F#K/51;C3@-GO82)LN
MELE/V%>B'M$6L-D:Y?Q&*RA B$B"?O*7X+?9FBL1A^,5I;/A)OE6RYMV>& \
MINND9*GCM<YAT:6:_889Y+]DQG.N*KY?)0=%H(#',7G4M>$_;YB"+Q]?])_W
M==$LBT4TA/9,:BT0=J2XV3,P8YT%-; ['SP:7!LFETGWVZX<LW1WU1^<?[PP
ME2 6[FM!061X^#^#@L@M#%7JE&31V@]:Z583T%Z10(DU8W^7&YJP^7V$T<><
M *TF+!P'.-!PT$N>FU^S)HMUYSDI28$JS.4\7X8JM' UZ@K&QMN*3)+"*J;M
MLUFP2Q]*-NC#)]X3+?H+@G]Q)ZY="?/6P!!:I7RY/2XJ]>CDR79FRO:7O)01
M_19HS;D.]JBD60^^ZHY'VS3ZQH8=,2+$SHCQD?'PJ[)%.'OG7.*7TRS7'\:I
M >W,2\ ^-I,,Z<=*@:Z/$7LG#\DF^]A^G>T1DG;A-&SBBCW1%@/%+8+WU0A=
MTK6NDC"-UV)UE? B1T%X7/YSW;4WFVQ)R@E29+-ZL(&XJB2D?FWC@"A%&RL,
M!%,0UTJ0*1(5"79!V[^:+_?04>SLG#_/O.O0/E%:%HOZIF &J&(]2.R17'>0
MT 6V\<+/H$Y<FH&M>U>"U'=D#3P[_4S=^9BLH,X)<5[0H^?SX<[%FQ\ZR-^D
M^"+G[$S3Z73NFA(MVR!(GC=UZ9/GV,LC@' $#QP5-2/,K _>Z@!I_R!5/15^
MI8Q?[Y:IRA1//3Z6=CR8<AC12<CZ%3*0KX;CD_./B6K:LR'O$F%+* [([4:L
M>S.V<>+PS)<6U-<WJ+X#A0TPPU.3&E]B/B.JIE[MJR")AQM'+[+F+IH[8Y,D
M*3_2Z\F%W.B^PA?01X[QKC+L'=IPQ-=UC@GBCVN8NZV^[^\JR4T@R"?=\;%)
M5CF4J2_U6VB*6>WDFU'V&:LA[!QC1 !#+]J)H04[ )5U:%DL1>98/+_M(E$C
MB(M"=Z;';0MIZL5ZK4%U-D[ 5EQ+I+FU]8AFU%,;7&GV[O42S$G<9NXJSYD.
M7*^9RQ&'Q^V[%.3R:5MZ1.+9HOU(]9\$N4C)I:G%&S:+ LD7: S(6R9Q0V-L
M:&3$V,CUHGO)I^U72E&-VF#E6OA)OS@]F;>:KXC6!7%]+>LEW']'R$>7_>.
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M1/H4FXF<\$A"OVOU(%%_H_9*:15E/&K415D_X0PH5K*0FCO,7HS[>!F9"9)
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M6CHKG4?R%OC&Q=*GR=7<[UUX"D:5[.@7>[3U?55OABK1M($9&5NQ15"X5[\
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MF;?=2BA/L?]'E/#%T I[HDJA6\5A/!<O(-Y'SY5^J'1Z)9*8L'JVNU&_Z!M
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MN%NT@?;V7IPOL+:[%3PC( WM50W\,K$SXLWBH1LBHI 8.>4)FZ5[S9EH0IE
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MGU!+ 0(4 Q0    ( (N5;TX?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (N5;TXGZ(<.@@   +$    0
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M965T,RYX;6Q02P$"% ,4    " "+E6].TLL01#<#   0#   &
M    @ %#$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MBY5O3K)%HD;&!   [A<  !@              ( !L!4  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (N5;TY0>Z$@&@8  !P@   8
M          "  :P:  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "+E6].P2U9.;0!  #2 P  &               @ '\(   >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ BY5O3A?R@7BT 0  T@,
M !@              ( !YB(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( (N5;TYB!;]OM@$  -(#   8              "  = D  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "+E6].UR"!G[0!
M  #2 P  &0              @ &\)@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( (N5;TYC'9?&M $  -(#   9              "
M :<H  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ BY5O
M3KQJJK:T 0  T@,  !D              ( !DBH  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "+E6].7NXIXZ\!  #2 P  &0
M        @ %]+   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( (N5;T[JV,3=L $  -(#   9              "  6,N  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ BY5O3F3K!>:T 0  T@,
M !D              ( !2C   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "+E6].5YM"9K8!  #2 P  &0              @ $U,@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (N5;TZ' <_Q
MLP$  -(#   9              "  2(T  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ BY5O3BV9IBZU 0  T@,  !D
M ( !##8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "+
ME6].GE]"4;0!  #2 P  &0              @ 'X-P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (N5;TZ%</26:0(   P)   9
M          "  >,Y  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ BY5O3LW"& ;$ 0  -P0  !D              ( !@SP  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "+E6].O:AAA<X!  "<
M!   &0              @ %^/@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( (N5;TZA-@EJM0$  -(#   9              "  8-
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ BY5O3L [
M@?BW 0  T@,  !D              ( !;T(  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " "+E6].6S<,;+0!  #2 P  &0
M    @ %=1   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M (N5;TZ*X89^LP$  -(#   9              "  4A&  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ BY5O3K%G* [L 0  @P4  !D
M             ( !,D@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "+E6].TX-I1\$!   W!   &0              @ %52@  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (N5;T[GS!MSE (
M $D)   9              "  4U,  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ BY5O3GC99+VK @  ,@D  !D              ( !
M&$\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "+E6].
M\V7C[JL"  !T"P  &0              @ 'Z40  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (N5;TX9R0?N: (  * '   9
M      "  =Q4  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ BY5O3ET9'JYA @  HP<  !D              ( !>U<  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "+E6].(:\*Y#X"  #3!@
M&0              @ $36@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( (N5;TX Z!"@+0(  (L&   9              "  8A<  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ BY5O3IQKWWD[
M P  S@T  !D              ( ![%X  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " "+E6].@P"C#E\"  #1!P  &0
M@ %>8@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (N5
M;T[ AE45N $  -(#   9              "  ?1D  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ BY5O3KRY]<I) @  *@<  !D
M         ( !XV8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " "+E6].:$CJ[\H!  !=!   &0              @ %C:0  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (N5;TXF!$,/N@4  "<@
M   9              "  61K  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ BY5O3J-:E(XF @  BP8  !D              ( !57$
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "+E6].+GK3
MDQ@'   @*@  &0              @ &R<P  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( (N5;TYK=5Y<,0(  (D&   9
M  "  0%[  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MBY5O3L_T$RIY P  -1   !D              ( !:7T  'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " "+E6]./F 8H%8"   @"   &0
M            @ $9@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( (N5;TYF>%VV%P0  .83   9              "  ::#  !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ BY5O3B_Q,9LO P
M5PX  !D              ( !](<  'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " "+E6].S&V,#5@"   D"   &0              @ %:
MBP  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (N5;TZ/
M@7J'P@0   89   9              "  >F-  !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ BY5O3J I. I5 @  ,@@  !D
M     ( !XI(  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (N5;TY,PF1 /9H  !:B @ 4              "
M ;R@  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( (N5;TX&+E1
M9@(  &P-   -              "  2L[ 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ BY5O3H5K@KY-!   J20   \              ( !O#T! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( (N5;TXMGDXW^0$  'HA   :
M      "  39" 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( (N5;TYWOQ-;U@$  #4A   3              "  6=$ 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !  $  <A$  &Y& 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Consolidatedstatementsofcashflows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Short-Term Promissory Notes and Unsecured Loans</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoans</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Convertible Promissory Notes and Warrant Agreements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockholdersDeficit</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/Intangibles</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Short-Term Promissory Notes and Unsecured Loans (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansTables</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperationsdetails</Role>
      <ShortName>Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/OrganizationAndNatureOfOperations</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/GoingConcern</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesDetails</Role>
      <ShortName>Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IntangiblesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Intangibles (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual</Role>
      <ShortName>Intangibles (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IntangiblesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Short-Term Promissory Notes and Unsecured Loans (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetails</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Short-Term Promissory Notes and Unsecured Loans (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansDetailsTextual</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoansTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Stockbasedcompensationdetailstextual</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersDeficitDetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockholdersDeficitTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Stockholders' Deficit (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersDeficitDetails1</Role>
      <ShortName>Stockholders' Deficit (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockholdersDeficitTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>050 - Disclosure - Stockholders' Deficit (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersDeficitDetailsTextual</Role>
      <ShortName>Stockholders' Deficit (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockholdersDeficitTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>051 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>052 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>053 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>054 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/DefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/DefinedContributionPlan</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nmtc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>055 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nmtc-20180930.xml</File>
    <File>nmtc-20180930.xsd</File>
    <File>nmtc-20180930_cal.xml</File>
    <File>nmtc-20180930_def.xml</File>
    <File>nmtc-20180930_lab.xml</File>
    <File>nmtc-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001213900-19-004295-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-19-004295-xbrl.zip
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M0:N^3<V[FG</**E-^/^M)+5YP&+V]@I)77I=!XE.(4BT+"T/85Q):=G3_//
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M_3'PSRS;9AYJ#LPQZ!LJ8+F/YN'Y,K,\[W42N3Z+JD)+)K1+OI'__!5H.Q-
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MW^QN"&\)^H^!TVYKT.L.R\F_ UA58:[3 TJ;Y5OGL&!MGQNYWD\S4,WO%:M
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M4<3\5\$3'UEY8D&U9#>;W7ZSI6AIJV#9&=YJ&<!L#\'R&!P0WFI9H=]K-]4
MZ#IP*1D4_KZ<8COE=WXZ$NQZ+%)$TPQ1."=D3C.EH6._L#>,LA!!OS@"W_3[
MI!U7!O+AUU\M'[8ZS6:W?5((J/A(X\G!E:X_U9LMUX]02(*5Y5^5S%,X"(.O
M<5GN!E#%1U^W.53]+7?"=/P%;#:\[]IGFR19-=M=M?[[",L5?2;-KNR"D-\C
MS19<]XI!Y+M6K-8&;91_97;:1UUUM>>=V38[G4&_UBNH:!S[VOJ.8:>[(PY
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M,Y?EMA)2DG/;R;!*:0\R6_81N5L>UT/#J!K.?2F_ZJ3_&, 9%4UE]_EK/U5
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MY:/(,DM+,KAM1*_'G N%LB(E&E0#0&6$R67PP) <6'A-)G-8:4,%>DM$:XO
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M=<Q^8]C;0HIM0YQ#G5C:?UD71]G^[5VU__( ,.Q?]U87[^5C2AS7.?V/@31
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M:#XA2,A7/%+P0D0M/>),55E]Q#6*+X2C*[%=%&%.$B_RMY+K*_&1!;!GB0^
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M+P0(Z902\[P[C\4B>=-U_++G;/Q"%1B;TM7+WB9IP#\KU:619]D_BK])?N"
MY7\3:AC-VN40?HL8)DB_=\=LRS7OL<"GR$% 7/_7IZW]$+_^:66$QIU\8HP
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M=5X459<8R*#=;G3ZJY&[]??N:1W=;KO1;*^6:+6,Y2R)JBQ%N59,TFIVUN[
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MHM%:H& Z?%Z=4!ZP1_!%,L&6BS2[BG?!='W;2QP:;,#0H+;X4$;JS8N-PD/
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MS_3HH6=Z#R:XTUFI)5:O/;1'H^'AWOA(*QFT^W9_.#C4^X['3'<Z:0614',
MKP08F/0.["AI]MEYGODQA.W>Q^!HLQF/[':W7G4J;\O#MMD0:9_9=+IMN]OM
M'9E*QQ(_Q;GTU]SV+V'B^%N?GOYISTZ_EE;S, 79>-*CL]UD0 9.>O:XW7_
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M"(0[O'4)4;H4'<V YJK>1B[AW'7K=G&\HF(XMAG3@I9$"5M.";\"CZRW7/G
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MD@<'"K8&JT3LT1UALN&+_?G6 U;,I6(T24Y^K=RL*5C6WXK?R:/%$\M_)XA
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M?U2J:%?\!W(I&"=0(YP/QBW=:-*\=],H_!!0]X<E(P_-PU7"(/X"7](+T >
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M)T]C(42D(]%EL-$[PUL(]%XOMF!QLY3[<HK.XW,/^Y.[B&4[=9,[UQ5-W$O
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M:S5&M#5,M!G2-)8T7V0N?IU:L9:O%^)%R(4Z';LSZ!TFDQ]+PWR8  MXL"Z
M,47X7C&YN!HBK2B:I+&X9MIY9D^U"J33K"^$D"O<7 9A:@Z:=O!-S<%3JCE8
MD[ENLNA/4X]PUEGTQT]N[XTF3S*Y?6V.]S;)[2;'^S3YT1<F0=KD&1]U,RM[
MQN<2C4VV[I/6G8U9\^BD^7,EC-@L]W&![K3,OUMPR5;9][I#@#V5TI@F'UT>
M6"7SB\N@P-I4S%J_ZUV8^G/T3T?N/)U))WV6[9F$\(_A9&QWAAWUJGSB1)(+
M9^:M_(1\WV+QE'<K7<29 W]-.(1]"AO2/+*\7C5D/D6A,M""SEIT +MPUCVY
M;6J_>"C7HP0NE:V*2:H8YE 9J["XF9/&;N$GN:Q6H.+22ZP5_KER4 AYH#HG
MM#=P6U "IXY?S'V5B'7_^"&-+Z\=9_7C&R^>^6$,9/VP>*T%,SYQ!.IU&"?Q
M9]PARC3[Z-SC,N,O<'I_\6&;_OE?%_^00U%&V@T8%VX4O_TK!5WW?9BXV0O4
M0[AU>/X_N8N?OWO-?W^=_/'V:[OS]3<G^(K;^Z7=_LK_^?+A:Z_]%0Y9_O/O
M_HD+.A8"7Z,8EF12G3V943Z/\/V'+V]A=ZQ+2R>8%ONPWK@+.$[)\\LB/.Q&
M%R2KV<G]=U*FOGZ,O%N,LP$'G F&"TSQ=1AA]4/(G3;>:<+R-7/TSYP=!3_]
MEQ-A?<>SSI4]#&V>G=IXD&W[%?6@WU+_WIH(52FY 3/Q^D;3HKIC61ZC)XZ0
MTY$B)R#AXW0:SR*/(^Y*^XBMERY%=!U+LO-N^Z>/:32[ >%M7<G?J2\[/[UB
M17$&9JPC8C+NW./\+\Y.A4%Q&A4#9D(#![*M51KAS4M0!1&)CMG\;0KYH#>,
M+O!*7>#BZ+0II7N>?Q.MF+)C2 >DFQV[H!B+$'<V0]21:_;E3_@F/RS^B*/A
MK$P" WGIO;*$AEHY"*E&N?W<-J4 Y_S2@^$=ZXZ9$LY^)8G5J2DW<Y#E23.A
M D/Q1:_5UC,'*K=7<4%MXJP4RX%191-;()30"J)0M(W4X"6;#S!+_6ROJ_S2
MCS9F30AEGB@)&@DN,H.9A#'Z_8'=A97]2?0LT=GFP""EY%Y'81S#CH0S."3J
MM_)E:$)AZL/?9/+ 9%]T[$Z'LWJF+HSB6G,T6L0)X-PD%:0\9A;D63,V(P_V
MVK9W 5Z@P)UQ&:PTVJOO6_G6K&.$E;P\I0H'![86SG^ZI)N%1Y^./]^M(L?X
M0_ST@[@+.6Z'[$AC/MW6@)D/#K7+E>1YO>BTY61:UKNUK,<#SG*+Y&-).,7Z
M8WW,I<,B!U>$249 &\I.P\T1FP <1J5I6L.U>_ !7W7E^V%2DI\PT@QG C(9
MI(?X*Y/.L5J(G!E1BC/'BELK,@AMC2:9=R*GR[[LV\/UO_#XK?F9X[9)F3%_
ME;EIZHN8%0FDS& YH6TSI>4!O[3PWYD#2=M;(4QBX.R6'^(R>?F8Y:F)&LR9
MHSQ].#:"$__F!.QP(;$QT8M?RFK-NNLAO2F!FV3'4&6.UIPQE,<.)W&&6BL_
M..X!>EM\KE(1:2S*31_RH2-/S>LPH @!;BTZ0V(D"QV4@/XU#\E;-..?X<AT
M96!;DS3R$LP=SN:0O5>\(@6)!'N&*W2C)6PM\#P6A%B>Y,#^T SG[JWKARO>
MHID/(GY&A2OIG#R /LA8WUJX(@4X=GSQ%V?JZ=+/1LK=X17"_PVC;Y25Z:R\
M1&S&M1NX$=(TC%;HV<2L0/@+!6?NV"!Q)$YH06%#'KT,O(4G<@8IYA S:Q0U
M[L3OX+/(7>%"@X2KIVRI2'EB 9IBG*XY-TV3Z2V"\FZ$>#)2?:]M^U)DFN07
MUCN\35W8 _)L"Q?_7.BYF6\=\W<QU1LNGQ>Y>=VZVX-[[MTR\(+&R.0HS%TC
MX$:"NPJ7=VY.7+<WH_Q;EQ)\"=P78XZ*U[GDQX5+"2M-^2KAQ+1,/F2S&:M?
M.=X<"**8@JS$FG%:L,A%#RBUA4R&J>/3<N,;UTWRN7N>K(R\S>5L"^6A(KF=
M!2%;$KS@<JIW?@N$U4')CCTP2T:#277.>#XK,)<." (^6*5)&5>9]U?!)?^(
MX0TO_G99CNKBY+JM,17F87;13\1Q*9:>)8Z0KC9IC2M^)),:^JU)AX_$3Z*G
M8&5$'G_:EL.8:CHM[]PR#,_(B;.P_E0=F1(8,PS5J<O*I4AHDW5&/;L]'-4&
M:X7CISB,*':F8E'@]2+LBF-/<2T@=5RLUZ)0;OM[R5X+AIX23*A5RM\(%PY6
M W'%5Y;5G;V-%;BED$UH&XY[]ICLPLQN*\Q(CV%E(]GY$'IA??GX=TY4#"Z1
ME5Y(K3*^R,>="[NA.^^<0"- SBJKVC,VD;,'Q*8@#_O,(HT\8H*R-;8*^P4K
M_8%]O=@ZE3D%J!BXZ_U[+>M*R[POGZSNT!Z/N&!)'<?:E(!"F3UOF]K;EO6[
M$R=<+.D!M\>0]KTP3:H.]HMAU^Z-)\3U(S1F>5"A3(A5E6E.15GU-\$P+\/S
M&\SS<R&@""P(>$7.2-8,7AJ8 AKB,F@F]MI 3<%QLO"P'W7^;51=RP$ .?W/
M;U^S&TR6T0#;TEA^38[--GQ-8 K6>;GV=5Q5K)+\,FL6"A,=#<#$NH\S$RO8
M-E;2LMXZQ>&+5)-2*;9F<-3A@D3W=>X0K_H45<_>\#7#UQXA64-</.L*42FI
MK!SN\F>,%4;W)O_"G-+'\LQE):&B/I".I/<?PGGB(^O(([L>XS0C@D)GE?)J
MKT+99U-9>M0K<-95GZ6=.5!"^N-4:FY,A=RRUO+ HY4J#1LZSQ.M^JU4FS^B
MUZ 1<SW1RO\ET;^O&!/@1+/=L[QV73%R=>'O8??Q-"\Y10UU=@#T?."&;LC3
MV_6/H#KAWY'U@T:$)F_/TZ.!9/HZ(1[ _P^U0X<O6L:_/FCI.TXBTXJRZ0CM
MO;3@BDF?HE19!3*Z!WSG@];RPBRA 3W+:FO(!3^8C+K*S4Q!JMIY-P!L8ETG
MQ<YX8H\&]17[AYW*@3>A_J#)AT=KU]X:;U[X89HZ'KB=Y.:%KT48.=K"CR-3
MI !M#,"%8;EGN(3=D5PN#B@WUBAMO\I>4;6K6*?Q[;'=1U%_][Y11Y[-CD=\
MK7:]+QQ:\RBURV4S!#($.C:!3HV@E3-3*7\WRQ@'L[4^[-04%623WMYPV;U6
M WU&<S^TF;K&('VD@]JU1[V1/>YV&T+N_5?R @EO75I8]]V0Q>Q\=KL'G+LQ
M]LZ%ZF8)IW01&E/O"2NJYT>I9V9)& (UG$ G-/5*\^O+V6VP_\H)@UN?LOYI
MSUB_EKCS,(75G)1;;S>9KCWICNS!: >+H)Z0>_ !0Z%-D]G/TGGZ1#HNI]YN
M#IW6I)X9'8(FIT$+?SY)TF;;'E(GX 74G)#!!:9AFJA"UAQ24*7,-DG^)LG_
MB23Y/T[&XM9IZ@=/VGQZ6:#O&:]-,SQVWX:+@V_L 48\U<[F9E@L)[ ^J08&
M"',?.;,$X1\(KN?E_\L:#SW34_=V*_/V))MS_)YA#TD8[ T?G#?7R$S)[4?I
M]4N)?[EH7G_<M7MK;/='WX;><-P:EZA83)['V?QH#5K*'NJU.AMG<^ LSEV(
MTC\(41XAIW/[;ESKO(D[6=YKQGF@1^-I.J";%<L1^.-G2*7U!3KUK*>_IM^C
M.4/-/4./'LDHJGU?$-_,.&P;ZE4_I[A'U;/U#,P<E[,]+L;;;[S]CXI=A?Y_
M@MLF4)^KV5^IQQ ^M*\&N,H<T1-OVT<-LQ'QI;0CB<"#[]TT"C\$&4Q\EUUH
MHSR"I(-/(81DI\WXL^HY"9Z.((JS&R>X=A4HKY=OJ$<#R9ZMP3P; KN6+MW:
M[E=W-Z'OWU^&=P&\'UND>'//B>Y;UI4?AS8Z "4L+>RG;?T1M:S/SM*9<S.6
MI?/O,"(4='@^*G39RAIG%+;F%9 3D<T%O/T,E^'['+?KV0/10:6PJ!N$2)_>
M6S?>$J%B$8I6O@];G7BJ!ZT$?N2FM?@7]3C#'B-J$^'!#HC+WKI6LR]C%W8[
MC:@M[-Q-',\G2F#'$*NC^M!TX !]B*Z=P/M/!FO^WJ&6O##DAY7+P(_Q*P/X
M:#C2T;?MBB\LKAN/GW;KBHUXYI:3)C<AALZ)\U0T-\K=!X(S=?#B98#<+]JM
M=KM#1[Y3-< J<A<NH3MO&L-<#G,Y'J5UK3MW9VX<@QR2(M.VW@6SE@)(-;KE
MF1_6BYWW[:(9&_<AL#[,DI"ZS[+B.+3S2M4?;G2->/T2:?KWWU_;F>HG6B(,
M[$X/M)U.OU;3H6Y!N&M"(Z/V"U)7(O6E#MHZI]515QWJ69-K^B#>B@URW5L7
MVZ12XYO4\0G]&_OND"*'G0^RGHC4IR=<++P9@J-K2G$K6Z#J;_!B8K<';?P5
M]U/(=>*%7[G>+<6SQ>)B5ZQ<*M&DV/'^,O1Z1"D"V&E(3QRC><AZ7TN4^0X9
MPERLDJ:=M3]$!3HGZ7I:UP?5R\BAW[#Z""(3Q*-+NJY::(K-AOY#<X WB'0&
M1Z0SB!8^ZC6\A]@E1+1[RKKIW%.CCM_2P-7,$-4@0[2GN..7$[Y[D6#J>*PA
MM&[ J YOU#:*^L1AXZBZ3LG4= .7*0AZ1T<*KCI.0]^0.M.BH$;\ !/'O__Q
M0QI?7CO.ZD<"J >;!^?^EMIHH3[_QHO1; "=_0O<QU]\^,T__^OB'_(AD ?A
MTOWB_%WQ.[P6>(D_N8N?OWO-?W^=_/'V:[OS]3<G^(H9$U_:[:_\GR\?OO;:
M7S^[J_SGW_TSQQ"+[)Y8R,)9>O[]CYMYHTI>8YZJ.!!Y#27_H<]NG<AS@J3P
M*1^P[,,Z7HA]GBYO"C\.HQ6P#6RKE29AE4BJ9L&;F&@%W]W 06OX[E:"HY 7
M\^'+6ZO3L2XM/@<6' 2WB$U9EFJ&B$T@XB;=PU"I 50"14=)U6Y7=Y'!5;->
MIZ*_X6_A-$:UG'U/7U[_=O5*RNL8!J5V'$'BWV,'0&Z#^&?K<TMK>^KQ_4U@
M4-^YLTF\X).R>PM\B%(&C )L@1<DUI<H7:Y8ON/KB->#7A#K[[-83V+?4\6K
M'#:^N8L(.=&F:6)A@UG?6WK<?,D6?4*HPSG[#MFQ53%S^C>U\'+@R9789A#S
MLF=A;_ ]MY->^([6R;#SO<UO=/17X(AS]5Z4[JH'HN@OBV/UV"_I.A&F3<;6
M2] .W17WD@;]#/?$BH'H/JPMAK,:QV[\JNIU^5>A3RYD!QG(?!"L,6_CF%]'
MC:%@@PGC'W<253BQ$UI?6R"XBV\*>)CRH* (1=$]!M6Q5ZXL'ZA[.?U8]C=$
M11<+":C=IZ DW*)+\J](XN)<05.-;[ YLMHCW'M<+1 8:8#=N*YA2!\V!Q^X
MNW')LPC_=4^-2%'O2X!))-@T6RV(1Z=SC*3BC0-&$&C$ &WJWZ(!KR2&MX2#
MD^#I9$J1 Q(.X7+ISO$5&2'B'!&1U;'^R H9MAAU'>I-67ABCFU^9QY/41X5
M:K2->V-S=T>\A]0RC;H?KUQ6[I;H@)('11^7FIA2>W18E;HP^@73SM!4]=_,
M]57&J40>SM[Q>5XP7$H&"/:VH^:M4R#38B%T4='I:)'BKUZU,HD!BB&27ZG_
M^2LJ'JN]HGRE<4/P6@ ]G)ER6.,N+]PY-646S A[@*>!((/&+;@;E(-T3/ N
MH!P)4V! "9TI6@YP)63P<G]@=+P2@4--1@OOJ?.S&3G8 #EHM)5SH%*Q89GR
M0E G1/*C2.8IPU-99V5L3A8 V_0MU0B,?LB->2F@IYPKI'(@3Y-=&K&];O83
M)Z\PO.AWR?V>'2+1D!T%'7< G4MO/#(#!P0>OSO3O3*? +?$@2^S5G0^MC$3
M83K4G 2'8?4HFPK9["E*992)\.[I/37!I!Z;)?Y9%9/,G"$DK&G%[ *H>^+&
M0Z<1IM+1:EF8V_D08!#2=QJ;EE)KZG*\D,EH.&2#[Y[AD.= )60(F8*5&2W"
M=RB9I_SW7EVY9!ORNBY@EFK^A0SI/VX49KW5K^BR QOV/:5B:WP!V]>F"3MO
MR0L*G!I($MTK9:IHC@G-:Q6%MQ[U27XY!=MDX26OA$DE?^YJ38YE[]P9-TDG
M/3DG*S0)@1:&RB0H;20V>,\ZVIN;T=R;80JG'[MP>LO<W=RAG8;^_*&E(Q4#
M/E;%YTX816+\BND7KM==Y*P>LAM/:7O+T+^GV-[CE\MV)J5BR:PJ\%TF%(7T
M0P$J168F1%%B;JP^;&@+E)?=3FO?LMYZBK[Z?N.0CU9.6NX.<I';D%Z_8D,N
MMIO*#CMRLLI2^LWG)._1L]E;O%"G61SPTL+WK5+9OZ2$J3!JU;.<7;:],0L:
MM@;'6-"IL>-EMVWA:FC*]DY:_4/L;O-PMSOMUO"H*SLM'WKCQ>@VXV"F"LRA
MY1MB\*@QN[Y&)I[U<6JW)DT^33NSHT\R4B:B;$W9YY>=X[#[QUS0+K68IY)?
M.[(?%7:.7/0C-&5S]\,?/B.V,V[UG@K;66?6_V\YSK.CW;SM/A_![-_?L#KV
M9'3!/-D9+F07*^WHB"G/E6[=SAK%XXAT>SS\)H4^\+84-]IZ(W;!B3@\$,,)
M#]9N<]E1<E;">>QPN.I]689>YT"OS2@?3RR2*+8I3IPH.8/@HLF#:!A!ZJ.]
MG_4L\7"Y@GF*8'Y=(E-5AA:Z>WS/H7Q7#^$=(@WU7*41T%6-K:D+FK2H5*M)
MFBAE2#R3C(&G=,]-OH#)%SBS? &3&G"HU(##V7"%<_ZF+'U^/(1/3&QQ&7I\
M;\]; R;QR-D6OXI(-$IT2A2L+'H2=4QE1_^1\RTV@:=?;,BSZ-CCWLCNC>JC
M H=,^K@X>'[%1O#X<EI%S@$\ZL#BMP,9;RQ&-^,126PS+TB<X-I#);4I;O9.
MV^YT=@@7-S1:,+#[O1WB!:<.#? IF$4(']&4+1OU[-'P8'OV:,L8]NW.H)Y+
M-)HQO X#&AOMF"!,FL,5<B9PI5'6'=MC<7HRI)%S/D>;ESSNV)-V__!+?K0$
M"%2;YNZMZX<KK+ 0"1$;E*;'DE/]MCT8/ %VU;,[DQWR%!O"KM:9GP0G=,E
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MF+,B3RRZ3NP^R>:UR,>8-!H!83V?G2U.Y'M,)<Z*<*,9J;NH#:Z\R-']3NH
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M]0TSCM1!Z5";TAE/[-$6K90>OB4G:ZQ$O_FL6_NEU>W!8@[2!&@XMKN='9H
M[<5Q'VUQ WMTY,6=II-KDS3JB_-0ZM:IU'/OUJ+=_/D[I/MWDE2'WE%:^<)9
M>O[]CYNIKO8/3DNOU>OAR&+O:.FY4:6<[N,\^;Q<)N%*3$A\( 4\T_)A!M.1
MZ<6KNG4B#P3Z)="&L]X+JY;?S\"Z4%]]IY,U+R1ZDTYK-,@VDC=74Z9@RZHU
M,/RB4OW"+S8V=]+2%GXP*0R-8@G&[=%D@C3,V;$O8SV+W=_=[5%YPHL*,VS6
M&O.MK8R.#?I]N\7-1ZN5PG7V3:W+Y4M6KYB%*S//KX[\,M6B1IQ)+?$BL%])
M() I!/2%HQ5=*80+!GJWKB,7T=DXZ_E%#X' ??(88WPKEKYD!8^FT@'Q4XJ:
MZ05F[[,BJ[WZ<6W(V]-3_-Z[=U=<!  /?(S" /Z<N5K;+I/S]WSX<Q':%)U;
M5G8\K/SY>,0,0.EU,U0U@<ES)<V[P/K#N=<R\W^]^OR+1"?3+MUG3,K!0B/K
MSQ4FRELOKS[_^8J>NVQ/JG K,8W&#6(.65Y:[)#*??CR2[CR9M:H,W[U8S;
MYUFXHK2=/\(Y9?K3;[6IX)OQQ4-X\:OL^FMS$#!,#)H46]>IQU";SC1,)4A3
MH7@ JZ*Y3TJ6,8*I0QQ4O9Q2"I)$\G2PY$H!#8"H19F>W&<%4TM]ZDXV=1#
M:LV8;(3Y/CHWPQR??$& $P38Z*58E+ZF/J SJ*\/"%=<'@"OB05!'Q8!YI?0
MP JZ2Q]\[LTIH$WA9]DG!2L]@OVK,4SB2=.82&4:J.'Y3247\/S?4K^6Z0-W
M?1^VF+5W.E6L76KV61V&;;WA8M?4BV^0*?VN59U2<N9;1K)C$.,\/,3_<>=
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MAB?X</O<7"R(2^P9$1Z(_T2(32^'$0\2]O-U%O1J )+F6EN,F4<-93$\0A\
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M4DM2I'[T?4O_X'H^N-=J)-0QP+G0)*7FSG5FA,R]=ZZSCI3QK?O%H(64-';
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M@\T.H-812/:_1 246A#P< @1GQ3,(Z7*HCX12PD40,09]C.3*F5IK"1/#)N
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MA\#M?5S8B8' QG5<O?RG\,)$<E#IH7B2F):9"/R3W@0/P5,&4'L>SB_UL+$
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MF1^-;^8Z6'=(,%MB0XH<W>'!=[44VN2!:7=L';2DH(^3HP,BR5H>-TZ.IGC
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MXUCF' @P?VO[L,T3IJ5B>L&%JI-3E?_ZN1P:?!!N2@Z*#Q=&:A6LS^XW$-E
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M)%'5M:(53T$Y#UAN7)$D51X7\>4XL"7=SL;)7.Q-GHE&<PRHB$;"'/E$ZE*
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M38^Z%7/A :M!57F@CU3ZKI4!_M&#XZ_ 8R(V>$&/M&%AZ .A_T>8LX*>^5!
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M]*2WIE+4#,LEE3V<"402RJE+C-O%!WJPS3O(Y?V]\/>C7-(DD=V^^WAL'%*
M:7R15[.J5_#GY%H2=Y'-Y#=26T%:2&KHKE9-/D]HL'#AS=N.<P+Y-2?F+U/
M>EZF!UYU>?E$ M>YM8GPD<Q-/"B[)[.5[5C.$BL HKP$_!YMZ??33U%?P9]>
M8K;$@I;XLN!B#*7PR1D*$CX 5W_Z*;Z.SP )D>K4B*2,$#X33([!<,D[# F"
M[/Z?^SBBMV&C_5A,#\#WPZ">2(-Z^D P* SP(SP?Q_PDF?T<P7SKFBPI:_<%
M@&6 DH)L YCP'33MA@9+PD".)[S]MC(?$%Y%&DI4N!1Y* V$IY4Y6[%X+;QW
MCH%?P ]>Y:Q-GR9\8$88?CSCTRPP[ C!!KMKL. K^PZ\;$Z^#?_QEN5S&9B.
M$W;'$(P'YY$,!-L1')JI%*7AL*@P!H37QIQ$(IKQV4$8D$YQ:N[ *S >9>"E
M0023$[U?H')./VAB'3?^,C>]F>5X-(LG#*9E?(X%H)T,]&>L&H^E$'D;8OR%
MF,)B0D+'#X22A>#@J[*A=LG"PEPK+UY" IV##N^98;X:OL% IX6%_':OC)*
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MI41V6.SYU&\,>%4TT04#5H[A]W9Y579=8UK,15>+^1B6O>'J:HA[X=;B-KJ
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M_3[&VJ:&=PYJL,10?X83[AO5L,L1TR9K$U=V@2Z0L$HZ)!3L5PI[1NVIL4S
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MH."P=XR(>=V5D=JK\+3LC//ZP>)76558- A.*(N]"*P);ZM?GI:3OZ2^(M.
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MA8HJ5S/5?6$ZD=AYW<6U@1([U9[;*2'P=:BGLP#QQ2RB][M6$*K'[+" 4"U
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MV,-@MHSNT.N9\0'#D:Z ^)E\YW]1&\P,^GL3-Y8S5SJ8$9Y:B/^.5XB5'C-
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M+-X K/+HR%\O-[SXN-[\^(^(9%1>R_4U>2:QYCG3;  ,P9-6Q:Z965IFX+&
M;@BM6<#3?AQ2KWVCZS0.^+NJN:0TDC9%^\,+',M3[<B21_BBNR'V*GDJBYQC
MGFC?<Q6]8%]S.R]%C5S%^!"NWQ:ATU[BFV+(E^90?"U\B%Z,193.>LFO[@6;
MCLRA_%KX,#VB;;7&#='G4<[T> I?X9O1;0#8Q%\C7<7,6>'RR7J_I+O,<GE0
M^ATTJ98Y[P362Q$4ATY,MW1?B,K5-GQIFR53QFQ%%YA792M\UZ#"=$Q%B9^P
M%W U7M61938"T./T4''V0:D[Q=#:E">O1N57H_*K4?G5J&P8OE=7F*F>TU@T
M69KP;,*:T!A5OQ_$A*SE 1Y#Q!Z%6H.AL#VX)5C+<+&<I&!.3CY8#+=V!870
M+EO?R;2FH)UVL+97Z2H0R^* <H=7SFVNU/V[KBY\1M\3B<74C4;3@0>(KJM-
ME4@*]BYZ7!;Y35GDA9^$%+%^+0F[ <;>F+%?N<BDD)R:>2K7*OKI9H+2RR4)
M[].&*+FU1]<3,.BFCS0ZH')IVJ2;0.S3KS:E4>]3J<N?LCU@-$YO[JNP('I/
MV&[GF]*H&ZAFI@M!/\# FR%[EQ83IAH.G2QHTU<+VJL%[=6"]FI!,ZPQ^5!L
M"S!JJ[?N-_Y!;&5BX'@,,+OT??97)E5"Q5W S61B7IO(91?$B4H'BY',CIBL
M&L<D-Q/V==$SN-3\9= +NC*K?-H+KB=Z**-8QQ0>">:&,H-!?B2;F2$[7%[\
M:Q)DDTSC=2/KAL(D9LA=H3U&B\[AFMLS 7VE-\\L7M/9U2ZZ3>E*2, ^^BTJ
MEONI$&1BLS T"OM:?]%:XH#+)7FV9&5UKY+-7K3!*YN0S(1+@O2Q$H=,^$/'
M16';ZR]Y&_"/UC%K-K99:4ZI"*.X9'S\PHY'?H)>O 1Q21&SF&KV&E@6=<WH
M)@]84[' Q*)DZQ.PA4<'HC O2VKC0Q!F)9MB%E]P[//HR,U* ]GP<2T>0&.?
M<OA5#(8N^[-,/)L=LQ&/849,IY&!1M<5W(SF6(A=9@Y6NYQ3\6.QTR&=!Z]>
M<3:,32;K32PA)PYREKQ)5T]QNB95,:H;3H=6)M(^L,; _O)1 D+D#3=P>Y$F
M<+,Z/FS<LOOKAS4FZ2;6F-8)EADWXHXYS(A^EG*C!$D \X_=%$N2M<@R,3%(
M^T#8#/:)T5W]A>TA;O!*+HK7A)3V([]97S*>TTWAF8172>$GC\RJ7+TU?5Q_
M\O^99F?,%U&73,M\% PW7ZDPQ;+OB Z/ZJ,@?$NVT06EXTC@U]6.(NLL=QGH
M5]DCNJO"3 *$5]%[$BR3-$X?U[Q*X@$.W77(J#]P,JWN:U4L;V.L>)8Z*YL;
MQR1@:81OLY0>A,5:*U-Y)V"'%UN"5 -T=^?-LZ(E.OJO?;'17[%2$7D:1R&K
M+W1!KR**UPA5<T<W41?*E X&0H%(3T9U!U<.*5KE1\=B,X%L03C;X<:7"+1*
M8E<T[E4,(PFQ$@)1&/D9=T64G#?BAC"N._HI?R@',>T.O>T4ABK#,HKF(\ F
M).M@ANF!"Y%5FU7G8F4[;\LL6%*M<@M$:[#6=86LD-5-'F(MS0@?'E5['@19
M2=H^V!0YG\>M7ZG>'TSZ0Y;6LB%3<Y!.O5;+%2_@26\2=:H[.M.RZ/&19*PR
MFZ3VDFE7R%):0V34"1^B8/.]L^*<Y=N]7T99^'^)K[KF*OM!ELZRL=#TX*P4
M>G0GP<NTS(IE#Q%N.T(6WW(EPSUT+@M''GY^OBA(IA2,64?(^EJ#=T@S=%9J
M1+H("FW*@YW36\Y$L;04O;P)7,B4C76E@V:E4*3T"I?3;_-ZN^$GBI:5%J<(
MKJ. )#D);RD1BI1"9KV]"5S<TW %Q!RBRQ*0!GJ0:/48]_4F<!%*8RB)%4!$
M)2.Y>QM;ZR0\+UG\ZRW)HK3*8<6W=,5>J.WK3>!R$]G8$<T ZLI'#EEOU96>
MA;!ES)$LS41O-+(%9]39FQZG.:0CPLV]&<&:XU/G\,HO*CVO4_+-1O&FQVT>
MZ0JU$;:;<'N2T3.W\!]9&%!%$YMU&<FEUA%%%V]ZQ%81':Y&#AC,(9*]G/O?
MYI_)=_XG=<IRDP&\Z7$;2#J@;*2+P52B\(&H %#=.2-^3LY)]?]^WEOBL;SI
M<1M4^@%NQ#_,R.+JD:%;_1JC_M[T.,TSW4$VHI6::<8,0]A.2;"RY_+U<6V2
M-M.@.VP" P6%YLD)=(. Y+,T9+WD+.R$#5=8@Y$[RAU+IZ)PHMO\'4,(0C=I
M[$KT  RLHQ8G1>G_TVH!%AEPP#0)3[=D'A57,3BX=6$O$A>V3Y1+JW*EY/-.
M&Q@O=\'L/.3O 9VP$_B3_Z)G;;L-C-^Y&6OWZ43D7*8X/^[2.+Y,L^]^%BJ4
M'K,!@(LU#U)]S!$>A5R_YF11QM?1HM^]?]L=N%2SL52Z2G47(1[O007BST1E
M'5=WA"WG[$Z,#3:<B[)^K)X_9J2J'?][EN:&-V=Q7UAO;(MRE,-#Y%$X7Z59
M$?VK3F*Q#UEE7E-V!*X*/52*!N PE;(Y-*?5!L17J]JK5>W5JF9[DC<6]H]K
M#LPH-8BLS[%;X8P (M(]=PL)"$H'\%H!7Y/T(2?9,\-\E3R5W!TE":(XXD="
M&Z,^<82C3\)G%U&)7#-+'/#B=9(Y82RT217E;$.8W425,4*7!4/;%SBKB<-=
MH_-M?)3Z/K^G:?@]BN?)X3%L%OQL/ #:-"<*K;,[0I<1ENV[XL7+$[ORGY,\
MR"+^#84?KZ(78*&>3GP5R$4/3+-N1BW6L:3$\L!KRH0HS]-LS6O)4/1?*>$!
MVV:N4S\!OE9OR&3A/"87:7$'V*OS#DWFE^7#;A#78SE#=1=B,?U'?@6^>&&^
M:F64+ZL:SPR;Y@8LZX+K BR6EEC&*D1X+B,B*N_I1[57"G5'\-NGBOOF\MH%
M] -(#<MUSK[X$-[)=G83[2U,T!KVWJ5?,)+#3PS$X7V)!Q,IF2QJ!GOWZ<I=
M&8(1RI!V+_2K[0CK2-.+]T:8K#SMR@*U6>Q^'-=7JS:"*GZ@)JNEQ?#+C%I2
M@P:%=9WI)<7!>!$EDV%IPXI&6:4?TZC@HN:.O&9&4+]E:!#YR>R3J-7>Q!U<
M><08Z]HR5IL)9@L"CWYM33)8]&D[(D*H0V_L<$8ZM* UL"N2?#6(12-#@"\-
M<9],W8YR.CH\;K1PW#GSC9X@VE4VQV$YNR?&,FG!P+=<^@L%^HRQ+1TD44]#
M$G?#I,PTF/>'HI!0[] :8_JJ9OB6W7,XH)2875^,!D-$=-^AU >$A#DKCKB#
M7Z&Q2?M 9LX<(@^Q6J>&B>=BM.OYODEYQU(5,O0LJ01+SV4>&2 ? C*WIGT!
M=T*-:,WN3$:UXXJN"V0R3OL"5:)$%,&SF^+UDU^P2K5KEN)5(4)Y)\ALG?:%
MJ,&)R):[8WIF";NJ]%S5KZFNITI@K.T+F;33OE#-X%K)%VYOB6Z)WM"YG9@5
M@"I%FRY3M?E D&E W2SECMBM9";77G*J+,#?_"SS%?FL9>TA\WC:$Y(>HMM,
MXZM5FO"MH*F@<[/0"439"3*%IV6IZ'&Z3"[>?*@Y>ADNF41$;2%S;UH6A!0>
MHM3A/#IB,SUNLKOH<5E<O) LB')RFT5!:^[4?\V5FDF?\2!S;SK05GJSP$H2
M<DMF@?"?95Y7-DWG81A5E-SZ$3V S_RGJ/#C&D1U *OL UW'@DS2Z<!0T N^
MG5SGDDVZ2GZ_4#@XR;9L?4]O>@I6GBY@G68J;\?"E2L^\%V4_WF9$=*DZ;X3
M7_V[=/>FIV#)Z8S83FYS<\FQ^*B WF'^2)D_6DQU@HZR$P_@34_!A-,#LYWL
MY=WEIU)J-=V\Z2E89HR1VDDPWEU"Y]%S%)(D[+F^VMV]V2E853HCUN8/A_()
M.]-651$U]V:G8';1(FRDYL3LLE5>F_O+/.;]A>J_KHLW.QF3BPYE(Y5A%A?;
MR4HV]Q*E[<RHGS<[!:N-.=1&H,-,.!H3&MV:HXR_+TL>]Q2MO=DIF%1T !LQ
M."G;=IWF^4VR&Q6R&T B$XF^IS<[!0M'%[";!W2WBF!KP>Z21-'I'@BZC>+-
M3L;.T0-X(TX,'BU[-6];E_PO!3N"MQ7.C!TD5(-XLU.PE?3$W<@=GR/,/$EX
MO<@H":(G9EY=2[;H+MV]V2E85CHC;J3LQ*ZRL['\;TI"M(A(N'&@,\BE9#Z"
M-SL9:TM'T(T(\;G#F/D<2OMX[T_!'&,&LQ$B!AL,ST30JCNGD-U^4^_]*=E>
MA.@:20VSN]CWRF<OBBP O@J65\A,WLE[?PIV&D.<C1R=^L;4S@ L_M#@M%/W
M\MZ?@N7%%&@C'B=VE^WMYSZ=!]Q[_S+-SI:L3-)5PBY(ODI.AMV]]R=CF>F"
MN)$<"N>6G= -[NY?1VO43_TJ9Q9=7^_]*9AVNL'=N-6[6);;7?K0S'[%_((3
M$K#??HN*Y:[10K92^X_HO3\9H\] )C0B=^+T4M/1*%EKS=&X:>>]/P73C!Q:
MPW2I]67,7+JU1S[+%WP(N29_6PL)J.SS:R;=UTRZJ#+I[H+2Y_ 2MC_>'+I2
M.'@BH@](U.:*DO0 3YDK9;:A;# FRK4H'>@T*[;%A#"95TM',$KG)6P/FQ17
ML2K$\I%B<)B!1:J+:7*!JKO!YLLU9KPI%$1)&.IG&S]N/<=I"LJ)>SA*JSN"
M)J  A$A0]_06DR](QNXT7TCV'+&WMDVZCS;Q.9NBN?A/VC/*YF=<Y>@UKQ,G
MEZQX*MA&CT=;.<KI@T4O IY'"-6I>1#02VO8>GS4:E2R+K#5TVVO>(GQ6H$=
MSQ[1^%S=^FMV8M;>_)0QG],DT,8Z&/2&+;#>U?YC" B1CM!2/;GYLZ;<[)K3
M[@&<N;BKI%0H=/FRT!NJ@2J_[;KHF1BL)3T@+-:[I.@,U8+6$/9I!?_$TUY"
M]Y';I>W=2!'8IB4BZG811664/L:+!+3Y6R'8$>X/J*SF1SE]L-]#1YI'5N^A
M,I_\\F'C:+=1A=2V8T476(.][54L,#9KL#LT]'].G_EG[K^G]\NTS'V&\9E^
MG9!$+2]]3UAS_PAB,V.!R_IZ],O_CV3I34+XA_=N4',*(=2OO$Z#P-;=&T&H
MG;F!*)6S'6<0-_9^=PJW% 4BFXX]-P-'=M:!3B!2FZD"!AYUUJ)TL"B9ML2$
M\-5"8B?LX@QRV ^147MWE72RE6ZQC.,<PLBE)Z6Q5\A.>TSF:17/]2 P'31-
MM:;U%Y^[4+"\S3HU0-8'1;F];KJ $@HF56U+WF=_17_DJJW/0R3TIX^V,UPI
M/C-)2*1GA@N1XN!<BFCT"5?B1*A@W/)TO.0V]@.UX4K= :C(7\?%)!:= I%+
M:Q3YODERKS8^[3>$+M;7A]<*)"YM1MV>KPUK+ X:%*A27^<76TM($6F+8Z>Z
M JS8-UQN)L_W6O1X=)>+O\JH6'\BQ3(-KRAOZD1MWQ.2Y<OHR4CTQF- EO9S
M)?ENX-&N^DMZQ,]7+ 3?>(UONT!6^QMG1>]A172%M%ZX$2ZWV3BB/$"+J'RC
MG%+S_&;:_I %_<87\3YP1 4=A5FCLNH641TKRMNFKC-D34!7<C9$;:5DHVOE
MFEF=S7UP#WI"%A<<7XW>0G99 K*U6=PL/ODOT:I<_9&RM-.WZ7>2T<M]F3U'
MS_3?%TFA2"'3=1S(^H2V9=F? 2XK2%;*V\UB[\GL'R0./ZYKE/](XU!N;3(?
M ;+RH!-I=H2.O!)E7C"]@)T@WY91L-ROFMA*%*AZ1AXT,&0M0E=[MP6.6"E5
M"5SR[G1L6YUQ.ZTN.6;AN].Q4O5 /G;A22OE[T['_F2,%ZK,I,TB>(!E"\>6
MVP%NIV4FI>B:"S0E,'I,Z'1*]17N.P\%6=S0B5S[\L!.H4H7^8DW)1[.TEQ9
MH4W5#;+\H2LU5HL74PG+1@5CFTR2J^XK>RTARR2ZDIP(HIW*E2X*EM1<(.'6
MWB4Y43OUAZR9Z-(J: 8<4TG,75MFBS=;*+=9%)")1N1&8T!69AS'&*P#[[1X
MYE["^CI9_7VZ[X"OL!T:]8>LX.C*<F@.W$[A37NK]X[$S'?G+%VM(N[5<4DX
M,_C$K!^?=.I3IW$@JS^Z7,7=&."TJ.?^Q&N,VM5NPHM/M.>L7+$:,!IDK4?7
MUZ.N;+!3\E,B[/K;^^70N%=S]$STVG./42"+.SH1;@_XN.IY+DB6-34-JVWF
M,U%[N0E[0%9]=+<YRZ':*=?IQ%>1F/NVT;:0M1U'\DZL0=HISZFI,]<X5ZGL
M]:*VD/4:G6R,4I!V"FQJQ'"?WI99L/1S\F7I9]69NUJE"0\_T<E%V1FR-*-3
M0>E1VRFX*=-&-J[@.Q]N:-+9X0V[0Y9N=*-_=,#MM-#FSDUE7A19]%"R![FT
MAS#[C 59X]&)9'LSP4[!3B?%2#8O@,S6$:=YF2F+&AOTABS]Z,Q7R! VIOJ>
MNRK7U\2O;K3L9;>R:AGKI(*^D"4@Q]%19:"=5OG<-TS4GJ@7+/,SN\9>1ZO(
M))I5WAFR..0HMAPY:CO%.NTLSFORZ,?,JJA8A)LVWOO3,=&(P6E+>HXHFM\I
M3_+K-,^IPIW0:10ECV64+WF4I*Y^O+:O]_[TC#)FH!L18S#/;-V>-K6[-X[
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MR33LPB0K1>%&FIUY)PW3U0RU1X4W 8GG'6N66F:4E2)W2&9J@PY\LG8BQ)N
M1!ICF:_=>86HGI]S)1I((1A$ES<!B:U&HB8,9YV5LH,XYG=+=0>:R884>!.T
MKQ?CWK"T3+)35='B]'S0XW[HK-+?$28W7F@IX>%"I1^S+!E3W50=EQH>Q'3<
MTQ: 879*2N*8PO*E*^.!*GP7@!IO<O3/-P ,LU-M$X>2T%K&5Q1JE.11P*,N
MQ[%X[7[3FQSU>Y%3MM@I$8ICTNV_F])_L=K@HTU H^][DQ_YA<F<19CJFEK2
MQ;?VD/NT\./1YJ7)Y[W)ZW.4 8<P568=VZHQVGP=1I@W_9%?M"SP#E-!6XNZ
M^"[2D6Y,>Q_UID?_CN6.+]K*NFCBOZ:CQW\M%CDI6)KN>4Y_,$J@(NT#$N>U
M1XPVMDO4'B2>2\5%\3*1TG[D<5OM@HR;LMA1_J<F7DO5#46<EDQ<8NGJX. )
M+]A2VIB;C.)U5-W XZ]TW-?)3 SIQ&6&);+*A? 0YO1H^7!KDSX<M(6-N-(M
M%(E>* *!9TWUOE)M\Z]317G5Z+!/)*#7IS_2F [#D@G>^863R[#YUX%#L;IK
M2"/Q!%M 5I^KDPJQLY<_[4>!P[-ZSCAGK, 4F>5B:9U'SU%(+],06UW[V\!Q
M7T@VNGV.G$)HF @O4PTO,\)L120C>3'F[!-]&S@T#'CVR3BB"P=#DRJYJ')%
MCVVZZRT$$QO?\,%A\R+W]S0WSX4\\!L01D<[8I5L"C89<^063988Y+._TF6<
M:C?#8+&T*D+Q+-F'C.<VWU"FM8GM-@2W7.YS5,UWC+;)WIS'8G_L)X(Q,C7=
M?T_OEVF9^TGX):(J$#%(V*3J VM%/)S$NYPV(M_&O#?F]IS^1)[IWMB3\^+^
ML':YGE*00T%D3KN/"G;\724ANPNS"C#J$US8WI$1"]M1+L6.69[?HF+)ZQNS
MJ^<R>KI/+Y(B*M;:LZ?C2*XL2L9J@50ZAL+4P\.C0 !*&8L*XEK<8R@K3>;P
M_#S*2$![,4_#,TH/_2[S[E8?GF:]86UM/5:9X&PU1XIGB58'BCX)\TX[1YF,
ML!VD!YB/Z=E'"GJ+*@F-;W@N/N<L$Y'Q67P@X)YF];[@\6P#IS&=L!SZL/,*
MH8?4'<F++&)OF?S%QJ0TSF%[X)Q0SG8!\>20LP#/KK$I*=/! 4[:!SB%TLCB
M5;/!W4T]SXJ6?.F_]F5+?^7=,<P2A7#G[ZZR!&'1! _!NO.],)>,=(WMM7"6
M#T>K8!WR3<+7%J'.MC4GC(56-;ISV+U:8,3H3_Y+M"I72E;OM %*CR.:HH<L
M/J04=AI_H@S2<K?=!BASBR%W#RBU<C"JJJ<<G!Y[%>=E5BZCSL!Y25QXF70$
MC^@)@I*Z2A-.^IG_%!5^S,'GK'QE]DS"RS2[+%E<-8N:]1-E@KO.8P$E!>DH
M+;'JV@\LGEO+B-EYG9A >N0(!DGU866RC<TFEP?,'_1*3\+MQ=[&#F1G8* 4
M&H-FB$7D5NSZ$J%O7*MO%BWB^(2C4Y)3)Q.K05>@_!+#!6>*#5.L@\]M#(S.
M<Y('6<1)N5G<TQTFIU!;1@K1?J_O[4U!+&!V]FE#>%:*R4B6VJ<T*9;Q>N>@
M6*5E(E7:I1V\*4CVZ^'+2HT(6[V5/O%Y[>:L(KF3>,B#CWA3$ =+>RJ4/2Y8
M*8LBNX(+M;W</!O6YS1YYBK!;G8LLJ_X;1(1;LXAZ<4>CB1O"F+Y&KX+0?/L
MF.JA*%^5F'J[*1BHW>DL?<:;@I@$Q[DN=N4#ICHEJCJ2G\EW_B=E\*#1 -X4
MQ$AI1_SF"+$5Z!B09J^Z!%=E]>I'4&T,J>7/>=/CM6<ZXP>Z*AM]-L8J6>0V
M?U-^4RQ)=K_TDQWXC8'-?<[8001YTQ,VA;KCF)UB&YV4?@NX5+!$&R0@-=[L
M2 VP@.RR4S[#]:3L ,OYE.Q BS<[4L,R&+-0%=80Z\&<V.K7]$;]A63/4=#G
MQB >QYL=L?FZ,U!,Y2KV?(59WJ@D5RE?X@[>[/BLW@:(3JF$PWXYE31WDBU(
M_C5O=N2&< ?LT-9/&#TEUC*-*4GY.?U($!5U$GL<B;"J^_&\+)84QK](^)5"
MS5I>\,R#/M_QR^!^@M>]DV,-_2#&A%E&F#ZN#U$-S:(U[,-X4FO9F!223<8Y
M!X\\!]>7PB\X897"S7B3)NP"J(E 5O8[ABQ=PR4OTUTUC,'C>KE'H39.5-@>
M/+.7EN%B.4G!G)Q\H(-CW @*85SM-Y\IKX4VZ'*G'6RN,.DJ$,OB@'($86)&
MD9%N7#=0'T@'#, 0QFH<T^?(Z:%CK.0'*5.W9")8 N9<A3X+NK+W:,,D0;PV
M!+/SD+\'=!Y;C"2(;X,9:_?I1!1@Y^Z]>N,>6#E=@'@9[-'@*"76H,A.AT:.
M,=GJ-.;7&9#JU:@Q%H_N;;#W?6>YMG#-S_%YZC)TS!V0AJF \_. !)3IG8YN
MBHK9BBF*SAGT39" 8E(#4($RK]4QJ@9BSKH,*.R-I;9:W91%7OA)&"6/.[RL
M__R1/$9)0O_XT8]5X=TCD^$JJ1>R"0O&6BM1F# SME* ZOL\T'3=H<%9BK,?
M;ZX>\G7\2$_;8"KK".Q$K6@ RF)VPA.UQ5<K\9XP$W6CKP--TLWW@1+!G>($
MW>6IE0A2F,FYT;B!)N?F^R@3YQWGY-SEJ94H6-"=4^+0.#(%0/G\3G&"[G/U
MQXBBW;Q[]$E4@HD\H&2#IV?NZLCRXPS1K9]4+&?G&9$PH,R)Q[7Q6V7V<83]
MRA]F$,YU<]J \DV>V'3OR&]4D<6NGW=**DJ<.E 7 H%2>9Z>%M29Z=JX;!S!
MF)/7:,S7:,S7:,S7:,S7:,S3"'YYC<9\C<;$*1_H")S7:,S7:$S4^JUHE]<=
M?_:_]B-&C#IF)_I@J)Z*;\_ZVH.^!A8?ZWB.6)^0*@:>Q':)93ZBT6N.?F):
MU:4D+RLWR6ZU-:F6I&@-$^/L>$\0O#S(T=O80"0"NJ=_[2(B67N8:.GQA:3"
MCU[QZ%! L8$(7O"R$R&O\=AN>7M,,UR#O>6/YBZ?@.Q;/TA@MEO^60G"QE'+
MI05P;PG>$291^ONS-.&9;DL_OB?9:JJ;KN-2\X.$<4-S^!0BNG?/'F8A<K[_
M'GSK-3K; O]T,=@X7"[J1.%C.UZ<Q7Z>UZ5Q3?PFA.V!W1YXXO4UIZR#S\)^
M+PB' RDWM?X"(NIQ/?8;93NCIT>>QE'HTY/E(BDHUXGL;5_5'-F3OD@XNQ+5
M@8'-02>B3&I%57< >X#7<=A,'B,\O(\O$6C3M%W1($F)^:5\R*,P\C-*FC)Y
MXV%#F$=V_90_E(.8=D3O1I0^\E?)O#B>Z7_NZ?=T3^7B'LB>N_4'B@$>3$:Q
M0RKUKW2R/O!OOW*>&PL)Y2NL72E!'SLNQ(70SVN/6JV_E[ ]\%NF:GT8R6B$
M;,Z]!,,/S_47?[.K&QQ/PCZ.WC''.:"DB#"9RK?4??97],?[S$]R/V $Z7=!
M;6=7+X"=#BVI'"2B,T*%:,&Y%B&F$\V!+!$>;K=9]$PO*[>Q'W ;EO9T$W>
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MX'<Q5#MMV%7$Z'Q'TP>FX3ZFR7/^>)KL]EYLH744X'#:1T6/0IS*X42.)P4
M(G6D_4 C:FD8=AWU],B<?K4XC6VB%C0"Y=2F1J6;^"A($;+BJIUF:H*NHYA>
M[E(OSD)^XR<C%Q9::0 64"4-4:+21R^D'ER$HC I(^5'&=-$?<!5I.CZ<!^%
M_H<H\8829T?V2PL87@FU:5$(D!Q$Q"B$*FC@>QAJH";D.E& 9+=+XML\\?]Q
M^^BQ[WQUR/G#&Y[48JZ*]%@ TQ?UU*GB  **"+ -D8"D 8E(59E\OK$\1QT*
M.QDL17#K9?>"PD/VYL'S]E(.:91GY6^Z EG\^F\\!$%Y,/]J^R&,O=@/O>@Z
MD1I5\S9@<#_:X832?):4=T6V B/)EE2 I(34O!B83.833>^3ZN7,*M2^]R+^
M)I#[H#3/_H1&];N(K]8B6"%<>Y.>9!GCONE3'174VE9!N?I>LN'M[?G=[>S;
M)6\\,YMKI6( N#G2R\6@^5& P$AR$0=WM2\*)- &147;L!!MJML/I!;#E)R2
M#$^,QV<BM")G9!.&,:R]=4Z][/$D#OA_SO]Y")^\B*TF.\E/O31]9:[C7[SH
M,)KL9XD,RF28TMJ310: P(Z@6OZ^]_)^>2*(EY-[^A#&,0^",T=Y/QARFHFV
MNA+".I31.%#3!.8,6.D'K8]@AFEM_7>=TKT7!N<O>QIGM-#&MJZ# @FTZZ"B
MK2N!Q3A2#*Q\B'5UWJRD4#D0SYVKD;P9^0W#&$!=;KNSXYK[0W-:40M1QY6>
M?QLTJK_,LV)1%8;X+9\9C0D9%!6#XR24:%_$.>-M>!]1N8[/-#]_\:,#CZ1^
M3)+@.8R&WNUJM[T93FB#84AY5_IJ,%)N'09)OJY@20G\#2*3,IU8KR VIGAN
MKUR$V,CL&"&$L4)VY@?:[BC5]W 8$,S:*->)TKQ8V)75I?0R].[#*,Q#FK$#
MD+BB>TRB@&DN?A#*7UTCEN9XH0V+!0>Z,M< %>6TFL!?D3.Z#?TP[\4'06.<
M2U.+SMC8"KB1P3%&"KB=QZ\<!E66#@.4<=)2I8K.1S40@@#I5!) ;AFL!<3
MSFG 5_?0?#\YQ'EV[;UZS'=T#+"IL$#;-25UO9!",9 4(S'&V)R)06>/]$)G
M=CLWC )@^Z0'&O0WM/&91XT [!BDH6E U/A8TA@,M'5F(T45FH8XZ%DLOSC[
MC1 !=PH<VRCZ@Z$2>O7,R<<DS>]HNGN?I&GR',8/QN_EM"B@+>4P7;TT2#[J
M#=N'.W;6N<=D'*W7OV?R&F99DKZ2.,F+X]R![1G_D+(-%"5>/+\*F)3+.97"
M#0GC,N!;ZHDP9D-IAN_(JMEG9AF= _"KY^XD,?O@.8_)?N8?8-3''K[A'\$"
MEJTS1EWO1%<##,AF3&4Y]JYDDC?5O9EX/]\O2 G@5\Q/^]JJ9GFRQ-=\]E)1
M[-Q[2*E(L)Y?I^Y%GO83(*6SDQ30;1B+Y/./AS HVO-@VI3S4QQF?I1DS/0N
M3[%>F\!E<AE9"WT*EQ[%VO:/NX@7<9:GHF[83[&WXRS_%PVN4[H+#SO'8),Q
M6FB?VIS^7ADY!DEJT UI ),"&F.(RIWB8@#QA0CSKF@DH&GXY''5CLL1GTYD
MP#_O(*40>< +$5L^(O,RGC:+(B]X%4JU><+KN 8H]BCX$=+2_!@=*TUQPM]Y
MNM]U8KKCU%_!8PHU&ZU]E7M9ZS"S17S9'R< T:6LXV6LQ>Y5]-[[61Y[LQ+W
MZ^<DMO1VQ_% N;<&%':%IQQ=W1.]$C8>D0/K3E.U%7I%FJ;;^J+BLC?4@&9&
M2NX>PXP4.XZD=,_6RB,UQ+M/#GD5PJGH_!:-I3?=:UK3/HH$T)8[&'$4UEMO
MMG%9:\U:Y]_2+E%9_5JE74;K4+BL&(,'8>LZ %PN[79A+D+J_-5F$O/2PC3V
MA[6&]J"D104=1-/3V0]G5Z-%X+HU'H&?,0]5?G,\^9K'>LEO>V]WP _@!B)J
M=.C6X5F_<I;%ZX!!)0/\#F!0D5GEP+=SWN5P<I+G:7A_R/E] \D3<NTM7>7$
MWNA/H#)0O&, ,U7F2?RVK !XX;^ES-.63PA4]4S&'FWW44 ;KF&Z!F*J<E19
M!U$,W,@N+O.'CR>]\+<B)Y/D_#]OOWW[]AW9>REYXC#_D[Q[NWG[5OR/9++F
MHW?('Y-4W&W)$/HMVPUT=T]3\L/;#>%R(\S>&?6+W[X3O_W#_R1Q4B()!<-(
MDI*D+JQHB0_/R=9@<Y@6(^C!0WBJ1>5+NVI%/3BX5*<>!4,N6EW,%' 33R1
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M.-^6N6X2(W?"&CDF%=%8GZ.[X8H=R@MQYL9$)8'1;YF-%Z/N#)C-GR;\6E?
M$?7ZO72*Y[!L:3:]Q$=:6Q@AA?8%3&E7/IL6NWFH(X_:UH-;.ZL/;MB)Q 0C
MF&#?\8B^J;WJ0D'9H=[JU3+XBQ@"(FA&+#30E1T0,%&1(GN:[/9)S&]93UY"
MZW=F(\C0Z#P%K;T@BU1H]3BFV]A(Q'I-]Q'M]-D@IM7C?NU%G"4[+^QEBBIC
M&L/ 8#$^!2UC0D=^D4/Q*#GM5]&'B 8A 8N7?1)MRFW5W  ":-4V1).N5AGY
M10[#%(^QI0&=&E8*EFUMOP(:25]YY289U XC2*#4[QAMFD;?UT6C[P($:.LL
M0M5%114:ZV(DA%HKH\< W;K<S>2HL$#;'25UXVW*%]M&4Y+JC>D9Z+&.SA[I
M1<_(*"E0@)U2+]EB+MB/QCF90Y#@@8TF%9K@!A]&Q#@\SK_Z2YA%.6JPU67(
MH%"Q_I0-4J58?UPWJ!:[1E'BR7VXS:O>EB6)L;7CGDX!N+T8K==KR8')#^W%
M84B6.#\[I SEM?A&XGTI_S7GYM6V<7 ZB8/3^BG%9_Z2HOV<8-1N+#<OR#/\
M93C8MUD\I""G(7(>(B<J7N>74_%G^JTP!'^AWYB/B D[;TQ7KOH%Q<2*1\F6
M)];7[4$.>_[C8Y+FA"U\5SP0DOGW^F=#&-[LKRF!LO,#":0$2H5>/.4/5=PU
MXB.2U_P+ZD/UX_XE)EW*,@@;-)]E&+26R\T/Y4TNR%$+2R%F.BI+ <W,)2S&
M8N[UF.6 9J;&@LA$SB.T("OK+X/#PF*3KW36*&K:9&Q%-]2/O"P+MZ$O9+I?
M\&;&LX;EO(C/&K8<G'36*"<3UJ,[W6#-L.,X:TQE8M-R/)<\XGHL[?*H'M"H
M?A6*B@4Q]<60YS!_E-;FS1=[/IE':@W/)_9?Y*C.)TXZ=.KYQ&[2]>\WU#1\
MIL_B+P[9>$9(P6/8AK2;&X*-M 2\TNRS'+!Z)8A%*%;[^W% 4\)EB^Q%/3U*
M]I'G4Y2E8ZQDW3!IT00CDCTMP^2Z3:VX=S/#!G>W:4BMS38NKZX6W,?V.3?N
ME!:M--N;%\7SYFE?[\V]QY\]9C1]"GVZ7*^+LJ"-MD;7O/0YJ=S%8BA\!=RY
M35]M*\PX,Z#5J!R\P?(DU6B4IF"$:G*PH>^77DLANBYER"H:;8(.-+AL1*]R
M[S4/\@4<N5;Y-U AWVDD-D]]-MX<8%AV/H)[5"(+EIKOUO'8IP&NV;3+:9+E
MV0T528IWB8&&Z9_H35&!!!R-Z51*H8 D!2BY2Z#5RQ(T^H+&M* Q3[!HEE5H
MQ:%:W/?56/#+$ ^2LV\5DZ/!AR2]+<X+<\:U!I!CCF\-\<(ASE7\D;>K*!$A
M<(OF8H#R#,;I93LO.T2BEURV%.G3JYO/(@.&QVS4 3[EYI\<Z.MC1J+TY.'1
M1.O9GVYAU)W]T7FJGBL#@6LHNMGC9TOH.,@<\EG$=&HP!NUVE\V/\D?[-WX&
M"#'[,B7-#OZ+ #T2CT5%IDP^*2L!EE?]'CN-)*]>E+_*I#S>3<SS'T/Z5!51
MVH4197L]QM5.TH4%324FM== HD@8YS2*V&\.7D0BMG.9"T.\AY0>WVUE:Y=/
M=F D-B1:K'C,HU!C]A9@/?UE;TI<%%?UJ&Y]S34?@3/LU\6NNF;WPE1,X+7>
MZ8ML_YC5E5R/P[$:U$"NO$&B>H0RO&$F,0W]G 8R ?C92X./Z7 O'F?]K9D$
MLZ.EXXV#\U6C*U]:<(0;(E >B5-FPY*FUDMKVHM<?@YY5$[(Z$Z9[)BH9T"B
M,:02LU$9]IH65E?8J_2YE$3IZ"#2$@LSH\K2:BB'5DCFB?U^@2+5_Z)I D/R
MN$8\KG"3L4J<DZV+/D"Z2[TXVU8UM"_BT\I+_YDYZ9]H^F >;YIK-HS/5:VX
M9?VTJ$3,,Y**YZHQJ9$3CIU(] @<I\7X5+&A[GLQ<'#<+<.'V=^1SL8*\9!G
MD!42'%E6TVSZQOG!I\54BQ8,R#IKR(SUJ_$3*+MY,#W?M.20[8/_K*]4LQ6U
MJDV8:4$NV6A4L!?Z&)F!))UK1NUB_=#1:I+)>O3:2X7:/A4!TQD<43.$H+ZF
M(<U=.69@A=\H ?$[BQ,(E:^891C]*+S!Q6E%YN[9;-QQC\X(V_KUR_]^R')1
M6. N452!+EM3TH"W(:!Q)B1'J-:KO6C2=T/_>0BS,*=%9HG4LC?43Q[B<$C,
MU)6L5UH.7$WUM?C=KV->S<RSO#MES4E=K+T(8!:ID\TE;(HX9K$*'N$LUE&F
MEI5^:F,I" *=<$QO)J'Z#;S@+AC0_A\I0K_.6C#JV.)EDW15;2]L'2: OJQU
MX<D$C5;6++H8?(8+>$,[!Q\NN%PSJOM%AXH4#519<K-0// D<GX_F6Y#J3%<
MGS#,(N0/#RE]X.^QMEY8^M%,VE5D@U^\.VL[HTMW>^PS/CROYRL?HG:]^%M>
MTNN.ICM1<.]3$E05DXPBH7--!?JT=#*?=(_:&TJ^>M\^$",0^ F?H"AZVIP"
MR_O4Y1C%U*)7,ZIZ-&Y2@VZW)*/<W[>BX151\ I)5'5>937^B';B/).5LXD]
M^,#8&C[1F&;9U?;V<)_Y:;A7Z&1U,&CB3*#1V*E<TGG>=WW/NVZ11AI8Q655
M R\*KW01]C2)YA<RC=&\-B4-GWC?8D2!71@&((OVSJ)*QL/ TZ8!ZR)VM3WU
MLL</4?*<=;N^CP5U]3C .XL-4Z;N,<8$F@,0 4%^*6$P]+:TI*DFXT_@WHN-
MP)FU31M"L/;V^4QSOHCK-'D* QJ\?_TIHVR;7^UIZO''R2?,27IB&H#J-I7V
MN.TR W3PSXDK0X^0A "7:,C]*_F:8V*^^S>D0D9J;&";=7ENU.1ZU7 TYG7Z
M;C"*#3F@![T*X'<2L1]&E"W\(O:3';U,,O;[Z1IC_*IGMKE17*3.Q\F1.X9J
M(L+5CYR*?,TG^X;_^5CT$2*.IA5'8\;1B$W"?\M_]CDS#Y)_)!G0;WB<EB6W
MM?F5Z5P3PRE%=NXYV25I'OY+%3,WO'KH(8)V>70T]G9(X\\H@B1S$P'NB(Q*
MG.5=5!<+2)_F7E:$\?E< 0UV,E=1,_CN<"!/"8$Q-:?!,$-HZ8T_C8JK^RA\
MD+UVF/46A7R:;R%E6Q[YBT2FZ:"QW?J]HP\U#(-.OM28Y\("ZV6$:R 9[?7!
M3)%Q1/<!,U&$+, _0_!^CL"\8M-_3F+NJ%_$S-C0++^*JVO3=BM'YLGOF()-
MTE=QG6J45^*,&R21Q)T3O1AA$LLS>8F+7,7-W)!N@]P:HTP;@7\[-RLOWH@C
M=5CR(HE;W0;W-?'Q(L3;9W_,1SUSSP_R[B8>XD,C#:;;A+'+%B2)'A/5A3JS
MPQ7QZE&#QH'K:GM&[_.S,//Y5[Y.Z2X\[*RC!^,(P:,(!C3K#N)<_CD4*<'(
MUP7@-X@N1%RHK ABQX]>"U44KN(4ZBK='91D>JVOVE;DXJQ5*[3%]7K98PP1
M.S3DCRIXF!YLR^Y[GYU4'V1[C\KL%;7PFZT_PE93$#3>N[7*-PO?C6*;[-,W
M,M'['4?XC!_"F/TAC!^,W'@;="">NQ6]78%MOM$9[C0D3%>% MXYGT0N]YHZ
M&XYX>9Z&]X=B-_;?\W#5U3%P'>V%+7][%HGH<*FAL (N$=L2!1+7W'[7J[UQ
M"UR3M=4-Y:^+"GU8Z$ ^A73Z,_;K,RJZ)#%;9A6)M$,,&IRTY$%78AO@/%Y9
M()"*JT9!:AP(W.ZYZ69GC'U!MU^3'%3@.-SQ!:D62FF0=$0AWK5)1Q8+=M%U
MX^%A*ZSSZNO"4%R6OH*10SF" <2''*-J1.66/D,% OW:;PH]]?/FV@F$=WMM
M*?KHA;T8A?!5Z0O/0#J$V>,BW33'XA)'^*WL'?"Y24+B8QOI/K5;K0=?.Y1]
M$?LI]3)Z1N5_&^EYQ8,@U]<!-IBA@]M67.C7P)! Y.L2_!N>-EIGW98/$E$^
M 9A$^FE55,W+,IK+ &>Y7Z'29&>32HN G@5:^!W.O,.]%P9G=$O3E ;G,AA[
M$@>BL<R)^)*F"7RNV*$2_)RY8;CK"VRD0",VA$!$)*;Y=OZ/DOI85&@)C!R-
MV9E04EO$\^7^3P2YWB"Y8*EVTW:!-A7/$36\'CCQQ95#=NV]\C?1TPU\#R$^
MN]ZGV7!CEX"D@$0129I"9T70?I@@A*9:(;".%KJ+#<6&3 ],E]<.E+L9'L*%
MQ^@.4FJ^$SDL:0 CR+IWI+$DIK2@B VF6CHMS>, (KR/XVVMH@UF:/-HQ849
M'L$C.O9.)GWTB>C\Q";L&'DDQ(([#_8;?.9W_EA4VD7,&^!->KWO@AG*U7#B
M@J5JJY"A?4\_"Q=J,F'W^6PR:>"L.*!=>Y^SXTI9P<O_YR'D/;AR]MGXU98R
M=*=5E08(H1T5$YK[K3]>Z_K<$HK48+.'XR9[)$XTLN4]\A-2LN7)M25MP[&W
MI4.-L-2!>QS&^]+(T1C'AM>_F-^O. 9_8AX_8MU3PS(DMTX+X9?A1<SL/6#9
MO54*[V+5 +4S0/L53ERQW.45,@RGA>6Y49-[?-$!@]TP)4J@0[_Z*2)-?$J#
M[ -C6.-E+<\8-37?6A10]EI/5__^6HXF7&Y:S_$Y (*#_!1RPD:; =VCP^ZC
M39!WJ[-3OVAY$Z-GE3.0]#'E10GW)6',KBS_P/A?-$U 9+3J?\$.>(D?BG=6
MHOF%S8M9,%?20*%J?4<=_/0VP WD=?N,LFG&2<5OWC+#JMZ+IH'I3%/"MA*>
MBV_*7< QU\].ZT<$&:FQR[Y"JQ:+<>U(O#B_EM$:D_DUH;'Q4BR[>Z2D*#:S
MC9+GF3B'["W5O(K-H)'R//.MJM#;/9#&O/O)Z$%>;DWBQPS*N=OT#?ZEU#(<
M,5<BBQ\H[-\CH6!)HXD;DO=,TW6)^K'3!-R0$9%ZJ=?BS2R]CCQ?=':QOEPU
MQ H="36F7K\/FJT-"V!202/P4F<FMQUBV>UX^2=1:7B@A>.^8,=^,79,R2!W
M9D@G1"'8DFRW-%VB3,[TOLAST?E,4TI2+^11_N30^Y;@$6X[;69V)6V&<F'?
MEEL* Z5L:^:&T2+T917T._BPPG$%5M)+4Z]VSD T]-P^ZWSL&&; 47BH.HW@
MZID.XH3T2&_HOL@(DO4"I_BA?5R8O,\!2O7R_'4-P43ZFV6N[N;RK6RH^SHM
M!W\C*3W$&?4/*7,YHL3K][%P)W*.!+^5B$3E6:EVI;4_U4,$J6NJ@[AK-D '
M 89<@"Y->I5R6P>O$"8"V-%BF@: [L9_C,R3AX=4*"SRT#Z;\58@]0>L]0EX
M->H%O^SQ59V>S(SJ4-,KS=J)/8,[L<9*UCA#H T-]03E:GO)3+0H#&OMCPZA
M '=#!^E2/BQAVXZ/D\6B<3EC1H2H-Q"VC!M[4;+QPP;@IP>Q"J15P>2A:LIF
M<2LS3#"A*D,JE5NH46%]N 8[AA#,5"(;&ZNL:=@N*]X+LRRM/.8C4JU#RM 2
MN/6UWX^:J)$1&KR/.VS-M UF:.MMQ849'G$@NLZ<3+I(%-LW2-\:/..83O#<
M%2T6)AC<U;'?Z#._5UE=M8EUT31,@FX=(=/ E X#5&1*2U6OR"H;O"%R.!FH
MB87@R:@5/7S[!<6?Q34< P9W$LSE37M&UX!#[)P/4?+\F7%!-%4L'Z'&P<#&
MYOVGHB0[I-3U_>?T^: =B!DX-K1W"<>Y(076QJMO'I<;?!U:H\;Y4'0!1MT>
M]OM(7+-Z4=TGM6&4XZ#QE)QAB3-/7-TCK#$]U\XSLMV3)YL<ZACJ,%*=CR9V
MCW;&#1(.<>=$3V\,-6QJ1DMPMXZ>CQ'OPRU;K6%W)]<0)D!0"89#I@Q"DO<S
M4;.HPSBNB&?4E5?;=KZ[ML/U19RS9?'\XEN>7FSJFLTZ)>A#S-GXIE&T5]O>
M,Q["L&M5+:\HQI6Q2/T6<R!PTU;C6/O>V>RRF5?R2EK)\H@>8Z[)-#*):<C>
M8<ZKU\;?8<XTWV1]7F>.G@2!>)C@164.Z45\6B48]]\W:=?YJ=%)U\Q17F<A
M(%[U2CQ6WFPQNU!/7*?/7_"+_RJ!?/ 5Z+CY:"T".O4>FM%,,WHUHW69^O96
M9[<HH^W]_R/CM96Q:O$:R5%B346M/G>LLHKIN2M%W=6@6W/4L$.)IER#'6;8
MVB^67%!5KPWZ58>Y[0#O8K(&Y;VJO:)58$%YM"#E$^JQK$X\,E?>:?<;5$ZQ
M0KOV99DX#G#M3(-WIA?+;1BHJ^3.RGOW*N(YNOP[@F<,(ZL];;VA%\/(-DE)
M_LC<#&S5P V$PN#&N 4PV7076ZF5CE8%-EUK6;A@!C7=MEQ0->5JIZ(VKU^6
M?S;M\N!P5N)#968G_#MI5-0CL]].*F#<?MNA7421G>1Y&MX?Q(S5Z:AS%-*>
MDXPB:0O-#!(Z6XJ+A@JSGHKKS$9TK!<'&PN4P5]IK\W*C@+R:E:V'[C!O_:S
M#W[AXR5QXR62X-:BRE(=S5IFVL5-1Q%P*X^;KY/=8#UR=)[P""^<='OY>*M"
MA-L?=F2!5H^43[NBQ5@PKU>\"@^.P#<V40UN[K$6\]H1KJOTP8O#?PG98=HW
M2Z(P$/]@VOB:26,I5U?;(FW4BV[9;X0[;]TQ=*;)H&)J<_&JNX>:>(5O\=G+
M>9)WLBW;);/)<'4278,5FR;UG"VWA]W.8SX6X\MM^!"+NRVF5=@>2PZQ2 "_
M9NOP,742FW5[:0.&\\QT5.JGSEJ_HR_Y^\@B!7*Y^:%?JRS 4?TF;4TB]FES
M&KY9JXE(/5/K,0N?C(C9,#UG69F32LV/QE=:>M,:/6R9??+)!\N/"3,]IYR?
M:6SJ$6D 02*""AIZU8[Y,%*,TW@D,/$.W8=0ARL&H5:_:#ZPF9DSPZ3U+#G<
MYR?WR2%OKLS9PME@AK9=5ESH/Q6L@(F )AX')QV9Q6EK)E'>HA"=M; 7;2,[
M8(%V[<U<'TC*\XCM05F' >KTJZ6JOQE-CVJ8K(CY!]0>Q33@J]N5FOG]5;G;
M%$.LX/;$E/J>^([)+%(KXDPOZLC*++)H8UK,4*Y>N2/9[<)<QFO$51E?%HU]
MTS(=PX5-[)""5<:QI'TH@[" %^?L%@:,)LCI8^MKT%AA1"G<S@;+%CNTX;+F
MAIV\KQ5[F](=85D6H#-C;O)O5@K&#O7:._]CD@3/812QM77? +B;-4ND4&;-
MEO;>N[T*"*41<_JT6B-FAW%M458OR=ER&:&$-E=F=*N%MWS_=@QV:2JM^$R/
MA=0:V1L3? "M"3S.?*8W1$J.%UG'Y+0HP'K9:.E2)6N=O^QIG.&T&09?2M\.
M0P,/% C.BC652VJ]:9S!1CA/ VTWW/DS(-D"$RE0"8]_X"WU49B86=G2VO#H
M;,_$'6)DCUSG6%M;\)X][B<>%32495)2TXL]BT<KP^]_^"[^J6K4Q?NP9/^_
MMG .!RB3SD\>4EHD&Z'*G33FS!G-_#3<EVE4S1<G1?FO5M(U&A.N%V2M]5:
MKGYMUNRCY7Y-IL ";7:5U UOS:K?(=IK+SMZC%4-.FNI%TNSNZUA%+"V3K?#
M##3,NEO+0&_I9%!L)!3)KQ,)<;##2"V4<B=9<6CU+52MX6I[FNRX@R\27XO7
M]^*IT>VCE])[7EZG[%#EVL9AZFS0-F\RMP8KZ+QY+THZ-1$"QU06_8@6=F;B
M5&@WT_OF<NWMUM1IP.S;9/[T[&!M MG9IK6#RH(Z NN&"+QOA)R0JGDB-K,Y
M.W]4^@6/#9UGR^AM[<0Y0.K%/291P 3H_)^',!?%"UQM[A@V:)LZ2NV@3!<
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MT*OQ@'MYTR1;>XEGB1*F5E FT^"Y-FXLSM:;T^."]ME&*!TN%)25SUZDH6J
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MASG*.:I]5,?/<QD].*.9GX;[(1E0U230HH"J[Z&G2QM'*2!( P3ZI>\T@HK
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MLQ@Q055LW]8KMR9*3PF8:=+L$JU5&H*;'%$505OM=E5'47JPH+'//B7#]R:
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M9]C9R!MXU,'VNE]SYIESIIO9A,AOPL8:9&[7=)TS[I)-F .F88Y(9['OB*X
MAFV,TZ=%E\>$K2^Z*0WL<_Y>FXNT(3'-BT(ELOOC<F2Z]_FQ^UCB#AU=$WCM
M%C+HX=.%G*'<?86VW118N;MU);Q'< &7O!^C5"=.G3;20&I@3NJ8+/QA+JT
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M*J8"=<<?.2FY;:&X+3&"J');JKLRR?<;1T 8!KG?2"\/Y&144E<\I,]"M=B
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M?7$V88<5/SH$(K^M=W#AC/#DI)0$W$)5+.(7,(6/Q<.0B1]ZW+T4>:UB9)V
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ML^THXR"%VRPS-#<;G%J4I/9>FW/+*8V"%?9(@9J;6=,^H@$:"D!6PI=H:@T
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MT"I>15O?V2_'$=EH%%$8: (MF986</.EE3PC,S:, 9TY4VF!RS"F%SG=&0>
MYI@)K:DRX=+LR5;D%XZ>"/Q'9-&,)6J9S*!ZFLE'?;%Q>VNXHR^\"N[)?28*
MXEI=9AAB!+W),*5ZN WV^[Z\%Z#LI%( 8S!=TTE],T#JUP4LR*.3R6)G>H-A
MAF[R]I-/RFL[>BIZI8O)3[U]F'N1T  9&T'3)QI\2-(/!UYFXB++#KSPAU$0
M;H990.)S<W"G*]?%(_Z&FR:Q%IYG@5=:K(R4F'F]%2)QDQ(Y:-[O8OQI,,:7
MC)%N;)SDY)7F)&2@"W0V#A+_P.V;V&9@Q'\^< ^6WY4]23%)&]Z\E CV-\D0
MR0CBB5_ECY3<>Q%'RP92QJ? R^F&A+$?'7A=W!(\?_1R\N@%Y)[?>9<XXH \
M4R9:^Y0^A<DABUY)4M?4)?>'G#P_AOXC83C8EW@FCS0*>)4E/F^>4B\[I*_?
M@OM/\ZHT=71V^A23%7>5G'VU;<PNVJY=TU1,;^4U&>$#]9G,*.[NJ,9;BJMM
M6]4*4%XG3"I;%/U&IE+Z)"AE"J&E.V5Y@SVC-%N$TC'E"4<JB$Z:N,M,7403
M9*O'0CR1F<X7<D8S/PW%LY&K[1T[4V;,8QV0#^4AV 056#3#B,[>F<8K'D5P
MN UI0/+?-F QU!=PHK!#TC8YQ &;^JO2_<@.]]4 '._6W#ZDT#6>B"!Q3XT[
M2=R)DO[4A@14225<4,E\:^JC1@9X)KLWGY(X?XQ>6W&I'1,FNU"0!@NH*Z.C
MKBMJQ=A.>%.,QN.QN!#D-PGREB'(W3&9B:+BE7_ @]#\K+1M>2[\-T)!1J]<
M@[0<F40>KJ2.X8<Y9*[,Z X==V#4*(ZF]%-S^&F2Y<N7>AJ8\>A*.PUQ;8%W
M]"TP/@\&MVI)GK4(IB_\9V2OX6?=8\N48NI/-_V2:_"B+3,O[_PYB65 L%WN
MF7;+.E?-5ZJSH=W5&>0Z82_D0+_0H.X;N.;+6LKO?:'\BH'M>^UB&:1:5_6;
M:F7]TOB-7E-UW S-12*J3R19Q?VRAD^'R'_%Q:U*TKQ"TAXXU)L.^[A+G';3
MEX0#C,SW1:#/#6Z0 1=Y-"E8XO_^(B,XLE&"G0<_VYQ'EY8US+D%O'AISXJ9
MBK8N.$*'R[).[CKNQH?I*\D'JLX>7WZ:9KLMDZDV-.'1!!<*O2MOFV5J0%'U
MQ_KMS3)K@,[O7HBS2[8ZD5-N2)WI(:=%X&6OS-4B$2H;)!\\.7W)36M>\73N
M!1R-7R9?'%W$[# @#D#95?Y(T[M'+VZ15W:W6KDMZ\35'9VO-_5K+*!0BR=I
MC341L2B>X!9WU:VFJ^NFN$M;, ]HQ3ZO<W^H@GW*S*'C\T!G42S+^*K3EK90
MD'J&=>N6;>S(@BX186AZA>]B&I4V#THKE?9=K;1+E7U1JNRNQL;@*N/Z,&-:
M&ET8&H!'UR5SR/-@++H;RN<G,RK64/@?[>0.OL2L2-+_EIR_\"Q[GMXF4S>*
MFQ:>$7:(P[S\Q5%$L==2^*X![,77A\>06BS;Z!D6S,) 7FX!?8,53*:#Q82N
M (7D8X";2;2<,3>.DVVC_"N2IV*0FEK]N@QD5<!E9\YELIKMM88*"_3%A)*Z
MT<HS24I^XB[C^7#V'N"U@#%-0UF(Q,NRQ \]3NASF#\V\SR::<]H/&0S.76I
M4E.BP-8U1UX1G!SRQR0-_T6#GWABNEBQ5!^B@O3[UZ)-.A7OS&ZX2E*UTAD.
MW"V\"K#8^M+<=6FRLRG+"-3SRO<&A;(I_$<Q]X8'W,OIB[>Q8@&0_7= 1,@D
MQKOL$G!<TQD1T2?A4E/5RJ'CY/150#L#BW'7]%K-3@T,ZX!+V#)9(()C>UL_
M_Q)P*((Y[JZJ9%*9D0!_1=];T)=W*]_G.=Q%?+66,O5I]I/-7AQK;W,OS9%<
MMH_S_ZHNLK,A[^E#&,?LQX58<QX'Q\F80D-RUXB<B]_A\4775IA J0?=U>"Y
M).DM]4+48"C#7#CR"WJ+^C(S"OJ\A\DAR(A<2'TE@B".!LWZ"YC">2AY(<5K
MZ/*B[?=DC7'[0@QE109Y_T'"AA@FM=M39@ 4]?7"F$@3_&O) % H8< [_^Z*
M$!NP\D"HLV$+WF69K.>X[_2-. YEN:JU0!DO;(ROQGQ)]_431'!YJT4K$80U
M7,!*;K5[>H/%?#F!P.H5N>T)#61I..\.EOH.<.'!NBA)B.C(AN,K5&/0'!X
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M2SUMG^1IU1.#D0_!@(ME&NEJ^E FE3"0F[Y*J)P]\".FC;S*MG/(N#[H><4
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MZZ6+_=OPTGW!J2LS" MZ.&? ^JM&?)6!F<)Y^T#3]X7(OW;CD&KGYIZ7;;.
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M$^"VRAP,X/#+%\551C-9D0,>1WY. +Z'%R''"N%4NFFU&=:9 >EJNS@4V]#
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M?_:N@W_7P;_KX >KF:,Y.FY#0K",U2*7*]Y/&W\'VG8^Z"EQ_=[=JK/PB;I
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MH\01;OKJKLX,TM&E%7^-($[!.>+H8+RBE4N?-CCV_P>Y,BV'M)\S@W2/L;+
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M]:7SB>9O]'QGO$=R-UYN#]A2PMV=*&*PP.6C._'C1OK.NZ0M;,'@GCRW"YC
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MJB7D68CB5^3?1/%-1K,FT"!A-Y2F"C4>"RP)G"&?^7M',[@3D)GFN_%82TQ
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M/B8! &YM=&,M,C Q.# Y,S N>'-D4$L! A0#%     @ BY5O3I[S.?1O"
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I=&,M,C Q.# Y,S!?<')E+GAM;%!+!08     !@ & (H!  "]7@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
